adenine has been researched along with HIV Coinfection in 1950 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our data support the use of tenofovir disoproxil fumarate and emtricitabine in pregnancy and our reassuring findings can be used to allay safety concerns among pregnant women." | 9.69 | Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial. ( Clark, R; Desmond, AC; Govender, V; Gray, G; Lombard, C; Mhlongo, O; Moodley, D; Naidoo, K; Naidoo, M; Newell, ML; Rooney, JF; Sebitloane, M, 2023) |
| " The combination of terms used was: (Children OR Youth OR Teenagers) AND HIV AND (Tenofovir OR "Antiretroviral therapy") AND ("Bone density" OR Osteoporosis OR Osteopenia)." | 9.41 | Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review. ( Gusmão, MBF; Melo, LC; Oliveira, VV; Santos, NMDS, 2023) |
| "When started in pregnancy, dolutegravir-containing regimens had superior virological efficacy at delivery compared with the efavirenz, emtricitabine, and tenofovir disoproxil fumarate regimen." | 9.41 | Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 ( Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021) |
| "In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes." | 9.34 | Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. ( Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK, 2020) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 9.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 9.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| "STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen." | 9.19 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification." | 9.19 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014) |
| "Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria." | 9.19 | Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. ( Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM, 2014) |
| "HIV-infected subjects ≥18 years, with HIV RNA≥1,000 copies/ml while using NNRTI plus 2 NRTIs, and naive to PIs were randomized to lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono-LPV/r) or tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand." | 9.16 | A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. ( Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S, 2012) |
| "Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure." | 9.15 | Atazanavir pharmacokinetics with and without tenofovir during pregnancy. ( Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM, 2011) |
| "AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening HIV RNA (< or ≥ 10(5) copies/mL)." | 9.15 | Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. ( Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC, 2011) |
| "The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations." | 9.13 | Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. ( Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S, 2008) |
| "Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions." | 9.13 | Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008) |
| "Tubulopathy with hypophosphatemia have been observed in HIV-positive patients receiving a tenofovir-containing regimen." | 9.12 | Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? ( Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N, 2006) |
| "We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine-lamivudine group)." | 9.12 | Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. ( Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ, 2006) |
| "Clinically stable HIV-infected patients receiving antiretroviral therapy containing stavudine 40 mg twice daily with a plasma HIV RNA < 200 copies/ml for at least 6 months were randomized to maintain stavudine 40 mg twice daily (d4T40 arm), to reduce to 30 mg twice daily (d4T30 arm), or to switch from d4T to tenofovir (TDF arm)." | 9.12 | The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. ( Arnaiz, JA; Blanco, JL; de Lazzari, E; Garrabou, G; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; López, S; Mallolas, J; Martinez, E; Milinkovic, A; Miró, O; Vidal, S, 2007) |
| "We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir." | 9.11 | Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. ( Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C, 2004) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 9.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "Tenofovir disoproxil fumarate (TDF) safety during pregnancy has important public health implications." | 8.89 | Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. ( Bulterys, M; Ellington, S; Kourtis, AP; Legardy-Williams, J; Wang, L, 2013) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)." | 8.82 | Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004) |
| "This report suggests the possibility of severe tenofovir-induced nephrotoxicity with combined acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus in the absence of other provoking factors such as use with protease inhibitors or advanced HIV disease, chronic kidney disease, and age." | 8.31 | Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report. ( Gill, S; Kalinoski, T; Mehboob, G; Mpejane, O; Zilwa, N, 2023) |
| "To examine the risk of incident hypertension and statin initiation among adult (age ≥18 years) health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared with propensity score-matched adults taking tenofovir disoproxil fumarate (TDF)." | 8.31 | Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins. ( Hechter, RC; Mefford, MT; Pak, KJ; Rivera, AS, 2023) |
| "Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women." | 8.12 | Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022) |
| "There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART)." | 8.12 | Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. ( Allerton, J; Castillo-Mancilla, J; Hsiao, NY; Hu, NC; Kabanda, S; Lesosky, M; Malaba, TR; Myer, L; Odayar, J; Orrell, C; Phillips, TK; Wiesner, L, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 8.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 8.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "To investigate whether the switch from tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) to tenofovir alafenamide (TAF)/FTC/RPV is associated with weight gain in people living with HIV (PLWHIV)." | 7.96 | The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. ( Berruti, M; Briano, F; Di Biagio, A; Taramasso, L, 2020) |
| "Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF)." | 7.91 | Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. ( Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Gardner, EM; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH, 2019) |
| "In human immunodeficiency virus (HIV)-infected patients, tenofovir disoproxil fumarate (TDF) may cause hypophosphatemia leading to osteomalacia due to renal phosphate wasting." | 7.80 | Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. ( Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R, 2014) |
| "To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity." | 7.80 | Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 7.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes." | 7.79 | HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013) |
| "The effect of tenofovir (TDF) alone or in combination with interferon on hepatitis D virus (HDV) replication is poorly characterized in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV." | 7.79 | Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. ( Boyd, A; Brichler, S; Chevallier-Queyron, P; Delaugerre, C; Girard, PM; Gordien, E; Lacombe, K; Maylin, S; Miailhes, P; Scholtès, C, 2013) |
| "Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year." | 7.79 | Tenofovir-associated proteinuria. ( Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D, 2013) |
| " Relationships between tenofovir use and proteinuria and chronic kidney disease (CKD) outcomes were examined using multivariable logistic regression models." | 7.79 | Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. ( Chernoff, MC; Hazra, R; Kopp, JB; Mofenson, LM; Patel, K; Purswani, M; Scott, GB; Seage, GR; Siberry, GK; Van Dyke, RB, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir." | 7.78 | Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "According to the European AIDS Clinical Society, tenofovir disoproxil fumarate can be used in HIV-infected pregnant women if started prior to pregnancy, although no data are available on the pharmacokinetics of tenofovir (TFV) during pregnancy." | 7.78 | Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. ( Benaboud, S; Bouazza, N; Chappuy, H; Firtion, G; Foissac, F; Hirt, D; Launay, O; Pannier, E; Rey, E; Tréluyer, JM; Urien, S, 2012) |
| "To compare the rate of decline of renal function in tenofovir- and abacavir-based antiretroviral therapy (ART) in low-body weight treatment-naïve patients with HIV infection." | 7.78 | Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. ( Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 7.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants." | 7.78 | Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. ( DiMeglio, LA; Griner, R; Hazra, R; Jacobson, DL; Kacanek, D; Mendez, H; Miller, T; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Tassiopoulos, K; Watts, DH; Williams, PL, 2012) |
| "The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models." | 7.78 | Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. ( Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM, 2012) |
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 7.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "We present an uncommon case of lactic acidosis after concomitant administration of Metformin and Tenofovir." | 7.77 | Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2011) |
| "We present 2 human immunodeficiency virus-infected patients with tenofovir disoproxil fumarate-induced Fanconi syndrome, leading to osteomalacia." | 7.77 | Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. ( Bronsveld, W; Haverkort, ME; Huitema, AD; Lips, P; Slieker, WA; ter Heine, R; van der Spek, BW, 2011) |
| "Some studies have suggested that exposure to antiretroviral therapy (ART) with abacavir is associated with an increased risk of acute myocardial infarction (AMI)." | 7.77 | Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. ( Bedimo, RJ; Drechsler, H; Tebas, P; Vidiella, G; Westfall, AO, 2011) |
| "This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009." | 7.77 | A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011) |
| " His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load." | 7.77 | HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011) |
| " This study assessed changes in bone-turnover markers, osteoprotegerin (OPG), soluble receptor activator for nuclear factor-κβ ligand (sRANKL), and inflammation in subjects initiating TDF- versus non-TDF-containing regimens, and determined the relationship between bone turnover, OPG/sRANKL and inflammation." | 7.77 | Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. ( Brown, TT; Labbato, D; McComsey, GA; Ross, AC; Storer, N, 2011) |
| "This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV)." | 7.76 | High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. ( Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L, 2010) |
| "25(OH) VDD is associated with tenofovir-linked hyperparathyroidism and also with higher eGFR." | 7.76 | Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. ( Bano, G; Copas, AJ; Gedela, K; Hay, PE; Pakianathan, MR; Rosenvinge, MM; Sadiq, ST; Sheehy, CA; Wilkinson, A, 2010) |
| "Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults." | 7.76 | Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. ( Cerini, C; Fabiano, V; Giacomet, V; Mora, S; Pivetti, V; Puzzovio, M; Viganò, A; Zamproni, I; Zuccotti, GV, 2010) |
| "The aim of the study was to identify and characterize hepatitis B virus (HBV) polymerase gene mutations associated with ongoing HBV replication in HIV/HBV-coinfected individuals receiving tenofovir (TDF)." | 7.75 | Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. ( Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK, 2009) |
| "Tenofovir disoproxil fumarate (TDF) is active against hepatitis B virus (HBV) and HIV." | 7.75 | Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. ( Alvarez-Uria, G; Ratcliffe, L; Vilar, J, 2009) |
| "We report 3 cases of patients with HIV/AIDS in whom Fanconi syndrome and nephrogenic diabetes insipidus developed secondary to use of an antiretroviral regimen containing tenofovir disoproxil fumarate and didanosine." | 7.75 | Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. ( Alvarez, S; Brumble, LM; Dwyer, JP; Irizarry-Alvarado, JM; Mendez, JC, 2009) |
| " Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date." | 7.75 | Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009) |
| "Despite the failure of tenofovir DF/FTC as prophylaxis, selection for drug-resistant transmission did not occur and the blunting of postinfection levels of viremia likely reduced the probability of subsequent forward transmissions during the acute phase." | 7.74 | Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. ( Carrington, M; Davis, B; Duh, FM; Jean-Pierre, P; La Roche, M; Markowitz, M; Mehandru, S; Mohri, H; Poles, M; Prada, N, 2008) |
| "To determine the spectrum of clinical manifestations of hypokalemia associated with tenofovir, we reviewed all reports of grades 3/4 hypokalemia received by Gilead Sciences Department of Safety and Public Health." | 7.74 | Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. ( Curtis, S; Rooney, JF; Shepp, DH, 2007) |
| "9-R-[2-(Phosphonomethoxy)propyl]-adenine (tenofovir) is an acyclic nucleoside phosphonate with antiviral activity against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)." | 7.74 | Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. ( Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC, 2007) |
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 7.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| "Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature." | 7.73 | Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005) |
| " To understand predictors of residual viremia, we measured HIV RNA levels <50 copies/mL in patients after 1 year of treatment with efavirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45), by use of an HIV RNA assay with a limit of detection of 2." | 7.73 | Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. ( Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK, 2005) |
| "We report two cases in which osteomalacia developed in patients on tenofovir-containing highly active antiretroviral therapy (HAART) in the context of Fanconi syndrome with hypophosphataemia." | 7.73 | The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. ( Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG, 2005) |
| "Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed." | 7.73 | Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005) |
| "We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection." | 7.73 | Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005) |
| "Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV)." | 7.73 | Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. ( Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R, 2006) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 7.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| "Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population." | 7.73 | Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006) |
| "Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine." | 7.72 | Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. ( Blanchard, JN; Canas, A; King, K; Lonergan, JT; Wohlfeiler, M, 2003) |
| "Emergence of lamivudine-resistant hepatitis B virus (HBV) is a major concern in human immunodeficiency virus (HIV) and HBV coinfected patients." | 7.72 | In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. ( Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V, 2004) |
| "Lactic acidosis is an uncommon but potentially life-threatening adverse effect of didanosine." | 7.72 | Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. ( Fung, HB; Guo, Y, 2004) |
| "To report a case of pancreatitis associated with the combined use of didanosine and tenofovir." | 7.72 | Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. ( Fulco, PP; Higginson, RT; Kirian, MA, 2004) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 7.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "Lamivudine-resistant hepatitis B virus (HBV) is found in about 15-32% of infected patients with or without co-infection with HIV-1 after 1 year of lamivudine therapy." | 7.71 | Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. ( Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P, 2001) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| " Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation." | 6.78 | Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? ( Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR, 2013) |
| " Factors associated with these drug-related adverse events are poorly characterized." | 6.78 | Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. ( Baldelli, S; Castagnoli, L; Cattaneo, D; Clementi, E; Fucile, S; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G, 2013) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s is a prospective, nonblinded, pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including 2 cohorts (with or without tenofovir) receiving atazanavir/ritonavir 300/100 mg once daily during the second trimester, 400/100 mg during the third trimester, and 300/100 mg postpartum (PP)." | 6.78 | Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. ( Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH, 2013) |
| "During follow-up, no bone fractures were reported to have occurred; 12/368 creatinines and seven out of 305 phosphates were grade one (16) or two (three) in 14 children with no effect of in utero tenofovir (p>0." | 6.77 | Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. ( Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E, 2012) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 6.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| "Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus." | 6.74 | Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. ( Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K, 2009) |
| "Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients." | 6.73 | Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. ( Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA, 2008) |
| "Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment." | 6.69 | A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999) |
| "Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation." | 6.48 | Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). ( Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R, 2012) |
| "Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 6.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
| "In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy." | 6.42 | Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| "Lactic acidosis is a rare but serious side effect in individuals receiving nucleoside reverse transcriptase inhibitors." | 5.91 | Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient. ( Isoda, A; Matsumoto, M; Mihara, M; Sawamura, M, 2023) |
| " Our data support the use of tenofovir disoproxil fumarate and emtricitabine in pregnancy and our reassuring findings can be used to allay safety concerns among pregnant women." | 5.69 | Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial. ( Clark, R; Desmond, AC; Govender, V; Gray, G; Lombard, C; Mhlongo, O; Moodley, D; Naidoo, K; Naidoo, M; Newell, ML; Rooney, JF; Sebitloane, M, 2023) |
| "Safety and efficacy data during pregnancy and up to 50 weeks post partum support the current recommendation of dolutegravir-based ART (particularly in combination with emtricitabine and tenofovir alafenamide) rather than efavirenz, emtricitabine, and tenofovir disoproxil fumarate, when started in pregnancy." | 5.69 | Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. ( Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L, 2023) |
| "A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped." | 5.56 | Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. ( Cattaneo, D; Filice, C; Gervasoni, C; Riva, A, 2020) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 5.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| " The combination of terms used was: (Children OR Youth OR Teenagers) AND HIV AND (Tenofovir OR "Antiretroviral therapy") AND ("Bone density" OR Osteoporosis OR Osteopenia)." | 5.41 | Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review. ( Gusmão, MBF; Melo, LC; Oliveira, VV; Santos, NMDS, 2023) |
| "When started in pregnancy, dolutegravir-containing regimens had superior virological efficacy at delivery compared with the efavirenz, emtricitabine, and tenofovir disoproxil fumarate regimen." | 5.41 | Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2 ( Amico, KR; Brummel, SS; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, J; Fairlie, L; Frenkel, LM; Hanley, S; Hoffman, RM; Holmes, LB; Jean-Philippe, P; João, E; Johnston, B; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Momper, JD; Moyo, S; Purdue, L; Rooney, JF; Sax, PE; Shapiro, RL; Stranix-Chibanda, L; Stringer, JS; Thoofer, NK; Ziemba, L, 2021) |
| "HIV worsens the natural history of chronic hepatitis B virus (HBV) infection." | 5.39 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013) |
| "Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 5.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
| "Small body weight was identified as an independent risk factor for tenofovir-associated renal dysfunction." | 5.37 | Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. ( Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2011) |
| " The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance." | 5.35 | Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008) |
| "In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, tenofovir disoproxil fumarate (TDF) use was associated with moderate or severe adverse pregnancy/neonatal outcomes." | 5.34 | Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. ( Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK, 2020) |
| "Acute interstitial nephritis was observed only in 1 of 19 patients without atazanavir or tenofovir treatment." | 5.34 | Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. ( Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP, 2007) |
| "The risk of hyperglycemia is increased in patients treated with ddI + TDF, particularly in those with lower weight." | 5.33 | Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. ( Barreiro, P; Barrios, A; Blanco, F; García-Benayas, T; González-Lahoz, J; Maida, I; Rendón, AL; Rivas, P; Rodríguez-Novóa, S; Soriano, V, 2006) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 5.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| " Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country)." | 5.19 | Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. ( Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C, 2014) |
| "A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months." | 5.19 | Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014) |
| "STRATEGY-PI is a 96 week, international, multicentre, randomised, open-label, phase 3b trial in which HIV-infected adults with a plasma HIV-1 RNA viral load of less than 50 copies per mL for at least 6 months who were taking a ritonavir-boosted protease inhibitor with emtricitabine plus tenofovir were randomly assigned (2:1) either to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue on their existing regimen." | 5.19 | Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o ( Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K, 2014) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a safe and efficacious switch option for virologically suppressed patients with HIV who have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a multitablet NNRTI-containing regimen and want a regimen simplification." | 5.19 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r ( Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K, 2014) |
| "Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria." | 5.19 | Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. ( Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM, 2014) |
| "We performed a two-centre randomized pilot study in virologically suppressed HIV-infected patients receiving tenofovir with osteopenia/osteoporosis (OsteoTDF study, ClinicalTrials." | 5.19 | Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). ( Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Escrig, R; Gutiérrez, M; Mateo, G; Negredo, E; Pérez-Álvarez, N; Puig, J, 2014) |
| "Within a randomized, placebo-controlled trial of daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF PrEP for HIV-1 prevention conducted among heterosexual HIV-1-serodiscordant couples, we assessed the impact of TDF and FTC/TDF use on male fertility, measured as incident pregnancy in female partners of men assigned to PrEP vs." | 5.19 | Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. ( Baeten, JM; Bukusi, EA; Celum, C; Heffron, R; Mugo, NR; Mujugira, A; Were, EO, 2014) |
| "In November 2010, the iPrEx study reported that preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women." | 5.17 | Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants. ( Andrasik, M; Broder, G; Fuchs, JD; Grove, D; Hammer, S; Karuna, ST; Koblin, B; Madenwald, T; Mayer, K; Sherwat, A; Sobieszczyk, ME, 2013) |
| "HIV-infected subjects ≥18 years, with HIV RNA≥1,000 copies/ml while using NNRTI plus 2 NRTIs, and naive to PIs were randomized to lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono-LPV/r) or tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand." | 5.16 | A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. ( Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S, 2012) |
| "Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure." | 5.15 | Atazanavir pharmacokinetics with and without tenofovir during pregnancy. ( Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM, 2011) |
| "AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening HIV RNA (< or ≥ 10(5) copies/mL)." | 5.15 | Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. ( Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC, 2011) |
| " This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naive HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL)." | 5.14 | Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. ( Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R, 2010) |
| "Therapy for chronic hepatitis B with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) is currently recommended for HIV-HBV coinfection." | 5.14 | Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. ( Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K, 2010) |
| "We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily." | 5.14 | Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. ( Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH, 2010) |
| "The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations." | 5.13 | Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. ( Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S, 2008) |
| "Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly assigned to continuous treatment or CD4 cell count-guided interruptions." | 5.13 | Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. ( Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P, 2008) |
| "Tubulopathy with hypophosphatemia have been observed in HIV-positive patients receiving a tenofovir-containing regimen." | 5.12 | Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? ( Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N, 2006) |
| "We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir-emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine-lamivudine group)." | 5.12 | Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. ( Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ, 2006) |
| "We conducted a multicenter, 1: 2 matched pair analysis comparing patients with HBV/HIV-coinfection starting an antiretroviral regimen including tenofovir plus lamivudine with patients who had highly replicative, lamivudine resistant HBe-antigen positive chronic hepatitis B and started with tenofovir as the only active HBV polymerase inhibitor subsequent to lamivudine." | 5.12 | Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. ( Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E, 2006) |
| "Clinically stable HIV-infected patients receiving antiretroviral therapy containing stavudine 40 mg twice daily with a plasma HIV RNA < 200 copies/ml for at least 6 months were randomized to maintain stavudine 40 mg twice daily (d4T40 arm), to reduce to 30 mg twice daily (d4T30 arm), or to switch from d4T to tenofovir (TDF arm)." | 5.12 | The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. ( Arnaiz, JA; Blanco, JL; de Lazzari, E; Garrabou, G; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; López, S; Mallolas, J; Martinez, E; Milinkovic, A; Miró, O; Vidal, S, 2007) |
| "We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir." | 5.11 | Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. ( Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C, 2004) |
| " Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | 5.10 | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen." | 5.10 | Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. ( Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M, 2003) |
| "Tenofovir (TFV) is the cornerstone of the treatment and prophylaxis of HIV infections." | 4.98 | Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. ( De Clercq, E, 2018) |
| "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations." | 4.98 | Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. ( Asriel, B; Chan, L; Eaton, EF; Wyatt, CM, 2018) |
| "A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhibitor-based single-tablet regimen." | 4.98 | Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. ( Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N, 2018) |
| "Efavirenz-based antiretroviral therapy is recommended for prevention of mother-to-child transmission of HIV with two programmatic options: lifelong therapy for all women or treatment until cessation of breastfeeding." | 4.90 | Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach. ( Back, DJ; Burger, D; Lamorde, M; Schapiro, JM, 2014) |
| "Tenofovir disoproxil fumarate (TDF) safety during pregnancy has important public health implications." | 4.89 | Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. ( Bulterys, M; Ellington, S; Kourtis, AP; Legardy-Williams, J; Wang, L, 2013) |
| "Twenty years after its original discovery, tenofovir has acquired a crucial position in the fight against human immunodeficiency virus (HIV)." | 4.88 | Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? ( De Clercq, E, 2012) |
| "The use of the acyclic nucleoside phosphonates, starting with (S)-HPMPA as the prototype, yielded three clinically approved antiviral drugs, cidofovir for the treatment of CMV retinitis in AIDS patients, adefovir dipivoxil for the treatment of chronic hepatitis B and tenofovir disoproxil fumarate for the treatment of HIV infections (AIDS) and HBV infections." | 4.87 | The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. ( De Clercq, E, 2011) |
| " Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)." | 4.82 | Adefovir dipivoxil in the treatment of chronic hepatitis B. ( Rivkin, AM, 2004) |
| "Adefovir dipivoxil (ADF) is a novel acyclic nucleoside analogue that has recently been approved for the treatment of chronic hepatitis B virus (HBV)." | 4.82 | Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. ( Danta, M; Dusheiko, G, 2004) |
| "This report suggests the possibility of severe tenofovir-induced nephrotoxicity with combined acute kidney injury, Fanconi syndrome, and nephrogenic diabetes insipidus in the absence of other provoking factors such as use with protease inhibitors or advanced HIV disease, chronic kidney disease, and age." | 4.31 | Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report. ( Gill, S; Kalinoski, T; Mehboob, G; Mpejane, O; Zilwa, N, 2023) |
| "To examine the risk of incident hypertension and statin initiation among adult (age ≥18 years) health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared with propensity score-matched adults taking tenofovir disoproxil fumarate (TDF)." | 4.31 | Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins. ( Hechter, RC; Mefford, MT; Pak, KJ; Rivera, AS, 2023) |
| "Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women." | 4.12 | Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022) |
| "There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART)." | 4.12 | Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. ( Allerton, J; Castillo-Mancilla, J; Hsiao, NY; Hu, NC; Kabanda, S; Lesosky, M; Malaba, TR; Myer, L; Odayar, J; Orrell, C; Phillips, TK; Wiesner, L, 2022) |
| "Tenofovir alafenamide (TAF) is a key component of HIV treatment, but pharmacokinetic data supporting the use of TAF during pregnancy are limited." | 4.12 | Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. ( Barr, E; Best, BM; Brooks, KM; Browning, R; Capparelli, EV; Chakhtoura, N; Deville, JG; Febo, IL; George, K; Knowles, K; Mirochnick, M; Paul, ME; Pinilla, M; Rungruengthanakit, K; Shapiro, DE; Stek, AM, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 4.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Across long-acting injectable cabotegravir scenarios, 15-28% more new HIV infections were averted compared with the baseline scenario (current tenofovir disoproxil fumarate and emtricitabine roll-out)." | 4.12 | Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. ( Delany-Moretlwe, S; Hosseinipour, MC; Jamieson, L; Johnson, LF; Meyer-Rath, G; Nichols, BE; Russell, C, 2022) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 4.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "To investigate whether the switch from tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) to tenofovir alafenamide (TAF)/FTC/RPV is associated with weight gain in people living with HIV (PLWHIV)." | 3.96 | The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. ( Berruti, M; Briano, F; Di Biagio, A; Taramasso, L, 2020) |
| "Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment." | 3.96 | Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. ( Kim, WR; Kwo, PY; Mannalithara, A; Sripongpun, P, 2020) |
| "Cases of HIV, while infrequent, have been reported during tenofovir disoproxil fumarate/emtricitabine use as pre-exposure prophylaxis (PrEP)." | 3.91 | Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention. ( Beste, LA; Garner, W; Maier, MM; Ohl, ME; Van Epps, P; Wilson, BM, 2019) |
| "Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF)." | 3.91 | Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. ( Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Coleman, SS; Coyle, RP; Ellison, L; Gardner, EM; Kiser, JJ; MaWhinney, S; Morrow, M; Zheng, JH, 2019) |
| " We used a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigate whether TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection." | 3.91 | Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques. ( Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S, 2019) |
| " The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia." | 3.85 | Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. ( Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M, 2017) |
| "We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy." | 3.83 | Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy. ( Dewar, RL; Kopp, JB; Lane, HC; Maldarelli, F; Manion, MM; Mikula, JM; Norman-Wheeler, JF; Ober, AG; Pau, AK; Suarez, LM, 2016) |
| "The CAPRISA 004 preexposure prophylaxis (PrEP) randomized trial demonstrated that women who used a vaginal gel containing the antiretroviral drug tenofovir (TFV) had a 39% lower risk of acquiring human immunodeficiency virus (HIV)." | 3.81 | Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. ( Abdool Karim, SS; Eshleman, SH; Garrett, N; Karim, QA; Laeyendecker, O; Longosz, AF; Naranbhai, V; Nason, M; Quinn, TC; Redd, AD, 2015) |
| "We report a case of acute kidney injury due to primary renal diffuse large B-cell lymphoma, which developed after initiation of tenofovir-containing antiretroviral therapy in a 28-year-old HIV-positive man." | 3.80 | Acute kidney injury as a presentation of primary renal diffuse large B-cell lymphoma in HIV. ( Churchill, DR; Fitzgerald, N; Gilleece, Y; Hughes, DJ; Konig, M; Moore-Moffatt, R; Sran, H; Webb, A, 2014) |
| "We examined CD4 cell count and plasma viral load patterns among Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing participants assigned to receive tenofovir/emtricitabine with participants assigned to receive placebo." | 3.80 | CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. ( Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC, 2014) |
| "In human immunodeficiency virus (HIV)-infected patients, tenofovir disoproxil fumarate (TDF) may cause hypophosphatemia leading to osteomalacia due to renal phosphate wasting." | 3.80 | Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. ( Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R, 2014) |
| "The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion." | 3.80 | An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion. ( Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T, 2014) |
| "To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity." | 3.80 | Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014) |
| "Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections." | 3.79 | Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. ( Baltussen, R; Boucher, CA; Nichols, BE; Nouwen, JL; Sloot, PM; Thuma, PE; van de Vijver, DA; van de Wijgert, J; van Dijk, JH, 2013) |
| " Using a routine workplace and community-based ART cohort in South Africa, we assessed single drug substitution, HIV RNA suppression, CD4 count increase, loss-from-care, and mortality between TDF, stavudine (d4T) 30 mg dose, and zidovudine (AZT)." | 3.79 | Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. ( Charalambous, S; Churchyard, GJ; Grant, AD; Hoffmann, CJ; Lewis, JJ; Velen, K, 2013) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 3.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| " We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0." | 3.79 | [Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013) |
| "This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes." | 3.79 | HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013) |
| "The effect of tenofovir (TDF) alone or in combination with interferon on hepatitis D virus (HDV) replication is poorly characterized in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV." | 3.79 | Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. ( Boyd, A; Brichler, S; Chevallier-Queyron, P; Delaugerre, C; Girard, PM; Gordien, E; Lacombe, K; Maylin, S; Miailhes, P; Scholtès, C, 2013) |
| "Emerging international guidelines for the prevention of mother-to-child transmission of HIV infection across sub-Saharan Africa call for the initiation of a triple-drug antiretroviral regimen containing tenofovir, a potentially nephrotoxic agent, in all HIV-infected pregnant women at the first antenatal clinic visit." | 3.79 | Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV. ( Bekker, LG; Kamkuemah, M; Kaplan, R; Myer, L, 2013) |
| "Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year." | 3.79 | Tenofovir-associated proteinuria. ( Bartlett, H; Gibson, A; Kelly, MD; Patten, J; Rowling, D, 2013) |
| " Relationships between tenofovir use and proteinuria and chronic kidney disease (CKD) outcomes were examined using multivariable logistic regression models." | 3.79 | Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. ( Chernoff, MC; Hazra, R; Kopp, JB; Mofenson, LM; Patel, K; Purswani, M; Scott, GB; Seage, GR; Siberry, GK; Van Dyke, RB, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir." | 3.78 | Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "According to the European AIDS Clinical Society, tenofovir disoproxil fumarate can be used in HIV-infected pregnant women if started prior to pregnancy, although no data are available on the pharmacokinetics of tenofovir (TFV) during pregnancy." | 3.78 | Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. ( Benaboud, S; Bouazza, N; Chappuy, H; Firtion, G; Foissac, F; Hirt, D; Launay, O; Pannier, E; Rey, E; Tréluyer, JM; Urien, S, 2012) |
| "To compare the rate of decline of renal function in tenofovir- and abacavir-based antiretroviral therapy (ART) in low-body weight treatment-naïve patients with HIV infection." | 3.78 | Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. ( Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2012) |
| "Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy." | 3.78 | Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012) |
| "Whereas tenofovir (TDF) exposure has been associated with decreased bone density, it remains unclear whether it is associated with increased risk of osteoporotic fractures." | 3.78 | Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. ( Bedimo, R; Drechsler, H; Maalouf, NM; Tebas, P; Zhang, S, 2012) |
| "Cox proportional hazards and marginal structural models evaluated associations between tenofovir and time to first occurrence of proteinuria (two consecutive urine dipstick measurements ≥30 mg/dl), rapid decline in kidney function (≥3 ml/min per 1." | 3.78 | Association of tenofovir exposure with kidney disease risk in HIV infection. ( Choi, AI; Deeks, SG; Estrella, M; Grunfeld, C; Li, Y; Scherzer, R; Shlipak, MG, 2012) |
| "To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving emtricitabine (FTC) or lamivudine (3TC), administered with tenofovir disoproxil fumarate (TDF) and either efavirenz (EFV) or a ritonavir-boosted protease inhibitor (PI; lopinavir or atazanavir)." | 3.78 | Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. ( Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P, 2012) |
| "To evaluate the association of tenofovir disoproxil fumarate (TDF) use during pregnancy with early growth parameters in HIV-exposed, uninfected (HEU) infants." | 3.78 | Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. ( DiMeglio, LA; Griner, R; Hazra, R; Jacobson, DL; Kacanek, D; Mendez, H; Miller, T; Mofenson, LM; Rich, KC; Seage, GR; Siberry, GK; Tassiopoulos, K; Watts, DH; Williams, PL, 2012) |
| "The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models." | 3.78 | Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. ( Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM, 2012) |
| "Data on the efficacy of lamivudine (LAM)-, tenofovir (TDF)- and emtricitabine (FTC)-based antiretroviral therapy (HAART) in HBV-HIV coinfection are limited." | 3.78 | Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. ( Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R, 2012) |
| "Nodular regenerative hyperplasia (NRH) leading to non-cirrhotic portal hypertension has been described in HIV-infected patients and has been linked to didanosine." | 3.77 | The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. ( Bénet, T; Billioud, C; Boibieux, A; Brochier, C; Chevallier, M; Cotte, L; Ferry, T; Miailhes, P; Scoazec, JY; Vanhems, P; Zoulim, F, 2011) |
| "to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding." | 3.77 | No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. ( Kaul, R; Raboud, JM; Tan, DH; Walmsley, SL, 2011) |
| "We present an uncommon case of lactic acidosis after concomitant administration of Metformin and Tenofovir." | 3.77 | Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. ( Alivanis, P; Aperis, G; Arvanitis, A; Paliouras, C; Zervos, A, 2011) |
| "Combination emtricitabine (FTC) or lamivudine (LAM) with tenofovir disoproxil (TDF) is the recommended first-line regime for treatment in chronic hepatitis B virus (HBV)/HIV co-infection." | 3.77 | Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. ( Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ, 2011) |
| "We present 2 human immunodeficiency virus-infected patients with tenofovir disoproxil fumarate-induced Fanconi syndrome, leading to osteomalacia." | 3.77 | Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. ( Bronsveld, W; Haverkort, ME; Huitema, AD; Lips, P; Slieker, WA; ter Heine, R; van der Spek, BW, 2011) |
| "Some studies have suggested that exposure to antiretroviral therapy (ART) with abacavir is associated with an increased risk of acute myocardial infarction (AMI)." | 3.77 | Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. ( Bedimo, RJ; Drechsler, H; Tebas, P; Vidiella, G; Westfall, AO, 2011) |
| "Therapy of chronic hepatitis B with HBV-polymerase inhibitors, in particular tenofovir or adefovir, may affect renal function." | 3.77 | Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. ( Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G, 2011) |
| "We reported previously that octadecyloxyethyl 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]adenine (ODE-(S)-HPMPA) was active against genotype 1b and 2a hepatitis C virus (HCV) replicons." | 3.77 | Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. ( Beadle, JR; Hostetler, KY; Hwu, JB; Prichard, MN; Schooley, RT; Valiaeva, N; Wyles, DL, 2011) |
| "This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009." | 3.77 | A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011) |
| " His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load." | 3.77 | HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011) |
| " This study assessed changes in bone-turnover markers, osteoprotegerin (OPG), soluble receptor activator for nuclear factor-κβ ligand (sRANKL), and inflammation in subjects initiating TDF- versus non-TDF-containing regimens, and determined the relationship between bone turnover, OPG/sRANKL and inflammation." | 3.77 | Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. ( Brown, TT; Labbato, D; McComsey, GA; Ross, AC; Storer, N, 2011) |
| "This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV)." | 3.76 | High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B. ( Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L, 2010) |
| "25(OH) VDD is associated with tenofovir-linked hyperparathyroidism and also with higher eGFR." | 3.76 | Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. ( Bano, G; Copas, AJ; Gedela, K; Hay, PE; Pakianathan, MR; Rosenvinge, MM; Sadiq, ST; Sheehy, CA; Wilkinson, A, 2010) |
| "Decreased bone mineral density (BMD) has been associated with the use of tenofovir disoproxil fumarate (TDF) in HIV-infected adults." | 3.76 | Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. ( Cerini, C; Fabiano, V; Giacomet, V; Mora, S; Pivetti, V; Puzzovio, M; Viganò, A; Zamproni, I; Zuccotti, GV, 2010) |
| "The aim of the study was to identify and characterize hepatitis B virus (HBV) polymerase gene mutations associated with ongoing HBV replication in HIV/HBV-coinfected individuals receiving tenofovir (TDF)." | 3.75 | Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. ( Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK, 2009) |
| "Tenofovir disoproxil fumarate (TDF) is active against hepatitis B virus (HBV) and HIV." | 3.75 | Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. ( Alvarez-Uria, G; Ratcliffe, L; Vilar, J, 2009) |
| "We report 3 cases of patients with HIV/AIDS in whom Fanconi syndrome and nephrogenic diabetes insipidus developed secondary to use of an antiretroviral regimen containing tenofovir disoproxil fumarate and didanosine." | 3.75 | Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. ( Alvarez, S; Brumble, LM; Dwyer, JP; Irizarry-Alvarado, JM; Mendez, JC, 2009) |
| " Because the metabolism of pravastatin is independent of the cytochrome P450 CYP3A4, this drug has become the preferred statin for treatment of dyslipidemia associated with human immunodeficiency virus (HIV) infection, with no cases of serious toxicity such as rhabdomyolysis reported to date." | 3.75 | Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. ( Cope, D; Iskander, E; Mikhail, N, 2009) |
| " We report a case of pulmonary aspergilloma in a severely immunocompromised patient with AIDS who stopped taking systemic antifungal treatment in April 1998 and remained well with little progression of invasive aspergillosis up until March 2002 when he died of acute pancreatitis related to a drug interaction of didanosine and tenofovir." | 3.75 | Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary? ( Yoganathan, K, 2009) |
| "Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment." | 3.75 | Lower limb high arterial flow induced by tenofovir and emtricitabine treatment. ( Cavassini, M; Hayoz, D; Mazzolai, L; Periard, D; Widmeier, A; Yerly, P, 2009) |
| " Previous studies have demonstrated an increased susceptibility to genital herpes in mice following repeated applications of nonoxynol-9 (N-9)." | 3.75 | Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. ( Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS, 2009) |
| "Despite the failure of tenofovir DF/FTC as prophylaxis, selection for drug-resistant transmission did not occur and the blunting of postinfection levels of viremia likely reduced the probability of subsequent forward transmissions during the acute phase." | 3.74 | Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. ( Carrington, M; Davis, B; Duh, FM; Jean-Pierre, P; La Roche, M; Markowitz, M; Mehandru, S; Mohri, H; Poles, M; Prada, N, 2008) |
| "To identify adverse effects of tenofovir use during pregnancy in HIV-infected women and their infants." | 3.74 | Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. ( Hayes, E; Mondy, K; Nurutdinova, D; Onen, NF; Overton, ET, 2008) |
| "To determine the spectrum of clinical manifestations of hypokalemia associated with tenofovir, we reviewed all reports of grades 3/4 hypokalemia received by Gilead Sciences Department of Safety and Public Health." | 3.74 | Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. ( Curtis, S; Rooney, JF; Shepp, DH, 2007) |
| "9-R-[2-(Phosphonomethoxy)propyl]-adenine (tenofovir) is an acyclic nucleoside phosphonate with antiviral activity against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)." | 3.74 | Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. ( Aldern, KA; Almond, MR; Beadle, JR; De Clercq, E; Hostetler, KY; Korba, BE; Lampert, BM; Neyts, J; Painter, GR; Trost, LC, 2007) |
| "We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy." | 3.74 | Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. ( Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V, 2008) |
| "5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD)." | 3.74 | Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. ( Gafni, RI; Hazra, R; Purdy, JB; Reynolds, JC; Zeichner, S, 2008) |
| "A previously healthy young man experienced several episodes of syncope while being treated with tenofovir, emtricitabine and nevirapine initiated during primary HIV-1 infection." | 3.74 | Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. ( Larsen, CS; Lybaek, D, 2008) |
| "Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature." | 3.73 | Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005) |
| " To understand predictors of residual viremia, we measured HIV RNA levels <50 copies/mL in patients after 1 year of treatment with efavirenz and lamivudine plus either tenofovir disoproxil fumarate (n=55) or stavudine (n=45), by use of an HIV RNA assay with a limit of detection of 2." | 3.73 | Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. ( Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK, 2005) |
| "We report on a Subsaharian patient with HIV infection and disseminated tuberculosis who developed acute, severe hypersensitivity reaction to efavirenz including acute renal failure in addition to liver and lung involvement, in the absence of skin changes or blood eosinophilia." | 3.73 | Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. ( Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L, 2006) |
| "We report two cases in which osteomalacia developed in patients on tenofovir-containing highly active antiretroviral therapy (HAART) in the context of Fanconi syndrome with hypophosphataemia." | 3.73 | The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. ( Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG, 2005) |
| "Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed." | 3.73 | Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. ( Berger, F; Corral, A; Mauss, S; Rockstroh, J; Rodés, B; Schwarze-Zander, C; Sheldon, JA; Soriano, V, 2005) |
| "We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection." | 3.73 | Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. ( Berger, A; Bickel, M; Carlebach, A; Klauke, S; Lutz, T; Staszewski, S; Stephan, C; Stuermer, M, 2005) |
| "Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV)." | 3.73 | Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. ( Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R, 2006) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 3.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| "Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population." | 3.73 | Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. ( Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A, 2006) |
| "Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine." | 3.72 | Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected]. ( Blanchard, JN; Canas, A; King, K; Lonergan, JT; Wohlfeiler, M, 2003) |
| "Human immunodeficiency virus (HIV)-infected patients (n = 153) failing antiretroviral therapy after exposure to compounds from all three drug families were monitored for 6 months after beginning a rescue intervention program including tenofovir (TDF)." | 3.72 | Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. ( Asensi, V; Barrios, A; Dalmau, D; de Mendoza, C; Domingo, P; Estrada, V; Galindo, MJ; Gálvez, J; Martín-Carbonero, L; Ribera, E; Soriano, V, 2003) |
| "Emergence of lamivudine-resistant hepatitis B virus (HBV) is a major concern in human immunodeficiency virus (HIV) and HBV coinfected patients." | 3.72 | In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. ( Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V, 2004) |
| "Lactic acidosis is an uncommon but potentially life-threatening adverse effect of didanosine." | 3.72 | Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. ( Fung, HB; Guo, Y, 2004) |
| "To report a case of pancreatitis associated with the combined use of didanosine and tenofovir." | 3.72 | Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. ( Fulco, PP; Higginson, RT; Kirian, MA, 2004) |
| "Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment." | 3.72 | Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004) |
| "This report investigates the pathomechanism of acute renal failure caused by toxic acute tubular necrosis after treatment with the antiretroviral agent adefovir." | 3.71 | Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. ( Bell, A; D'agati, VD; Kambham, N; Markowitz, GS; Tanji, K; Tanji, N, 2001) |
| "Lamivudine-resistant hepatitis B virus (HBV) is found in about 15-32% of infected patients with or without co-infection with HIV-1 after 1 year of lamivudine therapy." | 3.71 | Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. ( Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P, 2001) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "The therapeutic potential of the antiretroviral drug 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir) for the treatment of human immunodeficiency virus (HIV)- and human hepatitis B virus (HBV) infections is currently being explored in advanced clinical trials." | 3.70 | Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications. ( Hatse, S, 2000) |
| " Current studies include the effects of protease inhibitors on blood sugar, the effectiveness of twice a day Crixivan dosing, the effectiveness of adefovir dipivoxil in combination with protease inhibitors, the effectiveness of DMP 266 in combination with several drugs, and the effects of Oxandrolone on weight loss in women." | 3.70 | CRIA clinical trials. ( , 1998) |
| "Lenacapavir warrants further investigation as a potential antiretroviral used orally and as injection in combination with other antiretroviral drugs." | 3.30 | Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. ( Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA, 2023) |
| " This semimechanistic model describes the population pharmacokinetics of tenofovir when dosed as either TDF or TAF in an African population living with HIV and can be used as a tool for exposure prediction in patients, and to simulate alternative regimes to inform further clinical trials." | 3.30 | Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. ( Chandiwana, N; Denti, P; Kawuma, AN; Maartens, G; Sinxadi, P; Sokhela, SM; Venter, WDF; Wasmann, RE; Wiesner, L, 2023) |
| "Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months." | 3.30 | Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random ( Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F, 2023) |
| " Drug-related adverse events were more frequent with DTG/3TC (15%; leading to discontinuation in 4%) than TAF-based regimens (5%; leading to discontinuation in 1%) through week 144, but rates were comparable after week 48 (4%; leading to discontinuation in 1% in both groups)." | 3.11 | Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F ( Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2022) |
| " We observed significant dose-response relationships between number of HIV risk factors and PrEP drug concentrations." | 3.11 | Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial. ( Anderson, PL; Bekker, LG; Celum, C; Chirenje, ZM; Delany-Moretlwe, S; Donnell, D; Hosek, S; Marzinke, MA; Mgodi, N; Velloza, J, 2022) |
| "A crossover, randomized trial in healthy adults (NCT04244448) investigated the bioavailability of two off-label uses of BIC/TAF/FTC (50/200/25 mg), dissolved in water or crushed in apple compote, compared with the solid tablet." | 3.11 | Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. ( Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C, 2022) |
| " Week 48 virologic suppression (HIV-1 RNA <50 copies/mL), resistance, adverse events (AEs), and laboratory parameters were assessed." | 3.01 | Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. ( Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K, 2021) |
| " Due to binding interactions between polyvalent cations and bictegravir and the potential impact on antiretroviral efficacy, construction of a daily medication schedule to avoid interactions between the antiretroviral regimen and the supplements while promoting optimal dosing of each supplement was necessary; however there is currently no guidance on twice-daily cation dosing with coadministered bictegravir and limited guidance on multivitamin coadministration in this context." | 3.01 | Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature. ( Buscemi, L; Mossholder, B, 2023) |
| " Across the studies, one grade 3/4 adverse event was considered drug-related (intermediate uveitis)." | 3.01 | Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. ( Castro, H; Collins, IJ; Jesson, J; Judd, A; Leroy, V; Milanzi, E; O'Rourke, J; Penazzato, M; Renaud, F; Townsend, CL; Vicari, M, 2023) |
| " We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48 weeks." | 3.01 | Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. ( Avihingsanon, A; Chetchotisakd, P; Kiertiburanakul, S; Martin, H; Ratanasuwan, W; Siripassorn, K; Supparatpinyo, K; Wang, H; Wang, HY; Wong, T, 2023) |
| " Peer-reviewed publications were included if they met all criteria: adults (≥ 18 years of age) living with or without HIV; report any pharmacokinetic parameter or plasma concentration of at least one of the following ARVs: tenofovir alafenamide fumarate (TAF); doravirine (DOR), rilpivirine (RIL) and etravirine (ETR); darunavir (DRV), tipranavir (TPV) and fostemsavir (FTR); dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC) and elvitegravir (EVG); maraviroc (MVC); ibalizumab (IBA); cobicistat (COBI)." | 3.01 | Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review. ( Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG, 2023) |
| "TGM and TGW on at least 6 months of stable sex hormone therapy containing testosterone or estradiol (respectively) were enrolled in a 4-week study of directly observed dosing of daily oral coformulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF)." | 3.01 | Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. ( Anderson, PL; Bhasin, S; Defechereux, PA; Deutsch, MB; Glidden, DV; Grant, RM; O'Neal, J; Pellegrini, M; Sevelius, J; Yager, J; Yu, M, 2021) |
| " This phase I, open-label, 2-period, 1-way study assessed potential pharmacokinetic (PK) interactions between GSK3640254 and tenofovir alafenamide/emtricitabine (TAF/FTC; including the metabolite tenofovir [TFV]) in healthy volunteers." | 3.01 | A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. ( Butcher, L; Davidson, AM; Johnson, M; Joshi, SR; Lataillade, M; Min, S; Pene Dumitrescu, T; Webster, L; Xu, J; Zhan, J; Zimmerman, E, 2021) |
| "Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men." | 3.01 | Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. ( Asmuth, DM; Baeten, JM; Brainard, DM; Brunetta, JM; Carter, C; Cox, S; Das, M; Ebrahimi, R; Gilson, R; Henry, K; Kintu, A; Kronborg, G; Ogbuagu, O; Podzamczer, D; Ruane, PJ; Salazar, LC; Shao, Y; Spinner, CD; Whitlock, G; Wohl, D, 2021) |
| " Drug-related grade ≥2 adverse events and withdrawals due to adverse events occurred in 17 (4." | 2.94 | Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas ( Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B, 2020) |
| "TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)." | 2.94 | Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. ( Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020) |
| "No new HIV infections were observed after PrEP initiation." | 2.94 | Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. ( Baeten, JM; Bekker, LG; Celum, CL; Dallimore, J; Duyver, M; Gill, K; McConnell, M; Mendel, E; Morton, JF; Myers, L; Naidoo, K; Stein, G; Thomas, KK; van der Straten, A; Wiesner, L, 2020) |
| " At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h)." | 2.90 | Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). ( Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM, 2019) |
| "HPTN 067 assessed the feasibility of daily and non-daily dosing of open-label emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)-based pre-exposure prophylaxis (PrEP)." | 2.90 | Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. ( Amico, KR; Franks, J; Grant, RM; Hirsch-Moverman, Y; Hughes, JP; Li, M; Loquere, A; Mannheimer, S, 2019) |
| " Its clinical pharmacokinetic profile and influence on the cellular pharmacology of tenofovir diphosphate have not been reported." | 2.90 | Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. ( Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S, 2019) |
| " Few discontinued due to adverse events (2% D/C/F/TAF arm)." | 2.90 | Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/ ( Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E, 2019) |
| " We conducted a prospective, randomized, crossover pharmacokinetic study of TFV-DP in DBS during 33%, 67%, or 100% of daily dosing under directly observed therapy (DOT)." | 2.87 | Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. ( Anderson, PL; Buchbinder, S; Bushman, LR; Campbell, K; Castillo-Mancilla, JR; Gardner, EM; Ibrahim, M; Kiser, JJ; Liu, AY; MaWhinney, S; McHugh, C; Morrow, M; Seifert, SM; Wagner, T, 2018) |
| " Secondary outcomes included DBS TFV-DP concentrations of >1246 fmol/punch (ie, near-perfect adherence) and plasma FTC >350 ng/mL (consistent with dosing within the past 24 hours)." | 2.87 | Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. ( Anderson, P; Best, BM; Blumenthal, J; Collins, D; Corado, K; Daar, ES; Dubé, MP; Ellorin, E; Haubrich, R; Jain, S; Milam, J; Moore, DJ; Morris, SR; Sun, X; Young, J, 2018) |
| "In this study of 14 days each of vaginal and rectal application of TFV reduced-glycerin 1% gel, we found only a small degree of cross-compartment distribution of TFV in RF and vaginal fluids and no pharmacodynamic activity in ex vivo testing." | 2.87 | Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. ( Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018) |
| " The overall incidence and severity of adverse events was similar between groups, although headache occurred more frequently in the bictegravir group than in the boosted protease inhibitor group." | 2.87 | Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph ( Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P, 2018) |
| "Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug-drug interactions." | 2.84 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. ( Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D, 2017) |
| "The prevalence of obesity has increased dramatically in recent decades worldwide." | 2.82 | Antiretroviral therapy and weight gain in naive HIV-1 infected patient: a narrative review. ( Cyr-Yombi, J; Dupont, E, 2022) |
| " However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovir concentrations." | 2.82 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ ( Abram, ME; Brinson, C; Cheng, AK; Clumeck, N; Daar, ES; DeJesus, E; Gallant, JE; Johnson, M; Morales-Ramirez, J; Osiyemi, O; Plummer, A; Raffi, F; Rhee, MS; Ruane, P; Ward, D; Yan, M, 2016) |
| " The regimen was well tolerated and no discontinuations related to adverse events occurred." | 2.82 | Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. ( Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L, 2016) |
| " No subjects discontinued study drug because of an adverse event in the 48 weeks of randomized phase." | 2.80 | A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. ( Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K, 2015) |
| " Adverse events and serious adverse events were summarised by treatment group." | 2.80 | Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. ( Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A, 2015) |
| "The CAPRISA 004 trial showed that coitally dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently." | 2.80 | Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness. ( Abdool Karim, SS; Gengiah, TN; Karim, QA; Kashuba, AD; Werner, L; White, NR; Yang, KH, 2015) |
| "Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity." | 2.80 | Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. ( Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J, 2015) |
| " Pharmacokinetic sampling was performed on cohort 1 and 3 mothers and all infants." | 2.79 | Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. ( Emel, L; Eshleman, SH; Fowler, MG; George, K; Herron, C; Hudelson, SE; Joao, E; Kearney, B; Kreitchmann, R; Kumwenda, N; Mirochnick, M; Mofenson, L; Nielsen-Saines, K; Parsons, T; Pinto, J; Richardson, P; Santos, B; Sato, P; Taha, T, 2014) |
| " We assessed adherence (compared between groups and with nonstudy controls) and clinical and adverse events at weeks 1, 2 and 4, and efficacy at week 12." | 2.79 | Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. ( Carr, A; Ingersoll, A; McAllister, J; McNulty, A; Read, P; Tong, WW, 2014) |
| "Emtricitabine PK was unaffected." | 2.79 | Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. ( Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X, 2014) |
| "HIV-1 superinfection (SI) occurs when an infected individual acquires a distinct new viral strain." | 2.79 | Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. ( Abdool Karim, Q; Abdool Karim, SS; Bruno, D; Garrett, NJ; Martens, C; Mullis, CE; Porcella, SF; Quinn, TC; Redd, AD; Sheward, D; Wendel, SK; Werner, L; Williamson, C, 2014) |
| " Geometric-mean-ratios compared levels between each pair of dosing conditions." | 2.79 | Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). ( Anderson, PL; Bacchetti, P; Buchbinder, SP; Gandhi, M; Goggin, K; Grant, R; Greenblatt, RM; Huang, Y; Jin, C; Liu, AY; Stojanovski, K; Yang, Q, 2014) |
| " The most commonly observed adverse events were headache, nausea and flatulence, which occurred similarly across the three groups." | 2.79 | Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. ( Coakley, D; Kearney, B; Lee, WA; Markowitz, M; Miller, MD; Ruane, P; Squires, K; Wulfsohn, M; Zhong, L; Zolopa, A, 2014) |
| " The objective of this study was to compare changes in body composition between ritonavir-boosted atazanavir (ATV/r) and ritonavir-boosted lopinavir (LPV/r) over 96 weeks using data from a substudy of CASTLE, which compared once-daily ATV/r with twice-daily LPV/r, both in combination with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve patients with HIV-1 infection." | 2.79 | Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. ( DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ, 2014) |
| "Substance use history and testing for STIs should also inform individual decisions to start pre-exposure prophylaxis." | 2.79 | HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. ( Buchbinder, SP; Glidden, DV; Goicochea, P; Grant, RM; Guanira, JV; Liu, AY; Mayer, KH; McMahan, V, 2014) |
| " Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly study visit." | 2.79 | Adherence in the CAPRISA 004 tenofovir gel microbicide trial. ( Abdool Karim, Q; Abdool Karim, SS; Baxter, C; Grobler, A; MacQueen, KM; Madlala, BT; Mansoor, LE; Yende-Zuma, N, 2014) |
| "Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition." | 2.79 | HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. ( Baeten, JM; Bangsberg, DR; Brantley, J; Bumpus, NN; Celum, C; Donnell, D; Haberer, JE; Hendrix, C; Mugo, N; Mujugira, A; Ndase, P, 2014) |
| "Overall, 71 of 281 raltegravir recipients (25%) and 98 of 282 efavirenz recipients (35%) discontinued the study; discontinuations due to adverse events occurred in 14 (5%) and 28 (10%) patients in the respective groups." | 2.78 | Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. ( DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y, 2013) |
| " The MEMS-defined adherence for correct dosing (-0." | 2.78 | Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. ( Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B, 2013) |
| " HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months." | 2.78 | Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. ( Ackers, ML; Buchbinder, SP; Chillag, KL; Collins, BM; Grant, RM; Grohskopf, LA; Gvetadze, R; Liu, AY; Mayer, KH; Oʼhara, B; Pathak, SR; Paxton, LA; Rose, CE; Thompson, M, 2013) |
| "Pregnancy was assessed with monthly urine tests." | 2.78 | Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. ( Bangsberg, DR; Karim, QA; Mansoor, LE; Matthews, LT; Sibeko, S; Yende-Zuma, N, 2013) |
| " Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro." | 2.78 | Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L, 2013) |
| "To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®))." | 2.78 | Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. ( Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013) |
| " There were no significant differences between the numbers of ≥ Grade 2 adverse events across the arms of the study." | 2.78 | A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). ( Andrew, P; Ayudhya, RK; Carballo-Dieguez, A; Cranston, RD; Dai, JY; Hladik, F; Hoesley, C; Janocko, L; Mayer, K; McGowan, I; Piper, J, 2013) |
| " We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment." | 2.78 | Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. ( Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013) |
| "There were no colposcopic findings or adverse events attributable to either applicator." | 2.78 | A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel. ( Brache, V; Callahan, M; Cochon, L; Cohen, JA; Foster, J; Schwartz, J, 2013) |
| "73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg." | 2.78 | Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013) |
| "The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir." | 2.78 | Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013) |
| " Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation." | 2.78 | Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? ( Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR, 2013) |
| " Once-daily dosing without requirement for a pharmacokinetic booster makes dolutegravir-based therapy an attractive treatment option for HIV-1-infected treatment-naive patients." | 2.78 | Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. ( Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F, 2013) |
| " Median MEMS adherence rates were 98% (IQR: 93-100) for daily PrEP regimen, 91% (IQR: 73-97) for fixed intermittent dosing and 45% (IQR: 20-63) for post-coital dosing." | 2.78 | Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. ( Bahemuka, U; Bangsberg, DR; Barin, B; Bwanika, AN; Chetty, P; Fast, P; Haberer, JE; Kamali, A; Katende, D; Kibengo, FM; Mark, D; Priddy, FH; Rooney, JF; Ruzagira, E, 2013) |
| " Factors associated with these drug-related adverse events are poorly characterized." | 2.78 | Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. ( Baldelli, S; Castagnoli, L; Cattaneo, D; Clementi, E; Fucile, S; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Riva, A; Rizzardini, G, 2013) |
| " There was no significant increase of any genital adverse event in the tenofovir group." | 2.78 | Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. ( Baxter, C; Frolich, J; Grobler, A; Karim, QA; Karim, SS; Kharsany, AB; Maarshalk, S; Mansoor, LE; Miya, N; Mlisana, K; Sibeko, S; Sokal, DC; Yende-Zuma, N, 2013) |
| " Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported." | 2.78 | Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013) |
| " Twenty-four-hour pharmacokinetic curves were recorded in the third trimester (preferably week 33) and postpartum (preferably week 4-6)." | 2.78 | The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. ( Burger, DM; Colbers, AP; Giaquinto, C; Gingelmaier, A; Hawkins, DA; Ivanovic, J; Kabeya, K; Moltó, J; Rockstroh, JK; Sadiq, ST; Taylor, GP; Weizsäcker, K; Wyen, C, 2013) |
| " Drug concentrations at two trough values of 12 and 24 h after dosing (C(12) and C(24)), area under the concentration-curve values (AUC), maximum drug concentration (C(max)), and the time at which this concentration occurred (T(max)) in plasma were estimated with noncompartmental pharmacokinetic methods and compared to data from a subset of white subjects randomized to the RAL twice a day (plus TDF/FTC) arm of the QDMRK study, a phase III study of the safety and efficacy of once daily versus twice daily RAL in treatment naive patients." | 2.78 | Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. ( Blevins, S; Dumond, JB; Eron, JJ; Floris-Moore, M; Hudgens, MG; Kashuba, AD; Massengale, K; Pittard, D; Ragan, D; Richardson, A; Walsh, K; Wang, R; Wohl, DA, 2013) |
| " Overall incidences of all-causality treatment-related or grade 3/4 adverse events (AEs) or AE-related discontinuations were lower with lersivirine than with efavirenz, and serious AEs occurred at similar rates across treatment groups." | 2.78 | Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. ( Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E, 2013) |
| " Serum concentrations after vaginal dosing were 56-fold lower than after oral dosing (p<0." | 2.78 | MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. ( Bumpus, NN; Chen, BA; Gandham, S; Gomez, K; Guddera, V; Hendrix, CW; Hoesley, C; Justman, J; Minnis, AM; Nakabiito, C; Patterson, K; Richardson, BA; Salata, R; Soto-Torres, L, 2013) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s is a prospective, nonblinded, pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including 2 cohorts (with or without tenofovir) receiving atazanavir/ritonavir 300/100 mg once daily during the second trimester, 400/100 mg during the third trimester, and 300/100 mg postpartum (PP)." | 2.78 | Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. ( Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH, 2013) |
| " A subset of patients participated in an intensive pharmacokinetic evaluation of the atazanavir regimen (n = 18) and the lopinavir regimen (n = 21) at week 4." | 2.77 | Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. ( Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L, 2012) |
| "Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings." | 2.77 | Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. ( Anzala, O; Bangsberg, D; Barin, B; Chetty, P; Fast, P; Haberer, JE; Mark, D; Mugo, P; Mutua, G; Priddy, FH; Rooney, JF; Sanders, E, 2012) |
| "During follow-up, no bone fractures were reported to have occurred; 12/368 creatinines and seven out of 305 phosphates were grade one (16) or two (three) in 14 children with no effect of in utero tenofovir (p>0." | 2.77 | Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. ( Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E, 2012) |
| " The use of SF and PK-PD disease models can be a valuable tool to predict dose-response of NMEs and support rational dose selection for monotherapy trials." | 2.77 | From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework. ( Fang, J; Jadhav, PR, 2012) |
| " Safety endpoints included clinical adverse events (AEs) and mucosal safety parameters." | 2.77 | RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. ( Anton, PA; Bumpus, NN; Carballo-Diéguez, A; Cranston, RD; Cumberland, WG; Dennis, R; Elliott, J; Hendrix, CW; Janocko, L; Ju, C; Kashuba, A; Khanukhova, E; Mauck, C; McGowan, I; Richardson-Harman, N, 2012) |
| " Directly observed dosing in a separate study, the STRAND trial, yielded TFV-DP concentrations that, when analyzed according to the iPrEx model, corresponded to an HIV-1 risk reduction of 76% for two doses per week, 96% for four doses per week, and 99% for seven doses per week." | 2.77 | Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. ( Anderson, PL; Bekker, LG; Buchbinder, S; Bushman, LR; Casapía, M; Chariyalertsak, S; Glidden, DV; Grant, RM; Guanira, JV; Kallás, EG; Lama, JR; Liu, A; Mayer, KH; McMahan, V; Montoya-Herrera, O; Schechter, M; Veloso, VG, 2012) |
| " Use of exact dosing data halved unexplained variability in ATV clearance." | 2.77 | Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. ( Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B, 2012) |
| "This is the first pharmacokinetic modelling of antiretroviral disposition in BP and CVF." | 2.77 | Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. ( Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB, 2012) |
| " A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0." | 2.76 | Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S, 2011) |
| "Abacavir has been associated with an increased risk of acute myocardial infarction, but the pathogenic mechanisms remain unknown." | 2.76 | Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. ( García, N; Gutiérrez, F; Jarrin, I; Masiá, M; Padilla, S; Tormo, C, 2011) |
| " Decreases in estimated glomerular filtration rate occurred within the first few weeks of dosing in participants receiving EVG/COBI/FTC/TDF, remained within the normal range and did not progress at week 24 or 48; no participant experienced a clinical adverse event or discontinued study drug due to changes in serum creatinine or renal function." | 2.76 | Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. ( Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K, 2011) |
| " nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients." | 2.76 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011) |
| "ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)." | 2.76 | Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011) |
| "The probability of bone fractures and time to first fracture were not different across components." | 2.76 | Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG ( Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C, 2011) |
| " We report the pharmacokinetic parameters of tenofovir in combination with efavirenz, darunavir-ritonavir, or atazanavir-ritonavir in HIV-infected children." | 2.76 | Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. ( Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R, 2011) |
| "Significant pharmacokinetic interactions can result between acid-suppressing agents and some protease inhibitors (PIs) in the management of HIV infection." | 2.76 | Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. ( Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L, 2011) |
| " All regimens were safe and well tolerated." | 2.76 | Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. ( Bardeguez, A; Cotter, A; Fiscus, SA; Flynn, PM; Heckman, B; Huang, S; Jean-Philippe, P; Kearney, B; Mirochnick, M; Mofenson, LM; Purswani, M; Robbins, B; Rodman, J; Rooney, JF; Shapiro, DE; Thorpe, E; Van Rompay, KK; Watts, DH, 2011) |
| "Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies/mL and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a double-blind, noninferiority study to receive raltegravir or efavirenz, each combined with tenofovir/emtricitabine." | 2.76 | Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. ( Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J, 2011) |
| "Objective An open-label, three-period pharmacokinetic study was conducted to investigate the drug interaction potential between fosamprenavir (FPV) and tenofovir disoproxil fumarate (TDF)." | 2.75 | Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. ( Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD, 2010) |
| "Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year." | 2.75 | Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010) |
| " Treatment-related gastrointestinal adverse events were greater in patients taking lopinavir/ritonavir." | 2.75 | Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. ( Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R, 2010) |
| "Nucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown." | 2.75 | The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. ( Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A, 2010) |
| " The adverse event rate was similar between arms (except drug hypersensitivity, reported more in the abacavir/lamivudine arm)." | 2.75 | Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. ( Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C, 2010) |
| " No increase in the overall adverse event rates was observed." | 2.75 | Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. ( Abdool Karim, Q; Abdool Karim, SS; Arulappan, N; Baxter, C; Frohlich, JA; Gengiah, TN; Grobler, AC; Kharsany, AB; Maarschalk, S; Mansoor, LE; Mlisana, KP; Mlotshwa, M; Morris, L; Omar, Z; Sibeko, S; Taylor, D, 2010) |
| " Through 96 weeks, 77 subjects from each group discontinued prematurely; adverse or HIV-related events contributed to discontinuation of 36 subjects overall, with no significant differences between treatment groups." | 2.75 | Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t ( Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L, 2010) |
| "This study evaluated the relative bioavailability and pharmacokinetics of elvitegravir (EVG), emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), and a investigational pharmacoenhancer, cobicistat (GS-9350, COBI) coformulated as a fixed-dose combination tablet (FDC) compared with ritonavir-boosted EVG and FTC + TDF in healthy subjects." | 2.75 | Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. ( German, P; Hui, J; Kearney, BP; Warren, D; West, S, 2010) |
| "A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir." | 2.75 | Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. ( DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J, 2010) |
| " Pharmacokinetic data were available in 577 patients randomized to receive etravirine." | 2.75 | Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. ( Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ, 2010) |
| " Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals." | 2.75 | Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. ( Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF, 2010) |
| "Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus." | 2.74 | Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. ( Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K, 2009) |
| "Etravirine was administered as either 800 mg twice a day (bid) (phase II formulation in Study 1) or 200 mg bid (phase III formulation in Study 2) for 8 days followed by a 12 h pharmacokinetic evaluation." | 2.74 | Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. ( Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ, 2009) |
| " The only available formulation is an adult tablet, introducing the possibility of dosing errors in children." | 2.74 | Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. ( Boyd, K; Butler, K; Cliff, D; Doerholt, K; Gibb, D; Judd, A; Lyall, H; Menson, E; Riordan, A, 2009) |
| " Statistical analyses were performed on pharmacokinetic parameters: the area under the concentration-time curve from 0 to 4 h (AUC(0-4)), the maximum concentration of the drug (C(max)), and the residual concentration of the drug at the end of the dosing interval (C(trough)) for plasma and the AUC(0-4) and C(trough) for intracellular data." | 2.74 | Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. ( Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F, 2009) |
| " Significantly fewer drug-related clinical adverse events occurred in patients on raltegravir (n=124 [44." | 2.74 | Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. ( Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J, 2009) |
| "This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care." | 2.74 | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. ( Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW, 2009) |
| " Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily." | 2.74 | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). ( Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009) |
| " Pharmacokinetic profiles were also determined in HIV-1-infected patients dosed with raltegravir monotherapy versus raltegravir in combination with TDF and lamivudine." | 2.73 | Lack of a significant drug interaction between raltegravir and tenofovir. ( Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA, 2008) |
| "In two randomized, controlled trials, small differences in glomerular filtration rate over time were noted but no clinically relevant renal disease or adverse events were demonstrated in antiretroviral-naive patients treated with TDF through 144 weeks." | 2.73 | The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. ( Chen, SS; Cheng, AK; DeJesus, E; Enejosa, JV; Gallant, JE; Pozniak, AL; Winston, JA, 2008) |
| " Although frequency of severe renal toxicity was higher than has been reported in the literature, it was safe in patients with no comorbid renal conditions." | 2.73 | Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. ( Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S, 2008) |
| "Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients." | 2.73 | Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. ( Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA, 2008) |
| " Despite a twofold increase tenofovir plasma concentrations, no serious drug-related adverse event were recorded except for one patient experiencing an de Fanconi syndrome at week 2." | 2.73 | Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. ( Aubron-Olivier, C; Calvez, V; Deray, G; Dominguez, S; Ghosn, J; Izzedine, H; Katlama, C; Ktorza, N; Miller, M; Peytavin, G; Trylesinski, A; Wirden, M, 2007) |
| " Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA." | 2.73 | No change in calculated creatinine clearance after tenofovir initiation among Thai patients. ( Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S, 2007) |
| " Pharmacokinetic parameters estimated by noncompartmental method were reported as 90% confidence intervals (CIs) about the geometric mean ratio (GMR)." | 2.73 | Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. ( Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M, 2007) |
| "Atazanavir/ritonavir plasma concentrations were measured by liquid chromatography tandem mass spectrometry, and the geometric means of minimum and maximum concentrations (C(min), C(max)), the area under the time-concentration curve (AUC), half-life (t(1/2)) and total clearance (CL(tot)) were subject to a matched pairs-analysis." | 2.73 | Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. ( Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N, 2007) |
| "Changing from drugs that have significant mitochondrial toxicity to less toxic compounds may be of benefit in human immunodeficiency virus (HIV)-positive patients who receive highly active antiretroviral therapy." | 2.73 | Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. ( Cossarizza, A; Dentone, C; Di Biagio, A; Esposito, R; Ferraresi, R; Mussini, C; Nasi, M; Nemes, E; Pinti, M; Repetto, E; Rosso, R; Viscoli, C, 2008) |
| "Maraviroc 300 mg b." | 2.73 | The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ( Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA, 2008) |
| "Sexually-transmitted infections (STIs) continue to rise worldwide, imposing an enormous morbidity and mortality burden." | 2.72 | Topical microbicides for preventing sexually transmitted infections. ( Mwethera, PG; Obiero, J; Ogongo, P; Wiysonge, CS, 2021) |
| " Although 92% of the women reported at least one adverse event, the majority were mild (87%) and involved the genitourinary tract (70%)." | 2.72 | Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. ( El-Sadr, WM; Eshleman, SH; Gai, F; Hendrix, C; Justman, J; Kwiecien, A; Maslankowski, LA; Mâsse, B; Mayer, KH; Morrow, K; Rooney, JF; Soto-Torres, L, 2006) |
| " Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25." | 2.72 | Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. ( Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S, 2006) |
| " The steady-state, geometric mean AUC for the 24-h dosing interval was 2,920 ng." | 2.71 | Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. ( Balis, FM; Blanche, S; Bresson, JL; Coakley, DF; DeCarlo, E; Flaherty, JF; Hazra, R; Kearney, BP; Poblenz, M; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL; Zhong, L; Zuckerman, JA, 2004) |
| "Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C(min)), and virologic response." | 2.71 | Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. ( Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D, 2004) |
| " Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)." | 2.71 | Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. ( Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004) |
| "Adefovir dipivoxil was recently approved for the treatment of wild-type and lamivudine-resistant hepatitis B virus (HBV) infection." | 2.71 | Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. ( Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T, 2004) |
| "Treatment with nelfinavir was continued for another 7 days with the addition of 300 mg tenofovir once daily." | 2.71 | The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. ( Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H, 2005) |
| "Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy." | 2.71 | Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. ( Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B, 2005) |
| " We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children." | 2.71 | Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. ( Balis, FM; DeCarlo, E; Flaherty, J; Gafni, RI; Hazra, R; Kearney, BP; Maldarelli, F; Steinberg, SM; Tullio, AN; Worrell, CJ; Yale, K; Zeichner, SL, 2005) |
| "A total of 33 participants developed proximal renal tubular dysfunction during the trial, all but one in the ADV group." | 2.70 | A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. ( , 2002) |
| " Grade III or IV adverse events were limited to laboratory abnormalities, including elevated creatine phosphokinase and liver function tests, which resolved with or without drug discontinuation and without sequelae." | 2.70 | Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. ( Barditch-Crovo, P; Coakley, DF; Coleman, RL; Collier, A; Deeks, SG; Kahn, JO; Kearney, BP; Lamy, PD; Lietman, PS; McGowan, I; Miller, M; Safrin, S, 2001) |
| " All subjects tolerated dosing without significant adverse events." | 2.69 | Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. ( Barditch-Crovo, P; Cundy, KC; Deeks, SG; Hellmann, NS; Hwang, F; Kahn, JO; Lietman, PS; Rooney, JF; Safrin, S, 1998) |
| "Treatment for chronic hepatitis B as a once-daily oral dose was well tolerated and associated with significant and sustained reductions in serum HBV DNA levels during treatment." | 2.69 | A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. ( Chopra, KB; Gilson, RJ; Jaffe, HS; Murray-Lyon, IM; Nelson, MR; Newell, AM; Rice, SJ; Tedder, RS; Toole, J; Weller, IV, 1999) |
| " Patients were monitored for adverse effects." | 2.69 | Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group. ( Blanchard, S; Burchett, S; Coakley, DF; Culnane, M; Cundy, KC; Fridland, A; Hughes, WT; Purdue, L; Read, JS; Rodman, JH; Shenep, JL; Willoughby, R; Zimmer, B, 2000) |
| " These drug-drug interactions were not expected, the mechanism(s) is (are) not clear, and additional studies are warranted." | 2.69 | Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884. ( Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP, 2000) |
| "0 mg/kg of body weight were dose proportional and declined biexponentially, with an overall mean +/- standard deviation terminal half-life of 1." | 2.68 | Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. ( Barditch-Crovo, P; Collier, AC; Cundy, KC; Ebeling, D; Jaffe, HS; Toole, J; Walker, RE, 1995) |
| " Repeat infusions of PMEA at a dose of 1000 mg were safe and well tolerated." | 2.68 | Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study. ( Arends, S; Kamp, W; Schokker, J; van Halteren, E, 1996) |
| " Gastrointestinal complaints and reversible liver transaminase elevations were the most frequently noted adverse events." | 2.68 | Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. ( Barditch-Crovo, P; Cundy, KC; Ebeling, D; Hendrix, CW; Jaffe, HS; Lietman, PS; Toole, J, 1997) |
| "Adefovir dipivoxil is a novel nucleotide analogue with several promising in vitro anti-human immunodeficiency virus (HIV) characteristics." | 2.68 | The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. ( Cherrington, JM; Collier, A; Deeks, SG; Drew, WL; Hellmann, N; Jaffe, HS; Kahn, J; Lalezari, J; Lamy, PD; Li, W; Mulato, AS; Pavia, A; Rodrigue, D; Toole, J, 1997) |
| " Both treatments were safe and well-tolerated, and most adverse events were similar as mild to moderate in severity." | 2.66 | Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. ( Chen, Y; Lu, Y; Tao, X; Zhang, L; Zhou, Y, 2020) |
| " Recent dosing measures include antiretroviral levels in plasma or urine, as well as emtricitabine-triphosphate in dried blood spots (DBS) for those on tenofovir-emtricitabine-based therapy." | 2.66 | Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. ( Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA, 2020) |
| " BIC has demonstrated a high genetic barrier to resistance development in vitro, can be administered with or without food, and has a bioavailability of > 70%." | 2.61 | Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. ( Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J, 2019) |
| "Darunavir (DRV) was the last approved protease inhibitor (PI) and has been extensively used for the treatment of HIV in both naïve and experienced subjects due to its high genetic barrier and efficacy." | 2.58 | Darunavir for the treatment of HIV infection. ( Castagna, A; Lazzarin, A; Spagnuolo, V, 2018) |
| "Proteinuria is also now recognized as a common finding in individuals living with HIV." | 2.55 | Renal effects of novel antiretroviral drugs. ( Jones, R; Levy, JB; Milburn, J, 2017) |
| "TAF has a similar tolerability, safety, and effectiveness to TDF and probably less adverse events related to renal and bone density outcomes in the treatment of naive and experienced patients with HIV-1." | 2.53 | The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis. ( Lu, X; Wang, H; Xu, N; Yang, X, 2016) |
| " A dosing regimen according to body-weight-band has been established for pediatric use." | 2.52 | Review of tenofovir use in HIV-infected children. ( Aurpibul, L; Puthanakit, T, 2015) |
| " As a fixed-dose combination tablet given once daily, EFV/FTC/TDF was the first available STR combining efficacy, tolerability and convenience, with the simplest dosing schedule and smallest numbers of pills of any ART combination therapy." | 2.50 | Single-tablet regimens in HIV: does it really make a difference? ( Aldir, I; Horta, A; Serrado, M, 2014) |
| "Despite improvements in access to antiretroviral therapy and the use of simplified dosing regimens, HIV infection is still an important global public health problem." | 2.50 | An overview of antiretroviral pre-exposure prophylaxis of HIV infection. ( McGowan, I, 2014) |
| " Bayesian fixed-effect network meta-analysis models adjusting for the type of nucleoside reverse transcriptase inhibitor backbone (tenofovir disoproxil fumarate/emtricitabine [TDF/FTC] or abacavir/lamivudine [ABC/3TC]) were used to evaluate week 48 efficacy (HIV-RNA suppression to <50 copies/mL and change in CD4+ cells/µL) and safety (lipid changes, adverse events, and discontinuations due to adverse events) of DTG relative to all other treatments." | 2.50 | 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. ( Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY, 2014) |
| " However, since pre-exposure prophylaxis involves long-term administration of drugs to healthy individuals, it is important to monitor the long-term safety of FTC/TDF (e." | 2.49 | Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. ( Plosker, GL, 2013) |
| " In July of 2012, tenofovir/emtricitabine (TDF/FTC) was approved by the American Food and Drug Administration (FDA) for pre-exposure prophylaxis (PrEP) for long-term use in persons who exhibit frequent risky and unsafe sexual behaviour." | 2.49 | [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. ( Boot, J; Boucher, CA; Burger, DM; Fanoy, EB; Op de Coul, EL; Rump, BO; van Agtmael, MA; van de Vijver, DA, 2013) |
| "Several drugs are available to treat hepatitis B." | 2.49 | Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. ( Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L, 2013) |
| " Dosing strategies (e." | 2.48 | Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. ( Adams, JL; Kashuba, AD, 2012) |
| " There is a need for an effective and safe first-line regimen, to cope with the ever-increasing incidence of non-adherence and primary resistance." | 2.48 | WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. ( Okwundu, CI; Omeje, I, 2012) |
| " Although some trial results appear conflicting, behavioral factors, adherence to dosing and pharmacokinetic properties of the different tenofovir formulations and dosing approaches offer plausible explanations for most of the variations in effectiveness observed in different trials." | 2.48 | A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. ( Abdool Karim, SS; Baxter, C; Gengiah, TN; Kharsany, AB; Mansoor, LE, 2012) |
| "Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective." | 2.48 | New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012) |
| " Raltegravir must be dosed twice daily, as once daily raltegravir displays decreased virologic efficacy compared to twice daily dosing." | 2.48 | Role of raltegravir in HIV-1 management. ( Bookstaver, PB; Bryant, JE; Millisor, VE; Rokas, KE; Shamroe, CL; Sutton, SS; Weissman, SB, 2012) |
| "Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent." | 2.48 | Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012) |
| " There is a need for an effective and safe first-line regimen, to cope with the ever-increasing incidence of non-adherence and primary resistance." | 2.48 | WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. ( Okwundu, CI; Omeje, I, 2012) |
| " Optimal PrEP agents and dosing regimens now need to be identified." | 2.48 | Considerations regarding antiretroviral chemoprophylaxis in MSM. ( Grulich, AE; Poynten, IM; Zablotska, I, 2012) |
| "The Microbicide Trials Network 003 study, a large phase IIb trial, was unable to show that daily dosing with 1% tenofovir vaginal gel was effective for HIV prevention." | 2.48 | Current status of topical antiretroviral chemoprophylaxis. ( Szpir, M; Van Damme, L, 2012) |
| " Vaginal dosing achieves measurable tenofovir concentrations in the rectum and vice versa." | 2.48 | The clinical pharmacology of antiretrovirals for HIV prevention. ( Hendrix, CW, 2012) |
| "Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population, and it may worsen with HIV or be detected as HIV cutaneous manifestation." | 2.48 | Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). ( Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R, 2012) |
| " This review identifies important cellular pharmacology considerations for tenofovir and emtricitabine, which include drug penetration into relevant tissues and cell types, race/ethnicity/pharmacogenetics, gender, cellular activation state and appropriate episodic or alternative dosing strategies based on pharmacokinetic principles." | 2.47 | Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. ( Anderson, PL; Gardner, EM; Grant, RM; Kiser, JJ; Meditz, A; Rower, JE, 2011) |
| "Hypogonadism was first described in the setting of advanced AIDS and can be primary or secondary." | 2.47 | Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. ( Cotter, AG; Powderly, WG, 2011) |
| " More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy." | 2.47 | Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ( Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011) |
| " Despite its proven efficacy and safety, cases of kidney tubular dysfunction have increasingly been reported and concern exists about the risk of nephrotoxicity associated with the long-term use of TFV." | 2.46 | Renal toxicity associated with tenofovir use. ( Alvarez, E; Labarga, P; Rodriguez-Nóvoa, S; Soriano, V, 2010) |
| " Its favorable profile in terms of high efficacy, low toxicity and once-daily dosing makes TDF one of the most attractive antiretroviral agents, and therefore, it is widely used." | 2.45 | Pharmacogenetics of tenofovir treatment. ( Labarga, P; Rodriguez-Novoa, S; Soriano, V, 2009) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | 2.44 | Treatment of chronic hepatitis B infection: an update of Swedish recommendations. ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "In patients not requiring HAART, treatment of hepatitis B should preferably consist of drugs without activity against HIV, such as pegylated interferon or adefovir." | 2.44 | [Hepatitis B in patients with HIV infection]. ( Barreiro, P; García-Samaniego, J; Martín-Carbonero, L, 2008) |
| " This drug is administered orally in the form of disoproxil ester, which is deesterified to achieve a bioavailability of more than 20%." | 2.44 | [Tenofovir: pharmacology and interactions]. ( Azanza, JR; García Quetglas, E; Gómez-Giu, A; Sádaba, B, 2008) |
| " Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors." | 2.44 | [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors]. ( Fiorante, S; Pulido, F, 2008) |
| " regimen and it's recommended by most of the clinical guidelines as a start regimen in combination with two other drugs." | 2.44 | [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors]. ( Arribas López, JR; Bernardino de la Serna, JI; Mora Rillo, M, 2008) |
| "The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy." | 2.44 | [Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008) |
| " Individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose." | 2.44 | Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? ( Best, B; Goicoechea, M, 2007) |
| "Acute renal failure is common in HIV-infected patients and is associated with acute infection and medication-related nephrotoxicity." | 2.44 | HIV-1 infection and the kidney: an evolving challenge in HIV medicine. ( de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA, 2007) |
| " Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication." | 2.43 | Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. ( Lyseng-Williamson, KA; Plosker, GL; Reynolds, NA, 2005) |
| " These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice." | 2.43 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005) |
| " When atazanavir 300 mg was coadministered with ritonavir 100 mg on a once-daily dosage regimen, atazanavir AUC from 0 to 24 hours and minimum plasma concentration were increased by 3- to 4-fold and approximately 10-fold, respectively, compared with atazanavir 300 mg alone." | 2.43 | Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. ( Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM, 2005) |
| " Physicochemical properties, cellular permeation, renal toxicity, and bioavailability all had to be addressed during the development of these compounds." | 2.43 | Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. ( Lee, WA; Martin, JC, 2006) |
| " However, early HAART often consisted of drugs with complex dosing schedules, strict food requirements, treatment-limiting adverse effects, and the need to take 16-20 pills/day." | 2.43 | An update and review of antiretroviral therapy. ( Piacenti, FJ, 2006) |
| " Tenofovir requires surveillance of glomerular filtration rate and dosing interval adjustment when creatinine clearance is less than 50 ml/min and avoidance less than 30 ml/min." | 2.43 | Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. ( Arribas López, JR; Muñoz de Benito, RM, 2006) |
| " The approved dosage of tenofovir is 300 mg (one tablet) once/day with meals." | 2.42 | Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. ( Antoniou, T; Park-Wyllie, LY; Tseng, AL, 2003) |
| "The treatment plan for chronic hepatitis B needs to be individualized based on the stage of both viral infections and the available options." | 2.42 | Management of chronic hepatitis B in the HIV-infected patient. ( Thio, CL, 2004) |
| " The oral bioavailability of tenofovir is enhanced by administration with a high-fat meal, but is similar at steady state when administered with or without a typical meal." | 2.42 | Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. ( Flaherty, JF; Kearney, BP; Shah, J, 2004) |
| "In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy." | 2.42 | Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| " The recommended dosage of tenofovir DF in adults is 300 mg/d PO; pharmacokinetic and efficacy studies in children are ongoing." | 2.41 | Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. ( Fung, HB; Piacenti, FJ; Stone, EA, 2002) |
| " Our existing PK model, supported by an intravenous (IV) dosing dog study, was adapted to analyze mechanistic aspects underlying implant TAF delivery." | 1.91 | Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis. ( Baum, MM; Beliveau, M; Fanter, R; Gallay, PA; Gunawardana, M; Kuo, J; Marzinke, MA; Moss, JA; Ramirez, CM; Remedios-Chan, M; Sanchez, D; Trinh, M; Webster, P; Webster, S, 2023) |
| "Dolutegravir is a comparatively recent molecular entity that represents an advance over previous products." | 1.91 | Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor. ( Lunn, G, 2023) |
| "Although this weight gain is a multifactorial process in which lifestyle habits, physical exercise or diet have a great impact, antiretroviral treatment has been recently considered as one of the key causes of this increase according to different clinical trials and real-life cohorts." | 1.91 | Weight gain in HIV-infected patients. ( Galindo, MJ; González, CS; Lillo, IS; Rodríguez, AP, 2023) |
| " Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15-29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90-149 mL/min)." | 1.91 | Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. ( Alves Saldanha, S; Andre, P; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Desfontaine, V; Guidi, M; Kusejko, K; Thoueille, P, 2023) |
| " However, there is little data regarding the impact of this drug-drug Interaction in PLWH, which makes health care providers reluctant to prescribe them together." | 1.91 | The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report. ( Alamer, A; Almulhim, A; Alrashed, A; Alwafai, S; Cahusac, P; Damfu, N; Mohzari, YA; Musawa, MA; Zaeri, B, 2023) |
| "Lactic acidosis is a rare but serious side effect in individuals receiving nucleoside reverse transcriptase inhibitors." | 1.91 | Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient. ( Isoda, A; Matsumoto, M; Mihara, M; Sawamura, M, 2023) |
| "The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications." | 1.72 | Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). ( Antoniak, S; Begovac, J; Dragovic, G; Fleischhans, L; Gokengin, D; Harxhi, A; Hofman, S; Jilich, D; Kase, K; Kowalska, J; Lakatos, B; Matulionyte, R; Oprea, C; Papadopoulus, A; Rukhadze, N; Vassilenko, A; Vasyliev, M; Verhaz, A; Wasilewski, P; Yancheva, N, 2022) |
| " Systemic drug disposition during TAF implant dosing was explained by a multi-compartment pharmacokinetic (PK) model." | 1.72 | Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. ( Baum, MM; Beliveau, M; Buser, C; Caprioli, RM; Castonguay, AE; Gallay, PA; Gunawardana, M; Hendrix, CW; Kuo, J; Marzinke, MA; Moss, JA; Remedios-Chan, M; Reyzer, ML; Sanchez, D; Trinh, M; Tuck, M; Webster, P; Webster, S, 2022) |
| "In individuals with a history of PRT on TDF, 96 weeks of TAF was not associated with recurrent PRT or adverse effects on renal tubular function, bone turnover, or BMD." | 1.62 | Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate. ( Barbini, B; Burling, K; Campbell, L; Cromarty, B; Hamzah, L; Johnson, M; Jones, R; Post, FA; Samarawickrama, A; Williams, D; Winston, A, 2021) |
| " Because TDF can lead to renal impairment and a decrease in bone mineral density (BMD), the prodrug tenofovir alafenamide (TAF) may be considered a viable alternative with fewer adverse effects." | 1.62 | Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. ( Achterfeld, A; Herzer, K; Rashidi-Alavijeh, J; Straub, K; Wedemeyer, H; Willuweit, K, 2021) |
| "Pregnant women receiving TAF 10 mg with cobicistat or TAF 25 mg without boosting as part of clinical care had intensive pharmacokinetic assessments performed during the second and third trimesters, and 6-12 weeks postpartum." | 1.62 | Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. ( Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A, 2021) |
| " In rats, systemic and local findings were considered not adverse due to their low severity and reversibility; therefore, the "no observed adverse effect level" (NOAEL) was set at 1,000 μg/kg/day." | 1.62 | A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs. ( Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D, 2021) |
| " With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily." | 1.56 | Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV. ( Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T, 2020) |
| "Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF." | 1.56 | Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. ( Freedberg, KA; Horn, T; McCann, NC; Paltiel, AD; Walensky, RP, 2020) |
| "Conclusions: The patients were generally satisfied with the change in medication and well nformed about the dosage and advantages of TAF over TDF, but less well informed about the possible adverse effects of TAF." | 1.56 | Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine ( Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M, 2020) |
| "The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations." | 1.56 | Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. ( Arribas, JR; Del Amo, J; Díaz, A; Hernán, MA; Jarrín, I; Martínez, E; Moreno, S; Polo, R, 2020) |
| "Acute pancreatitis has also been reported recently with another INSTI, dolutegravir." | 1.56 | Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis. ( Goffard, JC; Henrard, S; Noure, L; Simeni Njonnou, SR, 2020) |
| "A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped." | 1.56 | Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. ( Cattaneo, D; Filice, C; Gervasoni, C; Riva, A, 2020) |
| " These findings provide reassurance that the combination of TAF, boosted PIs and ledipasvir/sofosbuvir is safe in HIV/HCV-coinfected populations." | 1.56 | Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. ( Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH, 2020) |
| " Using a murine model, we compared the plasma and tissue pharmacokinetics of TFV and various TFV prodrugs, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and hexadecyloxypropyl tenofovir (CMX157), after dosing as enema formulations with varying osmolality and ion content." | 1.51 | Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema. ( Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW, 2019) |
| "A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed." | 1.51 | Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide. ( Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N, 2019) |
| " IM SMC concentrations were low relative to PBMC, as were EN concentrations, suggesting differences in cell phenotype and lineage in the MGT; these differences in phenotype and pharmacology may have an impact on selecting and dosing ARVs used in cure strategies." | 1.51 | Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. ( Blake, KH; Chen, J; Cohen, MS; Dumond, JB; Gay, CL; Greene, SA; Kashuba, ADM; Maas, BM; Nelson, JAE; Prince, HMA; Schauer, AP; Sykes, C, 2019) |
| "High urine FTC and TFV concentrations could provide an indication of adherence to daily oral dosing with TDF or TAF-based regimens used for treatment and prevention." | 1.51 | Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. ( Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A, 2019) |
| " Although colonic biopsies should be collected in the absence of medium for accurate TFV concentrations, the presence of medium does not significantly impact TFV-DP-dependent pharmacokinetic or pharmacodynamic assays." | 1.48 | Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements. ( Bakshi, RP; Breakey, J; Fuchs, EJ; Jois, B; Manohar, M; Marzinke, MA, 2018) |
| "A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic study in patients receiving a TDF-containing regimen (TDF 300 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg) switched to a TAF-containing FDC regimen (TAF 10 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg)." | 1.48 | Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. ( Bares, SH; Dyavar, SR; Fletcher, CV; Havens, J; Lee, S; O'Neill, J; Podany, AT; Scarsi, KK; Swindells, S, 2018) |
| "Pregnancy is a time of increased HIV acquisition risk and pregnancy reduces concentrations of antiretrovirals used for treatment." | 1.48 | Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. ( Anderson, PL; Asiimwe, S; Baeten, JM; Bukusi, EA; Celum, C; Donnell, D; Haberer, JE; Heffron, R; Hendrix, CW; Katabira, E; Marzinke, MA; Mugo, NR; Mugwanya, K; Pyra, M; Thomas, KK, 2018) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 1.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| "Dapivirine was also impacted by microbiota, as drug bound irreversibly to bacteria, resulting in decreased antiviral activity." | 1.48 | Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics. ( Cameron, SA; Cheshenko, N; Frank, B; Fredricks, D; Herold, BC; Keller, MJ; Mesquita, PM; Reagle, K; Sinclair, S; Srinivasan, S; Taneva, E; Weinrick, B, 2018) |
| " Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations." | 1.48 | A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. ( Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018) |
| "Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)." | 1.46 | Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017) |
| "For emtricitabine, FGT:plasma was significantly lower in participant visits with low- vs intermediate-diversity mCT groups (P = ." | 1.46 | The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy. ( Donahue Carlson, R; Frisch, MB; Haaland, RE; Kraft, CS; Martin, A; Mehta, CC; Ofotokun, I; Patel, AS; Pau, CP; Read, TD; Sheth, AN, 2017) |
| " There were no discontinuations due to adverse events." | 1.43 | Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. ( Custodio, JM; Fordyce, M; Garner, W; Kearney, BP; Ling, KH; Ramanathan, S; Vimal, M, 2016) |
| "We present two cases of suspected tinea-immune reconstitution inflammatory syndrome from a large HIV clinic in rural Tanzania." | 1.43 | Immune reconstitution inflammatory syndrome associated with dermatophytoses in two HIV-1 positive patients in rural Tanzania: a case report. ( Hatz, C; Letang, E; Mapesi, H; Ramírez, A; Tanner, M, 2016) |
| "Kaposi sarcoma is a highly vascularised tumour affecting the skin, lymph nodes and viscera." | 1.42 | An interesting case of 'diabetic foot ulcer' in an HIV-positive patient. ( Chima-Okereke, C; Sivaprakasam, V, 2015) |
| "Due to the differences between bioavailability of efavirenz (EFV) and tenofovir (TDF), the single-tablet regimen of EFV/emtricitabine (FTC)/TDF is not approved as initial antiretroviral therapy (ART) in Europe by the European Medical Agency." | 1.42 | Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1. ( De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N, 2015) |
| "Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides." | 1.42 | Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. ( Agashe, H; Akil, A; Devlin, B; Dezzutti, CS; Hillier, SL; Moncla, BJ; Rohan, LC; Shi, Y; Uranker, K, 2015) |
| "Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir." | 1.42 | Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. ( Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S, 2015) |
| " As these anti-HIV lipid nanoparticles also prolonged plasma drug exposure, they hold promise as a long-acting dosage form for HIV patients in addressing residual virus in cells and tissue." | 1.42 | Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. ( Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J, 2015) |
| " These results provide a framework for future early investigations of antiretroviral efficacy in HIV prevention to optimize dosing strategies in clinical investigations." | 1.42 | Models for predicting effective HIV chemoprevention in women. ( Cohen, MS; Emerson, CW; Fedoriw, Y; Geller, EJ; Kashuba, AD; Nelson, JA; Nicol, MR; Patterson, KB; Prince, HM; Sykes, C, 2015) |
| " No serious adverse event related to tenofovir." | 1.42 | Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. ( Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O, 2015) |
| " Adherence to the dosing regimen has emerged as a critical factor determining efficacy outcomes of clinical trials." | 1.42 | Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. ( Baum, MM; Beliveau, M; Fanter, R; Gunawardana, M; Hendrix, CW; Marzinke, MA; Miller, CS; Moss, JA; Remedios-Chan, M; Smith, TJ; Yang, F, 2015) |
| "Intensive pharmacokinetic studies of tenofovir in a large, diverse cohort of HIV-infected women over 24 h at steady state were performed and factors that influenced exposure [assessed by areas under the concentration-time curves (AUCs)] identified." | 1.40 | Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. ( Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M, 2014) |
| " A dosage form containing DPV must be able to deliver the drug to the tissue site of action." | 1.40 | Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir. ( Akil, A; Cost, M; Devlin, B; Rohan, LC, 2014) |
| " A control group (n=34) received no drug, a second group (n=6) received oral tenofovir disoproxil fumarate/emtricitabine 3 days before each virus challenge and a third group (n=6) received the same dosing plus another dose 2 h after virus challenge." | 1.40 | Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. ( Anderson, PL; Bushman, LR; García-Lerma, JG; Glidden, DV; Heneine, W, 2014) |
| "This immune reconstitution inflammatory syndrome (TB-IRIS) can lead to significant morbidity and needs to be distinguished from TB recurrence due to ineffective treatment." | 1.40 | Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome. ( Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C, 2014) |
| "Nevirapine is an inducer of hepatic metabolism." | 1.40 | Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. ( Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014) |
| " The granule form carries a risk of dosing errors and has a particularly strong, unpleasant taste." | 1.40 | Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys. ( , 2014) |
| " No adverse events were observed, and there were no toxicological findings." | 1.40 | Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. ( Baum, MM; Brooks, AA; Butkyavichene, I; Dinh, CT; Lopez, G; Martin, A; Moss, JA; Smith, JM; Smith, TJ; Srinivasan, P, 2014) |
| " The authors studied ATV pharmacokinetic (PK) parameters among children who received atazanavir/ritonavir co-administered with TDF." | 1.40 | Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate. ( Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N, 2014) |
| "Liver fibrosis was measured using elastometry." | 1.40 | Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. ( Barreiro, P; Fernández-Montero, JV; Labarga, P; Mendoza, Cd; Sierra-Enguita, R; Soriano, V; Vispo, E, 2014) |
| "Hypertension was diagnosed in 19%, dyslipidemia in 27%, and diabetes mellitus in 3%." | 1.40 | High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors. ( Aiestarán, A; Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez, V; Pérez-Alvarez, N; Puig, J; Romero, R, 2014) |
| " Noncompartmental pharmacokinetic analysis was used to estimate PK parameters [area under the concentration-time curve over 24 h (AUC0-24h ) and maximal concentration (Cmax )]." | 1.39 | Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. ( Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N, 2013) |
| "HIV worsens the natural history of chronic hepatitis B virus (HBV) infection." | 1.39 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. ( Aguilera, A; Barreiro, P; del Romero, J; Mena, A; Pedreira, J; Plaza, Z; Poveda, E; Rodriguez, C; Sierra-Enguita, R; Soriano, V; Tomé, S; Vispo, E, 2013) |
| "Abacavir (ABC) has been associated with ischaemic cardiovascular events in HIV-infected patients, but the pathogenic mechanisms are unknown." | 1.39 | In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. ( Baldelli, F; Belfiori, B; Bonora, S; Conti, V; Falcinelli, E; Francisci, D; Giannini, S; Gresele, P; Guglielmini, G; Malincarne, L; Mezzasoma, A; Petito, E; Sebastiano, M, 2013) |
| "Possible designs for a PrEP phase 3 efficacy trial are obtained by considering scenarios for potential experimental PrEP and control regimens, including consideration of placebo and active controls, longer acting PrEP and alternate dosing schedules." | 1.39 | Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. ( Chen, YQ; Donnell, D; Fleming, TR; Hughes, JP; Wang, L, 2013) |
| "Rhabdomyolysis has rarely been described in patients on highly active antiretroviral therapy (HAART)." | 1.39 | Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy. ( Schrier, PB; Shah, HH; Spiegel, LR, 2013) |
| "Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV." | 1.39 | In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013) |
| "Although osteopenia is common in HIV-infected patients, there is by now limited data on the evolution of bone mineral density in this population." | 1.39 | Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. ( Assoumou, L; Bentata, M; Costagliola, D; Katlama, C; Kolta, S; Roux, C; Rozenberg, S; Simon, A; Viard, JP, 2013) |
| " Increasing epithelial thickness delayed initial TFV delivery to stroma and its decline: tmax increased but AUC at 24 hours was not significantly altered." | 1.39 | Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. ( Gao, Y; Katz, DF, 2013) |
| "To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients." | 1.39 | Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. ( Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A, 2013) |
| " Dosing was discontinued on day 30 and blood was collected on days 35, 45, and 60 during the washout period." | 1.39 | Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. ( Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Fernandez, C; Gardner, EM; Kiser, JJ; Langness, J; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH, 2013) |
| " After adjusting for age, gender, HIV risk factor, current CD4 count, pill burden and dosing interval, adherence was higher in patients with undetectable HIV RNA (P < 0." | 1.39 | Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. ( Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D, 2013) |
| "These data demonstrate that children and adolescents receiving standard TDF dosing of 300 mg once daily achieve higher intracellular TFV-DP concentrations than adults, despite lower plasma TFV concentrations." | 1.39 | Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. ( Acosta, EP; Baheti, G; Fletcher, CV; King, JR, 2013) |
| "Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 1.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
| "TDF/emtricitabine was less likely to be associated with detectable HBV than other regimens, including TDF monotherapy (odds ratio, 2." | 1.39 | Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. ( Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL, 2013) |
| " The gel also prevents infection in macaques when applied intravaginally or intrarectally prior to challenge with simian-human immunodeficiency virus (SHIV), but very little pharmacokinetic information for macaques is available to help extrapolate the data to humans and thus inform future development activities." | 1.38 | Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. ( Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N, 2012) |
| " Despite continued gel dosing postinfection, neither breakthrough infection had evidence of drug resistance by ultrasensitive testing of SHIV in plasma and vaginal lavage." | 1.38 | Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. ( Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J, 2012) |
| " The impact of changing the current gel formulation to reduce its osmolality was evaluated using pharmacokinetic assessments and local tissue effects in the rabbit." | 1.38 | Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. ( Clark, MR; Friend, DR, 2012) |
| " To summarize, the pharmacokinetic profile of efavirenz remained similar in the pregnant and non-pregnant rats." | 1.38 | Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats. ( Bhyrapuneni, G; Kandikere, V; Komarneni, P; Muddana, N; Mudigonda, K; Mukkanti, K; Nirogi, R; Saralaya, R, 2012) |
| " Adherence by type of ART and dosing frequency were compared by Brown-Mood median tests." | 1.38 | Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. ( Buscher, A; Giordano, TP; Hartman, C; Kallen, MA, 2012) |
| "Primary outcomes were major birth defects rates with exposure to all antivirals, individual classes, and drugs compared to population-based controls." | 1.38 | Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. ( Aguilar, C; Brown, RS; Buti, M; Fagan, EA; Leu, CS; Pereira, MR; Tilson, HH; Verna, EC, 2012) |
| " We developed a pharmacokinetic model for TDF and its active anabolite tenofovir-diphosphate (TFV-DP) and validated it with data from 4 different trials, including 4 distinct dosing regimes." | 1.38 | Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. ( Duwal, S; Schütte, C; von Kleist, M, 2012) |
| " With the increased realization of receptive anal intercourse among heterosexual couples often in conjunction with vaginal intercourse, having a safe and effective microbicide for both mucosal sites is critical." | 1.38 | Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. ( Buckheit, KW; Buckheit, RW; Dezzutti, CS; Gwozdz, G; Mahalingam, A; Shetler, C; Ugaonkar, SR, 2012) |
| "Fanconi syndrome is a side effect of tenofovir." | 1.37 | [Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir]. ( Kuijper, A; Mudrikova, T; Rookmaker, MB, 2011) |
| "We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting." | 1.37 | Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. ( Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011) |
| "Abacavir use has been associated with cardiovascular risk, but it is unknown whether this association may be partly explained by patients with kidney disease being preferentially treated with abacavir to avoid tenofovir." | 1.37 | Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. ( Choi, AI; Deeks, SG; Li, Y; Shlipak, MG; Vittinghoff, E; Weekley, CC, 2011) |
| " A total of 151 ATV plasma concentrations were obtained, and a population pharmacokinetic model was developed with NONMEM." | 1.37 | Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. ( Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S, 2011) |
| "Overall, the incidence of acute renal failure was 0." | 1.37 | Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. ( Chimsuntorn, S; Manosuthi, W; Nilkamhang, S; Prasithsirikul, W; Sungkanuparph, S; Tantanathip, P, 2011) |
| "He developed acute renal failure only 2 weeks after introduction of tenofovir-based antiretroviral therapy and then required 3 months of hemodialysis." | 1.37 | Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy. ( Bouldouyre, MA; Molina, JM; Pavie, J; Pillebout, E; Scemla, A; Verine, J, 2011) |
| "Small body weight was identified as an independent risk factor for tenofovir-associated renal dysfunction." | 1.37 | Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. ( Aoki, T; Gatanaga, H; Honda, H; Honda, M; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2011) |
| "Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients." | 1.37 | Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. ( Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N, 2011) |
| "Tenofovir concentrations were monitored on a routine basis and measured in 93 children aged 5 to 18 years; 283 tenofovir plasma concentrations were used to perform a population pharmacokinetic analysis." | 1.37 | Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. ( Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S, 2011) |
| "If abacavir or didanosine increase cardiovascular risk, it is likely not through the direct endothelial activation pathways tested in these experiments." | 1.37 | Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. ( Clauss, M; Desta, Z; Deuter-Reinhard, M; Green, L; Gupta, SK; Kim, C; Taylor, BM, 2011) |
| " Data on CD4 cell count, HIV viral load, metabolic parameters and adverse events of grade 3-4 are collected through an on-line system every six months." | 1.36 | Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. ( Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F, 2010) |
| " However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C." | 1.36 | N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. ( Moore, K; Radzio, J; Sluis-Cremer, N; Sonza, S; Tachedjian, G, 2010) |
| "We report an extreme case of high-grade needlestick exposure of a health-care worker to serum from multiple HIV-infected patients after trying to prematurely remove the respective tubes from an automated biochemical analyser." | 1.36 | Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker. ( Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E, 2010) |
| "To identify risk factors for acute renal failure (ARF) in HIV-infected patients." | 1.36 | Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. ( Bansi, L; Campbell, LJ; Cheserem, E; Hendry, BM; Ibrahim, F; Naftalin, C; Post, FA; Roe, J; Sabin, C, 2010) |
| " Renal biopsy revealed toxic acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing giant mitochondria visible by light microscopy." | 1.36 | Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. ( D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB, 2010) |
| "Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce." | 1.36 | Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010) |
| "Overall, 63 (13%) patients had chronic hepatitis B (HBsAg-positive), 115 (23%) had never been exposed to HBV (HBsAg-negative, anti-HBc-negative and anti-HBs-negative), 108 (22%) had signs of cured infection (anti-HBc-positive and anti-HBs-positive) and 209 (42%) had isolated anti-HBc (HBsAg-negative, anti-HBc-positive and anti-HBs-negative)." | 1.36 | Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire. ( Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N, 2010) |
| " The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance." | 1.35 | Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008) |
| "Abacavir-based treatment without HLA-B*5701 testing resulted in a projected 30." | 1.35 | The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. ( Freedberg, KA; Losina, E; Sax, PE; Schackman, BR; Scott, CA; Walensky, RP, 2008) |
| " When implementing HAART, physicians should be aware of and monitor potential patient misunderstanding of instructions on dosage and administration and for possible complications in medicinal combinations and potential side effects." | 1.35 | [A case of acute renal failure involving high amounts of tenofovir after HAART start]. ( Kasahara, K; Konishi, M; Maeda, K; Mikasa, K; Nakagawa, C; Uno, K; Yonekawa, S; Yoshimoto, E, 2008) |
| "6-h half-life (30%)." | 1.35 | Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Blanche, S; Coffié, P; Dabis, F; Ekouévi, DK; Hirt, D; Lalsab, S; Leang, SK; McIntyre, J; Nerrienet, E; Rey, E; Tréluyer, JM; Urien, S, 2009) |
| "It became evident that tenofovir DF (TDF) causes a modest and gradual decline in GFR, however, the impact of long-term use of TDF on tubular function has not been fully evaluated." | 1.35 | Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. ( Hanabusa, H; Kinai, E, 2009) |
| "In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy." | 1.35 | Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. ( Beijnen, JH; Huitema, AD; Jansen, RS; Mulder, JW; Smits, PH; Ter Heine, R; van Gorp, EC; Wagenaar, JF, 2009) |
| "Emtricitabine, a nucleoside reverse transcriptase inhibitor (RTI), and tenofovir disoproxil fumarate (tenofovir DF), a nucleotide RTI, as a fixed-dose combination tablet (emtricitabine/tenofovir DF) for once-daily oral administration, are used as the nucleoside/nucleotide RTI backbone in combination with other antiretroviral agents, including ritonavir-boosted protease inhibitors (PIs), in the treatment of adults with HIV-1 infection." | 1.35 | Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. ( Perry, CM, 2009) |
| " We report 12-month changes in renal profiles among 19 such patients (6 patients with history of and 13 patients with current renal disease) in the HIV Outpatient Study (HOPS) who initiated TDF-containing highly active antiretroviral therapy (HAART) during 2001-2005 with TDF dosed mostly at 300 mg once daily." | 1.35 | Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. ( Brooks, JT; Buchacz, K; Moorman, A; Wood, KC; Young, B, 2009) |
| "Chronic hepatitis B affects 5-10% of HIV patients in Western countries." | 1.35 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges? ( Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E, 2009) |
| "Once-daily treatment with ritonavir-boosted saquinavir was well tolerated and resulted in similar saquinavir drug exposure despite much lower ritonavir concentrations when compared with a twice-daily dosing schedule." | 1.35 | Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. ( Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N, 2009) |
| " We investigated the relationship of NVP dosing with safety and efficacy." | 1.35 | Safety and efficacy of once-daily nevirapine dosing: a multicohort study. ( Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009) |
| "A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection." | 1.35 | A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. ( De Clercq, E, 2009) |
| "The SCOLTA Project is a prospective, observational, multicenter study involving 25 infectious disease departments in Italy created to assess the incidence of severe adverse events in patients receiving new antiretroviral drugs." | 1.35 | Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. ( Bonfanti, P; Carradori, S; De Socio, GV; Grosso, C; Landonio, S; Madeddu, G; Marconi, P; Melzi, S; Miccolis, S; Mura, MS; Penco, G; Quirino, T; Ricci, E; Rosella, E, 2008) |
| " The clinical consequences of these substantial pharmacokinetic changes should be investigated." | 1.35 | Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. ( Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E, 2008) |
| " HIV-infected subjects > or =18 to <25 years old receiving (> or =28 days) 300/100 mg atazanavir-ritonavir plus 300 mg tenofovir disoproxil fumarate (TDF) plus one or more other nucleoside analogs underwent intensive 24-h pharmacokinetic studies following a light meal." | 1.35 | Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. ( Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM, 2008) |
| " A relatively uncommon adverse effect of this drug is Fanconi syndrome." | 1.35 | Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. ( Gupta, SK, 2008) |
| "We evaluated the impact of modelling intra-subject variability on the likelihood ratio test (LRT) and the Wald test based on non-linear mixed effects models in pharmacokinetic interaction and bioequivalence cross-over trials." | 1.34 | Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients. ( Mentré, F; Panhard, X; Piketti, C; Taburet, AM, 2007) |
| " We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination." | 1.34 | CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. ( Antinori, A; Antonucci, F; Barreiro, P; Carosi, G; De Silvestri, A; El Hamad, I; Ladisa, N; Lapadula, G; Maggiolo, F; Mandalia, S; Maserati, R; Migliorino, G; Pierotti, P; Sighinolfi, L; Soriano, V; Suter, F; Torti, C, 2007) |
| "Acute interstitial nephritis was observed only in 1 of 19 patients without atazanavir or tenofovir treatment." | 1.34 | Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. ( Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP, 2007) |
| " The US Food and Drug Administration's Adverse Event Reporting System was searched for reports of nephrolithiasis in HIV-infected patients taking an atazanavir-based regimen." | 1.34 | Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. ( Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM, 2007) |
| " We evaluated the possibility of a pharmacokinetic interaction between TFV and EFV by assessing cross-sectional and longitudinal data in 169 individuals receiving EFV." | 1.34 | Does tenofovir influence efavirenz pharmacokinetics? ( Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A, 2007) |
| "To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF)." | 1.34 | Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. ( Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D, 2007) |
| "A tenofovir DF expanded access program (EAP) was initiated in 2001; safety data were examined from this program and from the manufacturer's database, which contained reports of all postmarketing adverse drug reactions received up to 30 April 2005." | 1.34 | The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. ( Bischofberger, N; Chen, SS; Clotet, B; Cooper, DA; Curtis, S; Gazzard, B; Katlama, C; Lange, J; Lazzarin, A; Montaner, JS; Nelson, MR; Rooney, JF; Schewe, K; Smith, S; Wyatt, C, 2007) |
| "HPV infections have become a major problem in immunocompromised patients, particularly in HIV-positive subjects." | 1.34 | HPV oral infection. Case report of an HIV-positive Nigerian sex worker. ( Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R, 2007) |
| "We report a biopsy-proven case of acute renal failure that developed within weeks of initiating a HAART regimen containing tenofovir, and review the literature with specific attention to cases of renal failure occurring within 8 weeks of tenofovir initiation." | 1.34 | Early onset of tenofovir-induced renal failure: case report and review of the literature. ( Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR, 2007) |
| "017 microg/mL 9 hours after drug intake, the ddI concentration in seminal plasma remained detectable during the whole dosing interval with a median of 0." | 1.34 | Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen. ( Burger, DM; Droste, JA; Lange, JM; Lowe, SH; Prins, JM; Reiss, P; Repping, S; van der Veen, F; van Leeuwen, E, 2007) |
| "On day 1, 12 h pharmacokinetic profiles for saquinavir/ritonavir (1000/100 mg given twice daily) were obtained for 18 subjects." | 1.33 | Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. ( Back, D; Boffito, M; Di Perri, G; Gazzard, B; Hill, A; Moyle, G; Nelson, M; Pozniak, A; Stainsby-Tron, M; Tomkins, J, 2005) |
| " To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF." | 1.33 | The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. ( Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Tung, MY, 2005) |
| " TFV-DP also had persistent intracellular levels on TDF discontinuation (median half-life of 150 hours, range: 60 to >175 hours)." | 1.33 | Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. ( Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W, 2005) |
| "Despite the recent publication of case reports describing various manifestations of tenofovir-related nephrotoxicity, data regarding the incidence of and risk factors for this adverse effect are currently lacking." | 1.33 | Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. ( Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D, 2005) |
| " The relevance of a dosage adjustment based on BW/S(CR) should be further evaluated." | 1.33 | Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. ( Dupin, N; Jaffray, P; Jullien, V; Krivine, A; Lescoat, A; Lillo-Le Louet, A; Moachon, L; Pons, G; Rey, E; Salmon, D; Tréluyer, JM; Urien, S, 2005) |
| "Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found." | 1.33 | Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. ( Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006) |
| " A summary variable for any event--discontinuation for toxicity, treatment- emergent adverse event or abnormal laboratory values--indicated that 44 (28%) of 155 of those on high-dose ddI versus 13 (12%) of 105 on low-dose ddI developed any event (OR(unadj) 2." | 1.33 | Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons. ( Armon, C; Baker, RK; Holmberg, SD; Moorman, AC; Weidle, PJ; Wood, KC; Young, B, 2006) |
| "The risk of hyperglycemia is increased in patients treated with ddI + TDF, particularly in those with lower weight." | 1.33 | Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. ( Barreiro, P; Barrios, A; Blanco, F; García-Benayas, T; González-Lahoz, J; Maida, I; Rendón, AL; Rivas, P; Rodríguez-Novóa, S; Soriano, V, 2006) |
| " The single daily dosing was expected to improve adherence to treatment." | 1.33 | Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. ( Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F, 2006) |
| "We describe an acute hepatitis D virus superinfection in an HIV-1-infected patient under HAART treatment who was previously a chronic carrier of a surface negative HBV variant resistant to lamivudine." | 1.33 | Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant. ( Alloui, C; Bouhassoune, K; Calboreanu, A; Dény, P; Gordien, E; Legal, F; Podevin, P; Rico-Garcia, M; Salmon-Céron, D; Sogni, P, 2006) |
| " A two compartment pharmacokinetic model is employed to determine the time evolution of the intracellular concentrations of the active forms of drugs, and thereby drug efficacy." | 1.32 | Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. ( Dixit, NM; Perelson, AS, 2004) |
| "The management of chronic hepatitis B poses specific problems in the presence of human immunodeficiency virus (HIV) coinfection, because therapeutic approaches have to address both hepatitis B virus (HBV) and HIV infections." | 1.32 | Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. ( Camino, N; Núñez, M; Puoti, M; Soriano, V, 2003) |
| "Our study shows that ADV dosed at 10 mg/day for the treatment of LAM-resistant chronic hepatitis B in patients co-infected with HIV is not associated with renal tubular dysfunction or a significant change in renal function." | 1.32 | The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. ( Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M, 2004) |
| "Adefovir has been shown to be effective in the treatment of lamivudine-resistant HBV in HIV/HBV-coinfected patients." | 1.32 | Antiretroviral therapy and HIV/hepatitis B virus coinfection. ( Benhamou, Y, 2004) |
| " Plasma concentration of ddI was prospectively determined in eight of these patients receiving ddI 400 mg + TDF + NVP and 3 weeks after a ddI dosage reduction." | 1.32 | Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. ( Burger, D; Clotet, B; Grassi, J; Juan, M; Masmitjà, E; Moltó, J; Negredo, E; Paredes, R; Pruvost, A; Puig, J; Ribera, E; Ruiz, L; Viciana, P, 2004) |
| "We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease." | 1.31 | Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ( Coca, S; Perazella, MA, 2002) |
| " Advertising that promoted the improved drug has been withdrawn at the request of Project Inform because of the lack of warning labels necessary due to dosing problems." | 1.30 | Update on antivirals. ( , 1997) |
| " All three drugs are currently available through expanded access programs, are dosed either once or twice daily, and can be taken with or without food." | 1.30 | I want a new drug. An overview of three new anti-HIV drugs. ( Simmons, P, 1998) |
| " A clinical trial of the protease inhibitor Nelfinavir (Viracept) has shown that dosing twice a day may be as effective as the currently prescribed three times a day." | 1.30 | Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference. ( Prescott, LM, 1998) |
| "To study whether PMEA also affects visna virus infection in sheep, two groups of four lambs each were inoculated intracerebrally with 10(6." | 1.29 | Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. ( Balzarini, J; De Clercq, E; Georgsson, G; Naesens, L; Pálsson, PA; Thormar, H; Torsteinsdóttir, S, 1995) |
| " Taken together, these promising findings suggest that an orally bioavailable prodrug of MDL 74,968 should be developed for the treatment of HIV infection." | 1.29 | MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection. ( Ahmed, PS; Brennan, TM; Bridges, CG; Casara, P; Hornsperger, JM; Navé, JF; Taylor, DL; Tyms, AS, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 67 (3.44) | 18.2507 |
| 2000's | 659 (33.79) | 29.6817 |
| 2010's | 1019 (52.26) | 24.3611 |
| 2020's | 205 (10.51) | 2.80 |
| Authors | Studies |
|---|---|
| Orkin, C | 15 |
| Ajana, F | 5 |
| Kityo, C | 7 |
| Koenig, E | 9 |
| Natukunda, E | 1 |
| Gandhi-Patel, B | 1 |
| Wang, H | 11 |
| Liu, Y | 11 |
| Wei, X | 11 |
| White, K | 13 |
| Makadzange, T | 4 |
| Pikora, C | 1 |
| McNicholl, I | 5 |
| Collins, SE | 7 |
| Brainard, D | 4 |
| Chuck, SK | 4 |
| Campbell, L | 2 |
| Barbini, B | 2 |
| Burling, K | 2 |
| Cromarty, B | 1 |
| Hamzah, L | 5 |
| Johnson, M | 13 |
| Jones, R | 5 |
| Samarawickrama, A | 1 |
| Williams, D | 2 |
| Winston, A | 10 |
| Post, FA | 14 |
| Gelé, T | 1 |
| Chéret, A | 3 |
| Castro Gordon, A | 1 |
| Nkam, L | 1 |
| Furlan, V | 1 |
| Pallier, C | 1 |
| Becker, PH | 1 |
| Catalan, P | 1 |
| Goujard, C | 6 |
| Taburet, AM | 8 |
| Gasnault, J | 1 |
| Gouget, H | 1 |
| Barrail-Tran, A | 3 |
| Cobb, DA | 1 |
| Smith, N | 2 |
| Deodhar, S | 1 |
| Bade, AN | 1 |
| Gautam, N | 1 |
| Shetty, BLD | 1 |
| McMillan, J | 1 |
| Alnouti, Y | 1 |
| Cohen, SM | 1 |
| Gendelman, HE | 1 |
| Edagwa, B | 1 |
| Xia, H | 1 |
| Huang, XJ | 1 |
| Hu, Y | 2 |
| Gao, LY | 1 |
| Wu, Y | 4 |
| Wu, H | 2 |
| Yan, ZF | 1 |
| Ma, P | 1 |
| Teng, J | 1 |
| Zhu, C | 1 |
| Lyu, J | 2 |
| Pan, L | 2 |
| Zhang, M | 3 |
| Zhang, F | 2 |
| Roa, PE | 1 |
| Bazzi, R | 1 |
| Liou, BH | 4 |
| Cheng, CN | 1 |
| Lin, YT | 1 |
| Lin, YJ | 1 |
| Chuang, YC | 5 |
| Lin, KY | 5 |
| Liu, WC | 3 |
| Lin, SW | 1 |
| Kuo, CH | 1 |
| Sun, HY | 8 |
| Hung, CC | 8 |
| Lakatos, B | 1 |
| Kowalska, J | 1 |
| Antoniak, S | 1 |
| Gokengin, D | 1 |
| Begovac, J | 1 |
| Vassilenko, A | 1 |
| Wasilewski, P | 1 |
| Fleischhans, L | 1 |
| Jilich, D | 1 |
| Matulionyte, R | 1 |
| Kase, K | 1 |
| Papadopoulus, A | 1 |
| Rukhadze, N | 1 |
| Harxhi, A | 1 |
| Hofman, S | 1 |
| Dragovic, G | 1 |
| Vasyliev, M | 1 |
| Verhaz, A | 1 |
| Yancheva, N | 1 |
| Oprea, C | 1 |
| Joseph, NT | 1 |
| Satten, GA | 1 |
| Williams, RE | 1 |
| Haddad, LB | 1 |
| Jamieson, DJ | 2 |
| Sheth, AN | 4 |
| Badell, ML | 1 |
| Bukkems, VE | 1 |
| Necsoi, C | 2 |
| Hidalgo Tenorio, C | 1 |
| Garcia, C | 1 |
| Alba Alejandre, I | 1 |
| Weiss, F | 1 |
| Lambert, JS | 2 |
| van Hulzen, A | 1 |
| Richel, O | 1 |
| Te Brake, LHM | 1 |
| van der Meulen, E | 1 |
| Burger, D | 5 |
| Konopnicki, D | 1 |
| Colbers, A | 1 |
| Abuogi, LL | 1 |
| Castillo-Mancilla, J | 5 |
| Hampanda, K | 1 |
| Owuor, K | 1 |
| Odwar, T | 1 |
| Onono, M | 1 |
| Helova, A | 1 |
| Turan, JM | 1 |
| Anderson, PL | 45 |
| Castillo-Mancilla, JR | 15 |
| Edwards, JA | 1 |
| Brijkumar, J | 1 |
| Moosa, MY | 1 |
| Zhao, Y | 4 |
| Ofotokun, I | 6 |
| Johnson, BA | 1 |
| Lee, MH | 2 |
| Pillay, S | 1 |
| Pillay, M | 1 |
| Moodley, P | 1 |
| Kuritzkes, DR | 8 |
| Sunpath, H | 1 |
| Bushman, LR | 23 |
| Ellison, L | 10 |
| Marconi, VC | 3 |
| Odayar, J | 1 |
| Orrell, C | 6 |
| Phillips, TK | 2 |
| Hu, NC | 2 |
| Kabanda, S | 1 |
| Malaba, TR | 1 |
| Allerton, J | 1 |
| Wiesner, L | 6 |
| Hsiao, NY | 2 |
| Lesosky, M | 1 |
| Myer, L | 5 |
| Mayer, KH | 23 |
| Gelman, M | 2 |
| Holmes, J | 1 |
| Kraft, J | 1 |
| Melbourne, K | 3 |
| Mimiaga, MJ | 4 |
| Kow, CS | 1 |
| Ramachandram, DS | 1 |
| Hasan, SS | 1 |
| Osiyemi, O | 5 |
| De Wit, S | 6 |
| Bisshop, F | 2 |
| Portilla, J | 5 |
| Routy, JP | 2 |
| Wyen, C | 4 |
| Ait-Khaled, M | 2 |
| Leone, P | 1 |
| Pappa, KA | 5 |
| Wang, R | 7 |
| Wright, J | 2 |
| George, N | 1 |
| Wynne, B | 2 |
| Aboud, M | 2 |
| van Wyk, J | 4 |
| Smith, KY | 4 |
| Jennings, L | 1 |
| Robbins, RN | 1 |
| Nguyen, N | 2 |
| Ferraris, C | 1 |
| Leu, CS | 2 |
| Dolezal, C | 1 |
| Mgbako, O | 1 |
| Joska, J | 1 |
| Remien, RH | 1 |
| Brooks, KM | 8 |
| Pinilla, M | 2 |
| Stek, AM | 3 |
| Shapiro, DE | 4 |
| Barr, E | 2 |
| Febo, IL | 2 |
| Paul, ME | 1 |
| Deville, JG | 2 |
| George, K | 3 |
| Knowles, K | 2 |
| Rungruengthanakit, K | 2 |
| Browning, R | 1 |
| Chakhtoura, N | 5 |
| Capparelli, EV | 3 |
| Mirochnick, M | 8 |
| Best, BM | 5 |
| Sax, PE | 27 |
| Andreatta, K | 5 |
| Molina, JM | 26 |
| Daar, ES | 14 |
| Hagins, D | 6 |
| Acosta, R | 4 |
| D'Antoni, ML | 2 |
| Chang, S | 3 |
| Martin, R | 4 |
| Liu, H | 8 |
| Blair, C | 3 |
| Gallant, J | 5 |
| Martin, H | 18 |
| White, KL | 8 |
| Yang, T | 1 |
| Oliyai, R | 1 |
| Kent, KM | 1 |
| Choudhary, MC | 1 |
| Mellors, JW | 7 |
| Lee, WA | 4 |
| Cheng, AK | 23 |
| Rowe, SM | 1 |
| Clary, JC | 1 |
| Drummond, M | 1 |
| Derrick, C | 1 |
| Sanasi, K | 1 |
| Bookstaver, PB | 2 |
| Maggiolo, F | 14 |
| Rizzardini, G | 10 |
| Pulido, F | 6 |
| Vandekerckhove, L | 3 |
| Berenguer, J | 2 |
| Piontkowsky, D | 6 |
| Haubrich, R | 10 |
| McNicholl, IR | 1 |
| Gunawardana, M | 6 |
| Remedios-Chan, M | 5 |
| Sanchez, D | 4 |
| Webster, S | 4 |
| Castonguay, AE | 1 |
| Webster, P | 4 |
| Buser, C | 1 |
| Moss, JA | 9 |
| Trinh, M | 4 |
| Beliveau, M | 5 |
| Hendrix, CW | 19 |
| Marzinke, MA | 17 |
| Tuck, M | 1 |
| Caprioli, RM | 1 |
| Reyzer, ML | 1 |
| Kuo, J | 4 |
| Gallay, PA | 5 |
| Baum, MM | 9 |
| Kayes, T | 1 |
| Crane, H | 1 |
| Symonds, A | 1 |
| Dumond, J | 1 |
| Cottrell, M | 2 |
| Di Girolamo, J | 1 |
| Manandhar, S | 1 |
| Lim, TH | 1 |
| Gane, E | 1 |
| Kashuba, A | 9 |
| Levy, MT | 1 |
| de Gea Grela, A | 2 |
| Martín Carbonero, L | 1 |
| Micán, R | 5 |
| Bernardino, JI | 5 |
| Ramos, L | 1 |
| Valencia, ME | 2 |
| Schafer, JJ | 2 |
| Zimmerman, M | 1 |
| Walshe, C | 1 |
| Cerankowski, J | 1 |
| Shimada, A | 1 |
| Keith, SW | 1 |
| Coyle, RP | 6 |
| Morrow, M | 9 |
| MaWhinney, S | 12 |
| Coleman, SS | 6 |
| Zheng, JH | 11 |
| Kiser, JJ | 22 |
| Papatheodoridis, GV | 2 |
| Mimidis, K | 1 |
| Manolakopoulos, S | 1 |
| Gatselis, N | 1 |
| Goulis, J | 1 |
| Kapatais, A | 1 |
| Manesis, E | 1 |
| Vasiliadis, T | 1 |
| Triantos, C | 1 |
| Samonakis, D | 1 |
| Sevastianos, V | 1 |
| Karatapanis, S | 1 |
| Elefsiniotis, I | 1 |
| Deutsch, M | 1 |
| Mylopoulou, T | 1 |
| Papatheodoridi, M | 1 |
| Kranidioti, H | 1 |
| Agorastou, P | 1 |
| Karaoulani, T | 1 |
| Kyriazidou, A | 1 |
| Zisimopoulos, K | 1 |
| Dalekos, GN | 1 |
| Chen, GJ | 3 |
| Chen, LY | 2 |
| Hsieh, SM | 2 |
| Sheng, WH | 2 |
| Liu, WD | 3 |
| Huang, YS | 3 |
| Wu, PY | 2 |
| Chang, HY | 2 |
| Luo, YZ | 2 |
| Su, YC | 2 |
| Chang, SF | 2 |
| Chang, SY | 2 |
| Parveen, S | 1 |
| Tiwari, A | 1 |
| Singh, J | 1 |
| Shah, A | 1 |
| Armenia, D | 1 |
| Forbici, F | 4 |
| Bertoli, A | 1 |
| Berno, G | 1 |
| Malagnino, V | 2 |
| Gagliardini, R | 1 |
| Borghi, V | 4 |
| Gennari, W | 1 |
| Cicalini, S | 1 |
| Buonomini, A | 1 |
| Teti, E | 2 |
| Lanini, S | 1 |
| Latini, A | 1 |
| Sarmati, L | 2 |
| Mussini, C | 8 |
| Andreoni, M | 3 |
| Antinori, A | 11 |
| Perno, CF | 6 |
| Ceccherini-Silberstein, F | 5 |
| Santoro, MM | 4 |
| Cadiñanos, J | 4 |
| de Miguel, R | 1 |
| Busca, C | 4 |
| Valencia, E | 5 |
| Montes, ML | 5 |
| Montejano, R | 4 |
| Moreno, V | 3 |
| Pérez Valero, I | 1 |
| Serrano, L | 1 |
| González-García, J | 2 |
| Arribas, JR | 19 |
| Martín-Carbonero, L | 12 |
| Martínez-Sanz, J | 1 |
| Serrano-Villar, S | 1 |
| Muriel, A | 1 |
| García Fraile, LJ | 1 |
| Orviz, E | 1 |
| Mena de Cea, Á | 1 |
| Campins, AA | 1 |
| Moreno, S | 9 |
| Polo, R | 2 |
| García-Albéniz, X | 1 |
| Terán, C | 1 |
| Morales, M | 1 |
| Rial-Crestelo, D | 1 |
| Garcinuño, MA | 1 |
| García Del Toro, M | 1 |
| Hita, C | 1 |
| Gómez-Sirvent, JL | 1 |
| Buzón, L | 1 |
| Díaz de Santiago, A | 1 |
| Arellano, JP | 1 |
| Sanz, J | 5 |
| Bachiller, P | 1 |
| Alfaro, EM | 1 |
| Díaz-Brito, V | 2 |
| Masiá, M | 6 |
| Hernández-Torres, A | 1 |
| Guerra, JM | 1 |
| Santos, J | 9 |
| Arazo, P | 2 |
| Muñoz, L | 3 |
| Martínez de Salazar, P | 1 |
| Hernán, MA | 2 |
| Del Amo, J | 2 |
| Solanke, T | 1 |
| Kamau, F | 1 |
| Esterhuizen, T | 1 |
| Maartens, G | 6 |
| Khoo, S | 5 |
| Joska, JA | 1 |
| Kellermann, T | 1 |
| Strijdom, H | 1 |
| Decloedt, EH | 1 |
| Liu, W | 2 |
| Yu, S | 1 |
| Yan, B | 1 |
| Velloza, J | 1 |
| Donnell, D | 14 |
| Hosek, S | 5 |
| Chirenje, ZM | 2 |
| Mgodi, N | 4 |
| Bekker, LG | 13 |
| Delany-Moretlwe, S | 5 |
| Celum, C | 18 |
| Sun, L | 4 |
| He, Y | 3 |
| Xu, L | 2 |
| Zhao, F | 1 |
| Zhou, Y | 9 |
| Zhang, L | 7 |
| Peng, Q | 1 |
| Zhang, H | 2 |
| Zhang, Q | 6 |
| Cao, T | 1 |
| Song, Y | 2 |
| Wang, S | 1 |
| Rao, M | 1 |
| Jia, X | 1 |
| Liu, X | 4 |
| Zhou, J | 1 |
| Ju, B | 1 |
| Liu, J | 5 |
| Tapsoba, JD | 1 |
| Cover, J | 1 |
| Obong'o, C | 1 |
| Brady, M | 1 |
| Cressey, TR | 5 |
| Mori, K | 1 |
| Okomo, G | 1 |
| Kariithi, E | 1 |
| Obanda, R | 1 |
| Oluoch-Madiang, D | 1 |
| Chen, YQ | 2 |
| Drain, P | 1 |
| Duerr, A | 1 |
| Hikasa, S | 3 |
| Shimabukuro, S | 3 |
| Hideta, K | 3 |
| Higasa, S | 4 |
| Sawada, A | 3 |
| Tokugawa, T | 3 |
| Tanaka, K | 3 |
| Yanai, M | 3 |
| Kimura, T | 3 |
| Johnson, KA | 2 |
| Okochi, H | 3 |
| Arreguin, M | 1 |
| Watabe, J | 1 |
| Glidden, DV | 13 |
| Chattopadhyay, A | 1 |
| Imbert, E | 1 |
| Hickey, MD | 1 |
| Gandhi, M | 10 |
| Spinelli, M | 2 |
| Pyadushkina, EA | 1 |
| Derkach, EV | 1 |
| Sarowar, A | 1 |
| Coffin, CS | 1 |
| Fung, S | 1 |
| Wong, A | 1 |
| Doucette, K | 1 |
| Truong, D | 1 |
| Conway, B | 2 |
| Haylock-Jacobs, S | 1 |
| Ramji, A | 1 |
| Hansen, BE | 5 |
| Janssen, HLA | 1 |
| Cooper, C | 2 |
| Andrade, A | 4 |
| Fuchs, EJ | 4 |
| Abdul Massih, S | 1 |
| Breakey, J | 2 |
| Beselman, S | 1 |
| Buscemi, L | 1 |
| Mossholder, B | 1 |
| Hocqueloux, L | 3 |
| Lefeuvre, S | 1 |
| Bois, J | 1 |
| Brucato, S | 1 |
| Alix, A | 1 |
| Valentin, C | 1 |
| Peyro-Saint-Paul, L | 1 |
| Got, L | 1 |
| Fournel, F | 1 |
| Dargere, S | 1 |
| Prazuck, T | 4 |
| Fournier, A | 1 |
| Gregoire, N | 1 |
| Parienti, JJ | 6 |
| Dupont, E | 1 |
| Cyr-Yombi, J | 1 |
| Jamieson, L | 1 |
| Johnson, LF | 1 |
| Nichols, BE | 3 |
| Hosseinipour, MC | 5 |
| Russell, C | 1 |
| Meyer-Rath, G | 2 |
| Naidoo, A | 2 |
| Dooley, KE | 2 |
| Naidoo, K | 4 |
| Padayatchi, N | 1 |
| Yende-Zuma, N | 5 |
| Perumal, R | 1 |
| Dorse, G | 1 |
| Boodhram, R | 1 |
| Osuala, EC | 1 |
| Sidman, EF | 1 |
| Ondrush, NM | 1 |
| Aubert, A | 1 |
| Berger, JL | 1 |
| Hittinger Roux, A | 1 |
| N'Guyen, Y | 1 |
| Bani-Sadr, F | 4 |
| Tsai, MS | 3 |
| Chen, CP | 3 |
| Lee, CH | 4 |
| Lee, CY | 3 |
| Liu, CE | 3 |
| Tang, HJ | 4 |
| Hung, TC | 3 |
| Li, CW | 4 |
| Lee, YT | 3 |
| Yang, CJ | 3 |
| Bendala-Estrada, AD | 3 |
| Diaz-Almiron, M | 3 |
| Delgado-Hierro, A | 3 |
| Grau, S | 3 |
| Miró, JM | 8 |
| Olalla, J | 5 |
| Alcalá, JC | 3 |
| Castro, A | 3 |
| Rubio-Rodríguez, D | 3 |
| Rubio-Terrés, C | 3 |
| Fanter, R | 4 |
| Ramirez, CM | 3 |
| Dobard, CW | 3 |
| Peet, MM | 4 |
| Nishiura, K | 4 |
| Holder, A | 8 |
| Dinh, C | 6 |
| Mitchell, J | 5 |
| Khalil, G | 5 |
| Pan, Y | 5 |
| Singh, ON | 3 |
| McCormick, TJ | 3 |
| Agrahari, V | 5 |
| Gupta, P | 3 |
| Jonnalagadda, S | 3 |
| Heneine, W | 11 |
| Clark, MR | 9 |
| García-Lerma, JG | 10 |
| Doncel, GF | 8 |
| Partosh, D | 3 |
| Sherman, EM | 3 |
| Eckardt, PA | 3 |
| Unger, N | 3 |
| Montalvo, S | 3 |
| Zaman, M | 2 |
| Butt, MH | 2 |
| Siddique, W | 2 |
| Iqbal, MO | 2 |
| Nisar, N | 2 |
| Mumtaz, A | 2 |
| Nazeer, HY | 2 |
| Alshammari, A | 2 |
| Riaz, MS | 2 |
| Perna, A | 2 |
| Carleo, MA | 3 |
| Mascolo, S | 2 |
| Guida, A | 2 |
| Contieri, M | 2 |
| Sellitto, C | 2 |
| Hay, E | 2 |
| De Blasiis, P | 2 |
| Lucariello, A | 2 |
| Guerra, G | 2 |
| Baldi, A | 2 |
| De Luca, A | 8 |
| Maggi, P | 4 |
| Esposito, V | 2 |
| Walmsley, S | 5 |
| Clarke, R | 2 |
| Lee, T | 2 |
| Singer, J | 2 |
| Cheung, AM | 2 |
| Smaill, F | 2 |
| De Pokomandy, A | 2 |
| Trottier, S | 2 |
| Messina, E | 2 |
| Guaraldi, G | 5 |
| Bosch, B | 2 |
| Akpomiemie, G | 4 |
| Chandiwana, N | 5 |
| Sokhela, S | 5 |
| Hill, A | 13 |
| McCann, K | 5 |
| Qavi, A | 4 |
| Mirchandani, M | 2 |
| Venter, WDF | 8 |
| Gupta, SK | 11 |
| Berhe, M | 1 |
| Crofoot, G | 10 |
| Benson, P | 4 |
| Ramgopal, M | 5 |
| Sims, J | 2 |
| McDonald, C | 4 |
| Ruane, P | 9 |
| Sanchez, WE | 1 |
| Scribner, A | 2 |
| Liu, SY | 1 |
| VanderVeen, LA | 1 |
| Dvory-Sobol, H | 1 |
| Rhee, MS | 11 |
| Baeten, JM | 25 |
| de Salazar, A | 2 |
| Viñuela, L | 1 |
| Fuentes, A | 1 |
| Teyssou, E | 1 |
| Charpentier, C | 10 |
| Lambert-Niclot, S | 3 |
| Serrano-Conde, E | 1 |
| Pingarilho, M | 1 |
| Fabeni, L | 1 |
| De Monte, A | 1 |
| Stefic, K | 1 |
| Aguilera, A | 3 |
| Falces, I | 1 |
| Delgado, R | 1 |
| Fernandes, S | 1 |
| Diogo, I | 1 |
| Gomes, P | 1 |
| Paraskevis, D | 1 |
| Marcelin, AG | 11 |
| Garcia, F | 3 |
| Choi, J | 4 |
| Lim, YS | 2 |
| Kim, JH | 3 |
| Byun, KS | 1 |
| Yoo, BC | 1 |
| Bachelard, A | 1 |
| Isernia, V | 1 |
| Benalycherif, A | 2 |
| Mora, M | 1 |
| Donadille, C | 1 |
| Duvivier, C | 4 |
| Lacombe, K | 13 |
| El Mouhebb, M | 1 |
| Spire, B | 3 |
| Landman, R | 5 |
| Descamps, D | 10 |
| Peytavin, G | 19 |
| Assoumou, L | 2 |
| Ghosn, J | 6 |
| Lunn, G | 1 |
| Moodley, D | 1 |
| Lombard, C | 1 |
| Govender, V | 1 |
| Naidoo, M | 1 |
| Desmond, AC | 1 |
| Mhlongo, O | 1 |
| Sebitloane, M | 1 |
| Newell, ML | 1 |
| Clark, R | 1 |
| Rooney, JF | 24 |
| Gray, G | 6 |
| O'Rourke, J | 1 |
| Townsend, CL | 1 |
| Milanzi, E | 1 |
| Collins, IJ | 1 |
| Castro, H | 1 |
| Judd, A | 3 |
| Vicari, M | 1 |
| Jesson, J | 1 |
| Leroy, V | 1 |
| Penazzato, M | 1 |
| Renaud, F | 1 |
| Ritou, E | 1 |
| Satta, S | 1 |
| Petcherski, A | 1 |
| Daskou, M | 1 |
| Sharma, M | 2 |
| Vasilopoulos, H | 1 |
| Murakami, E | 1 |
| Shirihai, OS | 1 |
| Kelesidis, T | 1 |
| Perrone, V | 1 |
| Dovizio, M | 1 |
| Sangiorgi, D | 1 |
| Andretta, M | 1 |
| Bartolini, F | 1 |
| Cavaliere, A | 1 |
| Ciaccia, A | 1 |
| Chinellato, A | 1 |
| Costantini, A | 1 |
| Dell'Orco, S | 1 |
| Ferrante, F | 1 |
| Gentile, S | 1 |
| Lavalle, A | 1 |
| Moscogiuri, R | 1 |
| Mosele, E | 1 |
| Procacci, C | 1 |
| Re, D | 1 |
| Santoleri, F | 1 |
| Roccia, A | 1 |
| Degli Esposti, L | 1 |
| Avihingsanon, A | 9 |
| Chetchotisakd, P | 10 |
| Kiertiburanakul, S | 4 |
| Ratanasuwan, W | 3 |
| Siripassorn, K | 1 |
| Supparatpinyo, K | 2 |
| Wong, T | 1 |
| Wang, HY | 2 |
| Rodríguez, AP | 1 |
| Lillo, IS | 1 |
| González, CS | 1 |
| Galindo, MJ | 5 |
| Kawuma, AN | 1 |
| Wasmann, RE | 1 |
| Sinxadi, P | 3 |
| Sokhela, SM | 1 |
| Denti, P | 1 |
| Menard, A | 1 |
| Arvieux, C | 2 |
| Joly, V | 2 |
| Becker, A | 1 |
| Cabié, A | 3 |
| Delpierre, C | 1 |
| Allavena, C | 6 |
| Nasreddine, R | 1 |
| Florence, E | 1 |
| Yombi, JC | 1 |
| Henrard, S | 2 |
| Darcis, G | 2 |
| Van Praet, J | 1 |
| Allard, SD | 1 |
| Demeester, R | 1 |
| Messiaen, P | 1 |
| Ausselet, N | 1 |
| Delforge, M | 2 |
| Thoueille, P | 1 |
| Alves Saldanha, S | 1 |
| Desfontaine, V | 1 |
| Kusejko, K | 1 |
| Courlet, P | 1 |
| Andre, P | 1 |
| Cavassini, M | 16 |
| Decosterd, LA | 1 |
| Buclin, T | 2 |
| Guidi, M | 1 |
| Soldado-Folgado, J | 1 |
| Rins-Lozano, O | 1 |
| Arrieta-Aldea, I | 2 |
| Gonzále-Mena, A | 1 |
| Cañas-Ruano, E | 2 |
| Knobel, H | 7 |
| Garcia-Giralt, N | 1 |
| Güerri-Fernández, R | 2 |
| Pérez-Barragán, E | 1 |
| Guevara-Maldonado, MF | 1 |
| Mancilla-Galindo, J | 1 |
| Kammar-García, A | 1 |
| Ortiz-Hernández, A | 1 |
| Mata-Marín, JA | 2 |
| Pérez-Cavazos, S | 1 |
| Surial, B | 4 |
| Wandeler, G | 8 |
| Mateza, S | 1 |
| Bradford, Y | 1 |
| Chandiwana, NC | 1 |
| Ritchie, MD | 1 |
| Haas, DW | 4 |
| Pons-Faudoa, FP | 2 |
| Di Trani, N | 2 |
| Capuani, S | 1 |
| Hernandez, N | 1 |
| Wood, AM | 1 |
| Nehete, B | 1 |
| Niles, J | 1 |
| Shelton, KA | 1 |
| Kezar, S | 1 |
| Chua, CYX | 2 |
| Ittmann, MM | 1 |
| Nehete, PN | 1 |
| Arduino, RC | 2 |
| Nichols, JE | 1 |
| Grattoni, A | 3 |
| Chinula, L | 2 |
| Ziemba, L | 2 |
| Brummel, S | 1 |
| McCarthy, K | 2 |
| Coletti, A | 2 |
| Krotje, C | 2 |
| Johnston, B | 3 |
| Moyo, S | 2 |
| Stranix-Chibanda, L | 3 |
| Hoffman, R | 1 |
| Stringer, J | 1 |
| Jean-Philippe, P | 4 |
| Korutaro, V | 3 |
| Cassim, H | 2 |
| Fairlie, L | 4 |
| Masheto, G | 2 |
| Boyce, C | 1 |
| Frenkel, LM | 3 |
| Amico, KR | 10 |
| Purdue, L | 3 |
| Shapiro, R | 1 |
| Mmbaga, BT | 2 |
| Patel, F | 1 |
| Currier, JS | 6 |
| Lockman, S | 7 |
| Singh, VD | 1 |
| Singh, VK | 1 |
| Daharwal, SJ | 1 |
| DeKoven, S | 1 |
| Naccarato, M | 1 |
| Brumme, CJ | 1 |
| Tan, DHS | 1 |
| Vélez-Díaz-Pallarés, M | 2 |
| Esteban-Cartelle, B | 1 |
| Gramage-Caro, T | 2 |
| Montero-Llorente, B | 2 |
| Parro-Martín, MLÁ | 1 |
| Rodríguez-Sagrado, MÁ | 2 |
| Álvarez-Díaz, AM | 1 |
| Penner, J | 1 |
| Ombajo, LA | 1 |
| Otieno, D | 1 |
| Nkuranga, J | 1 |
| Mburu, M | 1 |
| Wahome, S | 1 |
| Pozniak, A | 15 |
| Bhagani, S | 2 |
| Gao, F | 2 |
| Hughes, JP | 3 |
| Hanscom, B | 1 |
| Corey, L | 1 |
| Cohen, MS | 9 |
| Edupuganti, S | 1 |
| Rees, H | 2 |
| Hosseinipour, M | 3 |
| Zilwa, N | 1 |
| Mpejane, O | 1 |
| Mehboob, G | 1 |
| Gill, S | 1 |
| Kalinoski, T | 1 |
| Guelar, A | 1 |
| Knobel, P | 1 |
| Villar-García, J | 1 |
| González-Mena, A | 2 |
| Canepa, C | 1 |
| Marcos, A | 1 |
| Abalat-Torrres, A | 1 |
| Alavian, G | 1 |
| Abbasian, L | 1 |
| Khalili, H | 2 |
| Alinaghi, SAS | 1 |
| Hasannezhad, M | 1 |
| Ashtiani, MF | 1 |
| Manshadi, SAD | 1 |
| Mikaeloff, F | 1 |
| Gelpi, M | 1 |
| Escos, A | 1 |
| Knudsen, AD | 1 |
| Høgh, J | 1 |
| Benfield, T | 1 |
| de Magalhães, JP | 1 |
| Nielsen, SD | 2 |
| Neogi, U | 2 |
| Toledo, T | 1 |
| Castro, T | 1 |
| Oliveira, VG | 1 |
| Veloso, VG | 6 |
| Grinsztejn, B | 5 |
| Cardoso, SW | 2 |
| Torres, TS | 2 |
| Estrela, R | 1 |
| Ramgopal, MN | 4 |
| Castagna, A | 11 |
| Cazanave, C | 2 |
| Dretler, R | 2 |
| Oka, S | 17 |
| Di Perri, G | 15 |
| Sutton, K | 1 |
| Sutherland-Phillips, D | 1 |
| Berni, A | 1 |
| Latham, CL | 1 |
| D'Amico, R | 2 |
| Pascual Bernáldez, M | 1 |
| Van Solingen-Ristea, R | 1 |
| Van Eygen, V | 1 |
| Patel, P | 3 |
| Chounta, V | 1 |
| Spreen, WR | 1 |
| Garges, HP | 1 |
| Smith, K | 1 |
| Huliciak, M | 1 |
| Lhotska, I | 1 |
| Kocova-Vlckova, H | 1 |
| Halodova, V | 1 |
| Dusek, T | 1 |
| Cecka, F | 1 |
| Staud, F | 1 |
| Vokral, I | 1 |
| Cerveny, L | 1 |
| Rivera, AS | 1 |
| Pak, KJ | 1 |
| Mefford, MT | 1 |
| Hechter, RC | 1 |
| Podzamczer, D | 20 |
| Imaz, A | 3 |
| Lopez-Lirola, A | 1 |
| Fanciulli, C | 1 |
| Hernández, C | 1 |
| Lagarde, M | 1 |
| Gutierrez, A | 1 |
| Curran, A | 6 |
| Morano, L | 2 |
| Montero-Alonso, M | 1 |
| Troya, J | 2 |
| Rigo, R | 1 |
| Casadellà, M | 1 |
| Navarro-Alcaraz, A | 1 |
| Ardila, F | 1 |
| Parera, M | 1 |
| Bernal, E | 1 |
| Echeverria, P | 4 |
| Estrada, V | 8 |
| Hidalgo-Tenorio, C | 1 |
| Macias, J | 2 |
| Prieto, P | 1 |
| Vivancos, MJ | 1 |
| Rivero, A | 5 |
| Aroza-Espinar, M | 1 |
| Merlán-Hermida, A | 1 |
| Suárez-Hormiga, L | 1 |
| Pérez-Arellano, JL | 2 |
| Mendoza, I | 1 |
| Lázaro, A | 1 |
| Espinosa, A | 1 |
| Sánchez, L | 1 |
| Horta, AM | 1 |
| Torralba, M | 1 |
| De Clercq, E | 13 |
| Zhang, Z | 3 |
| Huang, J | 4 |
| Li, G | 1 |
| Rocabert, A | 1 |
| Borjabad, B | 1 |
| Berrocal, L | 1 |
| Blanch, J | 1 |
| Inciarte, A | 1 |
| Chivite, I | 1 |
| Gonzalez-Cordon, A | 1 |
| Torres, B | 1 |
| Ambrosioni, J | 2 |
| Martinez-Rebollar, M | 1 |
| Laguno, M | 4 |
| De La Mora, L | 1 |
| Foncillas, A | 1 |
| Sempere, A | 1 |
| Rodriguez, A | 1 |
| Solbes, E | 1 |
| Llobet, R | 1 |
| Mallolas, J | 8 |
| Blanco, JL | 6 |
| De Lazzari, E | 3 |
| Martinez, E | 12 |
| Mohzari, YA | 1 |
| Musawa, MA | 1 |
| Alrashed, A | 1 |
| Zaeri, B | 1 |
| Damfu, N | 1 |
| Cahusac, P | 1 |
| Alwafai, S | 1 |
| Alamer, A | 1 |
| Almulhim, A | 1 |
| Isoda, A | 1 |
| Mihara, M | 1 |
| Matsumoto, M | 1 |
| Sawamura, M | 1 |
| Gusmão, MBF | 1 |
| Oliveira, VV | 1 |
| Santos, NMDS | 1 |
| Melo, LC | 1 |
| Willkom, M | 3 |
| Wei, L | 1 |
| Liu, YP | 6 |
| Graham, H | 4 |
| Quirk, E | 12 |
| Huhn, GD | 4 |
| Eron, JJ | 9 |
| Girard, PM | 24 |
| DeJesus, E | 42 |
| Petrovic, R | 2 |
| Luo, D | 2 |
| Van Landuyt, E | 3 |
| Lathouwers, E | 4 |
| Nettles, RE | 2 |
| Brown, K | 2 |
| Wong, EY | 1 |
| Coelho, LE | 1 |
| Landovitz, RJ | 3 |
| Ma, Q | 4 |
| Ocque, AJ | 1 |
| Morse, GD | 1 |
| Sanders, C | 1 |
| Burgi, A | 1 |
| Little, SJ | 2 |
| Letendre, SL | 1 |
| Gianotti, N | 5 |
| Raffi, F | 13 |
| Mateo-Garcia, MG | 1 |
| Ong, E | 1 |
| Shao, Y | 3 |
| Das, M | 14 |
| Calmy, A | 9 |
| Fehr, J | 4 |
| Stöckle, M | 3 |
| Bernasconi, E | 10 |
| Roth, B | 2 |
| Fux, CA | 10 |
| Kovari, H | 2 |
| Furrer, H | 17 |
| Rauch, A | 5 |
| Taramasso, L | 5 |
| Di Biagio, A | 13 |
| Riccardi, N | 1 |
| Briano, F | 2 |
| Di Filippo, E | 2 |
| Comi, L | 2 |
| Mora, S | 7 |
| Giacomini, M | 1 |
| Gori, A | 3 |
| Gankina, N | 1 |
| Pokrovsky, V | 1 |
| Voronin, E | 1 |
| Stephens, JL | 4 |
| Acosta, RK | 3 |
| Cao, H | 7 |
| Lee, MSL | 1 |
| Kishore, S | 1 |
| Hollenbeck, BL | 1 |
| Padival, S | 1 |
| Saag, MS | 6 |
| Goldstein, RH | 1 |
| Walensky, RP | 8 |
| Bailey, AC | 1 |
| Ibrahim, F | 2 |
| Musso, CG | 1 |
| Van Epps, P | 1 |
| Wilson, BM | 1 |
| Garner, W | 7 |
| Beste, LA | 1 |
| Maier, MM | 1 |
| Ohl, ME | 1 |
| Nishida, S | 1 |
| Milinkovic, A | 3 |
| Berger, F | 6 |
| Arenas-Pinto, A | 1 |
| Mauss, S | 10 |
| Fulco, PP | 5 |
| Leibrand Kaczmar, CR | 1 |
| Gomes, D | 1 |
| Smith, T | 1 |
| Gantner, P | 2 |
| Hessamfar, M | 1 |
| Souala, MF | 1 |
| Valin, N | 3 |
| Simon, A | 4 |
| Bouvet, E | 2 |
| Rouveix, E | 1 |
| Cotte, L | 4 |
| Hustache-Mathieu, L | 1 |
| Lebrette, MG | 3 |
| Truchetet, F | 2 |
| Galempoix, JM | 1 |
| Piroth, L | 3 |
| Pellissier, G | 1 |
| Muret, P | 3 |
| Rey, D | 7 |
| Turner, D | 2 |
| Drak, D | 1 |
| O'Connor, CC | 1 |
| Templeton, DJ | 2 |
| Gracey, DM | 3 |
| Hermansson, L | 1 |
| Yilmaz, A | 2 |
| Price, RW | 1 |
| Nilsson, S | 1 |
| McCallister, S | 15 |
| Zetterberg, H | 1 |
| Blennow, K | 1 |
| Gisslen, M | 2 |
| Rockstroh, J | 6 |
| Esser, S | 4 |
| Hufkens, V | 2 |
| Jezorwski, J | 2 |
| Opsomer, M | 2 |
| Zeuli, J | 2 |
| Rizza, S | 2 |
| Bhatia, R | 1 |
| Temesgen, Z | 2 |
| Shafran, SD | 2 |
| Su, JT | 1 |
| Simpson, SM | 1 |
| Sung, S | 1 |
| Tfaily, EB | 1 |
| Veazey, R | 1 |
| Marzinke, M | 2 |
| Qiu, J | 1 |
| Watrous, D | 1 |
| Widanapathirana, L | 1 |
| Pearson, E | 1 |
| Karunakaran, D | 1 |
| Grasperge, B | 1 |
| Dobek, G | 1 |
| Cain, CM | 1 |
| Hope, T | 2 |
| Kiser, PF | 5 |
| Gathe, J | 6 |
| Bolan, R | 2 |
| Simonson, RB | 1 |
| Benson, C | 1 |
| Dunn, K | 1 |
| Noe, S | 1 |
| Jonsson-Oldenbuettel, C | 1 |
| Jaeger, H | 3 |
| Portilla Sogorb, J | 1 |
| Nascimento, MC | 1 |
| Tenorio, AR | 1 |
| Gartland, MJ | 1 |
| Aizire, J | 1 |
| Flynn, PM | 6 |
| Butler, K | 3 |
| Siberry, GK | 4 |
| Fenton, T | 1 |
| Cababasay, M | 1 |
| Fowler, MG | 3 |
| Krakower, DS | 2 |
| Daskalakis, DC | 2 |
| Feinberg, J | 9 |
| Marcus, JL | 3 |
| Aschenbrenner, DS | 1 |
| Lozano, AB | 1 |
| Chueca, N | 1 |
| Fernández-Fuertes, E | 1 |
| Collado, A | 2 |
| Fernández, JM | 1 |
| Álvarez, M | 3 |
| Tao, X | 1 |
| Lu, Y | 2 |
| Chen, Y | 2 |
| Jain, MK | 4 |
| Hinestrosa, F | 1 |
| Asmuth, DM | 2 |
| Slim, J | 2 |
| Goldstein, D | 1 |
| Applin, S | 1 |
| Ryu, JH | 1 |
| Jiang, S | 3 |
| Cox, S | 7 |
| Nguyen-Cleary, T | 1 |
| Guyer, B | 6 |
| Rossaro, L | 1 |
| Haubrich, RH | 1 |
| Stellbrink, HJ | 11 |
| Lazzarin, A | 16 |
| Woolley, I | 1 |
| Llibre, JM | 7 |
| Biagi, MJ | 1 |
| Schriever, CA | 1 |
| Chiampas, TD | 1 |
| Michienzi, SM | 1 |
| Patel, MC | 1 |
| Young, JD | 1 |
| Badowski, ME | 1 |
| Eke, AC | 1 |
| Gebreyohannes, RD | 1 |
| Sheffield, JS | 1 |
| Fumagalli, L | 1 |
| Nozza, S | 2 |
| Galli, L | 3 |
| Valenti, D | 1 |
| Rizzi, M | 1 |
| Horn, T | 2 |
| McCann, NC | 2 |
| Freedberg, KA | 8 |
| Paltiel, AD | 5 |
| Del Rio, C | 2 |
| Armstrong, WS | 2 |
| Ledergerber, B | 5 |
| Günthard, HF | 4 |
| Schmid, P | 3 |
| Gardner, EM | 8 |
| Hoffmann, C | 4 |
| Schewe, K | 2 |
| Fenske, S | 2 |
| Buhk, T | 1 |
| Sabranski, M | 1 |
| Adam, A | 2 |
| Hansen, S | 1 |
| Berruti, M | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 3 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 2 |
| Wang, J | 7 |
| Huang, L | 2 |
| Hu, K | 1 |
| Guo, Z | 1 |
| Huang, H | 5 |
| Yang, R | 4 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 2 |
| Wang, B | 6 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 6 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 2 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 3 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 3 |
| Li, X | 5 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 5 |
| Liu, Z | 4 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 8 |
| Xu, N | 2 |
| Liu, S | 2 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 2 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 4 |
| Chen, L | 2 |
| Yang, X | 2 |
| Li, W | 5 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Zhu, Z | 2 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 2 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 2 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 2 |
| Zhai, X | 1 |
| Wang, C | 4 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Yan, R | 1 |
| Zhang, Y | 8 |
| Hu, Z | 2 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 2 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 2 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 8 |
| Zhao, R | 1 |
| Gu, Z | 2 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 5 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 3 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 3 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 9 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 2 |
| Yang, P | 1 |
| Yu, X | 2 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 4 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 7 |
| Hu, T | 1 |
| Wang, F | 2 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 4 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 12 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 2 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 3 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 6 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 4 |
| Chen, D | 6 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 5 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 2 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 2 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Xu, Y | 2 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 3 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 2 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 3 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 2 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Huang, Y | 4 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 3 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 2 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 2 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 2 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 2 |
| Shen, Y | 1 |
| Wang, Q | 3 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 2 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 5 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 5 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Xue, H | 1 |
| Zhang, W | 2 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 2 |
| Cai, S | 1 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 9 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 3 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 5 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 2 |
| Wang, D | 2 |
| Hu, M | 2 |
| Shen, H | 2 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 2 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 3 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 4 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 4 |
| Cao, WH | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 2 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Lacey, A | 1 |
| Savinelli, S | 1 |
| Barco, EA | 1 |
| Macken, A | 1 |
| Cotter, AG | 3 |
| Sheehan, G | 1 |
| Muldoon, E | 1 |
| Feeney, E | 1 |
| Mallon, PW | 2 |
| Tinago, W | 1 |
| Baker, J | 2 |
| Rolls, J | 1 |
| Fletcher, CV | 11 |
| Podany, AT | 3 |
| Thorkelson, A | 1 |
| Winchester, LC | 1 |
| Mykris, T | 1 |
| Anderson, J | 3 |
| Jorstad, S | 1 |
| Baker, JV | 1 |
| Schacker, TW | 1 |
| Sevenler, D | 1 |
| Bardon, A | 1 |
| Fernandez Suarez, M | 1 |
| Marshall, L | 1 |
| Toner, M | 1 |
| Sandlin, RD | 1 |
| Spinelli, MA | 3 |
| Haberer, JE | 13 |
| Chai, PR | 1 |
| Bermejo-Vicedo, T | 1 |
| André-Garnier, E | 2 |
| Hingrat, QL | 1 |
| Reliquet, V | 3 |
| Malet, I | 1 |
| Leducq, V | 1 |
| Rodallec, A | 1 |
| Ferré, V | 2 |
| Martorell, C | 1 |
| Wohl, D | 8 |
| Thompson, MA | 4 |
| Flamm, JA | 2 |
| Brinson, C | 9 |
| Clarke, A | 6 |
| Brainard, DM | 5 |
| Yager, J | 3 |
| Ibrahim, ME | 4 |
| McHugh, C | 3 |
| Parsons, TL | 1 |
| Gwenden, KN | 1 |
| Díaz, A | 1 |
| Jarrín, I | 2 |
| Adachi, E | 1 |
| Saito, M | 1 |
| Ikeuchi, K | 1 |
| Hoshina, T | 1 |
| Yotsuyanagi, H | 1 |
| Simeni Njonnou, SR | 1 |
| Noure, L | 1 |
| Goffard, JC | 1 |
| Iwuji, CC | 1 |
| Churchill, D | 3 |
| Bremner, S | 1 |
| Perry, N | 1 |
| To, Y | 1 |
| Lambert, D | 1 |
| Bruce, C | 1 |
| Waters, L | 3 |
| Geretti, AM | 2 |
| Riva, A | 3 |
| Cattaneo, D | 7 |
| Filice, C | 1 |
| Gervasoni, C | 6 |
| Parvangada, A | 1 |
| Collins, S | 1 |
| Massud, I | 3 |
| Ruone, S | 2 |
| Zlotorzynska, M | 1 |
| Haaland, R | 2 |
| Mills, P | 1 |
| Cong, ME | 3 |
| Kelley, K | 1 |
| Johnson, R | 2 |
| Kelley, CF | 2 |
| Sanchez, T | 1 |
| Spiegel, HML | 2 |
| Mounzer, KC | 1 |
| De Wet, JJ | 1 |
| Jessen, H | 2 |
| Grant, RM | 17 |
| Ruane, PJ | 5 |
| Wong, P | 2 |
| Ebrahimi, R | 9 |
| Zhong, L | 13 |
| Mathias, A | 1 |
| Callebaut, C | 16 |
| Coll, P | 1 |
| Hare, CB | 2 |
| Lee, YL | 1 |
| Cheng, CY | 1 |
| Tsai, HC | 1 |
| Huang, SH | 2 |
| Lee, YC | 1 |
| Hsieh, MH | 1 |
| Su, LS | 1 |
| Blum, J | 2 |
| Wyles, DL | 2 |
| Rowan, SE | 1 |
| Johnson, B | 1 |
| Gomez, J | 1 |
| Choi, YJ | 1 |
| Cendali, F | 1 |
| Haas, H | 1 |
| Roon, L | 1 |
| Pellegrini, M | 1 |
| Defechereux, PA | 1 |
| Yu, M | 1 |
| O'Neal, J | 1 |
| Bhasin, S | 1 |
| Sevelius, J | 1 |
| Deutsch, MB | 1 |
| Ferrández, JS | 1 |
| García, AL | 1 |
| Alonso-Vega, GG | 1 |
| González, AO | 1 |
| García, TM | 1 |
| Songtaweesin, WN | 1 |
| Kawichai, S | 2 |
| Phanuphak, N | 2 |
| Wongharn, P | 1 |
| Saisaengjan, C | 1 |
| Chinbunchorn, T | 1 |
| Janyam, S | 1 |
| Linjongrat, D | 1 |
| Puthanakit, T | 4 |
| Béguelin, C | 1 |
| Chave, JP | 1 |
| Boillat-Blanco, N | 1 |
| Doco-Lecompte, T | 1 |
| Walti, LN | 1 |
| Ting, J | 1 |
| Shreay, S | 1 |
| Bush, S | 1 |
| Martin, TCS | 1 |
| Hill, LA | 1 |
| Tang, ME | 1 |
| Balcombe, SM | 1 |
| Li, M | 2 |
| Dorsey, HG | 1 |
| Musoff, C | 1 |
| Jnr, DA | 1 |
| Schoen, N | 1 |
| Djan, K | 1 |
| Paintsil, E | 1 |
| Simmons, B | 2 |
| Moorhouse, M | 2 |
| Mashabane, N | 2 |
| Serenata, C | 3 |
| Masenya, M | 3 |
| Norris, S | 2 |
| Chersich, M | 2 |
| Lalla-Edward, S | 1 |
| Vos, A | 2 |
| Clayden, P | 3 |
| Abrams, E | 2 |
| Arulappan, N | 5 |
| Pilkington, V | 1 |
| Hughes, SL | 1 |
| Pepperrell, T | 1 |
| Gotham, D | 2 |
| Pozniak, AL | 10 |
| Stirrup, OT | 1 |
| Dunn, DT | 2 |
| Wood, BR | 1 |
| Bekerman, E | 1 |
| Babusis, D | 3 |
| Campigotto, F | 1 |
| Barouch, DH | 1 |
| Cihlar, T | 5 |
| Robles, G | 1 |
| Sauermilch, D | 1 |
| Starks, TJ | 1 |
| Rashidi-Alavijeh, J | 1 |
| Straub, K | 1 |
| Achterfeld, A | 1 |
| Wedemeyer, H | 1 |
| Willuweit, K | 1 |
| Herzer, K | 1 |
| Celum, CL | 4 |
| Gill, K | 2 |
| Morton, JF | 2 |
| Stein, G | 1 |
| Myers, L | 4 |
| Thomas, KK | 8 |
| McConnell, M | 1 |
| van der Straten, A | 5 |
| Duyver, M | 2 |
| Mendel, E | 1 |
| Dallimore, J | 1 |
| Momper, JD | 2 |
| Weinberg, A | 1 |
| Cielo, M | 1 |
| Denson, K | 1 |
| Smith, E | 3 |
| Espina, R | 1 |
| Ma, R | 1 |
| Zhang, YS | 1 |
| Xu, B | 1 |
| Tong, ZW | 1 |
| Zhao, CS | 1 |
| Zhao, RG | 1 |
| Ellsworth, GB | 1 |
| Burke, LA | 1 |
| Wells, MT | 1 |
| Mishra, S | 1 |
| Caffrey, M | 1 |
| Liddle, D | 1 |
| Madhava, M | 1 |
| O'Neal, C | 1 |
| Bushman, L | 2 |
| Stein, J | 1 |
| Gulick, RM | 6 |
| Kacanek, D | 2 |
| Huang, S | 3 |
| Nematadzira, TG | 1 |
| Taulo, F | 1 |
| Nakabiito, C | 4 |
| Lypen, K | 1 |
| Brown, E | 1 |
| Chi, BH | 9 |
| Saderup, AM | 1 |
| Libby, AM | 1 |
| Giovenco, D | 1 |
| Fynn, L | 1 |
| O'Rourke, S | 1 |
| Mesplède, T | 2 |
| Obiero, J | 2 |
| Ogongo, P | 1 |
| Mwethera, PG | 2 |
| Wiysonge, CS | 2 |
| Verdon, R | 2 |
| Le Moal, G | 2 |
| Bernard, L | 1 |
| Sunder, S | 1 |
| Roncato-Saberan, M | 1 |
| Ponscarme, D | 1 |
| Etienne, M | 1 |
| Viard, JP | 6 |
| Pasdeloup, T | 1 |
| Darasteanu, I | 1 |
| Pialoux, G | 4 |
| de la Blanchardière, A | 1 |
| Avettand-Fènoël, V | 1 |
| Louie, A | 1 |
| Phung, N | 1 |
| Zhang, K | 1 |
| Tallerico, RM | 1 |
| Kuncze, K | 1 |
| Koss, CA | 1 |
| Benet, LZ | 1 |
| Pontolillo, M | 1 |
| Piscitani, L | 1 |
| Ucciferri, C | 1 |
| Di Liberato, L | 1 |
| Bonomini, M | 1 |
| Vecchiet, J | 1 |
| Pene Dumitrescu, T | 1 |
| Joshi, SR | 1 |
| Zhan, J | 1 |
| Butcher, L | 1 |
| Zimmerman, E | 1 |
| Webster, L | 1 |
| Davidson, AM | 1 |
| Lataillade, M | 2 |
| Min, S | 2 |
| Brummel, SS | 1 |
| Hoffman, RM | 1 |
| Stringer, JS | 7 |
| João, E | 2 |
| Hanley, S | 1 |
| Holmes, LB | 1 |
| Shapiro, RL | 1 |
| Thoofer, NK | 1 |
| Currier, J | 4 |
| Romano, JW | 1 |
| Demkovich, ZR | 1 |
| Diana, F | 1 |
| Dobard, C | 2 |
| Feldman, PL | 2 |
| Ho, DK | 1 |
| Hope, TJ | 2 |
| Milad, M | 1 |
| Roller, S | 2 |
| Srinivasan, S | 2 |
| Veazey, RS | 1 |
| Zane, D | 2 |
| Peterson, S | 1 |
| Ibrahim, M | 2 |
| Moore, CM | 1 |
| Santos-Pereira, A | 1 |
| Triunfante, V | 1 |
| Araújo, PMM | 1 |
| Martins, J | 1 |
| Soares, H | 1 |
| Poveda, E | 7 |
| Souto, B | 1 |
| Osório, NS | 1 |
| Touizer, E | 1 |
| Alrubayyi, A | 1 |
| Rees-Spear, C | 1 |
| Fisher-Pearson, N | 1 |
| Griffith, SA | 1 |
| Muir, L | 1 |
| Pellegrino, P | 1 |
| Burns, F | 1 |
| Kinloch, S | 1 |
| Rowland-Jones, S | 1 |
| Gupta, RK | 2 |
| Gilson, R | 7 |
| Peppa, D | 1 |
| McCoy, LE | 1 |
| Aydin, E | 1 |
| Yilmaz Aydin, F | 1 |
| Demir, Y | 1 |
| Yildirim, Y | 1 |
| Celen, MK | 1 |
| Tsholwana, M | 1 |
| Kassim, S | 1 |
| Mukaka, S | 1 |
| Dye, BJ | 1 |
| Pathak, S | 2 |
| Donnell, DJ | 1 |
| Wilson, E | 1 |
| Yuha, K | 1 |
| Agyei, Y | 1 |
| Noble, H | 1 |
| Rose, SM | 1 |
| Fogel, JM | 1 |
| Adeyeye, A | 1 |
| Rooney, J | 5 |
| Lagoutte-Renosi, J | 1 |
| Flammang, M | 1 |
| Ducloux, D | 1 |
| Bamoulid, J | 1 |
| Royer, PY | 1 |
| Lepiller, Q | 1 |
| Clairet, AL | 1 |
| Davani, S | 1 |
| Shelton, J | 1 |
| Singh, R | 1 |
| Jain, R | 1 |
| Yang, B | 1 |
| Felx, M | 1 |
| Alessi, T | 1 |
| Ogbuagu, O | 1 |
| Salazar, LC | 1 |
| Henry, K | 8 |
| Kintu, A | 3 |
| Carter, C | 1 |
| Whitlock, G | 1 |
| Brunetta, JM | 1 |
| Kronborg, G | 3 |
| Spinner, CD | 2 |
| Goldwirt, L | 1 |
| Bauer, R | 1 |
| Liegeon, G | 1 |
| Charreau, I | 1 |
| Delaugerre, C | 14 |
| Pialou, G | 1 |
| Cua, E | 2 |
| Laghzal, A | 1 |
| Buschman, L | 1 |
| Mourah, S | 1 |
| Meyer, L | 1 |
| D'Angelo, AB | 1 |
| Westmoreland, DA | 1 |
| Carneiro, PB | 1 |
| Johnson, J | 3 |
| Grov, C | 1 |
| Kumar, P | 1 |
| Saag, M | 3 |
| Wurapa, AK | 1 |
| Brar, I | 4 |
| Hileman, CO | 1 |
| Ueaphongsukkit, T | 1 |
| Gatechompol, S | 2 |
| Surintrspanont, J | 1 |
| Iampenkhae, K | 1 |
| Avihingsanon, Y | 1 |
| Udomkarnjananun, S | 1 |
| Poli, A | 1 |
| Ripa, M | 1 |
| Chiappetta, S | 1 |
| Spagnuolo, V | 3 |
| Rovelli, C | 1 |
| Tambussi, G | 1 |
| Margot, N | 8 |
| Ram, R | 1 |
| Johnson, A | 1 |
| Miller, M | 9 |
| Ripin, D | 1 |
| Prabhu, VR | 1 |
| Boffito, M | 9 |
| Flexner, CW | 1 |
| Karris, MY | 1 |
| Cordova, E | 1 |
| Morganti, L | 1 |
| Odzak, A | 1 |
| Arcondo, F | 1 |
| Silva, M | 1 |
| Zylberman, M | 1 |
| Rodriguez, C | 5 |
| Margot, NA | 14 |
| Kulkarni, R | 2 |
| Porter, D | 4 |
| Abram, ME | 5 |
| Miller, MD | 29 |
| Kurmi, M | 1 |
| Singh, S | 1 |
| Lamorde, M | 2 |
| Watkins, M | 1 |
| Maek-A-Nantawat, W | 1 |
| Sapsirisavat, V | 1 |
| Thiansanguankul, W | 1 |
| Sophonphan, J | 4 |
| Thammajaruk, N | 2 |
| Ubolyam, S | 2 |
| Burger, DM | 7 |
| Ruxrungtham, K | 13 |
| Sauvage, AS | 1 |
| Moutschen, M | 1 |
| Gallagher, A | 1 |
| Quan, D | 1 |
| England, JT | 1 |
| Leitch, HA | 1 |
| Mills, A | 13 |
| Tebas, P | 11 |
| Custodio, J | 4 |
| Cheng, A | 23 |
| Workowski, K | 1 |
| Reynes, J | 5 |
| SenGupta, D | 5 |
| Ouyang, B | 1 |
| Zhou, F | 1 |
| Zhen, L | 1 |
| Peng, Y | 1 |
| Wang, G | 1 |
| Novick, TK | 1 |
| Choi, MJ | 1 |
| Rosenberg, AZ | 1 |
| McMahon, BA | 1 |
| Fine, D | 2 |
| Atta, MG | 4 |
| Hoornenborg, E | 1 |
| Prins, M | 1 |
| Achterbergh, RCA | 1 |
| Woittiez, LR | 1 |
| Cornelissen, M | 1 |
| Jurriaans, S | 1 |
| Kootstra, NA | 1 |
| Reiss, P | 15 |
| de Vries, HJC | 1 |
| Prins, JM | 4 |
| de Bree, GJ | 1 |
| Minisci, D | 2 |
| Baldelli, S | 3 |
| Mazzali, C | 1 |
| Giacomelli, A | 1 |
| Milazzo, L | 2 |
| Meraviglia, P | 4 |
| Resnati, C | 1 |
| Clementi, E | 4 |
| Galli, M | 4 |
| Tartaglia, A | 1 |
| Ferrara, SM | 1 |
| Sica, S | 1 |
| Santantonio, T | 1 |
| Donahue Carlson, R | 1 |
| Read, TD | 1 |
| Frisch, MB | 1 |
| Mehta, CC | 1 |
| Martin, A | 9 |
| Haaland, RE | 2 |
| Patel, AS | 1 |
| Pau, CP | 4 |
| Kraft, CS | 1 |
| Liu, AY | 13 |
| Seifert, SM | 2 |
| Wagner, T | 1 |
| Campbell, K | 1 |
| Buchbinder, S | 9 |
| Reinke, T | 1 |
| Moore, DJ | 2 |
| Jain, S | 3 |
| Dubé, MP | 5 |
| Young, J | 4 |
| Corado, K | 2 |
| Ellorin, E | 1 |
| Milam, J | 1 |
| Collins, D | 1 |
| Blumenthal, J | 3 |
| Anderson, P | 1 |
| Morris, SR | 2 |
| Shen, Z | 2 |
| Rodriguez-Garcia, M | 2 |
| Patel, MV | 2 |
| Bodwell, J | 2 |
| Kashuba, ADM | 5 |
| Wira, CR | 2 |
| Bakshi, RP | 1 |
| Manohar, M | 1 |
| Jois, B | 1 |
| Chan, L | 1 |
| Asriel, B | 1 |
| Eaton, EF | 1 |
| Wyatt, CM | 6 |
| Bares, SH | 2 |
| Havens, J | 1 |
| Dyavar, SR | 1 |
| O'Neill, J | 1 |
| Lee, S | 1 |
| Swindells, S | 3 |
| Scarsi, KK | 3 |
| Ma, B | 1 |
| Barth, A | 1 |
| McHale, CM | 1 |
| Lai, MT | 1 |
| Haas, B | 2 |
| Segal-Maurer, S | 1 |
| Thurman, AR | 3 |
| Chandra, N | 2 |
| Yousefieh, N | 2 |
| Kimble, T | 1 |
| Anderson, SM | 2 |
| Sykes, C | 10 |
| Schwartz, JL | 5 |
| Peyrani, P | 1 |
| Mallon, PWG | 1 |
| Castelli, F | 1 |
| Yan, M | 4 |
| Hodder, S | 1 |
| Squires, K | 5 |
| Kido, A | 1 |
| Smith, DE | 2 |
| Tom, M | 1 |
| Bowden, BH | 1 |
| Satsangi, S | 1 |
| Tieu, HV | 1 |
| Taylor, BS | 1 |
| Jones, J | 1 |
| Wilkin, TJ | 1 |
| MacBrayne, CE | 3 |
| Marks, KM | 1 |
| Fierer, DS | 1 |
| Naggie, S | 2 |
| Chung, RT | 1 |
| Hughes, MD | 6 |
| Kim, AY | 1 |
| Peters, MG | 2 |
| Higginson, RT | 2 |
| Negredo, E | 21 |
| Clotet, B | 23 |
| Justman, JE | 1 |
| Nair, GL | 1 |
| Piper, JM | 1 |
| Dai, JY | 3 |
| Pan, Z | 1 |
| Galaska, B | 1 |
| Levy, L | 1 |
| Balar, B | 1 |
| Kunjara Na Ayudhya, RP | 1 |
| Mushamiri, I | 1 |
| McGowan, I | 12 |
| Dezzutti, CS | 8 |
| Cahn, P | 2 |
| Rassool, M | 3 |
| Bloch, M | 3 |
| Homony, B | 1 |
| Hepler, D | 1 |
| Teppler, H | 6 |
| Hanna, GJ | 1 |
| Nguyen, BY | 6 |
| Greaves, W | 1 |
| Hoang, T | 1 |
| Date, AA | 1 |
| Ortiz, JO | 1 |
| Young, TW | 1 |
| Bensouda, S | 1 |
| Xiao, P | 1 |
| Rohan, L | 1 |
| Hendrix, C | 5 |
| Gumber, S | 1 |
| Villinger, F | 1 |
| Cone, RA | 1 |
| Hanes, J | 1 |
| Ensign, LM | 1 |
| Pyra, M | 1 |
| Heffron, R | 3 |
| Mugwanya, K | 1 |
| Bukusi, EA | 4 |
| Mugo, NR | 8 |
| Asiimwe, S | 1 |
| Katabira, E | 9 |
| Deeks, ED | 4 |
| Harris, M | 4 |
| Oguchi, G | 1 |
| Creticos, C | 2 |
| Rockstroh, JK | 8 |
| Laouri, M | 1 |
| Alsunaid, SR | 1 |
| Ashraf, H | 1 |
| Soubani, AO | 1 |
| Lee, SS | 1 |
| Havens, JP | 1 |
| Sayles, HR | 1 |
| O'Neill, JL | 1 |
| Taneva, E | 1 |
| Sinclair, S | 1 |
| Mesquita, PM | 5 |
| Weinrick, B | 1 |
| Cameron, SA | 1 |
| Cheshenko, N | 2 |
| Reagle, K | 1 |
| Frank, B | 1 |
| Fredricks, D | 1 |
| Keller, MJ | 3 |
| Herold, BC | 6 |
| Seneviratne, HK | 1 |
| Bumpus, NN | 6 |
| Njenda, DT | 1 |
| Aralaguppe, SG | 1 |
| Singh, K | 1 |
| Rao, R | 1 |
| Sönnerborg, A | 5 |
| Sarafianos, SG | 1 |
| Jain, P | 1 |
| Ballerini, A | 1 |
| Bruno, G | 1 |
| Hood, RL | 1 |
| Gupte, M | 1 |
| Susnjar, A | 1 |
| Shelton, K | 1 |
| Folci, M | 1 |
| Filgueira, CS | 1 |
| Nehete, P | 1 |
| Sastry, JK | 1 |
| Álvarez, H | 1 |
| Mariño, A | 2 |
| Valcarce, N | 1 |
| García-González, J | 1 |
| Díaz-Cambre, H | 1 |
| Garrett, KL | 1 |
| Maas, BM | 2 |
| Cottrell, ML | 3 |
| Prince, HA | 2 |
| Schauer, AP | 4 |
| White, N | 3 |
| Dumond, JB | 7 |
| Domingo, P | 18 |
| Mateo, MG | 2 |
| Gutierrez, MDM | 1 |
| Vidal, F | 4 |
| Greene, SA | 2 |
| Prince, HMA | 3 |
| Blake, KH | 1 |
| Nelson, JAE | 2 |
| Gay, CL | 3 |
| Cid-Silva, P | 1 |
| Fernández-Bargiela, N | 1 |
| Margusino-Framiñán, L | 1 |
| Balboa-Barreiro, V | 1 |
| Mena-De-Cea, Á | 1 |
| López-Calvo, S | 1 |
| Vázquez-Rodríguez, P | 1 |
| Martín-Herranz, I | 1 |
| Míguez-Rey, E | 1 |
| Castro-Iglesias, Á | 1 |
| Naing, C | 1 |
| Poovorawan, Y | 1 |
| Tong, KS | 1 |
| Squillace, N | 3 |
| Bozzi, G | 1 |
| Colella, E | 1 |
| Bandera, A | 2 |
| Cerva, C | 1 |
| Maffongelli, G | 1 |
| Niubó, J | 4 |
| Perez, E | 1 |
| Tiraboschi, JM | 2 |
| Morenilla, S | 1 |
| Garcia, B | 1 |
| Mandal, S | 2 |
| Kang, G | 3 |
| Prathipati, PK | 2 |
| Fan, W | 3 |
| Li, Q | 3 |
| Destache, CJ | 3 |
| Giacomet, V | 9 |
| Cossu, MV | 1 |
| Capetti, AF | 1 |
| Zuccotti, G | 1 |
| Arrington-Sanders, R | 1 |
| Wilson, CM | 5 |
| Perumean-Chaney, SE | 1 |
| Patki, A | 1 |
| Bahr, NC | 1 |
| Yarlagadda, SG | 1 |
| Pham, HT | 1 |
| Tsai, WC | 1 |
| Hsu, WT | 1 |
| Huang, YC | 1 |
| Chang, SC | 1 |
| Schneck, CD | 1 |
| Lutz, J | 1 |
| Majeed, S | 1 |
| Mannheimer, S | 1 |
| Hirsch-Moverman, Y | 1 |
| Franks, J | 1 |
| Loquere, A | 1 |
| Hoenigl, M | 1 |
| Hassan, A | 1 |
| Ellorin, EE | 1 |
| Abrams, EJ | 1 |
| Zerbe, A | 1 |
| Brittain, K | 1 |
| Gomba, Y | 1 |
| Norman, J | 1 |
| Goodman-Meza, D | 1 |
| Beymer, MR | 1 |
| Kofron, RM | 1 |
| Psaros, C | 3 |
| Jordan, WC | 1 |
| Wohl, AR | 1 |
| Maffuid, K | 1 |
| Poliseno, A | 1 |
| Chun, TW | 2 |
| Huiting, E | 1 |
| Stanczyk, FZ | 1 |
| Peery, AF | 1 |
| Dellon, ES | 1 |
| Adams, JL | 4 |
| Gay, C | 1 |
| Myers, JJ | 1 |
| Kang Dufour, MS | 1 |
| Koester, KA | 2 |
| Udoh, I | 1 |
| Frazier, R | 1 |
| Packard, R | 1 |
| Kennedy, K | 1 |
| Erguera, X | 1 |
| Horowitz, J | 1 |
| Grant, R | 7 |
| Burack, JH | 1 |
| Blake, K | 1 |
| Wohl, DA | 5 |
| Yazdanpanah, Y | 6 |
| Baumgarten, A | 1 |
| Barber, TJ | 1 |
| Albrecht, H | 3 |
| Martorell, CT | 2 |
| Huntley, R | 1 |
| Alexander, K | 2 |
| Kerr, BJ | 2 |
| Tilden, S | 1 |
| Cohen, S | 2 |
| Vittinghoff, E | 5 |
| Coleman, ME | 3 |
| Scott, H | 1 |
| Bacon, O | 3 |
| Elion, R | 9 |
| Kolber, MA | 3 |
| Buchbinder, SP | 7 |
| Lelièvre, JD | 1 |
| Parczewski, M | 1 |
| Ravel, J | 1 |
| Gajer, P | 1 |
| Townsend, L | 1 |
| Tuite, H | 1 |
| Nicol, MR | 3 |
| Eneh, P | 1 |
| Nakalega, R | 1 |
| Kaiser, T | 1 |
| Kabwigu, S | 1 |
| Isingel, E | 1 |
| Beksinska, M | 1 |
| Brown, TT | 3 |
| Staley, C | 1 |
| Kiweewa Matovu, F | 1 |
| Mallayasamy, S | 1 |
| Chaturvedula, A | 1 |
| Fossler, MJ | 1 |
| Sale, M | 1 |
| Goti, V | 1 |
| Sripongpun, P | 1 |
| Mannalithara, A | 1 |
| Kwo, PY | 1 |
| Kim, WR | 1 |
| Cunningham, D | 1 |
| Kaplun, O | 1 |
| Psevdos, G | 2 |
| Livermont, T | 1 |
| Fountain, J | 1 |
| Lupo, LD | 2 |
| Hall, L | 1 |
| Conway-Washington, C | 1 |
| Lipscomb, J | 2 |
| Deyounks, F | 2 |
| Park, Y | 1 |
| Lennox, JL | 5 |
| Wan, H | 3 |
| Rodgers, AJ | 3 |
| Walker, ML | 2 |
| DiNubile, MJ | 4 |
| Leavitt, R | 3 |
| Sklar, P | 3 |
| Prince, HM | 3 |
| Kendrick, RL | 1 |
| Jennings, SH | 1 |
| Malone, S | 1 |
| Corbett, AH | 2 |
| Patterson, KB | 7 |
| Forrest, A | 2 |
| Kashuba, AD | 15 |
| Bayonne Kombo, ES | 1 |
| Gathse, A | 1 |
| Childs, K | 1 |
| Joshi, D | 1 |
| Byrne, R | 1 |
| Bruce, M | 1 |
| Carey, I | 1 |
| Agarwal, K | 1 |
| Taylor, C | 1 |
| Vrouenraets, SM | 4 |
| Brady, JJ | 1 |
| Wit, FW | 5 |
| Brinkman, K | 4 |
| Sabin, CA | 4 |
| Plosker, GL | 2 |
| Duval, X | 4 |
| Nembot, G | 2 |
| Vigan, M | 1 |
| Vrijens, B | 2 |
| Panhard, X | 3 |
| Mentré, F | 3 |
| Grohskopf, LA | 1 |
| Chillag, KL | 2 |
| Gvetadze, R | 2 |
| Thompson, M | 6 |
| Collins, BM | 1 |
| Pathak, SR | 2 |
| Oʼhara, B | 2 |
| Ackers, ML | 1 |
| Rose, CE | 5 |
| Paxton, LA | 9 |
| Nishijima, T | 11 |
| Shimbo, T | 3 |
| Komatsu, H | 7 |
| Takano, M | 3 |
| Tanuma, J | 7 |
| Tsukada, K | 6 |
| Teruya, K | 8 |
| Gatanaga, H | 13 |
| Kikuchi, Y | 9 |
| Matthews, LT | 2 |
| Sibeko, S | 9 |
| Mansoor, LE | 12 |
| Bangsberg, DR | 10 |
| Karim, QA | 18 |
| Naranbhai, V | 8 |
| Samsunder, N | 6 |
| Sandler, NG | 1 |
| Roque, A | 1 |
| Abdool Karim, Q | 12 |
| Ndungʼu, T | 1 |
| Carr, WH | 2 |
| Altfeld, M | 3 |
| Douek, DC | 1 |
| Abdool Karim, SS | 18 |
| Chillag, K | 1 |
| Mayer, K | 4 |
| Grohskopf, L | 1 |
| Colfax, G | 1 |
| Collins, B | 1 |
| Ackers, M | 1 |
| Paxton, L | 3 |
| Hayashida, T | 2 |
| Urdiales, D | 2 |
| Pombo, M | 2 |
| del Arco, A | 3 |
| de la Torre, J | 2 |
| Prada, JL | 2 |
| Hotta, MT | 1 |
| Broderick, E | 1 |
| Boucher, CA | 5 |
| van Dijk, JH | 1 |
| Thuma, PE | 1 |
| Nouwen, JL | 1 |
| Baltussen, R | 1 |
| van de Wijgert, J | 1 |
| Sloot, PM | 1 |
| van de Vijver, DA | 4 |
| Chateau, ML | 1 |
| Denton, PW | 4 |
| Swanson, MD | 3 |
| Garcia, JV | 5 |
| Sued, O | 1 |
| Gallant, JE | 22 |
| Andrade-Villanueva, J | 6 |
| Antunes, F | 4 |
| Arastéh, K | 5 |
| Moyle, G | 10 |
| Szwarcberg, J | 7 |
| Ishisaka, M | 1 |
| Endo, T | 2 |
| Horiba, M | 2 |
| Kaneda, S | 1 |
| Uchiumi, H | 1 |
| Koibuchi, T | 1 |
| Naito, T | 2 |
| Yoshida, M | 1 |
| Tachikawa, N | 2 |
| Ueda, M | 1 |
| Yokomaku, Y | 1 |
| Fujii, T | 2 |
| Takada, K | 3 |
| Yamamoto, M | 2 |
| Matsushita, S | 1 |
| Tateyama, M | 1 |
| Tanabe, Y | 2 |
| Mitsuya, H | 3 |
| Vourvahis, M | 2 |
| Davis, J | 1 |
| Langdon, G | 1 |
| Layton, G | 1 |
| Choo, HW | 1 |
| Hansson, AG | 1 |
| Tawadrous, M | 2 |
| Hoesley, C | 3 |
| Cranston, RD | 2 |
| Andrew, P | 1 |
| Janocko, L | 2 |
| Carballo-Dieguez, A | 5 |
| Ayudhya, RK | 1 |
| Piper, J | 2 |
| Hladik, F | 2 |
| Kiage, JN | 1 |
| Heimburger, DC | 1 |
| Nyirenda, CK | 1 |
| Wellons, MF | 1 |
| Bagchi, S | 1 |
| Koethe, JR | 1 |
| Arnett, DK | 1 |
| Kabagambe, EK | 1 |
| Antonucci, G | 1 |
| Mazzotta, F | 1 |
| Angeletti, C | 1 |
| Girardi, E | 1 |
| Puoti, M | 6 |
| De Stefano, G | 1 |
| Grossi, P | 2 |
| Petrosillo, N | 1 |
| Pagano, G | 2 |
| Cassola, G | 1 |
| Orani, A | 1 |
| Sagnelli, C | 2 |
| Armignacco, O | 1 |
| Sagnelli, E | 2 |
| Fuchs, JD | 1 |
| Sobieszczyk, ME | 1 |
| Madenwald, T | 1 |
| Grove, D | 1 |
| Karuna, ST | 1 |
| Andrasik, M | 1 |
| Sherwat, A | 1 |
| Broder, G | 1 |
| Koblin, B | 1 |
| Hammer, S | 1 |
| Chaowanachan, T | 1 |
| Krogstad, E | 1 |
| Ball, C | 2 |
| Woodrow, KA | 1 |
| Fabiano, V | 2 |
| Viganò, A | 8 |
| Bedogni, G | 2 |
| Stucchi, S | 2 |
| Cococcioni, L | 1 |
| Zuccotti, GV | 6 |
| Ouattara, E | 1 |
| Danel, C | 2 |
| Moh, R | 1 |
| Gabillard, D | 2 |
| Konan, R | 1 |
| Carrou, JL | 1 |
| Bohoussou, F | 1 |
| Eholie, SP | 2 |
| Anglaret, X | 2 |
| Aguilar, A | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Sabin, C | 4 |
| Bansi, L | 3 |
| Dunn, D | 8 |
| Fearnhill, E | 2 |
| Boumis, E | 2 |
| Nicastri, E | 1 |
| Palamara, G | 1 |
| Callegaro, A | 1 |
| Francisci, D | 5 |
| Zoncada, A | 2 |
| Zazzi, M | 5 |
| Plaza, Z | 1 |
| Mena, A | 1 |
| Vispo, E | 9 |
| Sierra-Enguita, R | 2 |
| Tomé, S | 1 |
| Pedreira, J | 2 |
| Barreiro, P | 17 |
| del Romero, J | 2 |
| Soriano, V | 37 |
| Underhill, K | 2 |
| Morrow, KM | 3 |
| Cohen, JA | 1 |
| Brache, V | 1 |
| Foster, J | 1 |
| Cochon, L | 1 |
| Callahan, M | 1 |
| Schwartz, J | 1 |
| Wainberg, MA | 9 |
| Brun-Vezinet, F | 5 |
| Gatell, JM | 11 |
| Albert, J | 2 |
| Nachega, JB | 2 |
| Tang, MW | 2 |
| Rhee, SY | 2 |
| Bertagnolio, S | 2 |
| Ford, N | 6 |
| Holmes, S | 1 |
| Sigaloff, KC | 3 |
| Hamers, RL | 2 |
| de Wit, TF | 1 |
| Fleury, HJ | 1 |
| Kanki, PJ | 2 |
| Hawkins, CA | 1 |
| Wallis, CL | 2 |
| Stevens, W | 1 |
| van Zyl, GU | 1 |
| Manosuthi, W | 7 |
| Ngo-Giang-Huong, N | 2 |
| Belec, L | 2 |
| Peeters, M | 1 |
| Aghokeng, A | 1 |
| Bunupuradah, T | 5 |
| Burda, S | 1 |
| Cane, P | 1 |
| Cappelli, G | 2 |
| Dagnra, AY | 1 |
| Deshpande, AK | 1 |
| El-Katib, Z | 1 |
| Eshleman, SH | 5 |
| Fokam, J | 1 |
| Gody, JC | 1 |
| Katzenstein, D | 6 |
| Koyalta, DD | 1 |
| Kumwenda, JJ | 2 |
| Lallemant, M | 2 |
| Lynen, L | 4 |
| Moussa, S | 2 |
| Ndung'u, T | 3 |
| Nyambi, PN | 1 |
| Schapiro, JM | 2 |
| Schuurman, R | 1 |
| Sirivichayakul, S | 1 |
| Smith, D | 3 |
| Zolfo, M | 1 |
| Jordan, MR | 2 |
| Shafer, RW | 5 |
| Velen, K | 1 |
| Lewis, JJ | 1 |
| Charalambous, S | 2 |
| Grant, AD | 2 |
| Churchyard, GJ | 2 |
| Hoffmann, CJ | 4 |
| Woratanarat, K | 1 |
| Kanjanabuch, T | 1 |
| Suankratay, C | 1 |
| Funk, EK | 1 |
| Shaffer, A | 1 |
| Shivakumar, B | 1 |
| Sneller, M | 1 |
| Polis, MA | 1 |
| Masur, H | 2 |
| Heytens, L | 1 |
| Nelson, A | 2 |
| Kwan, R | 1 |
| Kottilil, S | 2 |
| Kohli, A | 2 |
| Falcinelli, E | 2 |
| Belfiori, B | 2 |
| Petito, E | 2 |
| Guglielmini, G | 1 |
| Malincarne, L | 1 |
| Mezzasoma, A | 1 |
| Sebastiano, M | 1 |
| Conti, V | 1 |
| Giannini, S | 1 |
| Bonora, S | 8 |
| Baldelli, F | 3 |
| Gresele, P | 2 |
| Njuguna, C | 1 |
| Kaplan, R | 4 |
| Wood, R | 3 |
| Lawn, SD | 1 |
| Lange, MM | 1 |
| Rogers, W | 1 |
| Dodds, S | 1 |
| Abgrall, S | 1 |
| Ingle, SM | 1 |
| May, MT | 1 |
| Costagliola, D | 5 |
| Mercie, P | 2 |
| Reekie, J | 1 |
| Samji, H | 1 |
| Gill, MJ | 1 |
| Crane, HM | 4 |
| Tate, J | 1 |
| Sterling, TR | 1 |
| Mugavero, MJ | 1 |
| Phillips, A | 3 |
| Manzardo, C | 1 |
| Wasmuth, JC | 1 |
| Stephan, C | 8 |
| Guest, JL | 1 |
| Gomez Sirvent, JL | 2 |
| Sterne, JA | 1 |
| Haire, B | 2 |
| Folayan, MO | 1 |
| Hankins, C | 1 |
| Sugarman, J | 2 |
| McCormack, S | 2 |
| Ramjee, G | 3 |
| Warren, M | 1 |
| Senn, H | 1 |
| Wilton, J | 1 |
| Fowler, S | 1 |
| Tan, DH | 3 |
| Feuth, T | 1 |
| van Baarle, D | 1 |
| Hoepelman, AI | 4 |
| Arends, JE | 1 |
| Wikman, P | 1 |
| Safont, P | 1 |
| Del Palacio, M | 1 |
| Moreno, A | 1 |
| Casado, JL | 1 |
| Ledwaba, J | 1 |
| Li, JF | 3 |
| Johnston, V | 1 |
| Hunt, G | 2 |
| Fielding, KL | 1 |
| Chaisson, RE | 1 |
| Johnson, JA | 4 |
| Morris, L | 4 |
| Sista, N | 1 |
| Fleming, TR | 1 |
| Baxter, C | 11 |
| Karim, SA | 4 |
| Karim, SS | 11 |
| Choopanya, K | 5 |
| Martin, M | 5 |
| Suntharasamai, P | 5 |
| Sangkum, U | 5 |
| Mock, PA | 5 |
| Leethochawalit, M | 4 |
| Chiamwongpaet, S | 4 |
| Kitisin, P | 1 |
| Natrujirote, P | 1 |
| Kittimunkong, S | 4 |
| Chuachoowong, R | 2 |
| Gvetadze, RJ | 4 |
| McNicholl, JM | 4 |
| Curlin, ME | 3 |
| Vanichseni, S | 5 |
| Morlat, P | 3 |
| Vivot, A | 1 |
| Vandenhende, MA | 1 |
| Dauchy, FA | 2 |
| Asselineau, J | 1 |
| Déti, E | 1 |
| Gerard, Y | 1 |
| Lazaro, E | 1 |
| Duffau, P | 1 |
| Neau, D | 3 |
| Bonnet, F | 3 |
| Chêne, G | 7 |
| Belavic, JM | 1 |
| Núñez, M | 7 |
| Mendes-Correa, MC | 3 |
| Rosenkranz, SL | 2 |
| Cillo, AR | 1 |
| Lu, D | 3 |
| Jacobson, JM | 3 |
| Lederman, M | 1 |
| Acosta, EP | 9 |
| Campbell, T | 2 |
| Flexner, C | 2 |
| Markowitz, M | 8 |
| Bredeek, UF | 2 |
| Ramanathan, S | 7 |
| Fordyce, MW | 6 |
| Yale, K | 7 |
| Cao, Y | 2 |
| Han, Y | 1 |
| Xie, J | 1 |
| Cui, Q | 1 |
| Song, X | 1 |
| Zhu, T | 1 |
| Li, T | 3 |
| Bach-Ngohou, K | 1 |
| Billaud, E | 2 |
| Sécher, S | 1 |
| Dejoie, T | 1 |
| Fakhouri, F | 1 |
| Boot, J | 1 |
| Rump, BO | 1 |
| Op de Coul, EL | 1 |
| van Agtmael, MA | 2 |
| Fanoy, EB | 1 |
| Boeke, AJ | 1 |
| Heijnen, AM | 1 |
| Lucey, JM | 1 |
| Hsu, P | 1 |
| Ziegler, JB | 1 |
| Shahar, E | 1 |
| Mugrabi, F | 1 |
| Kedem, E | 1 |
| Hassoun, G | 1 |
| Pollack, S | 1 |
| Shawn Justement, J | 1 |
| Murray, D | 1 |
| Kim, CJ | 1 |
| Blazkova, J | 1 |
| Hallahan, CW | 1 |
| Benko, E | 1 |
| Costiniuk, CT | 1 |
| Kandel, G | 1 |
| Ostrowski, M | 1 |
| Kaul, R | 2 |
| Moir, S | 1 |
| Casazza, JP | 1 |
| Koup, RA | 1 |
| Kovacs, C | 2 |
| Fauci, AS | 1 |
| Foisy, MM | 1 |
| Hughes, C | 1 |
| Hills-Nieminen, C | 1 |
| Singh, AE | 1 |
| Joffe, AM | 1 |
| Price, H | 1 |
| Pillay, D | 9 |
| de Vries-Sluijs, T | 1 |
| Kuzushita, N | 1 |
| Nüesch, R | 3 |
| Peters, M | 1 |
| Reiberger, T | 2 |
| Tan, L | 1 |
| Spiegel, LR | 1 |
| Schrier, PB | 1 |
| Shah, HH | 1 |
| Fortuna, S | 1 |
| Fabbiani, M | 3 |
| Digiambenedetto, S | 1 |
| Ragazzoni, E | 1 |
| Lisi, L | 1 |
| Cauda, R | 5 |
| Navarra, P | 2 |
| Zaaijer, HL | 3 |
| Siwale, M | 1 |
| Ive, P | 4 |
| Botes, ME | 1 |
| Stevens, WS | 3 |
| Rinke de Wit, TF | 1 |
| Moyle, GJ | 9 |
| Compston, J | 3 |
| Granier, C | 2 |
| Pearce, H | 2 |
| Sedani, S | 1 |
| Gartland, M | 1 |
| Dang, NT | 2 |
| Sivakumaran, H | 2 |
| Harrich, D | 2 |
| Coombes, AG | 2 |
| Pradat, P | 1 |
| Le Pogam, MA | 1 |
| Okon, JB | 1 |
| Trolliet, P | 1 |
| Miailhes, P | 8 |
| Brochier, C | 2 |
| Maynard, M | 1 |
| Bailly, F | 1 |
| Zoulim, F | 10 |
| Cournil, A | 2 |
| Peyriere, H | 1 |
| Psomas, C | 1 |
| Guiller, E | 1 |
| Chatron, M | 1 |
| Cristol, JP | 2 |
| Badiou, S | 2 |
| Echenique, IA | 1 |
| Rich, JD | 1 |
| Abbas, UL | 1 |
| Cambiano, V | 2 |
| Eaton, JW | 1 |
| Glaubius, R | 1 |
| Lythgoe, K | 1 |
| Mellors, J | 2 |
| Hallett, TB | 1 |
| Saguil, A | 1 |
| Shearer, K | 3 |
| Fox, MP | 5 |
| Maskew, M | 5 |
| Berhanu, R | 1 |
| Long, L | 4 |
| Sanne, I | 7 |
| Loos, D | 1 |
| Hadeler, J | 1 |
| Feucht, N | 1 |
| Schwerdtfeger, C | 1 |
| Schmid, RM | 1 |
| Lanzl, I | 1 |
| Koga, M | 1 |
| Itoda, I | 1 |
| Tei, M | 1 |
| Miyakawa, T | 1 |
| Pammi, M | 1 |
| Arumainayagam, J | 1 |
| Kumari, B | 1 |
| Ahmed-Jushuf, I | 1 |
| Carlin, EM | 1 |
| Chandramani, S | 1 |
| Riddell, L | 1 |
| Ghanem, M | 1 |
| Das, S | 2 |
| Gulholm, T | 1 |
| Jamani, S | 1 |
| Poynten, IM | 2 |
| Bifano, M | 1 |
| Hwang, C | 1 |
| Oosterhuis, B | 1 |
| Hartstra, J | 1 |
| Grasela, D | 1 |
| Tiessen, R | 1 |
| Velinova-Donga, M | 1 |
| Kandoussi, H | 1 |
| Sevinsky, H | 2 |
| Bertz, R | 3 |
| Koulla-Shiro, S | 2 |
| Sow, PS | 4 |
| Ngolle, M | 1 |
| Diallo, MB | 2 |
| Guèye, NF | 2 |
| Le Moing, V | 1 |
| Eymard-Duvernay, S | 2 |
| Delaporte, E | 4 |
| Wainwright, E | 1 |
| Sherrard, J | 1 |
| Duncan, S | 1 |
| Shine, B | 1 |
| Dorrell, L | 1 |
| Boyd, A | 9 |
| Brichler, S | 1 |
| Scholtès, C | 1 |
| Maylin, S | 6 |
| Chevallier-Queyron, P | 1 |
| Gordien, E | 2 |
| Rasch, MG | 2 |
| Helleberg, M | 1 |
| Feldt-Rasmussen, B | 2 |
| Larsen, CS | 2 |
| Pedersen, C | 2 |
| Pedersen, G | 1 |
| Gerstoft, J | 5 |
| Obel, N | 3 |
| Taha, T | 1 |
| Kreitchmann, R | 2 |
| Nielsen-Saines, K | 1 |
| Kumwenda, N | 1 |
| Pinto, J | 2 |
| Santos, B | 1 |
| Parsons, T | 1 |
| Kearney, B | 3 |
| Emel, L | 1 |
| Herron, C | 1 |
| Richardson, P | 1 |
| Hudelson, SE | 1 |
| Sato, P | 1 |
| Mofenson, L | 1 |
| Bickel, M | 3 |
| Khaykin, P | 2 |
| Schmidt, K | 1 |
| Buettner, M | 1 |
| Amann, K | 1 |
| Lutz, T | 9 |
| Gute, P | 3 |
| Haberl, A | 3 |
| Geiger, H | 1 |
| Brodt, HR | 2 |
| Jung, O | 1 |
| Menezes, CN | 2 |
| Crowther, NJ | 2 |
| Duarte, R | 2 |
| Van Amsterdam, D | 2 |
| Evans, D | 2 |
| Dickens, C | 2 |
| Dix-Peek, T | 2 |
| Prinsloo, A | 1 |
| Raal, F | 2 |
| Rosenberg, K | 1 |
| Arnoczy, G | 1 |
| Fichtenbaum, CJ | 4 |
| Taiwo, B | 2 |
| Hicks, C | 1 |
| McComsey, GA | 9 |
| Koletar, S | 1 |
| Sax, P | 1 |
| Ha, B | 8 |
| Massengale, K | 2 |
| Walsh, K | 2 |
| Stein, JH | 2 |
| Havens, PL | 5 |
| Stephensen, CB | 3 |
| Hazra, R | 11 |
| Rutledge, B | 3 |
| Bethel, J | 3 |
| Pan, CG | 3 |
| Woodhouse, LR | 3 |
| Van Loan, MD | 3 |
| Liu, N | 3 |
| Lujan-Zilbermann, J | 3 |
| Baker, A | 3 |
| Kapogiannis, BG | 4 |
| Gordon, CM | 2 |
| Mulligan, K | 5 |
| McAllister, J | 2 |
| Read, P | 1 |
| McNulty, A | 1 |
| Tong, WW | 1 |
| Ingersoll, A | 1 |
| Carr, A | 12 |
| Gentile, I | 1 |
| Bonadies, G | 1 |
| Buonomo, AR | 1 |
| Borrelli, F | 1 |
| Portella, G | 1 |
| Borgia, G | 1 |
| Zhiliang, H | 1 |
| Yongfeng, Y | 1 |
| Hudgens, MG | 3 |
| Cole, SR | 2 |
| Miller, WC | 1 |
| Hoffman, IF | 1 |
| Latkin, CA | 1 |
| Strathdee, SA | 1 |
| Shoptaw, S | 1 |
| Craig, AP | 1 |
| Gray, R | 1 |
| Jansson, J | 2 |
| Wilson, DP | 2 |
| Chopera, DR | 1 |
| Mann, JK | 1 |
| Mwimanzi, P | 1 |
| Omarjee, S | 1 |
| Kuang, XT | 1 |
| Ndabambi, N | 1 |
| Goodier, S | 2 |
| Martin, E | 1 |
| Brumme, ZL | 1 |
| Williamson, C | 4 |
| Brockman, MA | 1 |
| Tanaka, H | 1 |
| Arai, M | 1 |
| Tomoda, Y | 1 |
| Wada, T | 1 |
| Yago, K | 1 |
| Satoh, M | 1 |
| Katlama, C | 18 |
| Bentata, M | 1 |
| Roux, C | 1 |
| Kolta, S | 1 |
| Rozenberg, S | 1 |
| Katz, DF | 1 |
| Aldir, I | 1 |
| Horta, A | 1 |
| Serrado, M | 1 |
| Bender, BS | 1 |
| Kourtis, AP | 2 |
| Ellington, S | 1 |
| Legardy-Williams, J | 1 |
| Bulterys, M | 2 |
| Hughes, DJ | 1 |
| Fitzgerald, N | 1 |
| Sran, H | 1 |
| Konig, M | 1 |
| Moore-Moffatt, R | 1 |
| Webb, A | 1 |
| Gilleece, Y | 2 |
| Churchill, DR | 1 |
| Tourret, J | 1 |
| Deray, G | 6 |
| Isnard-Bagnis, C | 2 |
| Bulteel, N | 1 |
| Bansi-Matharu, L | 1 |
| Bibby, D | 1 |
| Hill, T | 4 |
| Nelson, M | 12 |
| Campbell, J | 2 |
| Wangisi, J | 5 |
| Ronald, A | 6 |
| Tumwesigye, E | 7 |
| Safren, SA | 1 |
| Ware, NC | 2 |
| Krows, M | 3 |
| Kidoguchi, L | 4 |
| Danjuma, MI | 1 |
| Mohamad-Fadzillah, NH | 1 |
| Nannini, P | 1 |
| Manfredini, V | 3 |
| Ramponi, G | 1 |
| Quiros-Roldan, E | 5 |
| Belonosova, E | 1 |
| Baril, JG | 2 |
| Brennan, C | 2 |
| Almond, S | 2 |
| Kibengo, FM | 1 |
| Ruzagira, E | 1 |
| Katende, D | 1 |
| Bwanika, AN | 1 |
| Bahemuka, U | 1 |
| Barin, B | 2 |
| Mark, D | 2 |
| Chetty, P | 2 |
| Fast, P | 2 |
| Kamali, A | 1 |
| Priddy, FH | 2 |
| Gilmore, HJ | 1 |
| Liu, A | 3 |
| McMahan, V | 7 |
| Goicochea, P | 4 |
| Vargas, L | 2 |
| Lubensky, D | 1 |
| Kamkuemah, M | 2 |
| Chariyalertsak, C | 1 |
| Wongthanee, A | 1 |
| Yotruean, K | 1 |
| Saokhieo, P | 1 |
| Guadamuz, T | 1 |
| Suwanvanichkij, V | 1 |
| Beyrer, C | 2 |
| Chariyalertsak, S | 5 |
| van Griensven, J | 3 |
| Phirum, L | 1 |
| Thai, S | 1 |
| Buyze, J | 1 |
| Zoungrana, J | 1 |
| Hema, A | 1 |
| Bado, G | 1 |
| Poda, GE | 1 |
| Kamboulé, EB | 1 |
| Kaboré, FN | 1 |
| Soré, I | 1 |
| Sawadogo, AB | 1 |
| Custodio, JM | 3 |
| Yin, X | 1 |
| Hepner, M | 1 |
| Ling, KH | 2 |
| Kearney, BP | 17 |
| Koenig, KF | 1 |
| Kalbermatter, S | 1 |
| Menter, T | 1 |
| Graber, P | 1 |
| Kiss, D | 1 |
| Maeda, K | 2 |
| Desai, DV | 1 |
| Aoki, M | 1 |
| Nakata, H | 2 |
| Kodama, EN | 1 |
| Jabłonowska, E | 1 |
| Wójcik, K | 1 |
| Piekarska, A | 1 |
| Ryom, L | 2 |
| Mocroft, A | 5 |
| Lundgren, JD | 4 |
| Brennan, AT | 2 |
| Baxi, SM | 1 |
| Greenblatt, RM | 2 |
| Bacchetti, P | 3 |
| Scherzer, R | 4 |
| Minkoff, H | 1 |
| Anastos, K | 3 |
| Cohen, M | 3 |
| Gange, SJ | 1 |
| Young, M | 3 |
| Shlipak, MG | 4 |
| Mi, D | 1 |
| Moe, SM | 1 |
| Gerber, F | 1 |
| Rohr, J | 1 |
| Chimbetete, C | 3 |
| Prozesky, H | 2 |
| Boulle, A | 2 |
| Gsponer, T | 1 |
| Zwahlen, M | 1 |
| Egger, M | 2 |
| Storto, A | 2 |
| Fofana, D | 1 |
| Soulie, C | 3 |
| Fourati, S | 2 |
| Wirden, M | 8 |
| Morand-Joubert, L | 5 |
| Masquelier, B | 5 |
| Flandre, P | 5 |
| Calvez, V | 13 |
| Landonio, S | 4 |
| Fucile, S | 2 |
| Castagnoli, L | 1 |
| Perry, CM | 3 |
| Chirwa, LI | 2 |
| Niska, RW | 1 |
| Segolodi, TM | 3 |
| Henderson, FL | 3 |
| Thigpen, MC | 3 |
| Matlhaba, O | 1 |
| Brooks, JT | 7 |
| Kallas, EG | 4 |
| Montoya-Herrera, O | 3 |
| Pilotto, J | 1 |
| Funderburg, NT | 2 |
| Chan, ES | 1 |
| Clagett, B | 1 |
| Pilch-Cooper, HA | 1 |
| Rodriguez, B | 2 |
| Daar, E | 2 |
| Kuritzkes, D | 1 |
| Lederman, MM | 1 |
| Redd, AD | 2 |
| Mullis, CE | 1 |
| Wendel, SK | 1 |
| Sheward, D | 1 |
| Martens, C | 1 |
| Bruno, D | 1 |
| Werner, L | 10 |
| Garrett, NJ | 2 |
| Porcella, SF | 1 |
| Quinn, TC | 2 |
| Rahman, SM | 1 |
| Vaidya, NK | 1 |
| Zou, X | 1 |
| Murnane, PM | 1 |
| Mugo, N | 3 |
| Campbell, JD | 4 |
| Bukusi, E | 3 |
| Mujugira, A | 6 |
| Tappero, J | 2 |
| Kahle, EM | 1 |
| Meng, J | 2 |
| Ezoulin, MJ | 1 |
| Youan, BB | 4 |
| Terris-Prestholt, F | 1 |
| Foss, AM | 1 |
| Cox, AP | 1 |
| Heise, L | 1 |
| Mertenskoetter, T | 4 |
| Vickerman, P | 1 |
| Watts, CH | 2 |
| Pezzani, D | 1 |
| Jin, C | 1 |
| Goggin, K | 1 |
| Stojanovski, K | 1 |
| Passmore, JA | 1 |
| Mwafongo, A | 2 |
| Nkanaunena, K | 1 |
| Hogg, E | 4 |
| Samaneka, W | 1 |
| Mulenga, L | 3 |
| Siika, A | 3 |
| Bowonwattanuwong, C | 2 |
| Jirajariyavej, S | 3 |
| Munsakul, W | 3 |
| Klinbuayaem, V | 3 |
| Mahanontharit, A | 4 |
| Hirschel, B | 15 |
| Ananworanich, J | 9 |
| Dufrene, SL | 1 |
| Okulicz, JF | 1 |
| Sukasem, C | 3 |
| Chamnanphon, M | 1 |
| Koomdee, N | 1 |
| Santon, S | 1 |
| Jantararoungtong, T | 1 |
| Prommas, S | 1 |
| Puangpetch, A | 1 |
| Solomon, MM | 2 |
| Lama, JR | 4 |
| Guanira, JV | 5 |
| Schechter, M | 3 |
| Burns, DN | 2 |
| Kim, HN | 1 |
| Rodriguez, CV | 1 |
| Van Rompaey, S | 1 |
| Thio, CL | 3 |
| Overton, ET | 2 |
| Martin, J | 1 |
| Geng, E | 1 |
| Mugavero, M | 1 |
| Mathews, WC | 1 |
| Boswell, S | 1 |
| Moore, R | 1 |
| Kitahata, MM | 3 |
| Zolopa, A | 5 |
| Coakley, D | 2 |
| Wulfsohn, M | 4 |
| Anderson, S | 1 |
| Hardy, H | 1 |
| Farajallah, A | 7 |
| DeGrosky, M | 1 |
| McGrath, D | 5 |
| Shaffer, D | 4 |
| Sawe, F | 3 |
| Bao, Y | 1 |
| Moses, A | 2 |
| Mitchell, D | 1 |
| Israr, M | 1 |
| Alam, S | 1 |
| Dinello, D | 1 |
| Kishel, J | 1 |
| Jia, R | 1 |
| Meyers, C | 1 |
| Ezinga, M | 1 |
| Wetzels, JF | 1 |
| Bosch, ME | 1 |
| van der Ven, AJ | 1 |
| Musonda, P | 1 |
| Mwango, A | 3 |
| Vinikoor, MJ | 2 |
| Davies, MA | 1 |
| Mweemba, A | 1 |
| Keiser, O | 2 |
| Estrella, MM | 2 |
| Moosa, MR | 1 |
| Jose, S | 1 |
| Campbell, LJ | 3 |
| Fisher, M | 13 |
| Leen, C | 3 |
| Walsh, J | 4 |
| Hay, P | 2 |
| Chadwick, D | 1 |
| Nitsch, D | 2 |
| Follansbee, S | 1 |
| Cohan, D | 3 |
| Weber, S | 2 |
| Sachdev, D | 1 |
| Hafkin, JS | 1 |
| Osborn, MK | 1 |
| Localio, AR | 1 |
| Amorosa, VK | 1 |
| Kostman, JR | 1 |
| Stern, JJ | 1 |
| De La Torre, P | 1 |
| Mounzer, K | 2 |
| Frank, I | 1 |
| Gross, R | 2 |
| Chang, KM | 1 |
| Lo Re, V | 1 |
| Mangioni, D | 1 |
| Muscatello, A | 1 |
| Crivellaro, C | 1 |
| Guerra, L | 1 |
| Messa, C | 1 |
| Gozlan, J | 6 |
| Simon, F | 3 |
| Blum, JD | 1 |
| Gengiah, TN | 7 |
| Upfold, M | 1 |
| Goodall, RL | 1 |
| Pattery, T | 1 |
| van Cauwenberge, A | 1 |
| Nkurunziza, P | 1 |
| Awio, P | 2 |
| Ndembi, N | 4 |
| Munderi, P | 5 |
| Gilks, CF | 4 |
| Kaleebu, P | 3 |
| Mngadi, KT | 2 |
| Maarschalk, S | 3 |
| Grobler, AC | 3 |
| Frohlich, JA | 4 |
| Madlala, B | 2 |
| Ngcobo, N | 2 |
| Cornman, DH | 1 |
| Fisher, J | 1 |
| Fisher, WA | 1 |
| Macqueen, KM | 8 |
| Vernazza, P | 6 |
| Weber, R | 4 |
| Battegay, M | 8 |
| Bucher, HC | 5 |
| Evans-Strickfaden, T | 1 |
| Gatcliffe, C | 1 |
| Adesoye, A | 1 |
| Omondi, MW | 1 |
| Danavall, D | 1 |
| Easley, K | 1 |
| Chen, CY | 1 |
| Hart, C | 3 |
| Madlala, BT | 1 |
| Grobler, A | 5 |
| Moyo, C | 3 |
| Weaver, MA | 3 |
| van Loggerenberg, F | 2 |
| Succop, S | 1 |
| Majola, N | 2 |
| Taylor, D | 8 |
| Anderson, AM | 1 |
| Fralich, T | 2 |
| Scharen-Guivel, V | 2 |
| Flaherty, JF | 7 |
| Fortin, C | 1 |
| Kalayjian, RC | 2 |
| Rachlis, A | 3 |
| Behrens, G | 2 |
| Rijnders, B | 2 |
| Cohen, C | 7 |
| Elion, RA | 1 |
| Vanveggel, S | 1 |
| Stevens, M | 2 |
| Rimsky, L | 1 |
| Thorpe, D | 1 |
| Bosse, M | 1 |
| DeMorin, J | 1 |
| Betancor, G | 2 |
| Nevot, M | 2 |
| Mendieta, J | 1 |
| Gómez-Puertas, P | 1 |
| Martínez, MA | 2 |
| Menéndez-Arias, L | 2 |
| Worrajittanon, D | 1 |
| Sawyer, JR | 1 |
| Hsiao, CB | 1 |
| Pujari, SN | 1 |
| Smith, C | 2 |
| Makane, A | 1 |
| Youle, M | 3 |
| Bele, V | 2 |
| Joshi, K | 2 |
| Dabhade, D | 1 |
| Haskelberg, H | 3 |
| Cordery, DV | 2 |
| Amin, J | 10 |
| Kelleher, AD | 3 |
| Cooper, DA | 17 |
| Emery, S | 10 |
| Scott, CA | 5 |
| Iyer, HS | 1 |
| Larson, BA | 1 |
| Rosen, S | 1 |
| Pertusati, F | 1 |
| Hinsinger, K | 1 |
| Flynn, ÁS | 1 |
| Powell, N | 1 |
| Tristram, A | 1 |
| Balzarini, J | 6 |
| McGuigan, C | 1 |
| Akil, A | 3 |
| Devlin, B | 2 |
| Cost, M | 3 |
| Rohan, LC | 5 |
| Kang, M | 1 |
| Hollabaugh, K | 1 |
| Pham, V | 1 |
| Koletar, SL | 4 |
| Wu, K | 1 |
| Smurzynski, M | 1 |
| Aberg, JA | 4 |
| Saeedi, R | 1 |
| Jiang, SY | 1 |
| Holmes, DT | 1 |
| Kendler, DL | 1 |
| Turner, KT | 1 |
| Zeh, C | 1 |
| Fonjungo, PN | 1 |
| Niska, R | 1 |
| Price, AJ | 1 |
| Kayange, M | 1 |
| Zaba, B | 1 |
| Chimbwandira, FM | 1 |
| Jahn, A | 1 |
| Chirwa, Z | 1 |
| Dasgupta, AN | 1 |
| Katundu, C | 1 |
| Saul, JL | 1 |
| Glynn, JR | 1 |
| Koole, O | 2 |
| Crampin, AC | 1 |
| Dellar, RC | 1 |
| Humphries, H | 1 |
| Ntombela, F | 1 |
| Luthuli, L | 1 |
| Pocock, N | 1 |
| Ebeling, PR | 2 |
| Allworth, A | 1 |
| De Castro, N | 2 |
| Arnold, V | 1 |
| Morgado, M | 1 |
| Pilotto, JH | 1 |
| Brites, C | 1 |
| Madruga, JV | 3 |
| Barcellos, NT | 1 |
| Santos, BR | 1 |
| Vorsatz, C | 1 |
| Fagard, C | 2 |
| Santini-Oliveira, M | 1 |
| Patey, O | 2 |
| Rokx, C | 2 |
| Verbon, A | 1 |
| Rijnders, BJ | 2 |
| Liegler, T | 3 |
| Abdel-Mohsen, M | 2 |
| Bentley, LG | 1 |
| Atchison, R | 1 |
| Schmidt, T | 1 |
| Javier, J | 1 |
| Mehrotra, M | 1 |
| Eden, C | 1 |
| Li, P | 1 |
| Wong, JK | 2 |
| Vogler, MA | 1 |
| Smeaton, LM | 1 |
| Wright, RL | 1 |
| Infante, R | 1 |
| Moran, LE | 1 |
| Godfrey, C | 4 |
| Demeter, LM | 1 |
| Johnson, VA | 3 |
| Pisaturo, M | 1 |
| Martini, S | 2 |
| Filippini, P | 2 |
| Coppola, N | 1 |
| Ayala-Sims, VA | 1 |
| Brantley, J | 2 |
| Ndase, P | 6 |
| Thongyen, S | 3 |
| Nilkamhang, S | 4 |
| Sungkanuparph, S | 6 |
| Gutierrez, Mdel M | 1 |
| Gallego-Escuredo, JM | 1 |
| Torres, F | 1 |
| Villarroya, J | 1 |
| Lamarca, K | 1 |
| Domingo, JC | 1 |
| Villarroya, F | 1 |
| Giralt, M | 1 |
| Kiarie, J | 5 |
| Were, E | 4 |
| Sivaprakasam, V | 1 |
| Chima-Okereke, C | 1 |
| Kruse, L | 1 |
| Stover, K | 1 |
| Henderson, H | 1 |
| Chakrabarti, LA | 1 |
| Boucherie, C | 1 |
| Bugault, F | 1 |
| Cumont, MC | 1 |
| Roussillon, C | 1 |
| Breton, G | 2 |
| Richert, L | 2 |
| Lortholary, O | 1 |
| Ortiz, R | 1 |
| Post, F | 2 |
| Maynard-Muet, M | 1 |
| Lebossé, F | 1 |
| Carrat, F | 2 |
| Bouix, C | 1 |
| Lascoux-Combe, C | 4 |
| Sogni, P | 2 |
| Barthe, Y | 1 |
| Pol, S | 4 |
| Cacoub, P | 2 |
| Papakonstantinou, VD | 2 |
| Chini, M | 2 |
| Mangafas, N | 2 |
| Stamatakis, GM | 1 |
| Tsogas, N | 2 |
| Tsoupras, AB | 2 |
| Psarra, K | 1 |
| Fragopoulou, E | 2 |
| Antonopoulou, S | 2 |
| Gargalianos, P | 3 |
| Demopoulos, CA | 2 |
| Lazanas, MC | 2 |
| Shaw, PN | 1 |
| Davis-Poynter, N | 1 |
| Rakhmanova, A | 1 |
| Banhegyi, D | 1 |
| Phillips, AN | 4 |
| Ristola, M | 1 |
| Grarup, J | 2 |
| Kirk, O | 3 |
| Dailly, E | 2 |
| Bonnet, B | 1 |
| Pineau, S | 1 |
| Boutoille, D | 1 |
| Bouquié, R | 1 |
| Raveleau, A | 1 |
| Bouchez, S | 1 |
| Schrijvers, R | 3 |
| Debyser, Z | 4 |
| Nguyen, T | 2 |
| Antela, A | 4 |
| Tien, PC | 3 |
| Deeks, SG | 8 |
| Grunfeld, C | 3 |
| Peralta, CA | 1 |
| McMahan, VM | 1 |
| Fernandez, T | 2 |
| Watanabe, T | 1 |
| Tokumoto, Y | 1 |
| Hirooka, M | 1 |
| Koizumi, Y | 2 |
| Tada, F | 1 |
| Ochi, H | 1 |
| Abe, M | 1 |
| Kumagi, T | 1 |
| Ikeda, Y | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Srinivasan, P | 2 |
| Smith, TJ | 4 |
| Butkyavichene, I | 3 |
| Brooks, AA | 1 |
| Dinh, CT | 2 |
| Smith, JM | 2 |
| Asmelash, A | 2 |
| Kaloustian, KW | 1 |
| Ogwu, A | 1 |
| Salata, R | 4 |
| Jafari, A | 1 |
| Dashti-Khavidaki, S | 1 |
| Morrow, RA | 1 |
| Hong, T | 1 |
| Fife, KH | 4 |
| Nakku-Joloba, E | 2 |
| Techasaensiri, C | 1 |
| Keadpudsa, S | 1 |
| Srimuan, A | 1 |
| Sahakijpicharn, T | 1 |
| Prasitsuebsai, W | 1 |
| King, HL | 1 |
| Keller, SB | 2 |
| Giancola, MA | 1 |
| Rodriguez, DA | 1 |
| Chau, JJ | 1 |
| Young, JA | 1 |
| Smith, DM | 2 |
| Russo, J | 1 |
| Abebe, KZ | 1 |
| Friend, DR | 8 |
| McGowan, IM | 2 |
| Clumeck, N | 3 |
| Mwamba, C | 1 |
| Kabeya, K | 2 |
| Matanda, S | 1 |
| Vaira, D | 1 |
| Kadiebwe, D | 1 |
| Kasamba, E | 1 |
| Milolo, C | 1 |
| Ilunga, J | 1 |
| Kapend, L | 1 |
| Prinapori, R | 2 |
| Gustinetti, G | 1 |
| Sticchi, L | 1 |
| Bruzzone, B | 4 |
| Viscoli, C | 5 |
| Gürtler, LG | 1 |
| Gallien, S | 1 |
| Cruciani, M | 2 |
| Mengoli, C | 1 |
| Malena, M | 1 |
| Serpelloni, G | 1 |
| Parisi, SG | 1 |
| Bosco, O | 1 |
| Agashe, H | 1 |
| Moncla, BJ | 1 |
| Hillier, SL | 2 |
| Shi, Y | 1 |
| Uranker, K | 2 |
| Sabo, JP | 1 |
| Kort, J | 1 |
| Ballow, C | 1 |
| Haschke, M | 1 |
| Fuhr, R | 1 |
| Girlich, B | 1 |
| Schobelock, M | 1 |
| Feifel, U | 1 |
| Lang, B | 1 |
| Elgadi, M | 1 |
| Agot, K | 5 |
| Corneli, AL | 3 |
| Wang, M | 5 |
| Ambia, J | 1 |
| Parker, C | 1 |
| Lemons, A | 1 |
| Malahleha, M | 4 |
| Lombaard, J | 5 |
| Van Damme, L | 13 |
| Andrade-Fuentes, K | 1 |
| López-De León, JI | 1 |
| Manjarrez-Téllez, B | 1 |
| Ramírez, JL | 1 |
| Gaytan-Martínez, J | 1 |
| Babiker, AG | 2 |
| George, EC | 1 |
| Hudson, F | 1 |
| Schwimmer, C | 1 |
| Saillard, J | 1 |
| Wallet, C | 1 |
| Jansson, PO | 1 |
| Van Leeuwen, R | 1 |
| Delfraissy, JF | 2 |
| Vella, S | 2 |
| Veselinovic, M | 1 |
| Yang, KH | 2 |
| LeCureux, J | 1 |
| Remling-Mulder, L | 1 |
| Akkina, R | 1 |
| Mendoza, Cd | 1 |
| Fernández-Montero, JV | 1 |
| Labarga, P | 12 |
| Amiel, C | 2 |
| Schneider, V | 3 |
| Guessant, S | 2 |
| Hamidi, M | 1 |
| Kherallah, K | 1 |
| Chas, J | 1 |
| Lependeven, C | 1 |
| Kitch, D | 3 |
| Tierney, C | 5 |
| Cohen, CR | 4 |
| Reinhart, S | 1 |
| Partisani, M | 2 |
| Baldeyrou, M | 1 |
| Batard, ML | 2 |
| Bernard-Henry, C | 2 |
| Cheneau, C | 2 |
| de Mautort, E | 2 |
| Priester, M | 2 |
| Fafi-Kremer, S | 1 |
| Pérez-Álvarez, N | 5 |
| Gutiérrez, M | 2 |
| Mateo, G | 1 |
| Puig, J | 11 |
| Escrig, R | 1 |
| Bonjoch, A | 7 |
| Deese, J | 5 |
| Ahmed, K | 5 |
| Manongi, R | 3 |
| Kapiga, S | 3 |
| Bedimo, RJ | 2 |
| Drechsler, H | 4 |
| Jain, M | 1 |
| Cutrell, J | 1 |
| Farukhi, I | 1 |
| Castanon, R | 1 |
| Maalouf, NM | 2 |
| Patel, DA | 1 |
| Snedecor, SJ | 1 |
| Tang, WY | 1 |
| Sudharshan, L | 1 |
| Lim, JW | 1 |
| Cuffe, R | 1 |
| Pulgar, S | 1 |
| Gilchrist, KA | 1 |
| Camejo, RR | 1 |
| Stephens, J | 2 |
| Nichols, G | 1 |
| Boettiger, DC | 1 |
| Saphonn, V | 1 |
| Lee, MP | 2 |
| Phanuphak, P | 2 |
| Pham, TT | 1 |
| Heng Sim, BL | 1 |
| Kumarasamy, N | 2 |
| Van Nguyen, K | 1 |
| Kantipong, P | 2 |
| Kamarulzaman, A | 1 |
| Chaiwarith, R | 1 |
| Law, MG | 1 |
| Radzio, J | 2 |
| Hanley, K | 1 |
| Ellis, S | 1 |
| Jenkins, L | 1 |
| Khwitshana, AK | 1 |
| Greeff, OB | 1 |
| Hurrell, T | 1 |
| Juega, J | 1 |
| Aiestarán, A | 1 |
| Pérez, V | 1 |
| Romero, R | 1 |
| Bonet, J | 1 |
| Naicker, N | 1 |
| Gray, C | 1 |
| Abdool-Karim, Q | 1 |
| Abdool-Karim, SS | 1 |
| Aurpibul, L | 2 |
| Kawasaki, Y | 2 |
| Tanaka, N | 2 |
| Mizushima, D | 1 |
| Aoki, T | 3 |
| Watanabe, K | 4 |
| Kinai, E | 5 |
| Honda, H | 3 |
| Yazaki, H | 5 |
| Were, EO | 1 |
| Pingen, M | 1 |
| Nijhuis, M | 1 |
| Mudrikova, T | 2 |
| van Laarhoven, A | 1 |
| Langebeek, N | 1 |
| Richter, C | 3 |
| Wensing, AM | 1 |
| Potard, V | 1 |
| Poizot-Martin, I | 1 |
| Mokhtari, S | 1 |
| Pradier, C | 2 |
| Rozenbaum, W | 2 |
| Ribaudo, HJ | 2 |
| Na, LH | 1 |
| Sagar, M | 1 |
| Cohn, SE | 1 |
| Aweeka, F | 1 |
| Presti, RM | 1 |
| Benson, CA | 1 |
| Baugh, BP | 1 |
| Leavitt, RY | 1 |
| Seekins, D | 2 |
| Succop, SM | 1 |
| Tappero, JW | 4 |
| Farquhar, C | 3 |
| John-Stewart, G | 3 |
| Coombs, RW | 3 |
| Frenkel, L | 3 |
| Bangsberg, D | 3 |
| Gorriz, JL | 1 |
| Gutiérrez, F | 8 |
| Trullàs, JC | 1 |
| Barril, G | 1 |
| Cervero, M | 1 |
| Cofán, F | 1 |
| Fulladosa, X | 1 |
| Gràcia, S | 1 |
| Iribarren, JA | 2 |
| López-Aldeguer, J | 1 |
| Lozano, F | 2 |
| Martínez-Castelao, A | 1 |
| Mazuecos, MA | 1 |
| Miralles, C | 4 |
| Montañés, R | 1 |
| Palacios, R | 5 |
| Pérez-Elías, MJ | 3 |
| Praga, M | 1 |
| Quereda, C | 1 |
| Santamaría, JM | 1 |
| Surgers, L | 1 |
| Viala, C | 1 |
| Fonquernie, L | 1 |
| Meynard, JL | 3 |
| Teller, RS | 2 |
| Lo, Y | 1 |
| Searls, K | 1 |
| Caraway, P | 1 |
| Predhomme, J | 2 |
| Meditz, AL | 1 |
| Yu, W | 1 |
| Guo, F | 1 |
| Lin, Q | 1 |
| Sun, P | 1 |
| Górgolas, M | 1 |
| Pappa, K | 1 |
| Nichols, WG | 1 |
| Cuffe, RL | 1 |
| Eron, J | 1 |
| Corneli, A | 3 |
| Mistry, N | 1 |
| Sereboe, L | 1 |
| Oakeshott, P | 1 |
| Freeling, JP | 1 |
| Koehn, J | 1 |
| Shu, C | 1 |
| Ho, RJ | 1 |
| Little, F | 1 |
| Todd, CS | 1 |
| Hubacher, D | 1 |
| Steiner, MJ | 1 |
| Otunga, S | 1 |
| Winston, J | 3 |
| Andrade-Villanueva, JF | 2 |
| Beraud, C | 1 |
| Dahlin, A | 1 |
| Wittwer, M | 1 |
| de la Cruz, M | 1 |
| Woo, JM | 1 |
| Bam, R | 1 |
| Flaherty, J | 5 |
| Ray, AS | 8 |
| Giacomini, KM | 1 |
| Jacot, TA | 1 |
| Thurman, A | 1 |
| Archer, DF | 1 |
| Cohen, SE | 2 |
| Doblecki-Lewis, S | 2 |
| Postle, BS | 2 |
| Feaster, DJ | 2 |
| Matheson, T | 2 |
| Trainor, N | 2 |
| Blue, RW | 2 |
| Estrada, Y | 2 |
| Castro, JG | 1 |
| Chege, W | 2 |
| Philip, SS | 2 |
| Emerson, CW | 1 |
| Nelson, JA | 1 |
| Fedoriw, Y | 1 |
| Geller, EJ | 1 |
| Defechereux, P | 2 |
| Fransen, K | 3 |
| De Baetselier, I | 3 |
| Crucitti, T | 3 |
| Bentley, G | 1 |
| Agingu, W | 1 |
| Damme, LV | 1 |
| Lum, EL | 1 |
| Lassman, C | 1 |
| Dlamini, S | 1 |
| Montague, C | 1 |
| Nkomonde, N | 1 |
| Mvandaba, N | 1 |
| Dawood, H | 1 |
| Katz, MH | 1 |
| Mugwanya, KK | 1 |
| Wyatt, C | 4 |
| Mandala, J | 3 |
| Nanda, K | 3 |
| Owino, F | 2 |
| Raffe, S | 1 |
| Sirirungsi, W | 1 |
| Urien, S | 8 |
| Harrison, L | 1 |
| Kamkon, J | 1 |
| Tawon, Y | 1 |
| Luekamlung, N | 1 |
| Thongpaen, S | 1 |
| Nilmanat, A | 1 |
| Jourdain, G | 1 |
| Le Coeur, S | 1 |
| Owen, A | 3 |
| Back, DJ | 4 |
| Lehman, DA | 1 |
| McCoy, CO | 1 |
| Weis, JF | 1 |
| Peterson, D | 1 |
| Mbara, G | 1 |
| Overbaugh, J | 1 |
| Matsen, FA | 1 |
| Callahan, R | 1 |
| Ogada, T | 1 |
| Della Negra, M | 2 |
| De Carvalho, AP | 2 |
| De Aquino, MZ | 2 |
| Pinto, JA | 1 |
| Da Silva, MT | 2 |
| Andreatta, KN | 1 |
| Graham, B | 2 |
| Quirk, EK | 1 |
| Carney, EF | 1 |
| Schoffelen, AF | 1 |
| Smit, C | 1 |
| van Lelyveld, SF | 1 |
| Vogt, L | 1 |
| Bauer, MP | 1 |
| Barth, RE | 1 |
| Kim, E | 1 |
| Kim, S | 1 |
| Hong, JH | 2 |
| Marrazzo, JM | 1 |
| Richardson, BA | 3 |
| Gomez, K | 3 |
| Nair, G | 1 |
| Palanee, T | 1 |
| Noguchi, L | 1 |
| Ganesh, S | 1 |
| Mkhize, B | 1 |
| Taljaard, M | 1 |
| Parikh, UM | 2 |
| Mâsse, B | 2 |
| Grossman, C | 1 |
| Watts, H | 1 |
| Skhosana, L | 1 |
| Steegen, K | 1 |
| Bronze, M | 1 |
| Lukhwareni, A | 1 |
| Letsoalo, E | 1 |
| Papathanasopoulos, MA | 1 |
| Carmona, SC | 1 |
| Mayor, S | 1 |
| Mitra, S | 1 |
| Priscilla, R | 1 |
| Rajeev, K | 1 |
| Sauradeep, S | 1 |
| Rajkumar, S | 1 |
| Cherian, AO | 1 |
| Guendel, I | 1 |
| Iordanskiy, S | 1 |
| Sampey, GC | 1 |
| Van Duyne, R | 1 |
| Calvert, V | 1 |
| Petricoin, E | 1 |
| Saifuddin, M | 1 |
| Kehn-Hall, K | 1 |
| Kashanchi, F | 1 |
| Van der Ende, ME | 6 |
| Laeyendecker, O | 1 |
| Nason, M | 1 |
| Longosz, AF | 1 |
| Garrett, N | 1 |
| Sricharoenchai, S | 1 |
| Wittawatmongkol, O | 1 |
| Sirisanthana, V | 1 |
| Phongsamart, W | 1 |
| Sudjaritruk, T | 1 |
| Chokephaibulkit, K | 1 |
| Saez-Llorens, X | 1 |
| Castaño, E | 1 |
| Rathore, M | 1 |
| Church, J | 1 |
| Deville, J | 1 |
| Gaur, A | 1 |
| Estripeaut, D | 1 |
| Arterburn, S | 3 |
| Enejosa, JV | 3 |
| Chuck, SL | 4 |
| McKenna, K | 1 |
| Perry, B | 1 |
| Malamatsho, F | 1 |
| Skhosana, J | 1 |
| Odhiambo, J | 1 |
| Labhardt, ND | 1 |
| Bader, J | 1 |
| Lejone, TI | 1 |
| Ringera, I | 1 |
| Puga, D | 1 |
| Glass, TR | 1 |
| Klimkait, T | 2 |
| Marszalek, RM | 1 |
| Bae-Harboe, YS | 1 |
| Mahalingam, M | 1 |
| Masterpol, K | 1 |
| Murrell, DE | 1 |
| Moorman, JP | 1 |
| Harirforoosh, S | 1 |
| Sepúlveda-Crespo, D | 1 |
| Sánchez-Rodríguez, J | 1 |
| Serramía, MJ | 1 |
| Gómez, R | 1 |
| De La Mata, FJ | 1 |
| Jiménez, JL | 1 |
| Muñoz-Fernández, MÁ | 1 |
| Shalit, P | 2 |
| Shamblaw, D | 3 |
| Thomas, A | 1 |
| Liu, HC | 9 |
| Lahiri, CD | 1 |
| Tao, S | 1 |
| Jiang, Y | 1 |
| Schinazi, RF | 1 |
| Vunnava, A | 1 |
| Sanford, S | 1 |
| Carey, D | 1 |
| Puls, R | 2 |
| Losso, M | 1 |
| Phanupak, P | 1 |
| Foulkes, S | 1 |
| Mohapi, L | 2 |
| Crabtree-Ramirez, B | 2 |
| Kumar, S | 1 |
| Belloso, W | 1 |
| Chaipung, B | 1 |
| Yin, MT | 1 |
| Trottier, B | 1 |
| Plummer, A | 6 |
| Miller, CS | 1 |
| Siemieniuk, RA | 1 |
| Bogoch, II | 1 |
| Barré-Sinoussi, F | 1 |
| Stone, L | 1 |
| Hankinson, SE | 1 |
| Balasubramanian, R | 1 |
| Ertel, K | 1 |
| Mabileau, G | 1 |
| Schwarzinger, M | 1 |
| Flores, J | 1 |
| Patrat, C | 1 |
| Luton, D | 1 |
| Epelboin, S | 1 |
| Mandelbrot, L | 1 |
| Matheron, S | 4 |
| Perez-Molina, JA | 1 |
| Rubio, R | 2 |
| Pasquau, J | 1 |
| Suárez-Lozano, I | 1 |
| Riera, M | 2 |
| Estébanez, M | 1 |
| Sanz-Moreno, J | 1 |
| Navarro, J | 2 |
| Esteban, H | 1 |
| Tso, FY | 1 |
| Yuan, Z | 2 |
| Wood, C | 1 |
| White, NR | 1 |
| Dickinson, L | 2 |
| Yapa, HM | 1 |
| Jackson, A | 2 |
| Else, L | 1 |
| Amara, A | 1 |
| Back, D | 5 |
| Karolia, Z | 1 |
| Higgs, C | 2 |
| Zhang, XQ | 1 |
| Kharsany, AB | 6 |
| Mindel, A | 1 |
| Tobin, SC | 1 |
| Biagi, M | 1 |
| Badowski, M | 1 |
| Chiampas, T | 1 |
| Vaughn, P | 1 |
| Shicker, L | 1 |
| Patel, M | 1 |
| Seidman, D | 1 |
| Aaron, E | 2 |
| Topalis, D | 1 |
| Snoeck, R | 1 |
| Andrei, G | 1 |
| Dhanireddy, S | 1 |
| DiPerri, G | 1 |
| Van Lunzen, J | 1 |
| Brunetta, J | 3 |
| Huhn, G | 1 |
| Rawlings, MK | 1 |
| Cardenas, G | 1 |
| Hitchcock, MJ | 1 |
| Gagneux-Brunon, A | 1 |
| Botelho-Nevers, E | 1 |
| Frésard, A | 1 |
| Lucht, F | 1 |
| Rower, C | 1 |
| McAllister, K | 1 |
| Klein, B | 1 |
| Meditz, A | 3 |
| Guida, LA | 1 |
| Tashima, K | 2 |
| Rashbaum, B | 2 |
| Fordyce, M | 4 |
| Vitoria, M | 1 |
| Hill, AM | 1 |
| Ford, NP | 1 |
| Doherty, M | 1 |
| Khoo, SH | 2 |
| Kitrinos, KM | 1 |
| Aguiar, C | 1 |
| Hendry, BM | 3 |
| Mallon, P | 2 |
| Pourcher-Martinez, V | 1 |
| Mikula, JM | 1 |
| Manion, MM | 1 |
| Maldarelli, F | 3 |
| Suarez, LM | 1 |
| Norman-Wheeler, JF | 1 |
| Ober, AG | 1 |
| Dewar, RL | 1 |
| Kopp, JB | 2 |
| Lane, HC | 1 |
| Pau, AK | 1 |
| Warpakowski, A | 2 |
| Boyd, MA | 1 |
| Ward, D | 2 |
| Morales-Ramirez, J | 1 |
| Gazzard, B | 17 |
| Achhra, AC | 1 |
| Nugent, M | 1 |
| Garcia, M | 1 |
| Godet, C | 1 |
| Beraud, G | 1 |
| Chagneau-Derrode, C | 1 |
| Roblot, F | 1 |
| Greig, SL | 1 |
| Milburn, J | 1 |
| Levy, JB | 1 |
| Vimal, M | 1 |
| Bischoff, M | 1 |
| Gibson, AK | 1 |
| Shah, BM | 1 |
| Nambiar, PH | 1 |
| Terrault, NA | 1 |
| Guillemi, SA | 1 |
| Ling, SH | 1 |
| Dahlby, JS | 1 |
| Yip, B | 3 |
| Hull, MW | 2 |
| Lima, VD | 2 |
| Hogg, RS | 3 |
| Werb, R | 2 |
| Montaner, JS | 8 |
| Mapesi, H | 1 |
| Ramírez, A | 1 |
| Tanner, M | 1 |
| Hatz, C | 1 |
| Letang, E | 1 |
| Kulkarni, M | 1 |
| Bannerman, T | 1 |
| Mantini, J | 1 |
| Thornton, B | 1 |
| Song, Q | 1 |
| Fang, L | 1 |
| Dinoso, J | 1 |
| Closson, EF | 1 |
| Battle, S | 1 |
| Herbst, JH | 1 |
| Denson, D | 1 |
| Pitts, N | 1 |
| Holman, J | 1 |
| Landers, S | 1 |
| Mansergh, G | 1 |
| Gaur, AH | 1 |
| Kizito, H | 2 |
| Prasitsueubsai, W | 1 |
| Rakhmanina, N | 1 |
| Chakraborty, R | 1 |
| Batra, J | 1 |
| Kosalaraksa, P | 1 |
| Luesomboon, W | 1 |
| Myers, M | 1 |
| Ting, L | 1 |
| Eriksen, J | 1 |
| Blaxhult, A | 1 |
| Carlander, C | 1 |
| Flamholc, L | 1 |
| Josephson, F | 1 |
| Karlström, O | 2 |
| Navér, L | 1 |
| Svedhem, V | 1 |
| Nugent, D | 1 |
| Fox, J | 1 |
| Snopková, S | 1 |
| Havlíčková, K | 1 |
| Husa, P | 1 |
| Humphreys, WG | 1 |
| Lai, Y | 1 |
| Minuesa, G | 1 |
| Albert, C | 1 |
| Pastor-Anglada, M | 1 |
| Martinez-Picado, J | 4 |
| Koepsell, H | 1 |
| Sampath, R | 1 |
| Corado, KC | 1 |
| Mosquera, MM | 1 |
| Peloquin, J | 1 |
| Bruggemans, A | 1 |
| LaMarca, A | 2 |
| de Wet, J | 2 |
| Valero, IP | 1 |
| Vandercam, B | 1 |
| Thalme, A | 1 |
| Stoeckle, M | 1 |
| Slama, L | 3 |
| Santana-Bagur, J | 1 |
| Stein, DK | 1 |
| Bellos, N | 2 |
| Scarsella, A | 1 |
| Clarke, AE | 1 |
| Rodríguez-Nóvoa, S | 9 |
| Morello, J | 3 |
| Maida, I | 4 |
| García-Gascó, P | 2 |
| González-Pardo, G | 2 |
| Parra, A | 1 |
| Jiménez-Nácher, I | 2 |
| Chintu, N | 4 |
| Cantrell, RA | 3 |
| Kankasa, C | 2 |
| Kruse, G | 3 |
| Mbewe, F | 3 |
| Sinkala, M | 3 |
| Smith, PJ | 1 |
| Stringer, EM | 5 |
| Murray, RJ | 1 |
| Lewis, FI | 1 |
| Brown, AJ | 1 |
| Rothova, A | 1 |
| Schneider, M | 1 |
| de Groot-Mijnes, JD | 1 |
| Calabresi, A | 3 |
| Lapadula, G | 6 |
| Tirelli, V | 2 |
| Costarelli, S | 3 |
| Cologni, G | 2 |
| Zaltron, S | 1 |
| Carosi, G | 6 |
| Torti, C | 10 |
| Van Rompay, KK | 3 |
| Durand-Gasselin, L | 3 |
| Brignolo, LL | 1 |
| Abel, K | 1 |
| Spinner, A | 1 |
| Jerome, C | 1 |
| Moore, J | 1 |
| Marthas, ML | 2 |
| Reiser, H | 1 |
| Bischofberger, N | 7 |
| Lindh, M | 1 |
| Uhnoo, I | 1 |
| Bläckberg, J | 1 |
| Duberg, AS | 1 |
| Friman, S | 1 |
| Fischler, B | 1 |
| Norkrans, G | 1 |
| Reichard, O | 1 |
| Sangfeldt, P | 1 |
| Söderström, A | 1 |
| Weiland, O | 1 |
| Wejstål, R | 1 |
| Wiström, J | 1 |
| Svarovskaia, ES | 4 |
| Feng, JY | 1 |
| Myrick, F | 1 |
| Goodman, D | 2 |
| Ly, JK | 1 |
| Kutty, N | 1 |
| Borroto-Esoda, K | 4 |
| Wright, MR | 1 |
| Rhodes, GR | 1 |
| Wenning, LA | 2 |
| Friedman, EJ | 1 |
| Kost, JT | 1 |
| Breidinger, SA | 1 |
| Stek, JE | 1 |
| Lasseter, KC | 1 |
| Gottesdiener, KM | 1 |
| Wagner, JA | 1 |
| Stone, JA | 1 |
| Iwamoto, M | 1 |
| D'Avolio, A | 5 |
| Sciandra, M | 1 |
| Siccardi, M | 2 |
| Baietto, L | 1 |
| Gonzalez de Requena, D | 2 |
| Ferrer, E | 3 |
| Sanchez, P | 1 |
| Puig, T | 1 |
| Cortes, C | 1 |
| Veloso, S | 1 |
| Pedrol, E | 4 |
| Leon, A | 6 |
| Torriani, FJ | 1 |
| Komarow, L | 1 |
| Parker, RA | 1 |
| Cotter, BR | 1 |
| Gerschenson, M | 5 |
| Mitchell, CK | 1 |
| Murphy, RL | 3 |
| Matthews, GV | 5 |
| Lewin, SR | 6 |
| Rerknimitr, R | 1 |
| Petcharapirat, P | 1 |
| Marks, P | 2 |
| Sasadeusz, J | 3 |
| Bowden, S | 4 |
| Locarnini, S | 4 |
| Dore, GJ | 7 |
| Kestenbaum, B | 2 |
| Harrington, RD | 2 |
| Prada, N | 1 |
| Davis, B | 1 |
| Jean-Pierre, P | 1 |
| La Roche, M | 1 |
| Duh, FM | 1 |
| Carrington, M | 1 |
| Poles, M | 1 |
| Mehandru, S | 1 |
| Mohri, H | 1 |
| Boelle, PY | 2 |
| Bonnard, P | 2 |
| Serfaty, L | 2 |
| Hsu, R | 1 |
| Lanier, ER | 4 |
| Rouse, EG | 1 |
| Oie, KL | 1 |
| Ross, LL | 4 |
| Redfield, RR | 3 |
| Morrow, JS | 1 |
| Schackman, BR | 5 |
| Losina, E | 3 |
| Winston, JA | 2 |
| Chen, SS | 6 |
| Hidalgo, C | 1 |
| Ríos, MJ | 1 |
| Gutiérrez-Ravé, V | 1 |
| Gálvez, MC | 1 |
| Mira, JA | 1 |
| López-Cortés, LF | 1 |
| Tural, C | 1 |
| Torres-Tortosa, M | 1 |
| de Los Santos Gil, I | 2 |
| Martín-Rico, P | 1 |
| Ríos-Villegas, MJ | 1 |
| Hernández-Burruezo, JJ | 1 |
| Merino, D | 1 |
| López-Ruz, MA | 1 |
| González-Serrano, M | 1 |
| Viciana, P | 4 |
| Pineda, JA | 2 |
| Pujari, S | 1 |
| Dravid, A | 1 |
| Gupte, N | 1 |
| Hogben, M | 1 |
| Liddon, N | 1 |
| Hawkins, T | 4 |
| Szczech, L | 2 |
| Young, B | 7 |
| Nurutdinova, D | 1 |
| Onen, NF | 1 |
| Hayes, E | 1 |
| Mondy, K | 1 |
| Hirt, D | 6 |
| Ekouévi, DK | 5 |
| Rey, E | 7 |
| Arrivé, E | 5 |
| Blanche, S | 10 |
| Amani-Bosse, C | 1 |
| Nerrienet, E | 5 |
| Kone, M | 1 |
| Leang, SK | 2 |
| McIntyre, J | 6 |
| Dabis, F | 8 |
| Tréluyer, JM | 9 |
| Amengual, JE | 1 |
| Ibrahim, S | 1 |
| Gardner, LB | 1 |
| Langmann, P | 1 |
| Winzer, R | 1 |
| Schirmer, D | 1 |
| Heinz, W | 1 |
| Leyh, M | 1 |
| Guhl, C | 1 |
| Weissbrich, B | 1 |
| Klinker, H | 1 |
| Kuhlmann, B | 3 |
| Underwood, MR | 1 |
| Irlbeck, DM | 1 |
| Gerondelis, P | 2 |
| Rouse, E | 2 |
| St Clair, MH | 1 |
| Trinh, L | 1 |
| Parkin, N | 3 |
| Lanier, E | 1 |
| Hoen, B | 1 |
| Chavanet, P | 1 |
| Schmitt, MP | 1 |
| Hoizey, G | 1 |
| Meyer, P | 1 |
| Diemer, M | 1 |
| May, T | 2 |
| Schmit, JL | 1 |
| Duong, M | 1 |
| Lang, JM | 2 |
| Theys, K | 3 |
| Vercauteren, J | 3 |
| Abecasis, AB | 3 |
| Libin, P | 1 |
| Deforche, K | 1 |
| Vandamme, AM | 4 |
| Camacho, R | 1 |
| Manfredi, R | 5 |
| Calza, L | 4 |
| Ingiliz, P | 1 |
| Valantin, MA | 8 |
| Thibault, V | 7 |
| Dominguez, S | 4 |
| Poynard, T | 5 |
| Benhamou, Y | 12 |
| Guest, G | 1 |
| Shattuck, D | 1 |
| Johnson, L | 2 |
| Akumatey, B | 2 |
| Clarke, EE | 1 |
| Chen, PL | 1 |
| Yoshimoto, E | 1 |
| Konishi, M | 1 |
| Uno, K | 1 |
| Nakagawa, C | 1 |
| Yonekawa, S | 1 |
| Kasahara, K | 1 |
| Mikasa, K | 1 |
| Metzner, KJ | 1 |
| Giulieri, SG | 1 |
| Knoepfel, SA | 1 |
| Rauch, P | 1 |
| Burgisser, P | 2 |
| Yerly, S | 2 |
| Roverato, A | 1 |
| Giovanardi, C | 1 |
| Ravera, F | 1 |
| Orlando, G | 1 |
| Esposito, R | 3 |
| Palella, F | 2 |
| Jaafar, A | 1 |
| Séronie-Vivien, S | 1 |
| Malard, L | 1 |
| Massip, P | 1 |
| Chatelut, E | 1 |
| Tack, I | 1 |
| Amini-Bavil-Olyaee, S | 1 |
| Sheldon, J | 4 |
| Trautwein, C | 1 |
| Tacke, F | 2 |
| Calleja, JL | 1 |
| Peñas, B | 1 |
| García-Samaniego, J | 1 |
| Coffié, P | 1 |
| Lalsab, S | 1 |
| Avit, D | 4 |
| Fischetti, L | 1 |
| Barry, SM | 1 |
| Shattock, RJ | 2 |
| Ribeiro, RM | 1 |
| Matthews, G | 2 |
| Locarnini, SA | 2 |
| Perelson, AS | 4 |
| Long, MC | 1 |
| King, JR | 3 |
| Okwundu, CI | 4 |
| Okoromah, CA | 2 |
| Audsley, J | 1 |
| Arrifin, N | 1 |
| Yuen, LK | 1 |
| Ayres, A | 1 |
| Crowe, SM | 2 |
| Bartholomeusz, A | 2 |
| Mijch, A | 1 |
| Wood, SM | 1 |
| Shah, SS | 1 |
| Steenhoff, AP | 1 |
| Meyers, KE | 1 |
| Kaplan, BS | 1 |
| Rutstein, RM | 1 |
| Seage, GR | 4 |
| Sloan, CE | 1 |
| Simcock, M | 2 |
| Opravil, M | 4 |
| Elzi, L | 4 |
| Azanza, JR | 1 |
| García Quetglas, E | 1 |
| Sádaba, B | 1 |
| Gómez-Giu, A | 1 |
| Fiorante, S | 1 |
| Bernardino de la Serna, JI | 1 |
| Mora Rillo, M | 1 |
| Arribas López, JR | 2 |
| López Bernaldo de Quirós, JC | 1 |
| Tuma, P | 2 |
| Barril Cuadrado, G | 1 |
| Miralles Alvarez, C | 1 |
| Willyard, C | 1 |
| Kakuda, TN | 5 |
| Schöller-Gyüre, M | 2 |
| De Smedt, G | 2 |
| Beets, G | 1 |
| Aharchi, F | 1 |
| Peeters, MP | 2 |
| Vandermeulen, K | 1 |
| Woodfall, BJ | 2 |
| Hoetelmans, RM | 2 |
| Riordan, A | 2 |
| Boyd, K | 1 |
| Cliff, D | 1 |
| Doerholt, K | 1 |
| Lyall, H | 3 |
| Menson, E | 1 |
| Gibb, D | 1 |
| Alvarez-Uria, G | 1 |
| Ratcliffe, L | 2 |
| Vilar, J | 1 |
| Herrera, C | 1 |
| Cranage, M | 1 |
| Anton, P | 2 |
| Solera, C | 2 |
| Medrano, J | 4 |
| Rivas, P | 2 |
| Albalater, M | 3 |
| Blanco, F | 4 |
| Perrot, S | 1 |
| Aslangul, E | 1 |
| Szwebel, T | 1 |
| Caillat-Vigneron, N | 1 |
| Le Jeunne, C | 1 |
| Pruvost, A | 5 |
| Théodoro, F | 3 |
| Levi, M | 1 |
| Ayen, R | 2 |
| Grassi, J | 4 |
| Silkiss, RZ | 1 |
| Lee, H | 1 |
| Gills Ray, VL | 1 |
| Margeridon-Thermet, S | 1 |
| Shulman, NS | 2 |
| Ahmed, A | 1 |
| Shahriar, R | 1 |
| Holmes, SP | 1 |
| Babrzadeh, F | 1 |
| Gharizadeh, B | 1 |
| Hanczaruk, B | 1 |
| Simen, BB | 1 |
| Egholm, M | 1 |
| Chaix, ML | 6 |
| Rouzioux, C | 5 |
| Coffie, PA | 1 |
| Kruy Leang, S | 1 |
| Srey, VH | 1 |
| N'Dri-Yoman, T | 2 |
| Diallo, A | 1 |
| Kim, C | 3 |
| Berzins, B | 1 |
| Libutti, DE | 2 |
| Weinstein, J | 1 |
| Shore, J | 1 |
| da Silva, B | 2 |
| Belsey, E | 1 |
| Irizarry-Alvarado, JM | 1 |
| Dwyer, JP | 1 |
| Brumble, LM | 1 |
| Alvarez, S | 1 |
| Mendez, JC | 1 |
| Fine, DM | 3 |
| Ribera Pascuet, E | 1 |
| Levenson, E | 1 |
| Morales-Ramirez, JO | 2 |
| Sloan, L | 3 |
| Ward, DJ | 1 |
| Maa, JF | 1 |
| Reilly, K | 1 |
| Ecker, J | 2 |
| McColl, D | 5 |
| Hanabusa, H | 2 |
| Arranz, JA | 1 |
| Loncá, M | 6 |
| Barragán, P | 4 |
| Ribera, E | 9 |
| Roca, V | 1 |
| Dalmau, D | 4 |
| Segura, F | 1 |
| Cosín, J | 1 |
| Barrufet, P | 1 |
| Casas, E | 1 |
| González, A | 1 |
| Pich, J | 2 |
| Cruceta, A | 1 |
| Arnaiz, JA | 2 |
| Egan, D | 1 |
| Cuenca, L | 1 |
| Michelet, C | 1 |
| Pétour, P | 2 |
| Monchecourt, F | 1 |
| Trylesinski, A | 6 |
| Mills, E | 2 |
| Colebunders, R | 3 |
| Kubo, M | 1 |
| Nishimura, Y | 1 |
| Shingai, M | 1 |
| Lee, W | 1 |
| Brenchley, J | 1 |
| Lafont, B | 1 |
| Buckler-White, A | 2 |
| Igarashi, T | 2 |
| Martin, MA | 2 |
| Waters, JM | 2 |
| O'Neal, W | 1 |
| Wakeford, C | 1 |
| Lansdon, EB | 1 |
| Harris, J | 1 |
| Ter Heine, R | 2 |
| Huitema, AD | 2 |
| Jansen, RS | 1 |
| Smits, PH | 1 |
| van Gorp, EC | 1 |
| Wagenaar, JF | 1 |
| Beijnen, JH | 2 |
| Mulder, JW | 3 |
| Mikhail, N | 1 |
| Iskander, E | 1 |
| Cope, D | 1 |
| Dauer, B | 2 |
| Stuermer, M | 2 |
| Klauke, S | 4 |
| Staszewski, S | 9 |
| Poindexter, A | 1 |
| Wheeless, A | 1 |
| Mauck, CK | 1 |
| Callahan, MM | 1 |
| Yoganathan, K | 1 |
| Tan, LK | 1 |
| Mandalia, S | 10 |
| Murungi, A | 1 |
| Grover, D | 1 |
| Atkins, M | 2 |
| Foster, C | 1 |
| Olmscheid, B | 1 |
| Pearce, G | 3 |
| Gibb, DM | 6 |
| Woodward, CL | 1 |
| Hall, AM | 4 |
| Williams, IG | 2 |
| Madge, S | 1 |
| Copas, A | 1 |
| Nair, D | 1 |
| Edwards, SG | 3 |
| Johnson, MA | 1 |
| Connolly, JO | 3 |
| Hughes, B | 1 |
| Benn, P | 1 |
| Sauret-Jackson, V | 1 |
| Cartledge, J | 2 |
| Ruff, C | 1 |
| Linney, A | 1 |
| Reilly, G | 4 |
| Weitner, L | 4 |
| Freiwald, M | 1 |
| Gallo, L | 1 |
| Ranneberg, R | 1 |
| Lackey, P | 1 |
| Kumar, PN | 1 |
| Sutherland-Phillips, DH | 1 |
| Vavro, C | 2 |
| Yau, L | 2 |
| Wannamaker, P | 1 |
| Shaefer, MS | 2 |
| Shahmanesh, M | 3 |
| Kingston, M | 1 |
| Wilkins, E | 3 |
| Ewan, J | 2 |
| Ross, L | 4 |
| Lanier, R | 1 |
| Gathe, JC | 1 |
| Hsu, RK | 1 |
| Paulsen, D | 1 |
| Buchacz, K | 4 |
| Moorman, A | 2 |
| Wood, KC | 4 |
| Lalama, C | 1 |
| Rosenkranz, S | 1 |
| Flanigan, T | 2 |
| Santana, J | 1 |
| Salomon, N | 1 |
| Reisler, R | 1 |
| Wiggins, I | 1 |
| Mildvan, D | 2 |
| Roehr, B | 2 |
| d'Ettorre, G | 4 |
| Ceccarelli, G | 2 |
| Turriziani, O | 1 |
| Andreotti, M | 1 |
| Massetti, P | 1 |
| Rizza, C | 1 |
| Antonelli, G | 1 |
| Mastroianni, CM | 4 |
| Vullo, V | 4 |
| Ainsworth, J | 1 |
| Easterbrook, P | 1 |
| Gompels, M | 2 |
| Hoffman, S | 3 |
| Mantell, JE | 3 |
| Rosen, RK | 2 |
| Gai, F | 4 |
| Enejosa, J | 4 |
| McColl, DJ | 4 |
| Pollard, RB | 2 |
| Berger, DS | 2 |
| Zhao, J | 3 |
| Williams-Diaz, A | 1 |
| Barnard, RJ | 1 |
| Laurent, C | 2 |
| Bourgeois, A | 1 |
| Mpoudi-Ngolé, E | 1 |
| Kouanfack, C | 1 |
| Ciaffi, L | 1 |
| Nkoué, N | 1 |
| Mougnutou, R | 1 |
| Ducos, J | 2 |
| Di Giambenedetto, S | 4 |
| Prosperi, M | 1 |
| Manca, N | 2 |
| Paraninfo, G | 2 |
| Ladisa, N | 2 |
| Trezzi, M | 1 |
| Cicconi, P | 5 |
| Corsi, P | 1 |
| Nasta, P | 3 |
| Giuntini, R | 1 |
| Martinelli, C | 2 |
| Ricci, E | 4 |
| Vichi, F | 1 |
| Gianelli, E | 1 |
| Madeddu, G | 4 |
| Abeli, C | 2 |
| Palvarini, L | 2 |
| Penco, G | 5 |
| Marconi, P | 5 |
| Grosso, C | 3 |
| Pellicano, G | 1 |
| Bonfanti, P | 4 |
| Quirino, T | 4 |
| Moore, RD | 2 |
| Fernández, JV | 1 |
| Costa, P | 1 |
| Bozzano, F | 1 |
| Fenoglio, D | 1 |
| Beltrame, A | 1 |
| Cenderello, G | 1 |
| Ferrea, G | 1 |
| De Maria, A | 1 |
| Sankawa, Y | 1 |
| Bodtländer, A | 1 |
| Knecht, GK | 1 |
| von Hentig, N | 2 |
| Kurowski, M | 2 |
| Lapsley, M | 1 |
| Chetty, K | 1 |
| O'Farrell, S | 1 |
| Unwin, RJ | 1 |
| Sawyer, W | 1 |
| Periard, D | 1 |
| Yerly, P | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Widmeier, A | 1 |
| Gottardi, M | 3 |
| Lanzafame, M | 4 |
| Lattuada, E | 3 |
| Soldani, F | 2 |
| Boccafoglio, F | 1 |
| Concia, E | 2 |
| Horberg, M | 1 |
| Tang, B | 1 |
| Towner, W | 2 |
| Silverberg, M | 1 |
| Bersoff-Matcha, S | 1 |
| Hurley, L | 1 |
| Chang, J | 1 |
| Blank, J | 1 |
| Quesenberry, C | 1 |
| Klein, D | 1 |
| Baker, D | 2 |
| Calcagno, A | 3 |
| Tettoni, MC | 3 |
| Perri, GD | 1 |
| Luber, AD | 2 |
| Condoluci, DV | 1 |
| Slowinski, PD | 1 |
| Andrews, M | 1 |
| Olson, K | 1 |
| Peloquin, CA | 1 |
| Pakes, GE | 2 |
| Ellis, GM | 1 |
| Aldrovandi, GM | 3 |
| Warrier, R | 1 |
| Nakamura, K | 1 |
| Vallier, N | 1 |
| Nguyen, A | 1 |
| Lange, JM | 4 |
| de Wolf, F | 1 |
| Jaffar, S | 1 |
| Amuron, B | 2 |
| Foster, S | 3 |
| Birungi, J | 1 |
| Levin, J | 2 |
| Namara, G | 1 |
| Nabiryo, C | 1 |
| Kyomuhangi, R | 1 |
| Opio, A | 1 |
| Bunnell, R | 1 |
| Mermin, J | 1 |
| Coutinho, A | 2 |
| Grosskurth, H | 6 |
| Collier, AC | 5 |
| Fischl, MA | 3 |
| Mollan, K | 2 |
| Peeples, L | 1 |
| Jahed, NC | 3 |
| Woodward, WC | 2 |
| Geiseler, PJ | 1 |
| Déti, EK | 1 |
| Thiébaut, R | 2 |
| Lawson-Ayayi, S | 2 |
| Dupon, M | 3 |
| Pellegrin, JL | 1 |
| Malvy, D | 1 |
| Tchamgoué, S | 1 |
| Mugyenyi, P | 3 |
| Walker, AS | 4 |
| Hakim, J | 6 |
| Reid, A | 3 |
| Darbyshire, JH | 3 |
| Ssali, F | 3 |
| Bray, D | 2 |
| Kabuye, G | 1 |
| Nsibambi, D | 2 |
| Kasirye, R | 1 |
| Zalwango, E | 2 |
| Nakazibwe, M | 1 |
| Kikaire, B | 1 |
| Nassuna, G | 1 |
| Massa, R | 1 |
| Fadhiru, K | 2 |
| Namyalo, M | 1 |
| Zalwango, A | 1 |
| Generous, L | 1 |
| Khauka, P | 2 |
| Rutikarayo, N | 1 |
| Nakahima, W | 1 |
| Mugisha, A | 1 |
| Todd, J | 1 |
| Muyingo, S | 1 |
| Ruberantwari, A | 1 |
| Yirrell, D | 2 |
| Lyagoba, F | 2 |
| Hughes, P | 1 |
| Aber, M | 1 |
| Lara, AM | 2 |
| Amurwon, J | 2 |
| Wakholi, BN | 2 |
| Whitworth, J | 1 |
| Wangati, K | 1 |
| Kajungu, D | 1 |
| Nakiyingi, J | 1 |
| Omony, W | 1 |
| Tumukunde, D | 2 |
| Otim, T | 1 |
| Kabanda, J | 1 |
| Musana, H | 1 |
| Akao, J | 1 |
| Kyomugisha, H | 2 |
| Byamukama, A | 1 |
| Sabiiti, J | 1 |
| Komugyena, J | 1 |
| Wavamunno, P | 1 |
| Mukiibi, S | 1 |
| Drasiku, A | 1 |
| Byaruhanga, R | 1 |
| Labeja, O | 1 |
| Katundu, P | 2 |
| Tugume, S | 2 |
| Namazzi, A | 1 |
| Bakeinyaga, GT | 1 |
| Katabira, H | 1 |
| Abaine, D | 1 |
| Tukamushaba, J | 1 |
| Anywar, W | 1 |
| Ojiambo, W | 1 |
| Angweng, E | 1 |
| Murungi, S | 2 |
| Haguma, W | 1 |
| Atwiine, S | 1 |
| Kigozi, J | 3 |
| Namale, L | 1 |
| Mukose, A | 1 |
| Mulindwa, G | 1 |
| Atwiine, D | 1 |
| Muhwezi, A | 1 |
| Nimwesiga, E | 1 |
| Barungi, G | 1 |
| Takubwa, J | 1 |
| Mwebesa, D | 1 |
| Kagina, G | 1 |
| Mulindwa, M | 1 |
| Ahimbisibwe, F | 1 |
| Mwesigwa, P | 1 |
| Akuma, S | 1 |
| Zawedde, C | 1 |
| Nyiraguhirwa, D | 1 |
| Tumusiime, C | 1 |
| Bagaya, L | 1 |
| Namara, W | 1 |
| Karungi, J | 1 |
| Kankunda, R | 1 |
| Enzama, R | 1 |
| Latif, A | 2 |
| Robertson, V | 2 |
| Chidziva, E | 2 |
| Bulaya-Tembo, R | 1 |
| Musoro, G | 1 |
| Taziwa, F | 1 |
| Chakonza, L | 1 |
| Mawora, A | 1 |
| Muvirimi, C | 1 |
| Tinago, G | 1 |
| Svovanapasis, P | 1 |
| Simango, M | 1 |
| Chirema, O | 1 |
| Machingura, J | 1 |
| Mutsai, S | 1 |
| Phiri, M | 1 |
| Bafana, T | 1 |
| Chirara, M | 2 |
| Muchabaiwa, L | 2 |
| Muzambi, M | 2 |
| Mutowo, J | 1 |
| Chivhunga, T | 1 |
| Chigwedere, E | 1 |
| Pascoe, M | 1 |
| Warambwa, C | 1 |
| Zengeza, E | 1 |
| Mapinge, F | 1 |
| Makota, S | 1 |
| Jamu, A | 1 |
| Ngorima, N | 1 |
| Chirairo, H | 1 |
| Chitsungo, S | 1 |
| Chimanzi, J | 1 |
| Maweni, C | 1 |
| Warara, R | 1 |
| Matongo, M | 1 |
| Mudzingwa, S | 1 |
| Jangano, M | 1 |
| Moyo, K | 1 |
| Vere, L | 1 |
| Mdege, N | 1 |
| Machingura, I | 1 |
| Kambungu, A | 1 |
| Lutwama, F | 1 |
| Mambule, I | 2 |
| Nanfuka, A | 1 |
| Walusimbi, J | 1 |
| Nabankema, E | 1 |
| Nalumenya, R | 2 |
| Namuli, T | 1 |
| Kulume, R | 1 |
| Namata, I | 1 |
| Nyachwo, L | 1 |
| Florence, A | 1 |
| Kusiima, A | 1 |
| Lubwama, E | 1 |
| Nairuba, R | 1 |
| Oketta, F | 1 |
| Buluma, E | 1 |
| Waita, R | 1 |
| Ojiambo, H | 1 |
| Sadik, F | 1 |
| Wanyama, J | 1 |
| Nabongo, P | 1 |
| Oyugi, J | 1 |
| Sematala, F | 1 |
| Muganzi, A | 1 |
| Twijukye, C | 1 |
| Byakwaga, H | 1 |
| Ochai, R | 1 |
| Muhweezi, D | 1 |
| Etukoit, B | 1 |
| Gilks, C | 2 |
| Boocock, K | 1 |
| Puddephatt, C | 1 |
| Grundy, C | 1 |
| Bohannon, J | 1 |
| Winogron, D | 1 |
| Burke, A | 1 |
| Babiker, A | 2 |
| Wilkes, H | 1 |
| Rauchenberger, M | 1 |
| Sheehan, S | 1 |
| Spencer-Drake, C | 1 |
| Taylor, K | 1 |
| Spyer, M | 2 |
| Ferrier, A | 1 |
| Naidoo, B | 1 |
| Goodall, R | 2 |
| Peto, L | 1 |
| Nanfuka, R | 1 |
| Mufuka-Kapuya, C | 1 |
| McCormick, A | 1 |
| Weller, I | 1 |
| Bahendeka, S | 1 |
| Bassett, M | 1 |
| Wapakhabulo, AC | 1 |
| Mapuchere, C | 1 |
| Mugurungi, O | 1 |
| Burke, C | 1 |
| Jones, S | 1 |
| Newland, C | 1 |
| Rahim, S | 2 |
| Smith, M | 1 |
| Snowden, W | 1 |
| Steens, JM | 1 |
| Breckenridge, A | 1 |
| McLaren, A | 1 |
| Hill, C | 1 |
| Matenga, J | 1 |
| Serwadda, D | 1 |
| Peto, T | 1 |
| Palfreeman, A | 2 |
| Borok, M | 1 |
| Horton, J | 1 |
| Giganti, M | 1 |
| Mulenga, LB | 2 |
| Tambatamba-Chapula, B | 1 |
| Reid, SE | 1 |
| Bolton-Moore, C | 2 |
| Mulenga, PL | 1 |
| Sheneberger, R | 3 |
| Mwaba, P | 1 |
| Larrousse, M | 4 |
| Pérez, I | 1 |
| Deulofeu, R | 1 |
| Casamitjana, R | 1 |
| Sluis-Cremer, N | 2 |
| Moore, K | 1 |
| Sonza, S | 1 |
| Tachedjian, G | 1 |
| Gervain, J | 1 |
| Horváth, G | 1 |
| Hunyady, B | 1 |
| Makara, M | 1 |
| Pár, A | 1 |
| Szalay, F | 1 |
| Tornai, I | 1 |
| Telegdy, L | 1 |
| Boothby, M | 2 |
| McGee, KC | 2 |
| Tomlinson, JW | 2 |
| Gathercole, LL | 2 |
| McTernan, PG | 2 |
| Shojaee-Moradie, F | 2 |
| Umpleby, AM | 2 |
| Nightingale, P | 2 |
| Wilson, SS | 1 |
| Fakioglu, E | 1 |
| Echevarria, J | 1 |
| Corral, J | 1 |
| David, N | 1 |
| Mancini, M | 2 |
| Percival, L | 1 |
| Wirtz, V | 4 |
| Absalon, J | 2 |
| Bender, MA | 1 |
| Lu, Z | 1 |
| Bittar, R | 1 |
| de Truchis, P | 1 |
| Bollens, D | 1 |
| Giral, P | 1 |
| Bonnefont-Rousselot, D | 1 |
| Aubron-Olivier, C | 3 |
| Marzolini, C | 1 |
| Altice, FL | 1 |
| Springer, SA | 1 |
| Bateman, C | 3 |
| Goicoechea, M | 3 |
| Bi, L | 1 |
| Kemper, C | 2 |
| Diamond, C | 2 |
| Sun, S | 2 |
| Richman, D | 1 |
| Louie, S | 2 |
| Baraboutis, IG | 1 |
| Papastamopoulos, V | 1 |
| Georgiou, O | 1 |
| Samarkos, M | 1 |
| Vrionis, E | 1 |
| Kotsianopoulou, M | 1 |
| Skoutelis, AT | 1 |
| Quinn, KJ | 1 |
| Emerson, CR | 1 |
| Dinsmore, WW | 1 |
| Donnelly, CM | 1 |
| Burty, C | 1 |
| Christian, B | 2 |
| Penalba, C | 1 |
| Salmon-Ceron, D | 2 |
| Rabaud, C | 3 |
| Krisko, JF | 2 |
| Powell, DA | 3 |
| Mathias, M | 1 |
| Kwak, YT | 2 |
| Martinez-Torres, F | 2 |
| Zou, W | 2 |
| Payne, DA | 2 |
| Estes, JD | 3 |
| Grant, PM | 1 |
| Taylor, J | 3 |
| Nevins, AB | 1 |
| Zolopa, AR | 2 |
| Maserati, R | 4 |
| De Silvestri, A | 2 |
| Uglietti, A | 2 |
| Colao, G | 1 |
| Di Pietro, M | 1 |
| Re, MC | 2 |
| Tinelli, C | 1 |
| Boyd, KL | 1 |
| Stöhr, W | 2 |
| Sharland, M | 1 |
| Shingadia, D | 1 |
| Weberschock, T | 1 |
| Gholam, P | 1 |
| Hueter, E | 1 |
| Flux, K | 1 |
| Hartmann, M | 1 |
| Hodder, SL | 1 |
| Grimm, K | 1 |
| Esker, S | 1 |
| Roat, E | 1 |
| Pinti, M | 3 |
| Nasi, M | 3 |
| Gibellini, L | 1 |
| De Biasi, S | 1 |
| Airoldi, M | 1 |
| Ravasio, V | 1 |
| Suter, F | 3 |
| Cossarizza, A | 4 |
| Seclen, E | 1 |
| de Mendoza, C | 7 |
| Wever, K | 1 |
| Dutta, A | 1 |
| Schwarzwald, HL | 1 |
| Edwards, MS | 1 |
| Landman, GW | 1 |
| Soonawala, D | 1 |
| Albalate, M | 1 |
| Weigel, R | 1 |
| Brown, LB | 1 |
| Mzinganjira, D | 1 |
| Mhango, B | 1 |
| Phiri, S | 1 |
| van Oosterhout, JJ | 1 |
| Weinberg, WG | 2 |
| Horton, JH | 1 |
| Lancaster, CT | 1 |
| Alvarez, E | 1 |
| Garvey, L | 1 |
| Latch, N | 1 |
| Erlwein, OW | 1 |
| Mackie, NE | 1 |
| Scullard, G | 2 |
| McClure, MO | 1 |
| Izzedine, H | 6 |
| Schneider, L | 1 |
| Norden, AG | 1 |
| Rieger, A | 2 |
| Khuong-Josses, MA | 1 |
| Branco, T | 1 |
| Pearce, HC | 1 |
| Givens, N | 1 |
| Lim, ML | 2 |
| Ptak, RG | 1 |
| Lampert, BM | 2 |
| Keilholz, L | 1 |
| Hartman, T | 1 |
| Buckheit, RW | 2 |
| Mankowski, MK | 1 |
| Osterling, MC | 1 |
| Almond, MR | 3 |
| Painter, GR | 3 |
| Ortu, F | 1 |
| Weimer, LE | 2 |
| Floridia, M | 3 |
| Manconi, PE | 1 |
| Malan, N | 1 |
| Su, J | 1 |
| Tungsiripat, M | 1 |
| Glesby, MJ | 1 |
| Moran, L | 1 |
| Jones, L | 1 |
| Alston-Smith, B | 3 |
| Ho, NA | 1 |
| Schmidt, RE | 1 |
| Crum-Cianflone, N | 1 |
| Ganesan, A | 1 |
| Teneza-Mora, N | 1 |
| Riddle, M | 1 |
| Medina, S | 1 |
| Barahona, I | 1 |
| Brodine, S | 1 |
| Barnas, D | 1 |
| Koontz, D | 1 |
| Bazmi, H | 1 |
| Bixby, C | 1 |
| Jemsek, J | 1 |
| Loubiere, S | 1 |
| Meiners, C | 1 |
| Sloan, C | 1 |
| Moore, S | 1 |
| Myint, MM | 1 |
| Galau, NH | 1 |
| Mack, N | 1 |
| Robinson, ET | 1 |
| Moffett, J | 1 |
| Johnson, LM | 1 |
| Kauf, TL | 1 |
| Farkouh, RA | 1 |
| Earnshaw, SR | 1 |
| Watson, ME | 1 |
| Maroudas, P | 1 |
| Chambers, MG | 1 |
| Pinnetti, C | 1 |
| Baroncelli, S | 1 |
| Villani, P | 1 |
| Fantoni, M | 1 |
| Tozzi, V | 3 |
| Anzidei, G | 1 |
| Cusato, M | 1 |
| Regazzi, M | 1 |
| Tamburrini, E | 2 |
| Naftalin, C | 1 |
| Cheserem, E | 1 |
| Roe, J | 1 |
| Cohen, J | 7 |
| Mlisana, KP | 3 |
| Omar, Z | 3 |
| Mlotshwa, M | 2 |
| van Luin, M | 1 |
| Bosch, M | 1 |
| van der Ven, A | 2 |
| Brouwer, AM | 1 |
| Keuter, M | 1 |
| Dofferhoff, T | 1 |
| Koopmans, PP | 1 |
| Sinn, K | 1 |
| Richardson, R | 1 |
| Pinho, JR | 2 |
| Yuen, L | 1 |
| Sitnik, R | 1 |
| Santana, RA | 1 |
| Gomes-Gouvêa, MS | 2 |
| Leite, OM | 1 |
| Martins, LG | 2 |
| Silva, MH | 2 |
| Gianini, RJ | 2 |
| Uip, DE | 2 |
| Delaney, JA | 1 |
| Biggs, ML | 1 |
| Shliplak, MG | 1 |
| Polak, JF | 1 |
| Kronmal, RA | 1 |
| Wanke, C | 1 |
| O'leary, D | 1 |
| Rosenvinge, MM | 1 |
| Gedela, K | 1 |
| Copas, AJ | 1 |
| Wilkinson, A | 1 |
| Sheehy, CA | 1 |
| Bano, G | 1 |
| Hay, PE | 1 |
| Pakianathan, MR | 1 |
| Sadiq, ST | 2 |
| Childs, KE | 1 |
| Fishman, SL | 1 |
| Constable, C | 1 |
| Gutierrez, JA | 1 |
| Dieterich, DT | 3 |
| Mullen, MP | 1 |
| Branch, AD | 1 |
| Cohen, D | 2 |
| Fredrick, L | 1 |
| Naylor, C | 1 |
| Bernstein, B | 1 |
| Cooper, RD | 2 |
| Wiebe, N | 1 |
| Keiser, P | 2 |
| Naicker, S | 2 |
| Tonelli, M | 2 |
| Baleta, A | 2 |
| German, P | 1 |
| Warren, D | 1 |
| West, S | 1 |
| Hui, J | 1 |
| Curto, J | 1 |
| Cates, W | 3 |
| Lalezari, JP | 1 |
| Osiyemi, OO | 1 |
| Ryan, R | 1 |
| Witek, J | 1 |
| Tosini, W | 1 |
| Muller, P | 1 |
| Benabdelmoumen, G | 1 |
| Peyrouse, E | 1 |
| Quertainmont, Y | 1 |
| Svicher, V | 1 |
| Alteri, C | 1 |
| Artese, A | 1 |
| Schols, D | 3 |
| Van Laethem, K | 2 |
| Alcaro, S | 1 |
| Costa, G | 1 |
| Tommasi, C | 1 |
| Zaccarelli, M | 4 |
| Narciso, P | 3 |
| Rami, A | 1 |
| Loustau-Ratti, V | 1 |
| Goderel, I | 1 |
| Sene, D | 1 |
| Rosenthal, E | 2 |
| de Vries-Sluijs, TE | 3 |
| Reijnders, JG | 2 |
| Pas, SD | 1 |
| Schutten, M | 1 |
| de Man, RA | 3 |
| Janssen, HL | 3 |
| Herlitz, LC | 1 |
| Mohan, S | 1 |
| Stokes, MB | 2 |
| Radhakrishnan, J | 1 |
| D'Agati, VD | 2 |
| Markowitz, GS | 2 |
| Mohammadi, D | 1 |
| Kruy, LS | 1 |
| Say, L | 1 |
| Hoy, J | 2 |
| Van Wijngaerden, E | 2 |
| Sprenger, HG | 1 |
| Lambert, J | 1 |
| Sture, G | 1 |
| Leather, D | 1 |
| Hughes, S | 1 |
| Zucchi, P | 1 |
| Ondounda, M | 1 |
| Tanon, A | 1 |
| Ehui, E | 1 |
| Ouattara, I | 1 |
| Kassi, A | 1 |
| Aba, YT | 1 |
| Aoussi, EF | 1 |
| Kakou, AR | 1 |
| Bissagnene, E | 1 |
| Kadio, A | 1 |
| Kerr, S | 1 |
| Chang, JJ | 1 |
| Piyawat, K | 1 |
| Napissanant, N | 1 |
| Lange, J | 2 |
| McCoy, SI | 1 |
| Padian, NS | 1 |
| De Beaudrap, P | 1 |
| Ndiaye, I | 1 |
| Diouf, A | 2 |
| Kane, CT | 1 |
| Etard, JF | 1 |
| Amadasi, S | 1 |
| Izzo, I | 3 |
| Allegri, R | 1 |
| Motta, D | 2 |
| Gatti, F | 2 |
| Cristini, G | 1 |
| Mendeni, M | 1 |
| Romanelli, F | 2 |
| Murphy, B | 1 |
| Rosso, R | 5 |
| Parodi, A | 1 |
| Torrisi, C | 1 |
| De Terlizzi, F | 1 |
| Vignolo, M | 1 |
| Wade, JR | 1 |
| Snoeck, E | 1 |
| Vis, P | 1 |
| Corbett, C | 1 |
| Nijs, S | 1 |
| Vingerhoets, J | 1 |
| Leopold, L | 1 |
| Gali, Y | 1 |
| Delezay, O | 1 |
| Brouwers, J | 1 |
| Addad, N | 1 |
| Augustijns, P | 1 |
| Bourlet, T | 1 |
| Hamzeh-Cognasse, H | 1 |
| Ariën, KK | 2 |
| Pozzetto, B | 1 |
| Vanham, G | 2 |
| Spaulding, A | 1 |
| Rutherford, GW | 1 |
| Siegfried, N | 1 |
| Chipato, T | 2 |
| Conradie, F | 1 |
| Stringer, E | 2 |
| Mngqibisa, R | 1 |
| Atwine, D | 1 |
| Kanyama, C | 1 |
| Wools-Kaloustian, K | 1 |
| Salata, RA | 1 |
| Walawander, A | 1 |
| Purcelle-Smith, E | 1 |
| Eshleman, S | 1 |
| Schooley, RT | 4 |
| Benaboud, S | 3 |
| Sim, KL | 1 |
| Veronese, F | 1 |
| DeGruttola, V | 3 |
| Becker, S | 2 |
| Zwerski, S | 1 |
| Burns, D | 1 |
| Bonacini, M | 2 |
| Rodríguez-Guardado, A | 1 |
| Tuset, M | 1 |
| Asensi, V | 3 |
| Lasnier, E | 1 |
| Wendum, D | 1 |
| Messou, E | 1 |
| Attia, A | 1 |
| Polneau, S | 1 |
| Toni, T | 1 |
| Chenal, H | 1 |
| Seyler, C | 1 |
| Wakasugi, N | 1 |
| Eholié, S | 1 |
| Puzzovio, M | 2 |
| Pivetti, V | 1 |
| Zamproni, I | 1 |
| Cerini, C | 2 |
| Figueras, M | 1 |
| Estany, C | 2 |
| Rosales, J | 1 |
| del Rio, L | 1 |
| di Gregorio, S | 1 |
| Gómez, G | 1 |
| Ragland, K | 1 |
| Monk, A | 1 |
| Springinsfeld, G | 1 |
| Martinot, M | 1 |
| Tortel, MC | 1 |
| Bénet, T | 1 |
| Billioud, C | 1 |
| Scoazec, JY | 1 |
| Ferry, T | 1 |
| Boibieux, A | 1 |
| Vanhems, P | 1 |
| Chevallier, M | 1 |
| Chaisiri, K | 1 |
| Bowonwatanuwong, C | 2 |
| Kasettratat, N | 1 |
| Soler-Palacín, P | 1 |
| Melendo, S | 1 |
| Noguera-Julian, A | 1 |
| Fortuny, C | 1 |
| Navarro, ML | 1 |
| Mellado, MJ | 1 |
| Garcia, L | 1 |
| Uriona, S | 1 |
| Martín-Nalda, A | 1 |
| Figueras, C | 1 |
| Perazella, MA | 3 |
| Michael, NL | 1 |
| Casapía, M | 2 |
| Guanira-Carranza, JV | 1 |
| Ramirez-Cardich, ME | 1 |
| Hance, RJ | 1 |
| Ganoza, C | 1 |
| Postle, B | 1 |
| McConnell, JJ | 1 |
| Lee, J | 2 |
| Jaffe, HS | 5 |
| Martinez, AI | 1 |
| Pais, R | 1 |
| Rower, JE | 2 |
| Bracciale, L | 2 |
| Doino, M | 2 |
| Sidella, L | 1 |
| Farina, S | 1 |
| Di Cristo, V | 1 |
| Randell, PA | 1 |
| Jackson, AG | 2 |
| Tjia, JF | 1 |
| Raboud, JM | 1 |
| Walmsley, SL | 1 |
| Goodman, DD | 1 |
| Bygrave, H | 2 |
| van Cutsem, G | 1 |
| Hilderbrand, K | 2 |
| Jouquet, G | 2 |
| Goemaere, E | 2 |
| Vlahakis, N | 2 |
| Triviño, L | 2 |
| Makakole, L | 2 |
| Kranzer, K | 2 |
| Gayton, JC | 1 |
| Burleson, D | 1 |
| Polenakovik, H | 1 |
| Laughlin, RT | 1 |
| Martin, L | 1 |
| Mallet, V | 1 |
| Vallet-Pichard, A | 1 |
| de Silva, T | 1 |
| Weiss, RA | 1 |
| Vermund, SH | 2 |
| Yende, N | 2 |
| Gengiah, T | 1 |
| Luthuli, LR | 1 |
| Veikley, W | 2 |
| Reddy, YS | 1 |
| Hu, C | 1 |
| Burchett, SK | 2 |
| Rossi, SS | 1 |
| Hawkins, E | 2 |
| Basar, M | 1 |
| Read, JS | 2 |
| Madan, RP | 1 |
| Torres, NM | 2 |
| Fazzari, MJ | 1 |
| Cho, S | 1 |
| Kalyoussef, S | 1 |
| Shust, G | 1 |
| Louissaint, N | 1 |
| Cohen, HW | 1 |
| Diament, EC | 1 |
| Lee, AC | 1 |
| Soto-Torres, L | 4 |
| Myers, GM | 1 |
| Broder, MS | 1 |
| Chang, EY | 1 |
| Bentley, TG | 1 |
| Juday, T | 1 |
| Uy, J | 2 |
| Aperis, G | 1 |
| Paliouras, C | 1 |
| Zervos, A | 1 |
| Arvanitis, A | 1 |
| Alivanis, P | 1 |
| Padilla, S | 4 |
| García, N | 1 |
| Tormo, C | 1 |
| Van Delft, Y | 1 |
| Moecklinghoff, C | 1 |
| De Meyer, S | 1 |
| Dierynck, I | 1 |
| Van de Casteele, T | 1 |
| Lavreys, L | 1 |
| de Béthune, MP | 1 |
| Picchio, G | 1 |
| D'Avino, A | 1 |
| Marzocchetti, A | 1 |
| Pérez-Rivera, AÁ | 1 |
| Sáez, P | 1 |
| León, E | 1 |
| Lozano de León-Naranjo, F | 1 |
| Martinelli, L | 1 |
| Masini, G | 1 |
| Kaptur, PE | 1 |
| Beadsworth, MB | 1 |
| Pennell, A | 1 |
| Phillips, M | 1 |
| Vilar, FJ | 1 |
| Duke, N | 1 |
| Aboh, S | 1 |
| Bosivert, N | 1 |
| Lueangniyomkul, A | 2 |
| Mankatitham, W | 2 |
| Chimsuntorn, S | 2 |
| Tantanathip, P | 2 |
| Suntisuklappon, B | 1 |
| O'Donnell, EP | 1 |
| Darin, KM | 1 |
| Gerzenshtein, L | 1 |
| Postelnick, MJ | 1 |
| Palella, FJ | 1 |
| Meesters, RJ | 1 |
| van Kampen, JJ | 1 |
| Scheuer, RD | 1 |
| Gruters, RA | 1 |
| Luider, TM | 1 |
| Schiffer, V | 1 |
| Warren, DR | 2 |
| Kuijper, A | 1 |
| Rookmaker, MB | 1 |
| Alukda, D | 1 |
| Sturgis, T | 1 |
| Youan, BC | 1 |
| Stitou, H | 1 |
| Desire, N | 1 |
| Tubiana, R | 4 |
| Trapani, F | 2 |
| Tedeschi, S | 1 |
| Piergentili, B | 1 |
| Colangeli, V | 2 |
| Viale, P | 2 |
| Pittrof, R | 1 |
| Sauer, U | 1 |
| French, P | 1 |
| Pimpinella, G | 1 |
| Malgarini, RB | 1 |
| Sellier, PO | 1 |
| Lafuente-Lafuente, C | 1 |
| Roques, P | 1 |
| Lee, DH | 1 |
| Vielemeyer, O | 1 |
| Cooper, V | 1 |
| Horne, R | 1 |
| Mayo, AJ | 1 |
| Mfalila, CK | 1 |
| Chu, H | 1 |
| Barry, AC | 1 |
| Kuruc, JD | 1 |
| McGee, KS | 1 |
| Kerkau, M | 1 |
| Sebastian, J | 1 |
| Fiscus, SA | 4 |
| Margolis, DM | 1 |
| Hicks, CB | 1 |
| Ferrari, G | 1 |
| Férir, G | 1 |
| Vermeire, K | 1 |
| Huskens, D | 1 |
| Van Damme, EJ | 1 |
| Kehr, JC | 1 |
| Dittmann, E | 1 |
| Markovitz, DM | 1 |
| Chan, DJ | 1 |
| Maruszak, H | 1 |
| Jeganathan, S | 1 |
| Choi, AI | 2 |
| Weekley, CC | 1 |
| Gracey, D | 1 |
| Post, J | 1 |
| MacLeod, C | 1 |
| McKenzie, P | 1 |
| Taylor, S | 4 |
| Gellermann, HJ | 1 |
| de Rossi, L | 2 |
| Cairns, V | 1 |
| Aung, W | 1 |
| Zheng, Q | 1 |
| Youngpairoj, AS | 1 |
| Kuklenyik, S | 1 |
| Lin, CY | 1 |
| Hanson, DL | 2 |
| Kersh, E | 1 |
| di Nello, F | 1 |
| Penagini, F | 1 |
| Caprio, C | 1 |
| de La Faille, R | 1 |
| Rigothier, C | 1 |
| Mehsen, N | 1 |
| Miremont-Salamé, G | 1 |
| Greib, C | 1 |
| Migrone, H | 1 |
| Gellermann, H | 1 |
| Haverkort, ME | 1 |
| van der Spek, BW | 1 |
| Lips, P | 1 |
| Slieker, WA | 1 |
| Bronsveld, W | 1 |
| Stephenson, J | 1 |
| Othieno, F | 1 |
| Fleming, E | 1 |
| Zein, S | 1 |
| Wahl, A | 1 |
| Welch, BD | 1 |
| Kay, MS | 1 |
| Gallay, P | 1 |
| Appella, E | 1 |
| Wepner, U | 1 |
| Pushpakom, SP | 1 |
| Liptrott, NJ | 1 |
| Hopper-Borge, E | 1 |
| Pirmohamed, M | 1 |
| Schader, SM | 2 |
| Colby-Germinario, SP | 2 |
| Schachter, JR | 1 |
| Brennan, A | 2 |
| Maotoe, T | 1 |
| Fox, M | 1 |
| Foissac, F | 3 |
| Dollfus, C | 1 |
| Firtion, G | 2 |
| Westfall, AO | 1 |
| Vidiella, G | 1 |
| Williams, BG | 1 |
| Gouws, E | 1 |
| Powderly, WG | 2 |
| Katsidzira, L | 1 |
| Hakim, JG | 2 |
| Yogev, R | 1 |
| Wiznia, A | 1 |
| Britto, P | 1 |
| Carey, V | 1 |
| Saumoy, M | 2 |
| Ordoñez-Llanos, J | 1 |
| Bonet, R | 1 |
| Filmann, N | 1 |
| Hueppe, D | 1 |
| Henke, J | 1 |
| Hegener, P | 1 |
| Athmann, C | 1 |
| Schmutz, G | 4 |
| Herrmann, E | 1 |
| Sturgis, TF | 2 |
| Prasithsirikul, W | 5 |
| Sopheak, T | 1 |
| Verpooten, GA | 1 |
| Chan, K | 1 |
| Raboud, J | 2 |
| Klein, MB | 1 |
| Machouf, N | 1 |
| Rourke, SB | 1 |
| Tsoukas, C | 1 |
| Loutfy, MR | 1 |
| Simiele, M | 2 |
| Rostagno, R | 1 |
| Bonasso, M | 1 |
| Romito, A | 1 |
| Imperiale, D | 1 |
| Numata, A | 1 |
| Akimoto, T | 1 |
| Toshima, M | 1 |
| Iwazu, Y | 1 |
| Otani, N | 1 |
| Miki, T | 1 |
| Sugase, T | 1 |
| Saito, O | 1 |
| Hamano, Y | 1 |
| Takemoto, F | 1 |
| Ueda, Y | 1 |
| Muto, S | 1 |
| Kusano, E | 1 |
| Valiaeva, N | 1 |
| Hwu, JB | 1 |
| Beadle, JR | 3 |
| Prichard, MN | 1 |
| Hostetler, KY | 3 |
| Sheppard, L | 1 |
| Pavie, J | 2 |
| Scemla, A | 1 |
| Bouldouyre, MA | 1 |
| Pillebout, E | 1 |
| Verine, J | 1 |
| Kohler, JJ | 1 |
| Hosseini, SH | 1 |
| Desimmie, BA | 1 |
| Gadot, L | 1 |
| Cleary, S | 1 |
| Chung, E | 1 |
| Patterson, K | 3 |
| Child, M | 2 |
| Mahnke, L | 1 |
| Fessel, WJ | 2 |
| Chau, Q | 1 |
| Leong, D | 1 |
| de Lastours, V | 1 |
| Fonsart, J | 1 |
| Burlacu, R | 1 |
| Gourmel, B | 1 |
| Rebolledo, BJ | 1 |
| Unnanuntana, A | 1 |
| Lane, JM | 1 |
| Honda, M | 3 |
| Nulvesu, L | 1 |
| Callegaro, AP | 1 |
| Kazazis, C | 1 |
| Nagata, N | 1 |
| Mathias, AA | 1 |
| Fernandez Garcia, E | 1 |
| Jayaweera, DT | 1 |
| Hardy, WD | 1 |
| van Eeden, A | 1 |
| Porcher, R | 1 |
| Rusconi, S | 2 |
| Ammassari, A | 1 |
| Lao, CK | 1 |
| Gruta, C | 1 |
| John, MD | 1 |
| Cocohoba, J | 1 |
| Schirmer, P | 1 |
| Winters, M | 1 |
| Holodniy, M | 1 |
| Sigal, A | 1 |
| Kim, JT | 1 |
| Balazs, AB | 1 |
| Dekel, E | 1 |
| Mayo, A | 1 |
| Milo, R | 1 |
| Baltimore, D | 1 |
| Fierro, T | 1 |
| Giganti, MJ | 1 |
| Sikazwe, I | 1 |
| Schuttner, L | 1 |
| Chintu, NT | 1 |
| Bouazza, N | 2 |
| Frange, P | 1 |
| Garcia, EF | 2 |
| Hoek, FJ | 2 |
| Abeling, NG | 1 |
| Krediet, RT | 2 |
| Tolley, EE | 2 |
| Tsui, S | 1 |
| Mehendale, S | 2 |
| Kohli, R | 2 |
| Bardeguez, A | 1 |
| Rodman, J | 1 |
| Robbins, B | 1 |
| Mofenson, LM | 3 |
| Watts, DH | 3 |
| Heckman, B | 1 |
| Thorpe, E | 1 |
| Cotter, A | 1 |
| Purswani, M | 2 |
| Budhathoki, C | 1 |
| Kiyasu, Y | 1 |
| Koganemaru, H | 1 |
| Hitomi, S | 1 |
| da Silva, AC | 1 |
| Guastini, CF | 1 |
| Leite, AG | 1 |
| Péré, H | 1 |
| Mbelesso, P | 1 |
| Dandy, M | 1 |
| Matta, M | 1 |
| De Dieu Longo, J | 1 |
| Grésenguet, G | 1 |
| Abraham, B | 1 |
| Razonable, RR | 1 |
| Yoshino, M | 2 |
| Yagura, H | 2 |
| Kushida, H | 1 |
| Yonemoto, H | 2 |
| Bando, H | 2 |
| Ogawa, Y | 1 |
| Yajima, K | 2 |
| Kasai, D | 1 |
| Taniguchi, T | 1 |
| Watanabe, D | 2 |
| Nishida, Y | 2 |
| Kuwahara, T | 2 |
| Uehira, T | 2 |
| Shirasaka, T | 2 |
| van Griensven, F | 1 |
| Rasmussen, TA | 2 |
| Tolstrup, M | 2 |
| Melchjorsen, J | 1 |
| Frederiksen, CA | 1 |
| Nielsen, US | 2 |
| Langdahl, BL | 2 |
| Østergaard, L | 2 |
| Laursen, AL | 3 |
| Nuttall, J | 1 |
| Allen, P | 1 |
| Roberts, J | 1 |
| Romano, J | 1 |
| Albini, L | 1 |
| Cesana, BM | 1 |
| Focà, E | 1 |
| Gotti, D | 1 |
| Bellagamba, R | 2 |
| Fezza, R | 1 |
| Sighinolfi, L | 2 |
| Manili, L | 1 |
| Barnes, L | 1 |
| Panteleeff, D | 2 |
| Shah, H | 1 |
| Revall, J | 2 |
| Morrison, S | 2 |
| Ondrejcek, L | 2 |
| Ingram, C | 1 |
| Lingappa, JR | 2 |
| Krakower, D | 2 |
| Shen, C | 1 |
| Mather, KJ | 1 |
| Agarwal, R | 1 |
| Mulcahy, F | 1 |
| Gölz, J | 1 |
| Teofilo, E | 1 |
| Vera, J | 1 |
| Körber, A | 1 |
| Ross, AC | 1 |
| Storer, N | 2 |
| Labbato, D | 1 |
| Schewe, CK | 3 |
| Clercq, ED | 1 |
| Sharma, S | 1 |
| Kuklenyik, Z | 1 |
| Smith, J | 1 |
| Novembre, FJ | 1 |
| Lorente, N | 1 |
| Fugon, L | 1 |
| Carrieri, MP | 1 |
| Andreo, C | 1 |
| Le Gall, JM | 1 |
| Cook, E | 1 |
| Aboulker, JP | 4 |
| Capitant, C | 1 |
| Marlow, HM | 1 |
| Berger, RE | 2 |
| Lada, O | 3 |
| Gervais, A | 3 |
| Branger, M | 2 |
| Roquebert, B | 2 |
| Collin, G | 4 |
| Fraqueiro, G | 2 |
| Moucari, R | 2 |
| Hamet, G | 1 |
| Martinot-Peignoux, M | 3 |
| Marcellin, P | 3 |
| López-Martínez, A | 1 |
| O'Brien, NM | 1 |
| Caro-Vega, Y | 1 |
| Sierra-Madero, J | 1 |
| Schleenvoigt, BT | 1 |
| Stallmach, A | 1 |
| Pletz, MW | 1 |
| Liao, S | 1 |
| Persson, A | 1 |
| Eley, T | 1 |
| Krystal, M | 1 |
| Porter, KA | 1 |
| Poole, C | 1 |
| Skinner-Adams, TS | 1 |
| Sawe, FK | 1 |
| McCarthy, JS | 1 |
| Meshnick, SR | 1 |
| Launay, O | 1 |
| Pannier, E | 1 |
| Chappuy, H | 1 |
| Malone, AM | 2 |
| Kennedy, S | 2 |
| Kopin, E | 2 |
| Nguyen, C | 2 |
| Gilman, J | 2 |
| Vincent, KL | 1 |
| Motamedi, M | 1 |
| Oliveira, M | 2 |
| Ibanescu, RI | 1 |
| Moisi, D | 2 |
| Montinaro, V | 1 |
| Bellacosa, C | 1 |
| Pietanza, S | 1 |
| Volpe, A | 1 |
| Graziano, G | 1 |
| Strippoli, GF | 1 |
| Angarano, G | 2 |
| Lampiris, HW | 1 |
| Kerr, SJ | 4 |
| Duncombe, C | 1 |
| Li, PC | 1 |
| Gill, JM | 1 |
| Taylor-Robinson, SD | 1 |
| Dolling, D | 1 |
| Delpech, V | 1 |
| Cane, PA | 1 |
| Crook, AM | 1 |
| Shepherd, J | 1 |
| Else, LJ | 1 |
| Gabiano, C | 1 |
| Salvini, F | 1 |
| Cellini, M | 1 |
| Green, L | 1 |
| Taylor, BM | 1 |
| Deuter-Reinhard, M | 1 |
| Desta, Z | 1 |
| Clauss, M | 1 |
| Kraft, E | 1 |
| Jenkins, AJ | 1 |
| Shaheen, NJ | 1 |
| Hogan, CM | 1 |
| Connick, E | 1 |
| Macatangay, B | 1 |
| Tashima, KT | 1 |
| Kallungal, B | 1 |
| Camp, R | 1 |
| Morton, T | 1 |
| Little, S | 1 |
| Tossonian, H | 1 |
| Lavocat, F | 3 |
| Gupta, A | 1 |
| Bugeja, A | 1 |
| Kirpalani, D | 1 |
| Grasso, C | 2 |
| Wyatt, MA | 1 |
| Safren, S | 1 |
| Leclerc, L | 1 |
| Pontrelli, G | 1 |
| Cotugno, N | 1 |
| Amodio, D | 1 |
| Zangari, P | 1 |
| Tchidjou, HK | 1 |
| Baldassari, S | 1 |
| Palma, P | 1 |
| Bernardi, S | 1 |
| O'Riordan, M | 2 |
| Libutti, D | 1 |
| Rowe, D | 1 |
| Harrill, D | 1 |
| Ando, M | 1 |
| Tsuchiya, K | 2 |
| Nitta, K | 1 |
| Tripathi, G | 1 |
| Harte, AL | 1 |
| Al-Daghri, NM | 1 |
| Bush, T | 1 |
| Overton, T | 1 |
| Hammer, J | 1 |
| Kojic, E | 1 |
| Conley, L | 1 |
| Bedimo, R | 1 |
| Fernando, M | 1 |
| Ziegler, J | 1 |
| White, CP | 1 |
| Post, JJ | 1 |
| Estrella, M | 1 |
| Melikian, GL | 1 |
| Kaufman, D | 1 |
| Troia-Cancio, PV | 1 |
| Robbins, GK | 1 |
| Kagan, R | 1 |
| Israelski, D | 1 |
| Lassel, L | 1 |
| Omeje, I | 2 |
| Amoroso, A | 2 |
| Etienne-Mesubi, M | 1 |
| Edozien, A | 1 |
| Ojoo, S | 1 |
| Obiefune, M | 1 |
| Hossain, MB | 1 |
| Stafford, K | 1 |
| Hirota, K | 1 |
| Otera, H | 1 |
| Tominari, S | 1 |
| Moquet, C | 1 |
| Coutherut, J | 1 |
| Ngom Gueye, NF | 1 |
| Cames, C | 1 |
| Taverne, B | 1 |
| Bork, K | 1 |
| Mureithi, MW | 1 |
| Poole, D | 1 |
| Reddy, S | 1 |
| Mkhwanazi, NP | 1 |
| Abdool Karim, S | 1 |
| Fidler, S | 2 |
| Fernandez, VA | 1 |
| Thomas, DB | 1 |
| Reiser, IW | 1 |
| Spitalewitz, S | 1 |
| Eluwa, GI | 1 |
| Badru, T | 1 |
| Agu, KA | 1 |
| Akpoigbe, KJ | 1 |
| Chabikuli, O | 1 |
| Hamelmann, C | 1 |
| Yeni, P | 2 |
| Crespo, M | 1 |
| Falco, V | 2 |
| Vidal-Sicart, S | 1 |
| Martinez, M | 1 |
| Williams, PL | 1 |
| Mendez, H | 1 |
| Jacobson, DL | 1 |
| Rich, KC | 1 |
| Griner, R | 1 |
| Tassiopoulos, K | 1 |
| Miller, T | 1 |
| DiMeglio, LA | 1 |
| Zhong, M | 1 |
| He, B | 1 |
| Bao, R | 1 |
| Han, C | 1 |
| Shi, W | 1 |
| Yan, H | 1 |
| Schäfer, J | 1 |
| Tan, J | 1 |
| Devadas, K | 1 |
| Ragupathy, V | 1 |
| Takeda, K | 1 |
| Hewlett, I | 1 |
| Mc Conville, C | 1 |
| Major, I | 1 |
| Woolfson, AD | 1 |
| Malcolm, RK | 1 |
| Islam, FM | 1 |
| van Straalen, JP | 1 |
| Tujios, SR | 1 |
| Lee, WM | 3 |
| Rastogi, R | 1 |
| Segarra, TJ | 1 |
| Huber, AM | 1 |
| Park, JE | 1 |
| Jensen, D | 1 |
| Erlandsen, EJ | 1 |
| Birn, H | 1 |
| Fernández-Morano, T | 1 |
| Aguilar-Bernier, M | 1 |
| Del Boz, J | 1 |
| Fúnez-Liébana, R | 1 |
| Rokas, KE | 1 |
| Shamroe, CL | 1 |
| Sutton, SS | 1 |
| Millisor, VE | 1 |
| Bryant, JE | 1 |
| Weissman, SB | 1 |
| Mutua, G | 1 |
| Sanders, E | 1 |
| Mugo, P | 1 |
| Anzala, O | 1 |
| Sulkowski, MS | 2 |
| Monteagudo-Chu, MO | 1 |
| Chang, MH | 1 |
| Fung, HB | 3 |
| Bräu, N | 1 |
| Valley-Omar, Z | 1 |
| Arney, L | 1 |
| Treurnicht, F | 1 |
| Abrahams, MR | 1 |
| Bandawe, G | 1 |
| Swanstrom, R | 2 |
| Marchand, C | 1 |
| Shetler, C | 2 |
| Lynam, JD | 1 |
| Friend, D | 1 |
| Kuhn, L | 1 |
| Ang, BC | 1 |
| Teoh, SC | 1 |
| Nirogi, R | 1 |
| Bhyrapuneni, G | 1 |
| Kandikere, V | 1 |
| Muddana, N | 1 |
| Saralaya, R | 1 |
| Komarneni, P | 1 |
| Mudigonda, K | 1 |
| Mukkanti, K | 1 |
| Edelman, EJ | 1 |
| Gordon, K | 1 |
| Rodriguez-Barradas, MC | 1 |
| Justice, AC | 1 |
| Russell, EC | 1 |
| Nathoo, K | 1 |
| Musoke, P | 1 |
| Aragonès, G | 1 |
| Pardo-Reche, P | 1 |
| Fernández-Sender, L | 1 |
| Rull, A | 1 |
| Beltrán-Debón, R | 1 |
| Rodríguez-Gallego, E | 1 |
| Camps, J | 1 |
| Joven, J | 1 |
| Alonso-Villaverde, C | 1 |
| Buscher, A | 1 |
| Hartman, C | 1 |
| Kallen, MA | 1 |
| Giordano, TP | 1 |
| Kaldor, J | 1 |
| Jordens, CF | 1 |
| Engsig, FN | 1 |
| Olczak, A | 2 |
| Grabczewska, E | 1 |
| Hoy, JF | 2 |
| Manning, TG | 1 |
| Gunaseelan, S | 1 |
| Bobardt, MD | 1 |
| Esch, T | 1 |
| Maskiewicz, R | 1 |
| Jadhav, PR | 1 |
| Chaweza, T | 1 |
| Garone, D | 1 |
| Giddy, J | 1 |
| Tuaillon, E | 1 |
| Lozano, C | 1 |
| Kuster, N | 1 |
| Poinso, A | 1 |
| Kania, D | 1 |
| Nagot, N | 1 |
| Mondain, AM | 1 |
| Pageaux, GP | 1 |
| Van de Perre, P | 1 |
| Brown, RS | 1 |
| Verna, EC | 1 |
| Pereira, MR | 1 |
| Tilson, HH | 1 |
| Aguilar, C | 1 |
| Buti, M | 1 |
| Fagan, EA | 1 |
| Zoutendijk, R | 1 |
| Kroon, FP | 2 |
| van der Eijk, AA | 2 |
| Sonneveld, MJ | 1 |
| Baden, LR | 1 |
| Gray, GE | 1 |
| Martinson, N | 1 |
| Kebaabetswe, PM | 1 |
| Smith, DK | 1 |
| Soud, FA | 1 |
| Mutanhaurwa, R | 1 |
| Kasonde, M | 1 |
| Abebe, D | 1 |
| Buliva, E | 1 |
| Johnson, S | 1 |
| Sukalac, T | 1 |
| Thomas, VT | 1 |
| Malotte, CK | 1 |
| Onyango, J | 1 |
| Temu, L | 1 |
| Monedi, MC | 1 |
| Mak'Oketch, P | 1 |
| Makanda, M | 1 |
| Reblin, I | 1 |
| Makatu, SE | 1 |
| Saylor, L | 1 |
| Kiernan, H | 1 |
| Kirkendale, S | 1 |
| Wong, C | 1 |
| Mastro, TD | 1 |
| Kakia, A | 1 |
| Odoyo, J | 1 |
| Mucunguzi, A | 1 |
| Twesigye, R | 1 |
| Ngure, K | 1 |
| Apaka, C | 1 |
| Tamooh, H | 1 |
| Gabona, F | 1 |
| Haugen, H | 1 |
| Emmanuel-Ogier, M | 1 |
| Uthman, OA | 1 |
| Sharp, V | 1 |
| Daly, F | 1 |
| Rossotti, R | 1 |
| Moioli, MC | 1 |
| Chianura, L | 1 |
| Errante, I | 1 |
| Orcese, C | 1 |
| Orso, M | 1 |
| Schiantarelli, C | 1 |
| Schlacht, I | 1 |
| Travi, G | 1 |
| Vigo, B | 1 |
| Villa, MR | 1 |
| Volonterio, A | 1 |
| Duwal, S | 1 |
| Schütte, C | 1 |
| von Kleist, M | 1 |
| Mikulska, M | 1 |
| Giacobbe, DR | 1 |
| Caligiuri, P | 1 |
| Durgiah, R | 1 |
| Haddad, M | 1 |
| Su, C | 1 |
| Gibbs, C | 1 |
| Johnson, DC | 1 |
| Chasela, C | 1 |
| Maliwichi, M | 1 |
| Akinkuotu, A | 1 |
| King, CC | 1 |
| van der Horst, C | 1 |
| Holmes, D | 2 |
| Kelly, MD | 1 |
| Gibson, A | 1 |
| Bartlett, H | 1 |
| Rowling, D | 1 |
| Patten, J | 1 |
| Garriga, C | 1 |
| Puertas, MC | 1 |
| Anta, L | 1 |
| Caballero, E | 1 |
| Jaén, A | 1 |
| Gatel, JM | 1 |
| Peraire, J | 2 |
| Vidal, C | 1 |
| Córdoba, J | 1 |
| López Aldeguer, J | 1 |
| Pérez-Romero, P | 1 |
| Leal, M | 2 |
| Palomares, JC | 1 |
| Viciana, I | 1 |
| Rodríguez, P | 1 |
| Gutiérrez, C | 1 |
| Pérez-Olmeda, M | 2 |
| Alcamí, J | 1 |
| Cañizares, A | 1 |
| Ocampo, A | 2 |
| Garrido, C | 2 |
| Manuzza, G | 1 |
| Pommer, P | 1 |
| Schmid, H | 2 |
| Tokarska-Schlattner, M | 1 |
| Füeßl, B | 1 |
| Röder, M | 1 |
| Kay, L | 1 |
| Attia, S | 1 |
| Lederer, SR | 1 |
| Goebel, FD | 5 |
| Schlattner, U | 2 |
| Bogner, JR | 3 |
| von Wyl, V | 2 |
| Miners, A | 1 |
| Lundgren, J | 1 |
| Sokal, DC | 1 |
| Frolich, J | 1 |
| Miya, N | 1 |
| Mlisana, K | 1 |
| Maarshalk, S | 1 |
| Giannarelli, D | 1 |
| Sterrantino, G | 1 |
| Monno, L | 1 |
| Capetti, A | 2 |
| Giacometti, A | 1 |
| Zablotska, I | 1 |
| Grulich, AE | 1 |
| Szpir, M | 1 |
| Lyseng-Williamson, KA | 2 |
| Scott, LJ | 1 |
| Fernandez, C | 2 |
| Langness, J | 1 |
| Mahalingam, A | 1 |
| Ugaonkar, SR | 1 |
| Gwozdz, G | 1 |
| Buckheit, KW | 1 |
| Zanaboni, D | 1 |
| Gnarini, M | 1 |
| Anton, PA | 1 |
| Richardson-Harman, N | 1 |
| Elliott, J | 1 |
| Khanukhova, E | 1 |
| Dennis, R | 1 |
| Cumberland, WG | 1 |
| Ju, C | 1 |
| Mauck, C | 1 |
| De Pablo, C | 1 |
| Orden, S | 1 |
| Calatayud, S | 1 |
| Martí-Cabrera, M | 1 |
| Esplugues, JV | 1 |
| Alvarez, A | 1 |
| Higasa, K | 1 |
| Kou, H | 1 |
| Du, X | 1 |
| Fu, Q | 1 |
| Nikolopoulos, G | 1 |
| Tsiodras, S | 1 |
| Bonovas, S | 1 |
| Hatzakis, A | 1 |
| Baeten, J | 1 |
| Schouten, JN | 1 |
| Koëter, T | 1 |
| Rossing, HH | 1 |
| Komuta, M | 1 |
| Verheij, J | 1 |
| van der Valk, M | 1 |
| Hinoshita, F | 1 |
| Tasato, D | 1 |
| Hoshimoto, K | 1 |
| Klassen, K | 1 |
| Martineau, AR | 1 |
| Wilkinson, RJ | 1 |
| Cooke, G | 1 |
| Courtney, AP | 1 |
| Hickson, M | 1 |
| Salvadori, C | 1 |
| Magistrelli, E | 1 |
| Di Bari, MA | 1 |
| Borderi, M | 1 |
| Valcour, V | 2 |
| Bhakeecheep, S | 2 |
| Bocchiola, B | 1 |
| Cahua, T | 1 |
| Panzini, P | 1 |
| Zandonà, D | 1 |
| Salpietro, S | 2 |
| Maillard, M | 1 |
| Danise, A | 1 |
| Pazzi, A | 1 |
| Johnson, TJ | 1 |
| Albright, TH | 1 |
| Nebeker, JS | 1 |
| Tuitupou, AL | 1 |
| Clark, JT | 1 |
| Fabian, J | 1 |
| McCabe, RT | 1 |
| Colbert, JA | 1 |
| Snoeck, J | 2 |
| Camacho, RJ | 2 |
| Menzaghi, B | 1 |
| Carenzi, L | 1 |
| Parruti, G | 1 |
| Orofino, G | 2 |
| Mura, MS | 3 |
| Baheti, G | 1 |
| Savic, RM | 1 |
| Verstuyft, C | 1 |
| John, MA | 1 |
| Macphail, P | 1 |
| Fafin, C | 1 |
| Pugliese, P | 1 |
| Durant, J | 1 |
| Mondain, V | 1 |
| Rahelinirina, V | 1 |
| De Salvador, F | 1 |
| Ceppi, C | 1 |
| Perbost, I | 1 |
| Roger, PM | 1 |
| Dellamonica, P | 1 |
| Esnault, V | 1 |
| Moranne, O | 1 |
| Semvua, HH | 1 |
| Mtabho, CM | 1 |
| Fillekes, Q | 1 |
| van den Boogaard, J | 1 |
| Kisonga, RM | 1 |
| Mleoh, L | 1 |
| Ndaro, A | 1 |
| Kisanga, ER | 1 |
| Aarnoutse, RE | 1 |
| Kibiki, GS | 1 |
| Boeree, MJ | 1 |
| Kosi, L | 1 |
| Payer, BA | 1 |
| Grabmeier-Pfistershammer, K | 1 |
| Strassl, R | 1 |
| Peck-Radosavljevic, M | 1 |
| Kendrick, RN | 1 |
| Garonzik, SM | 1 |
| Kunimoto, Y | 1 |
| Yasui, H | 1 |
| Touda, N | 1 |
| Okazaki, M | 1 |
| Noda, N | 1 |
| Ikeda, H | 1 |
| Hayashi, T | 1 |
| Takahashi, S | 2 |
| Shinomura, Y | 1 |
| Ishida, T | 1 |
| Miyamoto, A | 1 |
| Raphael, MC | 1 |
| Minnis, AM | 2 |
| Gandham, S | 2 |
| Guddera, V | 2 |
| Chen, BA | 2 |
| Justman, J | 4 |
| Kümmerle, T | 1 |
| Fätkenheuer, G | 3 |
| Barbé, F | 1 |
| Aimone-Gastin, I | 1 |
| Menezes, P | 1 |
| Chateau, M | 1 |
| Beck, EJ | 1 |
| Sangha, R | 1 |
| Brettle, R | 1 |
| Schwenk, A | 1 |
| Williams, I | 1 |
| Olin, JL | 1 |
| Spooner, LM | 1 |
| Klibanov, OM | 1 |
| Laprise, C | 1 |
| Dufresne, S | 1 |
| Trottier, H | 1 |
| Grondin, C | 1 |
| Colin de Verdiere, N | 1 |
| Tabuteau, S | 1 |
| Colbers, AP | 1 |
| Hawkins, DA | 1 |
| Gingelmaier, A | 1 |
| Weizsäcker, K | 1 |
| Ivanovic, J | 1 |
| Giaquinto, C | 1 |
| Taylor, GP | 1 |
| Moltó, J | 5 |
| Schülter, E | 1 |
| Grossman, Z | 1 |
| Struck, D | 1 |
| Blevins, S | 1 |
| Pittard, D | 1 |
| Ragan, D | 1 |
| Floris-Moore, M | 1 |
| Richardson, A | 1 |
| Than, S | 1 |
| Valluri, SR | 1 |
| Craig, C | 2 |
| McFadyen, L | 1 |
| Heera, J | 1 |
| Valdez, H | 2 |
| Rinehart, AR | 1 |
| Portsmouth, S | 2 |
| Kosmiski, L | 1 |
| Santana, JL | 1 |
| Fink, H | 1 |
| Teeratakulpisarn, N | 1 |
| Jadwattanakul, T | 1 |
| Chomchey, N | 1 |
| Hongchookiat, P | 1 |
| Mathajittiphun, P | 1 |
| Pinyakorn, S | 1 |
| Rungrojrat, P | 1 |
| Praihirunyakit, P | 1 |
| Shikuma, C | 1 |
| Bisi, L | 1 |
| Manzini, L | 1 |
| Hussar, DA | 1 |
| Martinez, LN | 1 |
| Breeze, S | 1 |
| Morrow, T | 1 |
| Diop, SA | 1 |
| Fortes-Déguénonvo, L | 1 |
| Seydi, M | 1 |
| Dieng, AB | 1 |
| Basse, CD | 1 |
| Manga, NM | 1 |
| Dia, NM | 1 |
| Ndaw, G | 1 |
| Ndour, CT | 1 |
| Soumaré, M | 1 |
| Diop, BM | 1 |
| Patel, K | 1 |
| Chernoff, MC | 1 |
| Scott, GB | 1 |
| Van Dyke, RB | 1 |
| Oboho, I | 1 |
| Abraham, AG | 1 |
| Benning, L | 1 |
| Sharma, A | 1 |
| Burian, P | 1 |
| Manosuthi, S | 1 |
| Sherman, AC | 1 |
| Trehanpati, N | 1 |
| Daucher, M | 1 |
| Davey, RT | 1 |
| Sarin, SK | 1 |
| Aral, SO | 1 |
| Murowchick, JB | 1 |
| Oyler, NA | 1 |
| Watson, V | 1 |
| Tjia, J | 1 |
| Ammara, A | 1 |
| Mohabeer, M | 1 |
| Bolland, MJ | 1 |
| Grey, A | 1 |
| Kenyon, C | 1 |
| Chiricozzi, A | 1 |
| Saraceno, R | 1 |
| Cannizzaro, MV | 1 |
| Nisticò, SP | 1 |
| Chimenti, S | 1 |
| Giunta, A | 1 |
| Ferrer, P | 1 |
| Alvarez, ML | 2 |
| Leeansyah, E | 1 |
| Cameron, PU | 1 |
| Solomon, A | 1 |
| Tennakoon, S | 1 |
| Velayudham, P | 1 |
| Gouillou, M | 1 |
| Spelman, T | 1 |
| Hearps, A | 1 |
| Fairley, C | 1 |
| Smit, de V | 1 |
| Pierce, AB | 1 |
| Armishaw, J | 1 |
| Koelsch, KK | 2 |
| Liu, JP | 1 |
| Chuah, J | 2 |
| Chan, PA | 1 |
| Huang, A | 1 |
| Kantor, R | 1 |
| Seaberg, EC | 1 |
| Revill, PA | 1 |
| Littlejohn, M | 1 |
| Finlayson, R | 1 |
| Saulynas, M | 1 |
| Nakamura, YM | 1 |
| Weinstein, MC | 1 |
| Pei, PP | 1 |
| Weil, E | 1 |
| Pulik, P | 1 |
| Goodrich, J | 1 |
| Mori, J | 1 |
| Abram, M | 1 |
| Bock, P | 1 |
| Parks, L | 1 |
| Fofana, DB | 1 |
| Visseaux, B | 1 |
| Campo, R | 1 |
| Khanlou, H | 3 |
| Logue, K | 1 |
| Dau, L | 1 |
| Bagnard, G | 1 |
| Lapalus, M | 1 |
| Qayyum, S | 1 |
| Dong, H | 1 |
| Kovacic, D | 1 |
| Sohail, S | 1 |
| Waters, B | 1 |
| Thornton, C | 1 |
| Corbett, CE | 1 |
| Bershteyn, A | 1 |
| Eckhoff, PA | 1 |
| Salassa, B | 1 |
| Bramato, C | 1 |
| Libanore, V | 1 |
| Motta, I | 1 |
| Bigliano, P | 1 |
| Orsucci, E | 1 |
| Stek, A | 1 |
| Caparelli, E | 1 |
| Rossi, S | 1 |
| Byroads, M | 1 |
| Skowron, G | 1 |
| Squires, KE | 2 |
| Goodwin, SD | 1 |
| Dusak, BA | 1 |
| Tolson, JM | 1 |
| Yuen, GJ | 1 |
| Prescott, LM | 2 |
| Shere-Wolfe, KD | 1 |
| Verley, JR | 1 |
| Chappey, C | 2 |
| Maroldo, L | 1 |
| Bates, M | 2 |
| Hellmann, NS | 2 |
| Petropoulos, CJ | 2 |
| Alcaide, ML | 1 |
| Kolber, M | 1 |
| Jayaweera, D | 1 |
| Díaz, B | 1 |
| Ríos, P | 1 |
| González-Lahoz, J | 7 |
| Ristig, MB | 1 |
| Crippin, J | 2 |
| Lisker-Melman, M | 2 |
| Kessels, L | 1 |
| Stone, EA | 1 |
| Piacenti, FJ | 2 |
| Stebbing, J | 3 |
| Barr, A | 1 |
| Bower, M | 3 |
| Eagan, L | 1 |
| James, JS | 9 |
| Coca, S | 1 |
| Antoniou, T | 3 |
| Park-Wyllie, LY | 1 |
| Tseng, AL | 1 |
| Bruno, R | 2 |
| Sacchi, P | 1 |
| Zocchetti, C | 1 |
| Ciappina, V | 1 |
| Filice, G | 1 |
| Créput, C | 1 |
| Gonzalez-Canali, G | 1 |
| Hill, G | 1 |
| Piketty, C | 5 |
| Kazatchkine, M | 1 |
| Nochy, D | 1 |
| Saah, AJ | 2 |
| Holder, DJ | 1 |
| Rhodes, RR | 1 |
| Shivaprakash, M | 1 |
| Bakshi, KK | 1 |
| Danovich, RM | 1 |
| Graham, DJ | 1 |
| Condra, JH | 1 |
| Louie, M | 2 |
| Hogan, C | 2 |
| Di Mascio, M | 2 |
| Hurley, A | 2 |
| Simon, V | 2 |
| Ruiz, N | 1 |
| Brun, S | 1 |
| Sun, E | 1 |
| Ho, DD | 1 |
| Karras, A | 1 |
| Lafaurie, M | 1 |
| Furco, A | 1 |
| Bourgarit, A | 1 |
| Droz, D | 1 |
| Sereni, D | 1 |
| Legendre, C | 1 |
| Martinez, F | 1 |
| Grim, SA | 1 |
| Isaacson, E | 3 |
| Sparidans, RW | 1 |
| Crommentuyn, KM | 1 |
| Schellens, JH | 1 |
| Chung, C | 1 |
| Padte, N | 1 |
| Lamy, P | 1 |
| Nolan, D | 2 |
| Mallal, S | 3 |
| Callens, S | 1 |
| De Schacht, C | 1 |
| Huyst, V | 1 |
| Vere Hodge, A | 1 |
| Lafeuillade, A | 1 |
| Jolly, P | 1 |
| Chadapaud, S | 1 |
| Hittinger, G | 1 |
| Lambry, V | 1 |
| Philip, G | 1 |
| Ferrazin, A | 2 |
| Bassetti, M | 2 |
| Ciravegna, BW | 1 |
| Bassetti, D | 2 |
| Chapman, T | 1 |
| McGavin, J | 1 |
| Noble, S | 1 |
| Kumar, A | 2 |
| Gross, M | 1 |
| Sentenac, S | 1 |
| Thuillier, A | 1 |
| Lechat, P | 2 |
| Aymard, G | 1 |
| Pecora Fulco, P | 1 |
| Kirian, MA | 2 |
| Blanchard, JN | 1 |
| Wohlfeiler, M | 1 |
| Canas, A | 1 |
| Lonergan, JT | 1 |
| Barrios, A | 5 |
| Gálvez, J | 1 |
| Pierone, G | 2 |
| Steinhart, CR | 1 |
| Bellos, NC | 1 |
| Becker, SL | 2 |
| Toole, JJ | 5 |
| Coakley, DF | 7 |
| Deresinski, S | 1 |
| Ristig, M | 1 |
| Lee, JC | 1 |
| Marosok, RD | 1 |
| Dixit, NM | 1 |
| Hoogewerf, M | 1 |
| Regez, RM | 1 |
| Schouten, WE | 1 |
| Weigel, HM | 1 |
| Frissen, PH | 1 |
| Camino, N | 3 |
| Balis, FM | 2 |
| Tullio, AN | 3 |
| DeCarlo, E | 3 |
| Worrell, CJ | 3 |
| Steinberg, SM | 2 |
| Poblenz, M | 1 |
| Bresson, JL | 2 |
| Zuckerman, JA | 1 |
| Zeichner, SL | 3 |
| Lai, CL | 1 |
| Ratziu, V | 1 |
| Yuen, MF | 1 |
| DeChristoforo, R | 1 |
| Penzak, SR | 1 |
| Hannon, H | 1 |
| Bagnis, CI | 1 |
| Beaufils, H | 1 |
| Sullivan, M | 1 |
| Brosgart, C | 3 |
| McKinney, RE | 1 |
| Cunningham, CK | 2 |
| Boyle, BA | 2 |
| Lu, B | 6 |
| Chen, JM | 1 |
| Wrin, T | 1 |
| Naeger, LK | 1 |
| Swaminathan, S | 1 |
| Rivkin, AM | 1 |
| Brundage, RC | 1 |
| Richardson, D | 1 |
| Lamba, H | 1 |
| Carter, M | 1 |
| García-Benayas, T | 4 |
| Ala, A | 1 |
| Earle, KE | 1 |
| Seneviratne, T | 1 |
| Shaker, J | 1 |
| Shoback, D | 1 |
| Paredes, R | 2 |
| Juan, M | 1 |
| Ruiz, L | 4 |
| Masmitjà, E | 1 |
| Hulot, JS | 3 |
| Vittecoq, D | 2 |
| Jais, CK | 1 |
| Launay-Vacher, V | 2 |
| Ramos, JM | 2 |
| Pascual, J | 2 |
| Chazallon, C | 3 |
| Vincent, I | 1 |
| Gérard, L | 3 |
| Clavel, F | 2 |
| Mao, S | 1 |
| Liotta, DC | 1 |
| Lerbaek, A | 1 |
| Kristiansen, TB | 1 |
| Katzenstein, TL | 1 |
| Mathiesen, L | 1 |
| Nielsen, C | 1 |
| Larsen, K | 1 |
| Nielsen, JO | 1 |
| Guerro, MF | 1 |
| Terrón, JA | 1 |
| Elías, MJ | 1 |
| Ruiz, MI | 1 |
| Agher, R | 1 |
| Shah, J | 1 |
| Berger, A | 2 |
| Mösch, M | 1 |
| Lennemann, TS | 1 |
| Stürmer, M | 2 |
| Suleiman, JM | 1 |
| Tamalet, C | 2 |
| Montès, B | 2 |
| Bocket, L | 1 |
| Izopet, J | 1 |
| Ruffault, A | 1 |
| Palmer, P | 2 |
| Muñoz-Moreno, JA | 1 |
| Galindos, MJ | 1 |
| Rodriguez Fumaz, C | 1 |
| Gel, S | 1 |
| Rodríguez, E | 1 |
| Videla, S | 1 |
| Cahour, A | 1 |
| Fisher, R | 1 |
| Clair, MS | 1 |
| Tisdale, M | 1 |
| Sauleda, S | 1 |
| Vea, AM | 1 |
| Viladés, C | 1 |
| Richart, C | 1 |
| Hansen, AB | 1 |
| Mathiesen, S | 1 |
| Alexandre, M | 1 |
| Prie, D | 1 |
| Leport, C | 2 |
| Vildei, JL | 1 |
| Woolley, IJ | 1 |
| Veitch, AJ | 1 |
| Harangozo, CS | 1 |
| Moyle, M | 1 |
| Korman, TM | 1 |
| Bonyhay, L | 1 |
| Bongiovanni, M | 3 |
| Melzi, S | 3 |
| Tordato, F | 2 |
| d'Arminio Monforte, A | 2 |
| Bini, T | 2 |
| Sterling, RK | 1 |
| Gallego, O | 1 |
| Aguero, J | 1 |
| Corral, A | 4 |
| Damond, F | 1 |
| Campa, P | 1 |
| Taieb, A | 1 |
| Delaunay, C | 2 |
| Ahmad, K | 1 |
| Stevens, RC | 1 |
| Blum, MR | 1 |
| Rousseau, FS | 1 |
| Scieux, C | 1 |
| Pham, PA | 2 |
| Hadziyannis, SJ | 1 |
| Zhuang, H | 1 |
| Zhou, YH | 1 |
| Danta, M | 1 |
| Dusheiko, G | 1 |
| Kagan, RM | 2 |
| Merigan, TC | 1 |
| Winters, MA | 1 |
| Heseltine, PN | 1 |
| Briozzo, A | 1 |
| Gatti, G | 1 |
| van Bömmel, F | 1 |
| Wünsche, T | 1 |
| Reinke, P | 1 |
| Bergk, A | 1 |
| Schürmann, D | 2 |
| Wiedenmann, B | 1 |
| Berg, T | 2 |
| Schildgen, O | 1 |
| Vogel, M | 1 |
| Däumer, M | 1 |
| Kaiser, R | 1 |
| Matz, B | 1 |
| Valer, L | 1 |
| Seminari, E | 1 |
| Fusetti, G | 1 |
| Boeri, E | 1 |
| Galli, A | 1 |
| Clementi, M | 1 |
| Stainsby-Tron, M | 1 |
| Tomkins, J | 1 |
| Segondy, M | 1 |
| Holm, S | 1 |
| Gatell, J | 2 |
| Siangphoe, U | 1 |
| Pumarola, T | 2 |
| Reynolds, NA | 1 |
| Krummel, T | 1 |
| Parvez-Braun, L | 1 |
| Frantzen, L | 1 |
| Lalanne, H | 1 |
| Marcellin, L | 1 |
| Hannedouche, T | 1 |
| Moulin, B | 1 |
| Bonn, D | 1 |
| Brook, G | 1 |
| Cargnel, A | 1 |
| Thio, C | 1 |
| Roudiere, L | 1 |
| Day, SL | 1 |
| Leake Date, HA | 1 |
| Bannister, A | 1 |
| Hankins, M | 1 |
| Havlir, DV | 1 |
| Strain, MC | 1 |
| Ignacio, CC | 1 |
| Polo, C | 1 |
| Iniguez, D | 1 |
| Ruiz, I | 1 |
| Parish, MA | 1 |
| Keruly, JC | 1 |
| Yeh, V | 1 |
| Farthing, C | 2 |
| Rendón, A | 2 |
| Sánchez-Conde, M | 1 |
| Sambeat, MA | 1 |
| Gil, P | 2 |
| Cooper, D | 1 |
| Coco, J | 2 |
| Lichtenstein, K | 2 |
| Rightmire, A | 2 |
| Sankoh, S | 1 |
| Wilber, R | 1 |
| Benech, H | 3 |
| Grau, E | 1 |
| García, E | 1 |
| Stocker, H | 1 |
| Breske, A | 1 |
| Koerber, A | 1 |
| Kopperman, M | 1 |
| Wiehler, H | 1 |
| Ross, B | 1 |
| Möcklinghoff, C | 1 |
| Becker, M | 1 |
| Massetti, AP | 2 |
| Lichtner, M | 1 |
| D'Agostino, C | 1 |
| Tung, MY | 1 |
| Kirstetter, M | 1 |
| Bonmarchand, M | 1 |
| Conan, F | 1 |
| Kalkias, L | 1 |
| Valleron, AJ | 1 |
| Giola, M | 1 |
| Basilico, C | 1 |
| Harmouche, H | 1 |
| Le Bras, P | 1 |
| Bignani, O | 1 |
| Pacanowski, J | 1 |
| Gelinck, LB | 1 |
| Claas, EC | 1 |
| Maitland, D | 2 |
| Hand, J | 1 |
| Angel-Moreno-Maroto, A | 1 |
| Suárez-Castellano, L | 1 |
| Hernández-Cabrera, M | 1 |
| Singh, JA | 1 |
| Mills, EJ | 1 |
| St Claire, RL | 1 |
| Clark, N | 1 |
| Chirhin, S | 1 |
| Yoong, D | 1 |
| Govan, V | 1 |
| Gough, K | 1 |
| Loutfy, M | 1 |
| Quimby, D | 1 |
| Brito, MO | 1 |
| Jullien, V | 3 |
| Jaffray, P | 1 |
| Krivine, A | 1 |
| Moachon, L | 1 |
| Lillo-Le Louet, A | 1 |
| Lescoat, A | 1 |
| Dupin, N | 1 |
| Salmon, D | 1 |
| Pons, G | 1 |
| Jülg, BD | 1 |
| Crispin, A | 1 |
| Cánovas, V | 1 |
| Orozco, C | 1 |
| Williams, J | 1 |
| Chadwick, DR | 1 |
| Parsonage, MJ | 1 |
| Wilkins, EG | 1 |
| Snowden, N | 1 |
| Issa, BG | 1 |
| Savage, MW | 1 |
| Le Tiec, C | 1 |
| Barrail, A | 1 |
| De Boever, CM | 1 |
| Terrier, N | 1 |
| Baillat, V | 1 |
| Milincovic, A | 1 |
| Biglia, A | 1 |
| van Leth, F | 1 |
| Geerlings, SE | 1 |
| Lo Cicero, M | 1 |
| Bulgheroni, E | 1 |
| Soster, F | 1 |
| Viganò, O | 1 |
| Clarke, E | 1 |
| Coates, T | 1 |
| Delaney, M | 1 |
| Flores, G | 1 |
| Gonsalves, G | 1 |
| Harrington, M | 1 |
| Moore, JP | 1 |
| Peterson, L | 1 |
| Rodés, B | 2 |
| Kuiper, M | 1 |
| Klausen, G | 1 |
| Chua, A | 1 |
| Wilson, D | 1 |
| Cawthorne, P | 1 |
| Ditmore, M | 1 |
| Susman, E | 1 |
| Karrer, U | 1 |
| Gayet-Ageron, A | 2 |
| Russotti, M | 1 |
| Speck, RF | 1 |
| Sheldon, JA | 1 |
| Schwarze-Zander, C | 2 |
| Rodriguez, AE | 1 |
| Liao, Q | 1 |
| Delahunty, T | 2 |
| Carlebach, A | 2 |
| Halima, Y | 2 |
| Collins, C | 1 |
| Martelli, L | 3 |
| Merlo, M | 2 |
| Sciannamblo, M | 1 |
| Gafni, RI | 3 |
| Morales, D | 1 |
| Wassmer, G | 1 |
| Girault, V | 1 |
| Droste, JA | 2 |
| Hekster, YA | 1 |
| Brenner, B | 1 |
| Mosis, D | 1 |
| Diaz, RS | 1 |
| Osterhaus, AD | 1 |
| Marriott, D | 1 |
| Campo, RE | 3 |
| Chuck, S | 1 |
| Beretta, S | 2 |
| Luraschi, P | 1 |
| Rombolà, G | 2 |
| López, S | 4 |
| Garrabou, G | 4 |
| Sanjurjo, E | 1 |
| Ramos, X | 1 |
| Infante, AB | 2 |
| Casademont, J | 2 |
| Cardellach, F | 3 |
| Miró, O | 4 |
| Maslankowski, LA | 1 |
| El-Sadr, WM | 3 |
| Kwiecien, A | 1 |
| Morrow, K | 2 |
| Fleury, H | 3 |
| Trimoulet, P | 1 |
| Pellegrin, I | 1 |
| Urbinelli, R | 1 |
| Le Teuff, G | 1 |
| Odeshoo, L | 1 |
| McLaren, C | 1 |
| El Sahly, HM | 1 |
| Teeter, L | 1 |
| Zerai, T | 1 |
| Andrade, RA | 1 |
| Munoz, C | 1 |
| Nnabuife, C | 1 |
| Hunter, R | 1 |
| Valle, M | 1 |
| Bravo, I | 1 |
| Heilek-Sneider, GM | 1 |
| Teague, A | 1 |
| Côté, HC | 2 |
| Magil, AB | 1 |
| Scarth, BJ | 1 |
| Gadawski, I | 1 |
| Wang, N | 1 |
| Yu, E | 1 |
| Zalunardo, N | 1 |
| Hogg, R | 1 |
| Harrigan, PR | 2 |
| Darder, M | 1 |
| Trotta, MP | 2 |
| Bonfigli, S | 1 |
| D'Arrigo, R | 1 |
| Concetta Bellocchi, M | 1 |
| Lorenzini, P | 1 |
| Comandini, UV | 1 |
| Federico Perno, C | 1 |
| Gazzard, BG | 2 |
| Balestre, E | 1 |
| Capdepont, S | 1 |
| Boucher, S | 2 |
| Butt, AA | 1 |
| Weidle, PJ | 1 |
| Baker, RK | 4 |
| Armon, C | 1 |
| Moorman, AC | 3 |
| Holmberg, SD | 2 |
| Rendón, AL | 1 |
| Mittan, A | 1 |
| Madelaine-Chambrin, I | 1 |
| Merli, S | 1 |
| Rapagna, F | 1 |
| Vento, S | 2 |
| Shepp, DH | 3 |
| Chiesi, A | 1 |
| Knysz, B | 1 |
| Nagy, GS | 1 |
| Laessig, KA | 1 |
| Lewis, LL | 1 |
| Hammerstrom, TS | 1 |
| Murillas, J | 1 |
| Ena, J | 1 |
| Quercia, R | 1 |
| Marechal, Eda S | 1 |
| Thevenet, S | 1 |
| Renaud, S | 1 |
| Kara, A | 1 |
| Tribut, O | 1 |
| Tattevin, P | 1 |
| Perré, P | 1 |
| Jolliet, P | 1 |
| Jenny-Avital, ER | 1 |
| Hussain, S | 1 |
| Khayat, A | 1 |
| Tolaymat, A | 1 |
| Rathore, MH | 1 |
| Sánchez-de la Rosa, R | 2 |
| Forbes, A | 1 |
| Piketti, C | 1 |
| Martin, JC | 1 |
| Cha, AE | 1 |
| Cirino, CM | 1 |
| Kan, VL | 1 |
| Aldern, KA | 2 |
| Wan, WB | 1 |
| Ciesla, SL | 1 |
| Lehmann, C | 1 |
| Frampton, JE | 1 |
| Croom, KF | 1 |
| Genka, I | 1 |
| Ueda, A | 1 |
| Kimura, S | 1 |
| Reynolds, JC | 2 |
| Tong, T | 1 |
| Greenberg, A | 1 |
| Blaas, S | 1 |
| Schneidewind, A | 1 |
| Glück, T | 1 |
| Salzberger, B | 1 |
| Macassa, E | 1 |
| Teglas, JP | 1 |
| Veber, F | 2 |
| Levy, V | 1 |
| Bouhassoune, K | 1 |
| Calboreanu, A | 1 |
| Alloui, C | 1 |
| Rico-Garcia, M | 1 |
| Legal, F | 1 |
| Dény, P | 1 |
| Podevin, P | 1 |
| Subbarao, S | 1 |
| Otten, RA | 1 |
| Ramos, A | 1 |
| Jackson, E | 1 |
| Monsour, M | 1 |
| Adams, DR | 1 |
| Bashirian, S | 1 |
| Butera, S | 1 |
| Janssen, R | 1 |
| Greenberg, AE | 1 |
| Folks, TM | 1 |
| Deig, E | 2 |
| Vidal, I | 1 |
| Wursthorn, K | 1 |
| Buggisch, P | 1 |
| Lutgehetmann, M | 1 |
| Zollner, B | 1 |
| Petersen, J | 1 |
| von Boemmel, F | 1 |
| Stoehr, A | 1 |
| Wolf, E | 1 |
| Ramos, B | 1 |
| Díaz-Pollán, B | 1 |
| Muñoz de Benito, RM | 1 |
| Laurence, J | 1 |
| Fakoya, A | 1 |
| Murphy, M | 1 |
| Krebs, M | 1 |
| Hess, G | 1 |
| Andersen, J | 1 |
| Lynch, P | 1 |
| Brosgart, CL | 3 |
| Sherman, KE | 1 |
| Polsky, B | 1 |
| Hulgan, T | 1 |
| Villard, E | 1 |
| Goyenvalle, C | 1 |
| Deray, AG | 1 |
| Ollivet, A | 1 |
| Durantel, S | 1 |
| Tran, N | 1 |
| Carradori, S | 2 |
| De Socio, G | 1 |
| Rossella, E | 1 |
| Chmiel, JS | 1 |
| Ktorza, N | 1 |
| Parekh, NK | 1 |
| Hester, J | 1 |
| Best, B | 2 |
| Mühlbayer, D | 1 |
| Röling, J | 1 |
| Sternfeld, T | 1 |
| Jülg, B | 2 |
| Nelson, PJ | 1 |
| Wallimann, T | 1 |
| Comanor, L | 1 |
| White, C | 1 |
| Kipnis, P | 1 |
| Elkin, C | 1 |
| Leung, K | 1 |
| Attar, N | 1 |
| Lavignolle-Aurillac, V | 1 |
| Schrive, MH | 1 |
| Recordon-Pinson, P | 1 |
| Ragnaud, JM | 1 |
| Klotman, PE | 1 |
| Polk, C | 1 |
| Chan-Tack, KM | 2 |
| Kopack, AM | 1 |
| De Munter, P | 1 |
| Schrooten, Y | 1 |
| Verbesselt, R | 1 |
| Van Ranst, M | 1 |
| Claas, GJ | 1 |
| Bogner, J | 1 |
| Jupimai, T | 3 |
| Le Braz, M | 1 |
| Chappell, BJ | 1 |
| Ranneberg, B | 1 |
| Lalama, CM | 1 |
| Shikuma, CM | 1 |
| Schouten, J | 2 |
| Pilcher, CD | 1 |
| Reichman, RC | 1 |
| Klingman, KL | 1 |
| Antonucci, F | 1 |
| El Hamad, I | 1 |
| Pierotti, P | 1 |
| Migliorino, G | 1 |
| Da Silva, D | 1 |
| Lee, TS | 1 |
| Lloyd, RM | 1 |
| Lewinski, MA | 1 |
| Potts, SJ | 1 |
| Gosling, J | 1 |
| Ripamonti, D | 1 |
| Shi, Q | 1 |
| Kaplan, RC | 1 |
| Hessol, NA | 1 |
| Cole, S | 1 |
| Vigen, C | 1 |
| Schmid, S | 1 |
| Moddel, M | 1 |
| Huber, M | 1 |
| Pfammatter, R | 1 |
| Keusch, G | 1 |
| Ambuhl, P | 1 |
| Wuthrich, RP | 1 |
| Moch, H | 1 |
| Varga, Z | 1 |
| Hatano, H | 1 |
| Hammond, SP | 1 |
| Wild, M | 1 |
| Gupta, S | 1 |
| Whitcomb, J | 1 |
| Gripshover, B | 1 |
| El Barkil, M | 1 |
| Gagnieu, MC | 1 |
| Guitton, J | 1 |
| Zilmer, K | 1 |
| Beniowski, M | 1 |
| Truffa, MM | 1 |
| Struble, KA | 1 |
| Birnkrant, DB | 1 |
| Mallet, VO | 1 |
| Dhalluin-Venier, V | 1 |
| Verkarre, V | 1 |
| Correas, JM | 1 |
| Rotger, M | 1 |
| Colombo, S | 1 |
| Décosterd, L | 1 |
| Telenti, A | 1 |
| Luque, A | 1 |
| Hulse, S | 1 |
| Shahzad, U | 1 |
| Tanzman, E | 1 |
| Antenozzi, S | 1 |
| Smith, B | 1 |
| Nelson, MR | 2 |
| Curtis, S | 2 |
| Smith, S | 1 |
| Lockhart, SM | 1 |
| Rathbun, RC | 1 |
| Stephens, JR | 1 |
| Baker, DL | 1 |
| Drevets, DA | 1 |
| Greenfield, RA | 1 |
| Salvaggio, MR | 1 |
| Vincent, S | 1 |
| Parks, DA | 1 |
| Jennings, HC | 1 |
| Taylor, CW | 1 |
| De Socio, GV | 1 |
| Rosella, E | 1 |
| Miccolis, S | 1 |
| Chmiel, J | 1 |
| Zelina, S | 1 |
| Christen, A | 1 |
| Zgraggen, S | 1 |
| Mohaupt, MG | 1 |
| Celesia, BM | 1 |
| Onorante, A | 1 |
| Nunnari, G | 1 |
| Mughini, MT | 1 |
| Mavilla, S | 1 |
| Massimino, SD | 1 |
| Russo, R | 1 |
| Vidal, S | 1 |
| Carten, ML | 2 |
| Aquilante, CL | 2 |
| Wolfe, P | 1 |
| King, TM | 2 |
| Colella, G | 1 |
| Masiello, A | 1 |
| Lanza, A | 1 |
| Pisapia, R | 1 |
| Cascone, A | 1 |
| Di Martino, F | 1 |
| Filippini, A | 1 |
| Binongo, JN | 1 |
| Palau, M | 1 |
| Jaffe, HW | 1 |
| Neubacher, D | 1 |
| Brim, NM | 1 |
| Cu-Uvin, S | 1 |
| Hu, SL | 1 |
| O'Bell, JW | 1 |
| Cafarelli, L | 1 |
| Borgonovo, S | 1 |
| Trost, LC | 1 |
| Neyts, J | 1 |
| Korba, BE | 1 |
| Patel, SM | 1 |
| Zembower, TR | 1 |
| Kanwar, YS | 1 |
| Ahya, SN | 1 |
| Hawkins, S | 1 |
| Harder, S | 1 |
| Bae, AS | 1 |
| Alleman, P | 1 |
| Lawoyin, T | 1 |
| Nyiama, T | 1 |
| Roselló, L | 1 |
| Gort, A | 1 |
| Planella, R | 1 |
| Cabau, J | 1 |
| Golub, SA | 1 |
| Rosenthal, L | 1 |
| Cohen, DE | 1 |
| Gaglio, PJ | 1 |
| Sterling, R | 1 |
| Daniels, E | 1 |
| Tedaldi, E | 1 |
| Nebbia, G | 1 |
| Garcia-Diaz, A | 1 |
| Ayliffe, U | 1 |
| Dervisevic, S | 1 |
| Tedder, R | 1 |
| Doerr, HW | 1 |
| Corona, G | 1 |
| Vaccher, E | 1 |
| Sandron, S | 1 |
| Sartor, I | 1 |
| Tirelli, U | 1 |
| Innocenti, F | 1 |
| Toffoli, G | 1 |
| Yeh, RF | 1 |
| Jung, BH | 1 |
| Rezk, NL | 1 |
| Bridges, AS | 1 |
| Stewart, PW | 1 |
| Gotuzzo, E | 1 |
| Mendo, F | 1 |
| Prada, G | 1 |
| Crumpacker, CS | 1 |
| Isaacs, RD | 1 |
| Gilde, LR | 1 |
| Ntemgwa, M | 1 |
| Lalonde, R | 1 |
| Micheli, V | 1 |
| Brenner, BG | 1 |
| Killingley, B | 1 |
| de Silva, TI | 1 |
| Griffin, MD | 1 |
| Dockrell, DH | 1 |
| Balán, IC | 1 |
| Rosen, R | 1 |
| Maslankowski, L | 2 |
| El-Sadr, W | 1 |
| Essig, M | 1 |
| Kaied, FA | 1 |
| Iordache, L | 1 |
| Longuet, P | 1 |
| Blanchet, F | 1 |
| Lowe, SH | 1 |
| van Leeuwen, E | 1 |
| van der Veen, F | 1 |
| Repping, S | 1 |
| Papaleo, A | 1 |
| Warszawski, J | 1 |
| Salomon, R | 1 |
| Dechaux, M | 1 |
| Wolbers, M | 2 |
| Hasse, B | 1 |
| Vernazza, PL | 2 |
| Kaufmann, G | 1 |
| Agrofoglio, L | 1 |
| Nelson, R | 1 |
| Chantratitra, W | 1 |
| Bourara, K | 1 |
| Liegler, TJ | 1 |
| Holmes, CB | 1 |
| Safrit, JT | 1 |
| Major-Wilson, H | 1 |
| Viani, RM | 1 |
| Liu, NX | 1 |
| Muenz, LR | 1 |
| Harris, DR | 1 |
| Tomei, C | 1 |
| Henry, M | 1 |
| Solas, C | 1 |
| Villacian, J | 1 |
| Colson, P | 1 |
| Chiesa, E | 1 |
| Matti, A | 1 |
| Sabbatini, F | 1 |
| Prati, F | 1 |
| Bedini, A | 1 |
| Weiss, J | 1 |
| Weis, N | 1 |
| Ketabi-Kiyanvash, N | 1 |
| Storch, CH | 1 |
| Haefeli, WE | 1 |
| Vela, JE | 1 |
| Boojamra, CG | 1 |
| Hui, H | 1 |
| Stray, K | 1 |
| Mackman, RL | 1 |
| Hynes, P | 1 |
| Urbina, A | 1 |
| McMeeking, A | 1 |
| Barisoni, L | 1 |
| Rabenou, R | 1 |
| Chayama, K | 1 |
| Murray, JM | 1 |
| Law, M | 2 |
| Hazuda, DJ | 1 |
| Srasuebkul, P | 1 |
| Klinbuayam, W | 1 |
| Repetto, E | 1 |
| Dentone, C | 1 |
| Nemes, E | 1 |
| Ferraresi, R | 1 |
| Szczech, LA | 1 |
| Witt, M | 1 |
| Bill, R | 1 |
| Van Derwarker, R | 1 |
| Fisher, A | 1 |
| Gutiérrez, S | 1 |
| Guillemi, S | 1 |
| Jahnke, N | 1 |
| Montessori, V | 1 |
| Shacklett, BL | 1 |
| Othieno, FA | 1 |
| Wei, BL | 1 |
| Wege, AK | 1 |
| Payne, D | 1 |
| Haase, AT | 1 |
| Oh, CH | 1 |
| Quiros-Roldan, ME | 1 |
| Nichelatti, M | 1 |
| Ceresoli, F | 1 |
| Gargiulo, F | 1 |
| Magoni, M | 1 |
| Lucas, GM | 1 |
| Abel, S | 1 |
| Russell, D | 1 |
| Whitlock, LA | 1 |
| Ridgway, CE | 1 |
| Muirhead, GJ | 1 |
| Laopraynak, N | 1 |
| Saenawat, S | 1 |
| Herrera, L | 1 |
| Zaffiri, L | 1 |
| Purdy, JB | 1 |
| Zeichner, S | 1 |
| Lybaek, D | 1 |
| Mieras, J | 1 |
| Bulgin-Coleman, D | 1 |
| Kantor, C | 1 |
| Shearer, J | 1 |
| Fontaine, L | 1 |
| Fath, M | 1 |
| Zahonero, N | 1 |
| Böni, J | 1 |
| Rickenbach, M | 1 |
| Carolo, G | 1 |
| Vallecillo-Sánchez, G | 1 |
| Guelar-Grimberg, A | 1 |
| Knobel-Freud, H | 1 |
| Castrillo-Bustamante, C | 1 |
| Vejo-Puente, E | 1 |
| Velasco-Montes, J | 1 |
| Hernández-Hernández, JL | 1 |
| Iribarren, J | 1 |
| Schapiro, J | 1 |
| Morén, C | 1 |
| Bellido, R | 1 |
| Salomon, H | 1 |
| Cherrington, JM | 4 |
| Mulato, AS | 4 |
| Chen, MS | 1 |
| Yarchoan, R | 2 |
| Foli, A | 1 |
| Sogocio, KM | 1 |
| Tsai, CC | 2 |
| Follis, KE | 2 |
| Sabo, A | 1 |
| Beck, TW | 2 |
| Grant, RF | 1 |
| Benveniste, RE | 1 |
| Black, R | 1 |
| Thormar, H | 1 |
| Georgsson, G | 1 |
| Pálsson, PA | 1 |
| Naesens, L | 1 |
| Torsteinsdóttir, S | 1 |
| Tabucchi, A | 1 |
| Carlucci, F | 1 |
| Consolmagno, E | 1 |
| Monari, P | 1 |
| Marinello, E | 1 |
| Pizzichini, M | 1 |
| Pagani, R | 1 |
| Lai, CY | 1 |
| Cundy, KC | 5 |
| Barditch-Crovo, P | 5 |
| Walker, RE | 1 |
| Ebeling, D | 2 |
| Toole, J | 4 |
| Bridges, CG | 1 |
| Taylor, DL | 1 |
| Ahmed, PS | 1 |
| Brennan, TM | 1 |
| Hornsperger, JM | 1 |
| Navé, JF | 1 |
| Casara, P | 1 |
| Tyms, AS | 1 |
| Arends, S | 1 |
| van Halteren, E | 1 |
| Kamp, W | 1 |
| Schokker, J | 1 |
| Lietman, PS | 3 |
| Collier, A | 3 |
| Lalezari, J | 1 |
| Pavia, A | 1 |
| Rodrigue, D | 1 |
| Drew, WL | 1 |
| Lamy, PD | 4 |
| Hellmann, N | 1 |
| Kahn, J | 1 |
| Lifson, JD | 2 |
| Berardi, CJ | 1 |
| Vasquez, GM | 1 |
| Agatep, E | 1 |
| Dehqanzada, ZA | 1 |
| Pedersen, NC | 1 |
| Hwang, F | 1 |
| Safrin, S | 2 |
| Kahn, JO | 2 |
| Anton, KE | 2 |
| Jaruga, P | 1 |
| Jaruga, B | 1 |
| Halota, W | 1 |
| Olinski, R | 1 |
| Crowe, S | 1 |
| Schwartz, MA | 1 |
| Gilson, RJ | 1 |
| Chopra, KB | 1 |
| Newell, AM | 1 |
| Murray-Lyon, IM | 1 |
| Rice, SJ | 1 |
| Tedder, RS | 1 |
| Weller, IV | 1 |
| Hughes, WT | 1 |
| Shenep, JL | 1 |
| Rodman, JH | 1 |
| Fridland, A | 1 |
| Willoughby, R | 1 |
| Blanchard, S | 1 |
| Culnane, M | 1 |
| Zimmer, B | 1 |
| Burchett, S | 1 |
| Passaro, DJ | 1 |
| Murlidharan, U | 1 |
| Israelski, DM | 1 |
| Van Doren, S | 1 |
| Katzenstein, DA | 1 |
| Wick, D | 1 |
| Self, SG | 1 |
| Hu, XJ | 2 |
| Acosta, E | 1 |
| Lagakos, SW | 1 |
| Freimuth, W | 1 |
| Snyder, S | 1 |
| Mills, C | 2 |
| Fischl, M | 2 |
| Pettinelli, C | 1 |
| Emau, P | 1 |
| Sun, JC | 1 |
| Tran, CA | 1 |
| Morton, WR | 1 |
| Raasch, R | 1 |
| Remmel, RP | 1 |
| Brown, CR | 1 |
| Endo, Y | 1 |
| Plishka, R | 1 |
| Hirsch, V | 1 |
| Hatse, S | 1 |
| Buch, S | 1 |
| Foresman, L | 1 |
| Narayan, O | 1 |
| Cheng, B | 1 |
| Gilden, D | 4 |
| Highleyman, L | 3 |
| Cadman, J | 2 |
| Simmons, P | 1 |
| Fakuda, D | 1 |
| Baker, R | 1 |
| Elwell, A | 1 |
| Arroyo, HT | 1 |
| Tanji, N | 1 |
| Tanji, K | 1 |
| Kambham, N | 1 |
| Bell, A | 1 |
| Fuller, MD | 1 |
| Palmer, S | 1 |
| Gilbert, H | 1 |
| Shaw, N | 1 |
| Buckheit, R | 1 |
| Fisher, EJ | 1 |
| Chaloner, K | 1 |
| Cohn, DL | 1 |
| Grant, LB | 1 |
| Alston, B | 1 |
| Schmetter, B | 1 |
| Sampson, J | 1 |
| Bochet, M | 1 |
| Fievet, MH | 1 |
| Vig, P | 1 |
| Gibbs, CS | 1 |
| Fry, J | 1 |
| Namini, H | 1 |
| Coleman, RL | 1 |
| Hudson, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Smith, A | 1 |
| Huff, B | 1 |
| Schwetz, BA | 1 |
| Thompson, CA | 1 |
| Williams, K | 1 |
| Pujol, G | 1 |
| Giles, C | 1 |
| Bestman-Smith, J | 1 |
| Boivin, G | 1 |
| Bombled, T | 1 |
| Bochet, MV | 1 |
| Polk, B | 1 |
| Myers, RA | 1 |
| Beall, G | 1 |
| Lampiris, H | 1 |
| Huengsberg, M | 1 |
| Bendele, RA | 1 |
| Richardson, FC | 1 |
| Hammer, SM | 1 |
| Vaida, F | 1 |
| Bennett, KK | 1 |
| Holohan, MK | 1 |
| Sheiner, L | 1 |
| Wheat, LJ | 1 |
| Mitsuyasu, RT | 1 |
| Valentine, FT | 1 |
| Rogers, MD | 1 |
| Karol, CN | 1 |
| Lewis, RH | 1 |
| Bessen, LJ | 1 |
| Bergamini, A | 1 |
| Milanese, G | 1 |
| Pauwels, R | 1 |
| Rocchi, G | 1 |
| Calio, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1[NCT03499483] | Phase 4 | 52 participants (Actual) | Interventional | 2019-01-24 | Completed | ||
| Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study[NCT02732730] | Phase 4 | 451 participants (Actual) | Interventional | 2016-10-12 | Completed | ||
| Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa: a Phase 3b, Open-label, Hybrid Type 2 Implementation and Effectiveness Trial[NCT06133686] | Phase 3 | 400 participants (Anticipated) | Interventional | 2024-04-01 | Not yet recruiting | ||
| A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With Drug-susceptible Tuberculosis on a Rifampicin-based Regimen[NCT04734652] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-02-18 | Recruiting | ||
| A Phase I Randomized, Placebo-controlled, Double-blind Study to Assess Safety, Pharmacokinetics, and Modeled Pharmacodynamics of a Vaginal Insert Containing Tenofovir Alafenamide and Elvitegravir[NCT06087913] | Phase 1 | 60 participants (Anticipated) | Interventional | 2023-11-08 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologica[NCT02603120] | Phase 3 | 567 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide [NCT02603107] | Phase 3 | 578 participants (Actual) | Interventional | 2015-11-20 | Completed | ||
| A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the C[NCT02269917] | Phase 3 | 1,149 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals[NCT02251236] | 14 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppress[NCT02616783] | Phase 3 | 167 participants (Actual) | Interventional | 2015-12-22 | Completed | ||
| A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/[NCT02652624] | Phase 3 | 472 participants (Actual) | Interventional | 2016-02-19 | Completed | ||
| "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"[NCT05761509] | 200 participants (Anticipated) | Observational | 2023-06-08 | Recruiting | |||
| Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)[NCT02998320] | Phase 3 | 101 participants (Actual) | Interventional | 2017-03-10 | Completed | ||
| A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects[NCT01815736] | Phase 3 | 1,443 participants (Actual) | Interventional | 2013-03-27 | Completed | ||
| A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicis[NCT02431247] | Phase 3 | 725 participants (Actual) | Interventional | 2015-07-06 | Completed | ||
| A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naïve Human[NCT03227861] | Phase 3 | 109 participants (Actual) | Interventional | 2017-07-31 | Completed | ||
| Efficacy and Safety of Dolutegravir + Lamivudine in Antiretroviral Treatment-naive Adults With HIV-1 Infection in a Multicenter Real-life Cohort Study[NCT04638686] | 185 participants (Actual) | Observational | 2020-06-15 | Completed | |||
| A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed[NCT03446573] | Phase 3 | 743 participants (Actual) | Interventional | 2018-01-18 | Completed | ||
| Randomized, Open-label and Multicentric Trial Evaluating the Non-inferiority of Antiretroviral Dual Therapy Taken 4 Consecutive Days Per Week Versus Antiretroviral Dual Therapy 7/7 Days Per Week in HIV-1 Infected Patients With Controlled Viral Load Under [NCT04867083] | Phase 3 | 440 participants (Anticipated) | Interventional | 2021-06-21 | Recruiting | ||
| A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
| Multicenter, National, Prospective, Open Label, Randomized, Pilot, Proof-of-concept Study on the Use of Rilpivirine Plus Darunavir/Cobicistat as Substitutive Agents in Virologic Suppressed Patients[NCT04064632] | Phase 4 | 1,609 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment[NCT05398393] | 150 participants (Anticipated) | Interventional | 2022-01-01 | Enrolling by invitation | |||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults[NCT02607930] | Phase 3 | 631 participants (Actual) | Interventional | 2015-11-13 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults[NCT02607956] | Phase 3 | 657 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| The Cellular Pharmacology of F-TAF in Dried Blood Spots[NCT02962739] | Phase 1 | 38 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial[NCT04519125] | Phase 2/Phase 3 | 950 participants (Anticipated) | Interventional | 2020-08-30 | Not yet recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegra[NCT03110380] | Phase 3 | 567 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At R[NCT02842086] | Phase 3 | 5,399 participants (Actual) | Interventional | 2016-09-02 | Active, not recruiting | ||
| I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones[NCT04050371] | Phase 4 | 48 participants (Actual) | Interventional | 2017-08-03 | Completed | ||
| PrEP Adherence Monitoring Using Dried Blood Spots[NCT02022657] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Optimizing an mHealth Intervention to Improve Uptake and Adherence of the HIV Pre-exposure Prophylaxis (PrEP) in Vulnerable Adolescents and Emerging Adults[NCT05262426] | 160 participants (Anticipated) | Interventional | 2021-12-27 | Recruiting | |||
| Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand[NCT03778892] | 200 participants (Actual) | Interventional | 2018-03-01 | Completed | |||
| Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction[NCT03115736] | Phase 2 | 24 participants (Actual) | Interventional | 2017-05-23 | Completed | ||
| WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks[NCT03122262] | Phase 3 | 1,110 participants (Actual) | Interventional | 2017-01-16 | Completed | ||
| A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-06-22 | Recruiting | ||
| A Pilot Prospective Cohort Evaluation of Uptake and Adherence to PrEP in Young South African Women[NCT03142256] | Phase 4 | 200 participants (Actual) | Interventional | 2017-03-24 | Active, not recruiting | ||
| Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289] | 1,578 participants (Actual) | Observational | 2003-06-09 | Completed | |||
| HIV Adherence Bottle Intervention Trial (HABIT)[NCT03772327] | 63 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention During Pregnancy and Postpartum in Adolescents and Young Women and Their Infants[NCT03386578] | Phase 2 | 390 participants (Actual) | Interventional | 2018-07-03 | Active, not recruiting | ||
| Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W[NCT02302547] | Phase 3 | 224 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects[NCT03836729] | Phase 1 | 16 participants (Actual) | Interventional | 2019-02-11 | Completed | ||
| Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants[NCT03048422] | Phase 3 | 643 participants (Actual) | Interventional | 2018-01-19 | Completed | ||
| A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), [NCT03631732] | Phase 3 | 496 participants (Actual) | Interventional | 2018-08-28 | Completed | ||
| A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests[NCT04712058] | 200 participants (Anticipated) | Interventional | 2021-01-20 | Recruiting | |||
| Bictegravir in the Elderly Living With HIV: Impact of Polypharmacy and Multimorbidity (BICEP)[NCT05064020] | 162 participants (Anticipated) | Observational | 2020-08-01 | Active, not recruiting | |||
| Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Virologically Suppressed Adults[NCT03532425] | Phase 4 | 28 participants (Actual) | Interventional | 2018-10-29 | Terminated (stopped due to Difficulties enrolling participants) | ||
| The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed HIV-Positive Patients Post-Renal Transplant[NCT04530630] | Phase 4 | 20 participants (Actual) | Interventional | 2020-11-09 | Active, not recruiting | ||
| "Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data (Same Day Treatment) Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Pa[NCT05606055] | Phase 4 | 100 participants (Actual) | Interventional | 2020-12-01 | Completed | ||
| The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients[NCT03789968] | 411 participants (Actual) | Observational | 2019-09-01 | Completed | |||
| CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM[NCT01761643] | Phase 4 | 398 participants (Actual) | Interventional | 2012-12-19 | Completed | ||
| A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC[NCT02469246] | Phase 3 | 567 participants (Actual) | Interventional | 2015-06-29 | Completed | ||
| A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women[NCT01768962] | Phase 1 | 14 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in [NCT02131233] | Phase 3 | 802 participants (Actual) | Interventional | 2014-05-23 | Completed | ||
| A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy[NCT05583006] | 60 participants (Anticipated) | Observational | 2023-11-06 | Recruiting | |||
| Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy.[NCT02012621] | 807 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Does Sex Hormone Therapy Decrease Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Active Metabolite Formation in Mucosal Tissues?[NCT02983110] | 12 participants (Actual) | Observational | 2016-11-30 | Completed | |||
| Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone[NCT02235662] | Phase 1 | 86 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera[NCT03377608] | 50 participants (Actual) | Observational | 2017-11-17 | Completed | |||
| Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1[NCT04904406] | Phase 4 | 95 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| Can the Weight Gain Associated With Use of Integrase Strand Inhibitors be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF in Patients Living With HIV? (DeLiTE)[NCT04665375] | Phase 4 | 25 participants (Anticipated) | Interventional | 2021-04-26 | Enrolling by invitation | ||
| IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect[NCT02384395] | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine b[NCT00389194] | Phase 4 | 120 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 C[NCT00528060] | Phase 2 | 35 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa[NCT00441298] | Phase 2 | 889 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-[NCT01108510] | Phase 3 | 698 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study)[NCT00544128] | Phase 4 | 109 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel[NCT01232803] | Phase 1 | 65 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)[NCT00495651] | Phase 3 | 2,073 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand[NCT00433030] | 2,816 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV[NCT02699736] | 23,000 participants (Actual) | Observational [Patient Registry] | 1994-01-31 | Enrolling by invitation | |||
| PC4PrEP: Integrating Pre-Exposure Prophylaxis (PrEP) Into Primary Care[NCT03617874] | 22 participants (Actual) | Interventional | 2020-02-28 | Completed | |||
| Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy[NCT02995005] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2018-05-24 | Completed | ||
| Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study[NCT04521920] | 17 participants (Actual) | Interventional | 2020-11-09 | Completed | |||
| Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men[NCT04772469] | 1,509 participants (Actual) | Interventional | 2021-03-22 | Completed | |||
| HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)[NCT02165202] | Phase 2 | 136 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)[NCT05333679] | 200 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand[NCT00119106] | Phase 2/Phase 3 | 2,413 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| PrEP Intervention for People Who Inject Substances and Use Methamphetamine[NCT04523519] | Phase 4 | 140 participants (Anticipated) | Interventional | 2021-04-30 | Recruiting | ||
| Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370] | Phase 4 | 10 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients[NCT00872417] | Phase 4 | 750 participants (Anticipated) | Interventional | 2009-03-31 | Not yet recruiting | ||
| Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680] | 303 participants (Actual) | Observational | 2015-10-31 | Active, not recruiting | |||
| Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function[NCT01294761] | 59 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287] | 14 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Randomized, Placebo-controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults With HIV Infection Being Treated With Antiretroviral Thera[NCT00490412] | 207 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV[NCT02457494] | 23 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Improving HIV Prevention Among Adolescent Girls and Young Women (AGYW) in Uganda[NCT05516602] | 314 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | |||
| Observational, Retrospective Analysis to Evaluate Switching to Raltegravir Plus Abacavir/Lamivudine in HIV-1-Infected Patients. ORASWIRAL Study[NCT02708342] | 100 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretrov[NCT01227824] | Phase 3 | 828 participants (Actual) | Interventional | 2010-10-19 | Completed | ||
| HIV Drug Resistance Profiles Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil[NCT04453436] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2020-09-01 | Not yet recruiting | |||
| A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa[NCT00931346] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2009-10-31 | Completed | ||
| Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana[NCT00448669] | Phase 2/Phase 3 | 1,219 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Assessing the Feasibility and Acceptability of a Peer Outreach and Navigation Intervention to Increase Pre-exposure Prophylaxis Uptake Among Women at High Risk for HIV[NCT03226873] | 66 participants (Actual) | Interventional | 2017-11-16 | Completed | |||
| First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study[NCT00660972] | Phase 1 | 40 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum[NCT06159582] | 120 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961] | 24 participants (Actual) | Interventional | 2018-09-20 | Active, not recruiting | |||
| Integrating PrEP Into Family Planning Services at Title X Clinics in the Southeastern US[NCT04097834] | 103 participants (Actual) | Observational | 2019-10-07 | Completed | |||
| A Comparative Effectiveness Demonstration Project for Linkage and Retention in PrEP Care for Men Who Have Sex With Men (PCA)[NCT03442192] | 20 participants (Actual) | Interventional | 2018-07-30 | Terminated (stopped due to COVID erupted and change in policy making all visits throughout hospital telemedicine) | |||
| A Phase 1 Pharmacokinetic Study of Varying Dosing Patterns on Tenofovir Concentrations in Hair[NCT00903084] | Phase 1 | 24 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection[NCT02556333] | Phase 2 | 1 participants (Actual) | Interventional | 2015-09-16 | Terminated | ||
| Chemoprophylaxis for HIV Prevention in Men[NCT00458393] | Phase 3 | 2,499 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.[NCT00192634] | Phase 4 | 357 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber[NCT00822315] | Phase 2 | 155 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B[NCT02889094] | 152 participants (Actual) | Observational | 2016-10-31 | Active, not recruiting | |||
| Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor for Determining Adherence Using Different Dosing Regimens of Disoproxil Fumarate/Emtricitabine (TDF/FTC)[NCT04870671] | Early Phase 1 | 14 participants (Actual) | Interventional | 2021-03-08 | Completed | ||
| Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples[NCT02572505] | 0 participants (Actual) | Interventional | 2015-11-30 | Withdrawn | |||
| Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen[NCT03646370] | 110 participants (Actual) | Observational | 2018-07-25 | Completed | |||
| A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects[NCT00118898] | Phase 3 | 1,864 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in[NCT01497899] | Phase 2 | 279 participants (Actual) | Interventional | 2011-12-28 | Completed | ||
| A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir D[NCT01475838] | Phase 3 | 438 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Diso[NCT01495702] | Phase 3 | 439 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Health Status of Transgender Women in French Guiana and Paris: a Cross-sectional View (TransGuyane)[NCT04962997] | 46 participants (Actual) | Observational | 2021-08-06 | Completed | |||
| Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC): Performance Evaluation of Novel POC HIV Tests in Baltimore[NCT04793750] | 408 participants (Anticipated) | Interventional | 2021-08-18 | Recruiting | |||
| Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples[NCT00557245] | Phase 3 | 4,758 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| The Study of Atazavanir/Ritonavir-based HAART in Thai HIV-infected Children[NCT01656109] | Phase 2 | 20 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study[NCT01772940] | Phase 4 | 425 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001)[NCT01066962] | Phase 3 | 800 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Pilot of an mHealth-enhanced, Safer Conception Intervention to Reduce HIV-1 Risk Among Kenyan HIV-1 Serodiscordant Couples[NCT03030768] | 74 participants (Actual) | Observational | 2016-02-29 | Completed | |||
| MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY[NCT01153217] | Phase 3 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients[NCT00677300] | Phase 4 | 85 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2[NCT04903847] | Phase 4 | 126 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | ||
| The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment[NCT00811954] | Phase 3 | 1,814 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Subs[NCT00851799] | 334 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers[NCT05652478] | Phase 2 | 120 participants (Anticipated) | Interventional | 2024-01-03 | Recruiting | ||
| First in Human Clinical Trial of a Next Generation, Long-acting Injectable, Combination Antiretroviral Therapy Platform[NCT05850728] | Phase 1 | 16 participants (Anticipated) | Interventional | 2023-04-01 | Recruiting | ||
| Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women[NCT00625404] | Phase 3 | 2,120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment[NCT01363011] | Phase 3 | 106 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa[NCT01691768] | Phase 2/Phase 3 | 372 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women[NCT00705679] | Phase 2 | 5,029 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Comparative Effectiveness of Individual Versus Group-level Interventions to Reduce HIV Risk Among African Immigrant Women[NCT06022809] | 424 participants (Anticipated) | Interventional | 2023-10-25 | Not yet recruiting | |||
| A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Act[NCT00528957] | Phase 3 | 97 participants (Actual) | Interventional | 2006-12-28 | Completed | ||
| A Randomised, Double-blind, Placebo-controlled, Trial to Compare the Safety and Efficacy of Reduced Dose Versus Standard Dose EFV Plus Two Nucleotides (N(t)RTI) in Antiretroviral-naïve HIV-infected Adults Over 96 Weeks[NCT01011413] | Phase 3 | 636 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506] | Phase 3 | 872 participants (Actual) | Interventional | 2012-12-26 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445] | Phase 3 | 872 participants (Actual) | Interventional | 2013-03-12 | Completed | ||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial[NCT01307488] | Phase 4 | 286 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Pa[NCT03493568] | Phase 3 | 100 participants (Actual) | Interventional | 2017-02-06 | Terminated (stopped due to The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF) | ||
| Training in mHealth Prevention With MSM[NCT05044013] | 90 participants (Anticipated) | Interventional | 2023-11-15 | Recruiting | |||
| A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF[NCT02121795] | Phase 3 | 668 participants (Actual) | Interventional | 2014-05-06 | Completed | ||
| A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents a[NCT01854775] | Phase 2/Phase 3 | 129 participants (Actual) | Interventional | 2013-05-06 | Active, not recruiting | ||
| A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults[NCT02397694] | Phase 2 | 98 participants (Actual) | Interventional | 2015-03-23 | Completed | ||
| A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF[NCT02345226] | Phase 3 | 881 participants (Actual) | Interventional | 2015-01-26 | Completed | ||
| A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabin[NCT02345252] | Phase 3 | 632 participants (Actual) | Interventional | 2015-01-26 | Completed | ||
| Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission[NCT00204308] | Phase 2 | 400 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults[NCT00977756] | 168 participants (Actual) | Observational | 2002-08-31 | Completed | |||
| Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection[NCT00192595] | Phase 4 | 36 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Multilevel Gaming Intervention for Persons on PrEP[NCT02611362] | 82 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy[NCT01490671] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
| Study of Placental Transfer of Tenofovir and Its Factors of Variability Using the Human Placental Perfusion Model[NCT02020083] | 369 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia[NCT00334256] | Phase 2 | 72 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV[NCT00053638] | Phase 3 | 345 participants | Interventional | 2003-02-28 | Completed | ||
| A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects[NCT00830804] | Phase 2 | 113 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection[NCT01869010] | 30 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial[NCT00225082] | 12 participants (Actual) | Observational | 2004-11-30 | Completed | |||
| Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on [NCT00365612] | Phase 4 | 300 participants (Anticipated) | Interventional | 2006-07-31 | Completed | ||
| A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects[NCT00244712] | Phase 4 | 688 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus [NCT00323544] | Phase 3 | 220 participants | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation[NCT00036452] | Phase 2 | 402 participants (Actual) | Interventional | Completed | |||
| An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone[NCT01105611] | Phase 4 | 40 participants (Anticipated) | Interventional | 2010-08-31 | Recruiting | ||
| A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™[NCT00369941] | Phase 3 | 566 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection[NCT01989910] | Phase 4 | 107 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial[NCT03058484] | 1,830 participants (Actual) | Interventional | 2015-05-01 | Completed | |||
| Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models[NCT02776254] | 3,100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660] | 192 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects[NCT00272779] | Phase 3 | 1,057 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infe[NCT00323492] | Phase 4 | 92 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients[NCT00214890] | Phase 2 | 21 participants (Actual) | Interventional | 2004-12-07 | Completed | ||
| CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF[NCT01701895] | 33 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects[NCT00549198] | Phase 4 | 392 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects[NCT00109603] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)[NCT05581160] | 332 participants (Anticipated) | Interventional | 2022-07-11 | Recruiting | |||
| Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression[NCT01387022] | 59 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| Fat Redistribution and Metabolic Change in HIV Infection (FRAM)[NCT00331448] | 1,483 participants | Observational | 2000-06-30 | Active, not recruiting | |||
| A Multicenter Study to Evaluate the Pharmacokinetic Profile and Safety of TMC125 Plus Tenofovir DF/Emtricitabine All Dosed Once Daily With and Without Darunavir (PREZISTA™)/ Ritonavir Once Daily in Antiretroviral naïve HIV-1 Infected Subjects[NCT00534352] | Phase 2 | 23 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treat[NCT00254046] | Phase 3 | 616 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treat[NCT00255099] | Phase 3 | 593 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Expo[NCT01505114] | Phase 2 | 594 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)[NCT04048382] | 57 participants (Actual) | Interventional | 2019-08-05 | Completed | |||
| Demonstration Project on the Feasibility to Implement a Pre-Exposure Oral Prophylaxis Program in Men Who Have Sex With Other Men and Transgender Women at Risk of Acquiring HIV[NCT03043326] | 1,000 participants (Anticipated) | Observational | 2017-01-23 | Recruiting | |||
| Connecting Resources for Urban Sexual Health[NCT02183909] | 380 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)[NCT01327651] | Phase 2 | 622 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project[NCT01632995] | 557 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Digital Star: HIV Prevention for Youth in Mental Health Treatment[NCT02921841] | 125 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| A Randomized, Placebo-controlled Trial of Oral Doxycycline for the Prevention of Syphilis in HIV-positive Men Who Have Sex With Men (MSM)[NCT02864550] | Phase 4 | 52 participants (Actual) | Interventional | 2019-08-15 | Active, not recruiting | ||
| The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection[NCT03205566] | Phase 4 | 38 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| A Study to Evaluate Clinical Benefits and Drawbacks of Antiretroviral Drugs as Pre-exposure Prophylaxis to Prevent HIV Infection Under Real-life Conditions Among Persons Who Pursue High-risk Sexual Practices: The Seville HIV PrEP Cohort[NCT05492565] | 500 participants (Anticipated) | Observational [Patient Registry] | 2020-01-01 | Enrolling by invitation | |||
| HIV Awal (Early) Testing & Treatment Indonesia Project Implementing 'Test and Treat' Strategies for HIV Treatment and Prevention in Key Populations in Indonesia: a Prospective Implementation Research Study (Phase 1 - Observational Phase)[NCT03429842] | 2,071 participants (Actual) | Observational | 2015-09-15 | Completed | |||
| Effect of Repeated Applications of Tenofovir Gel on Mucosal Mediators of Immunity and Intrinsic Antimicrobial Activity of Cervicovaginal Secretions in Women at Low Risk for HIV-1 Infection[NCT00594373] | Phase 1 | 30 participants (Actual) | Interventional | Completed | |||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response.[NCT00885482] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Atripla® (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Anti[NCT00869557] | Phase 2 | 71 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| CID 0821 - Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine[NCT00855413] | Phase 4 | 15 participants (Actual) | Interventional | 2009-03-31 | Terminated (stopped due to Study halted by sponsor due to slow enrollment.) | ||
| IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167] | Phase 1 | 6 participants (Actual) | Interventional | 2015-04-07 | Completed | ||
| CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis[NCT00924898] | Phase 4 | 92 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Treatment of Acute HIV Infection With the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate, A Pilot Study of Response to Therapy and HIV Pathogenesis[NCT01694420] | Phase 3 | 33 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.[NCT00389207] | Phase 3 | 576 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period)[NCT05382351] | Phase 2 | 238 participants (Anticipated) | Interventional | 2022-05-10 | Recruiting | ||
| A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected[NCT00892437] | Phase 2 | 85 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response in Peripheral Blood HIV Reservoir Dynamics[NCT04263207] | 100 participants (Anticipated) | Observational | 2020-02-04 | Suspended (stopped due to Study halted prematurely due to the difficulties in dedicating the human resources necessary to conduct the study deriving from the COVID-19 pandemic, but potentially will resume) | |||
| Efficacy and Safety of Switching From AZT to Tenofovir[NCT00647244] | Phase 4 | 40 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?[NCT00090779] | Phase 2 | 130 participants (Actual) | Interventional | 2005-01-31 | Terminated (stopped due to The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.) | ||
| A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1[NCT00594646] | Phase 4 | 100 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy[NCT00119379] | Phase 2 | 50 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419] | 699 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women[NCT01310023] | 3,400 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring[NCT02006264] | Phase 1 | 30 participants (Actual) | Interventional | 2013-11-19 | Completed | ||
| A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Kenya, Africa[NCT00971230] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2009-10-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antir[NCT01106586] | Phase 3 | 708 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease[NCT03696160] | Phase 3 | 447 participants (Actual) | Interventional | 2019-03-05 | Active, not recruiting | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naiv[NCT01095796] | Phase 3 | 707 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Immunogenetic Modulators of Mucosal Protection From HIV-1: The Kinga Study[NCT03701802] | 812 participants (Actual) | Observational | 2018-09-27 | Completed | |||
| "Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on Vaccinated Immune Attacks"[NCT05711810] | Phase 4 | 1 participants (Actual) | Interventional | 2023-01-02 | Completed | ||
| A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adu[NCT00984971] | Phase 1 | 18 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| The HIV Second-line Therapy AntiRetroviral Study in Patients Who Failed NNRTI-based Regimens[NCT00627055] | Phase 4 | 200 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir[NCT00592124] | Phase 2 | 168 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Multicenter, International, Prospective, Phase III, Randomized, Superiority Trial Comparing Two Maintenance Strategies With Mono or Bi-therapy of Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antire[NCT01905059] | Phase 3 | 265 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| IGHID 11601 - Measuring Antiretroviral Concentrations in Hair[NCT02768779] | 84 participants (Actual) | Observational | 2016-04-01 | Completed | |||
| Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)[NCT00825929] | 176 participants (Anticipated) | Observational | 2009-02-28 | Recruiting | |||
| Adolescent Master Protocol[NCT01418014] | 678 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintaine[NCT00724711] | Phase 4 | 312 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection[NCT00662545] | Phase 4 | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791] | Phase 1 | 66 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks[NCT02474316] | Phase 4 | 366 participants (Anticipated) | Interventional | 2014-08-31 | Recruiting | ||
| A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age[NCT00039741] | Phase 2/Phase 3 | 266 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretrovi[NCT00016718] | Phase 1/Phase 2 | 43 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copie[NCT00000892] | 300 participants | Interventional | Completed | ||||
| CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics[NCT00666055] | 11 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| Randomized Open Label Study Assessing the Antiviral Activity, Toxicity and Pharmacologic Interaction of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir as Part of a Salvage Regimen in HIV Infected Patients With Multiple Treatment Failures (ANR[NCT00122577] | Phase 2 | 50 participants | Interventional | 2002-03-31 | Terminated | ||
| An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin[NCT00100581] | 2 participants (Actual) | Interventional | Completed | ||||
| Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection[NCT00959894] | Phase 2 | 80 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial[NCT03933384] | Phase 4 | 420 participants (Anticipated) | Interventional | 2019-08-19 | Recruiting | ||
| Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children[NCT00260078] | Phase 1/Phase 2 | 75 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz[NCT00112047] | Phase 3 | 517 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel[NCT00111943] | Phase 2 | 200 participants (Actual) | Interventional | Completed | |||
| Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel[NCT00028132] | Phase 1 | 120 participants | Interventional | Completed | |||
| Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women[NCT00729573] | 518 participants (Actual) | Observational | 2009-11-30 | Completed | |||
| Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas[NCT00540605] | Phase 1 | 21 participants (Actual) | Interventional | Completed | |||
| Comparative Bioavailability Study of Two Efavirenz 600 mg Formulations in Healthy Volunteers.[NCT01704898] | Phase 4 | 12 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV[NCT00033163] | Phase 2 | 90 participants | Interventional | Completed | |||
| A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences[NCT00148759] | Phase 4 | 23 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients[NCT00100048] | Phase 2 | 206 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| CID 0706 - Safety, Tolerability, Pharmacokinetic, and Metabolic Features of Raltegravir Among African-American Men and Women With HIV Infection[NCT00667433] | Phase 1 | 38 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection[NCT00113126] | 526 participants | Interventional | 2002-01-31 | Completed | |||
| A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)[NCT01214759] | Phase 4 | 103 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients[NCT00002128] | Phase 1 | 15 participants | Interventional | Completed | |||
| A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options[NCT00042393] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease[NCT00051077] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| A Phase II, Randomized Trial of Amprenavir as Part of Dual Protease Inhibitor Regimens (Placebo-Controlled) in Combination With Abacavir, Efavirenz, and Adefovir Dipivoxil Versus Amprenavir Alone in HIV-Infected Subjects With Prior Exposure to Approved Pr[NCT00000912] | Phase 2 | 475 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02603120)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | -31 |
| ABC/DTG/3TC | 4 |
(NCT02603120)
Timeframe: Baseline
| Intervention | g/cm^2 (Mean) |
|---|---|
| B/F/TAF | 1.006 |
| ABC/DTG/3TC | 0.996 |
(NCT02603120)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | 0.156 |
| ABC/DTG/3TC | 0.299 |
(NCT02603120)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | 0.692 |
| ABC/DTG/3TC | 0.416 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02603120)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 93.6 |
| ABC/DTG/3TC | 95.0 |
The percentage of participants achieving HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02603120)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 1.1 |
| ABC/DTG/3TC | 0.4 |
(NCT02603120)
Timeframe: Baseline
| Intervention | g/cm^2 (Mean) |
|---|---|
| B/F/TAF | 1.124 |
| ABC/DTG/3TC | 1.103 |
(NCT02603107)
Timeframe: Baseline to Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| B/F/TAF | 25 |
| Stay on Baseline Regimen (SBR) | 0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02603107)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 92.1 |
| Stay on Baseline Regimen (SBR) | 88.9 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02603107)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 1.7 |
| Stay on Baseline Regimen (SBR) | 1.7 |
Change from reference in CD4+ cell count was assessed at Week 96. The change from reference in CD4+ count at a given time point is defined as: CD4+ at a given time point minus reference CD4+. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF (Comprising 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52])
| Intervention | cells per cubic millimeter (cells/mm^3) (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 32.07 |
| Switch to D/C/F/TAF | 13.07 |
Change from reference in eGFRcr (by CKD-EPI) was assessed at Week 96. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (<=)0.7 mg/dL: 144*(Scr/0.7)^-0.329*0.993^age; 2) Scr greater than (>)0.7 mg/dL: 144*(Scr/0.7)^-1.209*0.993^age. Male: 1) Scr <=0.9 mg/dL: 141*(Scr/0.9)^-0.411*0.993^age; 2) Scr >0.9 mg/dL: 141*(Scr/0.9)^-1.209*0.993^age. . For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mL/min/1.73 m^2 (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -1.3 |
| Switch to D/C/F/TAF | -0.7 |
Change from reference in eGFRcr (by Cockcroft-Gault formula) was assessed at Week 96. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)*(weight in kilogram [kg])/72*(serum creatinine in milligram per deciliter [mg/dL])=eGFRcr (milliliter per minute [mL/min]); Female: (140 - age in years)*(weight in kg)/72*(serum creatinine in mg/dL)*0.85=eGFRcr (mL/min). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | milliliter per minute (mL/min) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -0.9 |
| Switch to D/C/F/TAF | 0.0 |
Change from reference in eGFRcyst (by CKD-EPI) was assessed at Week 96. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) <=0.8 mg/L: 133*(Scyst/0.8)^-0.499*0.996^age (*0.932 if female); 2) Scyst >0.8 mg/L: 133*(Scyst/0.8)^-1.328*0.996^age (*0.932 if female). For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mL/min/1.73 m^2 (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -0.9 |
| Switch to D/C/F/TAF | 1.0 |
Change from reference in serum creatinine levels at Week 96 was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | micro mole per liter (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.0 |
| Switch to D/C/F/TAF | 0.0 |
Change from reference in UACR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | milligram per gram (mg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -0.63 |
| Switch to D/C/F/TAF | -0.93 |
Change from reference in UB2MGCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | microgram per gram (mcg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -68.22 |
| Switch to D/C/F/TAF | -110.31 |
Change from reference in UPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | milligram per gram (mg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -22.23 |
| Switch to D/C/F/TAF | -12.81 |
Change from reference in URBPCR was assessed at Week 96. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | microgram per gram (mcg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -25.08 |
| Switch to D/C/F/TAF | -39.07 |
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound (virologic rebound was defined as: confirmed HIV-1 RNA >=50 copies/mL up to, and including the upper bound of the Week 48 window) and with HIV-1 RNA value >=400 copies/mL or who discontinued with last HIV-1 RNA >=400 copies/mL. Number of participants who developed resistance to any of the study drug was determined. (NCT02269917)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 1 |
| Control (Baseline to Switch) | 3 |
Percent change from reference in FEPO4 at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ F/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 4.15 |
| Switch to D/C/F/TAF | -3.19 |
Percent change from reference in 25-OH Vitamin D at Week 96 were reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 24.6 |
| Switch to D/C/F/TAF | -1.9 |
Percent change from reference in PTH at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -17.171 |
| Switch to D/C/F/TAF | -20.466 |
Percent change from reference in serum CTX at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -10.192 |
| Switch to D/C/F/TAF | -21.755 |
Percent change from reference in serum P1NP levels at Week 96 was reported. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -19.899 |
| Switch to D/C/F/TAF | -18.466 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA >=50 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA >=50 copies/mL at premature discontinuation (irrespective of reason). Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at week 48. (NCT02269917)
Timeframe: Baseline up to Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 97.7 |
| Control (Baseline to Switch) | 97.8 |
Here Kaplan-Meier estimates percentage of participants with non-virologic rebound at Week 96. (NCT02269917)
Timeframe: Baseline to Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 96.7 |
| Switch to D/C/F/TAF | 97.8 |
Treatment adherence (defined as adherence of >95%) was assessed by the drug accountability cumulative through Week 96 (Approach 1). (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 91.6 |
| Switch to D/C/F/TAF | 87.3 |
Treatment adherence (defined as adherence of >95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 48, whichever came sooner (Approach 2). (NCT02269917)
Timeframe: Through Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 82.7 |
| Control (Baseline to Switch) | 77.2 |
Treatment adherence (defined as adherence of >95%) was assessed by the drug accountability cumulative treatment adherence up to time point where not more than one bottle was missing, or if available, through Week 96, whichever came sooner (Approach 2). (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 82.8 |
| Switch to D/C/F/TAF | 80.9 |
Treatment adherence (defined as adherence of >95%) was assessed by the drug accountability and was calculated cumulative from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study from Week 96 to end of extension. (NCT02269917)
Timeframe: Week 96 to end of extension (up to 42 months)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 89.5 |
| Switch to D/C/F/TAF | 89.4 |
Treatment adherence (defined as adherence of >95%) was assessed by the drug accountability cumulative through Week 48 (Approach 1). (NCT02269917)
Timeframe: Through Week 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 91.6 |
| Control (Baseline to Switch) | 85.3 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level >=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA >=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA >=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load [re]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 13.8 |
| Switch to D/C/F/TAF | 8.8 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level >=200 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA >=200 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA >=200 copies/mL at the study cutoff of Week 96 (that is, any last viral load [re]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.5 |
| Switch to D/C/F/TAF | 0.6 |
Virologic rebound was defined as: confirmed plasma human immunodeficiency virus - 1 (HIV-1) Ribonucleic Acid (RNA) level greater than or equal to (>=)50 copies per milliliter (copies/mL) up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA >=50 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 2.5 |
| Control (Baseline to Switch) | 2.1 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA level >=50 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA >=50 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA >=50copies/mL at the study cutoff of Week 96 (that is, any last viral load [re]test having occurred no later than 6 weeks after Week 96). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 3.1 |
| Switch to D/C/F/TAF | 2.3 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA >=20 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA >=20 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through 48 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 10.5 |
| Control (Baseline to Switch) | 11.4 |
Virologic rebound was defined as: confirmed plasma HIV-1 RNA >=200 copies/mL up to, and including the upper bound of the Week 48 window (ie, 54 weeks) and last available on-treatment (single) HIV-1 RNA >=200 copies/mL at premature discontinuation (irrespective of reason). Percentage of participants with virologic rebound were reported. (NCT02269917)
Timeframe: Through 48 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.4 |
| Control (Baseline to Switch) | 0.0 |
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed. (NCT02269917)
Timeframe: Week 96 to end of extension (up to 42 months)
| Intervention | cells/mm^3 (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | Week 96 + 42 months | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 706.4 | 707.6 | 713.3 | 712.7 | 730.4 | 732.0 | 714.3 |
| Switch to D/C/F/TAF | 681.3 | 676.2 | 686.1 | 686.4 | 685.8 | 733.3 | 705.6 |
Change from baseline in spine, hip, and femoral neck BMD T-Score was assessed at Week 24 and 48. T-score values >= -1.0 were considered normal, T-score values < -1.0 to -2.5 indicate osteopenia and T-score values < -2.5 indicate osteoporosis. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Spine BMD T-score: Baseline | Spine BMD T-score: Change at Week 24 | Spine BMD T-score: Change at Week 48 | Hip BMD T-score: Baseline | Hip BMD T-score: Change at Week 24 | Hip BMD T-score: Change at Week 48 | Femoral Neck BMD T-score: Baseline | Femoral Neck BMD T-score: Change at Week 24 | Femoral Neck BMD T-score: Change at Week 48 | |
| Control (Baseline to Switch) | -0.467 | -0.033 | -0.063 | -0.484 | -0.024 | -0.016 | -0.699 | -0.044 | -0.039 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -0.713 | 0.102 | 0.132 | -0.575 | 0.037 | 0.095 | -0.782 | 0.019 | 0.039 |
Change from baseline in CD4+ cell count was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Cells per cubic millimeter (cells/mm^3) (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 24 | Change at Week 48 | |
| Control (Baseline to Switch) | 641.7 | 8.5 | 9.1 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 653.3 | 14.3 | 21.0 |
Change from baseline in eGFRcr (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcr per CKD-EPI formula - Female: 1) Serum creatinine (Scr) less than or equal to (<=)0.7 mg/dL: 144*(Scr/0.7)^-0.329*0.993age; 2) Scr greater than (>)0.7 mg/dL: 144*(Scr/0.7)^-1.209*0.993age. Male: 1) Scr <=0.9 mg/dL: 141*(Scr/0.9)^-0.411*0.993age; 2) Scr >0.9 mg/dL: 141*(Scr/0.9)^-1.209*0.993age. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) | |
|---|---|---|
| Change at Week 24 | Change at Week 48 | |
| Control (Baseline to Switch) | -0.75 | -0.88 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -1.67 | -1.97 |
Change from baseline in eGFRcr (by Cockcroft-Gault formula) was assessed at Weeks 24 and 48. eGFRcr according to the Cockcroft Gault formula- Male: (140 - age in years)*(weight in kilogram [kg])/72*(serum creatinine in milligram per deciliter [mg/dL])=eGFRcr (milliliter per minute [mL/min]); Female: (140 - age in years)*(weight in kg)/72*(serum creatinine in mg/dL)*0.85=eGFRcr (mL/min). (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | milliliter per minute (mL/min) (Least Squares Mean) | |
|---|---|---|
| Change at Week 24 | Change at Week 48 | |
| Control (Baseline to Switch) | 0.20 | -0.20 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -0.38 | -0.94 |
Change from baseline in eGFRcyst (by CKD-EPI) was assessed at Weeks 24 and 48. eGFRcyst according to the CKD-EPI formula - 1) Serum Cystatin C (Scyst) <=0.8 mg/L: 133*(Scyst/0.8)^-0.499*0.996age (*0.932 if female); 2) Scyst >0.8 mg/L: 133*(Scyst/0.8)^-1.328*0.996age (*0.932 if female). (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) | |
|---|---|---|
| eGFRcyst: Change at Week 24 | eGFRcyst: Change at Week 48 | |
| Control (Baseline to Switch) | -0.93 | -1.76 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.21 | -0.42 |
Change from baseline in serum creatinine levels at Weeks 24 and 48 was assessed. (NCT02269917)
Timeframe: Baseline and Weeks 24 and 48
| Intervention | micro mole per liter (Least Squares Mean) | |
|---|---|---|
| Change at Week 24 | Change at Week 48 | |
| Control (Baseline to Switch) | 0.88 | 0.65 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 1.22 | 1.27 |
Change from baseline in UACR and UPCR was assessed at Weeks 24 and 48. Lower levels of albumin or protein in the urine indicates better proximal tubular function. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | milligram per gram (mg/g) (Median) | |||||
|---|---|---|---|---|---|---|
| UACR: Baseline | UACR: Change at Week 24 | UACR: Change at Week 48 | UPCR: Baseline | UPCR: Change at Week 24 | UPCR: Change at Week 48 | |
| Control (Baseline to Switch) | 7.14 | 0.44 | 0.40 | 62.90 | 0.07 | -7.37 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 6.20 | -0.78 | -0.76 | 61.56 | -14.63 | -22.25 |
Change from baseline in URBPCR and UB2MGCR was assessed at Weeks 24 and 48. Retinol binding protein is a marker of proximal tubular function. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | microgram per gram (mcg/g) (Median) | |||||
|---|---|---|---|---|---|---|
| URBPCR: Baseline | URBPCR: Change at Week 24 | URBPCR: Change at Week 48 | UB2MGCR: Baseline | UB2MGCR: Change at Week 24 | UB2MGCR: Change at Week 48 | |
| Control (Baseline to Switch) | 137.16 | 7.76 | 19.66 | 172.25 | 12.08 | 20.24 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 126.19 | -30.27 | -27.09 | 156.85 | -72.64 | -67.02 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score >= -1, osteopenia by a T-score >= -2.5 to <-1.0, and osteoporosis by a T-score <-2.5. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2). (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Hip region BMD | Spine region BMD | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.122 | 0.176 |
| Switch to D/C/F/TAF | 0.077 | 0.255 |
HIV-1 genotypes were analyzed from samples of participants with confirmed virologic rebound in case they had HIV-1 RNA values >=400 copies/mL at failure or at later time points, including participants who discontinued with last HIV-1 RNA >=400 copies/mL. Virologic rebound was defined as: confirmed plasma HIV-1 RNA level >=20 copies/mL up to and including Week 96, last available on-treatment (single) HIV-1 RNA >=20 copies/mL at premature discontinuation (irrespective of reason), and last available on-treatment HIV-1 RNA >=20 copies/mL at the study cutoff of Week 96 (that is, any last viral load [re]test having occurred no later than 6 weeks after Week 96). Number of participants who developed resistance to any of the study drug (DRV, FTC, and TFV/TAF) were reported. (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm), up to Week 48 (Control arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| DRV resistance-associated mutations (RAMs) | TFV RAMs | FTC RAMs | |
| Control (Baseline to Switch) | 0 | 0 | 0 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0 | 0 | 0 |
| Switch to D/C/F/TAF | 0 | 0 | 1 |
Percent change from baseline in bone biomarker: 25-hydroxy vitamin D was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent change (Mean) | |
|---|---|---|
| Percent change at Week 24 | Percent change at Week 48 | |
| Control (Baseline to Switch) | 4.2 | 24.9 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -3.0 | 25.2 |
Percent change from baseline in bone biomarker: PTH was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent change (Mean) | |
|---|---|---|
| Percent change at Week 24 | Percent change at Week 48 | |
| Control (Baseline to Switch) | 12.034 | 9.436 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -3.092 | -4.510 |
Percent change from baseline in bone biomarkers: P1NP and CTX was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent Change (Mean) | |||
|---|---|---|---|---|
| P1NP: Percent change at Week 24 | P1NP: Percent change at Week 48 | CTX: Percent change at Week 24 | CTX: Percent change at Week 48 | |
| Control (Baseline to Switch) | -0.027 | -3.751 | 16.312 | 5.433 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | -22.971 | -26.752 | -16.772 | -10.517 |
Percent change from baseline in spine and hip BMD was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Spine BMD: Percent change at Week 24 | Spine BMD: Percent change at Week 48 | Hip BMD: Percent change at Week 24 | Hip BMD: Percent change at Week 48 | |
| Control (Baseline to Switch) | 0.18 | 0.01 | 0.00 | -0.08 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 1.55 | 2.06 | 0.91 | 1.62 |
Percent change from baseline in urine FEPO4 was assessed at Weeks 24 and 48. (NCT02269917)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent change (Median) | |
|---|---|---|
| Percent change at Week 24 | Percent change at Week 48 | |
| Control (Baseline to Switch) | 8.55 | 8.57 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 3.58 | 8.42 |
"The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DXA scan. Positive values are best values and negative values are worst values of change. Percent change from reference in hip and spine BMD was assessed. For the D/C/F/TAF group, reference is the comparative treatment phase baseline as in Week 48 analysis (Reference 1). For the Switch to D/C/F/TAF (late switch) group, the last value prior to the switch was used as reference (reference 2)." (NCT02269917)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | percent change (Mean) | |
|---|---|---|
| Hip region BMD-T score | Spine region BMD-T score | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 0.0173 | 0.0193 |
| Switch to D/C/F/TAF | 0.0108 | 0.0279 |
An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social & functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. (NCT02269917)
Timeframe: Up to Week 48
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| Control (Baseline to Switch) | 6.3 | 1.9 | 4.8 | 1.3 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 5.6 | 1.2 | 4.6 | 1.4 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social & functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT02269917)
Timeframe: From Week 96 to end of extension (up to 42 months)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 5.7 | 2.1 | 7.3 | 1.1 |
| Switch to D/C/F/TAF | 5.0 | 1.5 | 7.7 | 2.1 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events were symptoms causing inability to perform usual social & functional activities. Grade 4 (Life-threatening) events were symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT02269917)
Timeframe: Through Week 96 (D/C/F/TAF arm) and from Week 52 to Week 96 (Switch to D/C/F/TAF arm)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 10.5 | 2.4 | 8.7 | 2.2 |
| Switch to D/C/F/TAF | 6.3 | 1.1 | 6.0 | 2.0 |
Percentage of participants with HIV RNA <50, <20, <200 copies/mL post Week 96 to end of extension were reported. (NCT02269917)
Timeframe: Week 96 to end of extension (up to 42 months)
| Intervention | percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 96 + 6 months (<50 copies/mL) | Week 96 + 12 months (<50 copies/mL) | Week 96 + 18 months (<50 copies/mL) | Week 96 + 24 months (<50 copies/mL) | Week 96 + 30 months (<50 copies/mL) | Week 96 + 36 months (<50 copies/mL) | Week 96 + 42 months (<50 copies/mL) | Week 96 + 6 months (<200 copies/mL) | Week 96 + 12 months (<200 copies/mL) | Week 96 + 18 months (<200 copies/mL) | Week 96 + 24 months (<200 copies/mL) | Week 96 + 30 months (<200 copies/mL) | Week 96 + 36 months (<200 copies/mL) | Week 96 + 42 months (<200 copies/mL) | Week 96 + 6 months (<20 copies/mL) | Week 96 + 12 months (<20 copies/mL) | Week 96 + 18 months (<20 copies/mL) | Week 96 + 24 months (<20 copies/mL) | Week 96 + 30 months (<20 copies/mL) | Week 96 + 36 months (<20 copies/mL) | Week 96 + 42 months (<20 copies/mL) | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 97.8 | 98.4 | 99.6 | 99.3 | 99.3 | 98.1 | 100 | 99.1 | 99.3 | 100 | 99.6 | 100 | 100 | 100 | 91.4 | 93.9 | 96.1 | 96.1 | 95.6 | 94.2 | 93.8 |
| Switch to D/C/F/TAF | 97.9 | 97.4 | 98.7 | 98.5 | 100 | 100 | 100 | 99.7 | 98.7 | 99.1 | 99.3 | 100 | 100 | 100 | 93.4 | 91.4 | 92.9 | 95.5 | 92.2 | 96.2 | 100 |
Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral [ARV]). (NCT02269917)
Timeframe: Week 96 to end of extension (up to 42 months)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | |
| Switch to D/C/F/TAF | 100 | 98.5 | 95.4 | 92.2 | 89.7 | 88.1 | 82.6 |
Percentage of participants with non-treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic rebound or having discontinued for reasons other than alternate access to D/C/F/TAF (or other antiretroviral [ARV]). (NCT02269917)
Timeframe: Week 96 to end of extension (up to 42 months)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | Week 96 + 42 months | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 100 | 98.1 | 94.3 | 91.6 | 89.4 | 87.0 | 84.9 | 81.7 |
Virologic rebound is defined as participants who show confirmed HIV-1 RNA >=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was >=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented. (NCT02269917)
Timeframe: Week 96 to end of extension (at every 6 months, up to 42 months)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | |
| Switch to D/C/F/TAF | 100 | 100 | 98.5 | 98.1 | 96.5 | 96.5 | 96.5 |
Virologic rebound is defined as participants who show confirmed HIV-1 RNA >=50 copies/mL, or for which the last available (single) HIV-1 RNA value on treatment was >=50 copies/mL. Here, Kaplan-Meier estimates (%) of non-virologic rebound at every 6 months interval are presented. (NCT02269917)
Timeframe: Week 96 to end of extension (at every 6 months, up to 42 months)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | Week 96 + 42 months | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 100 | 99.4 | 98.0 | 97.6 | 97.1 | 95.3 | 92.4 | 92.4 |
Percentage of participants with virologic failure based on HIV-1 RNA >=20, >=50, and >=200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic failure was defined by the FDA snapshot approach as having last available HIV-1 RNA >=20/50/200 copies/mL at Week 96; virologic failure - leading to discontinuation; virologic failure - discontinued due to other reason and last available HIV-1 RNA >=20/50/200 copies/mL. (NCT02269917)
Timeframe: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| >=20 copies/mL | >=50 copies/mL | >=200 copies/mL | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 6.8 | 1.2 | 0.3 |
| Switch to D/C/F/TAF | 6.0 | 1.7 | 0 |
Percentage of participants with virologic response based on HIV-1 RNA <20, <50, and <200 copies/mL threshold were analyzed at Week 48 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA <20/50/200 copies/mL. (NCT02269917)
Timeframe: Week 48
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| <20 copies/mL | <50 copies/mL | <200 copies/mL | |
| Control (Baseline to Switch) | 83.6 | 92.9 | 94.7 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 86.0 | 93.7 | 95.4 |
Percentage of participants with virologic response based on HIV-1 RNA <20, <50, and <200 copies/mL threshold were analyzed at Week 96 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as having last available HIV-1 RNA <20/50/200 copies/mL (observed case). (NCT02269917)
Timeframe: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| <20 copies/mL | <50 copies/mL | <200 copies/mL | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 85.3 | 90.7 | 91.2 |
| Switch to D/C/F/TAF | 89.8 | 93.8 | 95.5 |
Percentage of participants with virologic response based on HIV-1 RNA <20, <50, and <200 copies/mL threshold were analyzed at Week 96 using TLOVR algorithm approach. TLOVR was defined as sustained HIV-1 RNA <20/50/200 copies/mL. (NCT02269917)
Timeframe: Week 96 (Comprising up to Week 96 for D/C/F/TAF and 44 weeks of D/C/F/TAF exposure [that is, from the switch to D/C/F/TAF at Week 52 up to Week 96])
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| <20 copies/mL | <50 copies/mL | <200 copies/mL | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 79.6 | 89.6 | 91.7 |
| Switch to D/C/F/TAF | 88.1 | 94.3 | 95.7 |
Percentage of participants with virologic response based on HIV-1 RNA <20, <50, and <200 copies/mL threshold were analyzed at Week 48 using FDA snapshot approach. FDA Snapshot approach analysis was based on the last observed viral load data: virologic response was defined as HIV-1 RNA <20/50/200 copies/mL (observed case). (NCT02269917)
Timeframe: Week 48
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| <20 copies/mL | <50 copies/mL | <200 copies/mL | |
| Control (Baseline to Switch) | 88.4 | 93.7 | 94.2 |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 89.8 | 94.9 | 95.0 |
Predose (trough) plasma concentration (C0h) of darunavir was determined. Pharmacokinetic (PK) data was only analyzed for participants in the D/C/F/TAF group as per planned analysis. (NCT02269917)
Timeframe: Predose at Weeks 2, 4, 8, 12, 24, 36, and 48
| Intervention | Nanogram per milliliter (ng/mL) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 24 | Week 36 | Week 48 | |
| D/C/F/TAF (Test) (Baseline [BL] to End of Extension [EOE]) | 1775.29 | 1732.00 | 1910.30 | 1643.38 | 2022.99 | 1806.37 | 1899.79 |
(NCT02251236)
Timeframe: Baseline
| Intervention | ng/mL (Median) |
|---|---|
| Stribild Arm | 4.3 |
| Genvoya Arm | 2.72 |
(NCT02251236)
Timeframe: Week 24
| Intervention | ng/mL (Median) |
|---|---|
| Stribild Arm | 5.90 |
| Genvoya Arm | 3.09 |
(NCT02251236)
Timeframe: Baseline
| Intervention | ng/mL (Median) |
|---|---|
| Stribild Arm | 3.03 |
| Genvoya Arm | 0.49 |
(NCT02251236)
Timeframe: Week 24
| Intervention | ng/mL (Median) |
|---|---|
| Stribild Arm | 0.507 |
| Genvoya Arm | 0.481 |
(NCT02616783)
Timeframe: Baseline; Week 24
| Intervention | cells/μL (Mean) |
|---|---|
| E/C/F/TAF | 48 |
| Stay on Baseline Regimen | -4 |
(NCT02616783)
Timeframe: Baseline; Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| E/C/F/TAF | 56 |
| Stay on Baseline Regimen | -1 |
(NCT02616783)
Timeframe: Baseline; Week 24
| Intervention | Percent change (Mean) |
|---|---|
| E/C/F/TAF | 0.808 |
| Stay on Baseline Regimen | -0.537 |
(NCT02616783)
Timeframe: Baseline; Week 24
| Intervention | Percent change (Mean) |
|---|---|
| E/C/F/TAF | 1.625 |
| Stay on Baseline Regimen | -0.027 |
(NCT02616783)
Timeframe: Baseline; Week 48
| Intervention | Percent change (Mean) |
|---|---|
| E/C/F/TAF | 1.330 |
| Stay on Baseline Regimen | -0.726 |
(NCT02616783)
Timeframe: Baseline; Week 48
| Intervention | Percent change (Mean) |
|---|---|
| E/C/F/TAF | 2.237 |
| Stay on Baseline Regimen | -0.104 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02616783)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 94.5 |
| Stay on Baseline Regimen | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02616783)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 93.6 |
| Stay on Baseline Regimen | 94.5 |
(NCT02652624)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | 29 |
| Stay on Baseline Regimen | 26 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02652624)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 95.7 |
| Stay on Baseline Regimen | 95.3 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02652624)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 1.7 |
| Stay on Baseline Regimen | 1.7 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 90.6 |
| Stay on Baseline Treatment Regimen (SBR) | 85.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 92.8 |
| Stay on Baseline Treatment Regimen (SBR) | 89.1 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 96
| Intervention | cells/uL (Mean) | |
|---|---|---|
| Baseline | Change at Week 96 | |
| E/C/F/TAF | 701 | 60 |
| Stay on Baseline Treatment Regimen (SBR) | 689 | 42 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | cells/uL (Mean) | |||
|---|---|---|---|---|
| Baseline (NDA Data Cut) | Change at Week 48 (NDA Data Cut) | Baseline (All Participants) | Change at Week 48 (All Participants) | |
| E/C/F/TAF | 712 | 33 | 701 | 35 |
| Stay on Baseline Treatment Regimen (SBR) | 690 | 27 | 689 | 24 |
(NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | -0.01 | 0.00 |
| Stay on Baseline Treatment Regimen (SBR) | 0.04 | 0.03 |
"The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.~EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit." (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | -1.6 | -1.5 |
| Stay on Baseline Treatment Regimen (SBR) | -0.1 | -0.1 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 1.949 | 1.468 |
| Stay on Baseline Treatment Regimen (SBR) | -0.136 | -0.340 |
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 1.861 | 1.557 |
| Stay on Baseline Treatment Regimen (SBR) | -0.110 | -0.443 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 92.2 | 93.5 |
| Stay on Baseline Treatment Regimen (SBR) | 90.4 | 90.4 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| NDA Data Cut | All Participants | |
| E/C/F/TAF | 95.6 | 97.2 |
| Stay on Baseline Treatment Regimen (SBR) | 92.9 | 93.1 |
The AUCtau is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption. (NCT02431247)
Timeframe: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
| Intervention | h*ng/mL (Mean) |
|---|---|
| Tenofovir Alafenamide 10 mg [D/C/F/TAF (Test)] | 132.3117 |
AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post-dose. (NCT02431247)
Timeframe: 0 to 24 hours post dose
| Intervention | hours*nanogram per milliliter (h*ng/mL) (Mean) |
|---|---|
| Darunavir 800 mg [D/C/F/TAF] | 87909.3282 |
The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Week 48 were assessed. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | Cells per millimeter cube (cells/mm^3) (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 190.49 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 172.01 |
Change from baseline in eGFRcr was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR [>=90 mL/min]); Stage 2 (Mild CKD [60 to 90 mL/min]); Stage 3 (Moderate CKD [30 to 59mL/min]); Stage 4 (Severe CKD [15 to 29 mL/min]); Stage 5 (End Stage CKD [<15 mL/min]). The eGFRcr was assessed by calculating serum creatinine (Scr) using the equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m^2) = 144*(Scr/0.7)^-0.329*0.993^age (Scr =< 0.7 mg/dL) and eGFRcr mL/min/1.73m^2 = 144*(Scr/0.7)^-1.209*0.993^age (Scr >0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m^2 = 141*(Scr/0.9)^-0.411*0.993^age (Scr =<0.9 mg/dL) and eGFRcr mL/min/1.73m^2 = 141*(Scr/0.9)^-1.209*0.993^age (Scr >0.9 mg/dL) for male participants. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -6.04 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -9.16 |
Change from baseline in eGFRcr by cockcroft-gault formula at Week 48. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl [mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit (kilogram [kg]), C is the serum concentration of creatinine [mg/dL], R = 1 if the participant is male and = 0.85 if female. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | milliliter per minute (mL/min) (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -5.16 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -11.20 |
Change from baseline in eGFRcyst was calculated using the CKD-EPI equation as per which Stage 1 (normal or high GFR) >= 90 indicates normal kidney function; Stage 2 (Mild CKD): 60 to 89 mL/min indicates mildly reduced kidney function; Stage 3 (Moderate CKD): 30 to 59 mL/min indicates moderately reduced kidney function; Stage 4 (Severe CKD): 15 to 29 mL/min indicates severely reduced kidney function; Stage 5 (End Stage of CKD): <15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the equation: eGFRcyst mL/min/1.73m^2 = 133 * (Scyst/0,8)^-0.499 * 0.996^age [* 0.932 if female] (Scyst =<0.8 mg/L) and eGFRcr mL/min/1.73m^2 = 133 * (Scyst/0,8)^-1.328 * 0.996^age [* 0.932 if male] (Scyst >0.8 mg/L). (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 5.32 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 2.92 |
Change from baseline in log10 HIV-1 RNA levels were reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | log10 HIV-1 RNA copies per mL (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -2.95 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -2.91 |
Change from baseline in serum creatinine at Week 48 was reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | milligram per deciliter (mg/dL) (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.05 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 0.09 |
Change from baseline in UACR at Week 48 was reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | mg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.58 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -0.15 |
Change from baseline in UB2MGCR at Week 48 were reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | mcg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -30.42 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 18.36 |
Change from baseline in UPCR at Week 48 was reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | milligram per gram (mg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -15.72 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -10.53 |
Change from baseline in URBPCR at Week 48 were reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | microgram per gram (mcg/g) (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 7.00 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 35.02 |
Change from reference in ALP levels at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | U/L (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.9 |
| Switch to D/C/F/TAF | -9.7 |
The immunologic change was determined by changes in cluster of differentiation (CD4+) cell count. Change from reference in CD4+ cell count at Week 96 was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | cells/mm^3 (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 228.85 |
| Switch to D/C/F/TAF | 27.01 |
Change from reference in eGFRcr was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD). The eGFRcr was assessed by calculating serum creatinine (Scr) using the CKD-EPI equation: eGFRcr milliliter per minute per 1.72 meter square (mL/min/1.73m^2) = 144 * (Scr/0.7)^-0.329 * 0.993^age (Scr =< 0.7 mg/dL) and eGFRcr mL/min/1.73m^2 = 144 * (Scr/0.7)^-1.209 * 0.993^age (Scr >0.7 mg/dL) for female participants and eGFRcr mL/min/1.73m^2 = 141 x (Scr/0.9)^-0.411 x 0.993^age (Scr =<0.9 mg/dL) and eGFRcr mL/min/1.73m^2 = 141 * (Scr/0.9)^-1.209 x 0.993^age (Scr >0.9 mg/dL) for male participants. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mL/min/1.73 m^2 (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -5.6 |
| Switch to D/C/F/TAF | 2.3 |
Change from reference in eGFRcr by cockcroft-gault formula was reported. The eGFRcr was assessed by calculated creatinine clearance (CrCl) using the Cockcroft-Gault formula, and was assessed using CrCl [mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit (kilogram [kg]), C is the serum concentration of creatinine [mg/dL], R = 1 if the participant is male and = 0.85 if female. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mL/min (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -5.2 |
| Switch to D/C/F/TAF | 4.6 |
Change from reference in eGFRcyst was calculated using the CKD-EPI equation as per Stage 1 (normal or high GFR) to Stage 5 (End Stage of CKD): <15 mL/min indicate very severe or end stage kidney failure. The eGFRcyst was assessed by calculated serum cystatin C (Scyst) using the CKD-EPI equation: eGFRcyst mL/min/1.73m^2 = 133 * (Scyst/0,8)^-0.499 * 0.996^age [x 0.932 if female] (Scyst =<0.8 mg/L) and eGFRcr mL/min/1.73m^2 = 133 * (Scyst/0,8)^-1.328 * 0.996^age [* 0.932 if male] (Scyst >0.8 mg/L). Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mL/min/1.73 m^2 (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 4.4 |
| Switch to D/C/F/TAF | 0 |
Change from reference in 25-OH Vitamin D were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | nmol/L (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 21.3 |
| Switch to D/C/F/TAF | -10.3 |
Change from reference in PTH levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | pmol/L (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.290 |
| Switch to D/C/F/TAF | -1.283 |
Change from reference in serum CTX levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mcg/L (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.041 |
| Switch to D/C/F/TAF | -0.162 |
Change from reference in serum P1NP levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mcg/L (Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 2.817 |
| Switch to D/C/F/TAF | -11.963 |
Change from reference in log10 HIV-1 RNA levels were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for Test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | log10 HIV-1 RNA copies per mL (Least Squares Mean) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -2.72 |
| Switch to D/C/F/TAF | -0.0027 |
Change from reference in serum creatinine was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mg/dL (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.045 |
| Switch to D/C/F/TAF | -0.034 |
Change from reference in UACR at Week 96 was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.70 |
| Switch to D/C/F/TAF | -0.49 |
Change from reference in UB2MGCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mcg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -27.04 |
| Switch to D/C/F/TAF | -40.53 |
Change from reference in UPCR was reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF+ FTC/TDF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -15.46 |
| Switch to D/C/F/TAF | -1.40 |
Change from reference in URBPCR at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | mcg/g (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 13.70 |
| Switch to D/C/F/TAF | -35.53 |
Percent change from baseline in FEPO4 at Week 48 was reported. (NCT02431247)
Timeframe: Baseline and Week 48
| Intervention | Percent change (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 16.00 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 22.55 |
Percent change from reference in FEPO4 at Week 96 were reported. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | Percent change in urine FEPO4 (Median) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 18.52 |
| Switch to D/C/F/TAF | -7.51 |
Percentage of participants with a HIV-1 RNA < 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA < 20/50/200 copies per mL at Week 96), 2) virologic failure (HIV RNA greater than or equal to [>=] 20/50/200 copies per mL at Week 96), 3) no viral load data in the Week 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response. (NCT02431247)
Timeframe: At Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 85.1 |
| Switch to D/C/F/TAF | 94.2 |
Percentage of participants with a HIV-1 RNA < 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA < 20/50/200 copies per mL at Week 48), 2) virologic failure (HIV RNA greater than or equal to [>=] 20/50/200 copies per mL at Week 48), 3) no viral load data in the Week 48 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response. (NCT02431247)
Timeframe: At Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 91.4 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 88.4 |
C0-2h is defined as the plasma concentrations 2 hours after dosing. (NCT02431247)
Timeframe: 0 to 2 hours post dose
| Intervention | ng/mL (Mean) |
|---|---|
| Tenofovir Alafenamide 10 mg [D/C/F/TAF (Test)] | 11.9785 |
C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration. (NCT02431247)
Timeframe: 30 minutes to 4 hours postdose at Weeks 2, 4, 12, 24 and 48 and at 2 timepoints with at least 2.5 hours in between sampling at Week 8 and 36 (first sample between 1 and 4 hours postdose)
| Intervention | nanogram per milliliter (ng/mL) (Mean) |
|---|---|
| Darunavir 800 mg [D/C/F/TAF (Test)] | 1898.9100 |
The immunologic change was determined by Cluster of CD4+ cell count. CD4+ cell count post-Week 96 to end of extension were assessed. (NCT02431247)
Timeframe: Week 96 to end of extension (up to 3 years)
| Intervention | cells/mm^3 (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 790.2 | 779.4 | 789.8 | 781.9 | 741.6 | 784.7 |
| Switch to D/C/F/TAF | 749.7 | 774.3 | 758.4 | 784.1 | 736.7 | 778.4 |
Change from baseline in ALP at Weeks 24 and 48 was reported. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Units per liter (U/L) (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -3.2 | -1.1 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 12.0 | 15.1 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score >= -1, osteopenia by a T-score >= -2.5 to <-1.0, and osteoporosis by a T-score <-2.5. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | BMD T-score (Mean) | |||
|---|---|---|---|---|
| Hip region BMD T-score (Week 24) | Spine region BMD T-score (Week 24) | Hip region BMD T-score (Week 48) | Spine region BMD T-score (Week 48) | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.019 | -0.121 | 0.015 | -0.061 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -0.109 | -0.322 | -0.177 | -0.225 |
Change from baseline in 25-OH Vitamin D levels at Week 24 and 48 were reported. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | nanomol per liter (nmol/L) (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 12.7 | 16.9 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 22.1 | 28.3 |
Change from baseline in PTH at Weeks 24 and 48 were reported. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Picomol per liter (pmol/L) (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.113 | -0.004 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 0.777 | 0.633 |
Change from baseline in serum CTX at Weeks 24 and 48 were reported. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | mcg/L (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.047 | 0.046 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 0.283 | 0.226 |
Change from baseline in serum P1NP at Weeks 24 and 48 were reported. (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | microgram per liter (mcg/L) (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 1.892 | 0.065 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 24.679 | 24.251 |
BMD status was assessed using BMD T-scores; normal bone status was defined by a BMD T-score >= -1, osteopenia by a T-score >= -2.5 to <-1.0, and osteoporosis by a T-score <-2.5. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group. (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | BMD T-score (Mean) | |
|---|---|---|
| Hip region BMD T-score | Spine region BMD T-score | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.016 | -0.090 |
| Switch to D/C/F/TAF | 0.025 | 0.034 |
Number of participants with DRV, FTC, TDF/TAF resistance were reported. (NCT02431247)
Timeframe: Baseline to end of extension (up to 4 years)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| DRV resistance-associated mutations (RAMs) | TFV RAMs | FTC RAMs | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0 | 0 | 2 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 0 | 0 | 1 |
| Switch to D/C/F/TAF | 0 | 0 | 2 |
"The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by dual energy x-ray absorptiometry (DEXA) scan. Positive values are best values and negative values are worst values of change. Percent change from baseline in hip and spine BMD was assessed." (NCT02431247)
Timeframe: Baseline, Weeks 24 and 48
| Intervention | Percent change (Least Squares Mean) | |||
|---|---|---|---|---|
| Hip region BMD (Week 24) | Spine region BMD (Week 24) | Hip region BMD (Week 48) | Spine region BMD (Week 48) | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 0.29 | -1.34 | 0.17 | -0.68 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | -1.66 | -3.43 | -2.69 | -2.38 |
"The BMD is the amount of mineral in gram per square centimeter of bone, which was assessed by DEXA scan. Positive values are best values and negative values are worst values of change. Percent change from reference in hip and spine BMD was assessed. Here, reference 1 is the comparative phase baseline value in Week 48 analysis for test group and reference 2 is the last value prior to the switch for Control group." (NCT02431247)
Timeframe: From Reference 1 to Week 96 for D/C/F/TAF Group and Reference 2 to Week 96 for Switch to D/C/F/TAF
| Intervention | Percent change in BMD (Mean) | |
|---|---|---|
| Hip region BMD | Spine region BMD | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | -0.2565 | -0.9349 |
| Switch to D/C/F/TAF | 0.5467 | 0.4829 |
Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence >95% as assessed by drug accountability. (NCT02431247)
Timeframe: Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Baseline to Switch (double-blind treatment) | |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 82.6 |
Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence >95% as assessed by drug accountability. (NCT02431247)
Timeframe: Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Switch to End of Extension (open-label D/C/F/TAF) | |
| Switch to D/C/F/TAF | 88.7 |
Treatment adherence assessed by drug accountability (based on pill count) from start of treatment/switch to last study drug intake by determination of the cumulative treatment adherence in participants who returned all dispensed bottles prior to or at the last visit in the study. Adherent participants were defined as having an adherence >95% as assessed by drug accountability. (NCT02431247)
Timeframe: Baseline to Switch and switch to EOE to Open-Label D/C/F/TAF (Up to 3 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Baseline to Switch (double-blind treatment) | Switch to End of Extension (open-label D/C/F/TAF) | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 87.2 | 92.2 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT02431247)
Timeframe: Up to Weeks 48
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 4.7 | 0.6 | 4.7 | 1.9 |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 4.4 | 1.7 | 5.8 | 4.4 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT02431247)
Timeframe: Up to Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 11.6 | 0.8 | 10.8 | 2.8 |
| Switch to D/C/F/TAF | 3.7 | 1.4 | 2.7 | 0.3 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT02431247)
Timeframe: From Week 96 to end of extension (up to 3 years)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Grade 3 AEs | Grade 4 AEs | SAEs | Premature discontinuations due to AEs | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 3.5 | 0 | 3.2 | 1.0 |
| Switch to D/C/F/TAF | 5.2 | 1.3 | 4.8 | 1.3 |
Percentage of participants with HIV RNA <50, <20, and <200 copies/mL post Week 96 to end of extension were reported. (NCT02431247)
Timeframe: Week 96 to end of extension (up to 3 years)
| Intervention | percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 96 + 6 months (<50 copies/mL) | Week 96 + 12 months (<50 copies/mL) | Week 96 + 18 months (<50 copies/mL) | Week 96 + 24 months (<50 copies/mL) | Week 96 + 30 months (<50 copies/mL) | Week 96 + 36 months (<50 copies/mL) | Week 96 + 6 months (<20 copies/mL) | Week 96 + 12 months (<20 copies/mL) | Week 96 + 18 months (<20 copies/mL) | Week 96 + 24 months (<20 copies/mL) | Week 96 + 30 months (<20 copies/mL) | Week 96 + 36 months (<20 copies/mL) | Week 96 + 6 months (<200 copies/mL) | Week 96 + 12 months (<200 copies/mL) | Week 96 + 18 months (<200 copies/mL) | Week 96 + 24 months (<200 copies/mL) | Week 96 + 30 months (<200 copies/mL) | Week 96 + 36 months (<200 copies/mL) | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 97.7 | 99.0 | 98.1 | 97.5 | 94.7 | 100.0 | 85.8 | 89.7 | 92.4 | 90.1 | 89.5 | 94.7 | 99.7 | 100.0 | 98.7 | 97.5 | 96.5 | 100.0 |
| Switch to D/C/F/TAF | 96.3 | 96.7 | 98.2 | 95.7 | 91.4 | 68.8 | 88.2 | 91.6 | 92.8 | 87.0 | 84.5 | 62.5 | 99.3 | 99.5 | 98.2 | 97.8 | 98.3 | 87.5 |
Percentage of participants with HIV-1 RNA less than (<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA < 50 copies per mL; confirmed HIV-1 RNA >= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation. (NCT02431247)
Timeframe: At Week 48 and 96
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| At Week 48: < 20 Copies per mL | At Week 48: <50 Copies per mL | At Week 48: <200 Copies per mL | |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 79.9 | 88.7 | 91.7 |
Percentage of participants with HIV-1 RNA less than (<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA < 50 copies per mL; confirmed HIV-1 RNA >= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation. (NCT02431247)
Timeframe: At Week 48 and 96
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| At Week 96: <20 Copies per mL | At Week 96: <50 Copies per mL | At Week 96: <200 Copies per mL | |
| Switch to D/C/F/TAF | 78.4 | 93.8 | 96.9 |
Percentage of participants with HIV-1 RNA less than (<) 20, 50, and 200 copies per mL at Weeks 48 and 96 based on TLOVR algorithm were assessed. TLOVR requires sustained HIV-1 RNA < 50 copies per mL; confirmed HIV-1 RNA >= 50 copies per mL is considered as non-response (rebound); participant is considered non-responder after permanent discontinuation. (NCT02431247)
Timeframe: At Week 48 and 96
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| At Week 48: < 20 Copies per mL | At Week 48: <50 Copies per mL | At Week 48: <200 Copies per mL | At Week 96: <20 Copies per mL | At Week 96: <50 Copies per mL | At Week 96: <200 Copies per mL | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 82.6 | 91.2 | 93.1 | 73.2 | 85.1 | 86.7 |
Percentage of participants with HIV-1 RNA < 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA < 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA >= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response. (NCT02431247)
Timeframe: At Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| At week 48: <20 Copies per mL | At week 48: <200 Copies per mL | |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 79.3 | 90.6 |
Percentage of participants with HIV-1 RNA < 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA < 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA >= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response. (NCT02431247)
Timeframe: At Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| At week 96: <20 Copies per mL | At week 96: <200 Copies per mL | |
| Switch to D/C/F/TAF | 83.5 | 96.9 |
Percentage of participants with HIV-1 RNA < 20/200 copies per mL using FDA snapshot approach were reported. The snapshot approach classified participants into 3 outcome categories: 1) virologic success (HIV RNA < 20/50/200 copies per mL at Week 48 and 96), 2) virologic failure (HIV RNA >= 20/50/200 copies per mL at Week 48 and 96), 3) no viral load data in the Week 48 and 96 visit window (discontinued due to adverse event/death/other reason). The missing HIV-1 RNA is considered as non-response. (NCT02431247)
Timeframe: At Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| At week 48: <20 Copies per mL | At week 48: <200 Copies per mL | At week 96: <20 Copies per mL | At week 96: <200 Copies per mL | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 82.6 | 92.8 | 76.2 | 86.2 |
Percentage of participants with non-PDVF by Kaplan-Meier Estimates were reported. PDVF was defined as having virologic non-response (HIV-1 RNA <1 log10 reduction from baseline and >=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA >=50 copies/mL after confirmed consecutive HIV-1 RNA <50 copies/mL or confirmed >1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA >=400 copies/mL). (NCT02431247)
Timeframe: From Week 96 to end of extension (up to 2 years and 6 months)
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 100 | 99.6 | 99.6 | 98.6 | 97.3 | 97.3 |
| Switch to D/C/F/TAF | 100 | 99.2 | 99.2 | 97.8 | 97.8 | 92.5 |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA <1 log10 reduction from baseline and >=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA >=50 copies/mL after confirmed consecutive HIV-1 RNA <50 copies/mL or confirmed >1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA >=400 copies/mL). (NCT02431247)
Timeframe: Week 96 to end of extension (up to 3 years)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Participants who met PDVF | Virologic non-response | Virologic rebound | Viremic at final time point | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 1.0 | 0 | 1.0 | 0 |
| Switch to D/C/F/TAF | 2.1 | 0 | 1.4 | 0.7 |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA <1 log10 reduction from baseline and >=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA >=50 copies/mL after confirmed consecutive HIV-1 RNA <50 copies/mL or confirmed >1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA >=400 copies/mL). (NCT02431247)
Timeframe: From Baseline up to Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Participants who met PDVF (Baseline - Switch) | Virologic non-response (Baseline - Switch) | Virologic rebound (Baseline - Switch) | Viremic at final time point (Baseline - Switch) | |
| DRV/COBI+ FTC/TDF (Control) (Baseline to Switch) | 4.4 | 0 | 3.9 | 0.6 |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA <1 log10 reduction from baseline and >=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA >=50 copies/mL after confirmed consecutive HIV-1 RNA <50 copies/mL or confirmed >1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA >=400 copies/mL). (NCT02431247)
Timeframe: From Baseline up to Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Participants who met PDVF (Baseline - Week 96) | Virologic non-response (Baseline - Week 96) | Virologic rebound (Baseline-Week 96) | Viremic at final time point (Baseline-Week 96) | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 4.1 | 0.6 | 0.3 | 0.6 |
Percentage of participants with PDVF were reported. Protocol-defined virologic failure was defined as having virologic non-response (HIV-1 RNA <1 log10 reduction from baseline and >=50 copies/mL at the Week 8 visit, confirmed at the next visit), virologic rebound (confirmed HIV-1 RNA >=50 copies/mL after confirmed consecutive HIV-1 RNA <50 copies/mL or confirmed >1 log10 increase in HIV-1 RNA from nadir), or viremic at final time point (final available on treatment HIV-1 RNA >=400 copies/mL). (NCT02431247)
Timeframe: From Baseline up to Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Participants who met PDVF (Switch - Week 96) | Virologic non-response (Switch - Week 96) | Virologic rebound (Switch - Week 96) | Viremic at final time point (Switch - Week 96) | |
| Switch to D/C/F/TAF | 1.1 | 0 | 1.1 | 0 |
Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs). (NCT02431247)
Timeframe: From Week 96 to end of extension (up to 3 years)
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | |
| Switch to D/C/F/TAF | 100 | 97.4 | 94.1 | 89.5 | 86.4 | 79.1 |
Percentage of participants with time to treatment failure by Kaplan-Meier Estimates were reported. Treatment failure was defined as having either protocol-defined virologic failure or having discontinued for reasons other than alternate access to D/C/F/TAF (or other ARVs). (NCT02431247)
Timeframe: From Week 96 to end of extension (up to 3 years)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 96 | Week 96 + 6 months | Week 96 + 12 months | Week 96 + 18 months | Week 96 + 24 months | Week 96 + 30 months | Week 96 + 36 months | |
| D/C/F/TAF (Test) (Baseline to End of Extension [EOE]) | 100 | 98.9 | 95.6 | 90.6 | 87.1 | 84.8 | 84.8 |
Duration of hospitalizations in days was reported for those participants hospitalized during the course of the study. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this OM. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| D/C/F/TAF: Main Study | 5.0 |
Number of participants that required discontinuation after enrollment based on safety stopping rules were reported. Stopping rules include the following reasons: a). Estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) formula < 50 milliliter per minute (mL/min) b). Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to (>=) 2.5*upper limit of normal (ULN); c). Serum lipase >=1.5*ULN; d). Positive serum human chorionic gonadotropin pregnancy test (beta-hCG) for women of childbearing potential; e). Laboratory results that the investigator believes should result in discontinuation of study medication; f). Participants identified with active hepatitis C virus (HCV) infection that in the opinion of the investigator requires HCV treatment immediately or expected to be needed during the course of the study with agents not compatible with D/C/F/TAF FDC. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| D/C/F/TAF: Main Study | 3 |
Number of participants with emergency room visits was reported. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| D/C/F/TAF: Main Study | 19 |
Number of participants with hospitalizations (overnight) was reported. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| D/C/F/TAF: Main Study | 11 |
Percentage of participants developing RAMs and loss of phenotypic susceptibility, upon meeting PDVF were reported. Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA <1 log10 reduction from baseline, and HIV-1 RNA greater than or equal to (>=) 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA <50 copies/mL, a rebound in HIV 1 RNA to >= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a >1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 0 |
Percentage of participants discontinuing therapy due to AEs were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 0.9 |
Percentage of participants discontinuing therapy due to AEs were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. (NCT03227861)
Timeframe: Up to Week 96
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Extension Study | 1.3 |
Percentage of participants lost-to-follow-up throughout the 48 Weeks of treatment were reported. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 3.67 |
Percentage of participants meeting resistance stopping rules, requiring discontinuation of study treatment due to baseline resistance findings were reported. Investigator reviewed antiretroviral screening/baseline resistance data at Week 4, depending on availability of screening/baseline HIV genotypic drug resistance testing results from central laboratory. Participants who do not show full sensitivity to all drugs in the fixed-dose combination (FDC) study regimen according to the susceptibility assessment in the Genosure Prime report will be contacted to return to study site for early study treatment discontinuation (ESTD). Participants with identified resistance to lamivudine/Emtricitabine, attributed to the presence of the M184I/V mutation alone will be permitted to remain in the study. (NCT03227861)
Timeframe: Up to Day 35
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 0 |
Percentage of participants with HIV-1 RNA < 50 copies/mL were reported. (NCT03227861)
Timeframe: Week 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 81.7 |
Percentage of participants with a HIV-1 RNA < 50 copies per mL were assessed using FDA snapshot approach which defines a participant's virologic response status using only the viral load at the predefined time point within a window of time, along with study drug discontinuation status. If HIV RNA level is < 50 copies per mL at Week 48, it is considered as virologic success as per the snapshot approach. (NCT03227861)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| D/C/F/TAF: Main Study | 84.4 |
The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Weeks 12, 24 and 48 were assessed. (NCT03227861)
Timeframe: Baseline, Weeks 12, 24 and 48
| Intervention | Cells per millimeter cube (cells/mm^3) (Mean) | ||
|---|---|---|---|
| Change at Week 12 | Change at Week 24 | Change at Week 48 | |
| D/C/F/TAF: Main Study | 149.56 | 182.11 | 222.60 |
Change from baseline in log10 HIV-1 RNA viral load (<50/200 copies/mL) at Weeks 2, 4, 8, 12, 24, 36, and 48 were reported. (NCT03227861)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 48
| Intervention | log10 HIV-1 RNA copies per mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 24 | Change at Week 36 | Change at Week 48 | |
| D/C/F/TAF: Main Study | -1.65 | -2.02 | -2.43 | -2.78 | -3.08 | -3.14 | -3.14 |
The HIV treatment satisfaction questionnaire (HIVTSQ) is based on a 10-item self-reported scale that measures overall satisfaction with treatment. The HIVTSQ items are summed up to produce a treatment satisfaction score (0 to 60) and an individual satisfaction rating for each item (0 to 6). The higher the score, the greater the treatment satisfaction. (NCT03227861)
Timeframe: Weeks 4, 24, and 48
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Week 4 | Week 24 | Week 48 | |
| D/C/F/TAF: Main Study | 56.52 | 57.87 | 57.88 |
Median medical costs of care (United States of America [USA] dollars) based on healthcare resource utilization [HRU]) were reported. The cost of care specified for overnight hospitalization, hospital day care ward (without overnight), emergency room visit, general practitioner visit, specialist visit, nurse practitioner visit, physician assistant visit and Other visit. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | USA dollars (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Overnight hospitalization | Hospital day care ward (without overnight) | Emergency room visit | General practitioner visit | Specialist visit | Nurse practitioner visit | Physician assistant visit | Other visit | |
| D/C/F/TAF: Main Study | 2035.0 | 341.0 | 212.0 | 142.0 | 94.0 | 66.0 | 47.0 | 148.0 |
Number of participants with outpatient visits (in addition to study visits, including General practitioner visit, Specialist visit, Nurse practitioner visit, Physician assistant visit, Home healthcare nurse visit and Other visit) was reported. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| General practitioner visit | Specialist visit | Nurse practitioner visit | Physician assistant visit | Home healthcare nurse visit | Other visit | |
| D/C/F/TAF: Main Study | 33 | 28 | 16 | 6 | 0 | 25 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| D/C/F/TAF: Main Study | 11.9 | 0.9 |
AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events. (NCT03227861)
Timeframe: Up to Week 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| D/C/F/TAF: Extension Study | 7.5 | 2.5 |
Percentage of participants experiencing grade 3 and 4 laboratory abnormalities was assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Event (AE) Grading Table. Abnormal laboratory values with Grade 3 or higher (3=Severe; 4=potentially life-threatening) signifies an interruption of usual daily activity, requiring systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT: Grade 3 | ALT: Grade 4 | AST: Grade 3 | AST: Grade 4 | Calcium: Grade 3 | Calcium: Grade 4 | Glucose: Grade 3 | Glucose: Grade 4 | Hyperbilirubinemia: Grade 3 | Hyperbilirubinemia: Grade 4 | Hypophosphatemia: Grade 3 | Hypophosphatemia: Grade 4 | Sodium: Grade 3 | Sodium: Grade 4 | Absolute Lymphocytes Count: Grade 3 | Absolute Lymphocytes Count: Grade 4 | Platelet Count: Grade 3 | Platelet Count: Grade 4 | |
| D/C/F/TAF: Main Study | 0 | 2.8 | 0.9 | 3.7 | 0 | 0.9 | 0.9 | 0 | 2.8 | 0 | 0.9 | 0 | 0 | 0.9 | 0.9 | 0.9 | 0 | 0.9 |
Percentage of participants experiencing grade 3 and 4 laboratory abnormalities were assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Event (AE) Grading Table. Abnormal laboratory values with Grade 3 or higher (3=Severe; 4=potentially life-threatening) signifies an interruption of usual daily activity, requiring systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable. (NCT03227861)
Timeframe: Up to Week 96
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Glucose: Grade 3 | Glucose: Grade 4 | Hypophosphatemia: Grade 3 | Hypophosphatemia: Grade 4 | |
| D/C/F/TAF: Extension Study | 2.5 | 0 | 1.3 | 0 |
Percentage of participants with 100 % adherence based on participants self-report, using a 4-Day recall at Weeks 4, 8, 12, 24, 36, and 48 was reported. (NCT03227861)
Timeframe: Weeks 4, 8, 12, 24, 36, and 48
| Intervention | Percentage of participants (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 24 | Week 36 | Week 48 | |
| D/C/F/TAF: Main Study | 99.76 | 99.50 | 99.02 | 98.04 | 99.49 | 99.48 |
Percentage of Participants with resistance-associated mutations present at baseline were reported and included mutations in the domain of PR, RT (including nucleoside reverse transcriptase inhibitor [NRTIs] and non-nucleoside/nucleotide reverse transcriptase inhibitor [NNRTIs]), INI, RAMs as determined by the GenoSure Prime assay. Genotypes were not available for 7 participants due to failed amplification of viral deoxyribo nucleic acid (DNA) (that is, low viral load (VL) [<500 copies/mL], reduced viral fitness, compromised sample collection/handling, primer incompatibility). (NCT03227861)
Timeframe: Baseline (Day 1)
| Intervention | Percentage of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Primary PI RAM | Secondary PI RAM | Darunavir RAM | Emtricitabine RAM | NNRTI RAM | Primary INI RAM | Secondary INI RAM | |
| D/C/F/TAF: Main Study | 4.9 | 98.0 | 0 | 2.0 | 27.5 | 0 | 4.9 |
Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA <1 log10 reduction from baseline, and HIV-1 RNA >= 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA <50 copies/mL, a rebound in HIV 1 RNA to >= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a >1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result. (NCT03227861)
Timeframe: Week 24 and 48
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 24 | Week 48 | |
| D/C/F/TAF: Main Study | 0 | 0 |
Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA <1 log10 reduction from baseline, and HIV-1 RNA >= 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA <50 copies/mL, a rebound in HIV 1 RNA to >= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a >1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result. (NCT03227861)
Timeframe: Weeks 72 and 96
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 72 | Week 96 | |
| D/C/F/TAF: Extension Study | 10.6 | 9.1 |
Percentage of participants with retention in care completed and with documented clinical visit (within 90 days of discontinuation) were reported. (NCT03227861)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Retention in care: Completed | Documented Clinical Visit | |
| D/C/F/TAF: Main Study | 63.6 | 85.7 |
Percentage of participants with treatment adherence >95% based on pill count at Weeks 4, 8, 12, 24, 36, and 48 were reported. Treatment adherence was defined as having a treatment adherence of greater than (>) 95 percent (%) by pill count. (NCT03227861)
Timeframe: Weeks 4, 8, 12, 24, 36, and 48
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| >95% at Week 4 | >95% at Week 8 | >95% at Week 12 | >95% at Week 24 | >95% at Week 36 | >95% at Week 48 | |
| D/C/F/TAF: Main Study | 83.5 | 84.5 | 79.4 | 76.5 | 75.8 | 65.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants who discontinued the treatment due to adverse events have been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) |
|---|---|
| DTG+3TC FDC (Early Switch) | 23 |
| TAF-based Regimen (Early Switch) | 7 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Number of participants who discontinued the treatment due to adverse events have been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| DTG+3TC FDC (Early Switch) | 13 |
| TAF Based Regimen (Early Switch) | 2 |
Percentage of participants with plasma HIV-1 RNA <50 c/mL was evaluated using FDA snapshot algorithm at Week 24. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Percentage values are rounded off. (NCT03446573)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| DTG+3TC FDC (Early Switch) | 95 |
| TAF Based Regimen (Early Switch) | 96 |
Percentage of participants with plasma HIV-1 RNA <50 c/mL (virologic success) was evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG +3TC once daily compared to continuation of TBR over 48 weeks. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. (NCT03446573)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| DTG+3TC FDC (Early Switch) | 93.2 |
| TAF Based Regimen (Early Switch) | 93.0 |
Percentage of participants with plasma HIV-1 RNA >=50 c/mL was evaluated using FDA snapshot algorithm at Week 24. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. (NCT03446573)
Timeframe: Week 24
| Intervention | Percentage of participants (Number) |
|---|---|
| DTG+3TC FDC (Early Switch) | 0.3 |
| TAF Based Regimen (Early Switch) | 0.8 |
Percentage of participants with virologic failure (plasma HIV-1 RNA >=50 c/mL) was evaluated using FDA snapshot algorithm at Week 48. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. Intent-to-treat exposed (ITT-E) Population comprises of all randomized participants who received at least one dose of study treatment either DTG + 3TC or TBR. Participants were assessed according to the treatment to which the participant was randomized. Any participant receiving a treatment randomization number was considered to be randomized. (NCT03446573)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| DTG+3TC FDC (Early Switch) | 0.3 |
| TAF Based Regimen (Early Switch) | 0.5 |
"Serum samples were collected for analysis of 25-hydroxyvitamin D. Baseline value was latest pre-dose assessment (Day 1) with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for treatment, visit, Baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, BMI (continuous), smoking status, vitamin D use, Baseline biomarker (continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor.One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Nanomoles per liter (Mean) | |
|---|---|---|
| Week 24, n=351, 355 | Week 48, n=344, 343 | |
| DTG+3TC FDC (Early Switch) | 0.0 | -5.8 |
| TAF Based Regimen (Early Switch) | 2.1 | -3.5 |
"Serum samples were collected for the analysis of 25-hydroxyvitamin D. Baseline value was the value from latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for serum 25-hydroxyvitamin D in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Nanomoles per liter (Number) |
|---|---|
| Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 2 |
"Serum samples were collected for analysis of 25-hydroxyvitamin D. Baseline value is latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Nanomoles per liter (Mean) | |
|---|---|---|
| Week 96, n=315, 291 | Week 144, n=315, 303 | |
| DTG+3TC FDC (Early Switch) | -11.5 | -7.5 |
| TAF Based Regimen (Early Switch) | -2.2 | -1.9 |
"Serum samples were collected for analysis of bone biomarkers. Baseline is latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Micrograms per liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Bone-ALP, Week 96, n=316, 289 | Bone-ALP, Week 144, n=314, 301 | Osteocalcin, Week 96, n=315 , 288 | Osteocalcin, Week 144, n=315, 301 | P1NP, Week 96, n=316 ,290 | P1NP, Week 144, n=315, 302 | CTX-1, Week 96 ,n=315, 289 | CTX-1, Week 48, n=315, 300 | |
| DTG+3TC FDC (Early Switch) | -0.62 | -0.27 | -1.97 | -0.74 | 6.7 | 3.9 | 0.0201 | 0.0022 |
| TAF Based Regimen (Early Switch) | -0.79 | -0.40 | -0.10 | 1.21 | 4.7 | 3.5 | 0.0050 | -0.0104 |
"Serum samples were collected for analysis of bone biomarkers. Baseline was latest pre-dose assessment with a non-missing value (Day 1) . Change from Baseline is post-dose visit value minus Baseline value. Change from Baseline in bone biomarkers-serum bone-specific ALP (Bone-ALP), osteocalcin, serum P1NP and serum CTX-1 in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Micrograms per liter (Number) | |||
|---|---|---|---|---|
| Bone-ALP, Week 24, n=1 | Osteocalcin, Week 24, n=1 | P1NP, Week24, n=1 | CTX-1, Week 24,n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0.3 | 13.4 | 11 | 0.045 |
"Serum samples were collected for analysis of bone biomarkers. Baseline was latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for treatment, visit, Baseline third agent class, CD4+ cell count (continuous), age (continuous), sex, race, body mass index (BMI) (continuous), smoking status, vitamin D use, Baseline biomarker (continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor.One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Micrograms per liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Bone-ALP, Week 24, n=350, 354 | Bone-ALP, Week 48, n=343, 342 | Osteocalcin, Week 24, n=350 ,353 | Osteocalcin, Week 48, n=343, 342 | P1NP, Week24, n=349 ,356 | P1NP, Week48, n=342, 343 | CTX-1, Week 24,n=350,356 | CTX-1, Week 48, n=343, 343 | |
| DTG+3TC FDC (Early Switch) | -0.77 | -0.03 | -1.08 | -1.15 | 7.0 | 9.3 | 0.0350 | 0.0602 |
| TAF-based Regimen (Early Switch) | -1.05 | -0.34 | 0.26 | 0.69 | 5.0 | 6.4 | -0.0031 | 0.0310 |
"CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the TBR (TAF-based regimen) arm as efficacy of TAF and TDF are comparable." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Cells per cubic millimeter (Median) | |
|---|---|---|
| Week 24, n=351, 359 | Week 48, n=344, 345 | |
| DTG+3TC FDC (Early Switch) | 21.0 | 22.5 |
| TAF Based Regimen (Early Switch) | 6.0 | 11.0 |
"CD4+ cells are a type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+and evaluated by flow cytometry. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the TBR (TAF-based regimen) arm as efficacy of TAF and TDF are comparable" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Cells per cubic millimeter (Median) | |
|---|---|---|
| Week 96, n=315, 295 | Week 144, n=309, 301 | |
| DTG+3TC FDC (Early Switch) | 61.0 | 36.0 |
| TAF-based Regimen (Early Switch) | 45.0 | 35.0 |
"Blood samples were collected at specified time points to assess CD4+/CD8+ cell count ratio. It was assessed by flow cyclometry to evaluate the immunologic activity of switching to DTG+3TC once daily compared to continuation of TBR over 48 Weeks. Baseline (Day 1) values were the actual CD4+ cell count ratio values at pre-dose Day 1. Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the TBR (TAF-based regimen) arm as efficacy of TAF and TDF are comparable ." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Ratio (Median) | |
|---|---|---|
| Week 24, n=346, 358 | Week 48, n=342, 343 | |
| DTG+3TC FDC (Early Switch) | 0.010 | 0.030 |
| TAF Based Regimen (Early Switch) | 0.040 | 0.050 |
"Blood samples were collected at specified time points to assess CD4+/CD8+ cell count ratio and were evaluated by flow cyclometry to evaluate the immunologic activity of switching to DTG+3TC once daily compared to continuation of TBR over Weeks 96 and 144. Baseline (Day 1) values are the actual CD4+ cell count ratio values at pre-dose Day 1. Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and was presented within the TBR (TAF-based regimen) arm as efficacy of TAF and TDF are comparable" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Ratio (Median) | |
|---|---|---|
| Week 96, n=312, 292 | Week 144, n=307, 300 | |
| DTG+3TC FDC (Early Switch) | 0.035 | 0.060 |
| TAF-based Regimen (Early Switch) | 0.080 | 0.100 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset. Baseline was the latest pre-dose assessment value with a non-missing value (Day 1) and change from Baseline is defined as post-dose value minus Baseline value. (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| DTG+3TC FDC (Early Switch) | 1.2 | 1.1 |
| TAF Based Regimen (Early Switch) | 1.3 | 1.7 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Week 96, n=364, 369 | Week 144, n=364, 368 | |
| DTG+3TC FDC (Early Switch) | 0.7 | 0.2 |
| TAF Based Regimen (Early Switch) | 1.9 | 1.4 |
EQ-5D-5L questionnaire provides profile of participant function and global health state rating. Five-item measure has 1question assessing each of 5dimensions:mobility,self-care,usual activities,pain/discomfort,anxiety/depression and 5 levels for each dimension including 1=no problems,2=slight problems,3=moderate problems,4=severe problems,5=extreme problems. Health state is defined by combining levels of answers from each of 5 questions. Each health state is referred to in terms of a 5 digit code.Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state.EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health.Baseline is latest pre-dose assessment value with a non-missing value (Day 1).Change from Baseline is post-dose visit value minus Baseline value. (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Week 96, n=364, 370 | Week 144, n=364, 369 | |
| DTG+3TC FDC (Early Switch) | -0.0036 | -0.0151 |
| TAF Based Regimen (Early Switch) | -0.0038 | -0.0042 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Scores on a scale (Mean) | |
|---|---|---|
| Week 24 | Week 48 | |
| DTG+3TC FDC (Early Switch) | 0.0029 | 0.0037 |
| TAF Based Regimen (Early Switch) | 0.0046 | 0.0023 |
"Blood samples were collected at Baseline (Day 1), Week 24 and Week 48 to assess fasting lipids which included plasma cholesterol, plasma LDL cholesterol, plasma high density lipoprotein (HDL) cholesterol and plasma triglycerides. Baseline value was the value from the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Millimoles per liter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Plasma cholesterol, Week 24, n=282, 264 | Plasma cholesterol, Week 48, n=275, 263 | Plasma LDL Cholesterol, Week 24, n=282, 264 | Plasma LDL Cholesterol, Week 48, n=275, 263 | Plasma Triglycerides, Week 24, n=282, 264 | Plasma Triglycerides, Week 48, n=275, 263 | Plasma HDL Cholesterol, Week 24, n=282, 264 | Plasma HDL Cholesterol, Week 48, n=275, 263 | |
| DTG+3TC FDC (Early Switch) | -0.325 | -0.200 | -0.210 | -0.170 | -0.100 | -0.100 | -0.050 | 0.000 |
| TAF Based Regimen (Early Switch) | 0.000 | 0.100 | -0.060 | 0.070 | 0.060 | 0.100 | 0.050 | 0.050 |
"Blood samples were collected at Baseline (Day 1), weeks 24 and 48 visit (participant withdrew from the study at Week 36) to assess fasting lipids which included plasma cholesterol, plasma LDL cholesterol, plasma HDL cholesterol and plasma triglycerides. Baseline value was the value from the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for fasting lipids in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Millimoles per liter (Number) | |||
|---|---|---|---|---|
| Plasma cholesterol, Week 24, n=1 | Plasma LDL Cholesterol, Week 24, n=1 | Plasma Triglycerides, Week 24, n=1 | Plasma HDL Cholesterol, Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | -0.67 | 1.36 | 0.05 |
"Blood samples were collected at Baseline (Day 1), Weeks 96 and 144 to assess fasting lipids which includes plasma cholesterol, plasma LDL cholesterol, plasma HDL cholesterol and plasma triglycerides. Baseline value is the value from the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Millimoles per liter (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Plasma cholesterol, Week 96, n=238, 213 | Plasma cholesterol, Week 144, n=243, 230 | Plasma LDL Cholesterol, Week 96, n=238, 213 | Plasma LDL Cholesterol, Week 144, n=243, 230 | Plasma Triglycerides, Week 96, n=238, 213 | Plasma Triglycerides, Week 144, n=243, 230 | Plasma HDL Cholesterol, Week 96, n=238, 213 | Plasma HDL Cholesterol, Week 144, n=243, 230 | |
| DTG+3TC FDC (Early Switch) | -3.7 | -4.0 | -5.6 | -5.0 | -2.1 | -9.4 | -3.8 | -3.8 |
| TAF Based Regimen (Early Switch) | 1.2 | 3.8 | 1.7 | 4.2 | 4.9 | 2.2 | 0.0 | 3.8 |
"Serum samples assessed: renal inflammation biomarker serum creatinine.Baseline(Day 1)was value from latest pre-dose assessment with non-missing value. Change from Baseline is post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit, Baseline third agent class, CD4+ cell count(continuous), age(continuous), sex, race, BMI(continuous), presence of diabetes mellitus, presence of hypertension, Baseline biomarker(continuous), treatment by visit interaction, Baseline value by visit interaction, with visit as repeated factor. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Micromoles per liter (Mean) | |
|---|---|---|
| Week 24, n=351, 359 | Week 48, n=344, 345 | |
| DTG+3TC FDC (Early Switch) | 7.47 | 6.67 |
| TAF Based Regimen (Early Switch) | 3.11 | 2.18 |
"Serum samples were collected at Baseline, Week 24 and Week 48 to assess renal inflammation biomarker - serum creatinine. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline in serum creatinine in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Micromoles per liter (Number) |
|---|---|
| Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | -8 |
"Serum samples were collected to assess renal inflammation biomarker - serum creatinine. Baseline is defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Micromoles per liter (Mean) | |
|---|---|---|
| Week 96, n=316, 294 | Week 144, n=311, 302 | |
| DTG+3TC FDC (Early Switch) | 5.53 | 9.25 |
| TAF-based Regimen (Early Switch) | 0.58 | 5.17 |
"Serum samples were collected to assess renal biomarker. Baseline was latest pre-dose assessment value with non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. Adjusted mean and its corresponding standard error has been presented. Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for following:treatment, visit, Baseline third agent class, CD4+ cell count(continuous), age(continuous), sex, race, BMI(continuous), presence of diabetes mellitus, presence of hypertension, Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Milligrams per liter (Mean) | |
|---|---|---|
| Week 24, n=351, 357 | Week 48, n=344, 343 | |
| DTG+3TC FDC (Early Switch) | -0.03 | 0.00 |
| TAF Based Regimen (Early Switch) | -0.02 | 0.01 |
"Serum samples were collected at Baseline, Week 24 and Week 48 to assess renal inflammation biomarker - cystatin C. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline values for serum cystatin -C biomarker in TDF based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Milligrams per liter (Number) |
|---|---|
| Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 |
"Serum samples were collected to assess renal biomarker. Baseline is latest pre-dose assessment value with non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Milligrams per liter (Mean) | |
|---|---|---|
| Week 96, n=316, 290 | Week 144, n=315, 302 | |
| DTG+3TC FDC (Early Switch) | 0.07 | 0.13 |
| TAF-based Regimen (Early Switch) | 0.10 | 0.14 |
"Serum samples assessed:serum GFR from cystatin C and from creatinine adjusted using CKD-EPI Baseline(Day 1) was value from latest pre-dose assessment with non-missing value. Change from Baseline is post-dose visit value minus Baseline value.Adjusted mean and standard error is presented.Adjusted mean was estimated mean change from Baseline at each visit in each arm calculated from repeated measures model adjusting for treatment, visit, Baseline third agent class,CD4+ cell count(continuous),age(continuous), sex, race, BMI(continuous),presence of diabetes mellitus, presence of hypertension, Baseline biomarker(continuous), treatment by visit interaction, and Baseline value by visit interaction, with visit as repeated factor. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Milliliters/minute/1.73*meter square (Mean) | |||
|---|---|---|---|---|
| GFR from cystatin C CKD-EPI, Week 24, n=351, 357 | GFR from cystatin C CKD-EPI, Week 48, n=344, 343 | GFR from creatinine CKD-EPI, Week 24, n=351, 359 | GFR from creatinine CKD-EPI, Week 48, n=344, 345 | |
| DTG+3TC FDC (Early Switch) | 3.2 | 0.1 | -8.8 | -7.7 |
| TAF Based Regimen (Early Switch) | 1.5 | -1.6 | -3.8 | -2.9 |
"Serum samples were collected at Baseline, Week 24 and Week 48 to assess renal inflammation biomarkers - serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI. Baseline was defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Change from Baseline in serum GFR from cystatin C adjusted using CKD-EPI and serum GFR from creatinine adjusted using CKD-EPI in TDF-based regimen participants has been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 24 and 48
| Intervention | Milliliters/minute/1.73*meter square (Number) | |
|---|---|---|
| GFR from cystatin C CKD-EPI, Week 24, n=1 | GFR from creatinine CKD-EPI, Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | 4 |
"Serum samples were collected to assess serum GFR from cystatin C and from creatinine adjusted for BSA. Baseline is defined as the latest pre-dose assessment value with a non-missing value (Day 1). Change from Baseline is post-dose visit value minus Baseline value. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Milliliters/minute/1.73*meter square (Mean) | |||
|---|---|---|---|---|
| GFR from cystatin C CKD-EPI, Week 96, n=316, 290 | GFR from cystatin C CKD-EPI, Week 144, n=315, 302 | GFR from creatinine adjusted for BSA, Week 96, n=315, 294 | GFR from creatinine adjusted for BSA, Week 144, n=311, 300 | |
| DTG+3TC FDC (Early Switch) | -7.6 | -13.9 | -7.2 | -11.5 |
| TAF Based Regimen (Early Switch) | -11.7 | -15.8 | -1.9 | -7.0 |
"Urine samples were collected at Baseline, Week 24 and Week 48 to assess renal biomarkers - urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline was defined as the latest pre-dose assessment value with a non-missing value. (Day 1). Change from Baseline in UA/C was calculated as UA/C ratio at post-Baseline visit minus UA/C ratio calculated at Baseline. Change from Baseline in UP/C was calculated as UP/C ratio at post-Baseline visit minus UP/C ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Number) | |
|---|---|---|
| UA/C, Week 24, n=1 | UP/C, Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | 0.3 |
"Urine samples were collected at Baseline, Weeks 96 and 144. Baseline is defined as Day 1. Change from Baseline in UA/C is defined as UA/C ratio at post-Baseline visit minus UA/C ratio at Baseline. Change from Baseline in UP/C and UA/C is defined as UP/C and UA/C ratio at post-Baseline visit minus UP/C and UA/C ratio at Baseline, respectively. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Ratio (Geometric Mean) | |||
|---|---|---|---|---|
| UA/C, Week 96, n=208, 175 | UA/C, Week 144, n=202, 179 | UP/C, Week 96, n=245, 206 | UP/C, Week 144, n=237, 220 | |
| DTG+3TC FDC (Early Switch) | 1.058 | 1.203 | 1.048 | 1.182 |
| TAF-based Regimen (Early Switch) | 1.075 | 1.200 | 1.105 | 1.188 |
"Urine samples were collected at Baseline, Week 24 and Week 48. Baseline is defined as Day 1. Change from Baseline in UA/C was calculated as UA/C ratio at post-Baseline visit minus UA/C ratio calculated at Baseline. Estimated geometric mean adjusted ratio (each visit over Baseline) and 95% CI have been presented. Change from Baseline in UP/C and UA/C was calculated as UP/C and UA/C ratio at post-Baseline visit minus UP/C and UA/C ratio calculated at Baseline, respectively. Estimated geometric mean adjusted ratio (each visit over Baseline) and 95% CI have been presented. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Geometric Mean) | |||
|---|---|---|---|---|
| UA/C, Week 24, n=235, 230 | UA/C, Week 48, n=230, 224 | UP/C, Week 24, n=267, 261 | UP/C, Week 48, n=261, 257 | |
| DTG+3TC FDC (Early Switch) | 1.080 | 1.125 | 0.955 | 0.971 |
| TAF Based Regimen (Early Switch) | 1.022 | 1.059 | 0.976 | 1.016 |
"Urine biomarker samples were collected at Baseline, Weeks 24 and 48 to assess urine beta-2 microglobulin/urine creatinine. Geometric mean ratio (visit divided by Baseline) and 95% CI of geometric mean ratio has been presented. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine beta-2-microglobulin/urine creatinine was calculated as urine beta-2-microglobulin/urine creatinine ratio at post-Baseline visit minus urine beta-2-microglobulin/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 24, n=136, 141 | Week 48, n=126, 141 | |
| DTG+3TC FDC (Early Switch) | 0.991 | 0.973 |
| TAF Based Regimen (Early Switch) | 1.034 | 0.922 |
"Urine biomarker samples were collected at Baseline, Weeks 96 and 144 to assess urine beta-2 microglobulin/urine creatinine. Baseline (Day 1) value is the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine beta-2-microglobulin/urine creatinine is defined as urine beta-2-microglobulin/urine creatinine ratio at post-Baseline visit minus urine beta-2-microglobulin/urine creatinine ratio at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 96, n=109, 107 | Week 144, n=101, 97 | |
| DTG+3TC FDC (Early Switch) | 1.080 | 0.904 |
| TAF-based Regimen (Early Switch) | 0.986 | 0.958 |
"Urine biomarker samples were collected at Baseline and at Weeks 24 and 48 to assess urine phosphate. Geometric mean ratio (visit divided by Baseline) and 95% CI of geometric mean ratio has been presented. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine phosphate was calculated as urine phosphate at post-Baseline visit minus urine phosphate calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 24, n=348, 352 | Week 48, n=342, 340 | |
| DTG+3TC FDC (Early Switch) | 0.955 | 0.969 |
| TAF Based Regimen (Early Switch) | 0.940 | 0.970 |
"Urine biomarker samples were collected to assess urine phosphate. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine phosphate was calculated as urine phosphate at post-Baseline visit minus urine phosphate calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Number) |
|---|---|
| Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 2.9 |
"Urine biomarker samples were collected at Baseline, Weeks 96 and 144 to assess urine phosphate. Baseline (Day 1) value is the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine phosphate is defined as urine phosphate at post-Baseline visit minus urine phosphate at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 96, n=312, 286 | Week 144, n=313, 298 | |
| DTG+3TC FDC (Early Switch) | 0.960 | 0.890 |
| TAF Based Regimen (Early Switch) | 0.978 | 0.912 |
"Urine biomarker samples were collected at Baseline, Weeks 24 and 48 to assess urine retinol binding protein 4/urine creatinine. Geometric mean ratio (visit divided by Baseline) and 95% CI of geometric mean ratio has been presented. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in Urine retinol binding protein 4/urine creatinine ratio was calculated as Urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus Urine retinol binding protein 4/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 24, n=344, 343 | Week 48, n=340, 335 | |
| DTG+3TC FDC (Early Switch) | 0.860 | 1.063 |
| TAF Based Regimen (Early Switch) | 0.920 | 1.068 |
"Urine biomarker samples were collected to assess urine retinol binding protein 4/urine creatinine. Baseline (Day 1) value was the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in urine retinol binding protein 4/urine creatinine was calculated as urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus urine retinol binding protein 4/urine creatinine ratio calculated at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen." (NCT03446573)
Timeframe: Baseline (Day 1) and at weeks 24 and 48
| Intervention | Ratio (Number) |
|---|---|
| Week 24, n=1 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 1.04 |
"Urine biomarker samples were collected at Baseline, Weeks 96 and 144 to assess urine retinol binding protein 4/urine creatinine. Baseline (Day 1) value is the value from the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline in Urine retinol binding protein 4/urine creatinine ratio is defined as Urine retinol binding protein 4/urine creatinine ratio at post-Baseline visit minus Urine retinol binding protein 4/urine creatinine ratio at Baseline. One participant randomized to TBR but received TDF-based regimen and because the safety profiles of TDF and TAF differ, this participant was removed from the overall safety population and is presented in separate arm Randomized to TBR but received TDF-based regimen" (NCT03446573)
Timeframe: Baseline (Day 1) and at Weeks 96 and 144
| Intervention | Ratio (Geometric Mean) | |
|---|---|---|
| Week 96, n=310, 282 | Week 144, n=304, 288 | |
| DTG+3TC FDC (Early Switch) | 0.926 | 1.188 |
| TAF Based Regimen (Early Switch) | 0.851 | 1.227 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of TDF-based regimen participants with adverse events by maximum grade have been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | 1 | 0 | 0 | 0 |
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment . Number of TDF-based regimen participants with any SAE and common (>=2%) non-SAEs are presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any non-SAE (>=2%) | Any SAE | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 1 | 0 |
samples were collected up to the Week 36 visit for the analysis of clinical chemistry parameters: alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase (CK), creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted using chronic kidney disease-epidemiology collaboration (CKD-EPI), GFR from cystatin C adjusted using CKD-EPI, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol, phosphate and triglycerides. Any abnormality in clinical chemistry parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. (NCT03446573)
Timeframe: Up to Week 36
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Albumin, Grade 1 | Albumin, Grade 2 | Albumin, Grade 3 | Albumin, Grade 4 | ALP, Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | AST, Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Bilirubin, Grade 1 | Bilirubin, Grade 2 | Bilirubin, Grade 3 | Bilirubin, Grade 4 | CO2, Grade 1 | CO2, Grade 2 | CO2, Grade 3 | CO2, Grade 4 | Cholesterol, Grade 1 | Cholesterol, Grade 2 | Cholesterol, Grade 3 | Cholesterol, Grade 4 | CK, Grade 1 | CK, Grade 2 | CK, Grade 3 | CK, Grade 4 | Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Direct bilirubin, Grade 1 | Direct bilirubin, Grade 2 | Direct bilirubin, Grade 3 | Direct bilirubin, Grade 4 | GFR from creatinine adjusted using CKD EPI,Grade 1 | GFR from creatinine adjusted using CKD EPI,Grade 2 | GFR from creatinine adjusted using CKD EPI,Grade 3 | GFR from creatinine adjusted using CKD EPI,Grade 4 | GFR from cystatin C adjusted using CKD-EPI,Grade 1 | GFR from cystatin C adjusted using CKD-EPI,Grade 2 | GFR from cystatin C adjusted using CKD-EPI,Grade 3 | GFR from cystatin C adjusted using CKD-EPI,Grade 4 | Hypercalcemia, Grade 1 | Hypercalcemia, Grade 2 | Hypercalcemia, Grade 3 | Hypercalcemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hypocalcemia, Grade 1 | Hypocalcemia, Grade 2 | Hypocalcemia, Grade 3 | Hypocalcemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | LDL cholesterol, Grade 1 | LDL cholesterol, Grade 2 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Phosphate, Grade 1 | Phosphate, Grade 2 | Phosphate, Grade 3 | Phosphate, Grade 4 | Triglycerides, Grade 1 | Triglycerides, Grade 2 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Blood samples were collected up to the Week 36 visit for the analysis of hematology parameters-platelet count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters were evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. Only those TDF-based regimen participants with maximum post-Baseline emergent hematology toxicities in any of the hematology parameters have been presented. (NCT03446573)
Timeframe: Up to Week 36
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Leukocytes, Grade 1 | Leukocytes, Grade 2 | Leukocytes, Grade 3 | Leukocytes, Grade 4 | Neutrophils, Grade 1 | Neutrophils, Grade 2 | Neutrophils, Grade 3 | Neutrophils, Grade 4 | Platelets, Grade 1 | Platelets, Grade 2 | Platelets, Grade 3 | Platelets, Grade 4 | |
| Randomized to TBR But Received TDF-based Regimen (Early Switch) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| DTG+3TC FDC (Early Switch) | 57 | 217 | 50 | 9 | 3 |
| TAF Based Regimen (Early Switch) | 65 | 208 | 54 | 8 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| DTG+3TC FDC (Early Switch) | 102 | 170 | 19 | 3 | 1 |
| TAF Based Regimen (Early Switch) | 94 | 177 | 15 | 6 | 0 |
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment (NCT03446573)
Timeframe: Up to Week 148
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any non-SAE (>=2%) | Any SAE | |
| DTG+3TC FDC (Early Switch) | 307 | 57 |
| TAF-based Regimen (Early Switch) | 304 | 44 |
An AE is any untoward medical occurrence temporally associated with the use of a study treatment, whether or not considered related to study treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other important medical event as per medical or scientific judgment . Safety Population included all participants who received at least one dose of study treatment either DTG + 3TC or TBR. This population was based on the treatment the participant actually received. Number of participants with any SAE and common (>=2%) non-SAEs are presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any non-SAE (>=2%) | Any SAE | |
| DTG+3TC FDC (Early Switch) | 222 | 21 |
| TAF Based Regimen (Early Switch) | 204 | 16 |
HIV-associated conditions were recorded during the study and were assessed according to the 2014 CDC Classification System for HIV Infection in Adults. CDC classification for HIV were: Stage 1: No AIDS defining condition and CD4+ T-lymphocyte count: >=500 cells/mcL; Stage 2: No AIDS infection and CD4+ lymphocyte count: 200-499 cell/mcL and Stage 3:Documented AIDS defining condition or CD4+ T-lymphocye count <200 cells/mcL. Disease progression summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrollment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrollment to Death. (NCT03446573)
Timeframe: At Weeks 24 and 48
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| From CDC Stage 1 to CDC Stage 3 Event | From CDC Stage 2 to CDC Stage 3 Event | From CDC Stage 3 to new CDC Stage 3 Event | From CDC Stage 1, 2 or 3 to Death | No HIV-1 disease progression | |
| DTG+3TC FDC (Early Switch) | 1 | 0 | 0 | 1 | 367 |
| TAF Based Regimen (Early Switch) | 0 | 0 | 0 | 0 | 372 |
HIV-associated conditions were recorded during the study and assessed according to the 2014 CDC Classification System for HIV Infection in Adults. CDC classification for HIV is: Stage 1: No AIDS defining condition and CD4+ T-lymphocyte count: >=500 cells/mcL; Stage 2: No AIDS infection and CD4+ lymphocyte count: 200-499 cell/mcL and Stage 3: Documented AIDS-defining condition or CD4+ T-lymphocye count <200 cells/mcL. Indicators of clinical disease progression is defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrollment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrollment to Death. (NCT03446573)
Timeframe: At Weeks 96 and 144
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 96, From CDC Stage 1 to CDC Stage 3 Event | Week 96, From CDC Stage 2 to CDC Stage 3 Event | Week 96, From CDC Stage 3 to new CDC Stage 3 Event | Week 96, From CDC Stage 1, 2 or 3 to Death | Week 96, No HIV-1 disease progression | Week 144, From CDC Stage 1 to CDC Stage 3 Event | Week 144, From CDC Stage 2 to CDC Stage 3 Event | Week 144,From CDC Stage 3 to new CDC Stage 3 Event | Week 144, From CDC Stage 1, 2 or 3 to Death | Week 144, No HIV-1 disease progression | |
| DTG+3TC FDC (Early Switch) | 2 | 0 | 0 | 2 | 365 | 2 | 0 | 0 | 3 | 364 |
| TAF-based Regimen (Early Switch) | 0 | 0 | 0 | 0 | 372 | 0 | 1 | 0 | 0 | 371 |
Plasma samples were collected for drug resistance testing. Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with genotypic resistance to INSTI, NRTI, NNRTI and PI are summarized. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INSTI | NRTI | NNRTI | PI | |
| TAF Based Regimen (Early Switch) | 0 | 0 | 0 | 0 |
Plasma samples were collected for drug resistance testing. Number of participants, who met confirmed virologic withdrawal (CVW) criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with genotypic resistance to INSTI, nucleoside reverse transcriptase inhibitor (NRTI), NNRTI and PI was summarized. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INSTI | NRTI | NNRTI | PI | |
| TAF Based Regimen (Early Switch) | 0 | 0 | 0 | 0 |
Blood samples were collected up to Week 144 for the analysis of clinical chemistry parameters: ALT, albumin, ALP, AST, bilirubin, CO2, cholesterol, CK, creatinine, direct bilirubin, GFR from creatinine adjusted for BSA, GFR from cystatin C adjusted using CKD-EPI, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, LDL cholesterol, phosphate triglycerides and lactate dehydrogenase. Any abnormality in clinical chemistry parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Albumin, Grade 1 | Albumin, Grade 2 | Albumin, Grade 3 | Albumin, Grade 4 | ALP, Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | AST, Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Bilirubin, Grade 1 | Bilirubin, Grade 2 | Bilirubin, Grade 3 | Bilirubin, Grade 4 | CO2, Grade 1 | CO2, Grade 2 | CO2, Grade 3 | CO2, Grade 4 | Cholesterol, Grade 1 | Cholesterol, Grade 2 | Cholesterol, Grade 3 | Cholesterol, Grade 4 | CK, Grade 1 | CK, Grade 2 | CK, Grade 3 | CK, Grade 4 | Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Direct bilirubin, Grade 1 | Direct bilirubin, Grade 2 | Direct bilirubin, Grade 3 | Direct bilirubin, Grade 4 | GFR from creatinine adjusted using CKD EPI,Grade 1 | GFR from creatinine adjusted using CKD EPI,Grade 2 | GFR from creatinine adjusted using CKD EPI,Grade 3 | GFR from creatinine adjusted using CKD EPI,Grade 4 | GFR from cystatin C adjusted using CKD-EPI,Grade 1 | GFR from cystatin C adjusted using CKD-EPI,Grade 2 | GFR from cystatin C adjusted using CKD-EPI,Grade 3 | GFR from cystatin C adjusted using CKD-EPI,Grade 4 | Hypercalcemia, Grade 1 | Hypercalcemia, Grade 2 | Hypercalcemia, Grade 3 | Hypercalcemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hypocalcemia, Grade 1 | Hypocalcemia, Grade 2 | Hypocalcemia, Grade 3 | Hypocalcemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | LDL cholesterol, Grade 1 | LDL cholesterol, Grade 2 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Phosphate, Grade 1 | Phosphate, Grade 2 | Phosphate, Grade 3 | Phosphate, Grade 4 | Triglycerides, Grade 1 | Triglycerides, Grade 2 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | Lactate Dehydrogenase Grade 1 | Lactate Dehydrogenase Grade 2 | Lactate Dehydrogenase Grade 3 | Lactate Dehydrogenase Grade 4 | |
| DTG+3TC FDC (Early Switch) | 55 | 11 | 5 | 0 | 1 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 34 | 13 | 3 | 3 | 24 | 9 | 3 | 0 | 110 | 2 | 1 | 0 | 42 | 26 | 1 | 0 | 41 | 12 | 12 | 10 | 21 | 5 | 1 | 0 | 0 | 0 | 13 | 0 | 0 | 165 | 38 | 0 | 0 | 169 | 46 | 1 | 8 | 0 | 0 | 0 | 73 | 40 | 4 | 0 | 3 | 2 | 0 | 0 | 4 | 1 | 0 | 0 | 14 | 1 | 0 | 0 | 9 | 4 | 0 | 0 | 10 | 3 | 1 | 0 | 21 | 0 | 0 | 0 | 41 | 19 | 8 | 0 | 61 | 3 | 0 | 0 | 60 | 6 | 6 | 4 | 0 | 0 | 0 | 0 |
| TAF Based Regimen (Early Switch) | 49 | 9 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 45 | 9 | 0 | 3 | 12 | 4 | 1 | 0 | 97 | 4 | 0 | 0 | 70 | 34 | 2 | 0 | 30 | 13 | 12 | 10 | 12 | 2 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 101 | 24 | 1 | 0 | 183 | 58 | 1 | 9 | 0 | 0 | 0 | 77 | 31 | 4 | 0 | 2 | 1 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 2 | 0 | 0 | 10 | 3 | 0 | 0 | 7 | 0 | 0 | 0 | 26 | 2 | 0 | 0 | 56 | 24 | 9 | 0 | 71 | 9 | 0 | 0 | 77 | 15 | 5 | 2 | 1 | 0 | 0 | 0 |
Blood samples were collected up to Week 48 for the analysis of clinical chemistry parameters: alanine aminotransferase (ALT), albumin, alkaline phosphate (ALP), aspartate aminotransferase (AST), bilirubin, carbon dioxide (CO2), cholesterol, creatinine kinase (CK), creatinine, direct bilirubin, glomerular filtration rate (GFR) from creatinine adjusted for body surface area (BSA), GFR from cystatin C adjusted using chronic kidney disease-epidemiology collaboration (CKD-EPI), hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol, phosphate and triglycerides. Any abnormality in clinical chemistry parameters were evaluated according to the DAIDS toxicity scale From Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Albumin, Grade 1 | Albumin, Grade 2 | Albumin, Grade 3 | Albumin, Grade 4 | ALP, Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | AST, Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Bilirubin, Grade 1 | Bilirubin, Grade 2 | Bilirubin, Grade 3 | Bilirubin, Grade 4 | CO2, Grade 1 | CO2, Grade 2 | CO2, Grade 3 | CO2, Grade 4 | Cholesterol, Grade 1 | Cholesterol, Grade 2 | Cholesterol, Grade 3 | Cholesterol, Grade 4 | CK, Grade 1 | CK, Grade 2 | CK, Grade 3 | CK, Grade 4 | Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Direct bilirubin, Grade 1 | Direct bilirubin, Grade 2 | Direct bilirubin, Grade 3 | Direct bilirubin, Grade 4 | GFR from creatinine adjusted using CKD EPI,Grade 1 | GFR from creatinine adjusted using CKD EPI,Grade 2 | GFR from creatinine adjusted using CKD EPI,Grade 3 | GFR from creatinine adjusted using CKD EPI,Grade 4 | GFR from cystatin C adjusted using CKD-EPI,Grade 1 | GFR from cystatin C adjusted using CKD-EPI,Grade 2 | GFR from cystatin C adjusted using CKD-EPI,Grade 3 | GFR from cystatin C adjusted using CKD-EPI,Grade 4 | Hypercalcemia, Grade 1 | Hypercalcemia, Grade 2 | Hypercalcemia, Grade 3 | Hypercalcemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hypocalcemia, Grade 1 | Hypocalcemia, Grade 2 | Hypocalcemia, Grade 3 | Hypocalcemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | LDL cholesterol, Grade 1 | LDL cholesterol, Grade 2 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Phosphate, Grade 1 | Phosphate, Grade 2 | Phosphate, Grade 3 | Phosphate, Grade 4 | Triglycerides, Grade 1 | Triglycerides, Grade 2 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | |
| DTG+3TC FDC (Early Switch) | 24 | 6 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 21 | 7 | 1 | 1 | 17 | 5 | 1 | 0 | 73 | 1 | 0 | 0 | 27 | 12 | 1 | 0 | 28 | 4 | 9 | 6 | 16 | 3 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 135 | 26 | 0 | 0 | 52 | 5 | 1 | 7 | 0 | 0 | 0 | 56 | 21 | 2 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 5 | 3 | 0 | 0 | 7 | 1 | 0 | 0 | 8 | 0 | 0 | 0 | 28 | 13 | 6 | 0 | 38 | 2 | 0 | 0 | 34 | 4 | 4 | 4 |
| TAF Based Regimen (Early Switch) | 18 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 4 | 0 | 0 | 7 | 2 | 1 | 0 | 70 | 1 | 0 | 0 | 52 | 19 | 0 | 0 | 19 | 9 | 8 | 5 | 7 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 83 | 13 | 0 | 0 | 66 | 4 | 0 | 3 | 0 | 0 | 0 | 64 | 19 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 6 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 13 | 2 | 0 | 0 | 35 | 15 | 3 | 0 | 47 | 7 | 0 | 0 | 48 | 11 | 4 | 0 |
Blood samples were collected up to Week 144 for the analysis of hematology parameters-platelet count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters are were evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Leukocytes, Grade 1 | Leukocytes, Grade 2 | Leukocytes, Grade 3 | Leukocytes, Grade 4 | Neutrophils, Grade 1 | Neutrophils, Grade 2 | Neutrophils, Grade 3 | Neutrophils, Grade 4 | Platelets, Grade 1 | Platelets, Grade 2 | Platelets, Grade 3 | Platelets, Grade 4 | |
| DTG+3TC FDC (Early Switch) | 7 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 5 | 3 | 0 | 2 | 8 | 2 | 0 | 0 |
| TAF Based Regimen (Early Switch) | 2 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 5 | 8 | 0 | 2 | 7 | 1 | 0 | 0 |
Blood samples were collected up to Week 48 for the analysis of hematology parameters-platelet count, neutrophils, hemoglobin and leukocytes. Any abnormality in hematology parameters were evaluated according to the DAIDS toxicity scale from Grade 1 to 4: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Potentially life-threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the hematology parameters have been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Leukocytes, Grade 1 | Leukocytes, Grade 2 | Leukocytes, Grade 3 | Leukocytes, Grade 4 | Neutrophils, Grade 1 | Neutrophils, Grade 2 | Neutrophils, Grade 3 | Neutrophils, Grade 4 | Platelets, Grade 1 | Platelets, Grade 2 | Platelets, Grade 3 | Platelets, Grade 4 | |
| DTG+3TC FDC (Early Switch) | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 2 | 0 | 1 | 6 | 1 | 0 | 0 |
| TAF Based Regimen (Early Switch) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 5 | 1 | 0 | 0 |
Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with phenotypic resistance to INSTI,NNRT,NRTI and PI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences), which provided the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The phenotypic resistance was calculated using binary scoring system, where 0 was considered as sensitive and 1 as resistance. Phenotypic Resistance data for the following INSTI, NNRTI, NRTI and PI drugs in participants Meeting CVW Criteria has been presented. (NCT03446573)
Timeframe: Up to Week 144
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSTI, DTG, Sensitive | INSTI, DTG, Resistant | INSTI, Bictegravir (BIC), Sensitive | INSTI, BIC, Resistant | INSTI, Elvitegravir (EVG), Sensitive | INSTI, EVG, Resistant | INSTI, Raltegravir (RAL), Sensitive | INSTI, RAL, Resistant | NNRTI, Delavirdine (DLV), Sensitive | NNRTI, DLV, Resistant | NNRTI, Efavirenz (EFV), Sensitive | NNRTI, EFV, Resistant | NNRTI, Etravirine (ETR), Sensitive | NNRTI, ETR, Resistant | NNRTI, Nevirapine (NVP), Sensitive | NNRTI, NVP, Resistant | NNRTI, Rilpivirine (RPV), Sensitive | NNRTI, RPV, Resistant | NRTI, 3TC, Sensitive | NRTI, 3TC, Resistant | NRTI, Abacavir (ABC), Sensitive | NRTI, ABC, Resistant | NRTI, Zidovudine (AZT), Sensitive | NRTI, AZT, Resistant | NRTI, Stavudine (D4T), Sensitive | NRTI, D4T, Resistant | NRTI, Didanosine (DDI), Sensitive | NRTI, DDI, Resistant | NRTI, Emtricitabine (FTC), Sensitive | NRTI, FTC, Resistant | NRTI, Tenofovir (TDF), Sensitive | NRTI, TDF, Resistant | PI, Atazanavir (ATV), Sensitive | PI, ATV, Resistant | PI, Darunavir (DRV), Sensitive | PI, DRV, Resistant | PI, Fosamprenavir (FPV), Sensitive | PI, FPV, Resistant | PI, Indinavir (IDV), Sensitive | PI, IDV, Resistant | PI, Lopinavir (LPV), Sensitive | PI, LPV, Resistant | PI, Nelfinavir (NFV), Sensitive | PI, NFV, Resistant | PI, Ritonavir (RTV), Sensitive | PI, RTV, Resistant | PI, Saquinavir (SQV), Sensitive | PI, SQV, Resistant | PI, Tipranavir (TPV), Sensitive | PI, TPV, Resistant | |
| TAF Based Regimen (Early Switch) | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
Number of participants, who meet CVW criteria (one plasma HIV-1 RNA >=200 c/mL after Day 1 with immediate prior HIV RNA >=50 c/mL), with phenotypic resistance to INSTI, NNRTI,NRTI and PI were summarized. Assessment of antiviral activity of ART using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences), which provided the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The phenotypic resistance was calculated using binary scoring system, where 0 was considered as sensitive and 1 as resistance. Phenotypic Resistance data for the following INSTI, NNRTI, NRTI and PI drugs in participants Meeting CVW Criteria has been presented. (NCT03446573)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSTI, DTG, Sensitive | INSTI, DTG, Resistant | INSTI, Bictegravir (BIC), Sensitive | INSTI, BIC, Resistant | INSTI, Elvitegravir (EVG), Sensitive | INSTI, EVG, Resistant | INSTI, Raltegravir (RAL), Sensitive | INSTI, RAL, Resistant | NNRTI, Delavirdine (DLV), Sensitive | NNRTI, DLV, Resistant | NNRTI, Efavirenz (EFV), Sensitive | NNRTI, EFV, Resistant | NNRTI, Etravirine (ETR), Sensitive | NNRTI, ETR, Resistant | NNRTI, Nevirapine (NVP), Sensitive | NNRTI, NVP, Resistant | NNRTI, Rilpivirine (RPV), Sensitive | NNRTI, RPV, Resistant | NRTI, 3TC, Sensitive | NRTI, 3TC, Resistant | NRTI, Abacavir (ABC), Sensitive | NRTI, ABC, Resistant | NRTI, Zidovudine (AZT), Sensitive | NRTI, AZT, Resistant | NRTI, Stavudine (D4T), Sensitive | NRTI, D4T, Resistant | NRTI, Didanosine (DDI), Sensitive | NRTI, DDI, Resistant | NRTI, Emtricitabine (FTC), Sensitive | NRTI, FTC, Resistant | NRTI, Tenofovir (TDF), Sensitive | NRTI, TDF, Resistant | PI, Atazanavir (ATV), Sensitive | PI, ATV, Resistant | PI, Darunavir (DRV), Sensitive | PI, DRV, Resistant | PI, Fosamprenavir (FPV), Sensitive | PI, FPV, Resistant | PI, Indinavir (IDV), Sensitive | PI, IDV, Resistant | PI, Lopinavir (LPV), Sensitive | PI, LPV, Resistant | PI, Nelfinavir (NFV), Sensitive | PI, NFV, Resistant | PI, Ritonavir (RTV), Sensitive | PI, RTV, Resistant | PI, Saquinavir (SQV), Sensitive | PI, SQV, Resistant | PI, Tipranavir (TPV), Sensitive | PI, TPV, Resistant | |
| TAF Based Regimen (Early Switch) | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
Percentage of participants with plasma HIV-1 RNA <50 c/mL was evaluated using FDA snapshot algorithm at Weeks 96 and 144. (NCT03446573)
Timeframe: Weeks 96 and 144
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 96 | Week 144 | |
| DTG+3TC FDC (Early Switch) | 85.9 | 85.9 |
| TAF-based Regimen (Early Switch) | 79.0 | 81.7 |
Percentage of participants with plasma HIV-1 RNA >=50 c/mL was evaluated using FDA snapshot algorithm at Weeks 96 and 144. (NCT03446573)
Timeframe: Weeks 96 and 144
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Week 96 | Week 144 | |
| DTG+3TC FDC (Early Switch) | 0.3 | 0.3 |
| TAF-based Regimen (Early Switch) | 1.1 | 1.3 |
(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 62.5 |
| F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 69.4 |
| E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | 83.8 |
| F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) | 79.7 |
Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 95.8 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 98.6 |
| F/R/TAF + LDV/SOF | 98.6 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF + LDV/SOF | 1.4 |
| F/R/TAF + LDV/SOF | 1.4 |
(NCT02607930)
Timeframe: Baseline, Week 144
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | 299 |
| ABC/DTG/3TC | 317 |
(NCT02607930)
Timeframe: Baseline, Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | 235 |
| ABC/DTG/3TC | 228 |
(NCT02607930)
Timeframe: Baseline, open-label Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| All B/F/TAF | 330 |
| ABC/DTG/3TC to B/F/TAF | -4 |
(NCT02607930)
Timeframe: Baseline, Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | 287 |
| ABC/DTG/3TC | 288 |
(NCT02607930)
Timeframe: Baseline, open-label Week 96
| Intervention | cell/µL (Mean) |
|---|---|
| All B/F/TAF | 339 |
| ABC/DTG/3TC to B/F/TAF | -15 |
(NCT02607930)
Timeframe: Baseline, Week 144
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.11 |
| ABC/DTG/3TC | -3.10 |
(NCT02607930)
Timeframe: Baseline, Week 48
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.11 |
| ABC/DTG/3TC | -3.07 |
(NCT02607930)
Timeframe: Baseline, Week 96
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.09 |
| ABC/DTG/3TC | -3.10 |
(NCT02607930)
Timeframe: Baseline, Week 144
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -1.020 |
| ABC/DTG/3TC | -1.291 |
(NCT02607930)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -0.802 |
| ABC/DTG/3TC | -1.148 |
(NCT02607930)
Timeframe: Baseline, Week 96
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -1.128 |
| ABC/DTG/3TC | -1.262 |
(NCT02607930)
Timeframe: Baseline, Week 144
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -0.371 |
| ABC/DTG/3TC | 0.035 |
(NCT02607930)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -0.772 |
| ABC/DTG/3TC | -0.552 |
(NCT02607930)
Timeframe: Baseline, Week 96
| Intervention | percentage change (Mean) |
|---|---|
| B/F/TAF | -0.705 |
| ABC/DTG/3TC | -0.219 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 78.0 |
| ABC/DTG/3TC | 82.2 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 87.6 |
| ABC/DTG/3TC | 87.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 83.4 |
| ABC/DTG/3TC | 84.8 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 81.5 |
| ABC/DTG/3TC | 84.1 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 92.4 |
| ABC/DTG/3TC | 93.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit. (NCT02607930)
Timeframe: Baseline, open-label Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 99.2 |
| ABC/DTG/3TC to B/F/TAF | 100 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607930)
Timeframe: Baseline, open-label Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 74.8 |
| ABC/DTG/3TC to B/F/TAF | 83.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607930)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 87.9 |
| ABC/DTG/3TC | 89.8 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit. (NCT02607930)
Timeframe: Baseline, open-label Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 97.7 |
| ABC/DTG/3TC to B/F/TAF | 99.5 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607930)
Timeframe: Baseline, open-label Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 66.2 |
| ABC/DTG/3TC to B/F/TAF | 85.4 |
(NCT02607956)
Timeframe: Baseline, Week 144
| Intervention | cells/μL (Mean) |
|---|---|
| B/F/TAF | 278 |
| DTG + F/TAF | 289 |
(NCT02607956)
Timeframe: Baseline, Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| B/F/TAF | 180 |
| DTG + F/TAF | 201 |
(NCT02607956)
Timeframe: Baseline, open-label Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| All B/F/TAF | 304 |
| DTG + F/TAF to B/F/TAF | 9 |
(NCT02607956)
Timeframe: Baseline, Week 96
| Intervention | cells/μL (Mean) |
|---|---|
| B/F/TAF | 237 |
| DTG + F/TAF | 281 |
(NCT02607956)
Timeframe: Baseline, open-label Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| All B/F/TAF | 336 |
| DTG + F/TAF to B/F/TAF | -10 |
(NCT02607956)
Timeframe: Baseline, Week 144
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.06 |
| DTG + F/TAF | -3.11 |
(NCT02607956)
Timeframe: Baseline, Week 48
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.07 |
| DTG + F/TAF | -3.12 |
(NCT02607956)
Timeframe: Baseline, Week 96
| Intervention | log10 copies/mL (Mean) |
|---|---|
| B/F/TAF | -3.08 |
| DTG + F/TAF | -3.10 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 77.5 |
| DTG + F/TAF | 79.1 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 82.2 |
| DTG + F/TAF | 87.1 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 77.5 |
| DTG + F/TAF | 80.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 81.9 |
| DTG + F/TAF | 84.0 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 89.4 |
| DTG + F/TAF | 92.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 99.2 |
| DTG + F/TAF to B/F/TAF | 99.6 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 75.3 |
| DTG + F/TAF to B/F/TAF | 84.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 84.1 |
| DTG + F/TAF | 86.5 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 99.5 |
| DTG + F/TAF to B/F/TAF | 99.1 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| All B/F/TAF | 68.1 |
| DTG + F/TAF to B/F/TAF | 87.5 |
Tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS) respective to dosing regimens of 33%, 67%, 100% of daily dosing. (NCT02962739)
Timeframe: Assessed weekly for 9 months
| Intervention | fmol/punch (Mean) |
|---|---|
| DOT 33% | 657 |
| DOT 67% | 1451 |
| DOT 100% | 2381 |
(NCT03110380)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| B/F/TAF | 18 |
| DTG + F/TAF | 36 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT03110380)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 93.3 |
| DTG + F/TAF | 91.1 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT03110380)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 0.4 |
| DTG + F/TAF | 1.1 |
(NCT02842086)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| Descovy (DVY) | -0.01 |
| Truvada (TVD) | 0.01 |
(NCT02842086)
Timeframe: Baseline, Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| Descovy (DVY) | 0.01 |
| Truvada (TVD) | 0.03 |
"The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.~HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:~Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or~Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or~Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)" (NCT02842086)
Timeframe: When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)
| Intervention | HIV-1 infections per 100 PY (Number) |
|---|---|
| Descovy (DVY) | 0.160 |
| Truvada (TVD) | 0.342 |
"The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study.~HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab:~Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or~Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or~Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)" (NCT02842086)
Timeframe: When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)
| Intervention | HIV-1 infections per 100 PY (Number) |
|---|---|
| Descovy (DVY) | 0.159 |
| Truvada (TVD) | 0.297 |
Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%. (NCT02842086)
Timeframe: Baseline, Week 96
| Intervention | Percent Change (Mean) |
|---|---|
| Descovy (DVY) | 0.565 |
| Truvada (TVD) | -1.048 |
Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%. (NCT02842086)
Timeframe: Baseline, Week 48
| Intervention | Percent Change (Mean) |
|---|---|
| Descovy (DVY) | 0.218 |
| Truvada (TVD) | -0.968 |
Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%. (NCT02842086)
Timeframe: Baseline, Week 48
| Intervention | Percent Change (Mean) |
|---|---|
| Descovy (DVY) | 0.512 |
| Truvada (TVD) | -1.061 |
Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%. (NCT02842086)
Timeframe: Baseline, Week 96
| Intervention | Percent Change (Mean) |
|---|---|
| Descovy (DVY) | 0.831 |
| Truvada (TVD) | -1.426 |
"Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.~For urine creatinine, value of < 1 was handled as a missing value in its summary and the calculation of related ratios." (NCT02842086)
Timeframe: Baseline, Week 48
| Intervention | Percent Change (Median) |
|---|---|
| Descovy (DVY) | -10.6 |
| Truvada (TVD) | 15.4 |
"Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.~For urine creatinine, value of < 1 was handled as a missing value in its summary and the calculation of related ratios." (NCT02842086)
Timeframe: Baseline, Week 96
| Intervention | Percent Change (Median) |
|---|---|
| Descovy (DVY) | -14.5 |
| Truvada (TVD) | 14.1 |
"Percent Change = Change from baseline at Week 96 visit/value at baseline * 100%.~For urine creatinine, value of < 1 was handled as a missing value in its summary and the calculation of related ratios." (NCT02842086)
Timeframe: Baseline, Week 96
| Intervention | Percent Change (Median) |
|---|---|
| Descovy (DVY) | 0.3 |
| Truvada (TVD) | 21.4 |
"Percent Change = Change from baseline at Week 48 visit/value at baseline * 100%.~For urine creatinine, value of < 1 was handled as a missing value in its summary and the calculation of related ratios." (NCT02842086)
Timeframe: Baseline, Week 48
| Intervention | Percent Change (Median) |
|---|---|
| Descovy (DVY) | 0.1 |
| Truvada (TVD) | 20.0 |
(NCT02842086)
Timeframe: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Descovy (DVY) | 76.1 |
| Truvada (TVD) | 79.1 |
(NCT02842086)
Timeframe: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Descovy (DVY) | 93.7 |
| Truvada (TVD) | 93.6 |
Tenofovir diphosphate concentration in dried blood spots at week 4 (NCT04050371)
Timeframe: After 4 weeks of daily observed dosing of FTC/TDF
| Intervention | fmol/punch (Median) |
|---|---|
| Transgender Women | 973.5 |
| Transgender Men | 1078 |
Estradiol concentrations in blood plasma by LC-MS/MS (NCT04050371)
Timeframe: Baseline and after 4 weeks of daily FTC/TDF
| Intervention | pg/mL (Median) | |
|---|---|---|
| Week 0 | Week 4 | |
| Transgender Men | 24.2 | 23.1 |
| Transgender Women | 141.5 | 116 |
Total testosterone concentrations in blood plasma by LC-MS/MS (NCT04050371)
Timeframe: Baseline and after 4 weeks of daily FTC/TDF
| Intervention | ng/dL (Median) | |
|---|---|---|
| Week 0 | Week 4 | |
| Transgender Men | 559 | 595 |
| Transgender Women | 56.5 | 56.7 |
TFV-DP concentrations in DBS respective to dosing regimens of 33%, 67%, 100% of daily dosing. (NCT02022657)
Timeframe: Assessed every 2 weeks during the dosing periods and at steady-state, week 12 for the first dosing period and week 36 for the second dosing period.
| Intervention | fmol/punch (Mean) |
|---|---|
| DOT-DBS Dosing 33% | 530 |
| DOT-DBS Dosing 67% | 997 |
| DOT-DBS Dosing 100% | 1605 |
Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
| Intervention | hour (Median) |
|---|---|
| DTG 50mg q.d. | 32.8 |
| EVG/COBI 150/150mg q.d. | 7.6 |
| DRV/COBI 800/150 mg q.d. | NA |
| EFV 600 mg q.d. (Outside THA) | 65.6 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
| Intervention | unitless (Median) |
|---|---|
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 0.15 |
| DTG 50mg q.d. | 1.25 |
| EVG/COBI 150/150mg q.d. | 0.91 |
| DRV/COBI 800/150 mg q.d. | 0.07 |
| ATV/COBI 300/150 mg q.d. | 0.07 |
| TFV 300mg q.d. | 0.88 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
| Intervention | unitless (Median) |
|---|---|
| TAF 10mg q.d. w/COBI | 0.97 |
| EFV 600 mg q.d. (Outside THA) | 0.67 |
| EFV 600mg q.d. | 0.49 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 0.2 |
| RAL 400mg b.i.d. | 1.5 |
| ETR 200mg b.i.d. | 0.52 |
| MVC 150 or 300mg b.i.d. | 0.33 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.14 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.16 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | 0.19 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.12 |
| RPV 25mg q.d. | 0.55 |
| ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d. | 0.18 |
| DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d. | 0.18 |
Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum
| Intervention | pg/mL (Median) |
|---|---|
| ATV/RTV/TFV 300/100/300mg q.d. With ENG | 604 |
| LPV/RTV 400/100 b.i.d. With ENG | 428 |
| EFV 600mg q.d. With ENG | 125 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.
| Intervention | mcg*hr/mL (Median) | |
|---|---|---|
| Before contraceptive initiation | After contraceptive initiation | |
| LPV/RTV 400/100 b.i.d. With ENG | 115.97 | 100.20 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.
| Intervention | mcg*hr/mL (Median) | |
|---|---|---|
| Before contraceptive initiation | After contraceptive initiation | |
| ATV/RTV/TFV 300/100/300mg q.d. With ENG | 53.96 | 55.25 |
| EFV 600mg q.d. With ENG | 53.64 | 56.65 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 20 | 21 |
| MVC 150 or 300mg b.i.d. | 8 | 7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/RTV Arm 1: 300/100mg q.d. | 1 | 12 | 12 |
| DRV/COBI 800/150 mg q.d. | 3 | 4 | 14 |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 7 | 16 | 22 |
| DRV/RTV 600/100mg b.i.d. | 7 | 19 | 22 |
| DRV/RTV 800/100mg q.d. | 9 | 19 | 22 |
| DTG 50mg q.d. | 9 | 20 | 23 |
| EFV 600 mg q.d. (Outside THA) | 12 | 33 | 34 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 8 | 29 | 27 |
| ETR 200mg b.i.d. | 5 | 13 | 7 |
| EVG/COBI 150/150mg q.d. | 8 | 10 | 18 |
| FPV/RTV 700/100mg b.i.d. | 8 | 26 | 22 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 10 | 19 | 26 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 9 | 30 | 27 |
| ATV/COBI 300/150 mg q.d. | 1 | 2 | 5 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 15 | 14 |
| RAL 400mg b.i.d. | 11 | 33 | 30 |
| RPV 25mg q.d. | 14 | 26 | 25 |
| TAF 10mg q.d. w/COBI | 15 | 23 | 22 |
| TAF 25mg q.d. | 13 | 23 | 24 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 10 | 24 | 18 |
| TFV 300mg q.d. | 2 | 27 | 27 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1 | 11 | 12 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 7 | 23 | 32 |
Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
| Intervention | mcg/mL (Median) | |||
|---|---|---|---|---|
| 2-10 hours after birth | 18-28 hours after birth | 36-72 hours after birth | 5-9 days after birth | |
| DRV/COBI 800/150 mg q.d. | 0.35 | 1.43 | 1.87 | 1.72 |
| DTG 50mg q.d. | 1.73 | 1.53 | 1.00 | 0.06 |
| EFV 600 mg q.d. (Outside THA) | 1.1 | 1.0 | 0.9 | 0.4 |
| EVG/COBI 150/150mg q.d. | 0.132 | 0.032 | 0.005 | 0.005 |
Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | ng*hour/mL (Geometric Mean) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | NA | 2717 | 3645 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 55.1 | 51.8 | 79.6 |
| DRV/RTV 600/100mg b.i.d. | 45.8 | 45.9 | 61.7 |
| FPV/RTV 700/100mg b.i.d. | 43.50 | 32.15 | 51.60 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 34.2 | 33.5 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 4.5 | 8.3 | 5.3 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 14.9 | 16.1 | 27.1 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 72 | 96 | 133 |
| RAL 400mg b.i.d. | 6.6 | 5.4 | 11.6 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 25.33 | 18.85 | 36.20 |
| ATV/RTV Arm 1: 300/100mg q.d. | 88.2 | 41.9 | 57.9 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 30.6 | 45.7 | 48.8 |
| DRV/COBI 800/150 mg q.d. | 50.00 | 42.05 | 95.55 |
| DRV/RTV 800/100mg q.d. | 64.6 | 63.5 | 103.9 |
| DTG 50mg q.d. | 47.6 | 49.2 | 65.0 |
| EFV 600 mg q.d. (Outside THA) | 47.30 | 60.02 | 62.70 |
| EVG/COBI 150/150mg q.d. | 15.3 | 14.0 | 21.0 |
| TAF 10mg q.d. w/COBI | 0.197 | 0.206 | 0.216 |
| TAF 25mg q.d. | 0.171 | 0.212 | 0.271 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 0.181 | 0.257 | 0.283 |
| TFV 300mg q.d. | 1.9 | 2.4 | 3.0 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 14.5 | 28.8 | 39.6 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 26.2 | 37.7 | 58.7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 55.4 | 58.3 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| RPV 25mg q.d. | 1.969 | 1.669 | 2.387 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 5.44 | 5.10 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 2.82 | 2.20 | 3.90 |
| ATV/RTV Arm 1: 300/100mg q.d. | NA | 3.6 | 4.1 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 3.11 | 4.51 | 4.52 |
| DRV/COBI 800/150 mg q.d. | 4.59 | 3.67 | 7.04 |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 6.22 | 6.55 | 8.96 |
| DRV/RTV 600/100mg b.i.d. | 5.64 | 5.53 | 7.78 |
| DRV/RTV 800/100mg q.d. | 6.77 | 5.78 | 8.11 |
| DTG 50mg q.d. | 3.62 | 3.54 | 4.85 |
| EFV 600 mg q.d. (Outside THA) | 3.87 | 5.13 | 4.41 |
| FPV/RTV 700/100mg b.i.d. | 5.61 | 5.12 | 6.75 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 3.89 | 3.62 | 5.37 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 5.1 | 5.0 |
| TFV 300mg q.d. | 0.250 | 0.245 | 0.298 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1.2 | 2.5 | 4.1 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 2.73 | 3.56 | 5.43 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 0.70 | 1.01 | 0.63 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 8.4 | 10.7 | 14.6 |
| RAL 400mg b.i.d. | 2.250 | 1.770 | 3.035 |
| RPV 25mg q.d. | 0.145 | 0.134 | 0.134 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | ng/mL (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | 448 | 647 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| EVG/COBI 150/150mg q.d. | 1447.1 | 1432.8 | 1713.1 |
| TAF 10mg q.d. w/COBI | 80.4 | 91.2 | 98.2 |
| TAF 25mg q.d. | 69.7 | 96 | 133 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 87.8 | 107 | 141 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | 108 | 128 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 2.84 | 2.52 | 4.51 |
| DRV/RTV 600/100mg b.i.d. | 2.12 | 2.22 | 2.51 |
| FPV/RTV 700/100mg b.i.d. | 2.12 | 1.64 | 2.87 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 0.47 | 0.52 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 0.36 | 0.48 | 0.38 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.13 | 0.13 | 0.28 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 3.7 | 5.1 | 7.2 |
| RAL 400mg b.i.d. | 0.0621 | 0.064 | 0.0797 |
"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 0.21 | 0.21 | 0.61 |
| ATV/RTV Arm 1: 300/100mg q.d. | 2.0 | 0.7 | 1.2 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.49 | 0.71 | 0.90 |
| DRV/COBI 800/150 mg q.d. | 0.33 | 0.27 | 1.43 |
| DRV/RTV 800/100mg q.d. | 0.99 | 1.17 | 2.78 |
| DTG 50mg q.d. | 0.73 | 0.93 | 1.28 |
| EFV 600 mg q.d. (Outside THA) | 1.49 | 1.48 | 1.94 |
| EVG/COBI 150/150mg q.d. | 0.0258 | 0.0487 | 0.3771 |
| TAF 10mg q.d. w/COBI | 0.00195 | 0.00195 | 0.00195 |
| TAF 25mg q.d. | 0.00195 | 0.00195 | 0.00195 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 0.00195 | 0.00195 | 0.00195 |
| TFV 300mg q.d. | 0.039 | 0.054 | 0.061 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 0.3 | 0.5 | 0.8 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.44 | 0.57 | 1.26 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 1.60 | 2.05 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| RPV 25mg q.d. | 0.063 | 0.056 | 0.081 |
"Feasibility of using the AdhereTech Smart Pill Bottles in individuals living with HIV as measured by the proportion of participants that complete the study compared between arms. A statistically lower proportion in the AdhereTech bottle arm compared to the routine counseling arm would suggest use of the bottle is not feasible." (NCT03772327)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Routine Counseling + AdhereTech Bottle | 25 |
| Routine Counseling | 26 |
"Analyze participant's self-reported adherence using National Institutes of Health AIDS Clinical Trials Group (ACTG) standardized and validated questionnaire of number of days with no missed doses of medication over prior 4 days (minimum 0, maximum 4). Number of days with missed doses was dichotomized to no missed doses (100% adherence) and ≥ 1 missed dose." (NCT03772327)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Routine Counseling + AdhereTech Bottle | 18 |
| Routine Counseling | 20 |
"This is a measure of qualitative HIV RNA outcome. The number of participants converting from detectable (HIV RNA ≥ 20 copies/mL) at baseline to undetectable (HIV RNA < 20 copies/mL) at week 12 in the AdhereTech bottle arm versus the routine counseling only arm." (NCT03772327)
Timeframe: Baseline and Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Routine Counseling + AdhereTech Bottle | 3 |
| Routine Counseling | 7 |
Comparative changes in quantitative HIV viral load between baseline and Week 12 in the AdhereTech bottle arm versus the routine counseling only arm. (NCT03772327)
Timeframe: Baseline and Week 12
| Intervention | copies/mL (Median) | |
|---|---|---|
| Baseline | Week 12 | |
| Routine Counseling | 28 | 26 |
| Routine Counseling + AdhereTech Bottle | 19 | 19 |
Using dried blood spots from red blood cells, TFV-DP levels will be assessed. (NCT03772327)
Timeframe: Baseline and Week 12
| Intervention | fmol/punch (Median) | |
|---|---|---|
| Baseline | Week 12 | |
| Routine Counseling | 1108 | 1084 |
| Routine Counseling + AdhereTech Bottle | 1230 | 1887 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 250.4 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 9787.5 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 221.9 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 13.14 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 7.688 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 203.4 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 71.81 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC | 1.500 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC | 1.00 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC | 3.000 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC | 1811 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 9421.0 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 24.53 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 215.4 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours*nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 229.1 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 1.411 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 175.1 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 13.30 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 82.92 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 1 and 2 hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 0.7883 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 8.244 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC+GSK3640254 | 5.000 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC+GSK3640254 | 1.500 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC+GSK3640254 | 1.000 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Hours (Median) |
|---|---|
| TAF/FTC+GSK3640254 | 3.000 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis. (NCT03836729)
Timeframe: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
| Intervention | Nanogram per milliliter (Geometric Mean) |
|---|---|
| TAF/FTC+GSK3640254 | 1701 |
An adverse events (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before (NCT03836729)
Timeframe: Up to Day 24
| Intervention | Participants (Number) | |
|---|---|---|
| Non-SAEs | SAEs | |
| TAF/FTC | 9 | 0 |
| TAF/FTC+GSK3640254 | 3 | 0 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Millimeters of mercury (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Baseline | SBP, Day 2 | SBP, Day 3 | SBP, Day 4 | SBP, Day 5 | SBP, Day 7 | DBP, Baseline | DBP, Day 2 | DBP, Day 3 | DBP, Day 4 | DBP, Day 5 | DBP, Day 7 | |
| TAF/FTC | 123.3 | 124.7 | 121.5 | 120.6 | 121.0 | 124.1 | 75.3 | 75.4 | 73.8 | 75.4 | 73.9 | 78.2 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Units per Liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Amylase, Baseline | Amylase, Day 7 | Amylase, Day 14 | Lipase, Baseline | Lipase, Day 7 | Lipase, Day 14 | |
| TAF/FTC | 56.4 | 54.1 | 53.6 | 22.2 | 18.2 | 16.9 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | International units per Liter (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, Baseline | Alkaline phosphatase, Day 7 | Alkaline phosphatase, Day 14 | AST, Baseline | AST, Day 7 | AST, Day 14 | ALT, Baseline | ALT, Day 7 | ALT, Day 14 | GGT Baseline | GGT Day 7 | GGT Day 14 | LDH, Baseline | LDH, Day 7 | LDH, Day 9 | CK, Baseline | CK, Day 7 | CK, Day 14 | |
| TAF/FTC | 60.9 | 58.3 | 63.4 | 24.6 | 18.4 | 17.6 | 26.6 | 24.4 | 20.4 | 1.76 | 1.91 | 2.40 | 138.0 | 123.4 | 126.0 | 219.6 | 116.6 | 120.4 |
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Millimoles per Liter (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, Baseline | Glucose, Day 7 | Glucose, Day 14 | Cholesterol, Baseline | Cholesterol, Day 7 | Cholesterol, Day 14 | Anion gap, Baseline | Anion gap, Day 7 | Anion gap, Day 14 | Calcium, Baseline | Calcium, Day 7 | Calcium, Day 14 | CO2, Baseline | CO2, Day 7 | CO2, Day 14 | Chloride, Baseline | Chloride, Day 7 | Chloride, Day 14 | Phosphate, Baseline | Phosphate, Day 7 | Phosphate, Day 14 | Potassium, Baseline | Potassium, Day 7 | Potassium, Day 14 | Sodium, Baseline | Sodium, Day 7 | Sodium, Day 14 | Triglycerides, Baseline | Triglycerides, Day 7 | Triglycerides, Day 14 | BUN, Baseline | BUN, Day 7 | BUN, Day 14 | |
| TAF/FTC | 5.111 | 4.951 | 4.791 | 4.253 | 4.249 | 3.864 | 8.7 | 10.6 | 10.9 | 2.359 | 2.387 | 2.387 | 31.7 | 30.1 | 30.8 | 103.3 | 102.2 | 101.3 | 1.078 | 1.094 | 1.103 | 4.25 | 4.28 | 4.22 | 139.4 | 138.8 | 138.8 | 1.076 | 1.168 | 1.033 | 4.441 | 4.423 | 4.246 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Micromoles per liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Baseline | Creatinine, Day 7 | Creatinine, Day 14 | Total bilirubin, Baseline | Total bilirubin, Day 7 | Total bilirubin, Day 14 | Direct bilirubin, Baseline | Direct bilirubin, Day 7 | Direct bilirubin, Day 14 | |
| TAF/FTC | 80.16 | 85.85 | 87.52 | 9.64 | 11.89 | 11.74 | 1.76 | 1.91 | 2.40 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Grams per Liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Protein, Baseline | Total Protein, Day 7 | Total Protein, Day 14 | Globulin, Baseline | Globulin, Day 7 | Globulin, Day 14 | Albumin, Baseline | Albumin, Day 7 | Albumin, Day 14 | |
| TAF/FTC | 69.8 | 72.4 | 72.6 | 25.9 | 28.4 | 28.7 | 43.9 | 44.0 | 43.9 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose
| Intervention | Milliseconds (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Baseline | PR Interval, Day 1, 2 hours post-dose | PR Interval, Day 1, 4 hours post-dose | QRS Duration, Baseline | QRS Duration, Day 1, 2 hours post-dose | QRS Duration, Day 1, 4 hours post-dose | QT Interval, Baseline | QT Interval, Day 1, 2 hours post-dose | QT Interval, Day 1, 4 hours post-dose | QTcF Interval, Baseline | QTcF Interval, Day 1, 2 hours post-dose | QTcF Interval, Day 1, 4 hours post-dose | QTcB Interval, Baseline | QTcB Interval, Day 1, 2 hours post-dose | QTcB Interval, Day 1, 4 hours post-dose | |
| TAF/FTC | 161.3 | 162.8 | 159.4 | 91.0 | 89.9 | 91.3 | 377.8 | 370.3 | 383.6 | 391.6 | 386.7 | 390.3 | 398.8 | 394.6 | 393.3 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose
| Intervention | Beats per minute (Mean) | ||
|---|---|---|---|
| Baseline | Day 1, 2 hours post-dose | Day 1, 4 hours post-dose | |
| TAF/FTC | 67.6 | 69.1 | 64.4 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | pH (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 6.22 | 5.88 | 6.03 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Beats per minute (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | 73.9 | 72.8 | 70.1 | 69.9 | 72.3 | 66.3 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Breaths per minute (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | 14.0 | 12.5 | 13.5 | 13.5 | 15.3 | 14.6 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Ratio (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 1.0136 | 1.0143 | 1.0147 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Degree Celsius (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | 36.49 | 36.33 | 36.34 | 36.41 | 36.34 | 36.25 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, and 14
| Intervention | Giga cells per liter (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Period 1 Baseline | Basophils, Period 1 Day 7 | Basophils, Period 1 Day 14 | Eosinophils, Period 1 Baseline | Eosinophils, Period 1 Day 7 | Eosinophils, Period 1 Day 14 | Monocytes, Period 1 Baseline | Monocytes, Period 1 Day 7 | Monocytes, Period 1 Day 14 | Leukocytes, Period 1 Baseline | Leukocytes, Period 1 Day 7 | Leukocytes, Period 1 Day 14 | Lymphocytes, Period 1 Baseline | Lymphocytes, Period 1 Day 7 | Lymphocytes, Period 1 Day 14 | Neutrophils, Period 1 Baseline | Neutrophils, Period 1 Day 7 | Neutrophils, Period 1 Day 14 | Platelets, Period 1 Baseline | Platelets, Period 1 Day 7 | Platelets, Period 1 Day 14 | |
| TAF/FTC | 0.046 | 0.041 | 0.040 | 0.225 | 0.204 | 0.205 | 0.522 | 0.536 | 0.571 | 6.18 | 6.10 | 6.45 | 1.945 | 1.699 | 1.683 | 3.441 | 3.628 | 3.954 | 253.3 | 256.6 | 275.1 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Trillion cells per liter (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 4.977 | 5.166 | 5.203 |
Blood samples were collected at indicated time points for analysis for hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Proportion of red blood cells in blood (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 0.4264 | 0.4384 | 0.4453 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Grams per liter (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 142.0 | 148.1 | 150.4 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCH. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Picograms (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 28.63 | 28.75 | 28.98 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Femtoliters (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 85.92 | 85.09 | 85.85 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Micromoles per liter (Mean) | ||
|---|---|---|---|
| Baseline | Day 7 | Day 14 | |
| TAF/FTC | 5.9255 | 3.3860 | 3.3860 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Millimeters of mercury (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Day 2 | SBP, Day 3 | SBP, Day 4 | SBP, Day 5 | SBP, Day 7 | DBP, Day 2 | DBP, Day 3 | DBP, Day 4 | DBP, Day 5 | DBP, Day 7 | |
| TAF/FTC | 1.4 | -1.8 | -2.7 | -2.3 | 0.8 | 0.1 | -1.6 | 0.1 | -1.4 | 2.9 |
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter like alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | International units per Liter (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, Day 7 | Alkaline phosphatase, Day 14 | AST, Day 7 | AST, Day 14 | ALT, Day 7 | ALT, Day 14 | GGT Day 7 | GGT Day 14 | LDH, Day 7 | LDH, Day 14 | CK, Day 7 | CK, Day 14 | |
| TAF/FTC | -2.6 | 2.4 | -6.2 | -6.9 | -2.1 | -6.2 | 0.2 | -1.7 | -14.6 | -12.0 | -103.0 | -99.2 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Millimoles per Liter (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, Day 7 | Glucose, Day 14 | Cholesterol, Day 7 | Cholesterol, Day 14 | Anion gap, Day 7 | Anion gap, Day 14 | Calcium, Day 7 | Calcium, Day 14 | CO2, Day 7 | CO2, Day 14 | Chloride, Day 7 | Chloride, Day 14 | Phosphate, Day 7 | Phosphate, Day 14 | Potassium, Day 7 | Potassium, Day 14 | Sodium, Day 7 | Sodium, Day 14 | Triglycerides, Day 7 | Triglycerides, Day 14 | BUN, Day 7 | BUN, Day 14 | |
| TAF/FTC | -0.160 | -0.320 | -0.004 | -0.389 | 1.9 | 2.2 | 0.028 | 0.028 | -1.6 | -0.9 | -1.1 | -2.0 | 0.017 | 0.026 | 0.03 | -0.03 | -0.6 | -0.6 | 0.092 | -0.044 | -0.018 | -0.195 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Units per Liter (Mean) | |||
|---|---|---|---|---|
| Amylase, Day 7 | Amylase, Day 14 | Lipase, Day 7 | Lipase, Day 14 | |
| TAF/FTC | -2.3 | -2.8 | -4.0 | -5.3 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Micromoles per liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Creatinine, Day 7 | Creatinine, Day 14 | Total bilirubin, Day 7 | Total bilirubin, Day 14 | Direct bilirubin, Day 7 | Direct bilirubin, Day 14 | |
| TAF/FTC | 5.69 | 7.36 | 2.25 | 2.10 | 0.15 | 0.64 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Grams per Liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Protein, Day 7 | Total Protein, Day 14 | Globulin, Day 7 | Globulin, Day 14 | Albumin, Day 7 | Albumin, Day 14 | |
| TAF/FTC | 2.6 | 2.9 | 2.5 | 2.8 | 0.1 | 0.1 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose
| Intervention | Milliseconds (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Day 1, 2 hours post-dose | PR Interval, Day 1, 4 hours post-dose | QRS Duration, Day 1, 2 hours post-dose | QRS Duration, Day 1, 4 hours post-dose | QT Interval, Day 1, 2 hours post-dose | QT Interval, Day 1, 4 hours post-dose | QTcF Interval, Day 1, 2 hours post-dose | QTcF Interval, Day 1, 4 hours post-dose | QTcB Interval, Day 1, 2 hours post-dose | QTcB Interval, Day 1, 4 hours post-dose | |
| TAF/FTC | 1.5 | -1.9 | -1.1 | 0.3 | -7.5 | 5.8 | -4.9 | -1.3 | -4.1 | -5.4 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose
| Intervention | Beats per minute (Mean) | |
|---|---|---|
| Day 1, 2 hours post-dose | Day 1, 4 hours post-dose | |
| TAF/FTC | 1.5 | -3.3 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Trillion cells per liter (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | 0.189 | 0.226 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Proportion of red blood cells in blood (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | 0.0121 | 0.0189 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Grams per liter (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | 6.1 | 8.4 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like MCH. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Picograms (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | 0.13 | 0.36 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Femtoliters (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | -0.83 | -0.07 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, and 14
| Intervention | Giga cells per liter (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Period 1 Day 7 | Basophils, Period 1 Day 14 | Eosinophils, Period 1 Day 7 | Eosinophils, Period 1 Day 14 | Monocytes, Period 1 Day 7 | Monocytes, Period 1 Day 14 | Leukocytes, Period 1 Day 7 | Leukocytes, Period 1 Day 14 | Lymphocytes, Period 1 Day 7 | Lymphocytes, Period 1 Day 14 | Neutrophils, Period 1 Day 7 | Neutrophils, Period 1 Day 14 | Platelets, Period 1 Day 7 | Platelets, Period 1 Day 14 | |
| TAF/FTC | -0.005 | -0.006 | -0.021 | -0.020 | 0.014 | 0.049 | -0.08 | 0.27 | -0.246 | -0.262 | 0.188 | 0.513 | 3.3 | 21.8 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | pH (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | -0.34 | -0.19 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Beats per minute (Mean) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | -1.2 | -3.8 | -4.0 | -1.6 | -7.6 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Breaths per minute (Mean) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | -1.5 | -0.5 | -0.5 | 1.3 | 0.6 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Ratio (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | 0.0007 | 0.0011 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 2, 3, 4, 5 and 7
| Intervention | Degree Celsius (Mean) | ||||
|---|---|---|---|---|---|
| Day 2 | Day 3 | Day 4 | Day 5 | Day 7 | |
| TAF/FTC | -0.16 | -0.15 | -0.09 | -0.15 | -0.24 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 7, 14
| Intervention | Micromoles per liter (Mean) | |
|---|---|---|
| Day 7 | Day 14 | |
| TAF/FTC | -2.5395 | -2.5395 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Millimeters of mercury (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Baseline, n= 16 | SBP, Day 4, n=15 | SBP, Day 7, n=15 | SBP, Day 9, n=15 | SBP, Day 10, n=15 | DBP, Baseline, n= 16 | DBP, Day 4, n= 15 | DBP, Day 7, n= 15 | DBP, Day 9, n= 15 | DBP, Day 10, n= 15 | |
| TAF/FTC+GSK3640254 | 120.4 | 119.3 | 120.8 | 117.9 | 123.7 | 74.4 | 74.3 | 77.9 | 70.3 | 72.1 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Units per Liter (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Amylase, Baseline, n= 16 | Amylase, Day 3, n= 16 | Amylase, Day 7, n= 15 | Amylase, Day 9, n= 15 | Lipase, Baseline, n= 16 | Lipase, Day 3, n= 16 | Lipase, Day 7, n= 15 | Lipase, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 53.6 | 56.8 | 52.7 | 55.7 | 16.9 | 24.6 | 17.5 | 21.0 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | International units per Liter (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, Baseline Day 3, n= 16 | Alkaline phosphatase, Day 3, n= 16 | Alkaline phosphatase, Day 7, n= 15 | Alkaline phosphatase, Day 9, n= 15 | AST, Baseline, n= 16 | AST, Day 3, n= 16 | AST, Day 7, n= 15 | AST, Day 9, n= 15 | ALT, Baseline, n= 16 | ALT, Day 3, n= 16 | ALT, Day 7, n= 15 | ALT, Day 9, n= 15 | GGT, Baseline, n= 16 | GGT, Day 3, n= 16 | GGT, Day 7, n= 15 | GGT, Day 9, n= 15 | LDH, Baseline, n= 16 | LDH, Day 3, n= 16 | LDH, Day 7, n= 15 | LDH, Day 9, n= 15 | CK, Baseline, n= 16 | CK, Day 3, n= 16 | CK, Day 7, n= 15 | CK, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 63.4 | 67.1 | 65.4 | 61.8 | 17.6 | 16.2 | 17.2 | 17.6 | 20.4 | 18.4 | 18.5 | 19.7 | 2.40 | 2.14 | 2.41 | 1.95 | 126.0 | 119.0 | 118.0 | 119.2 | 120.4 | 123.8 | 135.8 | 122.2 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Millimoles per Liter (Mean) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, Baseline, n= 16 | Glucose, Day 3, n= 15 | Glucose, Day 7, n= 15 | Glucose, Day 9, n= 15 | Cholesterol, Baseline, n= 16 | Cholesterol, Day 3, n=15 | Cholesterol, Day 7, n= 15 | Cholesterol, Day 9, n= 16 | Anion gap, Baseline, n= 16 | Anion gap, Day 3, n= 16 | Anion gap, Day 7, n= 15 | Anion gap, Day 9, n= 15 | Calcium, Baseline, n= 16 | Calcium, Day 3, n= 16 | Calcium, Day 7, n= 15 | Calcium, Day 9, n= 15 | CO2, Baseline, n= 16 | CO2, Day 3, n= 16 | CO2, Day 7, n= 15 | CO2, Day 9, n= 15 | Chloride, Baseline, n= 16 | Chloride, Day 3, n= 16 | Chloride, Day 7, n= 15 | Chloride, Day 9, n= 15 | Phosphate, Baseline, n= 16 | Phosphate, Day 3, n= 16 | Phosphate, Day 7, n= 15 | Phosphate, Day 9, n= 15 | Potassium, Baseline, n= 16 | Potassium, Day 3, n= 16 | Potassium, Day 7, n= 15 | Potassium, Day 9, n= 15 | Sodium, Baseline, n= 16 | Sodium, Day 3, n= 16 | Sodium, Day 7, n= 15 | Sodium, Day 9, n=15 | Triglycerides, Baseline, n= 16 | Triglycerides, Day 3, n= 16 | Triglycerides, Day 7, n= 15 | Triglycerides, Day 9, n= 15 | BUN, Baseline, n= 16 | BUN, Day 3, n= 16 | BUN, Day 7, n= 15 | BUN Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 4.791 | 5.027 | 5.129 | 4.950 | 3.864 | 3.875 | 3.894 | 3.822 | 10.9 | 10.5 | 10.3 | 10.5 | 2.387 | 2.399 | 2.424 | 2.421 | 30.8 | 30.3 | 30.7 | 30.5 | 101.3 | 103.6 | 101.9 | 102.7 | 1.103 | 1.165 | 1.112 | 1.117 | 4.22 | 4.23 | 4.21 | 4.35 | 138.8 | 140.2 | 138.8 | 139.3 | 1.033 | 1.029 | 1.120 | 0.961 | 4.246 | 4.558 | 4.260 | 4.263 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Micromoles per liter (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Baseline, n= 16 | Creatinine, Day 3, n= 16 | Creatinine, Day 7, n= 15 | Creatinine, Day 9, n= 15 | Total bilirubin, Baseline, n= 16 | Total bilirubin, Day 3, n= 16 | Total bilirubin, Day 7, n= 15 | Total bilirubin, Day 9, n= 15 | Direct bilirubin, Baseline, n= 16 | Direct bilirubin, Day 3, n= 16 | Direct bilirubin, Day 7, n= 15 | Direct bilirubin, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 87.52 | 85.18 | 91.53 | 88.27 | 11.44 | 10.62 | 11.33 | 9.68 | 2.40 | 2.14 | 2.41 | 1.95 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Grams per Liter (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Protein, Baseline, n= 16 | Total Protein, Day 3, n= 16 | Total Protein, Day 7, n= 15 | Total Protein, Day 9, n= 15 | Globulin, Baseline, n= 16 | Globulin, Day 3, n= 16 | Globulin, Day 7, n= 15 | Globulin, Day 9, n= 15 | Albumin, Baseline, n= 16 | Albumin, Day 3, n= 16 | Albumin, Day 7, n= 15 | Albumin, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 72.6 | 72.8 | 75.7 | 73.3 | 28.7 | 28.9 | 30.9 | 28.8 | 43.9 | 43.9 | 44.8 | 44.5 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
| Intervention | Milliseconds (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Baseline, n= 16 | PR Interval, Day 1, 2 hours post-dose, n= 16 | PR Interval, Day 1, 4 hours post-dose, n= 16 | PR Interval, Day 4, Pre-dose, n= 15 | PR Interval, Day 4, 2 hours post-dose, n= 15 | PR Interval, Day 4, 4 hours post-dose, n= 15 | PR Interval, Day 7, Pre-dose, n= 15 | PR Interval, Day 7, 2 hours post-dose, n= 15 | PR Interval, Day 7, 4 hours post-dose, n= 15 | PR Interval, Day 9 post-dose, n= 15 | QRS Duration, Baseline, n= 16 | QRS Duration, Day 1, 2 hours post-dose, n= 16 | QRS Duration, Day 1, 4 hours post-dose, n= 16 | QRS Duration, Day 4, Pre-dose, n= 15 | QRS Duration, Day 4, 2 hours post-dose, n= 15 | QRS Duration, Day 4, 4 hours post-dose, n= 15 | QRS Duration, Day 7, Pre-dose, n= 15 | QRS Duration, Day 7, 2 hours post-dose, n= 15 | QRS Duration, Day 7, 4 hours post-dose, n= 15 | QRS Duration, Day 9 post-dose, n= 15 | QT Interval, Baseline, n= 16 | QT Interval, Day 1, 2 hours post-dose, n= 16 | QT Interval, Day 1, 4 hours post-dose, n= 16 | QT Interval, Day 4, Pre-dose, n= 15 | QT Interval, Day 4, 2 hours post-dose, n= 15 | QT Interval, Day 4, 4 hours post-dose, n= 15 | QT Interval, Day 7, Pre-dose, n= 15 | QT Interval, Day 7, 2 hours post-dose, n= 15 | QT Interval, Day 7, 4 hours post-dose, n= 15 | QT Interval, Day 9 post-dose, n= 15 | QTcF Interval, Baseline, n= 16 | QTcF Interval, Day 1, 2 hours, n= 16 | QTcF Interval, Day 1, 4 hours post-dose, n= 16 | QTcF Interval, Day 4, Pre-dose, n= 15 | QTcF Interval, Day 4, 2 hours post-dose, n= 15 | QTcF Interval, Day 4, 4 hours post-dose, n= 15 | QTcF Interval, Day 7, Pre-dose, n= 15 | QTcF Interval, Day 7, 2 hours post-dose, n= 15 | QTcF Interval, Day 7, 4 hours post-dose, n= 15 | QTcF Interval, Day 9 post-dose, n= 15 | QTcB Interval, Baseline, n= 16 | QTcB Interval, Day 1, 2 hours post-dose, n= 16 | QTcB Interval, Day 1, 4 hours post-dose, n= 16 | QTcB Interval, Day 4, Pre-dose, n= 15 | QTcB Interval, Day 4, 2 hours post-dose, n= 15 | QTcB Interval, Day 4, 4 hours post-dose, n= 15 | QTcB Interval, Day 7, Pre-dose, n= 15 | QTcB Interval, Day 7, 2 hours post-dose, n= 15 | QTcB Interval, Day 7, 4 hours post-dose, n= 15 | QTcB Interval, Day 9 post-dose, n= 15 | |
| TAF/FTC+GSK3640254 | 167.3 | 160.4 | 163.6 | 167.1 | 160.7 | 163.7 | 164.9 | 164.3 | 163.9 | 168.8 | 91.4 | 88.9 | 90.1 | 91.8 | 91.8 | 91.1 | 94.5 | 92.7 | 91.6 | 94.3 | 377.7 | 365.1 | 375.9 | 385.6 | 371.5 | 383.9 | 381.7 | 369.9 | 384.1 | 382.4 | 390.0 | 385.6 | 392.4 | 395.0 | 388.3 | 393.4 | 393.0 | 383.8 | 389.5 | 396.8 | 395.7 | 396.4 | 400.4 | 399.2 | 396.2 | 398.0 | 398.3 | 390.5 | 391.9 | 404.0 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
| Intervention | Beats per minute (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline, n= 16 | Day 1, 2 hours post-dose, n= 16 | Day 1, 4 hours post-dose, n= 16 | Day 4, Pre-dose, n= 15 | Day 4, 2 hours post-dose, n= 15 | Day 4, 4 hours post-dose, n= 15 | Day 7, Pre-dose, n= 15 | Day 7, 2 hours post-dose, n= 15 | Day 7, 4 hours post-dose, n= 15 | Day 9 post-dose, n= 15 | |
| TAF/FTC+GSK3640254 | 66.5 | 71.5 | 69.3 | 65.1 | 68.9 | 65.3 | 65.9 | 67.4 | 63.3 | 67.7 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | pH (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 6.03 | 6.22 | 6.07 | 6.07 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Beats per minute (Mean) | ||||
|---|---|---|---|---|---|
| Baseline, n= 16 | Day 4, n=15 | Day 7, n=15 | Day 9, n=15 | Day 10, n=15 | |
| TAF/FTC+GSK3640254 | 70.5 | 71.9 | 71.4 | 69.2 | 79.0 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Breaths per minute (Mean) | ||||
|---|---|---|---|---|---|
| Baseline, n= 16 | Day 4, n=15 | Day 7, n=15 | Day 9, n=15 | Day 10, n=15 | |
| TAF/FTC+GSK3640254 | 15.6 | 12.5 | 13.3 | 14.9 | 14.3 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 1.0147 | 1.0178 | 1.0170 | 1.0151 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Degree Celsius (Mean) | ||||
|---|---|---|---|---|---|
| Baseline, n= 16 | Day 4, n=15 | Day 7, n=15 | Day 9, n=15 | Day 10, n=15 | |
| TAF/FTC+GSK3640254 | 36.49 | 36.37 | 36.40 | 36.46 | 36.53 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Giga cells per liter (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Period 2 Baseline, n= 16 | Basophils, Period 2 Day 3, n= 15 | Basophils, Period 2 Day 7, n= 15 | Basophils, Period 2 Day 9, n= 15 | Eosinophils, Period 2 Baseline, n= 16 | Eosinophils, Period 2 Day 3, n= 15 | Eosinophils, Period 2 Day 7, n= 15 | Eosinophils, Period 2 Day 9, n= 16 | Monocytes, Period 2 Baseline, n= 16 | Monocytes, Period 2 Day 3, n= 16 | Monocytes, Period 2 Day 7, n= 15 | Monocytes, Period 2 Day 9, n= 15 | Leukocytes, Period 2 Baseline, n= 16 | Leukocytes, Period 2 Day 3, n= 16 | Leukocytes, Period 2 Day 7, n= 15 | Leukocytes, Period 2 Day 9, n= 15 | Lymphocytes, Period 2 Baseline, n= 16 | Lymphocytes, Period 2 Day 3, n= 16 | Lymphocytes, Period 2 Day 7, n= 15 | Lymphocytes, Period 2 Day 9, n= 15 | Neutrophils, Period 2 Baseline, n= 16 | Neutrophils, Period 2 Day 3, n= 16 | Neutrophils, Period 2 Day 7, n= 15 | Neutrophils, Period 2 Day 9, n= 15 | Platelets, Period 2 Baseline, n= 16 | Platelets, Period 2 Day 3, n= 16 | Platelets, Period 2 Day 7, n= 15 | Platelets, Period 2 Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.040 | 0.036 | 0.038 | 0.043 | 0.208 | 0.185 | 0.157 | 0.153 | 0.545 | 0.492 | 0.448 | 0.421 | 6.20 | 5.14 | 5.39 | 5.51 | 1.718 | 1.560 | 1.570 | 1.563 | 3.724 | 2.857 | 3.189 | 3.324 | 274.3 | 283.4 | 294.0 | 290.4 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Trillion cells per liter (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 5.203 | 5.090 | 5.190 | 5.001 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Proportion of red blood cells in blood (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.4453 | 0.4306 | 0.4444 | 0.4247 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Grams per liter (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 150.4 | 146.4 | 149.1 | 143.9 |
Blood samples were collected at indicated time-points for analysis of hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Picograms (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 28.98 | 28.88 | 28.83 | 28.87 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Femtoliters (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 85.85 | 84.83 | 85.85 | 85.20 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Micromoles per liter (Mean) | |||
|---|---|---|---|---|
| Baseline, n= 16 | Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 3.3860 | 3.3860 | 3.3860 | 3.3860 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Millimeters of mercury (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| SBP, Day 4 | SBP, Day 7 | SBP, Day 9 | SBP, Day 10 | DBP, Day 4 | DBP, Day 7 | DBP, Day 9 | DBP, Day 10 | |
| TAF/FTC+GSK3640254 | -0.3 | 1.1 | -1.7 | 4.1 | 0.1 | 3.7 | -4.0 | -2.1 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | International units per Liter (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline phosphatase, Day 3, n= 16 | Alkaline phosphatase, Day 7, n= 15 | Alkaline phosphatase, Day 9, n= 15 | AST, Day 3, n= 16 | AST, Day 7, n= 15 | AST, Day 9, n= 15 | ALT, Day 3, n= 16 | ALT, Day 7, n= 15 | ALT, Day 9, n= 15 | GGT, Day 3, n= 16 | GGT, Day 7, n= 15 | GGT, Day 9, n= 15 | LDH, Day 3, n= 16 | LDH, Day 7, n= 15 | LDH, Day 9, n= 15 | CK, Day 3, n= 16 | CK, Day 7, n= 15 | CK, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 3.7 | 2.6 | -1.0 | -1.4 | -0.5 | -0.1 | -2.0 | -1.9 | -0.7 | -0.9 | -1.4 | -1.9 | -7.0 | -8.2 | -7.0 | 3.4 | 11.3 | -2.3 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Millimoles per Liter (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, Day 3, n= 15 | Glucose, Day 7, n= 15 | Glucose, Day 9, n= 15 | Cholesterol, Day 3, n=15 | Cholesterol, Day 7, n= 15 | Cholesterol, Day 9, n= 16 | Anion gap, Day 3, n= 16 | Anion gap, Day 7, n= 15 | Anion gap, Day 9, n= 15 | Calcium, Day 3, n= 16 | Calcium, Day 7, n= 15 | Calcium, Day 9, n= 15 | CO2, Day 3, n= 16 | CO2, Day 7, n= 15 | CO2, Day 9, n= 15 | Chloride, Day 3, n= 16 | Chloride, Day 7, n= 15 | Chloride, Day 9, n= 15 | Phosphate, Day 3, n= 16 | Phosphate, Day 7, n= 15 | Phosphate, Day 9, n= 15 | Potassium, Day 3, n= 16 | Potassium, Day 7, n= 15 | Potassium, Day 9, n= 15 | Sodium, Day 3, n= 16 | Sodium, Day 7, n= 15 | Sodium, Day 9, n= 15 | Triglycerides, Day 3, n= 16 | Triglycerides, Day 7, n= 15 | Triglycerides, Day 9, n= 15 | BUN, Day 3, n= 16 | BUN, Day 7, n= 15 | BUN, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.236 | 0.315 | 0.136 | 0.011 | 0.102 | 0.030 | -0.4 | -0.5 | -0.3 | 0.013 | 0.037 | 0.033 | -0.5 | -0.1 | -0.4 | 2.3 | 0.6 | 1.3 | 0.062 | 0.002 | 0.007 | 0.01 | -0.03 | 0.10 | 1.4 | 0.1 | 0.6 | -0.003 | 0.111 | -0.049 | 0.312 | -0.031 | -0.028 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Units per Liter (Mean) | |||||
|---|---|---|---|---|---|---|
| Amylase, Day 3, n= 16 | Amylase, Day 7, n= 15 | Amylase, Day 9, n= 15 | Lipase, Day 3, n= 16 | Lipase, Day 7, n= 15 | Lipase, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 3.3 | -1.9 | 1.1 | 7.7 | 0.0 | 3.5 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Micromoles per liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Day 3, n= 16 | Creatinine, Day 7, n= 15 | Creatinine, Day 9, n= 15 | Total bilirubin, Day 3, n= 16 | Total bilirubin, Day 7, n= 15 | Total bilirubin, Day 9, n= 15 | Direct bilirubin, Day 3, n= 16 | Direct bilirubin, Day 7, n= 15 | Direct bilirubin, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -2.34 | 3.53 | 0.28 | -0.82 | -0.26 | -1.91 | -0.26 | -0.03 | -0.49 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Grams per Liter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Protein, Day 3, n= 16 | Total Protein, Day 7, n= 15 | Total Protein, Day 9, n= 15 | Globulin, Day 3, n= 16 | Globulin, Day 7, n= 15 | Globulin, Day 9, n= 15 | Albumin, Day 3, n= 16 | Albumin, Day 7, n= 15 | Albumin, Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.1 | 3.1 | 0.8 | 0.2 | 2.3 | 0.2 | -0.1 | 0.9 | 0.6 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
| Intervention | Milliseconds (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Day 1, 2 hours post-dose, n= 16 | PR Interval, Day 1, 4 hours post-dose, n= 16 | PR Interval, Day 4, Pre-dose, n= 15 | PR Interval, Day 4, 2 hours post-dose, n= 15 | PR Interval, Day 4, 4 hours post-dose, n= 15 | PR Interval, Day 7, Pre-dose, n= 15 | PR Interval, Day 7, 2 hours post-dose, n= 15 | PR Interval, Day 7, 4 hours post-dose, n= 15 | PR Interval, Day 9 post-dose, n= 15 | QRS Duration, Day 1, 2 hours post-dose, n= 16 | QRS Duration, Day 1, 4 hours post-dose, n= 16 | QRS Duration, Day 4, Pre-dose, n= 15 | QRS Duration, Day 4, 2 hours post-dose, n= 15 | QRS Duration, Day 4, 4 hours post-dose, n= 15 | QRS Duration, Day 7, Pre-dose, n= 15 | QRS Duration, Day 7, 2 hours post-dose, n= 15 | QRS Duration, Day 7, 4 hours post-dose, n= 15 | QRS Duration, Day 9 post-dose, n= 15 | QT Interval, Day 1, 2 hours post-dose, n= 16 | QT Interval, Day 1, 4 hours post-dose, n= 16 | QT Interval, Day 4, Pre-dose, n= 15 | QT Interval, Day 4, 2 hours post-dose, n= 15 | QT Interval, Day 4, 4 hours post-dose, n= 15 | QT Interval, Day 7, Pre-dose, n= 15 | QT Interval, Day 7, 2 hours post-dose, n= 15 | QT Interval, Day 7, 4 hours post-dose, n= 15 | QT Interval, Day 9 post-dose, n= 15 | QTcF Interval, Day 1, 2 hours post-dose, n= 16 | QTcF Interval, Day 1, 4 hours post-dose, n= 16 | QTcF Interval, Day 4, Pre-dose, n= 15 | QTcF Interval, Day 4, 2 hours post-dose, n= 15 | QTcF Interval, Day 4, 4 hours post-dose, n= 15 | QTcF Interval, Day 7, Pre-dose, n= 15 | QTcF Interval, Day 7, 2 hours post-dose, n= 15 | QTcF Interval, Day 7, 4 hours post-dose, n= 15 | QTcF Interval, Day 9 post-dose, n= 15 | QTcB Interval, Day 1, 2 hours post-dose, n= 16 | QTcB Interval, Day 1, 4 hours post-dose, n= 16 | QTcB Interval, Day 4, Pre-dose, n= 15 | QTcB Interval, Day 4, 2 hours post-dose, n= 15 | QTcB Interval, Day 4, 4 hours post-dose, n= 15 | QTcB Interval, Day 7, Pre-dose, n= 15 | QTcB Interval, Day 7, 2 hours post-dose, n= 15 | QTcB Interval, Day 7, 4 hours post-dose, n= 15 | QTcB Interval, Day 9 post-dose, n= 15 | |
| TAF/FTC+GSK3640254 | -6.8 | -3.7 | -0.5 | -6.9 | -3.9 | -2.7 | -3.3 | -3.7 | 1.2 | -2.5 | -1.4 | 0.5 | 0.5 | -0.2 | 3.3 | 1.5 | 0.3 | 3.0 | -12.6 | -1.8 | 7.3 | -6.8 | 5.6 | 3.5 | -8.4 | 5.8 | 4.1 | -4.4 | 2.4 | 6.1 | -0.6 | 4.5 | 4.1 | -5.1 | 0.6 | 7.9 | 0.7 | 4.7 | 5.5 | 2.5 | 4.3 | 4.6 | -3.2 | -1.7 | 10.3 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
| Intervention | Beats per minute (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 1, 2 hours post-dose, n= 16 | Day 1, 4 hours post-dose, n= 16 | Day 4, Pre-dose, n= 15 | Day 4, 2 hours post-dose, n= 15 | Day 4, 4 hours post-dose, n= 15 | Day 7, Pre-dose, n= 15 | Day 7, 2 hours post-dose, n= 15 | Day 7, 4 hours post-dose, n= 15 | Day 9 post-dose, n= 15 | |
| TAF/FTC+GSK3640254 | 5.0 | 2.8 | -0.5 | 3.3 | -0.3 | 0.3 | 1.8 | -2.3 | 2.1 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Trillion cells per liter (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -0.113 | 0.000 | -0.189 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Proportion of red blood cells in blood (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -0.0147 | -0.0007 | -0.0204 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Grams per liter (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -3.9 | -1.1 | -6.4 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Picograms (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -0.11 | -0.21 | -0.17 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Femtoliters (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -1.02 | -0.17 | -0.82 |
Blood samples were collected at indicated timepoints for analysis for hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Giga cells per liter (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Period 2 Day 3, n= 15 | Basophils, Period 2 Day 7, n= 15 | Basophils, Period 2 Day 9, n= 15 | Eosinophils, Period 2 Day 3, n=15 | Eosinophils, Period 2 Day 7, n=15 | Eosinophils, Period 2 Day 9, n=16 | Monocytes, Period 2 Day 3, n= 16 | Monocytes, Period 2 Day 7, n= 15 | Monocytes, Period 2 Day 9, n= 15 | Leukocytes, Period 2 Day 3, n= 16 | Leukocytes, Period 2 Day 7, n= 15 | Leukocytes, Period 2 Day 9, n= 15 | Lymphocytes, Period 2 Day 3, n= 16 | Lymphocytes, Period 2 Day 7, n= 15 | Lymphocytes, Period 2 Day 9, n= 15 | Neutrophils, Period 2 Day 3, n= 16 | Neutrophils, Period 2 Day 7, n= 15 | Neutrophils, Period 2 Day 9, n= 15 | Platelets, Period 2 Day 3, n= 16 | Platelets, Period 2 Day 7, n= 15 | Platelets, Period 2 Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | -0.004 | -0.002 | 0.003 | -0.023 | -0.039 | -0.043 | -0.053 | -0.077 | -0.104 | -1.06 | -0.61 | -0.49 | -0.158 | -0.105 | -0.111 | -0.868 | -0.417 | -0.282 | 9.2 | 19.8 | 16.2 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | pH (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.19 | 0.10 | 0.10 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Beats per minute (Mean) | |||
|---|---|---|---|---|
| Day 4 | Day 7 | Day 9 | Day 10 | |
| TAF/FTC+GSK3640254 | 2.4 | 1.9 | -0.3 | 9.5 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Breaths per minute (Mean) | |||
|---|---|---|---|---|
| Day 4 | Day 7 | Day 9 | Day 10 | |
| TAF/FTC+GSK3640254 | -3.2 | -2.4 | -0.8 | -1.5 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Ratio (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.0031 | 0.0024 | 0.0005 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 4, 7, 9, and 10
| Intervention | Degree Celsius (Mean) | |||
|---|---|---|---|---|
| Day 4 | Day 7 | Day 9 | Day 10 | |
| TAF/FTC+GSK3640254 | -0.10 | -0.07 | -0.01 | 0.07 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value. (NCT03836729)
Timeframe: Baseline and at Days 3, 7, 9
| Intervention | Micromoles per liter (Mean) | ||
|---|---|---|---|
| Day 3, n= 16 | Day 7, n= 15 | Day 9, n= 15 | |
| TAF/FTC+GSK3640254 | 0.0000 | 0.0000 | 0.0000 |
Change in maternal antepartum weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline through before delivery (up to one day prior)
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.378 |
| Arm 2: Maternal DTG+FTC/TDF | 0.319 |
| Arm 3: Maternal EFV/FTC/TDF | 0.291 |
Change in maternal weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline to 50 weeks postpartum
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | -0.027 |
| Arm 2: Maternal DTG+FTC/TDF | -0.050 |
| Arm 3: Maternal EFV/FTC/TDF | -0.084 |
Change in maternal postpartum weight per week based on generalized estimating equations (NCT03048422)
Timeframe: Delivery to 50 weeks postpartum
| Intervention | kg/week (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.014 |
| Arm 2: Maternal DTG+FTC/TDF | -0.008 |
| Arm 3: Maternal EFV/FTC/TDF | -0.032 |
Count of infants with HIV-1 antiretroviral drug resistance mutations (to any antiretroviral drug) at the time of infant HIV diagnosis, based on laboratory blood test results. (NCT03048422)
Timeframe: From birth through 50 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 Infants | 1 |
| Arm 2 Infants | 0 |
| Arm 3 Infants | 1 |
The Kaplan-Meier estimate of the cumulative probability of infant deaths from birth through 50 weeks after birth. (NCT03048422)
Timeframe: Birth through 50 weeks after birth
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 1.0 |
| Arm 2 Infants | 2.0 |
| Arm 3 Infants | 6.9 |
The Kaplan-Meier estimate of the cumulative probability of infants acquiring HIV-1 infection from birth through 50 weeks after birth based on nucleic acid test results. (NCT03048422)
Timeframe: Birth through 50 weeks after birth
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 0.98 |
| Arm 2 Infants | 0.50 |
| Arm 3 Infants | 0.55 |
The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause. (NCT03048422)
Timeframe: Birth through Week 50 postpartum
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arms 1 and 2 Infants | 26.8 |
| Arm 3 Infants | 30.9 |
The Kaplan-Meier estimate of the cumulative probability of infants experiencing grade 3 or higher adverse events, including events resulting in death due to any cause. (NCT03048422)
Timeframe: From birth through Week 50 postpartum
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1 Infants | 25.3 |
| Arm 2 Infants | 28.6 |
| Arm 3 Infants | 30.9 |
"The Kaplan-Meier estimate of the cumulative probability of women experiencing grade 3 or higher adverse events, including events resulting in death due to any cause.~Time to first maternal grade 3 or higher adverse event was defined as the first grade 3 or higher adverse event that occurred after randomization and before 74 weeks of follow-up. The timeframe of 74 weeks was determined by adding up 56 weeks of postpartum follow-up to the mean duration of antepartum follow-up, which was 18 weeks." (NCT03048422)
Timeframe: From randomization up to 74 weeks
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 25.1 |
| Arm 2: Maternal DTG+FTC/TDF | 30.8 |
| Arm 3: Maternal EFV/FTC/TDF | 27.9 |
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 27.9 |
| Arm 3: Maternal EFV/FTC/TDF | 27.9 |
Maternal change in creatinine clearance per week based on generalized estimating equations (NCT03048422)
Timeframe: Baseline to 50 weeks postpartum
| Intervention | mL/min (Mean) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | -0.980 |
| Arm 2: Maternal DTG+FTC/TDF | -0.887 |
| Arm 3: Maternal EFV/FTC/TDF | -0.935 |
Percentage of infants born small for gestational age (<10th percentile adjusted for sex assigned at birth) based on Intergrowth 21st Standards (NCT03048422)
Timeframe: Birth
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 Infants | 16.3 |
| Arm 2 Infants | 22.5 |
| Arm 3 Infants | 20.5 |
Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (<20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (<37 completed weeks), or small for gestational age (<10th percentile by INTERGROWTH 21st Standards) (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 24.1 |
| Arm 2: Maternal DTG+FTC/TDF | 32.9 |
| Arm 3: Maternal EFV/FTC/TDF | 32.7 |
Percentage of mother-infant pairs with an adverse pregnancy outcome. Adverse pregnancy outcome includes spontaneous abortion (<20 weeks gestation), stillbirth (≥20 weeks gestation), preterm delivery (<37 completed weeks), or small for gestational age (<10th percentile per INTERGROWTH 21st Standards) (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 28.4 |
| Arm 3: Maternal EFV/FTC/TDF | 32.7 |
Percentage of mother-infant pairs with an adverse pregnancy outcome or major congenital anomaly. Adverse pregnancy outcomes include spontaneous abortions (<20 weeks gestation), stillbirths (≥20 weeks gestation), preterm deliveries (<37 weeks gestation), and infants small for gestational age (<10th percentile per INTERGROWTH 21st Standards). Major congenital anomaly was defined consistent with the definition of malformation provided by Holmes and Westgate (i.e., a structural abnormality with surgical, medical, or cosmetic importance) and evaluated by an internal study team blinded to treatment arm. (NCT03048422)
Timeframe: Delivery through 50 weeks postpartum
| Intervention | percentage of mother-infant pairs (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 24.1 |
| Arm 2: Maternal DTG+FTC/TDF | 32.9 |
| Arm 3: Maternal EFV/FTC/TDF | 33.2 |
Percentage of mother-infant pairs with preterm deliveries (<37 weeks gestation) resulting in live born infant (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 5.8 |
| Arm 2: Maternal DTG+FTC/TDF | 9.4 |
| Arm 3: Maternal EFV/FTC/TDF | 12.1 |
Percentage of mothers with HIV-1 antiretroviral (ARV) drug resistance mutations at the time of maternal virologic failure. Virologic failure was defined as two consecutive plasma HIV-1 RNA viral loads <200 copies/mL on or after 24 weeks on study. Drug resistance mutations were assessed using the Stanford algorithm, and all ARV regimens were assessed for mutations. (NCT03048422)
Timeframe: From 24 weeks after randomization through Week 50 postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 0.92 |
| Arm 2: Maternal DTG+FTC/TDF | 1.86 |
| Arm 3: Maternal EFV/FTC/TDF | 6.16 |
Percentage of mothers with HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: 50 weeks postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 96.3 |
| Arm 3: Maternal EFV/FTC/TDF | 96.4 |
Percentage of mothers with HIV-1 RNA less than 50 copies/mL at delivery using batched test results obtained from central laboratory (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 94.4 |
| Arm 3: Maternal EFV/FTC/TDF | 78.8 |
Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at 50 weeks postpartum based on FDA snapshot algorithm using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: 50 weeks postpartum
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 75.6 |
| Arm 2: Maternal DTG+FTC/TDF | 77.7 |
| Arm 3: Maternal EFV/FTC/TDF | 76.3 |
Percentage of mothers with virologic success of HIV-1 RNA less than 200 copies/mL at delivery based on FDA snapshot algorithm using real-time test results obtained from site laboratories (NCT03048422)
Timeframe: Delivery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Maternal DTG+FTC/TAF | 88.9 |
| Arm 2: Maternal DTG+FTC/TDF | 92.6 |
| Arm 3: Maternal EFV/FTC/TDF | 81.0 |
Time to first viral HIV-1 RNA less than 200 copies/mL through delivery, determined using real-time results obtained from site laboratories (NCT03048422)
Timeframe: Randomization to delivery
| Intervention | weeks (Mean) |
|---|---|
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 4.26 |
| Arm 3: Maternal EFV/FTC/TDF | 6.49 |
Infant creatinine clearance based on Schwartz formula (NCT03048422)
Timeframe: Delivery and 26 weeks postpartum
| Intervention | mL/min (Mean) | |
|---|---|---|
| Delivery | 26 Weeks Postpartum | |
| Arm 1 Infants | 52.7 | 134.8 |
| Arm 2 Infants | 53.1 | 123.6 |
| Arm 3 Infants | 49.0 | 135.0 |
Percentage of mothers with plasma HIV-1 RNA viral load less than 200 copies/mL at delivery determined using real-time test results obtained at site laboratories. This outcome was evaluated in the non-inferiority (primary outcome) and superiority (secondary outcome) analyses. The intention-to-treat analysis included all randomized women who had viral load data available. The per-protocol analysis excluded women who modified randomized treatment (stopped, paused, switched, added any treatment) before viral load evaluation at delivery, with the exception of women who modified randomized treatment for use of a concomitant medication. (NCT03048422)
Timeframe: Delivery
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Intention-to-Treat Analysis | Per-Protocol Analysis | |
| Arm 3: Maternal EFV/FTC/TDF | 91.0 | 91.4 |
| Arms 1 and 2: Maternal DTG+FTC/TAF and DTG+FTC/TDF | 97.5 | 97.5 |
The analysis includes values up to 1 day after permanent discontinuation of study treatment. (NCT03631732)
Timeframe: Baseline to Week 24
| Intervention | cells/uL (Mean) |
|---|---|
| B/F/TAF | 13 |
| Stay on Baseline Regimen (SBR) | 1 |
The analysis includes values up to 1 day after permanent discontinuation of study treatment. (NCT03631732)
Timeframe: Baseline to Week 24
| Intervention | cells/uL (Mean) |
|---|---|
| B/F/TAF | 13 |
| Stay on Baseline Regimen (SBR) | 4 |
The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF. (NCT03631732)
Timeframe: Baseline to Week 48
| Intervention | cells/uL (Mean) |
|---|---|
| B/F/TAF | 7 |
| Delayed B/F/TAF | -8 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation. (NCT03631732)
Timeframe: First B/F/TAF dose date up to Week 72 plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 83.3 |
| Delayed B/F/TAF | 69.3 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'. (NCT03631732)
Timeframe: First B/F/TAF dose date up to Week 72 plus 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 87.8 |
| Delayed B/F/TAF | 80.4 |
The percentage of participants who had HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT03631732)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 96.3 |
| Stay on Baseline Regimen (SBR) | 94.5 |
The percentage of participants who had HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT03631732)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 99.3 |
| Stay on Baseline Regimen (SBR) | 98.0 |
The percentage of participants who had HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF. (NCT03631732)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 94.5 |
| Delayed B/F/TAF | 96.9 |
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT03631732)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 0.6 |
| Stay on Baseline Regimen (SBR) | 1.8 |
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF. (NCT03631732)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| B/F/TAF | 0.9 |
| Delayed B/F/TAF | 0 |
Proportion of participants adherent to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations > 719 fmol/punch at Week 12 and the last on-drug visit. (NCT01761643)
Timeframe: Baseline to Week 48
| Intervention | % participants with > 719 fmol/punch (Number) | |
|---|---|---|
| Wk 12 | Wk 48 | |
| SoC + iTab | 91.7 | 83.4 |
| Standard of Care (SoC) | 85.6 | 81.6 |
Proportion of participants with perfect adherence to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations > 1246 fmol/punch at Week 12 and the last on-drug visit. (NCT01761643)
Timeframe: Baseline to Week 48
| Intervention | % participants with > 1246 fmol/punch (Number) | |
|---|---|---|
| Wk 12 | Wk 48 | |
| SoC + iTab | 50.8 | 51 |
| Standard of Care (SoC) | 43.9 | 37.4 |
Determine the rate of HIV seroconversion in PrEP users and compare the iTAB to SOC arms for number of new infections as a proportion at 48 weeks and end of study. (NCT01761643)
Timeframe: Up to 2.5 years after baseline
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Wk 48 | End of Study | |
| SoC + iTab | 2 | 2 |
| Standard of Care (SoC) | 0 | 0 |
(NCT02469246)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| F/TAF | -30 |
| ABC/3TC | 2 |
(NCT02469246)
Timeframe: Baseline; Week 96
| Intervention | cells/μL (Mean) |
|---|---|
| F/TAF | -29 |
| ABC/3TC | 10 |
(NCT02469246)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| F/TAF | 0.169 |
| ABC/3TC | 0.021 |
(NCT02469246)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| F/TAF | 0.246 |
| ABC/3TC | 0.086 |
(NCT02469246)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| F/TAF | 0.081 |
| ABC/3TC | -0.052 |
(NCT02469246)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| F/TAF | 0.178 |
| ABC/3TC | 0.235 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 85.7 |
| ABC/3TC | 87.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 80.4 |
| ABC/3TC | 86.2 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 88.6 |
| ABC/3TC | 92.4 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 82.1 |
| ABC/3TC | 88.4 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 1.8 |
| ABC/3TC | 0.7 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF | 2.5 |
| ABC/3TC | 1.1 |
CD4 cells were counted from blood collected at baseline and week 96, and the change from baseline determined from week 96 minus baseline values. (NCT02131233)
Timeframe: Baseline and Week 96
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Reformulated Raltegravir | 261.6 |
| Raltegravir | 262.2 |
CD4 cells were counted from blood collected at baseline and week 48, and the change from baseline determined from week 48 minus baseline values. (NCT02131233)
Timeframe: Baseline and Week 48
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Reformulated Raltegravir | 232.0 |
| Raltegravir | 234.1 |
"From blood samples collected at week 48, HIV-1 RNA levels were determined by the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification (LoQ) of 40 copies/mL. The NC=F approach as defined by FDA snapshot approach was used as the primary approach to analysis where all missing data were treated as failures regardless of the reason." (NCT02131233)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 88.9 |
| Raltegravir | 88.3 |
"From blood samples collected at week 96, HIV-1 RNA levels were determined by the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification (LoQ) of 40 copies/mL. The NC=F approach as defined by FDA snapshot approach was used as the primary approach to analysis where all missing data were treated as failures regardless of the reason." (NCT02131233)
Timeframe: Week 96
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 81.5 |
| Raltegravir | 80.1 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE (NCT02131233)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 1.1 |
| Raltegravir | 2.3 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE (NCT02131233)
Timeframe: Up to Week 96
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 1.3 |
| Raltegravir | 2.3 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. An investigator who is a qualified physician evaluated whether or not an AE was drug-related. (NCT02131233)
Timeframe: Up to Week 98 (96 weeks of treatment + 2 weeks of follow up)
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 26.4 |
| Raltegravir | 28.6 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. An investigator who is a qualified physician evaluated whether or not an AE was drug-related. (NCT02131233)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 25.0 |
| Raltegravir | 27.1 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. (NCT02131233)
Timeframe: Up to Week 98 (96 weeks of treatment + 2 weeks of follow up)
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 9.6 |
| Raltegravir | 15.8 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. (NCT02131233)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 6.2 |
| Raltegravir | 9.4 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. An investigator who is a qualified physician evaluated whether or not a SAE is drug-related. (NCT02131233)
Timeframe: Up to Week 98 (96 weeks of treatment + 2 weeks of follow up)
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 0.2 |
| Raltegravir | 0.8 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. An investigator who is a qualified physician evaluated whether or not a SAE is drug-related. (NCT02131233)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 0.2 |
| Raltegravir | 0.8 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT02131233)
Timeframe: Up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 83.2 |
| Raltegravir | 88.0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT02131233)
Timeframe: Up to Week 98 (96 weeks of treatment + 2 weeks of follow up)
| Intervention | Percentage of participants (Number) |
|---|---|
| Reformulated Raltegravir | 90.8 |
| Raltegravir | 94.0 |
HIV viral load, binary cutoff at assay level of detection (<20 copies/mL vs. >= 20 copies/mL); reference group: drug concentration (TFV-DP) < 350 femtomole (fmol)/punch vs. drug concentration (TFV-DP) >= 1850 fmol/punch; adjusted odds ratio calculated using generalized estimating equations; concentration cutoffs established in prior research of healthy volunteers (NCT02012621)
Timeframe: Up to 48 Weeks
| Intervention | Adjusted odds ratio (aOR) (Number) |
|---|---|
| Study Cohort | 73.5 |
HIV viral load, binary cutoff at assay level of detection (<20 copies/mL vs. >= 20 copies/mL); drug concentration (TFV-DP) <800 femtomole (fmol)/punch) vs reference group of drug concentration (TFV-DP) >= 1650 fmol/punch; adjusted odds ratio calculated using generalized estimating equations (NCT02012621)
Timeframe: Up to 48 Weeks
| Intervention | Adjusted odds ratio (aOR) (Number) |
|---|---|
| Study Cohort | 4.7 |
HIV viral load, binary cutoff at assay level of detection (<20 copies/mL vs. >= 20 copies/mL); reference group: three-month self-reported adherence <28.5% vs. three-month self-reported adherence 100%; adherence cutoffs established in prior research (NCT02012621)
Timeframe: Up to 48 Weeks
| Intervention | Adjusted odds ratio (aOR) (Number) |
|---|---|
| Study Cohort | 8.5 |
(NCT02384395)
Timeframe: Baseline, Week 24
| Intervention | copies/mL (Median) |
|---|---|
| DTG/3TC/ABC FDC | -590211 |
Sign/symptom, lab toxicity, or clinical events, or Grade 3 or higher AE that is definitely, probably, or possibly related to study treatment (NCT02384395)
Timeframe: Baseline through Week 96
| Intervention | Participants (Count of Participants) |
|---|---|
| DTG/3TC/ABC FDC | 1 |
Total number of participants on study at Week 24 with an HIV-1 RNA level less than 200 copies/mL (NCT02384395)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| DTG/3TC/ABC FDC | 34 |
Proportion of participants completing Week 48 with an HIV-1 RNA level less than 50 copies/mL (NCT02384395)
Timeframe: Week 48
| Intervention | proportion of participants (Number) |
|---|---|
| DTG/3TC/ABC FDC | 0.88 |
(NCT01108510)
Timeframe: Baseline to Week 144
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 310 |
| ATV+RTV+FTC/TDF | 332 |
(NCT01108510)
Timeframe: Baseline to Week 192
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 350 |
| ATV+RTV+FTC/TDF | 343 |
(NCT01108510)
Timeframe: Baseline to Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 213 |
| ATV+RTV+FTC/TDF | 219 |
(NCT01108510)
Timeframe: Baseline to Week 96
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 277 |
| ATV+RTV+FTC/TDF | 287 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm. (NCT01108510)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 72.1 |
| ATV+RTV+FTC/TDF | 74.1 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 192 was analyzed using the snapshot algorithm. (NCT01108510)
Timeframe: Week 192
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 71.6 |
| ATV+RTV+FTC/TDF | 79.7 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the prespecified time point within an allowed window of time, along with study drug discontinuation status. (NCT01108510)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 85.2 |
| ATV+RTV+FTC/TDF | 87.4 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm. (NCT01108510)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 77.9 |
| ATV+RTV+FTC/TDF | 79.3 |
Defined as self-reported opioid use in prior month (NCT04521920)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 6 |
Defined as self-reported opioid use in prior month. (NCT04521920)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 5 |
Measured via negative HIV test. (NCT04521920)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 8 |
Measured via negative HIV test. (NCT04521920)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 3 |
Defined as the number of participants who remain on treatment (MOUD or PrEP). (NCT04521920)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 13 |
Defined as the number of participants who remain on treatment (MOUD or PrEP). (NCT04521920)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medication and Telemedicine Follow up | 12 |
Number of participants experiencing any Grade 2 or higher clinical and laboratory AEs to evaluate the safety of the injectable product, TMC278 LA (1200 mg dose administered at Weeks 4, 12, 20, 28, 36 and 44), through 48 weeks after initial injection (at Week 52) in women in SSA and the US. (NCT02165202)
Timeframe: Up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Rilpivirine | 59 |
| Placebo | 31 |
Mean number of days that participants took study drug based on study drug diaries by study group. (NCT00119106)
Timeframe: Participants were asked about adherence at 3 month visits, up to 6.9 years.
| Intervention | days (Mean) |
|---|---|
| Tenofovir | 84 |
| Placebo | 84 |
Number of Participants with adverse clinical events in tenofovir and placebo arms (NCT00119106)
Timeframe: Up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 1098 |
| Placebo | 1083 |
Plasma HIV RNA concentrations. (NCT00119106)
Timeframe: Among people who seroconverted, viral load was measured at month 1, 2, and every 4 months after HIV seroconversion
| Intervention | Copies/mL (Mean) |
|---|---|
| Tenofovir | 929829 |
| Placebo | 120061 |
"Number of Participants reporting injecting and sharing needles:~Assessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing." (NCT00119106)
Timeframe: Participants were asked about injecting and needle sharing behaviors at enrollment and every 3 month visit, up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 58 |
| Placebo | 59 |
Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups. (NCT00119106)
Timeframe: Specimens collected at the time of HIV seroconversion
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir | 0 |
| Placebo | 0 |
Number of participants (NCT00119106)
Timeframe: At enrolment
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir Group | 251 |
| Placebo Group | 271 |
Kaplan Meier survival curve. (NCT00119106)
Timeframe: From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years
| Intervention | Infections/ 100 person-years (Number) |
|---|---|
| Tenofovir | 17 |
| Placebo | 33 |
Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities (NCT00119106)
Timeframe: Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years
| Intervention | participants (Number) |
|---|---|
| Tenofovir | 3 |
| Placebo | 3 |
Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 3466 |
| TAF With a Boosted PI | 743 |
| TAF With a Boosted PI and LDV/SOF | 868 |
Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks
| Intervention | fmol/2x7mm punches (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 36014 |
| TAF With a Boosted PI | 6735 |
| TAF With a Boosted PI and LDV/SOF | 6100 |
Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks
| Intervention | fmol/10^6 cells (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 83.0 |
| TAF With a Boosted PI | 926 |
| TAF With a Boosted PI and LDV/SOF | 1129 |
Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mL/min/1.73 m^2 (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 86.7 |
| TAF With a Boosted PI | 91.0 |
| TAF With a Boosted PI and LDV/SOF | 88.1 |
Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mg/g (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 134 |
| TAF With a Boosted PI | 118 |
| TAF With a Boosted PI and LDV/SOF | 97.3 |
Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | ug/g (Geometric Mean) | |
|---|---|---|
| β2M:Cr ratio | RBP:Cr ratio | |
| TAF With a Boosted PI | 224 | 242 |
| TAF With a Boosted PI and LDV/SOF | 178 | 146 |
| TDF With a Boosted PI | 419 | 436 |
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data. (NCT01227824)
Timeframe: Week 4, Week 24, and Week 48
| Intervention | Micrograms*hour per milliliter(µg*hr/mL) (Geometric Mean) |
|---|---|
| DTG 50 mg Once a Day | 53.6 |
The number of participants with plasma HIV-1 RNA level <50 c/mL was assessed at Week 96. (NCT01227824)
Timeframe: Week 96
| Intervention | Participants (Number) |
|---|---|
| DTG 50 mg Once a Day | 332 |
| RTG 400 mg BID | 314 |
Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with <50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication. (NCT01227824)
Timeframe: Baseline up to Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| DTG 50 mg Once a Day | 88 |
| RTG 400 mg BID | 85 |
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). (NCT01227824)
Timeframe: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
| Intervention | cells/mm^3 (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline n=411, 411 | Week 4, n=398, 403 | Week 8, n=398, 402 | Week 12, n=392, 397 | Week 16, n=394, 392 | Week 24, n=392, 389 | Week 32, n=384, 375 | Week 40, n=371, 357 | Week 48, n=374, 357 | Week 60, n=367, 355 | Week 72, n=360, 350 | Week 84, n=351, 338 | Week 96, n=343, 328 | |
| DTG 50 mg Once a Day | 379.2 | 474.2 | 502.3 | 513.3 | 536.4 | 582.0 | 606.5 | 609.1 | 623.8 | 635.6 | 635.2 | 668.0 | 679.8 |
| RTG 400 mg BID | 374.3 | 471.8 | 502.4 | 518.3 | 550.1 | 580.8 | 618.7 | 623.1 | 641.2 | 648.5 | 664.0 | 677.5 | 672.4 |
Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). (NCT01227824)
Timeframe: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
| Intervention | log10 c/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline n=411, 411 | Week 4, n=402, 406 | Week 8, n=397, 402 | Week 12, n=396, 395 | Week 16, n=395, 388 | Week 24, n=393, 390 | Week 32, n=386, 377 | Week 40, n=375, 358 | Week 48, n=374, 358 | Week 60, n=366, 355 | Week 72, n=361, 350 | Week 84, n=352, 338 | Week 96, n=342, 329 | |
| DTG 50 mg Once a Day | 4.538 | 1.718 | 1.646 | 1.626 | 1.620 | 1.643 | 1.620 | 1.603 | 1.606 | 1.605 | 1.601 | 1.607 | 1.599 |
| RTG 400 mg BID | 4.599 | 1.800 | 1.709 | 1.672 | 1.648 | 1.655 | 1.636 | 1.601 | 1.599 | 1.599 | 1.605 | 1.614 | 1.630 |
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). (NCT01227824)
Timeframe: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
| Intervention | Cells per cubic millimeter (cells/mm^3) (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline n=411, 411 | Week 4, n=398, 403 | Week 8, n=398, 402 | Week 12, n=392, 397 | Week 16, n=394, 392 | Week 24, n=392, 389 | Week 32, n=384, 375 | Week 40, n=371, 357 | Week 48, n=374, 357 | Week 60, n=367, 355 | Week 72, n=360, 350 | Week 84, n=351, 338 | Week 96, n=343, 328 | |
| DTG 50 mg Once a Day | 379.2 | 93.3 | 121.6 | 130.7 | 155.1 | 199.3 | 223.4 | 224.1 | 238.9 | 247.8 | 247.8 | 281.3 | 292.2 |
| RTG 400 mg BID | 374.3 | 97.2 | 126.6 | 145.1 | 173.0 | 204.2 | 241.3 | 239.8 | 257.5 | 264.2 | 278.6 | 292.9 | 286.2 |
Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles). (NCT01227824)
Timeframe: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
| Intervention | log10 c/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline n=411, 411 | Week 4, n=402, 406 | Week 8, n=397, 402 | Week 12, n=396, 395 | Week 16, n=395, 388 | Week 24, n=393, 390 | Week 32, n=386, 377 | Week 40, n=375, 358 | Week 48, n=374, 358 | Week 60, n=366, 355 | Week 72, n=361, 350 | Week 84, n=352, 338 | Week 96, n=342, 329 | |
| DTG 50 mg Once a Day | 4.538 | -2.817 | -2.897 | -2.908 | -2.917 | -2.896 | -2.907 | -2.920 | -2.915 | -2.912 | -2.917 | -2.932 | -2.938 |
| RTG 400 mg BID | 4.599 | -2.801 | -2.886 | -2.918 | -2.943 | -2.933 | -2.947 | -2.946 | -2.942 | -2.937 | -2.932 | -2.916 | -2.901 |
The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. (NCT01227824)
Timeframe: Week 4, Week 24, and Week 48
| Intervention | Micrograms per milliliter (µg/mL) (Geometric Mean) | |
|---|---|---|
| Cmax | Ctau | |
| DTG 50 mg Once a Day | 3.69 | 1.10 |
Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell. (NCT01227824)
Timeframe: Week 48 and Week 96
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Week 48, genotypic | Week 48, phenotypic | Week 96, genotypic | Week 96, phenotypic | |
| DTG 50 mg Once a Day | 0 | 1 | 0 | 1 |
| RTG 400 mg BID | 1 | 2 | 1 | 2 |
The number of participants with plasma HIV-1 RNA level <400 c/mL was assessed at Week 48 and Week 96. (NCT01227824)
Timeframe: Week 48 and Week 96
| Intervention | Participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| DTG 50 mg Once a Day | 369 | 338 |
| RTG 400 mg BID | 356 | 321 |
All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product (NCT01227824)
Timeframe: From Baseline until Week 96
| Intervention | Participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT | ALP | AST | CO2 content/bicarbonate | Cholesterol | CK | Creatinine | Hyperglycaemia | Hyperkalemia | Hypernatremia | Hypoglycaemia | Hypokalemia | Hyponatremia | LDL cholesterol calculation | Lipase | Phosphorus, inorganic | Total bilirubin | Triglycerides | Hemoglobin | Platelet count | Total neutrophils | White Blood Cell count | |
| DTG 50 mg Once a Day | 57 | 7 | 67 | 58 | 90 | 61 | 11 | 70 | 7 | 4 | 17 | 10 | 34 | 74 | 55 | 65 | 27 | 7 | 10 | 19 | 54 | 19 |
| RTG 400 mg BID | 70 | 15 | 75 | 67 | 73 | 47 | 7 | 87 | 4 | 6 | 27 | 15 | 48 | 49 | 62 | 71 | 24 | 8 | 5 | 19 | 48 | 7 |
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death. (NCT01227824)
Timeframe: From Baseline until Week 96
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any category condition | Any Category B condition | Any Category C condition | Any death | Progression from CAT A to CAT C | Progression from CAT B to CAT C | Progression from CAT C to new CAT C | Progression from CAT A, B, or C to death | |
| DTG 50 mg Once a Day | 10 | 3 | 6 | 1 | 4 | 3 | 0 | 1 |
| RTG 400 mg BID | 8 | 3 | 4 | 1 | 2 | 1 | 1 | 1 |
Participants who seroconverted had blood samples taken at the time of infection and at one month and six months post seroconversion to detect any HIV resistance mutations. (NCT00448669)
Timeframe: At time HIV infection diagnosed,1 month post-time of HIV infection diagnosis, and 6 months post-time of HIV infection diagnosis
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF-FTC, Condoms, Risk Counseling | 1 |
| Placebo, Condoms, Risk Counseling | 1 |
Study medication was stopped when HIV infected was diagnosed. Seroconvertors were referred for clinical care and followed an additional year with scheduled quarterly CD4+ cell count assessments. A model-estimated geometric mean of the CD4+ cell counts by each treatment group was evaluated. (NCT00448669)
Timeframe: 1-year post seroconversion
| Intervention | cells/microliter (Geometric Mean) |
|---|---|
| TDF-FTC Seroconvertor Group | 500 |
| Placebo Seroconvertor Group | 466 |
Study visits were scheduled every 30 days until completion of the study and during monthly study visits, we performed testing for HIV infection. At completion of the study, we tested all participants for HIV infection, using an enzyme-linked immunosorbent assay (ELISA).The primary efficacy end point was the difference in the rates of HIV infection between participants assigned to receive TDF-FTC and those assigned to receive placebo. The initial efficacy analysis included all study participants who were randomly assigned to receive a study medication (intention-to-treat cohort). (NCT00448669)
Timeframe: Monthly, for up to 3 years
| Intervention | infections/100 person-years (Number) |
|---|---|
| TDF-FTC, Condoms, Risk Counseling | 1.2 |
| Placebo, Condoms, Risk Counseling | 3.1 |
Study visits were scheduled every 30 days until completion of the study, and participants were instructed to return to the clinic for evaluation in the event of an illness. Participants reported any adverse effects at monthly visits and interim visits. (NCT00448669)
Timeframe: Monthly, for up to 3 years
| Intervention | percentage of participants with AE (Number) |
|---|---|
| TDF-FTC, Condoms, Risk Counseling | 91.2 |
| Placebo, Condoms, Risk Counseling | 88.2 |
The rates of adherence to study medication by treatment arm was assessed over the entire course of the study. This comparison was done by assessing the percentage of pills taken by participants within each study arm. The difference between the 2 arms was compared with a Fisher' exact test. (NCT00448669)
Timeframe: 36 months
| Intervention | Percentage of pills taken (Mean) |
|---|---|
| TDF-FTC, Condoms, Risk Counseling | 93.5 |
| Placebo, Condoms, Risk Counseling | 93.6 |
We assessed condom use of the enrolled participants by face-to-face interviews (at baseline and monthly thereafter) and provided a comprehensive package of HIV prevention services, including individualized counseling on risk reduction, free male and female condoms, and screening for sexually transmitted infections followed, if applicable, by partner notification and treatment. (NCT00448669)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
| Placebo, Condoms, Risk Counseling | 113 | 86 | 90 | 83 | 66 | 61 | 67 | 45 | 49 | 45 | 36 | 33 | 30 |
| TDF-FTC, Condoms, Risk Counseling | 124 | 94 | 97 | 92 | 73 | 67 | 70 | 55 | 57 | 55 | 51 | 36 | 54 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
An HIV RNA decline of >=0.5 log by day 10 will be considered to be an adequate virologic response, to proceed to the second phase of the study. (NCT02556333)
Timeframe: 10 days
| Intervention | log HIV RNA copies/mL (Number) |
|---|---|
| TAF Treatment | 0.01 |
CD4 cell count for HIV infected participants during the trial (NCT00458393)
Timeframe: at the time infection was detected
| Intervention | cells per cubic mm (Mean) |
|---|---|
| TDF/FTC | 495 |
| Placebo | 502 |
Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status. (NCT00458393)
Timeframe: At 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 332 |
| Placebo | 348 |
Diagnosis of gonorrhea during the follow-up period by PCR (NCT00458393)
Timeframe: All of follow-up period, median of 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 18 |
| Placebo | 30 |
Creatinine which reach grade 1 (mild, 1.1 to 1.3 local upper limit of normal) or higher by the US Division of AIDS grading table (version 1) or a 50% increase in creatinine from the baseline value. The DAIDS table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf (NCT00458393)
Timeframe: Duration of follow-up, median 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 32 |
| Placebo | 24 |
Number of participants with at least 1 Grade 2, 3, or 4 clinical adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf (NCT00458393)
Timeframe: Entire follow-up, median 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 157 |
| Placebo | 162 |
Number of participants with at least one Grade 2, 3, or 4 laboratory adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf (NCT00458393)
Timeframe: Entire follow-up, median 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 70 |
| Placebo | 79 |
Grade 3 or higher phosphorous toxicity (hypophosphatemia) by the Division of AIDS Grading Table (severe, level at or below 1.9 mg/dL) (NCT00458393)
Timeframe: The entire follow-up period, median 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 13 |
| Placebo | 10 |
"A hepatic flare is defined as an increase in alanine transaminase or aspartate transaminase to >5 fold upper limit of normal at any visit, or an increase to >2.5 fold upper limit of normal for 3 months, within 24 weeks of permanently stopping study drug.~More details in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752387/" (NCT00458393)
Timeframe: Quarterly lab tests through a median follow-up of 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 0 |
| Placebo | 0 |
Confirmed HIV infection (NCT00458393)
Timeframe: Monthly follow-up through a median of 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 48 |
| Placebo | 83 |
Number of participants who have at least 1 confirmed syphilis infection during the study (NCT00458393)
Timeframe: All Follow-Up median of 1.2 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 147 |
| Placebo | 132 |
Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline (NCT00458393)
Timeframe: Total study follow-up, a median of 1.2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| TDF/FTC | 65 |
| Placebo | 60 |
Participants self-report of the number of sexual partners with HIV positive or unknown status in the previous 12 weeks with whom they had condomless anal sex (NCT00458393)
Timeframe: At 24 weeks
| Intervention | count (Median) |
|---|---|
| TDF/FTC | 0 |
| Placebo | 0 |
Percent change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in fasting total cholesterol from baseline (NCT00458393)
Timeframe: Baseline and Week 24
| Intervention | percent change from baseline (Median) |
|---|---|
| TDF/FTC | -3.2 |
| Placebo | -1.1 |
Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Body Fat from Baseline by dual-energy x-ray absorptiometry (NCT00458393)
Timeframe: Baseline and Week 24
| Intervention | percent change from baseline (Median) |
|---|---|
| TDF/FTC | 0.0 |
| Placebo | 3.8 |
Percentage Change (Percentage Change (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in Triglycerides from Baseline from a fasting sample. (NCT00458393)
Timeframe: Baseline and Week 24
| Intervention | percent change from baseline (Median) |
|---|---|
| TDF/FTC | 0.0 |
| Placebo | 0.0 |
Percentage of missed doses by estimate during computer assisted structured interview (NCT00458393)
Timeframe: Week 24
| Intervention | percentage of doses taken (Mean) |
|---|---|
| TDF/FTC | 91.0 |
| Placebo | 91.2 |
Estimated proportion of missed doses by pill count (assuming pills taken in unreturned bottles) (NCT00458393)
Timeframe: At 24 weeks
| Intervention | proportion of pills not returned (Mean) |
|---|---|
| TDF/FTC | 0.92 |
| Placebo | 0.93 |
Self-reported total number of sexual partners in the previous 12 weeks. (NCT00458393)
Timeframe: 24 weeks
| Intervention | Count (Median) |
|---|---|
| TDF/FTC | 3 |
| Placebo | 3 |
HIV-RNA in log10 units among HIV infected participants at the time closest to HIV detection (NCT00458393)
Timeframe: At the time closest to HIV detection
| Intervention | log RNA copies per ml (Mean) |
|---|---|
| TDF/FTC | 5.2 |
| Placebo | 5.1 |
Genotypic resistance by clinical assays among the seroconverters from baseline to the end of the study treatment period (NCT00458393)
Timeframe: at the time of HIV acquisition
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Infected at Enrollment (prior to randomization) | Infected after Randomization | |
| Placebo | 1 | 0 |
| TDF/FTC | 2 | 0 |
% Change from baseline in bone mineral density (100 * [(value at 24 weeks- value at baseline)/ (value at baseline)]) in in hip and L1-L4 spine by dual-energy x-ray absorptiometry (NCT00458393)
Timeframe: baseline and week 24.
| Intervention | percent change from baseline (Mean) | |
|---|---|---|
| L1-L4 Spine bone mineral density | Hip bone mineral density | |
| Placebo | 0.32 | 0.29 |
| TDF/FTC | -0.59 | -0.34 |
Participants were to be followed for 96 weeks after the last enrollment. Accrual was expected to take 96 weeks, thus the planned follow-up time was 96 to 192 weeks, dependent on when in the study the participant enrolled. This outcome summarizes that total amount of actual follow-up in weeks from randomization to last contact. (NCT00118898)
Timeframe: Follow-up time was variable, median follow-up was 138 weeks
| Intervention | Weeks (Median) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 141.4 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 133.3 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 141.6 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 137.3 |
Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables. As-treated analysis censored at 1st modification of initially assigned regimen, participants who never started treatment were excluded. (NCT00118898)
Timeframe: Over all study follow-up while on initially assigned treatment, median follow-up was 120 weeks
| Intervention | participants (Number) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 145 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 182 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 137 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 156 |
Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks and before 24 weeks or >=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: Follow-up time was variable, median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | participants (Number) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 162 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 246 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 157 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 233 |
Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: Follow-up time was variable, median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | participants (Number) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 152 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 239 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 138 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 216 |
Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks and before 24 weeks or >=200 copies/mL at or after 24 weeks. (NCT00118898)
Timeframe: Follow-up time was variable, median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | participants (Number) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 57 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 72 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 57 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 83 |
Emergence of resistant virus was assessed by genotypic testing performed at Stanford University for all participants who met criteria for virologic failure and retrospectively on baseline samples from these participants. Major mutations were defined by International AIDS Society-United States of America (2008), as well as T69D, L74I, G190C/E/Q/T/V for reverse transcriptase and L24I, F53L, I54V/A/T/S, G73C/S/T/A, N88D for protease. (NCT00118898)
Timeframe: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | participants (Number) |
|---|---|
| EFV, FTC/TDF, and Placebo ABC/3TC | 27 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 41 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 5 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 12 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (mean of pre-entry and entry values). (NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | Cells/mm3 (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 163 | 220.5 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 188 | 250.5 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 175 | 251.5 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 177.5 | 250.3 |
Only fasting results are included. The protocol did not require that samples be collected fasting. (NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | mg/dL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 8 | 9 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 10 | 11 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 5 | 4 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 8 | 7 |
Only fasting results are included. The protocol did not require that samples be collected fasting. (NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | mg/dL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 14 | 13.5 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 23 | 18 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 8 | 10 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 20 | 18 |
Only fasting results are included. The protocol did not require that samples be collected fasting. (NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | mg/dL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 22 | 23 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 35 | 33 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 11 | 14 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 30 | 25 |
Only fasting results are included. The protocol did not require that samples be collected fasting. (NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | mg/dL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 10 | 9 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 15 | 14 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 14 | 11 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 24 | 33 |
Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables. As-treated analysis censored at 1st modification of initially assigned regimen, participants who never started treatment were excluded. (NCT00118898)
Timeframe: At week 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 78 | 70 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 64 | 58 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 79 | 73 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 73 | 66 |
Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks and before 24 weeks or >=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: At week 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 79 | 70 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 64 | 54 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 80 | 73 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 66 | 57 |
Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: At week 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 80 | 73 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 67 | 56 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 86 | 77 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 73 | 62 |
Kaplan-Meier estimate of the cumulative survival probability at week 48 and 96. Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks and before 24 weeks or >=200 copies/mL at or after 24 weeks. (NCT00118898)
Timeframe: At week 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 94 | 90 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 88 | 85 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 92 | 89 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 88 | 83 |
"AIDS-defining illnesses were defined per CDC category C definition. HIV-1 related events were defined per CDC category B definition. Events underwent study chair review for classification. See link below for more details.~http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm" (NCT00118898)
Timeframe: Follow-up time was variable, median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Death | AIDS-defining illness | HIV-1 relatated event | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 6 | 14 | 56 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 11 | 25 | 61 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 6 | 20 | 57 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 8 | 23 | 63 |
(NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Number of Participants with RNA data at Week 48 | Number with HIV-1 RNA <200 copies/ml at Week 48 | Number of Participants with RNA data at Week 96 | Number with HIV-1 RNA <200 copies/ml at Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 415 | 398 | 379 | 362 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 400 | 377 | 361 | 342 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 416 | 391 | 384 | 368 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 411 | 372 | 374 | 346 |
(NCT00118898)
Timeframe: At Weeks 48 and 96
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Number of Participants with RNA data at Week 48 | Number with HIV-1 RNA <50 copies/ml at Week 48 | Number of Participants with RNA data at Week 96 | Number with HIV-1 RNA <50 copies/ml at Week 96 | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 415 | 372 | 379 | 345 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 400 | 346 | 361 | 328 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 416 | 348 | 384 | 345 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 411 | 322 | 374 | 317 |
Blood samples for determining virologic failure were obtained at visit weeks 16 and 24 , and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks after randomization and before 24 weeks, or >=200 copies/mL at or after 24 weeks. The 5th percentile for time to virologic failure is the time (in weeks) at which 5% of the participants have experienced virologic failure. (NCT00118898)
Timeframe: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | Weeks (Number) | |
|---|---|---|
| 5th percentile time to virologic failure | 10th percentile time to virologic failure | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 36 | 96 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 24 | 36 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 24 | 84 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 24 | 36 |
Grade 3/4 safety event is defined as a grade 3 or 4 sign, symptom, or laboratory abnormality that is at least one grade higher than at baseline, total bilirubin and creatine kinase (CPK) were excluded. Grading used the Division of AIDS (DAIDS) 2004 Severity of Adverse Events Tables. (NCT00118898)
Timeframe: All follow-up while on initially assigned regimen; the median (25th, 75th percentile) follow-up while on initial regimen was 120 (54, 156) weeks and the range was 0 to 205 weeks.
| Intervention | Weeks (Number) | ||
|---|---|---|---|
| 5th percentile time to a grade 3/4 safety event | 10th percentile time to a grade 3/4 safety event | 25th percentile time to a grade 3/4 safety event | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 2.6 | 7.9 | 59.3 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 1.3 | 2.0 | 16.0 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 3.0 | 8.1 | 81.4 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 1.3 | 3.9 | 44.4 |
Blood samples for determining virologic failure were obtained at 16 and 24 weeks, and every 12 weeks thereafter. Virologic failure was defined as a confirmed plasma HIV-1 RNA level >= 1000 copies/mL at or after 16 weeks and before 24 weeks or >=200 copies/mL at or after 24 weeks. Treatment modification was defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | Weeks (Number) | ||
|---|---|---|---|
| 5th percentile time to regimen failure | 10th percentile time to regimen failure | 25th percentile time to regimen failure | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 4 | 16 | 72 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 4 | 4 | 24 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 4 | 16 | 84 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 4 | 4 | 36 |
Treatment modification is defined as the 1st modification of the regimen, including a permanent discontinuation, switch, or substitution. (NCT00118898)
Timeframe: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
| Intervention | Weeks (Number) | ||
|---|---|---|---|
| 5th percentile time to treatment modification | 10th percentile time to treatment modification | 25th percentile time to treatment modification | |
| EFV, FTC/TDF, and Placebo ABC/3TC | 3.4 | 15.0 | 83.7 |
| EFV, Placebo FTC/TDF, and ABC/3TC | 1.4 | 2.1 | 27.4 |
| RTV-boosted ATV, FTC/TDF, and Placebo ABC/3TC | 7.9 | 24.9 | 108.9 |
| RTV-boosted ATV, Placebo FTC/TDF, and ABC/3TC | 1.6 | 5.0 | 43.6 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01497899)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 88.4 |
| E/C/F/TDF | 89.7 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01497899)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 88.4 |
| E/C/F/TDF | 87.9 |
(NCT01497899)
Timeframe: Baseline; Weeks 24 and 48
| Intervention | cells/uL (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 24 | Change at Week 48 | |
| E/C/F/TAF | 404 | 165 | 177 |
| E/C/F/TDF | 394 | 179 | 204 |
(NCT01497899)
Timeframe: Baseline; Weeks 24 and 48
| Intervention | log10 copies/mL (Mean) | ||
|---|---|---|---|
| Baseline | Change at Week 24 | Change at Week 48 | |
| E/C/F/TAF | 4.63 | -3.20 | -3.22 |
| E/C/F/TDF | 4.69 | -3.26 | -3.33 |
(NCT01475838)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 40 |
| PI+RTV+FTC/TDF | 32 |
(NCT01475838)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 61 |
| PI+RTV+FTC/TDF | 71 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 93.8 |
| PI+RTV+FTC/TDF | 87.1 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01475838)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 86.9 |
| PI+RTV+FTC/TDF | 69.8 |
(NCT01495702)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 56 |
| NNRTI+FTC/TDF | 58 |
(NCT01495702)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 83 |
| NNRTI+FTC/TDF | 101 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 93.4 |
| NNRTI+FTC/TDF | 88.1 |
The FDA-defined Snapshot algorithm was used, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time. (NCT01495702)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 86.6 |
| NNRTI+FTC/TDF | 80.4 |
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 6 |
| NVP/LPV_r | 4 |
| NoNVP/NVP | 19 |
| NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 15 |
| NVP/LPV_r | 0 |
| NoNVP/NVP | 35 |
| NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 32 |
| NVP/LPV_r | 10 |
| NoNVP/NVP | 42 |
| NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 20 |
| NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
| Intervention | cells/mm^3 (Median) | |
|---|---|---|
| Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
| NoNVP/LPV_r | 172 | 256 |
| NoNVP/NVP | 172 | 223 |
| NVP/LPV_r | 201 | 278 |
| NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
| Intervention | Percent of participants (Number) | |
|---|---|---|
| week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
| NoNVP/LPV_r | 14 | 20 |
| NoNVP/NVP | 14 | 17 |
| NVP/LPV_r | 4 | 12 |
| NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
| Intervention | percent of participants (Number) | |
|---|---|---|
| week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
| NoNVP/LPV_r | 86 | 87 |
| NoNVP/NVP | 90 | 93 |
| NVP/LPV_r | 88 | 95 |
| NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
| Intervention | weeks (Number) | ||
|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | |
| NVP/LPV_r | 60 | 84 | NA |
| NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
| Intervention | weeks (Number) | ||
|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | |
| NoNVP/LPV_r | 12 | 36 | 132 |
| NoNVP/NVP | 24 | 36 | NA |
Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Number of live-born infants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 4 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 4 |
| Placebo | 5 |
The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.057 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | -0.005 |
| Placebo | -0.079 |
The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | events per 100 person years (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 0.65 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.50 |
| Placebo | 1.99 |
The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.006 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.036 |
| Placebo | -0.033 |
"Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.~N. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics)." (NCT00557245)
Timeframe: Up to 36 months
| Intervention | participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 102 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 76 |
| Placebo | 85 |
Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 118 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 115 |
| Placebo | 118 |
"HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.~Both seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1)." (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 1 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| Placebo | 0 |
Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of visits (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 14 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 13 |
| Placebo | 13 |
Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of doses taken of dispensed (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 97 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 97 |
| Placebo | 97 |
The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.021 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.009 |
| Placebo | -0.056 |
Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of visits (Number) | |
|---|---|---|
| Missed any doses | Missed 2+ consecutive doses | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 15 | 4 |
| Placebo | 15 | 4 |
| Tenofovir Disoproxil Fumarate (TDF) | 15 | 4 |
The cumulative incidence of discontinuation for toxicity by week 96 was estimated using competing risks with treatment discontinuation for other reasons considered as a competing event; participants completing the study on the RAL or PI component of their randomized regimen were considered censored at the earliest of the date of last patient contact and off study date. (NCT00811954)
Timeframe: From study entry to week 96
| Intervention | cumulative events per 100 persons (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 14 |
| Arm B: RAL + FTC/TDF | 1 |
| Arm C: DRV/RTV + FTC/TDF | 5 |
"The cumulative incidence of first adverse event (with and without total bilirubin and creatine kinase and measured from study entry) by week 96 was estimated using methods for competing risks. Discontinuation of randomized treatment prior to an adverse event was considered a competing event.~The time to the first of any post-entry Grade 2, 3, or 4 sign or symptom, or Grade 3 or 4 laboratory abnormality while on randomization. The protocol required reporting of signs and symptoms and laboratory values as follow: all signs and symptoms grade ≥2 post-entry to week 48, signs and symptoms grade >3 after week 48, and laboratory values grade >3 and all signs, symptoms, and laboratory values that led to a change in treatment, regardless of grade throughout out all post-entry follow-up." (NCT00811954)
Timeframe: From study entry to week 96
| Intervention | cumulative events per 100 persons (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 81 |
| Arm B: RAL + FTC/TDF | 59 |
| Arm C: DRV/RTV + FTC/TDF | 65 |
"The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 96.~Time to virologic failure was defined as the first time from study entry to the first of two consecutive HIV-1 RNA >1000 copies/mL at or after week 16 and before week 24, or >200 copies/mL at or after week 24. Week 16 is defined to occur between 14 (98 days) and 18 weeks (126 days) after study entry, week 24 is defined to occur between 22 (154 days) and 26 (182 days) after study entry, and week 96 is defined to occur between 88 (616 days) and 104 (728 days) after study entry." (NCT00811954)
Timeframe: From study entry to week 96
| Intervention | cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 13 |
| Arm B: RAL + FTC/TDF | 10 |
| Arm C: DRV/RTV + FTC/TDF | 15 |
"The Kaplan-Meier estimate of the cumulative probability of TROVR by week 96.~A composite TLOVR endpoint defined in the CDER of the FDA document Guidance for Industry - Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Consideration for Accelerated and Traditional Approval (Appendix B, pages 20) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.~If participants never achieved a confirmed HIV-1 RNA≤200 cp/mL (on two consecutive visits) prior to death, permanent discontinuation of randomized treatment, or time of last available HIV-1 RNA evaluation, TLOVR was equal to 0; otherwise, TLOVR was the earliest time of permanent discontinuation of randomized treatment prior to study close-out period, time to confirmed levels >200 cp/mL, or time to death. If TLOVR is immediately preceded by a single missing scheduled visit or multiple consecutive missing scheduled visits, TLOVR is replaced by the first such missing visit." (NCT00811954)
Timeframe: From study entry to week 96
| Intervention | cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 31 |
| Arm B: RAL + FTC/TDF | 16 |
| Arm C: DRV/RTV + FTC/TDF | 24 |
The incidence of death or AIDS defining events (CDC category C) was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence. (NCT00811954)
Timeframe: Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 1.55 |
| Arm B: RAL + FTC/TDF | 1.64 |
| Arm C: DRV/RTV + FTC/TDF | 2.14 |
The incidence of targeted serious non-AIDS defining events was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence. (NCT00811954)
Timeframe: Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 2.38 |
| Arm B: RAL + FTC/TDF | 2.24 |
| Arm C: DRV/RTV + FTC/TDF | 2.69 |
The number of participants with ATV/RTV or DRV/RTV resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure. (NCT00811954)
Timeframe: At the virologic failure at any time throughout the study (up to 213 weeks)
| Intervention | participants (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 0 |
| Arm B: RAL + FTC/TDF | 0 |
| Arm C: DRV/RTV + FTC/TDF | 0 |
The number of participants with INI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure. (NCT00811954)
Timeframe: At the virologic failure at any time throughout the study (up to 213 weeks)
| Intervention | participants (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 1 |
| Arm B: RAL + FTC/TDF | 1 |
| Arm C: DRV/RTV + FTC/TDF | 1 |
The number of participants with NRTI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure. (NCT00811954)
Timeframe: At the virologic failure at any time throughout the study (up to 213 weeks)
| Intervention | participants (Number) |
|---|---|
| Arm A: ATV/RTV + FTC/TDF | 8 |
| Arm B: RAL + FTC/TDF | 7 |
| Arm C: DRV/RTV + FTC/TDF | 3 |
The absolute levels of CD4+ T-cell counts (cells/mm3) (NCT00811954)
Timeframe: At Weeks 24, 48, 96, and 144
| Intervention | cells/mm^3 (Mean) | |||
|---|---|---|---|---|
| week 24 (nA=582, nB=574, nC=579) | week 48 (nA=564, nB=565, nC=559) | week 96 (nA=523, nB=541, nC=525) | week 144 (nA=395, nB=418, nC=394) | |
| Arm A: ATV/RTV + FTC/TDF | 462 | 524 | 587 | 622 |
| Arm B: RAL + FTC/TDF | 460 | 526 | 596 | 631 |
| Arm C: DRV/RTV + FTC/TDF | 457 | 509 | 564 | 596 |
Change was calculated as the CD4+ T-cell count at week (24, 48, 96, and 144) minus the baseline CD4+ T-cell count (NCT00811954)
Timeframe: Study entry to weeks 24, 48, 96, and 144
| Intervention | cells/mm^3 (Mean) | |||
|---|---|---|---|---|
| week 24 (nA=582, nB=574, nC=579) | week 48 (nA=564, nB=565, nC=559) | week 96 (nA=523, nB=541, nC=525) | week 144 (nA=395, nB=418, nC=394) | |
| Arm A: ATV/RTV + FTC/TDF | 157 | 218 | 284 | 324 |
| Arm B: RAL + FTC/TDF | 153 | 218 | 288 | 325 |
| Arm C: DRV/RTV + FTC/TDF | 147 | 201 | 256 | 288 |
Only fasting results are included. Change was calculated as the fasting HDL cholesterol at week (48, 96, and 144) minus the baseline fasting HDL cholesterol. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| week 48 (nA=522, nB=542, nC=506) | week 96 (nA=490, nB=505, nC=488) | week 144 (nA=364, nB=397, nC=363) | |
| Arm A: ATV/RTV + FTC/TDF | 6 | 7 | 8 |
| Arm B: RAL + FTC/TDF | 5 | 6 | 6 |
| Arm C: DRV/RTV + FTC/TDF | 5 | 5 | 7 |
Only fasting results are included. Change was calculated as the fasting plasma glucose at week (48, 96, and 144) minus the baseline fasting plasma glucose. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| week 48 (nA=517, nB=535, nC=506) | week 96 (nA=489, nB=499, nC=481) | week 144 (nA=353, nB=392, nC=358) | |
| Arm A: ATV/RTV + FTC/TDF | 2.2 | 3.0 | 2.2 |
| Arm B: RAL + FTC/TDF | 1.3 | 0.9 | 0.9 |
| Arm C: DRV/RTV + FTC/TDF | 2.1 | 2.5 | 3.6 |
Only fasting results are included. Change was calculated as the fasting total cholesterol at week (48, 96, and 144) minus the baseline fasting total cholesterol. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| week 48 (nA=521, nB=542, nC=507) | week 96 (nA=490, nB=505, nC=490) | week 144 (nA=364, nB=397, nC=363) | |
| Arm A: ATV/RTV + FTC/TDF | 13 | 16 | 20 |
| Arm B: RAL + FTC/TDF | 1 | 3 | 6 |
| Arm C: DRV/RTV + FTC/TDF | 15 | 14 | 19 |
Only fasting results are included. Change was calculated as the fasting triglycerides at week (48, 96, and 144) minus the baseline fasting triglycerides. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| week 48 (nA=522, nB=542, nC=507) | week 96 (nA=490, nB=505, nC=490) | week 144 (nA=364, nB=397, nC=363) | |
| Arm A: ATV/RTV + FTC/TDF | 18 | 19 | 12 |
| Arm B: RAL + FTC/TDF | -9 | -9 | -4 |
| Arm C: DRV/RTV + FTC/TDF | 16 | 16 | 20 |
"Only risk score estimated with fasting lipid results were included. Change was calculated as the Framingham 10-year risk of MI or coronary death at week (48, 96, and 144) minus the baseline Framingham 10-year risk of MI or coronary death. Framingham 10-year risk of MI or coronary death was calculated using Hear Coronary Heart Disease (10-year risk) found at https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-10-year-risk.php.~Framingham 10-year risk of MI or coronary death was calculated according to age, laboratory values of total cholesterol and HDL cholesterol, smoking status, systolic blood pressure, and treatment for hypertension. The Framingham 10-year risk of MI or coronary death was calculated as: for males: <0 point (<1 percent risk) up to ≥17 points (≥30 percent risk); whereas for females: <9 points (<1 percent risk) up to ≥25 points (≥30 percent risk). Higher scores indicate high cardiovascular risk." (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | percent risk (Mean) | ||
|---|---|---|---|
| week 48 (nA=509, nB=537, nC=492) | week 96 (nA=479, nB=493, nC=470) | week 144 (nA=347, nB=383, nC=349) | |
| Arm A: ATV/RTV + FTC/TDF | 0.4 | 0.5 | 0.6 |
| Arm B: RAL + FTC/TDF | 0.0 | 0.2 | 0.4 |
| Arm C: DRV/RTV + FTC/TDF | 0.4 | 0.4 | 0.9 |
Change was calculated as the waist circumference (based on mid-waist circumference) at week (48, 96, and 144) minus the baseline waist circumference. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | cm (Mean) | ||
|---|---|---|---|
| week 48 (nA=555, nB=551, nC=547) | week 96 (nA=512, nB=526, nC=517) | week 144 (nA=425, nB=419, nC=409) | |
| Arm A: ATV/RTV + FTC/TDF | 2.3 | 3.3 | 3.6 |
| Arm B: RAL + FTC/TDF | 3.1 | 4.0 | 4.0 |
| Arm C: DRV/RTV + FTC/TDF | 2.1 | 2.8 | 3.4 |
Change was calculated as the waist:height ratio at week (48, 96, and 144) minus the baseline waist:height ratio. (NCT00811954)
Timeframe: Study entry to weeks 48, 96, and 144
| Intervention | cm:cm (Mean) | ||
|---|---|---|---|
| week 48 (nA=555, nB=551, nC=547) | week 96 (nA=512, nB=526, nC=517) | week 144 (nA=425, nB=419, nC=409) | |
| Arm A: ATV/RTV + FTC/TDF | 0.01 | 0.02 | 0.02 |
| Arm B: RAL + FTC/TDF | 0.02 | 0.02 | 0.02 |
| Arm C: DRV/RTV + FTC/TDF | 0.01 | 0.02 | 0.02 |
Self-reported percentage of anti-HIV medications participant had taken during the last month at weeks 4, 24, 48, 96, and 144. (NCT00811954)
Timeframe: At Weeks 4, 24, 48, 96, and 144
| Intervention | percentage of prescribed medication (Mean) | ||||
|---|---|---|---|---|---|
| week 4 (nA=584, nB=590, nC=583) | week 24 (nA=570, nB=568, nC=562) | week 48 (nA=555, nB=547, nC=536) | week 96 (nA=508, nB=525, nC=507) | week 144 (nA=361, nB=376, nC=350) | |
| Arm A: ATV/RTV + FTC/TDF | 98 | 97 | 96 | 96 | 97 |
| Arm B: RAL + FTC/TDF | 97 | 97 | 97 | 96 | 97 |
| Arm C: DRV/RTV + FTC/TDF | 98 | 96 | 96 | 96 | 98 |
"Right common carotid artery intima-media thickness was measured by ultrasound scan at study entry and weeks 48, 96 and 144.~The annual rate of change in right common carotid artery intima-media thickness (CIMT) was estimated over 144 weeks from study entry using mixed effects linear regression model that adjusted for screening HIV-1 RNA level and Framingham risk score stratification factors." (NCT00851799)
Timeframe: Study entry, week 144
| Intervention | micron/year (Mean) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 8.2 |
| Cohort B: RAL + FTC/TDF | 10.7 |
| Cohort C: DRV/RTV + FTC/TDF | 12.9 |
"Brachial artery flow mediated dilation was measured by brachial artery reactivity tests. All results reflect measures captured from participants who reported fasting and not smoking for at least 8 hours prior to FMD assessments.~The change from study entry to week 24 in brachial artery FMD (%) was defined as the maximum FMD (%) calculated from resting heart rate (RH) 60 seconds and RH 90 seconds, relative to resting brachial artery diameter." (NCT00851799)
Timeframe: Study entry, week 24
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | -0.05 |
| Cohort B: RAL + FTC/TDF | -0.27 |
| Cohort C: DRV/RTV + FTC/TDF | 0.15 |
Bone mineral density (BMD) of the hip was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and study week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | -3.7 |
| Cohort B: RAL + FTC/TDF | -2.2 |
| Cohort C: DRV/RTV + FTC/TDF | -3.3 |
Bone mineral density (BMD) of the lumber spine was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and study week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | -4.0 |
| Cohort B: RAL + FTC/TDF | -1.6 |
| Cohort C: DRV/RTV + FTC/TDF | -3.1 |
Bone mineral density (BMD) of the total body was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and study week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | -1.9 |
| Cohort B: RAL + FTC/TDF | -0.9 |
| Cohort C: DRV/RTV + FTC/TDF | -1.0 |
Lean mass was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 1.8 |
| Cohort B: RAL + FTC/TDF | 1.7 |
| Cohort C: DRV/RTV + FTC/TDF | 0.1 |
Subcutaneous abdominal fat (SAT) was evaluated by single slice abdominal computerized tomography scans at study entry and week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 10.3 |
| Cohort B: RAL + FTC/TDF | 11.8 |
| Cohort C: DRV/RTV + FTC/TDF | 11.4 |
Total limb fat was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 9.8 |
| Cohort B: RAL + FTC/TDF | 6.3 |
| Cohort C: DRV/RTV + FTC/TDF | 7.9 |
Trunk fat was evaluated by dual-energy x-ray absorptiometry (DXA) scans at study entry and week 96. The percent change was calculated as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 10.8 |
| Cohort B: RAL + FTC/TDF | 13.5 |
| Cohort C: DRV/RTV + FTC/TDF | 9.7 |
Visceral abdominal fat (VAT) was evaluated by single slice abdominal computerized tomography scans at study entry and week 96. The percent change was calculated as as ((week 96 value - study entry value) / study entry value)) x 100. (NCT00851799)
Timeframe: Study entry, week 96
| Intervention | percent (Median) |
|---|---|
| Cohort A: ATV/RTV + FTC/TDF | 10.7 |
| Cohort B: RAL + FTC/TDF | 16.2 |
| Cohort C: DRV/RTV + FTC/TDF | 9.5 |
The absolute levels of CD4+ T-cell counts (cells/mm^3) measured at study entry and weeks 24, 48, 96 and 144. (NCT00851799)
Timeframe: Study entry, weeks 24, 48, 96 and 144
| Intervention | cell/mm^3 (Median) | ||||
|---|---|---|---|---|---|
| Study Entry | Week 24 | Week 48 | Week 96 | Week 144 | |
| Cohort A: ATV/RTV + FTC/TDF | 350 | 509 | 573 | 634 | 658 |
| Cohort B: RAL + FTC/TDF | 343 | 445 | 496 | 569 | 613 |
| Cohort C: DRV/RTV + FTC/TDF | 355 | 464 | 528 | 567 | 560 |
The change in absolute FMD was defined as the maximum absolute FMD from the RH 60 and 90 second measurements, from study entry to weeks 4, 24, and 48 (unit of measure millimeters). All results reflect measures captured from participants who reported fasting and not smoking for at least 8 hours prior to FMD assessments. (NCT00851799)
Timeframe: Study entry, weeks 4, 24 and 48
| Intervention | mm (Mean) | ||
|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.002 | -0.002 | 0.002 |
| Cohort B: RAL + FTC/TDF | 0.012 | -0.004 | 0.005 |
| Cohort C: DRV/RTV + FTC/TDF | -0.005 | 0.008 | -0.001 |
"Brachial artery flow mediated dilation was measured by brachial artery reactivity tests. All results reflect measures captured from participants who reported fasting and not smoking for at least 8 hours prior to FMD assessments.~The change from study entry to weeks 4 and 48 in brachial artery FMD (%) was defined as the maximum FMD (%) calculated from resting heart rate (RH) 60 seconds and RH 90 seconds, relative to resting brachial artery diameter." (NCT00851799)
Timeframe: Study entry, weeks 4 and 48
| Intervention | percent (Mean) | |
|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 48 | |
| Cohort A: ATV/RTV + FTC/TDF | -0.04 | -0.04 |
| Cohort B: RAL + FTC/TDF | 0.22 | -0.08 |
| Cohort C: DRV/RTV + FTC/TDF | -0.15 | -0.11 |
Change was calculated as (CD4+ T-cell count at week 24, 48, 96, or 144) - (CD4+ T-cell count at study entry). (NCT00851799)
Timeframe: Study entry to weeks 24, 48, 96, and 144
| Intervention | cell/mm^3 (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | Change from study entry to week 144 | |
| Cohort A: ATV/RTV + FTC/TDF | 161 | 209 | 280 | 305 |
| Cohort B: RAL + FTC/TDF | 133 | 191 | 247 | 279 |
| Cohort C: DRV/RTV + FTC/TDF | 118 | 194 | 248 | 227 |
Calculated LDL-C (unit of measure mg/dL) was measured at study entry and weeks 4, 24, 48 and 96 from participants who reported fasting for at least 8 hours prior to assessment; all results were centrally laboratory tested in batch. Change in calculated LDL-C was calculated as (week 4, 24, 48 or 96 result) - (study entry result). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | mg/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0 | 2 | 1 | 2 |
| Cohort B: RAL + FTC/TDF | -3 | -2 | -1 | -1 |
| Cohort C: DRV/RTV + FTC/TDF | 1 | 3 | 5 | 6 |
Glucose (unit of measure mg/dL) was measured at study entry and weeks 4, 24, 48 and 96; all results reflect measures captured from participants who reported fasting for at least 8 hours prior to assessment. Change was calculated as (fasting result during at week 4, 24, 48 or 96) - (fasting result at study entry). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | mg/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 3 | 4 | 4 | 3 |
| Cohort B: RAL + FTC/TDF | 3 | 4 | 4 | 6 |
| Cohort C: DRV/RTV + FTC/TDF | 2 | 4 | 2 | 2 |
HDL cholesterol (unit of measure mg/dL) was measured at study entry and weeks 4, 24, 48 and 96 from participants who reported fasting for at least 8 hours prior to assessment; all results were centrally laboratory tested in batch. Change in HDL-C was calculated as (week 4, 24, 48 or 96 result) - (study entry result). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | mg/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | -1 | 3 | 2 | 4 |
| Cohort B: RAL + FTC/TDF | -2 | 3 | 2 | 4 |
| Cohort C: DRV/RTV + FTC/TDF | -3 | 0 | 1 | 4 |
Insulin (unit of measure uIU/dL) was measured at study entry and weeks 4, 24, 48 and 96; all results reflect measures captured from participants who reported fasting for at least 8 hours prior to assessment. Change was calculated as (fasting result during at week 4, 24, 48 or 96) - (fasting result at study entry). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | uIU/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 4.0 | 4.0 | 4.0 | 3.5 |
| Cohort B: RAL + FTC/TDF | 3.0 | 3.0 | 3.0 | 3.0 |
| Cohort C: DRV/RTV + FTC/TDF | 3.0 | 2.0 | 3.0 | 2.0 |
Total cholesterol (TC, unit of measure mg/dL) was measured at study entry and weeks 4, 24, 48 and 96 from participants who reported fasting for at least 8 hours prior to assessment; all results were centrally laboratory tested in batch. Change in TC was calculated as (week 4, 24, 48 or 96 result) - (study entry result). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | mg/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 4 | 9 | 8 | 12 |
| Cohort B: RAL + FTC/TDF | -7 | -4 | -1 | 1 |
| Cohort C: DRV/RTV + FTC/TDF | 3 | 7 | 12 | 14 |
Triglyceride (TG, unit of measure mg/dL) was measured at study entry and weeks 4, 24, 48 and 96 from participants who reported fasting for at least 8 hours prior to assessment; all results were centrally laboratory tested in batch. Change in TG was calculated as (week 4, 24, 48 or 96 result) - (study entry result). (NCT00851799)
Timeframe: Study entry, weeks 4, 24, 48 and 96
| Intervention | mg/dL (Median) | |||
|---|---|---|---|---|
| Change from study entry to week 4 | Change from study entry to week 24 | Change from study entry to week 48 | Change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 14 | 6 | 9 | 10 |
| Cohort B: RAL + FTC/TDF | -12 | -16 | -13 | -7 |
| Cohort C: DRV/RTV + FTC/TDF | 15 | 2 | 8 | 0 |
D-dimer was measured at study entry and weeks 48 and 96 (unit of measure ug/ml). Fold change from study entry to week 48 or week 96 was calculated as (week 48 value or week 96 value) / (study entry value). Results identified above or below the limit of quantification were imputed at the quantification limit of the respective assay. (NCT00851799)
Timeframe: Study entry, weeks 48 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 48 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.57 | 0.52 |
| Cohort B: RAL + FTC/TDF | 0.73 | 0.72 |
| Cohort C: DRV/RTV + FTC/TDF | 0.65 | 0.65 |
hsCRP was measured at study entry and weeks 48 and 96 (unit of measure ug/ml). Fold change from study entry to week 48 or week 96 was calculated as (week 48 value or week 96 value) / (study entry value). Results identified above or below the limit of quantification were imputed at the quantification limit of the respective assay. (NCT00851799)
Timeframe: Study entry, weeks 48 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 48 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.75 | 0.85 |
| Cohort B: RAL + FTC/TDF | 0.88 | 0.78 |
| Cohort C: DRV/RTV + FTC/TDF | 0.78 | 1.31 |
IL-6 was measured at study entry and weeks 48 and 96 (unit of measure pg/ml). Fold change from study entry to week 48 or week 96 was calculated as (week 48 value or week 96 value) / (study entry value). Results identified above or below the limit of quantification were imputed at the quantification limit of the respective assay. (NCT00851799)
Timeframe: Study entry, weeks 48 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 48 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.62 | 0.89 |
| Cohort B: RAL + FTC/TDF | 0.71 | 0.82 |
| Cohort C: DRV/RTV + FTC/TDF | 0.75 | 0.89 |
Percent expression of CD38+HLADR+ on CD4+ was measured at study entry and weeks 24 and 96 (unit of measure percent). Fold change from study entry to week 24 or week 96 was calculated as (week 24 value or week 96 value) / (study entry value). (NCT00851799)
Timeframe: Study entry, weeks 24 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 24 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.49 | 0.38 |
| Cohort B: RAL + FTC/TDF | 0.51 | 0.34 |
| Cohort C: DRV/RTV + FTC/TDF | 0.52 | 0.37 |
Percent expression of CD38+HLADR+ on CD8+ was measured at study entry and weeks 24 and 96 (unit of measure percent). Fold change from study entry to week 24 or week 96 was calculated as (week 24 value or week 96 value) / (study entry value). (NCT00851799)
Timeframe: Study entry, weeks 24 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 24 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.51 | 0.35 |
| Cohort B: RAL + FTC/TDF | 0.56 | 0.36 |
| Cohort C: DRV/RTV + FTC/TDF | 0.59 | 0.38 |
Soluble CD14 was measured at study entry and weeks 48 and 96 (unit of measure ng/ml). Fold change from study entry to week 48 or week 96 was calculated as (week 48 value or week 96 value) / (study entry value). Results identified above or below the limit of quantification were imputed at the quantification limit of the respective assay. (NCT00851799)
Timeframe: Study entry, weeks 48 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 48 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 1.01 | 0.98 |
| Cohort B: RAL + FTC/TDF | 0.91 | 0.90 |
| Cohort C: DRV/RTV + FTC/TDF | 1.00 | 0.98 |
Soluble CD163 was measured at study entry and weeks 48 and 96 (unit of measure ng/ml). Fold change from study entry to week 48 or week 96 was calculated as (week 48 value or week 96 value) / (study entry value). Results identified above or below the limit of quantification were imputed at the quantification limit of the respective assay. (NCT00851799)
Timeframe: Study entry, weeks 48 and 96
| Intervention | Fold change (Median) | |
|---|---|---|
| Fold change from study entry to week 48 | Fold change from study entry to week 96 | |
| Cohort A: ATV/RTV + FTC/TDF | 0.54 | 0.51 |
| Cohort B: RAL + FTC/TDF | 0.62 | 0.56 |
| Cohort C: DRV/RTV + FTC/TDF | 0.61 | 0.58 |
CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks (NCT00625404)
Timeframe: Up to 16 weeks
| Intervention | cells/mL (Mean) |
|---|---|
| Truvada Arm | 579.3 |
| Placebo Arm | 601.4 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal (NCT00625404)
Timeframe: cumulative toxicity through 52 weeks of product use and 4 weeks post product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 4 |
| Placebo Arm | 2 |
Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 6 |
| Placebo Arm | 8 |
Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 45 |
| Placebo Arm | 40 |
The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration. (NCT00625404)
Timeframe: 10-26 months per site
| Intervention | Number of adverse events (Number) |
|---|---|
| Truvada Arm | 2257 |
| Placebo Arm | 2384 |
"Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).~participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time." (NCT00625404)
Timeframe: up to 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens. (NCT00625404)
Timeframe: Cumulative HIV infection between enrollment and 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 33 |
| Placebo Arm | 35 |
Difference in mean number of reported sexual partners between final study visit and enrollment visit (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | mean number of sexual partners (Mean) |
|---|---|
| Truvada Arm | -0.14 |
| Placebo Arm | -0.13 |
Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Truvada Arm | 87 |
| Placebo Arm | 89 |
Viral load at the time of HIV detection, HIV conversion and through 16 weeks (NCT00625404)
Timeframe: up to 16 weeks
| Intervention | log copies/mL (Log Mean) |
|---|---|
| Truvada Arm | 4.40 |
| Placebo Arm | 4.37 |
Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications (NCT00625404)
Timeframe: up to 60 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 20 |
| Placebo Arm | 10 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TDF (Cohort 1) | 84.8 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| COBI+PI+2 NRTIs (Cohort 2) | 90.4 |
Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 1 (treatment-naive). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24
| Intervention | mL/min (Number) | |||
|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 24 | |
| E/C/F/TDF (Cohort 1) | 81.6 | -12.1 | -7.3 | -3.3 |
Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 2 (treatment-experienced). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24
| Intervention | mL/min (Median) | |||
|---|---|---|---|---|
| Baseline | Change at Week 2 (n=13) | Change at Week 4 (n=13) | Change at Week 24 (n=11) | |
| COBI+PI+2 NRTIs (Cohort 2) | 82.5 | 1.6 | 7.0 | -4.1 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 33) | Change at Week 24 (n = 30) | |
| E/C/F/TDF (Cohort 1) | 77.6 | 0.3 |
Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 33) | Change at Week 24 (n = 30) | |
| E/C/F/TDF (Cohort 1) | 77.1 | -7.4 |
Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min (Median) | |
|---|---|---|
| Baseline (n = 73) | Change at Week 24 (n = 67) | |
| COBI+PI+2 NRTIs (Cohort 2) | 71.4 | -3.7 |
Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min (Median) | |
|---|---|---|
| Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
| E/C/F/TDF (Cohort 1) | -7.6 | -7.9 |
Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Week 48
| Intervention | mL/min (Median) | |
|---|---|---|
| Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
| COBI+PI+2 NRTIs (Cohort 2) | -3.8 | -5.0 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
| E/C/F/TDF (Cohort 1) | 1.6 | 12.6 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
| COBI+PI+2 NRTIs (Cohort 2) | -4.7 | -2.8 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
| E/C/F/TDF (Cohort 1) | 1.9 | 12.4 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
| COBI+PI+2 NRTIs (Cohort 2) | -4.7 | -2.4 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 33) | Change at Week 24 (n = 30) | |
| E/C/F/TDF (Cohort 1) | 76.9 | 0.3 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 73) | Change at Week 24 (n = 67) | |
| COBI+PI+2 NRTIs (Cohort 2) | 78.2 | -2.8 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 73) | Change at Week 24 (n = 67) | |
| COBI+PI+2 NRTIs (Cohort 2) | 78.6 | -2.7 |
Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Baseline (n = 73) | Change at Week 24 (n = 67) | |
| COBI+PI+2 NRTIs (Cohort 2) | 65.8 | -3.4 |
Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
| E/C/F/TDF (Cohort 1) | -12.1 | -12.9 |
Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
| Intervention | mL/min/1.73 m^2 (Median) | |
|---|---|---|
| Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
| COBI+PI+2 NRTIs (Cohort 2) | -3.9 | -2.8 |
Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 1 (treatment-naive). (NCT01363011)
Timeframe: Baseline; Week 24
| Intervention | mL/min (Median) | |
|---|---|---|
| Baseline (n = 33) | Change at Week 24 (n = 30) | |
| E/C/F/TDF (Cohort 1) | 72.9 | -5.2 |
Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 1 (treatment-naive). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any AE | Drug-related AE | Grade 3 or higher AE | AE leading to drug discontinuation | Serious AE | AE of proximal renal tubulopathy | |
| E/C/F/TDF (Cohort 1) | 100.0 | 48.5 | 21.2 | 12.1 | 18.2 | 0 |
Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 2 (treatment-experienced). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any AE | Drug-related AE | Grade 3 or higher AE | AE leading to drug discontinuation | Serious AE | AE of proximal renal tubulopathy | |
| COBI+PI+2 NRTIs (Cohort 2) | 93.2 | 27.4 | 28.8 | 11.0 | 15.1 | 0 |
Laboratory abnormalities were summarized for Cohort 1 (treatment-naive) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any laboratory abnormality | Grade 3 or 4 laboratory abnormality | |
| E/C/F/TDF (Cohort 1) | 100.0 | 39.4 |
Laboratory abnormalities were summarized for Cohort 2 (treatment-experienced) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any laboratory abnormality | Grade 3 or 4 laboratory abnormality | |
| COBI+PI+2 NRTIs (Cohort 2) | 100.00 | 50.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 (n = 33) | Week 96 (n = 27) | |
| E/C/F/TDF (Cohort 1) | 78.8 | 88.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 (n = 73) | Week 96 (n = 54) | |
| COBI+PI+2 NRTIs (Cohort 2) | 82.2 | 90.7 |
AUCtau was analyzed for Cohort 1 (treatment-naive) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | h*ng/mL (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 24 | |
| E/C/F/TDF (Cohort 1) | 16554.7 | 12704.1 | 9799.7 |
AUCtau was analyzed for Cohort 2 (treatment-experienced) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | h*ng/mL (Mean) | ||
|---|---|---|---|
| Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
| COBI+PI+2 NRTIs (Cohort 2) | 12458.0 | 11165.3 | 13980.5 |
Cmax was analyzed for Cohort 1 (treatment-naive) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | ng/mL (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 24 | |
| E/C/F/TDF (Cohort 1) | 1734.6 | 1522.9 | 1266.4 |
Cmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
| COBI+PI+2 NRTIs (Cohort 2) | 1366.7 | 1297.7 | 1568.6 |
Ctau was analyzed for Cohort 1 (treatment-naive) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | ng/mL (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 24 | |
| E/C/F/TDF (Cohort 1) | 150.5 | 37.3 | 24.2 |
Ctau was analyzed for Cohort 2 (treatment-experienced) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
| COBI+PI+2 NRTIs (Cohort 2) | 79.9 | 71.3 | 139.8 |
t1/2 was analyzed for Cohort 1 (treatment-naive) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | hours (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 24 | |
| E/C/F/TDF (Cohort 1) | 6.14 | 3.57 | 3.63 |
t1/2 was analyzed for Cohort 2 (treatment-experienced) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | hours (Median) | ||
|---|---|---|---|
| Week 2 (n = 13) | Week 4 (n = 12) | Week 24 (n = 10) | |
| COBI+PI+2 NRTIs (Cohort 2) | 4.37 | 3.98 | 3.77 |
Tmax was analyzed for Cohort 1 (treatment-naive) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | hours (Number) | ||
|---|---|---|---|
| Week 2 | Week 4 | Week 24 | |
| E/C/F/TDF (Cohort 1) | 4.00 | 2.00 | 4.00 |
Tmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
| Intervention | hours (Median) | ||
|---|---|---|---|
| Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
| COBI+PI+2 NRTIs (Cohort 2) | 3.92 | 4.92 | 3.00 |
Time to HIV infection was calculated as the difference between estimated date of infection (midpoint between the last negative HIV test date and the first confirmed positive HIV test date) and enrolment date, plus one. Where a participant has a positive PCR and a negative rapid test on the same date, the date of infection is calculated as 14 days prior to this date. Women who do not become HIV positive before their last study visit will be censored on the day of their last negative HIV test. Their follow-up time will be calculated as the difference between date of censoring and enrolment date, plus one. (NCT01691768)
Timeframe: Between 2012 and 2015, up to 28 months
| Intervention | Incidence rate/100 women years (Number) |
|---|---|
| Intervention | 3.5 |
| Control | 3.6 |
This is mean log transformed HIV viral load measured at the first visit post HIV infection. (NCT01691768)
Timeframe: Between 2012 and 2015, up to 28 months
| Intervention | log10 copies/ml (Mean) |
|---|---|
| Intervention | 4.4 |
| Control | 4.8 |
For the calculation of the incidence rate, seroconversion was assumed to have occurred at the midpoint between the first positive HPV test and the previous HPV negative test. (NCT01691768)
Timeframe: Between 2012 and 2015, up to 28 months
| Intervention | Incidence rate/100 women years (Number) |
|---|---|
| Intervention | 1.0 |
| Control | 3.0 |
Self-reported adherence to the tenofovir gel dosing strategy.Gel adherence was defined as the estimated proportion of reported sex acts covered by two gel doses and calculated for each woman by dividing half the number of returned used applicators each month by the number of reported sex acts that month.For participants attending 2-3 monthly clinic visits, their number of gels used in the last 30 days will be estimated as the total number of returned used gels, divided by the number of days between the current and the previous visit, times 30. (NCT01691768)
Timeframe: Between 2012 and 2015, up to 28 months
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 70.2 |
| Control | 65.2 |
Percentage of participants with detectable tenofovir levels from vaginal samples at 12 months of follow-up. All drug levels below limit of quantification were considered to be undetectable. (NCT01691768)
Timeframe: All participants with drug levels at 12 months of follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 39.5 |
| Control | 43.6 |
Time to pregnancy, was as the difference between the estimated date of conception and the enrolment date, plus one. The date of conception was defined as 14 days after the last normal menstrual period or the estimated date of delivery minus 40 weeks if the first date of last normal menstrual period is not available or the midpoint between the date of the first positive pregnancy test and the date of the previous negative pregnancy test. The censoring time for a woman who did not become pregnant during the study equals the difference between the calculated censoring date and the enrolment date, plus one. (NCT01691768)
Timeframe: Between 2012 and 2015, up to 28 months
| Intervention | Incidence rate/100 women years (Number) |
|---|---|
| Intervention | 4.9 |
| Control | 5.1 |
This is the number of participants who reported that they liked the study product. The questionnaire was administered at study exit, therefore participants who were loss to follow-up and those who died could not complete the questionnaire. (NCT01691768)
Timeframe: At study completion, up to 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 180 |
| Control | 170 |
The primary endpoint is the mean number of returned used applicators per month. Since participants in the intervention arm followed two and three monthly schedule (as opposed to monthly in the intervention arm), the number of returned used applicators per month for each participant will be estimated as the total number of returned applicators at that visit divided by the number of days since the previous visit, multiplied by 30. Thus a uniform distribution of gel use will be assumed in participants whom we did not see monthly. Intent to treat and per protocol analyses were carried out of this outcome. Intent to treat population includes all participants who were randomized, met pre-randomization eligibility criteria and who have post-enrollment follow-up data. The per protocol population is a subset of the intent to treat population.The per-protocol analysis excluded visits where no gel had been dispensed for >120 days. (NCT01691768)
Timeframe: Between 2012 to 2015, up to 28 months
| Intervention | Used gel applicators per month (Least Squares Mean) | |
|---|---|---|
| Intent to treat analyses | Per protocol analyses | |
| Control | 5.7 | 5.8 |
| Intervention | 5.2 | 5.5 |
This measure describes the number of participants with elevated serum creatinine levels, the only safety outcome of concern where a significant difference was detected between an active arm and the corresponding placebo arm. (NCT00705679)
Timeframe: Throughout study, up to 2.5 years
| Intervention | participants (Number) |
|---|---|
| Oral TDF | 4 |
| Oral TDF-FTC | 13 |
| Oral Placebo | 2 |
| TFV Gel | 9 |
| Gel Placebo | 3 |
This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | cases per 100 person-years (Number) |
|---|---|
| Oral TDF | 6.3 |
| Oral Placebo | 4.2 |
This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | cases per 100 person-years (Number) |
|---|---|
| Oral TDF-FTC | 4.7 |
| Oral Placebo | 4.6 |
This is the number of HIV-1 infections divided by the amount of person-years of follow-up time to HIV-1 infection status, multiplied by 100 (per 100 person-years). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | cases per 100 person-years (Number) |
|---|---|
| TFV Gel | 6.0 |
| Placebo Gel | 6.8 |
Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | participants (Number) |
|---|---|
| Oral TDF | 52 |
| Oral Placebo | 35 |
Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | participants (Number) |
|---|---|
| Oral TDF-FTC | 61 |
| Oral Placebo | 60 |
Participants were followed for up to 30 months. Participants were tested monthly for HIV-1 and positive rapid test results were confirmed by means of an enzyme-linked immunosorbent assay (EIA) and subsequent Western blotting (WB). (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | participants (Number) |
|---|---|
| TFV Gel | 61 |
| Placebo Gel | 70 |
Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. Note that the data for both of these arms were censored on the date when sites were asked to discontinue treatment in the oral TDF group. (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | person-years (Number) |
|---|---|
| Oral TDF | 823 |
| Oral Placebo | 838 |
Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | person-years (Number) |
|---|---|
| Oral TDF-FTC | 1284 |
| Oral Placebo | 1308 |
Participants were followed for up to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. (NCT00705679)
Timeframe: For up to 30 months of follow-up
| Intervention | person-years (Number) |
|---|---|
| TFV Gel | 1024 |
| Placebo Gel | 1030 |
The primary resistance mutations for the study were pre-defined as K65R and K70E (which confer resistance to TDF), and M184I and M184V (which confer resistance to FTC), for their potential to cause a decrease in susceptibility to the study drug. K65R, K70E, and M184I were not detected in HIV-1 from any HIV-1 seroconverters while on study product. The number of HIV-1 seroconverters while on study with the M184V resistance mutation are reported for this outcome measure. (NCT00705679)
Timeframe: Throughout study, up to 2.5 years
| Intervention | participants (Number) | |
|---|---|---|
| M184V mutation | No M184V mutation | |
| Gel Placebo | 0 | 68 |
| Oral Placebo | 0 | 60 |
| Oral TDF | 0 | 58 |
| Oral TDF-FTC | 1 | 54 |
| TFV Gel | 0 | 60 |
This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 144 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -139 |
| (Stavudine or Zidovudine)/TDF | -146 |
| All TDF | -142 |
This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 192 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -304 |
| (Stavudine or Zidovudine)/TDF | -177 |
| All TDF | -233 |
This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 240 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -369 |
| (Stavudine or Zidovudine)/TDF | -296 |
| All TDF | -329 |
This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 288 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -346 |
| (Stavudine or Zidovudine)/TDF | -256 |
| All TDF | -302 |
This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 336 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -415 |
| (Stavudine or Zidovudine)/TDF | -283 |
| All TDF | -350 |
This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 384 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -620 |
| (Stavudine or Zidovudine)/TDF | -305 |
| All TDF | -512 |
This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 432 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -795 |
| (Stavudine or Zidovudine)/TDF | -302 |
| All TDF | -631 |
This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: Baseline and 48 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -97 |
| Stavudine or Zidovudine | -11 |
| All TDF | 2 |
This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 480 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -923 |
| (Stavudine or Zidovudine)/TDF | -448 |
| All TDF | -813 |
This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 528 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -710 |
| All TDF | -710 |
This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 96 weeks
| Intervention | cells/mm^3 (Mean) |
|---|---|
| Tenofovir DF | -77 |
| (Stavudine or Zidovudine)/TDF | -56 |
| All TDF | -67 |
This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 144 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 0.8 |
| (Stavudine or Zidovudine)/TDF | -0.1 |
| All TDF | 0.3 |
This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 192 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 1.1 |
| (Stavudine or Zidovudine)/TDF | 0.6 |
| All TDF | 0.8 |
This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 240 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 1.3 |
| (Stavudine or Zidovudine)/TDF | -0.9 |
| All TDF | 0.1 |
This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 288 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 2.0 |
| (Stavudine or Zidovudine)/TDF | 0.5 |
| All TDF | 1.3 |
This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 336 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 2.0 |
| (Stavudine or Zidovudine)/TDF | 0.8 |
| All TDF | 1.4 |
This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 384 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 0.5 |
| (Stavudine or Zidovudine)/TDF | 1.6 |
| All TDF | 0.9 |
This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 432 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 0.3 |
| (Stavudine or Zidovudine)/TDF | 2.9 |
| All TDF | 1.1 |
This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: Baseline and 48 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 0.3 |
| Stavudine or Zidovudine | 1.1 |
| All TDF | 0.6 |
This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 480 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 2.3 |
| (Stavudine or Zidovudine)/TDF | 5.0 |
| All TDF | 2.9 |
This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 528 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 4.5 |
| All TDF | 4.5 |
This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: Baseline and 96 weeks
| Intervention | percentage (Mean) |
|---|---|
| Tenofovir DF | 1.3 |
| (Stavudine or Zidovudine)/TDF | -0.1 |
| All TDF | 0.6 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: 192 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 70.6 |
| (Stavudine or Zidovudine)/TDF | 82.5 |
| All TDF | 77.0 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: 240 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 70.6 |
| (Stavudine or Zidovudine)/TDF | 75.7 |
| All TDF | 73.2 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: 288 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 81.5 |
| (Stavudine or Zidovudine)/TDF | 67.6 |
| All TDF | 73.4 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: 336 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 90.9 |
| (Stavudine or Zidovudine)/TDF | 100.0 |
| All TDF | 95.3 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: 384 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100.0 |
| (Stavudine or Zidovudine)/TDF | 100.0 |
| All TDF | 100.0 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: 432 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100.0 |
| (Stavudine or Zidovudine)/TDF | 85.7 |
| All TDF | 95.0 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: 480 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 88.9 |
| (Stavudine or Zidovudine)/TDF | 100.0 |
| All TDF | 90.9 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: 528 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100.0 |
| All TDF | 100.0 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: 144 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 73.7 |
| (Stavudine or Zidovudine)/TDF | 87.5 |
| All TDF | 80.8 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 83.3 |
| Stavudine or Zidovudine | 91.8 |
| All TDF | 85.4 |
This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: 96 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 81.6 |
| (Stavudine or Zidovudine)/TDF | 85.4 |
| All TDF | 83.5 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 144 weeks of exposure to TDF. (NCT00528957)
Timeframe: 144 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 63.2 |
| (Stavudine or Zidovudine)/TDF | 75.0 |
| All TDF | 69.2 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 192 weeks of exposure to TDF. (NCT00528957)
Timeframe: 192 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 67.6 |
| (Stavudine or Zidovudine)/TDF | 75.0 |
| All TDF | 71.6 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 240 weeks of exposure to TDF. (NCT00528957)
Timeframe: 240 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 70.6 |
| (Stavudine or Zidovudine)/TDF | 73.0 |
| All TDF | 71.8 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 288 weeks of exposure to TDF. (NCT00528957)
Timeframe: 288 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 81.5 |
| (Stavudine or Zidovudine)/TDF | 62.2 |
| All TDF | 70.3 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 336 weeks of exposure to TDF. (NCT00528957)
Timeframe: 336 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 86.4 |
| (Stavudine or Zidovudine)/TDF | 90.5 |
| All TDF | 88.4 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 384 weeks of exposure to TDF. (NCT00528957)
Timeframe: 384 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 88.2 |
| (Stavudine or Zidovudine)/TDF | 100.0 |
| All TDF | 92.3 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 432 weeks of exposure to TDF. (NCT00528957)
Timeframe: 432 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100.0 |
| (Stavudine or Zidovudine)/TDF | 71.4 |
| All TDF | 90.0 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 48 weeks of exposure to randomized study drug. (NCT00528957)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 70.8 |
| Stavudine or Zidovudine | 85.7 |
| All TDF | 68.5 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 480 weeks of exposure to TDF. (NCT00528957)
Timeframe: 480 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 77.8 |
| (Stavudine or Zidovudine)/TDF | 50.0 |
| All TDF | 72.7 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 528 weeks of exposure to TDF. (NCT00528957)
Timeframe: 528 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 100.0 |
| All TDF | 100.0 |
This is the percentage of participants with HIV-1 RNA < 50 copies/mL after 96 weeks of exposure to TDF. (NCT00528957)
Timeframe: 96 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 76.3 |
| (Stavudine or Zidovudine)/TDF | 68.3 |
| All TDF | 72.2 |
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA < 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT00528957)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 88.6 |
| Stavudine or Zidovudine | 89.6 |
This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT00528957)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Tenofovir DF | 75.0 |
| Stavudine or Zidovudine | 81.3 |
Change from baseline to week 96 in estimate creatinine clearance between randomised treatment arms (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | millilitres per minute (Mean) |
|---|---|
| 600mg Efavirenz | -0.17 |
| 400mg Efavirenz | 1.59 |
Change from baseline to week 96 in fasted insulin levels (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | mU per litre (Mean) |
|---|---|
| 600mg Efavirenz | -0.11 |
| 400mg Efavirenz | 0.3 |
Mean change from baseline to week 96 in CD4+ T-cell count/mm3 between the two treatment arms (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | cells per mm3 (Mean) |
|---|---|
| 600mg Efavirenz | 209 |
| 400mg Efavirenz | 235 |
Percentage of participants in each of the treatment arms with centrally quantified plasma HIV-1 RNA viral load <200 copies/mL 48 weeks after randomisation. (NCT01011413)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 600mg Efavirenz | 92.2 |
| 400mg Efavirenz | 94.1 |
Steady-state efavirenz mid-dosing interval plasma concentrations (NCT01011413)
Timeframe: Week 4
| Intervention | milligram per Litre (Geometric Mean) |
|---|---|
| 600mg Efavirenz | 2.85 |
| 400mg Efavirenz | 2.10 |
Change from baseline to week 96 in fasted total cholesterol, high density cholesterol and low density cholesterol, and glucose between randomised treatment arms (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | mmol per Litre (Mean) | |||
|---|---|---|---|---|
| Total cholesterol mmol/L | HDL mmol/L | LDL mmol/L | Blood glucose mmol/L | |
| 400mg Efavirenz | 0.54 | 0.30 | 0.16 | 0.40 |
| 600mg Efavirenz | 0.62 | 0.35 | 0.21 | 0.24 |
Change from baseline to week 96 in alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels between randomised treatment arms (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | Units per Litre (Mean) | ||
|---|---|---|---|
| Alanine aminotransferase | Aspartate aminotransferase | Alkaline phosphatase | |
| 600 mg Efavirenz | 6.53 | 1.71 | 26.75 |
| Efavirenz 400 mg | 0.64 | -1.23 | 21.23 |
Percentage of participants in each of the two treatment arms with plasma HIV-1 RNA <400 copies/mL and <50 copies/mL at 48 and 96 weeks after randomisation (NCT01011413)
Timeframe: Baseline and 2 years
| Intervention | participants (Number) | |
|---|---|---|
| HIV-1 RNA <50cp/mL | HIV-1 RNA <400cp/mL | |
| 600 mg Efavirenz | 268 | 280 |
| Efavirenz 400 mg | 277 | 291 |
(NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 323 |
| E/C/F/TDF | 310 |
(NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 235 |
| E/C/F/TDF | 221 |
(NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 285 |
| E/C/F/TDF | 271 |
(NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.04 |
| E/C/F/TDF | 0.08 |
(NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.08 |
| E/C/F/TDF | 0.11 |
(NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.05 |
| E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.826 |
| E/C/F/TDF | -3.475 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.951 |
| E/C/F/TDF | -3.515 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.865 |
| E/C/F/TDF | -3.200 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.809 |
| E/C/F/TDF | -3.023 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.337 |
| E/C/F/TDF | -2.956 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.907 |
| E/C/F/TDF | -3.053 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -24.6 |
| E/C/F/TDF | 60.4 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -32.8 |
| E/C/F/TDF | 18.0 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -33.5 |
| E/C/F/TDF | 32.5 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 37.4 |
| E/C/F/TDF | 106.9 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 11.3 |
| E/C/F/TDF | 75.0 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 6.9 |
| E/C/F/TDF | 51.2 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 93.1 |
| E/C/F/TDF | 92.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 31.3 | 6.0 | 0.2 |
| E/C/F/TDF | 37.1 | 7.0 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 25.8 | 4.6 | 0 |
| E/C/F/TDF | 32.3 | 4.9 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 28.8 | 5.1 | 0.2 |
| E/C/F/TDF | 33.9 | 5.8 | 0.2 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 48 | Week 96 | Week 144 | |
| E/C/F/TAF | 86.4 | 84.4 | 84.6 |
| E/C/F/TDF | 87.3 | 83.6 | 80.1 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 96 | Week 144 | |
| E/C/F/TAF | 89.2 | 86.9 |
| E/C/F/TDF | 88.2 | 83.1 |
(NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 225 |
| E/C/F/TDF | 200 |
(NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| E/C/F/TAF | 274 |
| E/C/F/TDF | 260 |
(NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.08 |
| E/C/F/TDF | 0.12 |
(NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| E/C/F/TAF | 0.04 |
| E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.364 |
| E/C/F/TDF | -3.023 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -0.420 |
| E/C/F/TDF | -2.603 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.278 |
| E/C/F/TDF | -2.759 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Mean) |
|---|---|
| E/C/F/TAF | -1.017 |
| E/C/F/TDF | -2.516 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -29.3 |
| E/C/F/TDF | 32.3 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | -31.0 |
| E/C/F/TDF | 35.2 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 16.9 |
| E/C/F/TDF | 73.7 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
| Intervention | percent change (Median) |
|---|---|
| E/C/F/TAF | 13.3 |
| E/C/F/TDF | 51.7 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 91.6 |
| E/C/F/TDF | 88.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| E/C/F/TAF | 84.0 |
| E/C/F/TDF | 82.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 48 | Week 96 | |
| E/C/F/TAF | 82.4 | 78.7 |
| E/C/F/TDF | 80.7 | 76.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 27.3 | 4.7 | 0 |
| E/C/F/TDF | 31.6 | 4.6 | 0 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| E/C/F/TAF | 31.8 | 5.4 | 0 |
| E/C/F/TDF | 36.9 | 5.1 | 0 |
(NCT02121795)
Timeframe: Baseline; Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| F/TAF + 3rd Agent | 20 |
| FTC/TDF + 3rd Agent | 21 |
(NCT02121795)
Timeframe: Baseline; Week 96
| Intervention | cells/μL (Mean) |
|---|---|
| F/TAF + 3rd Agent | 50 |
| FTC/TDF + 3rd Agent | 46 |
Hip BMD was assessed by DXA scan. (NCT02121795)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| F/TAF + 3rd Agent | 1.856 |
| FTC/TDF + 3rd Agent | -0.289 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT02121795)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| F/TAF + 3rd Agent | 1.236 |
| FTC/TDF + 3rd Agent | -0.071 |
Spine BMD was assessed by DXA scan. (NCT02121795)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| F/TAF + 3rd Agent | 1.662 |
| FTC/TDF + 3rd Agent | -0.109 |
Spine BMD was assessed by DXA scan. (NCT02121795)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| F/TAF + 3rd Agent | 2.159 |
| FTC/TDF + 3rd Agent | -0.109 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02121795)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF + 3rd Agent | 91.6 |
| FTC/TDF + 3rd Agent | 90.9 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02121795)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF + 3rd Agent | 83.5 |
| FTC/TDF + 3rd Agent | 86.1 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02121795)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF + 3rd Agent | 94.3 |
| FTC/TDF + 3rd Agent | 93.0 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02121795)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| F/TAF + 3rd Agent | 88.6 |
| FTC/TDF + 3rd Agent | 89.1 |
The percentage of participants with HIV-1 RNA < 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 94.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 97.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 94.0 |
The percentage of participants with HIV-1 RNA < 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 94.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 97.9 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 94.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 90.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 93.8 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 90.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 92.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 95.8 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 92.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 24 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 400 copies/mL at Week 48 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 98.1 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 100.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed based on missing = failure analyses. (NCT01854775)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 96.3 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 23840.1 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 332.9 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 188.9 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 33813.9 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 29666.6 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 366.4 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | cells/μL (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 471 | 191 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | cells/μL (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 471 | 224 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 23.6 | 7.7 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 23.6 | 9.3 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | copies/mL (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 4.62 | -3.25 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | copies/mL (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 4.62 | -3.26 |
"Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:~Fatal~Life-threatening~Disabling/incapacitating~Results in hospitalization or prolongs a hospital stay~A congenital abnormality~Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above." (NCT01854775)
Timeframe: From first dose date up to Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any TEAEs | SAEs | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 81.3 | 8.3 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | cells/μL (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 961 | -118 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | cells/µL (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 961 | -66 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 38.2 | -0.8 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 38.2 | -0.6 |
"TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:~Fatal~Life-threatening~Disabling/incapacitating~Results in hospitalization or prolongs a hospital stay~A congenital abnormality~Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above." (NCT01854775)
Timeframe: From first dose date up to Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any TEAEs | SAEs | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 73.9 | 0 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | cells/μL (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 1153 | -137 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | cells/µL (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 1153 | -179 |
(NCT01854775)
Timeframe: Baseline, Week 24
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 24 | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 35.9 | 0.0 |
(NCT01854775)
Timeframe: Baseline, Week 48
| Intervention | percentage of CD4+ cell (Mean) | |
|---|---|---|
| Baseline | Change at Week 48 | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 35.9 | 0.2 |
"TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious:~Fatal~Life-threatening~Disabling/incapacitating~Results in hospitalization or prolongs a hospital stay~A congenital abnormality~Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above." (NCT01854775)
Timeframe: From first dose date up to Week 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any TEAEs | SAEs | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 70.4 | 3.7 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) | ||
|---|---|---|---|
| FTC | TFV | COBI | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 14424.4 | 287.6 | 8240.8 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | hr*ng/mL (Mean) | ||
|---|---|---|---|
| FTC | TFV | COBI | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 20629.2 | 440.2 | 15890.7 |
AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | hr*ng/mL (Mean) | ||
|---|---|---|---|
| FTC | TFV | COBI | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 19468.1 | 334.9 | 14485.2 |
Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | L/hr (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 6.7 | 68.6 |
Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | L/hr (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 6.3 | 31.9 |
Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | L/hr (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 3.4 | 18.5 |
Cmax is defined as the maximum concentration of drug. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| EVG | TAF | FTC | TFV | COBI | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 2229.6 | 166.8 | 2265.0 | 17.6 | 1202.4 |
Cmax is defined as the maximum concentration of drug. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| EVG | TAF | FTC | TFV | COBI | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 3055.2 | 313.3 | 3397.4 | 26.1 | 2079.4 |
Cmax is defined as the maximum concentration of drug. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| EVG | TAF | FTC | TFV | COBI | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 3297.2 | 286.6 | 3007.4 | 19.6 | 1525.5 |
Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| EVG | FTC | TFV | COBI | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 300.8 | 102.4 | 10.0 | 25.0 |
Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT01854775)
Timeframe: (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| EVG | FTC | TFV | COBI | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 370.0 | 114.9 | 15.1 | 96.0 |
Ctau is defined as the observed drug concentration at the end of the dosing interval. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| EVG | FTC | TFV | COBI | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 277.5 | 82.5 | 11.4 | 23.0 |
Vz is defined as the volume of distribution of the drug after intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
| Intervention | liters (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 60.5 | 49.7 |
Vz is defined as the volume of distribution of the drug after intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
| Intervention | liters (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 46.8 | 28.6 |
Vz is defined as the volume of distribution of the drug after intravenous administration. (NCT01854775)
Timeframe: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
| Intervention | liters (Mean) | |
|---|---|---|
| EVG | TAF | |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 28.5 | 16.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02397694)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| BIC + F/TAF | 93.8 |
| DTG + F/TAF | 93.9 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02397694)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| BIC + F/TAF | 96.9 |
| DTG + F/TAF | 90.9 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02397694)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| BIC + F/TAF | 96.9 |
| DTG + F/TAF | 93.9 |
(NCT02397694)
Timeframe: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
| Intervention | percentage of participants (Number) |
|---|---|
| BIC + F/TAF | 87.7 |
| DTG + F/TAF | 72.7 |
(NCT02397694)
Timeframe: First dose date up to last dose (maximum duration: 58 Weeks) plus 30 days (During Double-Blinded Randomized Phase)
| Intervention | percentage of participants (Number) |
|---|---|
| BIC + F/TAF | 87.5 |
| DTG + F/TAF | 87.5 |
(NCT02397694)
Timeframe: Baseline; Week 24
| Intervention | CD4 Cell Count (/μL) (Mean) |
|---|---|
| BIC + F/TAF | 190 |
| DTG + F/TAF | 155 |
(NCT02397694)
Timeframe: Baseline; Week 48
| Intervention | CD4 Cell Count (/μL) (Mean) |
|---|---|
| BIC + F/TAF | 258 |
| DTG + F/TAF | 188 |
(NCT02397694)
Timeframe: Baseline; Week 12
| Intervention | CD4 Cell Count (/μL) (Mean) |
|---|---|
| BIC + F/TAF | 170 |
| DTG + F/TAF | 173 |
(NCT02397694)
Timeframe: Baseline; Week 12
| Intervention | log10 copies/mL (Mean) |
|---|---|
| BIC + F/TAF | -3.03 |
| DTG + F/TAF | -3.15 |
(NCT02397694)
Timeframe: Baseline; Week 24
| Intervention | log10 copies/mL (Mean) |
|---|---|
| BIC + F/TAF | -3.09 |
| DTG + F/TAF | -3.12 |
(NCT02397694)
Timeframe: Baseline; Week 48
| Intervention | log10 copies/mL (Mean) |
|---|---|
| BIC + F/TAF | -3.09 |
| DTG + F/TAF | -3.11 |
AUCtau is defined as the area under the concentration-time curve of the drug over time. (NCT02397694)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
| Intervention | h*ng/mL (Mean) | |||
|---|---|---|---|---|
| BIC | FTC | TAF | TFV | |
| BIC + F/TAF | 139778.8 | 11605.4 | 247.4 | 316.0 |
| DTG + F/TAF | NA | 14689.8 | 245.6 | 369.4 |
Cmax is the maximum observed plasma concentration of the drug. (NCT02397694)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| BIC | FTC | TAF | TFV | |
| BIC + F/TAF | 9344.3 | 1919.1 | 249.1 | 19.1 |
| DTG + F/TAF | NA | 2157.1 | 260.8 | 20.9 |
t1/2 was defined as the terminal elimination half-life of the drug (NCT02397694)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
| Intervention | hours (Median) | |||
|---|---|---|---|---|
| BIC | FTC | TAF | TFV | |
| BIC + F/TAF | 16.73 | 5.46 | 0.37 | 37.74 |
| DTG + F/TAF | NA | 5.70 | 0.42 | 34.47 |
Tmax was defined as the time to Cmax. (NCT02397694)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
| Intervention | hours (Median) | |||
|---|---|---|---|---|
| BIC | FTC | TAF | TFV | |
| BIC + F/TAF | 2.00 | 1.50 | 1.00 | 1.50 |
| DTG + F/TAF | NA | 1.50 | 1.00 | 2.00 |
Ctau was defined as the observed drug concentration at the end of the dosing interval. (NCT02397694)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours postdose at Week 4 or 8
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| BIC | FTC | TFV | |
| BIC + F/TAF | 3508.6 | 76.6 | 10.7 |
| DTG + F/TAF | NA | 102.6 | 12.2 |
(NCT02345226)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| FTC/RPV/TAF | 23 |
| EFV/FTC/TDF | 12 |
(NCT02345226)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| FTC/RPV/TAF | 12 |
| EFV/FTC/TDF | 6 |
The HIV Symptoms Index was a 20-item, self-reported measure that addressed presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Twenty HIV symptoms including Fatigue, Fever, Dizziness, Hand/Foot Pain, Memory Loss, Nausea, Diarrhea, Sadness, Nervous/anxious, Sleep Trouble, Skin Problems, Cough, Headache, Appetite Loss, Stomach Pain, Muscle/Joint Pain, Sex Problems, Change in Fat Deposits, Weight Loss, and Hair Loss were assessed. There were 5 possible responses (0 = I don't have this symptom; 1 = It doesn't bother me; 2 = It bothers me a little; 3 = It bothers me; and 4 = It bothers me a lot) for each HIV symptom. Total HIV Symptoms Index Score was derived from all 20 HIV symptoms by counting the number of bothersome symptoms. Total score would be missing if any of the individual items were missing. (NCT02345226)
Timeframe: Baseline; Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| FTC/RPV/TAF | 0 |
| EFV/FTC/TDF | -1 |
The HIV Symptoms Index was a 20-item, self-reported measure that addressed presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Twenty HIV symptoms including Fatigue, Fever, Dizziness, Hand/Foot Pain, Memory Loss, Nausea, Diarrhea, Sadness, Nervous/anxious, Sleep Trouble, Skin Problems, Cough, Headache, Appetite Loss, Stomach Pain, Muscle/Joint Pain, Sex Problems, Change in Fat Deposits, Weight Loss, and Hair Loss were assessed. There were 5 possible responses (0 = I don't have this symptom; 1 = It doesn't bother me; 2 = It bothers me a little; 3 = It bothers me; and 4 = It bothers me a lot) for each HIV symptom. Total HIV Symptoms Index Score was derived from all 20 HIV symptoms by counting the number of bothersome symptoms. Total score would be missing if any of the individual items were missing. (NCT02345226)
Timeframe: Baseline; Week 96
| Intervention | units on a scale (Mean) |
|---|---|
| FTC/RPV/TAF | 0 |
| EFV/FTC/TDF | -1 |
Hip BMD was assessed by DXA scan. (NCT02345226)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.831 |
| EFV/FTC/TDF | -0.617 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT02345226)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.279 |
| EFV/FTC/TDF | -0.134 |
Spine BMD was assessed by DXA scan. (NCT02345226)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.645 |
| EFV/FTC/TDF | -0.045 |
Spine BMD was assessed by DXA scan. (NCT02345226)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.701 |
| EFV/FTC/TDF | 0.126 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345226)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 90.0 |
| EFV/FTC/TDF | 92.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345226)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 85.2 |
| EFV/FTC/TDF | 85.1 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345226)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 1.1 |
| EFV/FTC/TDF | 0.9 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345226)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 0.7 |
| EFV/FTC/TDF | 0.9 |
(NCT02345252)
Timeframe: Baseline; Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| FTC/RPV/TAF | 9 |
| FTC/RPV/TDF | -1 |
(NCT02345252)
Timeframe: Baseline; Week 96
| Intervention | cells/µL (Mean) |
|---|---|
| FTC/RPV/TAF | 12 |
| FTC/RPV/TDF | 16 |
Hip BMD was assessed by DXA scan. (NCT02345252)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.623 |
| FTC/RPV/TDF | -0.613 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT02345252)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.040 |
| FTC/RPV/TDF | -0.245 |
Spine BMD was assessed by DXA scan. (NCT02345252)
Timeframe: Baseline; Week 48
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 1.613 |
| FTC/RPV/TDF | 0.075 |
Spine BMD was assessed by DXA scan. (NCT02345252)
Timeframe: Baseline; Week 96
| Intervention | percentage change (Mean) |
|---|---|
| FTC/RPV/TAF | 2.039 |
| FTC/RPV/TDF | -0.250 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the US FDA-defined snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345252)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 93.7 |
| FTC/RPV/TDF | 93.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345252)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 89.2 |
| FTC/RPV/TDF | 88.5 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345252)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 0.6 |
| FTC/RPV/TDF | 0 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02345252)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| FTC/RPV/TAF | 0.6 |
| FTC/RPV/TDF | 1.0 |
Intracellular TFV-DP will be measured in red blood cells using dried blood spots. TFV-DP levels provide a measure of long-term adherence over the preceding month (like hemoglobin A1C). The level of intracellular TFV-DP can be used to estimate how many doses/week the participant is taking on average (e.g. 7/wk on average, 4-7/wk on average, 2-4/wk on average, <2/wk on average). (NCT02611362)
Timeframe: 24 weeks
| Intervention | fmol/punch (Mean) |
|---|---|
| Intervention | 810.4 |
| Comparison | 574.6 |
"The HIV Knowledge Scale assesses knowledge about issues such as risks for HIV, using 5 items with true, false, or do not know response options. Total scores range from 0 to 5. Higher scores indicate greater knowledge." (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 4.1 |
| Comparison | 4.2 |
Rollnick's Readiness Ruler will be used to assess motivation for adherence to medication and medical visits. Respondents rate how ready they are to take PrEP as prescribed on a scale from 1 (not ready) to 10 (ready to be consistent or already consistent) each month. (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 9.1 |
| Comparison | 9.8 |
This six item measure assesses social support for taking medications, going to medical appointments and other tasks related to adherence using Likert style items with a four point scale. Scores range from 6 to 24 Higher scores indicate greater social support. (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 21.4 |
| Comparison | 21.2 |
Results report the week 48 change from baseline (week 48 - baseline) in CD4 count. Baseline CD4 count was computed as the mean of CD4 count values at pre-entry and study entry. (NCT00830804)
Timeframe: From start of study treatment through week 48
| Intervention | cells/mm3 (Median) |
|---|---|
| RAL + DRV/RTV | 200 |
Results report the week 24 change from week 0 (week 24 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. (NCT00830804)
Timeframe: From start of study treatment through week 24
| Intervention | mg/dL (Median) |
|---|---|
| RAL + DRV/RTV | 16.0 |
Results report the week 48 change from week 0 (week 48 - week 0) fasting low-density lipoprotein (LDL). For participants whose calculated fasting LDL and direct fasting LDL were both reported, only the calculated fasting LDL was used. Direct fasting LDL was reported when the participant had high fasting triglyceride. (NCT00830804)
Timeframe: From start of study treatment through week 48
| Intervention | mg/dL (Median) |
|---|---|
| RAL + DRV/RTV | 17 |
Results report the week 1 change from baseline (week 1 - baseline) in HIV-1 RNA. Baseline HIV-1 RNA was computed as the mean of the log10 HIV-1 RNA values at pre-entry and study entry. (NCT00830804)
Timeframe: Baseline and week 1
| Intervention | log10 copies/ml (Median) |
|---|---|
| RAL+DRV/RTV | -1.67 |
Results report the number of participants who had integrase resistance mutation(s) detected at the time of virologic failure. (NCT00830804)
Timeframe: From 12 weeks after starting study treatment to week 52
| Intervention | participants (Number) |
|---|---|
| RAL+DRV/RTV | 5 |
"At each study visit, adherence was measured in terms of the number of missed doses each participant had over a 4-day recall for each drug. Adherence for all study visit weeks were combined for an overall measure of adherence. Participants who had zero missed doses on all weeks in all drugs while on study were classified as having an overall perfect adherence." (NCT00830804)
Timeframe: From one week after starting study treatment to week 52
| Intervention | participants (Number) |
|---|---|
| RAL + DRV/RTV | 95 |
Results report the number of participants who had protease resistance mutation(s) detected at the time of virologic failure. (NCT00830804)
Timeframe: From 12 weeks after starting study treatment to week 52
| Intervention | participants (Number) |
|---|---|
| RAL+DRV/RTV | 0 |
Plasma trough concentrations (ng/ml) of Darunavir (DRV) below the detection limit (50 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 20-28 hours after the last DRV dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. (NCT00830804)
Timeframe: From start of study treatment to week 52
| Intervention | ng/ml (Median) |
|---|---|
| RAL+DRV/RTV | 1218 |
Plasma trough concentrations (ng/ml) of Raltegravir (RAL) below the detection limit (10 ng/ml) were replaced by half the corresponding lower limit of quantitation. Geometric mean of trough concentrations obtained within the prescribed trough time (within 9-15 hours after the last RAL dose) was computed for each participant. For participants who experienced virologic failure (see primary outcome measure definition), only those concentrations on or before virologic failure confirmation were used in the geometric mean computation. (NCT00830804)
Timeframe: From start of study treatment to week 52
| Intervention | ng/ml (Median) |
|---|---|
| RAL+DRV/RTV | 117 |
Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Results report the percentage of participants who had grade 3 or higher events, or events of any grade which led to a permanent change or discontinuation of study treatment, which occurred any time from start of treatment to end of treatment. (NCT00830804)
Timeframe: From start of study treatment to week 52
| Intervention | proportion of participants (Number) |
|---|---|
| RAL+DRV/RTV | 0.20 |
Virologic failure is defined as: at week 12, confirmed plasma HIV-1 RNA >= 1000 copies/ml or confirmed rebound from the week 4 value by >0.5 log10 copies/ml (for subjects with week 4 value <= 50 copies/ml, confirmed rebound to >50 copies/ml); at week 24 or later, confirmed value > 50 copies/ml. Viral load confirmation was scheduled 7-35 days after initial virologic failure. The proportion was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. (NCT00830804)
Timeframe: From start of study treatment to week 24
| Intervention | Proportion of participants (Number) |
|---|---|
| RAL+DRV/RTV | 0.16 |
The proportion of participants with virologic failure (see primary outcome measure for definition) and/or premature treatment discontinuation/modification and/or death was estimated using Kaplan-Meier method. An adaptation of Greenwood's variance estimate was used in constructing the confidence interval. (NCT00830804)
Timeframe: From start of study treatment to Week 24
| Intervention | Proportion of participants (Number) |
|---|---|
| RAL+DRV/RTV | 0.21 |
Results report the week 24 change from week 0 (week 24 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. (NCT00830804)
Timeframe: From start of study treatment through week 24
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Fasting Total Cholesterol | Fasting High-density Lipoprotein | Fasting Triglyceride | |
| RAL + DRV/RTV | 31.5 | 6.5 | 24.5 |
Results report the week 48 change from week 0 (week 48 - week 0) fasting total cholesterol, high-density lipoprotein and triglyceride. (NCT00830804)
Timeframe: From start of study treatment through week 48
| Intervention | mg/dL (Median) | ||
|---|---|---|---|
| Fasting Total Cholesterol | Fasting High-density Lipoprotein | Fasting Triglyceride | |
| RAL + DRV/RTV | 30 | 9 | 23 |
Results report the number of participants who had resistance to non-nucleoside reverse transciptase inhibitors (NNRTI), nucleoside reverse transciptase inhibitors (NRTI) and protease inbitors (PI) based on genotypic resistance testing done prior to participant's entry into the study. Participants are classified into one (and only one category) based on the maximum number of drug class resistance seen for the participant. (NCT00830804)
Timeframe: At screening
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| With NNRTI mutations only | With NRTI mutations only | With Both NNRTI and NRTI mutations | With PI mutations only | With PI, NNRTI and NRTI mutations | No Resistance Detected | |
| RAL + DRV/RTV | 9 | 8 | 1 | 2 | 1 | 91 |
Results report the percentage of participants with plasma HIV-1 RNA < 50 copies/ml or <200 copies/ml at week 24. (NCT00830804)
Timeframe: From start of study treatment to week 24
| Intervention | proportion of participants (Number) | |
|---|---|---|
| With HIV-1 RNA < 50 copies/ml | With HIV-1 RNA < 200 copies/ml | |
| RAL+DRV/RTV | 0.79 | 0.93 |
Results report the percentage of participants with plasma HIV-1 RNA <50 copies/ml or <200 copies/ml at week 48. (NCT00830804)
Timeframe: From start of study treatment to week 48
| Intervention | proportion of participants (Number) | |
|---|---|---|
| With HIV-1 RNA < 50 copies/ml | With HIV-1 RNA < 200 copies/ml | |
| RAL+DRV/RTV | 0.71 | 0.86 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48. The percentage of participants with HIV-1 RNA <50 copies/mL were tabulated by treatment arm with stratification by baseline HIV-1 RNA (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 67.5 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 67.2 |
A blood sample was drawn to determine the CD4+ cell count at Weeks 48 and 96. Change from baseline was defined as CD4+ cell count at week 96 minus CD4+ cell count at baseline. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | cells per cmm (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 201.0 | 250.0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 173.0 | 246.5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. Change from baseline was defined as HIV-1 RNA level at Weeks 48 and 96 minus HIV-1 RNA level at baseline. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | log10 copies/mL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | -3.142 | -3.114 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | -3.131 | -3.165 |
A blood sample was drawn for participants failing to respond to therapy and the mutations present in the virus were identified. New mutations that developed to the NRTI class at the time of failure that no longer responded to lamivudine or emtricitabine were tabulated by drug class. (NCT00244712)
Timeframe: Baseline and time of virologic failure (up to Week 96)
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance NRTI class (M184V, M/V,M/I,A/V,I,M/I/V) | Reduced pheno susceptibility to lamivudine/M184V | Reduced phen susceptibility to lamivudine/M184M/V | Reduced pheno susceptibility to lamivudine/M184M/I | Reduced pheno susceptibility to lamivudine/M184A/V | Reduced pheno susceptibility to lamivudine/M184I | Reduced pheno suscept. to lamivudine/M184M/I/V | Reduced pheno suscept. to emtricitabine/M184V | Reduced pheno suscept. to emtricitabine/M184M/V | Reduced pheno suscept. to emtricitabine/M184M/I | Reduced pheno suscept. to emtricitabine/M184A/V | Reduced pheno suscept. to emtricitabine/M184I | Reduced pheno suscept. to emtricitabine/M184M/I/V | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 11 | 4 | 3 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 0 | 0 | 0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 17 | 9 | 0 | 1 | 1 | 1 | 1 | 9 | 0 | 1 | 1 | 1 | 1 |
A blood sample was drawn for participants failing to respond to therapy and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of failure was tabulated by drug class. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. (NCT00244712)
Timeframe: Baseline and time of virologic failure (up to Week 96)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| No. with paired genotypes at baseline and wk 96 | Participants with treatment-emergent mutations | NRTI-associated mutations | NNRTI-associated mutations | PI-associated mutations | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 45 | 18 | 11 | 4 | 11 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 41 | 22 | 17 | 3 | 7 |
The number of participants that failed to respond to therapy based on the protocol definition of virologic failure (PDVF) was tabulated. PDVF was defined as either no confirmed HIV-1 RNA <200 copies/mL or HIV-1 RNA rebound >= 200 copies/mL on two consecutive occasions. (NCT00244712)
Timeframe: Baseline to Week 96
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Protocol-defined virologic failure | Fail to confirm HIV-1 RNA <200 copies/mL by wk 24 | Confirmed HIV-1 RNA rebound to >= 200 copies/mL | Suspected HIV-1 RNA rebound to >= 200 copies/mL | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 49 | 21 | 28 | 12 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 48 | 24 | 24 | 11 |
The number of participants that experienced symptoms of a suspected abacavir hypersensitivity reaction was tabulated. The number of participants that developed laboratory signs of proximal renal tubule dysfunction was tabulated. (NCT00244712)
Timeframe: Baseline through 96 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants (Par.) with suspected ABC HSR | Mild or Grade 1 | Moderate or Grade 2 | Severe or Grade 3 | Not Applicable | Par. with proximal renal tubule dysfunction | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 14 | 1 | 8 | 4 | 1 | 0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 3 | 0 | 2 | 1 | 0 | 5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 75.2 | 70.9 | 93.8 | 71.4 | 63.9 | 58.4 | 92.8 | 60.1 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71.3 | 66.4 | 92.2 | 66.2 | 61.2 | 56.3 | 96.3 | 56.9 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA <100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 76 | 72 | 94 | 72 | 65 | 60 | 92 | 61 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71 | 66 | 91 | 65 | 60 | 55 | 97 | 56 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA >=100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 75 | 70 | 94 | 71 | 63 | 56 | 93 | 59 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71 | 67 | 94 | 68 | 63 | 58 | 96 | 58 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48. The percentage of participants with HIV-1 RNA <50 copies/mL at Week 48 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| TLOVR | Obs | M/D=F | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 62.6 | 84.3 | 64.3 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 61.1 | 86.8 | 62.3 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Week 96 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M=F, Switch Included | TLOVR | Obs | M/D=F | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 59.9 | 52.1 | 86.9 | 56.4 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 58.0 | 51.0 | 91.3 | 54.5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA <100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | MD=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | MD=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 71 | 67 | 89 | 68 | 63 | 57 | 89 | 59 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 69 | 62 | 88 | 62 | 58 | 52 | 94 | 54 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48 and 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA >=100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 63 | 57 | 78 | 59 | 56 | 46 | 84 | 54 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 65 | 60 | 86 | 62 | 58 | 51 | 88 | 55 |
Mean change from baseline at Week 156 in CD4 cell count (cells/mm3) (NCT00369941)
Timeframe: Baseline and Week 156
| Intervention | CD4 Cell Count (cells/mm3) (Mean) |
|---|---|
| MK-0518 400 mg b.i.d. | 331.7 |
| Efavirenz 600 mg q.h.s. | 295.2 |
Mean change from baseline at Week 240 in CD4 cell count (cells/mm3) (NCT00369941)
Timeframe: Baseline and Week 240
| Intervention | CD4 Cell Count (cells/mm3) (Mean) |
|---|---|
| MK-0518 400 mg b.i.d. | 373.7 |
| Efavirenz 600 mg q.h.s. | 311.6 |
Mean change from baseline at Week 96 in CD4 cell count (cells/mm3) (NCT00369941)
Timeframe: Baseline and Week 96
| Intervention | CD4 Cell Count (cells/mm3) (Mean) |
|---|---|
| MK-0518 400 mg b.i.d. | 239.6 |
| Efavirenz 600 mg q.h.s. | 224.8 |
Mean change from baseline at Week 48 in CD4 cell count (cells/mm3) (NCT00369941)
Timeframe: Baseline and Week 48
| Intervention | CD4 Cell Count (cells/mm3) (Mean) |
|---|---|
| MK-0518 400 mg b.i.d. | 189.1 |
| Efavirenz 600 mg q.h.s. | 163.3 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <400 copies/mL at Week 156. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 224 |
| Efavirenz 600 mg q.h.s. | 203 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <400 copies/mL at Week 240. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 206 |
| Efavirenz 600 mg q.h.s. | 181 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <400 copies/mL at Week 48. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 252 |
| Efavirenz 600 mg q.h.s. | 241 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <400 copies/mL at Week 96. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 240 |
| Efavirenz 600 mg q.h.s. | 229 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <50 copies/mL at Week 156. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 212 |
| Efavirenz 600 mg q.h.s. | 192 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <50 copies/mL at Week 240. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 198 |
| Efavirenz 600 mg q.h.s. | 171 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <50 copies/mL at Week 96. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 228 |
| Efavirenz 600 mg q.h.s. | 222 |
Antiretroviral activity was evaluated for participants who achieved HIV RNA level <50 copies/mL at Week 48. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) |
|---|---|
| MK-0518 400 mg b.i.d. | 241 |
| Efavirenz 600 mg q.h.s. | 230 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-related LAEs | Did Not Discontinue With Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-related LAEs | Did Not Discontinue With Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse events (AEs) in this study were defined as drug-related if the investigator considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued with Drug-related LAEs | Did Not Discontinue with Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-related LAEs | Did Not Discontinue With Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With LAEs | Did Not Discontinue With LAEs | |
| Efavirenz 600 mg q.h.s. | 3 | 279 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With LAEs | Did Not Discontinue With LAEs | |
| Efavirenz 600 mg q.h.s. | 3 | 279 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued with LAEs | Did Not Discontinue with LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With LAEs | Did Not Discontinue With LAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
All participant deaths in the span of 156 weeks on study were recorded. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Died | Did Not Die | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 4 | 277 |
All participant deaths in the span of 240 weeks on study were recorded. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Died | Did Not Die | |
| Efavirenz 600 mg q.h.s. | 5 | 277 |
| MK-0518 400 mg b.i.d. | 5 | 276 |
All participant deaths in the span of 48 weeks on study were recorded. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Died | Did Not Die | |
| Efavirenz 600 mg q.h.s. | 0 | 282 |
| MK-0518 400 mg b.i.d. | 2 | 279 |
All participant deaths in the span of 96 weeks on study were recorded. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Died | Did Not Die | |
| Efavirenz 600 mg q.h.s. | 0 | 282 |
| MK-0518 400 mg b.i.d. | 3 | 278 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With CAEs | Did Not Discontinue With CAEs | |
| Efavirenz 600 mg q.h.s. | 21 | 261 |
| MK-0518 400 mg b.i.d. | 13 | 268 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With CAEs | Did Not Discontinue With CAEs | |
| Efavirenz 600 mg q.h.s. | 25 | 257 |
| MK-0518 400 mg b.i.d. | 14 | 267 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued with CAEs | Did Not Discontinue with CAEs | |
| Efavirenz 600 mg q.h.s. | 17 | 265 |
| MK-0518 400 mg b.i.d. | 9 | 272 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With CAEs | Did Not Discontinue With CAEs | |
| Efavirenz 600 mg q.h.s. | 17 | 265 |
| MK-0518 400 mg b.i.d. | 10 | 271 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-related CAEs | Did Not Discontinue With Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 14 | 268 |
| MK-0518 400 mg b.i.d. | 3 | 278 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-related CAEs | Did Not Discontinue With Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 14 | 268 |
| MK-0518 400 mg b.i.d. | 3 | 278 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued with Drug-related CAEs | Did not Discontinue with Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 11 | 271 |
| MK-0518 400 mg b.i.d. | 3 | 278 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Drug-Related CAEs | Did Not Discontinue With Drug-Related CAEs | |
| Efavirenz 600 mg q.h.s. | 12 | 270 |
| MK-0518 400 mg b.i.d. | 3 | 278 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious CAEs | Did Not Discontinue With Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 6 | 276 |
| MK-0518 400 mg b.i.d. | 10 | 271 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious CAEs | Did Not Discontinue With Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 10 | 272 |
| MK-0518 400 mg b.i.d. | 11 | 270 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued with Serious CAEs | Did Not Discontinue with Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 4 | 278 |
| MK-0518 400 mg b.i.d. | 7 | 274 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious CAEs | Did Not Discontinue With Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 5 | 277 |
| MK-0518 400 mg b.i.d. | 8 | 273 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious Drug-related CAEs | Did Not Discontinue With Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 1 | 280 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious Drug-related CAEs | Did Not Discontinue With Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 1 | 280 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontiued with Serious Drug-related CAEs | Did Not Discontinue with Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 1 | 280 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Discontinued With Serious Drug-related CAEs | Did Not Discontinue With Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 1 | 280 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With CAEs | Without CAEs | |
| Efavirenz 600 mg q.h.s. | 276 | 6 |
| MK-0518 400 mg b.i.d. | 267 | 14 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With CAEs | Without CAEs | |
| Efavirenz 600 mg q.h.s. | 276 | 6 |
| MK-0518 400 mg b.i.d. | 271 | 10 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With CAEs | Without CAEs | |
| Efavirenz 600 mg q.h.s. | 274 | 8 |
| MK-0518 400 mg b.i.d. | 265 | 16 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With CAEs | Without CAEs | |
| Efavirenz 600 mg q.h.s. | 272 | 10 |
| MK-0518 400 mg b.i.d. | 253 | 28 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With drug-related CAEs | Without drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 225 | 57 |
| MK-0518 400 mg b.i.d. | 139 | 142 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With drug-related CAEs | Without drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 226 | 56 |
| MK-0518 400 mg b.i.d. | 146 | 135 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Drug-related CAEs | Without Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 217 | 65 |
| MK-0518 400 mg b.i.d. | 124 | 157 |
"Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With drug-related CAEs | Without drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 220 | 62 |
| MK-0518 400 mg b.i.d. | 132 | 149 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Drug-related LAEs | Without Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 33 | 249 |
| MK-0518 400 mg b.i.d. | 22 | 259 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Drug-related LAEs | Without Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 43 | 239 |
| MK-0518 400 mg b.i.d. | 26 | 255 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Drug-related LAEs | Without Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 24 | 258 |
| MK-0518 400 mg b.i.d. | 14 | 267 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Drug-related LAEs | Without Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 29 | 253 |
| MK-0518 400 mg b.i.d. | 18 | 263 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Efavirenz 600 mg q.h.s. | 41 | 241 |
| MK-0518 400 mg b.i.d. | 27 | 254 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Efavirenz 600 mg q.h.s. | 63 | 219 |
| MK-0518 400 mg b.i.d. | 41 | 240 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Efavirenz 600 mg q.h.s. | 77 | 205 |
| MK-0518 400 mg b.i.d. | 56 | 225 |
A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| Efavirenz 600 mg q.h.s. | 53 | 229 |
| MK-0518 400 mg b.i.d. | 33 | 248 |
Participants with dizziness, insomnia, somnolence, concentration impaired, depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, auditory hallucination, completed suicide, and major depression (NCT00369941)
Timeframe: 8 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Nervous System Symptoms | Without Nervous System Symptoms | |
| Efavirenz 600 mg q.h.s. | 147 | 135 |
| MK-0518 400 mg b.i.d. | 57 | 224 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious CAEs | Without Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 46 | 236 |
| MK-0518 400 mg b.i.d. | 46 | 235 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious CAEs | Without Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 57 | 225 |
| MK-0518 400 mg b.i.d. | 57 | 224 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious CAEs | Without Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 27 | 255 |
| MK-0518 400 mg b.i.d. | 28 | 253 |
Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose. (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious CAEs | Without Serious CAEs | |
| Efavirenz 600 mg q.h.s. | 33 | 249 |
| MK-0518 400 mg b.i.d. | 37 | 244 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 6 | 276 |
| MK-0518 400 mg b.i.d. | 6 | 275 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 7 | 275 |
| MK-0518 400 mg b.i.d. | 8 | 273 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 5 | 277 |
| MK-0518 400 mg b.i.d. | 4 | 277 |
"Serious CAEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 5 | 277 |
| MK-0518 400 mg b.i.d. | 6 | 275 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related LAEs | Without Serious Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related LAEs | Without Serious Drug-related LAEs | |
| Efavirenz 600 mg q.h.s. | 0 | 282 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose.~Adverse experiences (AEs) in this study were defined as drug-related if the investigator, who is a qualified physician, considered the AE as possibly, probably, or definitely related to MK-0518 or efavirenz alone or in combination with TRUVADA® or to TRUVADA® alone according to his/her best clinical judgment." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious Drug-related CAEs | Without Serious Drug-related CAEs | |
| Efavirenz 600 mg q.h.s. | 0 | 282 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose." (NCT00369941)
Timeframe: 156 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious LAEs | Without Serious LAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose." (NCT00369941)
Timeframe: 240 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious LAEs | Without Serious LAEs | |
| Efavirenz 600 mg q.h.s. | 2 | 280 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose." (NCT00369941)
Timeframe: 48 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious LAEs | Without Serious LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
"A laboratory AE is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the study product, whether or not considered related to the use of the product.~Serious AEs are any AEs occurring at any dose that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer; or is an overdose." (NCT00369941)
Timeframe: 96 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| With Serious LAEs | Without Serious LAEs | |
| Efavirenz 600 mg q.h.s. | 1 | 281 |
| MK-0518 400 mg b.i.d. | 0 | 281 |
Virological response to achieve HIV RNA copies <20 copies/mL at week 48 of both arms. (NCT01989910)
Timeframe: At week 48 of both arms
| Intervention | Participants (Count of Participants) |
|---|---|
| Raltegravir | 41 |
| Efavirenz | 36 |
Virological response to achieve HIV RNA copies <400 copies/mL at week 48 of both arms. (NCT01989910)
Timeframe: At week 48 of both arms
| Intervention | Participants (Count of Participants) |
|---|---|
| Raltegravir | 41 |
| Efavirenz | 36 |
The proportion of treatment failure, defined as detectable HIV RNA copies copies/mL, at week 48 for both arms. (NCT01989910)
Timeframe: At week 48 of both arms
| Intervention | Participants (Count of Participants) |
|---|---|
| Raltegravir | 2 |
| Efavirenz | 2 |
AUC(TAU) was derived from the plasma concentration versus time data. It was calculated from time 0 to 12 hours for LPV and RTV in the LPV/RTV regimen, 0-24 hours for ATV and RTV in the ATV/RTV regimen, and 0-24 hours for tenofovir in both regimens at Week 4. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 28605 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 90945 |
AUC (0-24) was derived from plasma concentration versus time data. It was estimated as 2 times the AUC(TAU) based on 12-hour PK. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6724 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 8011 |
AUC (TAU) was derived from plasma concentration versus time data.It was calculated from time 0-24 hours for tenofovir in LPV/RPV and ATV/RTV regimen at Week 4. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 3272 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3675 |
Cmax was derived from plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 959.8 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 657.4 |
Cmax was derived from plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 352.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 380.7 |
Cmin was derived from plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 50.52 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 179.0 |
Cmin was derived from plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 72.46 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 84.98 |
IQ defined as Cmin at week 4 divided by protein binding adjusted EC90 values for the respective protease inhibitor (ATV or LPV) derived from individual participant clinical isolates. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 27.33 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 35.91 |
Cmax was derived from plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given every day (QD) and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given twice daily (BID) and TDF given QD.
| Intervention | nanogram(ng)/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 2897 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 10654 |
Mean change from baseline in BMI at Week 48 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48.
| Intervention | kg/m^2 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 1.5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1.1 |
(NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | kg/m^2 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 1.6 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1.0 |
Mean change From baseline in BMI at Week 96 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | kg/m^2 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 2.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1.2 |
Mean change from baseline in body weight at Week 48 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | kg (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3 |
Mean change from baseline in weight at Week 96 (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | kg (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3 |
Mean change from baseline in CD4 count among treated participants was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | cells/mm^3 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 268 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 290 |
Mean change from baseline in CD4 cell counts was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48.
| Intervention | c/mm^3 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 203 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 219 |
Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement is associated with a decrease in values. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | Ratio (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.05 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.00 |
Mean changes from baseline in trunk-to-limb fat ratio as measured by DEXA, an x-ray scan used to measure bone mineral density. Clinical improvement was associated with a decrease in values. (NCT00272779)
Timeframe: DEXA scans were taken at Baseline (Day 1) and at Weeks 48.
| Intervention | Ratio (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.04 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.02 |
Mean change from baseline in waist circumference at Week 48 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | cm (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 2 |
Mean change From baseline in waist circumference at Week 96 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | cm (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 2 |
Mean change from baseline in waist-to-hip-ratio at Week 48 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | ratio (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.02 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.01 |
Mean change from baseline in waist-to-hip-ratio at Week 96 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | ratio (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.02 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.01 |
Mean change in BMI from baseline at Week 48 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | kg/m^2 (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 1.3 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.8 |
Mean change from baseline in fasting glucose at Week 48. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48.
| Intervention | mg/dL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 2 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0 |
Mean change from baseline in fasting insulin at Week 48. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48.
| Intervention | micro units (µU)/mL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 2.5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.2 |
Mean change in body weight from baseline was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | kg (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 2.0 |
Mean change in body weight from baseline was determined. (NCT00272779)
Timeframe: Physical examination was performed at Baseline (Day 1) and Weeks 48 and 96.
| Intervention | kg (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3 |
Mean change from baseline in fasting glucose at Week 96 was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | mg/dL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1.0 |
Mean change from baseline in fasting insulin at Week 96. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | µU/mL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.1 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.8 |
Cmin was derived from the plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 526.4 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 5944 |
The MACS adherence questionnaire asks patients how many medication doses they missed during the previous day, 2 days, 3 days and 4 days. Adherence to regimen was defined as taking 100% of medicine (all doses and numbers of pills as prescribed for each medicine). This strict adherence cut-off was based on the guidelines stating that anything less than excellent adherence may result in a virus breakthrough and development of resistance. (NCT00272779)
Timeframe: Week 48
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 330 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 316 |
TLOVR defines responders at Week 48 as participants with confirmed HIV RNA <400 c/mL through Week 48 without intervening virologic rebound or treatment discontinuation. Virologic rebound is defined as confirmed on-treatment HIV RNA <400 c/mL or last on-treatment HIV RNA <400 c/mL followed by discontinuation. Participants are considered failures in this analysis if they experienced virologic rebound at or before Week 48, discontinued before Week 48, never responded by Week 48, never received study therapy or had missing HIV RNA at Week 48 and beyond. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 377 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 363 |
HIV RNA < 400 c/mL is a less stringent measure of viral suppression (highest threshold of assay) and indicates that a participant responded to treatment. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 377 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 365 |
HIV RNA <400 c/mL is a less stringent measure of viral suppression (highest threshold of assay) and indicates that a participant has responded to treatment. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 350 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 330 |
HIV RNA < 50 c/mL is the most stringent measure of viral suppression (lowest threshold of assay) and indicates that a participant has responded to treatment. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 327 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 302 |
HIV RNA < 50 c/mL is the most stringent measure of viral suppression (lowest threshold of assay) and indicates that a participant responded to treatment. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | Participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 343 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 338 |
Lipoatrophy, redistribution of body fat was defined as >= 20% decrease in limb fat. The percentage of participants with lipoatrophy from baseline was determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 7 |
EC90/50=concentration of drug inducing 90%/50% of its maximal response. Protein binding adjusted EC90 for ATV and LPV were derived from phenotypically measured individual EC50 values at baseline using the following formula: Protein binding adjusted EC90 (ng/mL) = scale factor × molecular weight of the free base × EC50 micrometer(μM)/ unbound fraction (fu). Scale factor relates EC50 to EC90 (value of 3 and 2 for ATV and LPV, respectively); fu: estimated unbound fraction of ATV and LPV in vivo (0.14 and 0.02 for ATV and LPV respectively). (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 19.01 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 162.7 |
Changes from baseline in log10 HIV RNA levels were calculated. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | c/mL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -3.21 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -3.19 |
Changes from baseline in log10 HIV RNA levels were calculated. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | c/mL (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -3.09 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -3.13 |
T-half was derived from the plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | Hr (Mean) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 10.31 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 13.89 |
Tmax was derived from the plasma concentration versus time data. (NCT00272779)
Timeframe: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 Hrs post dosing with ATV/RTV and TDF all given QD and at predose, 1, 2, 3, 4, 6, 8, 12 Hrs post dosing with LPV/RTV given BID and TDF given QD.
| Intervention | Hr (Median) |
|---|---|
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 3.00 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 4.00 |
The IBS-QoL questionnaire has 34 items and an overall score and 8 subscale scores: dysphoria,interference with activity,body image,health worry, food avoidance,social reaction,sexual, and relationships. Overall and subscores transformed to a 0-100 scale (0=lowest score, 100=highest possible score). Scores between these values represent the percentage of the total possible score achieved. Higher scores=better IBS-related QoL. A 14-point change from BL in IBS-QoL score in women with moderate to severe functional bowel disorders is a minimally important difference based on pain and satisfaction. (NCT00272779)
Timeframe: IBS-QoL is administered at baseline (Day 1) and Week 4.
| Intervention | Units on Scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (306, 316) | Dysphoria (317, 325) | Interference with activity (319, 327) | Body image (321, 329) | Health worry (319, 330) | Food avoidance (319, 329) | Social reaction (316, 327) | Sexual (320, 329) | Relationships (321, 328) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 3.2 | 3.3 | 3.1 | 1.6 | 6.0 | 4.0 | 1.9 | 3.7 | 1.2 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.7 | -0.1 | -1.9 | -1.3 | 2.0 | -1.7 | -0.8 | -0.1 | -0.6 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted (adj) p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Non-HDL Cholesterol: RETN_097 WT | Fasting Non-HDL Cholesterol: RETN_097 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 12.50 | 13.23 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 26.98 | 52.28 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | ng/dL (Mean) | |
|---|---|---|
| Fasting PAI-1: APOE_R176C WT | ||
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 5.98 | -117.27 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 7.30 | -5.94 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Triglycerides: APOE_C130R WT | Fasting Triglycerides: APOE_C130R MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 23.27 | 13.92 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 70.71 | 131.56 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Triglycerides: RETN_097 WT | Fasting Triglycerides: RETN_097 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 21.41 | 27.21 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 68.06 | 157.87 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Triglycerides: RETN_2265 WT | Fasting Triglycerides: RETN_2265 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 19.61 | 28.70 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 65.83 | 148.95 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Triglycerides: RETN_598 WT | Fasting Triglycerides: RETN_598 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 20.23 | 25.78 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 61.66 | 123.28 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Fasting Triglycerides: RETN_734 WT | Fasting Triglycerides: RETN_734 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 23.35 | 21.16 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 75.12 | 155.28 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Fasting TNF-alpha: IL6_5309 WT | Fasting TNF-alpha: IL6_5309 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -1.19 | 6.01 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -2.68 | 1.41 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Fasting TNF-alpha: RS11030679 WT | Fasting TNF-alpha: RS11030679 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 7.58 | 0.02 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.13 | 1.27 |
The IBS-QoL questionnaire has 34 items and an overall score and 8 subscale scores: dysphoria,interference with activity,body image,health worry, food avoidance,social reaction,sexual, and relationships. Overall and subscores transformed to a 0-100 scale (0=lowest score, 100=highest possible score). Scores between these values represent the percentage of the total possible score achieved. Higher scores=better IBS-related QoL. A 14-point change from BL in IBS-QoL score in women with moderate to severe functional bowel disorders is a minimally important difference based on pain and satisfaction. (NCT00272779)
Timeframe: IBS-QoL is administered at baseline (Day 1) and Week 12.
| Intervention | Units on Scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (301. 310) | Dysphoria (308, 319) | Interference with activity (310, 320) | Body image (316, 321) | Health worry (312, 320) | Food avoidance (316, 322) | Social reaction (311, 316) | Sexual (317, 321) | Relationships (313, 320) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4.6 | 4.7 | 5.1 | 2.1 | 7.9 | 5.6 | 3.3 | 4.7 | 3.5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.2 | 1.2 | -0.4 | -0.1 | 3.6 | -0.6 | -0.4 | -0.4 | 0.0 |
The IBS-QoL questionnaire has 34 items and an overall score and 8 subscale scores: dysphoria,interference with activity,body image,health worry, food avoidance,social reaction,sexual, and relationships. Overall and subscores transformed to a 0-100 scale (0=lowest score, 100=highest possible score). Scores between these values represent the percentage of the total possible score achieved. Higher scores=better IBS-related QoL. A 14-point change from BL in IBS-QoL score in women with moderate to severe functional bowel disorders is a minimally important difference based on pain and satisfaction. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 24
| Intervention | Units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (290, 289) | Dysphoria (295, 298) | Interference with activity (294, 297) | Body image (299, 300) | Health worry (297, 300) | Food avoidance (299, 300) | Social reaction (295, 297) | Sexual (299, 299) | Relationships (297, 297) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4.3 | 4.4 | 4.4 | 1.8 | 7.5 | 5.6 | 3.2 | 4.3 | 3.3 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1.4 | 1.8 | 0.0 | 1.1 | 5.3 | 0.4 | 0.4 | 0.8 | 1.2 |
Medical Outcomes Study HIV Health Survey (MOS-HIV) is developed to assess a patient's health and functional status associated with HIV infection. The MOS-HIV questionnaire is applied to participants with adequate linguistic skills. The subscale and summary scores range from 0-100 with a higher score indicating better health. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 24.
| Intervention | Units on Scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Health Summary (317, 314) | Mental Health Summary (317, 314) | Overall Health Perception Subscale (325, 320) | Physical Function Subscale (324, 325) | Role Function Subscale (325, 325) | Social Function Subscale (327, 322) | Cognitive Function Subscale (326, 324) | Pain Subscale (327, 325) | Mental Health Subscale (325, 326) | Energy/Fatigue Subscale (323, 326) | Health Distress Subscale (323, 326) | Quality of Life Subscale (327, 326) | Health Transition Subscale (327, 326) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4.1 | 5.3 | 15.2 | 7.6 | 10.6 | 8.5 | 5.6 | 7.4 | 6.4 | 7.1 | 14.4 | 9.9 | 13.1 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3.3 | 4.8 | 13.0 | 5.0 | 6.5 | 7.1 | 3.0 | 8.6 | 7.4 | 7.5 | 13.9 | 7.1 | 10.7 |
MOS-HIV is developed to assess a participant's health and functional status associated with HIV infection. The questionnaire is applied to participants with adequate linguistic skills and consists of 35 items. The questionnaire derives an overall health score and 10 subscale scores (health transitions, pain, physical functioning, role functioning, social functioning, cognitive functioning, mental health, energy/fatigue, health distress and quality of life).The subscale and summary scores range from 0-100 with a higher score indicating better health. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | Units on Scale (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Health Summary (296, 287) | Mental Health Summary (296, 287) | Overall Health Perception Subscale (305, 297) | Physical Function Subscale (303, 298) | Role Function Subscale (307, 298) | Social Function Subscale (308, 295) | Cognitive Function Subscale (307, 300) | Pain Subscale (308, 297) | Mental Health Subscale (306, 300) | Energy/Fatigue Subscale (304, 300) | Health Distress Subscale (304, 300) | Quality of Life Subscale (308, 300) | Health Transition Subscale (308, 300) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 3.8 | 6.0 | 15.6 | 5.8 | 8.5 | 9.2 | 4.8 | 8.3 | 8.3 | 8.4 | 14.3 | 12.9 | 11.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3.3 | 5.6 | 13.7 | 5.3 | 8.1 | 7.4 | 5.6 | 8.0 | 8.7 | 7.9 | 15.0 | 8.4 | 8.8 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. SAT and TAT were measured by computed tomography (CT). (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | cm^2 (Mean) | |
|---|---|---|
| SAT-to-TAT Ratio: CCDC122_5980 WT | SAT-to-TAT Ratio: CCDC122_5980 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0.03 | 0.11 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0.03 | 0.02 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. VAT was measured by computed tomography (CT). (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | cm^2 (Mean) | |
|---|---|---|
| VAT: RETN_730 WT | VAT: RETN_730 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -2.95 | 23.29 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 13.69 | -1.05 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. VAT and TAT were measured by computed tomography (CT). (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | cm^2 (Mean) | |
|---|---|---|
| VAT-to-TAT Ratio: CCDA122_5980 WT | VAT-to-TAT Ratio: CCDA122_5980 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -0.03 | -0.11 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.03 | -0.02 |
The change-from-baseline was defined as the difference between the averages of post-treatment time points (Weeks 48 and 96) and baseline. Association analysis for each SNP was performed using a minor allele carrier (MAC) composed of heterozygous and rare homozygous genotypes, and wild type (WT, common homozygous). False discovery rate (FDR)-adjusted p-values were calculated for each phenotype-genotype pair. VAT was measured by computed tomography (CT). (NCT00272779)
Timeframe: Baseline (Day 1), Week 48, and Week 96.
| Intervention | cm^2 (Mean) | |
|---|---|---|
| VAT: BRUNOL_1842 WT | VAT: BRUNOL_1842 MAC | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 23.45 | -3.20 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 10.38 | -1.76 |
Mean change from baseline in fasting lipids, for fasting total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, and triglycerides at Week 48 were determined. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48.
| Intervention | milligrams/deciliter (mg/dL) (Mean) | ||||
|---|---|---|---|---|---|
| Fasting total Cholesterol (n=373, 337) | Fasting HDL Cholesterol (n=371, 335) | Fasting Non-HDL Cholesterol (n=371, 335) | Fasting LDL Cholesterol (n=372, 335) | Fasting Triglycerides (n=373, 337) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 19 | 9 | 10 | 12 | 20 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 38 | 12 | 26 | 18 | 70 |
Mean change from baseline in fasting lipids at Week 96 was determined. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Fasting total Cholesterol (n=342, 291) | Fasting HDL Cholesterol (n=341, 291) | Fasting Non-HDL Cholesterol (n=341, 291) | Fasting LDL Cholesterol (n=342, 291) | Fasting Triglycerides (n=342, 291) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 20 | 7.0 | 13.0 | 12.0 | 16.0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 37 | 10.0 | 27.0 | 17.0 | 63.0 |
Mean percent change from baseline in BMD of arms, legs, trunk and total body was measured using DEXA, an X-ray scan technique. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96
| Intervention | g/cm^2 (Mean) | |||
|---|---|---|---|---|
| Bone Mineral Density of Both Arms | Bone Mineral Density of Both Legs | Bone Mineral Density of Trunk | Bone Mineral Density of Total Body | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -1 | -2 | -3 | -3 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -2 | -3 | -5 | -4 |
Mean percent change from baseline in BMD of arms, legs, trunk and total body was measured using DEXA, an X-ray scan technique. (NCT00272779)
Timeframe: DEXA scans were taken at Baseline (Day 1) and Week 48.
| Intervention | grams/ centimeters ^2 (g/cm^2) (Mean) | |||
|---|---|---|---|---|
| Bone Mineral Density of Both Arms | Bone Mineral Density of Both Legs | Bone Mineral Density of Trunk | Bone Mineral Density of Total Body | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -1 | -2 | -4 | -2 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -1 | -2 | -4 | -3 |
The mean percent change from baseline in limb, trunk and total body fat was measured by DEXA. Limb fat: a physical sign of lipoatrophy, clinical improvement in limb fat is associated with a decrease in values. Trunk fat: a physical sign of lipohypertrophy, clinical improvement in trunk fat is associated with a decrease in values. Total body fat: association of many factors like trunk fat, limb fat, weight etc. Clinical improvement in total body fat cannot be predicted based solely an increase or decrease of these values. (NCT00272779)
Timeframe: DEXA scans were performed at baseline (within 30 days of starting study treatment), and at Weeks 48.
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Trunk Fat | Limb Fat | Total Body Fat | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 26 | 22 | 23 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 16 | 17 | 15 |
The mean percent change from baseline in limb, trunk and total body fat was measured by DEXA. Limb fat: a physical sign of lipoatrophy, clinical improvement in limb fat is associated with a decrease in values. Trunk fat: physical sign of lipohypertrophy, clinical improvement in trunk fat is associated with a decrease in values. Total body fat: association of many factors like trunk fat, limb fat, weight etc. Clinical improvement in total body fat cannot be predicted based solely an increase or decrease of these values. (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | Percentage (Mean) | ||
|---|---|---|---|
| Trunk Fat | Limb Fat | Total Body Fat | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 34 | 27 | 29 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 16 | 15 | 15 |
(NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | Ratio (Mean) | ||
|---|---|---|---|
| VAT-to-TAT Ratio (n = 95,68) | VAT-to-SAT Ratio (n = 95, 68) | Trunk-to-Limb Fat Ratio (n = 106, 71) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | -0.04 | -0.22 | 0.05 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | -0.02 | -0.09 | 0.00 |
AEs:new,untoward medical occurrences/worsening of pre-existing medical condition,drug-related or not.SAEs:any AE that:resulted in death;was life threatening;resulted in a persistent or significant disability/incapacity;resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; was cancer;or overdose.Discontinuation from study was due either to an AE or was conducted at the investigator's discretion.AEs represented here include SAEs, which are not included in the AE count represented in the AE xml upload section. As such, these numbers may not match. (NCT00272779)
Timeframe: From baseline (Day 1) to Week 48.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Deaths | Other SAEs | AEs | AEs leading to discontinuation | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6 | 51 | 400 | 11 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 6 | 42 | 399 | 15 |
AEs:new,untoward medical occurrences/worsening of pre-existing medical condition,drug-related or not.SAEs:any AE that:resulted in death;was life threatening;resulted in a persistent or significant disability/incapacity;resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; was cancer;or overdose.Discontinuation from study was due either to an AE or was conducted at the investigator's discretion.AEs represented here include SAEs, which are not included in the AE count represented in the AE xml upload section. As such, these numbers may not match. (NCT00272779)
Timeframe: From Day 1 through Week 96
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Deaths | Serious Adverse Events (SAEs) | Adverse Events (AEs) leading to discontinuation | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6 | 63 | 13 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 6 | 50 | 22 |
Serum electrolytes abnormalities,graded per modified WHOcriteria.Ranges were:hypercarbia:Grade3:41-45milliequivalents(meq)/L,Grade4:>45meq/L;hypocarbia:Grade3:10-14 meq/L,Grade4:<10 meq/L;hypercalcemia:Grade3:12.6 - 13.5 mg/dL,Grade 4:>13.5 mg/dL;hypocalcemia:6.1-6.9mg/dL,Grade4:<6.1mg/dL;hyperchloremia:Grade 3: 121-125 meq/L,Grade4:>125meq/L;hypochloremia:Grade 3:80-84 meq/L,Grade4:<80meq/L;hyperkalemia:Grade3:6.6-7.0meq/L,Grade4:>7.0meq/L;hypokalemia:Grade3:2.0-2.4 meq/L,Grade4:<2.0meq/L;hypernatremia:Grade3:158-165 meq/L,Grade4:>165meq/L;hyponatremia:Grade 3:116-122 meq/L,Grade 4:115 meq/L. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypercarbia (n = 435, 431) | Hypocarbia (n = 435, 431) | Hypercalcemia (n = 435, 431) | Hypocalcemia (n = 435, 431) | Hyperchloremia (n = 435, 431) | Hypochloremia (n = 435, 431) | Hyperkalemia (n = 435, 430) | Hypokalemia (n = 435, 430) | Hypernatremia (n = 435, 431) | Hyponatremia (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0 | 8 | 0 | 4 | 0 | 2 | 1 | 1 | 2 | 2 |
Serum electrolytes abnormalities,graded per modified WHOcriteria.Ranges were:hypercarbia:Grade3:41-45milliequivalents(meq)/L,Grade4:>45meq/L;hypocarbia:Grade3:10-14 meq/L,Grade4:<10 meq/L;hypercalcemia:Grade3:12.6 - 13.5 mg/dL,Grade 4:>13.5 mg/dL;hypocalcemia:6.1-6.9mg/dL,Grade4:<6.1mg/dL;hyperchloremia:Grade 3: 121-125 meq/L,Grade4:>125meq/L;hypochloremia:Grade 3:80-84 meq/L,Grade4:<80meq/L;hyperkalemia:Grade3:6.6-7.0meq/L,Grade4:>7.0meq/L;hypokalemia:Grade3:2.0-2.4 meq/L,Grade4:<2.0meq/L;hypernatremia:Grade3:158-165 meq/L,Grade4:>165meq/L;hyponatremia:Grade 3:116-122 meq/L,Grade 4:115 meq/L. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypercarbia (n = 435, 431) | Hypocarbia (n = 435, 431) | Hypercalcemia (n = 435, 431) | Hypocalcemia (n = 435, 431) | Hyperchloremia (n = 435, 431) | Hypochloremia (n = 435, 431) | Hyperkalemia (n = 435, 430) | Hypokalemia (n = 435, 430) | Hypernatremia (n = 435, 431) | Hyponatremia (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0 | 7 | 0 | 4 | 0 | 0 | 1 | 1 | 0 | 1 |
Laboratory measurements marked as abnormal, per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), at any study time point. The following Grade 3 and 4 definitions specify the criteria for MAs in fasting glucose: hypoglycemia: Grade 3: 30-39 mg/dL, Grade 4: <30 mg/dL; hyperglycemia: 251-500 mg/dL, Grade 4: >500 mg/dL. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |
|---|---|---|
| Hyperglycemia (n = 434, 428) | Hypoglycemia (n = 434, 428) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 3 | 1 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 2 | 0 |
Laboratory measurements marked as abnormal, per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), at any study time point. The following Grade 3 and 4 definitions specify the criteria for MAs in fasting glucose: hypoglycemia: Grade 3: 30-39 mg/dL, Grade 4: <30 mg/dL; hyperglycemia: 251-500 mg/dL, Grade 4: >500 mg/dL. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |
|---|---|---|
| Hyperglycemia (n = 434, 428) | Hypoglycemia (n = 434, 428) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 1 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 1 | 0 |
Laboratory measurements marked as abnormal, as per NCEP-ATP-III guided categories. The following definitions specify the criteria for MAs in fasting lipids: Total cholesterol: Grade 3: 240 - 300 mg/dL, Grade 4: >=240 mg/dL, triglycerides: Grade 3: 200 - <500 mg/dL, Grade 4: >=500 mg/dL. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |
|---|---|---|
| Total Cholesterol (n = 434, 428) | Triglycerides (n = 434, 428) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 47 | 3 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 108 | 18 |
Laboratory measurements marked as abnormal, as per National Cholesterol Education Program (NCEP)- Adult Treatment Panel (ATP)-III guided categories. The following definitions specify the criteria for MAs in fasting lipids: Total cholesterol: Grade 3: 240 - 300 mg/dL, Grade 4: >=240 mg/dL, triglycerides: Grade 3: 200 - <500 mg/dL, Grade 4: >=500 mg/dL. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |
|---|---|---|
| Total Cholesterol (n = 434, 428) | Triglycerides (n = 434, 428) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 30 | 2 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 77 | 15 |
Hematology abnormalities were graded per modified World Health Organization (WHO) criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria were: Hemoglobin: Grade 3: 6.5-7.9 g/dL, Grade 4: <6.5 g/dL; Hematocrit: Grade 3: >=19.5 - 24%, Grade 4: <19.5%; platelet count: Grade 3: 20,000- 49, 999/ mm^3, Grade 4: <20,000/mm^3; INR: Grade 3 Absolute Neutrophil Count (ANC): Grade 3: >= 500 - <750/mm^3, Grade 4: <500/mm^3; PT: Grade 3: 1.51 - 3.0*ULN, Grade 4: >3*ULN; WBC: Grade 3: >=800 to <1000/mm^3, Grade 4: <80/mm^3. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Hematocrit (n= 434, 431) | Hemoglobin (n= 434, 431) | INR (n= 435, 431) | Neutrophils (n = 434, 431) | Platelets ( n= 433, 430) | PT (n = 435, 431) | WBC (n = 434, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 2 | 6 | 14 | 5 | 6 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 6 | 6 | 11 | 3 | 1 | 16 | 0 |
Hematology abnormalities were graded per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria were: Hemoglobin: Grade 3: 6.5-7.9 g/dL, Grade 4: <6.5 g/dL; Hematocrit: Grade 3: >=19.5 - 24%, Grade 4: <19.5%; platelet count: Grade 3: 20,000- 49, 999/ mm^3, Grade 4: <20,000/mm^3; INR: Grade 3 Absolute Neutrophil Count (ANC): Grade 3: >= 500 - <750/mm^3, Grade 4: <500/mm^3; PT: Grade 3: 1.51 - 3.0*ULN, Grade 4: >3*ULN; WBC: Grade 3: >=800 to <1000/mm^3, Grade 4: <80/mm^3. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Hematocrit (n= 434, 431) | Hemoglobin (n= 434, 431) | INR (n= 435, 431) | Neutrophils (n = 434, 431) | Platelets ( n= 433, 431) | Prothrombin time (n = 435, 431) | WBC (n = 434, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 3 | 7 | 21 | 5 | 9 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 6 | 7 | 18 | 7 | 1 | 24 | 1 |
Liver function tests abnormalities were graded as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), while albumin was graded as per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE). Grade 3 and 4 criteria were: alanine aminotransferase (ALT), aspartate aminotransferase(AST), alkaline phosphatase: Grade 3: 5.1- 10*ULN, Grade 4: >10*ULN; direct and total bilirubin: Grade 3: 2.6- 5*ULN, Grade 4: >5*ULN, Albumin: Grade 3: <2g/dL. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| ALT (n= 435, 431) | AST (n = 435, 430) | Albumin (n = 435, 431) | Alkaline Phosphatase (n= 435, 430) | Direct Bilirubin (n = 435, 430) | Total Bilirubin (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 8 | 9 | 0 | 1 | 37 | 146 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 6 | 2 | 0 | 1 | 4 | 1 |
Liver function tests abnormalities were graded as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), while albumin was graded as per NCI-CTCAE. Grade 3 and 4 criteria were: ALT, AST, alkaline phosphatase: Grade 3: 5.1- 10*ULN, Grade 4: >10*ULN; direct and total bilirubin: Grade 3: 2.6- 5*ULN, Grade 4: >5*ULN, Albumin: Grade 3: <2g/dL. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| ALT (n= 435, 431) | AST (n = 435, 430) | Albumin (n = 435, 431) | Alkaline Phosphatase (n= 435, 430) | Total Bilirubin (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 11 | 11 | 0 | 1 | 192 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 7 | 5 | 0 | 1 | 3 |
Renal function test abnormalities were graded as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria were: Blood urea nitrogen (BUN): Grade 3: 5.1- 10*ULN, Grade 4: >10*ULN; Creatinine: Grade 3: 3.1 - 6*ULN, Grade 4: >6*ULN; low phosphorous (hypophosphatemia): Grade 3: 1.0- 1.4 mg/dL, Grade 4: <1.0mg/dL; high uric acid (hyperuricemia): Grade 3: 12.1 - 15.0 mg/dL, Grade 4: >15.0 mg/dL. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| BUN (n = 435, 431) | Creatinine (n = 435, 431) | Phosphorus (n = 435, 431) | Uric acid (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 1 | 0 | 0 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0 | 1 | 1 | 3 |
Renal function test abnormalities were graded as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria were: BUN: Grade 3: 5.1- 10*ULN, Grade 4: >10*ULN; Creatinine: Grade 3: 3.1 - 6*ULN, Grade 4: >6*ULN; low phosphorous (hypophosphatemia): Grade 3: 1.0- 1.4 mg/dL, Grade 4: <1.0mg/dL; high uric acid (hyperuricemia): Grade 3: 12.1 - 15.0 mg/dL, Grade 4: >15.0 mg/dL. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| BUN (n = 435,431) | Creatine (n = 435, 431) | Phosphorous (n = 435, 431) | Uric acid (n = 435, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 0 | 1 | 0 | 1 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 0 | 2 | 1 | 4 |
Laboratory measurements marked as abnormal, as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria in serum enzymes were: CPK: Grade 3: 5.1 - 10.0 * ULN, Grade 4: >10* ULN; Lipase: Grade 3: 2.10 - 5.0* ULN, Grade 4: 5.0* ULN. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |
|---|---|---|
| CPK (n=435, 430) | Lipase (n=435, 430) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 34 | 9 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 28 | 9 |
Laboratory measurements marked as abnormal, as per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe). Grade 3 and 4 criteria in serum enzymes were: Creatine phosphokinase (CPK): Grade 3: 5.1 - 10.0 * upper limit of normal (ULN), Grade 4: >10* ULN; Lipase: Grade 3: 2.10 - 5.0* ULN, Grade 4: 5.0* ULN. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |
|---|---|---|
| CPK (n = 435, 430) | Lipase (n = 435, 430) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 22 | 6 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 20 | 6 |
Laboratory measurements marked as abnormal, per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), at any study time point. The following Grade 3 and 4 definitions specify the criteria for MAs in urinalysis: Proteinuria: Grade 3: 4= or >2-3.5 g loss/day, Grade 4: >3.5 g loss/day. (NCT00272779)
Timeframe: At Screening (Day -30), Baseline (Day 1), Week 4, 12, 24, 36, and 48.
| Intervention | Participants (Number) | |
|---|---|---|
| Glycosuria (n = 434, 431) | Proteinuria (n = 434, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 4 | 3 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 3 | 1 |
Laboratory measurements marked as abnormal, per modified WHO criteria (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = very severe), at any study time point. The following Grade 3 and 4 definitions specify the criteria for MAs in urinalysis: Proteinuria: Grade 3: 4= or >2-3.5 g loss/day, Grade 4: >3.5 g loss/day. (NCT00272779)
Timeframe: At screening (Day -30), baseline (Day 1), Week 4, 12, 24, 36, 48, 60, 72, 84 and 96.
| Intervention | Participants (Number) | |
|---|---|---|
| Glycosuria (n = 434, 431) | Proteinuria (n = 434, 431) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 6 | 5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 5 | 6 |
19 genes of interest were selected from previous results or literature, and 34 SNPs were genotyped. Phenotype-Genotype analysis was performed using 31 of the SNPs. The genotypes of each SNP were further classified as either a minor allele carrier (MAC) group composed of heterozygous and rare homozygous genotypes, or wild type [WT, common homozygous]. (NCT00272779)
Timeframe: Baseline visit
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RETN_097 WT | RETN_097 MAC | APOE_R176C WT | APOE_R176C MAC | CCDC122_5980 WT | CCDC122_5980 MAC | IL6_5309 WT | IL6_5309 MAC | RS11030679 WT | RS11030679 MAC | APOE_C130R WT | APOE_C130R MAC | RETN_2265 WT | RETN_2265 MAC | RETN_598 WT | RETN_598 MAC | RETN_734 WT | RETN_734 MAC | BRUNOL_1842 WT | BRUNOL_1842 MAC | RETN_730 WT | RETN_730 MAC | |
| All Participants With Pharmacogenetic Blood Samples | 164 | 35 | 182 | 16 | 126 | 71 | 57 | 141 | 112 | 87 | 169 | 30 | 146 | 53 | 119 | 80 | 175 | 22 | 121 | 77 | 99 | 100 |
Virologic failure participants defined as participants who were never suppressed (HIV RNA < 400 c/mL) and on study through Week 48, or who rebounded to HIV RNA ≥ 400 c/mL, and those who discontinued due to insufficient viral load response using CVR (NC=F). IAS-USA=International AIDS Society-United States of America, PI=protease inhibitor, RTI=reverse transcription inhibitor, TAMS=Thymidine Analogue-Associated Mutations, NRTI=non-nucleotide reverse transcriptase inhibitor, M184/V= Methionine-to-valine mutation at position 184 (in reverse transcription [RT] gene), FC=fold change (NCT00272779)
Timeframe: Baseline (Day 1) and Week 96.
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Virologic Failure, Week 96 (HIV RNA >= 400 c/mL) | Paired Genotypes (n = 28, 29) | Paired Phenotypes (n= 28, 29) | IAS-USA major PI substitutions (n = 26, 26) | IAS-USA minor PI substitutions (n = 26, 26) | PI polymorphisms without IAS-USA (n=26, 26) | PI phenotypic resistance (ATV/RTV FC >5.2 (25, 23) | PI phenotypic resistance (LPV/RTV FC>9 (25,23) | PI phenotypic resistance (Other PIs [25, 23]) | NRTI substitutions (TAMS [26, 26]) | NRTI substitutions (M184I/V [26, 26]) | RTI phenotypic resistance (FC [n = 25, 23]) | RTI phenotypic resistance (TDF [n = 25, 23]) | RTI phenotypic resistance (Other NRTI [n =25, 23]) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 28 | 26 | 25 | 1 | 1 | 11 | 1 | 0 | 3 | 1 | 5 | 5 | 0 | 5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 29 | 26 | 23 | 0 | 1 | 14 | 0 | 1 | 6 | 3 | 7 | 5 | 2 | 6 |
Participants with virologic failure are those who never suppressed (HIV RNA <400 c/mL) and were on study through Week 48, or who rebounded to HIV RNA >= 400 c/mL and those who discontinued due to insufficient viral load response. IAS=International AIDS Society, PI=protease inhibitor, RTI=reverse transcription inhibitor, TAMS=Thymidine Analogue-Associated Mutations, NRTI=non-nucleotide reverse transcriptase inhibitor, M184V= Methionine-to-valine mutation at position 184 (in reverse transcription [RT] gene), FC=fold change (NCT00272779)
Timeframe: Baseline (Day 1) and Week 48
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Virologic Failure, Week 48 (HIV RNA >= 400 c/mL) | Paired Genotypes (n = 27, 26) | Paired Phenotypes (n= 27, 26) | IAS-defined major PI substitutions (n = 17, 15) | Other IAS-defined PI substitutions (n = 17, 15) | PI phenotypic resistance (ATV/RTV FC>5.2 (n=18,16) | PI phenotypic resistance (LPV/RTV FC >9 (n=18, 16) | PI phenotypic resistance (Other PIs )(n=18, 16) | RTI Substitutions , TAMS (n= 17,15) | RTI Substitutions , M184V (n = 17,15) | RTI phenotypic resistance, FTC FC>3.5 (n = 18, 16) | RTI phenotypic resistance, TDF FC >1.4(n = 18, 16) | RTI phenotypic resistance, Other NRTIs(n = 18, 16) | |
| ATV 300 mg QD + RTV 100 mg QD + TDF 300 mg QD + FTC 200 mg QD | 27 | 17 | 18 | 1 | 6 | 1 | 0 | 4 | 1 | 3 | 4 | 0 | 5 |
| LPV 400mg BID + RTV 100mg BID + TDF 300 mg QD + FTC 200 mg QD | 26 | 15 | 16 | 0 | 2 | 0 | 0 | 4 | 1 | 3 | 3 | 1 | 5 |
Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | cells/mm^3 (Median) |
|---|---|
| Truvada | 17.5 |
| Maintain Baseline Regimen | 16.0 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | Ratio (Median) |
|---|---|
| Truvada | 0.0 |
| Maintain Baseline Regimen | 0.0 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | mmol/L (Median) |
|---|---|
| Truvada | -0.1 |
| Maintain Baseline Regimen | 0.0 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | mmol/L (Median) |
|---|---|
| Truvada | -0.4 |
| Maintain Baseline Regimen | -0.1 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | Ratio (Median) |
|---|---|
| Truvada | -0.5 |
| Maintain Baseline Regimen | -0.1 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | mmol/L (Median) |
|---|---|
| Truvada | -0.8 |
| Maintain Baseline Regimen | -0.1 |
Centralized laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | mmol/L (Median) |
|---|---|
| Truvada | -0.5 |
| Maintain Baseline Regimen | -0.1 |
Local laboratory assessment. Change = Week 12 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 12
| Intervention | mg/L (Median) |
|---|---|
| Truvada | 0.4 |
| Maintain Baseline Regimen | 0.7 |
Change = Week 48 value minus baseline value. (NCT00323492)
Timeframe: Baseline to Week 48
| Intervention | cells/mm^3 (Median) |
|---|---|
| Truvada | 35.0 |
| Maintain Baseline Regimen | 40.0 |
Centralized laboratory assessment (NCT00323492)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Truvada | 0 |
| Maintain Baseline Regimen | 0 |
(NCT00323492)
Timeframe: 48 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Truvada | 80 |
| Maintain Baseline Regimen | 80 |
(NCT00323492)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Truvada | 0 |
| Maintain Baseline Regimen | 0 |
(NCT00323492)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Truvada | 96 |
| Maintain Baseline Regimen | 98 |
Eligible patients will be randomized into two monotherapy arms (TDF and ABC) for a short (one week) viral dynamics and pharmacokinetics evaluation to determine their potency. After a one-month washout period, all patients will start a dual-therapy of ABC+TDF. Viral dynamics and pharmacokinetics of the dual-therapy will be evaluated during the first week of the treatment. EFV will be added to the regimen after one week of the dual-therapy administered. Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy) (NCT00214890)
Timeframe: Baseline and day 7
| Intervention | log(10) copies/mL per day (Median) |
|---|---|
| Tenofovir | -0.11 |
| Abacavir | -0.15 |
Subjects will be randomized to either TDF or ABC PO route for 7 days, which involves a fixed number of subjects. A sample size of 20 subjects (10 ABC and 10 TDF monotherapy and 20 ABC+TDF dual-therapy in HIV-positive patients). We determined the count of NRTI-associated mutations that emerged after 7 days of ABC or TDF monotherapy or after 7 days of dual NRTI therapy with ABC + TDF. (NCT00214890)
Timeframe: 7 days
| Intervention | mutations (Number) |
|---|---|
| Tenofovir | 0 |
| Abacavir | 0 |
Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) compared to the dual NRTI regimen of TDF+ABC as assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy, baseline and day 49 for dual therapy.) (NCT00214890)
Timeframe: 49 days
| Intervention | log(10) copies/mL per day (Median) | |
|---|---|---|
| monotherapy | dual therapy (combined TDF+ABC) | |
| Abacavir | -.15 | -.16 |
| Tenofovir | -.11 | -.16 |
"At day 49 of Sequence 2 a 24-hour post dose intracellular (PBMC) should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL intracellular (PBMC) samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK:~Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days~Intracellular ddNTP concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy" (NCT00214890)
Timeframe: 49 days
| Intervention | fmol/10^6 cells (Median) | |
|---|---|---|
| monotherapy | dual therapy | |
| Abacavir | 72.2 | 80.9 |
| Tenofovir | 49.3 | 108.1 |
"At day 49 of Sequence 2 a 24-hour post dose plasma sample should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL plasma samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK:~Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days~Plasma NRTI and intracellular ddNTP concentrations were measured 7 days after treatment with ABC or TDF alone and were compared to levels obtained after 7 days of treatment with both drugs" (NCT00214890)
Timeframe: 49 days
| Intervention | (mcg/mL)*hr (Median) | |
|---|---|---|
| monotherapy | dual therapy | |
| Abacavir | 12.54 | 13.62 |
| Tenofovir | 3.82 | 4.09 |
"At day 1 and day 63 a PBMC sample for RT-PCR of nucleoside analogue transport enzymes (enzymes for efflux, influx) will be collected. The day 1 specimen should be stored and sent with day 8 PK specimens to USC. Day 63 specimen should be sent to USC after collection and processing.~Blood volume: 20 mL Blood volume: 20 mL" (NCT00214890)
Timeframe: Day 1 and Day 63
| Intervention | fmol/10^6 cells (Median) | |
|---|---|---|
| dGTP concentrations | dATP concentrations | |
| Abacavir | 2464 | 3314 |
| Tenofovir | 4026 | 3238 |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | cells/millimeters cubed (mm^3) (Median) |
|---|---|
| ABC/3TC FDC | 110.0 |
| TDF/FTC FDC | 100.0 |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | cells/mm^3 (Median) |
|---|---|
| ABC/3TC FDC | 150.0 |
| TDF/FTC FDC | 150.0 |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | cells/mm^3 (Median) |
|---|---|
| ABC/3TC FDC | 235.0 |
| TDF/FTC FDC | 220.0 |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline albumin value by the urine creatinine value. Albumin is measured in milligrams per millimole (mg/mmol). (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ratio (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 0.872 |
| TDF/FTC FDC | 0.973 |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline B2M value by the urine creatinine value. B2M, beta 2 microglobulin (measured in mg/mmol). (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ratio (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 0.542 |
| TDF/FTC FDC | 0.984 |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ug/L (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 1.111 |
| TDF/FTC FDC | 2.542 |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline NAG value by the urine creatinine value. NAG, N-acetyl-B-glucosaminidase (measured in micromoles per hour per millimole [umol/h/mmol]). (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ratio (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 0.868 |
| TDF/FTC FDC | 0.939 |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ug/L (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 3.01 |
| TDF/FTC FDC | 5.79 |
P1NP is a bone biomarker that was analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | micrograms per Liter (ug/L) (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 1.2 |
| TDF/FTC FDC | 1.4 |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline RBP value by the urine creatinine value. RBP, retinol binding protein (measured in micrograms per millimole [ug/mmol]). (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | ratio (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 1.099 |
| TDF/FTC FDC | 1.550 |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | nanograms per Liter (ng/L) (Geometric Mean) |
|---|---|
| ABC/3TC FDC | 89.9 |
| TDF/FTC FDC | 203.6 |
Change from baseline was calculated as the Week 24 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) * (mass in kg) * (0.85 if female) divided by 72 * serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram; CG, Cockcroft-Gault. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | mL/min (Mean) |
|---|---|
| ABC/3TC FDC | 4.27 |
| TDF/FTC FDC | 2.54 |
Change from baseline was calculated as the Week 48 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) * (mass in kg) * (0.85 if female) divided by 72 * serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | mL/min (Mean) |
|---|---|
| ABC/3TC FDC | 2.66 |
| TDF/FTC FDC | 3.80 |
Change from baseline was calculated as the Week 96 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) * (mass in kg) * (0.85 if female) divided by 72 * serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | mL/min (Mean) |
|---|---|
| ABC/3TC FDC | 4.37 |
| TDF/FTC FDC | 2.68 |
Change from baseline was calculated as the Week 24 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m^2) = 175 * (Scr)^-1.154 * (Age)^-0.203 * (0.742 if female) * (1.212 if African American) (conventional units). mL, milliliters; min, minute; m^2, meters squared; Scr, serum creatinine. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| ABC/3TC FDC | 2.78 |
| TDF/FTC FDC | 0.43 |
Change from baseline was calculated as the Week 48 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m^2) = 175 * (Scr)^-1.154 * (Age)^-0.203 * (0.742 if female) * (1.212 if African American) (conventional units). mL, milliliters; min, minute; m^2, meters squared; Scr, serum creatinine; BMI, body mass index. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | milliliters per minute (mL/min)/1.73 m^2 (Mean) |
|---|---|
| ABC/3TC FDC | 0.22 |
| TDF/FTC FDC | 1.18 |
Change from baseline was calculated as the Week 96 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m^2) = 175 * (Scr)^-1.154 * (Age)^-0.203 * (0.742 if female) * (1.212 if African American) (conventional units). mL, milliliters; min, minute; m^s, meters squared; Scr, serum creatinine. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| ABC/3TC FDC | 1.48 |
| TDF/FTC FDC | -1.15 |
BMD is a measure (grams per cm^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -1.19 |
| TDF/FTC FDC | -2.73 |
BMD is a measure (grams per cm^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -1.90 |
| TDF/FTC FDC | -3.56 |
BMD is a measure (grams per cm^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -2.17 |
| TDF/FTC FDC | -3.55 |
BMD is a measure (grams [g] per centimeters cubed [cm^3]) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -2.12 |
| TDF/FTC FDC | -3.30 |
BMD is a measure (grams per cm^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -1.59 |
| TDF/FTC FDC | -2.41 |
BMD is a measure (grams per cm^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | percent change (Mean) |
|---|---|
| ABC/3TC FDC | -0.87 |
| TDF/FTC FDC | -1.70 |
Participants were asked at each visit whether or not they utilized unplanned healthcare resources. (NCT00549198)
Timeframe: Baseline to Week 96
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4, Yes, n=178, 183 | Week 4, No, n=178, 183 | Week 12, Yes, n=162, 177 | Week 12, No, n=162, 177 | Week 24, Yes, n=156, 173 | Week 24, No, n=156, 173 | Week 36, Yes, n=148, 169 | Week 36, No, n=148, 169 | Week 48, Yes, n=137, 161 | Week 48, No, n=137, 161 | Week 60, Yes, n=129, 148 | Week 60, No, n=129, 148 | Week 72, Yes, n=126, 139 | Week 72, No, n=126, 139 | Week 84, Yes, n=121, 136 | Week 84, No, n=121, 136 | Week 96, Yes, n=113, 135 | Week 96, No, n=113, 135 | |
| ABC/3TC FDC | 60 | 118 | 56 | 106 | 70 | 86 | 48 | 100 | 44 | 93 | 47 | 82 | 48 | 78 | 34 | 87 | 30 | 83 |
| TDF/FTC FDC | 49 | 134 | 47 | 130 | 59 | 114 | 50 | 119 | 36 | 125 | 44 | 104 | 40 | 99 | 24 | 108 | 17 | 118 |
Viral resistance was measured using blood samples collected from participants throughout the study. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. Virological failure was defined as any one of: participant does not achieve a 1 log10 copies (cop)/mL decrease in plasma HIV-1 RNA by Week (Wk) 4, or has two consecutive plasma HIV-1 RNA measures >=400 cop/mL separated by at least 2-4 wk after being previously <=400 cop/mL on/after Wk 4, or has two consecutive plasma HIV-1 RNA measures >400 cop/mL separated by at least 2-4 wk on/after Wk 24. (NCT00549198)
Timeframe: Week 96
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any treatment-emergent mutation | NRTI | NNRTI | |
| ABC/3TC FDC | 4 | 4 | 2 |
| TDF/FTC FDC | 0 | 0 | 0 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented. (NCT00549198)
Timeframe: Baseline to Week 24
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any event | Drug hypersensitivity | Rash | Dizziness | Hypersensitivity | Drug eruption | |
| ABC/3TC FDC | 26 | 11 | 2 | 0 | 3 | 1 |
| TDF/FTC FDC | 14 | 1 | 3 | 2 | 0 | 1 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented. (NCT00549198)
Timeframe: Baseline to Week 48
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any event | Drug hypersensitivity | Bone density decreased | Rash | Dizziness | Hypersensitivity | Drug eruption | |
| ABC/3TC FDC | 29 | 11 | 0 | 2 | 1 | 3 | 1 |
| TDF/FTC FDC | 21 | 1 | 2 | 3 | 3 | 0 | 1 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented. (NCT00549198)
Timeframe: Baseline to Week 96
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any event | Drug hypersensitivity | Bone density decreased | Rash | Dizziness | Hypersensitivity | Abnormal dreams | Drug eruption | Depression | |
| ABC/3TC FDC | 33 | 11 | 0 | 2 | 1 | 3 | 3 | 1 | 0 |
| TDF/FTC FDC | 28 | 1 | 8 | 3 | 3 | 0 | 0 | 1 | 2 |
"The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a normal, healthy, 30-year-old female. The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD." (NCT00549198)
Timeframe: Week 24
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Osteopenia, spine, n=147, 173 | Osteporosis, spine, n=147, 173 | Osteopenia, hip, n=149, 170 | Osteoporosis, hip, n=149, 170 | |
| ABC/3TC FDC | 41 | 16 | 38 | 4 |
| TDF/FTC FDC | 68 | 9 | 54 | 1 |
"The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a normal, healthy, 30-year-old female. The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD." (NCT00549198)
Timeframe: Week 48
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Osteopenia, spine, n=132, 147 | Osteporosis, spine, n=132, 147 | Osteopenia, hip, n=130, 147 | Osteoporosis, hip, n=130, 147 | |
| ABC/3TC FDC | 41 | 15 | 37 | 4 |
| TDF/FTC FDC | 57 | 5 | 50 | 0 |
"The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a normal, healthy, 30-year-old female. The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD." (NCT00549198)
Timeframe: Week 96
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Osteopenia, spine, n=64, 82 | Osteporosis, spine, n=64, 82 | Osteopenia, hip, n=65, 80 | Osteoporosis, hip, n=65, 80 | |
| ABC/3TC FDC | 21 | 5 | 20 | 0 |
| TDF/FTC FDC | 34 | 3 | 31 | 0 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| >=2%, spine, n=142, 165 | >=6%, spine, n=142, 165 | >=2%, hip, n=137, 160 | >=6%, hip, n=137, 160 | |
| ABC/3TC FDC | 73 | 10 | 38 | 1 |
| TDF/FTC FDC | 115 | 17 | 93 | 6 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| >=2%, spine, n=125, 141 | >=6%, spine, n=125, 141 | >=2%, hip, n=119, 140 | >=6%, hip, n=119, 140 | |
| ABC/3TC FDC | 51 | 5 | 54 | 3 |
| TDF/FTC FDC | 84 | 13 | 111 | 17 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| >=2%, spine, n=59, 79 | >=6%, spine, n=59, 79 | >=2%, hip, n=58, 76 | >=6%, hip, n=58, 76 | |
| ABC/3TC FDC | 21 | 3 | 33 | 1 |
| TDF/FTC FDC | 39 | 8 | 52 | 13 |
mL, milliliter; min, minute; m^2, meters squared (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| >=10 mL/min, MDRD | >=10 mL/min, Cockcroft-Gault | >=20 mL/min, MDRD | >=20 mL/min, Cockcroft-Gault | >=10%, MDRD | >=10%, Cockcroft-Gault | >=20%, MDRD | >=20%, Cockcroft-Gault | |
| ABC/3TC FDC | 16 | 16 | 4 | 3 | 15 | 10 | 2 | 2 |
| TDF/FTC FDC | 26 | 20 | 6 | 4 | 24 | 17 | 3 | 3 |
mL, milliliter; min, minute; m^2, meters squared (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| >=10 mL/min, MDRD | >=10 mL/min, Cockcroft-Gault | >=20 mL/min, MDRD | >=20 mL/min, Cockcroft-Gault | >=10%, MDRD | >=10%, Cockcroft-Gault | >=20%, MDRD | >=20%, Cockcroft-Gault | |
| ABC/3TC FDC | 23 | 15 | 4 | 4 | 21 | 11 | 4 | 3 |
| TDF/FTC FDC | 21 | 14 | 3 | 2 | 21 | 9 | 2 | 0 |
mL, milliliter; min, minute; m^2, meters squared (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| >=10 mL/min, MDRD | >=10 mL/min, Cockcroft-Gault | >=20 mL/min, MDRD | >=20 mL/min, Cockcroft-Gault | >=10%, MDRD | >=10%, Cockcroft-Gault | >=20%, MDRD | >=20%, Cockcroft-Gault | |
| ABC/3TC FDC | 15 | 11 | 4 | 4 | 15 | 12 | 3 | 3 |
| TDF/FTC FDC | 38 | 19 | 7 | 5 | 27 | 16 | 6 | 4 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection. (NCT00549198)
Timeframe: Week 24
| Intervention | participants (Number) | |
|---|---|---|
| <50 copies/mL | <400 copies/mL | |
| ABC/3TC FDC | 126 | 147 |
| TDF/FTC FDC | 144 | 168 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection. (NCT00549198)
Timeframe: Week 48
| Intervention | participants (Number) | |
|---|---|---|
| <50 copies/mL | <400 copies/mL | |
| ABC/3TC FDC | 121 | 130 |
| TDF/FTC FDC | 145 | 151 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection. (NCT00549198)
Timeframe: Week 96
| Intervention | participants (Number) | |
|---|---|---|
| <50 copies/mL | <400 copies/mL | |
| ABC/3TC FDC | 98 | 110 |
| TDF/FTC FDC | 113 | 126 |
Normal: GFR >=60 mL/min/1.73 m^2 and creatinine ratio <=200 mg/g GFR; Stage 1: GFR >=90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 2: GFR >=60-<90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 3: GFR >=30-<60 mL/min/1.73 m^2; Stage 4: GFR >=15-<30 mL/min/1.73 m^2; Stage 5: GFR <15 mL/min/1.73 m^2. mL, milliliter; min, minute; m^2, meters squared; mg, milligram; g, gram. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Normal | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | |
| ABC/3TC FDC | 97 | 11 | 5 | 1 | 0 | 0 |
| TDF/FTC FDC | 114 | 15 | 5 | 1 | 0 | 0 |
Normal: GFR >=60 mL/min/1.73 m^2 and creatinine ratio <=200 mg/g GFR; Stage 1: GFR >=90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 2: GFR >=60-<90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 3: GFR >=30-<60 mL/min/1.73 m^2; Stage 4: GFR >=15-<30 mL/min/1.73 m^2; Stage 5: GFR <15 mL/min/1.73 m^2. mL, milliliter; min, minute; m^2, meters squared; mg, milligram; g, gram. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Missing | Normal | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | |
| ABC/3TC FDC | 12 | 90 | 7 | 3 | 0 | 0 | 0 |
| TDF/FTC FDC | 19 | 106 | 5 | 3 | 0 | 0 | 0 |
Normal: GFR >=60 mL/min/1.73 m^2 and creatinine ratio <=200 mg/g GFR; Stage 1: GFR >=90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 2: GFR >=60-<90 mL/min/1.73 m^2 and creatinine ratio >200 mg/g; Stage 3: GFR >=30-<60 mL/min/1.73 m^2; Stage 4: GFR >=15-<30 mL/min/1.73 m^2; Stage 5: GFR <15 mL/min/1.73 m^2. mL, milliliter; min, minute; m^2, meters squared; mg, milligram; g, gram. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Missing | Normal | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | |
| ABC/3TC FDC | 11 | 75 | 3 | 4 | 0 | 0 | 0 |
| TDF/FTC FDC | 18 | 83 | 4 | 4 | 0 | 0 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <40 mg/dL, low; 40-<60 mg/dL, normal; >=60 mg/dL, high. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Low to low | Low to normal | Low to high | Normal to low | Normal to normal | Normal to high | High to low | High to normal | High to high | |
| ABC/3TC FDC | 19 | 72 | 10 | 0 | 12 | 26 | 0 | 0 | 10 |
| TDF/FTC FDC | 36 | 66 | 9 | 1 | 30 | 12 | 0 | 3 | 5 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <40 mg/dL, low; 40-<60 mg/dL, normal; >=60 mg/dL, high. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Low to low | Low to normal | Low to high | Normal to low | Normal to normal | Normal to high | High to low | High to normal | High to high | |
| ABC/3TC FDC | 17 | 67 | 18 | 0 | 11 | 27 | 0 | 0 | 10 |
| TDF/FTC FDC | 28 | 73 | 10 | 0 | 23 | 20 | 0 | 3 | 5 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <40 mg/dL, low; 40-<60 mg/dL, normal; >=60 mg/dL, high. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Low to low | Low to normal | Low to high | Normal to low | Normal to normal | Normal to high | High to low | High to normal | High to high | |
| ABC/3TC FDC | 11 | 66 | 25 | 0 | 8 | 30 | 0 | 0 | 10 |
| TDF/FTC FDC | 23 | 75 | 13 | 0 | 17 | 27 | 0 | 1 | 7 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <200 mg/dL, desirable; 200-<240 mg/dL, borderline high; >=240 mg/dL, high. mg, milligram; dL, deciliter. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Desirable to desirable | Desirable to borderline high | Desirable to high | Borderline high to desirable | Borderline high to borderline high | Borderline high to high | High to desirable | High to borderline high | High to high | |
| ABC/3TC FDC | 54 | 47 | 32 | 1 | 2 | 10 | 0 | 0 | 3 |
| TDF/FTC FDC | 104 | 29 | 9 | 3 | 9 | 6 | 0 | 0 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <200 mg/dL, desirable; 200-<240 mg/dL, borderline high; >=240 mg/dL, high. mg, milligram; dL, deciliter. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Desirable to desirable | Desirable to borderline high | Desirable to high | Borderline high to desirable | Borderline high to borderline high | Borderline high to high | High to desirable | High to borderline high | High to high | |
| ABC/3TC FDC | 46 | 52 | 36 | 1 | 2 | 10 | 0 | 0 | 3 |
| TDF/FTC FDC | 96 | 37 | 9 | 1 | 9 | 8 | 0 | 0 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <200 mg/dL, desirable; 200-<240 mg/dL, borderline high; >=240 mg/dL, high. mg, milligram; dL, deciliter. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Desirable to desirable | Desirable to borderline high | Desirable to high | Borderline high to desirable | Borderline high to borderline high | Borderline high to high | High to desirable | High to borderline high | High to high | |
| ABC/3TC FDC | 39 | 49 | 46 | 1 | 2 | 10 | 0 | 0 | 3 |
| TDF/FTC FDC | 86 | 47 | 10 | 1 | 9 | 8 | 0 | 0 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <150 mg/dL, normal; 150-<200 mg/dL, borderline high; 200-<500 mg/dL, high; >=500 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal to normal | Normal to borderline high | Normal to high | Normal to very high | Borderline high to normal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to normal | High to borderline high | High to high | High to very high | Very high to normal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 63 | 21 | 23 | 0 | 5 | 5 | 9 | 0 | 2 | 5 | 12 | 3 | 0 | 0 | 0 | 1 |
| TDF/FTC FDC | 78 | 19 | 9 | 0 | 7 | 10 | 15 | 0 | 6 | 3 | 15 | 0 | 0 | 0 | 1 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <150 mg/dL, normal; 150-<200 mg/dL, borderline high; 200-<500 mg/dL, high; >=500 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal to normal | Normal to borderline high | Normal to high | Normal to very high | Borderline high to normal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to normal | High to borderline high | High to high | High to very high | Very high to normal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 55 | 22 | 30 | 0 | 4 | 5 | 11 | 0 | 2 | 4 | 12 | 4 | 0 | 0 | 0 | 1 |
| TDF/FTC FDC | 70 | 23 | 12 | 1 | 6 | 7 | 19 | 0 | 5 | 3 | 15 | 0 | 0 | 0 | 1 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <150 mg/dL, normal; 150->200 mg/dL, borderline high; 200-<500 mg/dL, high;>= 500 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal to normal | Normal to borderline high | Normal to high | Normal to very high | Borderline high to normal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to normal | High to borderline high | High to high | High to very high | Very high to normal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 47 | 25 | 34 | 1 | 4 | 4 | 11 | 1 | 2 | 4 | 11 | 5 | 0 | 0 | 0 | 1 |
| TDF/FTC FDC | 55 | 31 | 20 | 1 | 5 | 8 | 19 | 0 | 5 | 2 | 16 | 0 | 0 | 0 | 1 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <100 mg/dL, optimal; 100-<130 mg/dL, near/above optimal; 130-<160 mg/dL, borderline high; 160-<190 mg/dL, high; >=190 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 24
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Optimal to optimal | Optimal to near or above optimal | Optimal to borderline high | Optimal to high | Optimal to very high | Near or above optimal to optimal | Near or above optimal to near or above optimal | Near or above optimal to borderline high | Near or above optimal to high | Near or above optimal to very high | Borderline high to optimal | Borderline high to near or above optimal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to optimal | High to near or above optimal | High to borderline high | High to high | High to very high | Very high to optimal | Very high to near or above optimal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 22 | 41 | 22 | 6 | 1 | 0 | 6 | 17 | 12 | 4 | 0 | 1 | 2 | 4 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| TDF/FTC FDC | 46 | 43 | 11 | 1 | 0 | 5 | 22 | 11 | 5 | 1 | 0 | 6 | 3 | 3 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <100 mg/dL, optimal; 100-<130 mg/dL, near/above optimal; 130-<160 mg/dL, borderline high; 160-<190 mg/dL, high; >=190 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Optimal to optimal | Optimal to near or above optimal | Optimal to borderline high | Optimal to high | Optimal to very high | Near or above optimal to optimal | Near or above optimal to near or above optimal | Near or above optimal to borderline high | Near or above optimal to high | Near or above optimal to very high | Borderline high to optimal | Borderline high to near or above optimal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to optimal | High to near or above optimal | High to borderline high | High to high | High to very high | Very high to optimal | Very high to near or above optimal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 20 | 38 | 27 | 8 | 1 | 0 | 4 | 19 | 12 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| TDF/FTC FDC | 42 | 46 | 12 | 1 | 0 | 3 | 21 | 13 | 6 | 1 | 0 | 3 | 5 | 4 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. <100 mg/dL, optimal; 100-<130 mg/dL, near/above optimal; 130-<160 mg/dL, borderline high; 160-<190 mg/dL, high; >=190 mg/dL, very high. (NCT00549198)
Timeframe: Baseline, Week 96
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Optimal to optimal | Optimal to near or above optimal | Optimal to borderline high | Optimal to high | Optimal to very high | Near or above optimal to optimal | Near or above optimal to near or above optimal | Near or above optimal to borderline high | Near or above optimal to high | Near or above optimal to very high | Borderline high to optimal | Borderline high to near or above optimal | Borderline high to borderline high | Borderline high to high | Borderline high to very high | High to optimal | High to near or above optimal | High to borderline high | High to high | High to very high | Very high to optimal | Very high to near or above optimal | Very high to borderline high | Very high to high | Very high to very high | |
| ABC/3TC FDC | 18 | 35 | 29 | 9 | 3 | 0 | 4 | 17 | 12 | 6 | 0 | 1 | 2 | 3 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| TDF/FTC FDC | 37 | 46 | 17 | 1 | 0 | 1 | 19 | 16 | 7 | 2 | 0 | 3 | 5 | 3 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment. (NCT00549198)
Timeframe: Week 24
| Intervention | participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, Grade 3 | Cholesterol, Grade 4 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Non-HDL cholesterol, Grade 3 | Non-HDL cholesterol, Grade 4 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | Alanine aminotransferase, Grade 3 | Alanine aminotransferase, Grade 4 | Aspartate aminotransferase, Grade 3 | Aspartate aminotransferase, Grade 4 | Alkaline phosphatase, Grade 3 | Alkaline phosphatase, Grade 4 | Creatinine kinase, Grade 3 | Creatinine kinase, Grade 4 | Phosphorus inorganic, Grade 3 | Phosphorus inorganic, Grade 4 | Lipase, Grade 3 | Lipase, Grade 4 | Hyperkalaemia, Grade 3 | Hyperkalaemia, Grade 4 | Glomerular filtration rate, MDRD, Grade 3 | Glomerular filtration rate, MDRD, Grade 4 | Total neutrophils, Grade 3 | Total neutrophils, Grade 4 | Thrombocytopenia, Grade 3 | Thrombocytopenia, Grade 4 | |
| ABC/3TC FDC | 6 | 0 | 8 | 0 | 19 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 2 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
| TDF/FTC FDC | 1 | 0 | 3 | 0 | 5 | 0 | 0 | 0 | 3 | 1 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment. (NCT00549198)
Timeframe: Week 48
| Intervention | participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, Grade 3 | Cholesterol, Grade 4 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Non-HDL cholesterol, Grade 3 | Non-HDL cholesterol, Grade 4 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | Alanine aminotransferase, Grade 3 | Alanine aminotransferase, Grade 4 | Aspartate aminotransferase, Grade 3 | Aspartate aminotransferase, Grade 4 | Alkaline phosphatase, Grade 3 | Alkaline phosphatase, Grade 4 | Total bilirubin Grade 3 | Total bilirubin, Grade 4 | Creatinine kinase, Grade 3 | Creatinine kinase, Grade 4 | Phosphorus inorganic, Grade 3 | Phosphorus inorganic, Grade 4 | Lipase, Grade 3 | Lipase, Grade 4 | Hyperkalaemia, Grade 3 | Hyperkalaemia, Grade 4 | Glomerular filtration rate, MDRD, Grade 3 | Glomerular filtration rate, MDRD, Grade 4 | Total neutrophils, Grade 3 | Total neutrophils, Grade 4 | Thrombocytopenia, Grade 4 | ||
| ABC/3TC FDC | 7 | 0 | 9 | 0 | 20 | 0 | 3 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 5 | 2 | 0 | 2 | 1 | 0 | 2 | 3 | 1 | 0 |
| TDF/FTC FDC | 1 | 0 | 3 | 0 | 6 | 0 | 0 | 0 | 4 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 0 | 0 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug therapy. (NCT00549198)
Timeframe: Week 96
| Intervention | participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, Grade 3 | Cholesterol, Grade 4 | LDL cholesterol, Grade 3 | LDL cholesterol, Grade 4 | Non-HDL cholesterol, Grade 3 | Non-HDL cholesterol, Grade 4 | Triglycerides, Grade 3 | Triglycerides, Grade 4 | Alanine aminotransferase, Grade 3 | Alanine aminotransferase, Grade 4 | Aspartate aminotransferase, Grade 3 | Aspartate aminotransferase, Grade 4 | Alkaline phosphatase, Grade 3 | Alkaline phosphatase, Grade 4 | Total bilirubin, Grade 3 | Total bilirubin, Grade 4 | Creatinine kinase, Grade 3 | Creatinine kinase, Grade 4 | Phosphorus inorganic, Grade 3 | Phosphorus inorganic, Grade 4 | Lipase, Grade 3 | Lipase, Grade 4 | Hyperkalaemia, Grade 3 | Hyperkalaemia, Grade 4 | Glomerular filtration rate, MDRD, Grade 3 | Glomerular filtration rate, MDRD, Grade 4 | Total neutrophils, Grade 3 | Total neutrophils, Grade 4 | Thrombocytopenia, Grade 3 | Thrombocytopenia, Grade 4 | |
| ABC/3TC FDC | 9 | 0 | 13 | 0 | 22 | 0 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 6 | 4 | 0 | 2 | 1 | 0 | 3 | 5 | 1 | 0 |
| TDF/FTC FDC | 1 | 0 | 5 | 0 | 5 | 0 | 0 | 0 | 4 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 2 | 2 | 3 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 3 | 0 | 0 |
Difference between 12 months and randomisation CD4+ count was calculated and then summarised (NCT01387022)
Timeframe: Measured at 12 months post ART initiation
| Intervention | cells/uL (Median) |
|---|---|
| Tenofovir-containing Regimen | 217 |
| Tenofovir-sparing Regimen | 174 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 7 |
| Tenofovir-sparing Regimen | 12 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 1 |
| Tenofovir-sparing Regimen | 1 |
Treatment failure is defined as viral load > 50 copies/ml, antiretroviral regimen changes for treatment failure or death (NCT01387022)
Timeframe: 12 months post ART intiation or until time of death
| Intervention | participants (Number) |
|---|---|
| Tenofovir-containing Regimen | 4 |
| Tenofovir-sparing Regimen | 5 |
At visit Days 14 & 28, samples were collected pre-dose and at 1, 2, 3, 4, 6, 9, and 12 hours post-dose. An additional sample was taken at 24 hours (Day 15 or 29 as applicable) post-dose. (NCT00534352)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment A: TMC125 + TDF/FTC | 23 |
| Treatment B: TMC125 + TDF/FTC + DRV/Rtv | 21 |
(NCT00534352)
Timeframe: Baseline, Day 8, 14, 22, 28 & 42 and Week 48
| Intervention | Percent Change from Baseline (Median) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=23) | Day 8 (n=20) | Day 14 (n=20) | Day 22 (n=20) | Day 28 (n=21) | Day 42 (n=19) | Week 48 (n=14) | |
| TDF/FTC +/- TMC125 +/- DRV/Rtv | 26.2 | 0.1 | 4.2 | 1.8 | 3.0 | 4.2 | 3.8 |
CD4+ Cell Count (x 10^6 cell/L): Baseline and Median Changes From Baseline (ITT-Observed Case). (NCT00534352)
Timeframe: Baseline, Day 8, 14, 22, 28 & 42 ans Week 48
| Intervention | x 10^6 cell/L (Median) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=23) | Day 8 (n=20) | Day 14 (n=20) | Day 22 (n=20) | Day 28 (n=21) | Day 42 (n=19) | Week 48 (n=14) | |
| TDF/FTC +/- TMC125 +/- DRV/Rtv | 403.0 | 45.5 | 94.0 | 59.0 | 62.0 | 56.0 | 160.0 |
Log10 Viral Load (HIV-1 RNA copies/mL): Mean Changes From Baseline(ITT-Observed Case). (NCT00534352)
Timeframe: Baseline, Day 8, 14, 22, 28 & 42 and Week 48
| Intervention | copies/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=23) | Day 8 (n=19) | Day 14 (n=21) | Day 22 (n=19) | Day 28 (n=20) | Day 42 (n=20) | Week 48 (n=13) | |
| TDF/FTC +/- TMC125 +/- DRV/Rtv | 4.19 | -1.41 | -1.71 | -1.77 | -1.86 | -2.04 | -2.30 |
"Number of participants with Treatment-Emergent Graded Laboratory Abnormalities (Worst Grade): Glucose- Hypoglycemia.~Worst Grade is based on the DAIDS toxicity grading scale 0-5: No Toxicity-Death." (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 | Grade 2 | |
| Optional Extension | 1 | 0 |
| Treatment A | 0 | 0 |
| Treatment B | 2 | 1 |
| Treatment C | 0 | 0 |
"Number of Participants with Treatment-Emergent Graded Laboratory Abnormalities (Worst Grade): Glucose-Hyperglycemia.~Worst Grade is based on the National Institute of Allergy and Infectious Diseases Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity grading scale, 0,1,2,3,4 and 5 : None, Mild, Moderate, Severe, Life-threatening and Death." (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 | Grade 2 | |
| Optional Extension | 2 | 1 |
| Treatment A | 1 | 1 |
| Treatment B | 2 | 0 |
| Treatment C | 0 | 1 |
"Number of participants with Treatment-Emergent Graded Laboratory Abnormalities (Worst Grade): Lipids- Total Cholesteral.~Worst Grade is based on the DAIDS toxicity grading scale, 0-5 : No Toxicity-Death." (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 | Grade 2 | |
| Optional Extension | 1 | 0 |
| Treatment A | 0 | 0 |
| Treatment B | 0 | 0 |
| Treatment C | 2 | 0 |
"Number of participants with Treatment-Emergent Graded Laboratory Abnormalities(Worst Grade): Lipids- Low-density lipoprotein (LDL) Direct.~Worst Grade is based on the DAIDS toxicity grading scale, 0-5 : No Toxicity-Death." (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 | Grade 2 | |
| Optional Extension | 1 | 1 |
| Treatment A | 0 | 0 |
| Treatment B | 0 | 0 |
| Treatment C | 1 | 1 |
"Number of participants with Treatment-Emergent Graded Laboratory Abnormalities(Worst Grade): Lipids- Triglycerides.~Worst Grade is based on the DAIDS toxicity grading scale, 0-5 : No Toxicity-Death." (NCT00534352)
Timeframe: Day 1 through 48 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 | Grade 2 | |
| Optional Extension | 0 | 0 |
| Treatment A | 0 | 0 |
| Treatment B | 0 | 0 |
| Treatment C | 0 | 0 |
"Number of participants with Treatment-Emergent Non-Graded Laboratory Abnormalities(Worst Abnormality): Glucose- Insulin.~Normal Range: 3.0 - 27.0 ulU/mL" (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participant (Number) | |
|---|---|---|
| Below 3.0 ulU/mL | Above 27.0 ulU/mL | |
| Optional Extension | 1 | 3 |
| Treatment A | 1 | 1 |
| Treatment B | 2 | 3 |
| Treatment C | 1 | 2 |
"Number of participants with Treatment-Emergent Non-Graded Laboratory Abnormalities(Worst Abnormality): Lipids- High-density lipoprotein (HDL).~Normal Range:~40 - 59 mG/dL 1.03 - 1.53 mmol/L" (NCT00534352)
Timeframe: Day 1 through 42 and Week 48
| Intervention | participants (Number) | |
|---|---|---|
| Below 40 mG/dL (1.03 mmol/L) | Above 59 mG/dL (1.53 mmol/L) | |
| Optional Extension | 2 | 1 |
| Treatment A | 4 | 0 |
| Treatment B | 8 | 0 |
| Treatment C | 6 | 0 |
Virologic Response < 50 HIV-1 RNA Copies/mL (ITT-Observed Case). (NCT00534352)
Timeframe: Day 8, 14, 22, 28, 42 and Week 48
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 8 (n=19) | Day 14 (n=21) | Day 22 (n=19) | Day 28 (n=20) | Day 42 (n=20) | Week 48 (n=13) | |
| TDF/FTC +/- TMC125 +/- DRV/Rtv | 0 | 3 | 4 | 6 | 7 | 10 |
participants had Occurrence of Grade 3 or higher adverse events (AEs) (NCT01505114)
Timeframe: Through Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 | 18 |
| Arm 2 | 24 |
| Arm 3 | 20 |
| Arm 4 | 28 |
Participants will be asked to self-report their PrEP use over the past seven days on a follow up questionnaire. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 8 |
| Usual Care (UC) | 10 |
Participants will be asked if they have attended an appointment for PrEP consultation on a follow up questionnaire. It will be confirmed by reviewing their medical records. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 10 |
| Usual Care (UC) | 11 |
Participants will be asked if they have filled their PrEP prescription on a follow up questionnaire. It will be confirmed by reviewing their medical records. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 11 |
| Usual Care (UC) | 10 |
Participants will be asked to self-report their PrEP initiation on a follow up questionnaire. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 11 |
| Usual Care (UC) | 12 |
Participants will be asked if they have received a PrEP prescription on a follow up questionnaire. It will be confirmed by reviewing their medical records. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 12 |
| Usual Care (UC) | 12 |
Participants will be asked if they have scheduled an appointment for PrEP consultation on a follow up questionnaire. It will be confirmed by reviewing their medical records. (NCT04048382)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient Navigation (PN) | 10 |
| Usual Care (UC) | 11 |
"Below I reported the number of sex acts as reported based on the adjusted electronic and self-reported sexual activity data, also the number of pills needed for 100% coverage. 100% coverage means all sex events (excluding oral sex) are covered; Note: sex act is considered as covered if at least one pill is taken 96 hours prior the sexual activity and at least one additional pill is taken within 24 hours after the sexual activity (same coverage definition for all three arms)" (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | Number of pills needed for 100% coverage (Number) |
|---|---|
| Daily Dosing, Cape Town | 2097 |
| Time-driven Dosing, Cape Town | 1552 |
| Event-driven Dosing, Cape Town | 1906 |
| Daily Dosing, Bangkok | 1746 |
| Time-driven Dosing, Bangkok | 1573 |
| Event-driven Dosing, Bangkok | 1268 |
| Daily Dosing, Harlem | 1244 |
| Time-driven Dosing, Harlem | 1390 |
| Event-driven Dosing, Harlem | 1582 |
(NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | % of Correctly Timed Adherence (Number) |
|---|---|
| Daily Dosing, Cape Town | 75 |
| Time-driven Dosing, Cape Town | 65 |
| Event-driven Dosing, Cape Town | 53 |
| Daily Dosing, Bangkok | 85 |
| Time-driven Dosing, Bangkok | 79 |
| Event-driven Dosing, Bangkok | 65 |
| Daily Dosing, Harlem | 65 |
| Time-driven Dosing, Harlem | 47 |
| Event-driven Dosing, Harlem | 41 |
The total pills actually used over the follow-up period was calculated based on the adjusted electronic and self-reported pill-use data. It could be more or less than required by study design (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | Number of pills actually used (Number) |
|---|---|
| Daily Dosing, Cape Town | 7349 |
| Time-driven Dosing, Cape Town | 2852 |
| Event-driven Dosing, Cape Town | 2000 |
| Daily Dosing, Bangkok | 8285 |
| Time-driven Dosing, Bangkok | 3713 |
| Event-driven Dosing, Bangkok | 2157 |
| Daily Dosing, Harlem | 5507 |
| Time-driven Dosing, Harlem | 2468 |
| Event-driven Dosing, Harlem | 2356 |
Only the listing of AE related to study product are presented here. See outcome measure 6 for the listing of adverse events (AEs) by grade and arm. (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood and lymphatic system disorders | Cardiac disorders | Ear and labyrinth disorders | Eye disorders | Gastrointestinal disorders | General disorders and administration site conditio | Hepatobiliary disorders | Immune system disorders | Infections and infestations | Injury, poisoning and procedural complications | Investigations | Metabolism and nutrition disorders | Musculoskeletal and connective tissue disorders | Neoplasms benign, malignant, and unspecified | Nervous system disorders | Pregnancy, puerperium and perinatal conditions | Psychiatric disorders | Renal and urinary disorders | Reproductive system and breast disorders | Respiratory, thoracic and mediastinal disorders | Skin and subcutaneous tissue disorders | Social circumstances | Vascular disorders | |
| Daily Dosing, Bangkok | 0 | 1 | 0 | 1 | 9 | 1 | 0 | 0 | 0 | 10 | 23 | 0 | 2 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Daily Dosing, Cape Town | 0 | 0 | 0 | 0 | 18 | 4 | 0 | 0 | 1 | 3 | 10 | 2 | 1 | 0 | 17 | 0 | 3 | 10 | 1 | 2 | 4 | 0 | 0 |
| Daily Dosing, Harlem | 0 | 0 | 0 | 0 | 13 | 3 | 0 | 0 | 0 | 13 | 9 | 4 | 0 | 0 | 7 | 0 | 2 | 8 | 0 | 2 | 1 | 0 | 1 |
| Event-driven Dosing, Bangkok | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 10 | 10 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 |
| Event-driven Dosing, Cape Town | 0 | 0 | 0 | 0 | 24 | 6 | 0 | 1 | 2 | 7 | 12 | 6 | 0 | 0 | 21 | 0 | 1 | 10 | 1 | 2 | 3 | 0 | 0 |
| Event-driven Dosing, Harlem | 1 | 0 | 0 | 0 | 16 | 4 | 0 | 0 | 0 | 10 | 7 | 5 | 3 | 0 | 5 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 |
| Time-driven Dosing, Bangkok | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 7 | 12 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Time-driven Dosing, Cape Town | 2 | 0 | 0 | 0 | 17 | 1 | 0 | 0 | 0 | 4 | 13 | 5 | 0 | 0 | 17 | 0 | 1 | 5 | 0 | 1 | 5 | 0 | 0 |
| Time-driven Dosing, Harlem | 2 | 0 | 0 | 0 | 13 | 9 | 0 | 0 | 0 | 16 | 9 | 5 | 0 | 0 | 4 | 0 | 2 | 9 | 0 | 0 | 2 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Enrollment | Week 4 | Week 5 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 | Week 26 | Week 30 | |
| Cape Town, South Africa, Seroconverted Participant #8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |
|---|---|---|
| Enrollment | Week 4 | |
| Cape Town, South Africa, Seroconverted Participant #1 | 0 | 1 |
| Harlem, United States, Seroconverted Participant #1 | 0 | 1 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||
|---|---|---|---|
| Enrollment | Week 4 | Week 5 | |
| Bangkok, Thailand, Seroconverted Participant #2 | 0 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||
|---|---|---|---|
| Enrollment | Week 4 | Week 6 | |
| Bangkok, Thailand, Seroconverted Participant #1 | 0 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |||
|---|---|---|---|---|
| Enrollment | Week 4 | Week 5 | Week 6 | |
| Cape Town, South Africa, Seroconverted Participant #2 | 0 | 0 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Enrollment | Week 4 | Week 5 | Week 6 | Week 10 | Week 14 | Week 18 | |
| Harlem, United States, Seroconverted Participant #2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cape Town, South Africa, Seroconverted Participant #6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Enrollment | Week 4 | Week 5 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 | |
| Cape Town, South Africa, Seroconverted Participant #4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cape Town, South Africa, Seroconverted Participant #5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cape Town, South Africa, Seroconverted Participant #7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Only the listing of drug resistance test by arm among all participants who seroconvert while on study are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Enrollment | Week 4 | Week 5 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 | Week 26 | |
| Cape Town, South Africa, Seroconverted Participant #3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) |
|---|---|
| Week 22 | |
| Cape Town, South Africa, Seroconverted Participant #5 | 5887760 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |
|---|---|---|
| Week 14 | Week 18 | |
| Harlem, United States, Seroconverted Participant #2 | 1567040 | 73030 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |
|---|---|---|
| Week 26 | Week 30 | |
| Cape Town, South Africa, Seroconverted Participant #3 | 503950 | 10910 |
| Cape Town, South Africa, Seroconverted Participant #8 | 400 | 400 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||
|---|---|---|---|
| Day 3 | Week 4 | Week 6 | |
| Harlem, United States, Seroconverted Participant #1 | 400 | 40900 | 83260 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |||
|---|---|---|---|---|
| Day 3 | Week 4 | Week 5 | Week 6 | |
| Bangkok, Thailand, Seroconverted Participant #2 | 78450 | 710 | 1570 | 5070 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | |||
|---|---|---|---|---|
| Week 18 | Week 22 | Week 26 | Week 30 | |
| Cape Town, South Africa, Seroconverted Participant #7 | 83010 | 136310 | 25020 | 29390 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||
|---|---|---|---|---|---|
| Enrollment | Day 3 | Week 4 | Week 5 | Week 10 | |
| Cape Town, South Africa, Seroconverted Participant #1 | 20 | 400 | 3460 | 5732050 | 416070 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||
|---|---|---|---|---|---|
| Week 14 | Week 18 | Week 22 | Week 26 | Week 30 | |
| Cape Town, South Africa, Seroconverted Participant #6 | 2100 | 3710 | 127480 | 220830 | 193130 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||
|---|---|---|---|---|---|
| Week 6 | Week 10 | Week 14 | Week 18 | Week 22 | |
| Cape Town, South Africa, Seroconverted Participant #4 | 400 | 400 | 400 | 650 | 400 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 3 | Week 4 | Week 5 | Week 10 | Week 14 | Week 18 | Week 22 | Week 26 | Week 30 | |
| Cape Town, South Africa, Seroconverted Participant #2 | 400 | 3667690 | 3938670 | 93040 | 93660 | 114520 | 178210 | 89970 | 35210 |
Only the listing of plasma HIV RNA levels among all participants who seroconvert while on study are presented here. See outcome measure 12 for the listing of drug resistance test by arm. (NCT01327651)
Timeframe: From Enrollment to week 30 (end of self-administered dosing)
| Intervention | viral load (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 3 | Week 4 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 | Week 26 | Week 30 | |
| Bangkok, Thailand, Seroconverted Participant #1 | 40 | 749590 | 92960 | 1799950 | 119720 | 127330 | 178070 | 96180 | 36140 |
Below we presented the percentages of total cohort with TFV-DP concentrations consistent with >=2 pills/week in women who also report sex in the last 7 day for each arm. For Cape Town and Bangkok, TFV-DP in PBMC was analyzed, for Harlem site, the TFV-DP in DBS (dried blood spot) was analyzed. Note: PBMC >5.2 fmol/10^6 cells is considered as participants taken >=2 tablets per week; DBS >=326 fmol/punch is considered as participants taken >=2 tablets per week (NCT01327651)
Timeframe: week 10, 18 and 30, which is 4 weeks, 12 weeks, and 24 weeks after randomization
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Week 10 | Week 18 | Week 30 | |
| Daily Dosing, Bangkok | 31 | 28 | 22 |
| Daily Dosing, Cape Town | 33 | 29 | 19 |
| Daily Dosing, Harlem | 13 | 11 | 9 |
| Event-driven Dosing, Bangkok | 30 | 24 | 13 |
| Event-driven Dosing, Cape Town | 25 | 10 | 12 |
| Event-driven Dosing, Harlem | 5 | 3 | 3 |
| Time-driven Dosing, Bangkok | 29 | 30 | 18 |
| Time-driven Dosing, Cape Town | 16 | 16 | 13 |
| Time-driven Dosing, Harlem | 8 | 10 | 3 |
"Coverage will be determined based on the adjusted electronic and self-reported pill-use data. Specifically, a sex act will be considered as covered if at least one pill is taken 96 hours prior the sexual activity and at least one additional pill is taken within 24 hours after the sexual activity. If participant only took pill before the sexual activity (within 96 hours), but no pill taken after sexual activity (within 24 hours), then we considered it as pre-exposure covered. likewise, if participant only took pill after sexual activity (within 24 hours), but did not taken pill before sexual activity (within 96 hours), then we considered it as post-exposure covered. If participant did not taken pill before and after sexual activity, then it was considered as not covered. Note that the same pill can be both pre-exposure dose and a post-exposure dose if events are closely spaced. At no time should a participant in the intermittent arm be taking more pills than the daily arm." (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | percentage of sexual exposures (Number) | |||
|---|---|---|---|---|
| % completely covered | % pre-exposure coverage | % post-exposure coverage | % uncovered | |
| Daily Dosing, Bangkok | 85 | 11 | 1 | 3 |
| Daily Dosing, Cape Town | 75 | 21 | 1 | 3 |
| Daily Dosing, Harlem | 66 | 24 | 2 | 8 |
| Event-driven Dosing, Bangkok | 74 | 19 | 5 | 3 |
| Event-driven Dosing, Cape Town | 52 | 33 | 8 | 7 |
| Event-driven Dosing, Harlem | 52 | 29 | 6 | 13 |
| Time-driven Dosing, Bangkok | 84 | 12 | 3 | 1 |
| Time-driven Dosing, Cape Town | 56 | 30 | 9 | 5 |
| Time-driven Dosing, Harlem | 47 | 30 | 8 | 15 |
The self-reported symptom/side effect scores for common symptoms/side effects including headache, dizziness, cramping, abdominal pain, and flatulence. Collected during clinic visits. All the presented numbers are the percent of visits with each side effects (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | percent of visits between week 6 to 30 (Number) | |
|---|---|---|
| Neurologic side effect | Gastrointestinal side effects | |
| Daily Dosing, Bangkok | 14.2 | 13.1 |
| Daily Dosing, Cape Town | 12.4 | 10.6 |
| Daily Dosing, Harlem | 6.1 | 8 |
| Event-driven Dosing, Bangkok | 13.3 | 10.5 |
| Event-driven Dosing, Cape Town | 7.8 | 5.4 |
| Event-driven Dosing, Harlem | 4.5 | 7.1 |
| Time-driven Dosing, Bangkok | 14.3 | 8.5 |
| Time-driven Dosing, Cape Town | 6.0 | 8.8 |
| Time-driven Dosing, Harlem | 3.3 | 5.8 |
Only the listing of adverse events (AEs) by grade and arm are presented here. See outcome measure 10 for the listing of AE by relationship to study product (NCT01327651)
Timeframe: From week 6 (randomization week) to week 30 (end of self-administered dosing)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood and lymphatic system disorders : Mild72291137 | Blood and lymphatic system disorders : Mild72291143 | Blood and lymphatic system disorders : Mild72291138 | Blood and lymphatic system disorders : Mild72291139 | Blood and lymphatic system disorders : Mild72291140 | Blood and lymphatic system disorders : Mild72291141 | Blood and lymphatic system disorders : Mild72291142 | Blood and lymphatic system disorders : Mild72291144 | Blood and lymphatic system disorders : Mild72291145 | Cardiac disorders72291137 | Cardiac disorders72291143 | Cardiac disorders72291138 | Cardiac disorders72291139 | Cardiac disorders72291140 | Cardiac disorders72291141 | Cardiac disorders72291142 | Cardiac disorders72291144 | Cardiac disorders72291145 | Ear and labyrinth disorders72291137 | Ear and labyrinth disorders72291143 | Ear and labyrinth disorders72291144 | Ear and labyrinth disorders72291142 | Ear and labyrinth disorders72291138 | Ear and labyrinth disorders72291139 | Ear and labyrinth disorders72291140 | Ear and labyrinth disorders72291141 | Ear and labyrinth disorders72291145 | Eye disorders72291137 | Eye disorders72291143 | Eye disorders72291138 | Eye disorders72291139 | Eye disorders72291140 | Eye disorders72291141 | Eye disorders72291142 | Eye disorders72291144 | Eye disorders72291145 | Gastrointestinal disorders72291137 | Gastrointestinal disorders72291143 | Gastrointestinal disorders72291142 | Gastrointestinal disorders72291138 | Gastrointestinal disorders72291139 | Gastrointestinal disorders72291140 | Gastrointestinal disorders72291141 | Gastrointestinal disorders72291144 | Gastrointestinal disorders72291145 | General disorders and administration site conditio72291137 | General disorders and administration site conditio72291142 | General disorders and administration site conditio72291143 | General disorders and administration site conditio72291140 | General disorders and administration site conditio72291138 | General disorders and administration site conditio72291139 | General disorders and administration site conditio72291141 | General disorders and administration site conditio72291144 | General disorders and administration site conditio72291145 | Hepatobiliary disorders72291137 | Hepatobiliary disorders72291142 | Hepatobiliary disorders72291143 | Hepatobiliary disorders72291138 | Hepatobiliary disorders72291139 | Hepatobiliary disorders72291140 | Hepatobiliary disorders72291141 | Hepatobiliary disorders72291144 | Hepatobiliary disorders72291145 | Immune system disorders72291137 | Immune system disorders72291142 | Immune system disorders72291143 | Immune system disorders72291138 | Immune system disorders72291139 | Immune system disorders72291140 | Immune system disorders72291141 | Immune system disorders72291144 | Immune system disorders72291145 | Infections and infestations72291137 | Infections and infestations72291142 | Infections and infestations72291143 | Infections and infestations72291138 | Infections and infestations72291139 | Infections and infestations72291140 | Infections and infestations72291141 | Infections and infestations72291144 | Infections and infestations72291145 | Injury, poisoning and procedural complications72291137 | Injury, poisoning and procedural complications72291142 | Injury, poisoning and procedural complications72291138 | Injury, poisoning and procedural complications72291139 | Injury, poisoning and procedural complications72291140 | Injury, poisoning and procedural complications72291141 | Injury, poisoning and procedural complications72291143 | Injury, poisoning and procedural complications72291144 | Injury, poisoning and procedural complications72291145 | Investigations72291137 | Investigations72291142 | Investigations72291138 | Investigations72291139 | Investigations72291140 | Investigations72291141 | Investigations72291143 | Investigations72291144 | Investigations72291145 | Metabolism and nutrition disorders72291137 | Metabolism and nutrition disorders72291142 | Metabolism and nutrition disorders72291141 | Metabolism and nutrition disorders72291138 | Metabolism and nutrition disorders72291139 | Metabolism and nutrition disorders72291140 | Metabolism and nutrition disorders72291143 | Metabolism and nutrition disorders72291144 | Metabolism and nutrition disorders72291145 | Musculoskeletal and connective tissue disorders72291137 | Musculoskeletal and connective tissue disorders72291142 | Musculoskeletal and connective tissue disorders72291138 | Musculoskeletal and connective tissue disorders72291139 | Musculoskeletal and connective tissue disorders72291140 | Musculoskeletal and connective tissue disorders72291141 | Musculoskeletal and connective tissue disorders72291143 | Musculoskeletal and connective tissue disorders72291144 | Musculoskeletal and connective tissue disorders72291145 | Nervous system disorders72291137 | Nervous system disorders72291142 | Nervous system disorders72291141 | Nervous system disorders72291138 | Nervous system disorders72291139 | Nervous system disorders72291140 | Nervous system disorders72291143 | Nervous system disorders72291144 | Nervous system disorders72291145 | Pregnancy, puerperium and perinatal conditions72291137 | Pregnancy, puerperium and perinatal conditions72291142 | Pregnancy, puerperium and perinatal conditions72291140 | Pregnancy, puerperium and perinatal conditions72291144 | Pregnancy, puerperium and perinatal conditions72291141 | Pregnancy, puerperium and perinatal conditions72291138 | Pregnancy, puerperium and perinatal conditions72291139 | Pregnancy, puerperium and perinatal conditions72291143 | Pregnancy, puerperium and perinatal conditions72291145 | Psychiatric disorders72291141 | Psychiatric disorders72291142 | Psychiatric disorders72291137 | Psychiatric disorders72291144 | Psychiatric disorders72291143 | Psychiatric disorders72291138 | Psychiatric disorders72291139 | Psychiatric disorders72291140 | Psychiatric disorders72291145 | Renal and urinary disorders72291137 | Renal and urinary disorders72291142 | Renal and urinary disorders72291139 | Renal and urinary disorders72291138 | Renal and urinary disorders72291140 | Renal and urinary disorders72291141 | Renal and urinary disorders72291143 | Renal and urinary disorders72291144 | Renal and urinary disorders72291145 | Reproductive system and breast disorders72291137 | Reproductive system and breast disorders72291140 | Reproductive system and breast disorders72291142 | Reproductive system and breast disorders72291138 | Reproductive system and breast disorders72291139 | Reproductive system and breast disorders72291143 | Reproductive system and breast disorders72291145 | Reproductive system and breast disorders72291141 | Reproductive system and breast disorders72291144 | Respiratory, thoracic and mediastinal disorders72291137 | Respiratory, thoracic and mediastinal disorders72291142 | Respiratory, thoracic and mediastinal disorders72291145 | Respiratory, thoracic and mediastinal disorders72291140 | Respiratory, thoracic and mediastinal disorders72291138 | Respiratory, thoracic and mediastinal disorders72291139 | Respiratory, thoracic and mediastinal disorders72291141 | Respiratory, thoracic and mediastinal disorders72291143 | Respiratory, thoracic and mediastinal disorders72291144 | Skin and subcutaneous tissue disorders72291137 | Skin and subcutaneous tissue disorders72291138 | Skin and subcutaneous tissue disorders72291142 | Skin and subcutaneous tissue disorders72291140 | Skin and subcutaneous tissue disorders72291139 | Skin and subcutaneous tissue disorders72291141 | Skin and subcutaneous tissue disorders72291143 | Skin and subcutaneous tissue disorders72291144 | Skin and subcutaneous tissue disorders72291145 | Social circumstances72291142 | Social circumstances72291145 | Social circumstances72291137 | Social circumstances72291138 | Social circumstances72291139 | Social circumstances72291140 | Social circumstances72291141 | Social circumstances72291143 | Social circumstances72291144 | Vascular disorders72291142 | Vascular disorders72291137 | Vascular disorders72291141 | Vascular disorders72291140 | Vascular disorders72291144 | Vascular disorders72291138 | Vascular disorders72291139 | Vascular disorders72291143 | Vascular disorders72291145 | Neoplasms benign, malignant, and unspecified72291144 | Neoplasms benign, malignant, and unspecified72291139 | Neoplasms benign, malignant, and unspecified72291141 | Neoplasms benign, malignant, and unspecified72291138 | Neoplasms benign, malignant, and unspecified72291140 | Neoplasms benign, malignant, and unspecified72291143 | Neoplasms benign, malignant, and unspecified72291137 | Neoplasms benign, malignant, and unspecified72291142 | Neoplasms benign, malignant, and unspecified72291145 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe | Potentically Life Threatening | Death | None | Mild | Moderate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 30 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 41 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 41 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 9 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 41 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 41 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Bangkok | 44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Bangkok | 46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Harlem | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Cape Town | 56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Time-driven Dosing, Cape Town | 55 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Cape Town | 59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Bangkok | 60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Daily Dosing, Harlem | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Event-driven Dosing, Harlem | 60 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Only the cross table between drug resistance by arm are presented here. See outcome measure 11 for the listing of plasma HIV RNA levels, and outcome measure 12 for the listing of drug resistance test by arm among all participants who seroconvert while on study. (NCT01327651)
Timeframe: From enrollment to week 30 (end of self-administered dosing)
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before Randomization72291147 | Before Randomization72291146 | Before Randomization72291148 | After Randomization (Daily dosing)72291146 | After Randomization (Daily dosing)72291147 | After Randomization (Daily dosing)72291148 | After Randomization (Time-driven dosing)72291147 | After Randomization (Time-driven dosing)72291146 | After Randomization (Time-driven dosing)72291148 | After Randomization (Event-driven dosing)72291147 | After Randomization (Event-driven dosing)72291146 | After Randomization (Event-driven dosing)72291148 | |||||||||||||
| Drug Resistance | No Drug Resistance | |||||||||||||||||||||||
| Cape Town, South Africa | 1 | |||||||||||||||||||||||
| Bangkok, Thailand | 0 | |||||||||||||||||||||||
| Harlem, United States | 1 | |||||||||||||||||||||||
| Cape Town, South Africa | 190 | |||||||||||||||||||||||
| Bangkok, Thailand | 193 | |||||||||||||||||||||||
| Harlem, United States | 237 | |||||||||||||||||||||||
| Harlem, United States | 0 | |||||||||||||||||||||||
| Cape Town, South Africa | 59 | |||||||||||||||||||||||
| Bangkok, Thailand | 60 | |||||||||||||||||||||||
| Harlem, United States | 59 | |||||||||||||||||||||||
| Cape Town, South Africa | 58 | |||||||||||||||||||||||
| Harlem, United States | 60 | |||||||||||||||||||||||
| Cape Town, South Africa | 0 | |||||||||||||||||||||||
| Cape Town, South Africa | 60 | |||||||||||||||||||||||
| Bangkok, Thailand | 59 | |||||||||||||||||||||||
Mean duration of interruptions (NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | Days (Number) |
|---|---|
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 65 |
Number of study drug interruptions (NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | interruptions (Number) |
|---|---|
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 86 |
(NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | participant with acquired HIV resistance (Number) |
|---|---|
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 1 |
Medication possession ratio is defined as the number of dispensed pills divided by the number of days between visits (NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | percent (Number) |
|---|---|
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 85.9 |
(NCT01632995)
Timeframe: Measured through enrollment (Week 0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Potentially eligible clients | Participants enrolled | |
| Participants Assessed for Participation | 921 | 557 |
(NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | Percent of Participants (Number) | ||||
|---|---|---|---|---|---|
| % with protective TFV-DP levels at week 4 | % with protective TFV-DP levels at week 12 | % with protective TFV-DP levels at week 24 | % with protective TFV-DP levels at week 36 | % with protective TFV-DP levels at week 48 | |
| Participants With DBS Testing | 86 | 85 | 82 | 85 | 80 |
(NCT01632995)
Timeframe: Measured through enrollment (Week 0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Potentially eligible clients | Declined participation | |
| Participants Assessed for Participation | 921 | 364 |
(NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | events (Number) | |
|---|---|---|
| Serious adverse events | Creatinine elevations | |
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 19 | 23 |
(NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | partners (Mean) | |
|---|---|---|
| Mean Anal sex partners at baseline | Mean Anal sex partners at week 48 | |
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 10.9 | 9.3 |
(NCT01632995)
Timeframe: Participants were followed for 48 weeks, or up to the point of early termination
| Intervention | participants (Number) | |
|---|---|---|
| Acute HIV infection at baseline | HIV seroconversion during follow-up | |
| Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) | 3 | 2 |
"A six-item scale assessing adolescents' perceived abilities to manage emotional upset (e.g., In the past three months, I have had trouble controlling my feelings.) in sexual situations. Scores range from 6 to 24 with higher scores indicated poorer perceived ability to manage emotional upset in sexual situations." (NCT02921841)
Timeframe: 3 months post-intervention (average 6 months)
| Intervention | score on a scale (Mean) |
|---|---|
| DSTAR | 9.39 |
| DHEALTH | 8.90 |
"On a scale of 0 to 100, participants report how likely it is that they will use a condom when they have sex in the next 3 months. Zero represented I will not use a condom, 50 represented I will use a condom half the time., and 100 represented I will use a condom all the time.." (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | units on a scale (Mean) |
|---|---|
| DSTAR | 58.75 |
| DHEALTH | 61.84 |
Number of times a condom was used during oral, vaginal, and/or anal sex (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | times a condom was used (Mean) |
|---|---|
| DSTAR | 3.33 |
| DHEALTH | 2.36 |
Number of days alcohol was used in the past 30 days (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | days (Mean) |
|---|---|
| DSTAR | 5.71 |
| DHEALTH | 7.57 |
Number of days marijuana was used in the past 30 days (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | days (Mean) |
|---|---|
| DSTAR | 15.83 |
| DHEALTH | 8.60 |
Number of oral, vaginal, and/or anal sexual occurrences in the past 3 months. (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | sexual acts (Mean) |
|---|---|
| DSTAR | 13.75 |
| DHEALTH | 9.40 |
HIV Knowledge Questionnaire. A 18-item (true, false, uncertain) scale surveys routes of transmission, casual contact misconceptions, general information and course of illness. Scores range from 0-18 with higher scores indicating greater HIV knowledge. (NCT02921841)
Timeframe: 3 months post-intervention
| Intervention | score on a scale (Mean) |
|---|---|
| DSTAR | 11.10 |
| DHEALTH | 10.98 |
Number of sexual partners in the past 3 months. (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | sexual partners (Mean) |
|---|---|
| DSTAR | 2.06 |
| DHEALTH | 2.00 |
Number of drinks reported on days that a participant drank alcohol in the past 30 days (NCT02921841)
Timeframe: 3-months post-intervention
| Intervention | alcoholic drinks (Mean) |
|---|---|
| DSTAR | 3.14 |
| DHEALTH | 10.50 |
"The scale contains 13 items that reflect the context of condom use, such as could use a condom when I'm very upset. Scores range from 13 to 52 with higher scores indicated lower self-efficacy for HIV prevention." (NCT02921841)
Timeframe: 3 months post-intervention
| Intervention | score on a scale (Mean) |
|---|---|
| DSTAR | 37.83 |
| DHEALTH | 37.37 |
Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician. (NCT03205566)
Timeframe: Through Study completion, an average of 55 days
| Intervention | Adverse event (Number) |
|---|---|
| Arm A Raltegravir | 12 |
| Arm B Raltegravir Lamivudine | 15 |
"The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .~High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL" (NCT03205566)
Timeframe: Through Study completion, an average of 55 days
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Plasma: High Dose Challenge in rectal tissue | Plasma: Low viral dose challenge in rectal tissue | Rectal: high viral dose challenge in rectal tissue | Rectal: Low viral dose challenge in rectal tissue | Plasma: high viral dose challenge in vaginal tissu | Plasma: low viral dose challenge in vaginal tissue | Plasma: high dose in vaginal tissue | Plasma: low dose in vaginal tissue | |
| Lamivudine During Combination Treatment | 265.10 | 265.10 | 1722.02 | 1722.02 | 266.40 | 169.10 | 1557.80 | 1437.80 |
| Raltegravir | NA | 979.8 | NA | 729.36 | NA | 979.8 | NA | 607.60 |
| Raltegravir During Combination Treatment | 669.90 | 669.90 | 862.35 | 862.35 | 828.60 | 281.60 | 648.24 | 273.02 |
Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time from first dose of drug to maximum rectal ex vivo protection from high titer HIV infection | Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infection | Time from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection | ||
| Raltegravir | 3 | 2 | 2.67 | 3 |
Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infection | Time from first dose of drug to maximum rectal ex vivo protection from High titer HIV infection | Time from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection | ||
| Raltegravir Lamivudine | 2 | 2 | 3 | 3.67 |
Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed. (NCT03205566)
Timeframe: 5 days post last dose
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Time to cessation of rectal ex vivo protection from high HIV dose challenge post ART at steady state | Time to cessation of rectal ex vivo protection from low HIV dose challenge post ART at steady state | Time to cessation of vaginal ex vivo protection from high HIVdose challenge post ART at steady state | Time to cessation of vaginal ex vivo protection from low HIV dose challenge post ART at steady state | |
| Raltegravir | 3.33 | NA | 4 | 5 |
| Raltegravir Lamivudine | NA | NA | NA | NA |
(NCT00885482)
Timeframe: 48 weeks
| Intervention | patients (Number) |
|---|---|
| Single Arm | 1 |
Change = Week 48 value minus baseline value (NCT00869557)
Timeframe: Baseline to Week 48
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 240 |
| Atripla | 166 |
Change = Week 24 value minus baseline value (NCT00869557)
Timeframe: Baseline to Week 24
| Intervention | cells/µL (Mean) |
|---|---|
| Stribild | 161 |
| Atripla | 117 |
The percentage of participants with plasma HIV-1 RNA < 50 copies/mL at Week 24 was summarized. (NCT00869557)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 89.6 |
| Atripla | 87.0 |
The percentage of participants with plasma HIV-1 RNA < 50 copies/mL at Week 48 was summarized. (NCT00869557)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 89.6 |
| Atripla | 87.0 |
Change = Week 24 or 48 value minus baseline value (NCT00869557)
Timeframe: Baseline to Weeks 24 and 48
| Intervention | log_10 copies/mL (Mean) | |
|---|---|---|
| Baseline to Week 24 | Baseline to Week 48 | |
| Atripla | -2.88 | -2.71 |
| Stribild | -2.87 | -2.89 |
The percentage of participants with virologic success at Weeks 24 and 48 assessed using the FDA-defined snapshot analysis for an HIV-1 RNA cutoff of 50 copies/mL was summarized. (NCT00869557)
Timeframe: Baseline to Weeks 24 and 48
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Virologic Success at Week 24 | Virologic Success at Week 48 | |
| Atripla | 87.0 | 82.6 |
| Stribild | 89.6 | 91.7 |
Total number of adverse events observed that were possibly or definitely related to study treatment through week 48 (NCT00855413)
Timeframe: Enrollment to week 48
| Intervention | adverse events (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 13 |
Change in overall z score from baseline to week 24 or 48. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. (NCT00855413)
Timeframe: Baseline to Week 24 or 48
| Intervention | z score (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | 4.23 |
(NCT00855413)
Timeframe: From enrollment through Week 48
| Intervention | r value (Number) |
|---|---|
| Acute HIV Infection Treatment Group | NA |
(NCT00855413)
Timeframe: Baseline to Week 24 and 48
| Intervention | r value (Number) |
|---|---|
| Acute HIV Infection Treatment Group | -.82 |
Average HIV RNA detected in the ileal biopsy specimens per participant over weeks 4 and 48. (NCT00855413)
Timeframe: Weeks 4 and 48
| Intervention | copies/mL (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | 40 |
Total cumulative levels of HIV RNA detected in the semen of participants from enrollment through week 48. (NCT00855413)
Timeframe: From enrollment through 48 weeks
| Intervention | copies/mL (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | 2541 |
(NCT00855413)
Timeframe: HIV RNA level at enrollment
| Intervention | copies/mL (Median) |
|---|---|
| Acute HIV Infection Treatment Group | 1,000,000 |
(NCT00855413)
Timeframe: Week 4 and week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 240 |
(NCT00855413)
Timeframe: Weeks 0-4 and weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 1296 |
(NCT00855413)
Timeframe: between Week 4-12 and between Weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 83,749 |
(NCT00855413)
Timeframe: Week 4 and week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 25 |
(NCT00855413)
Timeframe: between Week 4-12 and between Weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 83,749 |
(NCT00855413)
Timeframe: Weeks 0-4 and weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 185 |
(NCT00855413)
Timeframe: Week 4 and Week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 22 |
(NCT00855413)
Timeframe: Weeks 0-4 and Weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 22 |
(NCT00855413)
Timeframe: between week 4-12 and between Weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 14,698 |
(NCT00855413)
Timeframe: week 0, week 24
| Intervention | cells/mm^3 (Median) |
|---|---|
| Acute HIV Infection Treatment Group | 158 |
(NCT00855413)
Timeframe: 48 weeks from enrollment
| Intervention | cells/mm^3 (Median) |
|---|---|
| Acute HIV Infection Treatment Group | 349 |
(NCT00855413)
Timeframe: From enrollment to the date of HIV RNA suppression, assessed up to Week 48
| Intervention | days (Median) |
|---|---|
| Acute HIV Infection Treatment Group | 59 |
(NCT00855413)
Timeframe: Week 4 and week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 10 |
(NCT00855413)
Timeframe: between week 4-12 and between weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 987 |
(NCT00855413)
Timeframe: Weeks 0-4 and weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 9 |
(NCT00855413)
Timeframe: Week 4 and week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 4 |
(NCT00855413)
Timeframe: Weeks 0-4 and weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 12 |
(NCT00855413)
Timeframe: between Week 4-12 and between Weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 34 |
(NCT00855413)
Timeframe: Weeks 0-4 and Weeks 12, 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 2 |
(NCT00855413)
Timeframe: Week 4 and week 48
| Intervention | ng/mL (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 2 |
(NCT00855413)
Timeframe: between week 4-12 and between weeks 36-48
| Intervention | ng/g (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 96 |
(NCT00855413)
Timeframe: Enrollment to Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 1 |
(NCT00855413)
Timeframe: Week 4 and Week 48
| Intervention | participants (Number) |
|---|---|
| Acute HIV Infection Treatment Group | 0 |
(NCT00855413)
Timeframe: Week 2 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 8 |
(NCT00855413)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 3 |
(NCT00855413)
Timeframe: Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 3 |
Virologic response defined as plasma HIV RNA measurement <200 copies/mL at week 24 (NCT00855413)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 13 |
Virologic response to study treatment defined as plasma HIV RNA measurement <50 copies/mL at week 48 (NCT00855413)
Timeframe: 48 weeks from enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 9 |
Neuropsychological performance was assessed at week 2 or 4, week 24 and week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score of neurocognitive functioning was created by averaging all tests. Participants also completed Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. (NCT00855413)
Timeframe: Week 24
| Intervention | z score (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | -0.40 |
Neuropsychological performance was assessed at baseline (week 2 or 4), week 24 and week 48 in the following domain (measures): Premorbid/language (Wide Range Achievement Test (WRAT) 4 - Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score of neurocognitive functioning was created by averaging all tests. Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. (NCT00855413)
Timeframe: Week 48
| Intervention | z score (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | -.45 |
Neuropsychological performance was assessed at Week 2 or 4, Week 24 and Week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test-Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency. An overall summary score was created by averaging all tests. Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS). Best available demographically corrected normative data were utilized to create z scores. A negative z score denotes below-average performance relative to a US normative comparison population. A higher z score is a better outcome. (NCT00855413)
Timeframe: Week 2 or 4
| Intervention | z score (Mean) |
|---|---|
| Acute HIV Infection Treatment Group | -0.69 |
Prevalence of any of the surveillance drug resistance mutations associated with resistance to antiretroviral medications listed by the World Health Organization (NCT00924898)
Timeframe: At enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 17 |
Baseline genotypic resistance defined as presence of any surveillance drug resistance mutation to any drug in the study treatment listed by the World Health Organization (NCT00924898)
Timeframe: At enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 71 |
Number of participants wtih HIV RNA level <50 copies/mL at week 96 (NCT00924898)
Timeframe: HIV RNA level at 96 weeks following enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 65 |
Number of participants with a HIV RNA level <200 copies/mL at week 24 (NCT00924898)
Timeframe: HIV RNA level prior to or at week 24 following enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 81 |
HIV RNA level <50 copies/mL at week 48 (NCT00924898)
Timeframe: HIV RNA level at week 48 following enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute HIV Infection Treatment Group | 71 |
Number of days from ART initiation to HIV RNA suppression <50 copies/mL (NCT00924898)
Timeframe: Number of days from start of study treatment until HIV RNA suppression, assessed through week 96
| Intervention | days (Median) |
|---|---|
| Acute HIV Infection Treatment Group | 105 |
(NCT01694420)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Quad FDC | 28 |
(NCT01694420)
Timeframe: 48 weeks
| Intervention | participants (Number) |
|---|---|
| Quad FDC | 22 |
(NCT01694420)
Timeframe: 48 weeks
| Intervention | participants (Number) |
|---|---|
| Quad FDC | 24 |
(NCT01694420)
Timeframe: 48 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| Quad FDC | 3 | 0 |
(NCT01694420)
Timeframe: 48 weeks
| Intervention | days (Median) | |
|---|---|---|
| HIV RNA <200 copies/mL | HIV RNA <50 copies/mL | |
| Quad FDC | 26 | 54 |
Proportion of Patients reporting CNS (central nervous system) side effects of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 41 |
| Nevirapine BID | 41 |
| Atazanvir/Ritonavir | 37 |
Proportion of Patients reporting hepatic events of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 26 |
| Nevirapine BID | 24 |
| Atazanvir/Ritonavir | 92 |
Proportion of Patients reporting rash of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 75 |
| Nevirapine BID | 64 |
| Atazanvir/Ritonavir | 74 |
Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response. (NCT00389207)
Timeframe: Baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 12.00 |
| Nevirapine BID | 12.14 |
| Nevirapine QD+BID | 12.00 |
| Atazanvir/Ritonavir | 23.71 |
Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | cells/mm^3 (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in CD4+ count to Week 4 | Change in CD4+ count to Week 8 | Change in CD4+ count to Week 12 | Change in CD4+ count to Week 24 | Change in CD4+ count to Week 36 | Change in CD4+ count to Week 48 | Change in CD4+ count to Week 60 | Change in CD4+ count to Week 72 | Change in CD4+ count to Week 84 | Change in CD4+ count to Week 96 | Change in CD4+ count to Week 108 | Change in CD4+ count to Week 120 | Change in CD4+ count to Week 132 | Change in CD4+ count to Week 144/EOT | |
| Atazanvir/Ritonavir | 86.1 | 98.0 | 110.9 | 133.8 | 163.4 | 183.6 | 208.2 | 231.9 | 246.4 | 251.6 | 267.2 | 269.2 | 281.3 | 285.8 |
| Nevirapine QD+BID | 77.2 | 105.6 | 120.3 | 134.4 | 160.1 | 168.2 | 184.8 | 213.7 | 223.0 | 217.7 | 231.2 | 231.3 | 243.4 | 251.0 |
Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in Framingham score to Week 48 | Change in Framingham score to Week 96 | Change in Framingham score to Week 144/EOT | |
| Atazanvir/Ritonavir | 0.66 | 1.19 | 0.82 |
| Nevirapine QD+BID | 0.50 | 0.93 | 1.14 |
Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in MHS score to Week 48 | Change in MHS score to Week 96 | Change in MHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 4.52 | 4.89 | 4.70 |
| Nevirapine QD+BID | 6.09 | 6.10 | 4.76 |
QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in PHS score to Week 48 | Change in PHS score to Week 96 | Change in PHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 3.35 | 3.00 | 3.35 |
| Nevirapine QD+BID | 3.34 | 3.19 | 2.22 |
Calculations based on the MDRD algorithm. (NCT00389207)
Timeframe: From baseline to Week 48, 96, 144
| Intervention | mL/min/1.73 m^2 (Mean) | ||
|---|---|---|---|
| change baseline to week 48 (N=143, 128, 271, 173) | change baseline to week 96 (N=130, 122, 252, 157) | change baseline to week 144 (N=163, 168, 331, 174) | |
| Atazanvir/Ritonavir | -7.18 | -11.53 | -9.56 |
| Nevirapine BID | -5.92 | -10.02 | -6.33 |
| Nevirapine QD | -3.91 | -6.93 | -3.27 |
| Nevirapine QD+BID | -4.86 | -8.42 | -4.82 |
Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| total cholesterol, week 48 (N=138,122,164) | total cholesterol, week 96 (N=124,114,147) | total cholesterol, week 144 (N=154,155,160) | LDL-c, week 48 (N=136,117,159) | LDL-c, week 96 (N=119,110,145) | LDL-c, week 144 (N=151,150,157) | HDL, week 48(N=138,122,164) | HDL, week 96 (N=124,114,147) | HDL, week 144(N=154,155,160) | |
| Atazanvir/Ritonavir | 20.84 | 29.99 | 28.13 | 10.58 | 19.19 | 17.61 | 3.49 | 4.74 | 5.73 |
| Nevirapine BID | 29.54 | 36.87 | 30.66 | 17.70 | 21.66 | 17.95 | 11.59 | 13.33 | 10.47 |
| Nevirapine QD | 29.28 | 39.17 | 33.12 | 16.54 | 21.93 | 21.42 | 12.06 | 13.86 | 12.61 |
Change of hsCRP from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/L (Mean) | ||
|---|---|---|---|
| hsCRP, week 48 (N=142,126,173) | hsCRP, week 96 (N=128,120,157) | hsCRP, week 144 (N=160,164,174) | |
| Atazanvir/Ritonavir | -0.70 | 0.35 | 0.04 |
| Nevirapine BID | -0.67 | -0.79 | -0.02 |
| Nevirapine QD | -1.01 | -1.54 | -0.09 |
Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,122,164) | total triglycerides, week 96 (N=124,114,147) | total triglycerides, week 144 (N=154,155,160) | |
| Atazanvir/Ritonavir | 0.20 | 0.28 | 0.17 |
| Nevirapine BID | -0.33 | -0.25 | -0.07 |
| Nevirapine QD | -0.37 | -0.22 | -0.24 |
Change of total triglycerides from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,120,164) | total triglycerides, week 96 (N=124,113,147) | total triglycerides, week 144 (N=153,153,159) | |
| Atazanvir/Ritonavir | 36.28 | 30.45 | 27.11 |
| Nevirapine BID | 1.67 | 5.35 | 6.11 |
| Nevirapine QD | 0.08 | 9.34 | -3.46 |
Changes frombaseline apolipoprotein A1 & B (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | g/L (Mean) | |||||
|---|---|---|---|---|---|---|
| apolipoprotein A1, week 48 (N=134,121,156) | apolipoprotein A1, week 96 (N=115,106,141) | apolipoprotein A1, week 144 (N=144,140,148) | apolipoprotein B, week 48 (N=134,120,156) | apolipoprotein B, week 96 (N=115,106,141) | apolipoprotein B, week 144 (N=144,139,148) | |
| Atazanvir/Ritonavir | 0.08 | 0.07 | 0.06 | 0.03 | 0.03 | 0.03 |
| Nevirapine BID | 0.23 | 0.23 | 0.14 | 0.03 | -0.00 | 0.05 |
| Nevirapine QD | 0.23 | 0.23 | 0.16 | 0.00 | 0.00 | 0.01 |
Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Number of substitutions (Number) | ||
|---|---|---|---|
| Emtricitabine-associated substitutions at Week 48 | Tenofovir-associated substitutions at Week 48 | Nevirapine-associated substitutions at Week 48 | |
| Atazanvir/Ritonavir | 0 | 0 | 0 |
| Nevirapine QD+BID | 21 | 11 | 34 |
Number of patients with AE elevated serum glucose (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with glycaemic abnormalities | Number without glycaemic abnormalities | |
| Atazanvir/Ritonavir | 3 | 190 |
| Nevirapine QD+BID | 0 | 376 |
Number of patients with AE lipodystrophy (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with lipodystrophy | Number without lipodystrophy | |
| Atazanvir/Ritonavir | 1 | 192 |
| Nevirapine QD+BID | 1 | 375 |
Cost effectiveness assessment by number of patients with non-scheduled physician visits (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Number between baseline and Week 24 | Number between Week 24 and Week 48 | Number between Week 48 and Week 96 | Number between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 35 | 35 | 28 | 35 |
| Nevirapine QD+BID | 74 | 45 | 58 | 58 |
Cost effectiveness assessment by number of patients hospitalized (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | Patients (Number) | |||
|---|---|---|---|---|
| Number hospitalized between baseline and Week 24 | Number hospitalized between Week 24 and Week 48 | Number hospitalized between Week 48 and Week 96 | Number hospitalized between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 2 | 5 | 5 | 1 |
| Nevirapine QD+BID | 8 | 6 | 5 | 9 |
(NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) | ||
|---|---|---|---|
| DAIDS 2 moderate | DAIDS 3 severe | DAIDS 4 potential lifethreatening | |
| Atazanvir/Ritonavir | 72 | 39 | 9 |
| Nevirapine BID | 84 | 28 | 15 |
| Nevirapine QD | 74 | 30 | 9 |
(NCT00389207)
Timeframe: at Week 48, 96, 144
| Intervention | participants (Number) | ||
|---|---|---|---|
| virologic failure at Week 48 | virologic failure at Week 96 | virologic failure at Week 144 | |
| Atazanvir/Ritonavir | 25 | 13 | 17 |
| Nevirapine BID | 25 | 25 | 28 |
| Nevirapine QD | 20 | 15 | 19 |
| Nevirapine QD+BID | 45 | 40 | 47 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 2 | 2 | 2 | 5 |
| Nevirapine BID | 2 | 3 | 6 | 6 |
| Nevirapine QD | 2 | 3 | 3 | 4 |
| Nevirapine QD+BID | 4 | 6 | 9 | 10 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 5 | 12 | 10 | 15 |
| Nevirapine BID | 2 | 5 | 6 | 9 |
| Nevirapine QD | 3 | 4 | 4 | 8 |
| Nevirapine QD+BID | 5 | 9 | 10 | 17 |
VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<400 copies /mL at Week 4 | Proportion with VL<400 copies /mL at Week 8 | Proportion with VL<400 copies /mL at Week 12 | Proportion with VL<400 copies /mL at Week 24 | Proportion with VL<400 copies /mL at Week 36 | Proportion with VL<400 copies /mL at Week 48 | Proportion with VL<400 copies /mL at Week 60 | Proportion with VL<400 copies /mL at Week 72 | Proportion with VL<400 copies /mL at Week 84 | Proportion with VL<400 copies /mL at Week 96 | Proportion with VL<400 copies /mL at Week 108 | Proportion with VL<400 copies /mL at Week 120 | Proportion with VL<400 copies /mL at Week 132 | Proportion with VL<400 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.287 | 0.679 | 0.834 | 0.956 | 0.966 | 0.977 | 0.988 | 0.988 | 0.994 | 0.987 | 1.000 | 0.994 | 0.993 | 0.986 |
| Nevirapine QD+BID | 0.365 | 0.714 | 0.856 | 0.924 | 0.968 | 0.985 | 0.993 | 0.996 | 0.988 | 1.000 | 0.996 | 1.000 | 0.996 | 0.991 |
VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<50 copies /mL at Week 4 | Proportion with VL<50 copies /mL at Week 8 | Proportion with VL<50 copies /mL at Week 12 | Proportion with VL<50 copies /mL at Week 24 | Proportion with VL<50 copies /mL at Week 36 | Proportion with VL<50 copies /mL at Week 48 | Proportion with VL<50 copies /mL at Week 60 | Proportion with VL<50 copies /mL at Week 72 | Proportion with VL<50 copies /mL at Week 84 | Proportion with VL<50 copies /mL at Week 96 | Proportion with VL<50 copies /mL at Week 108 | Proportion with VL<50 copies /mL at Week 120 | Proportion with VL<50 copies /mL at Week 132 | Proportion with VL<50 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.09 | 0.25 | 0.412 | 0.779 | 0.83 | 0.886 | 0.901 | 0.915 | 0.896 | 0.924 | 0.968 | 0.955 | 0.947 | 0.929 |
| Nevirapine QD+BID | 0.107 | 0.304 | 0.515 | 0.842 | 0.907 | 0.931 | 0.959 | 0.965 | 0.972 | 0.98 | 0.964 | 0.976 | 0.971 | 0.952 |
Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia) (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | patients (Number) | |
|---|---|---|
| Number with serum lipid abnormalities | Number without serum lipid abnormalities | |
| Atazanvir/Ritonavir | 4 | 189 |
| Nevirapine QD+BID | 9 | 367 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 143 | 50 |
| Nevirapine BID | 113 | 75 |
| Nevirapine QD | 121 | 67 |
| Nevirapine QD+BID | 234 | 142 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 126 | 67 |
| Nevirapine BID | 124 | 64 |
| Nevirapine QD | 126 | 62 |
| Nevirapine QD+BID | 250 | 126 |
Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 142 | 51 |
| Nevirapine QD+BID | 261 | 115 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96. (NCT00389207)
Timeframe: From baseline to Week 96
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 149 | 44 |
| Nevirapine BID | 122 | 66 |
| Nevirapine QD | 131 | 57 |
| Nevirapine QD+BID | 253 | 123 |
Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with tr.-emerg. AIDS-def.illness | Number without tr.-emerg. AIDS-def.illness | |
| Atazanvir/Ritonavir | 7 | 186 |
| Nevirapine QD+BID | 26 | 350 |
Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with AIDS-def. illness leading to death | Number without AIDS-def. illness leading to death | |
| Atazanvir/Ritonavir | 0 | 193 |
| Nevirapine QD+BID | 3 | 373 |
The change from baseline in CD4 cell count at Week 24 was analyzed. (NCT00892437)
Timeframe: Baseline to Week 24
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 200 |
| ATV+RTV+FTC/TDF | 202 |
The change from baseline in CD4 cell count at Week 48 was analyzed. (NCT00892437)
Timeframe: Baseline to Week 48
| Intervention | cells/μL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | 243 |
| ATV+RTV+FTC/TDF | 213 |
The change from baseline in log_10 HIV-1 RNA at Week 24 was analyzed. (NCT00892437)
Timeframe: Baseline to Week 24
| Intervention | log_10 copies/mL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | -2.80 |
| ATV+RTV+FTC/TDF | -2.97 |
The change from baseline in log_10 HIV-1 RNA at Week 48 was analyzed. (NCT00892437)
Timeframe: Baseline to Week 48
| Intervention | log_10 copies/mL (Mean) |
|---|---|
| ATV+COBI+FTC/TDF | -2.79 |
| ATV+RTV+FTC/TDF | -2.96 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed using the missing = failure method, where participants with missing data were considered to have failed to achieve the endpoint. (NCT00892437)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 84.0 |
| ATV+RTV+FTC/TDF | 89.7 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the missing = failure method. (NCT00892437)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| ATV+COBI+FTC/TDF | 82.0 |
| ATV+RTV+FTC/TDF | 89.7 |
(NCT00090779)
Timeframe: 96 weeks since randomization
| Intervention | participants (Number) |
|---|---|
| IT Arm | 2 |
| DT Arm | 8 |
The study provided fixed-dose combination emtricitabine/tenofovir DF 200/300 mg orally once daily and lopinavir/ritonavir 200/50 mg administered either as two tablets twice daily or four tablets once daily, for the first 36 weeks for individuals in the IT arm. (NCT00090779)
Timeframe: At Week 36
| Intervention | participants (Number) |
|---|---|
| IT Arm | 8 |
The clinical, virologic, or immunologic criteria for treatment initiation or re-initiation include CD4 count below 350 cells/mm^3 on two consecutive determinations at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, (2) confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, (3) confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or (4) CDC Category B or C diagnosis. (NCT00090779)
Timeframe: 96 weeks since randomization
| Intervention | Participants (Number) |
|---|---|
| IT Arm | 7 |
| DT Arm | 23 |
"The primary endpoint is (i) the average of log10 viral loads (VL) at wks 72 and 76 for participants who continued to wk 72 off ARV for the DT arm, (ii) average wk 72 and 76 VL for those who continued to wk 36 off ARV for the IT arm and (iii) an assigned VL rank for the failures who needed ARVs or met criteria for entry into Step 2 prior to these study visits. The assigned rank for the failures was either the last observed rank carried forward or the worst rank relative to the other possible outcomes. This approach was designed to, if anything, bias against finding a treatment effect. To illustrate, consider five participants who enter the study (A, B, C, D, and E), 4 of whom (A, B, C, D) make it to 72 wks off therapy with RNA levels that increase from A to D. Participant E enters Step 2 at wk 12, at which time his RNA is in the 50th percentile. This rank would be carried forward, so the rank order of the log10 HIV-1 RNA endpoints would be A B E C D." (NCT00090779)
Timeframe: At Weeks 72 and 76
| Intervention | rank (Median) |
|---|---|
| IT Arm | 26.0 |
| DT Arm | 49.3 |
"The primary endpoint is (i) average wk 36 and 40 VL for those who continued to wk 36 off ARV for the DT arm, (ii) average wk 72 and 76 VL for those who continued to wk 36 off ARV for the IT arm and (iii) an assigned VL rank for the failures who needed ARVs or met criteria for entry into Step 2 prior to these study visits. The assigned rank for the failures was either the last observed rank carried forward or the worst rank relative to the other possible outcomes. This approach was designed to, if anything, bias against finding a treatment effect. To illustrate, consider five participants who enter the study (A, B, C, D, and E), 4 of whom (A, B, C, D) make it to 72 wks off therapy with RNA levels that increase from A to D. Participant E enters Step 2 at wk 12, at which time his RNA is in the 50th percentile. This rank would be carried forward, so the rank order of the log10 HIV-1 RNA endpoints would be A B E C D." (NCT00090779)
Timeframe: IT arm (weeks 72 and 76) and DT arm ( weeks 36 and 40)
| Intervention | rank (Median) |
|---|---|
| IT Arm | 26.0 |
| DT Arm | 48.5 |
(NCT00090779)
Timeframe: IT arm (weeks 36, 60, 72, 84 and 96) and DT arm (weeks 0, 24, 36, 48 and 60)
| Intervention | Change in Log10 transformed CD4 Counts (Mean) | |||
|---|---|---|---|---|
| IT arm (wk 60- wk 36) vs. DT arm (wk 24- wk 0) | IT arm (wk 72- wk 36) vs. DT arm (wk 36- wk 0) | IT arm (wk 84- wk 36) vs. DT arm (wk 48- wk 0) | IT arm (wk 96- wk 36) vs. DT arm (wk 60- wk 0) | |
| DT Arm | -0.02 | -0.03 | -0.06 | -0.02 |
| IT Arm | -0.11 | -0.10 | -0.10 | -0.12 |
5th, 10th, 25th, 50th, 75th and 90th percentiles in weeks from randomization for DT arm or from week 36 for IT arm to meeting the criteria for treatment initiation or re-initiation which include two consecutive CD4 count below 350 cells/mm^3 at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or CDC Category B or C diagnosis. (NCT00090779)
Timeframe: 96 weeks since randomization
| Intervention | weeks (Number) | |||||
|---|---|---|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | 50th percentile | 75th percentile | 90th percentile | |
| DT Arm | 6.9 | 12.3 | 26.3 | 60.0 | 96.0 | 96.0 |
| IT Arm | 5.1 | 10.4 | 22.7 | 58.1 | NA | NA |
5th, 10th, 25th, 50th, 75th and 90th percentiles in weeks from randomization to meeting the criteria for treatment initiation or re-initiation which include CD4 count below 350 cells/mm^3 on two consecutive measurements at least 4 weeks apart, at least 12 weeks into the study or 12 weeks post-treatment discontinuation, confirmed CD4 count below 200 cells/mm^3 or CD4 percent below 14% at any time on study, confirmed HIV-1 RNA level above 750,000 copies/mL 4 weeks into the study or above 200,000 copies/mL 12 weeks or more into the study, or CDC Category B or C diagnosis. (NCT00090779)
Timeframe: 96 weeks since randomization
| Intervention | weeks (Number) | |||||
|---|---|---|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | 50th percentile | 75th percentile | 90th percentile | |
| DT Arm | 6.9 | 12.3 | 26.3 | 60.0 | 96.0 | 96.0 |
| IT Arm | 6.3 | 13.0 | 36.4 | 72.0 | NA | NA |
5th, 10th, 25th, 50th and 75th percentiles in weeks from randomization to treatment initiation or death (NCT00090779)
Timeframe: 5 years since randomization
| Intervention | weeks (Number) | ||||
|---|---|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | 50th percentile | 75th percentile | |
| DT Arm | 13.9 | 20.9 | 43.7 | 97.3 | 157.7 |
| IT Arm | 36 | 36.9 | 67.1 | 96.4 | 163.3 |
Of participants that were evaluable at 3 months post initiation of treatment, how many became HIV-1 infected (NCT00594646)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
Pill counts performed at 14 and 28 days (NCT00594646)
Timeframe: 28 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Completed as prescribed | Stopped or Modified regimen | Lost to follow-up | |
| Group 1 | 57 | 28 | 15 |
Subcutaneous abdominal fat mitochondrial DNA (mtDNA) (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | copies/cell (Median) |
|---|---|
| Uridine Supplementation | -169 |
| Switch to TDF | 321 |
Change in hip bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | hip BMD, g/cm^2 (Median) |
|---|---|
| Uridine Supplementation | 0.45 |
| Switch to TDF | -3.3 |
Change in limb fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | limb fat (kg) (Median) |
|---|---|
| Uridine Supplementation | 0.1 |
| Switch to TDF | 0.4 |
Change in lumbar spine bone mineral density (BMD) as measured by dual-energy x-ray absorbtiometry (DEXA) scan (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | lumbar spine BMD, g/cm^2 (Median) |
|---|---|
| Uridine Supplementation | 0.39 |
| Switch to TDF | 0.0 |
Peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA), measured in copies/cell (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | copies/cell (Median) |
|---|---|
| Uridine Supplementation | -24 |
| Switch to TDF | -52 |
Change in trunk fat as measured by dual-energy x-ray absorbtiometry (DEXA) scan (NCT00119379)
Timeframe: Baseline to Week 48
| Intervention | trunk fat (kg) (Median) |
|---|---|
| Uridine Supplementation | 0.2 |
| Switch to TDF | 0.7 |
Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product (NCT02006264)
Timeframe: 14 days of vaginal ring use
| Intervention | Adverse events (Number) |
|---|---|
| TDF Intravaginal Ring | 7 |
| Placebo Intravaginal Ring | 1 |
Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period (NCT02006264)
Timeframe: 14 days of vaginal ring use
| Intervention | Adverse events (Number) |
|---|---|
| TDF Intravaginal Ring | 2 |
| Placebo Intravaginal Ring | 0 |
TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
| Intervention | ng/mg (Median) |
|---|---|
| TDF Intravaginal Ring | 5.4 |
TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
| Intervention | fmol/mg (Median) |
|---|---|
| TDF Intravaginal Ring | 120 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | ng/mL (Median) | ||||
|---|---|---|---|---|---|
| C-max CVF VAG TDF | C-max CVF ECX TDF | C-max CVF VAG TFV | C-max CVF ECX TFV | C-max Plasma TFV | |
| TDF Intravaginal Ring | 240000 | 210000 | 91000 | 85000 | 1.9 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | h (Median) | ||||
|---|---|---|---|---|---|
| T-max CVF VAG TDF | T-max CVF ECX TDF | T-max CVF VAG TFV | T-max CVF ECX TFV | T-max Plasma TFV | |
| TDF Intravaginal Ring | 6 | 5 | 14 | 7 | 14 |
TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | ngxd/mL (Median) | ||||
|---|---|---|---|---|---|
| AUC0-14 (days 0-14), CVF VAG TDF | AUC0-14 (days 0-14), CVF ECX TDF | AUC0-14 (days 0-14), CVF VAG TFV | AUC0-14 (days 0-14), CVF ECX TFV | AUC0-14 (days 0-14), Plasma TFV | |
| TDF Intravaginal Ring | 2000000 | 1300000 | 1100000 | 970000 | 9.4 |
(NCT01106586)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 86.1 |
| ATV/r + FTC/TDF | 84.8 |
(NCT01106586)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 91.5 |
| ATV/r + FTC/TDF | 88.5 |
(NCT01106586)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 77.6 |
| ATV/r + FTC/TDF | 74.6 |
(NCT01106586)
Timeframe: Week 192
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 78.4 |
| ATV/r + FTC/TDF | 73.1 |
(NCT01106586)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 83.3 |
| ATV/r + FTC/TDF | 82.3 |
(NCT01106586)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 89.5 |
| ATV/r + FTC/TDF | 86.8 |
Change = value of the relevant time point minus the baseline value (NCT01106586)
Timeframe: Baseline; Weeks 48, 96, 144, and 192
| Intervention | cells/µL (Mean) | |||
|---|---|---|---|---|
| Change at Wk 48 (Stribild, n=334; ATV/r, n=321) | Change at Wk 96 (Stribild, n=317; ATV/r, n=315) | Change at Wk 144 (Stribild, n=297; ATV/r, n=286) | Change at Wk 192 (Stribild, n=69; ATV/r, n=72) | |
| ATV/r + FTC/TDF | 211 | 261 | 293 | 340 |
| Stribild | 207 | 256 | 280 | 338 |
(NCT01095796)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 85.9 |
| Atripla | 83.2 |
(NCT01095796)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 88.8 |
| Atripla | 85.5 |
(NCT01095796)
Timeframe: Week 144
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 80.2 |
| Atripla | 75.3 |
(NCT01095796)
Timeframe: Week 192
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 76.1 |
| Atripla | 78.1 |
(NCT01095796)
Timeframe: Week 96
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 84.2 |
| Atripla | 81.5 |
(NCT01095796)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Stribild | 87.6 |
| Atripla | 84.1 |
Change = value of the relevant time point minus the baseline value (NCT01095796)
Timeframe: Baseline; Weeks 48, 96, 144, and 192
| Intervention | cells/µL (Mean) | |||
|---|---|---|---|---|
| Change at Wk 48 (Stribild, n=325; Atripla, n=315) | Change at Wk 96 (Stribild, n=307; Atripla, n=302) | Change at Wk 144 (Stribild, n=294; Atripla, n=283) | Change at Wk 192 (Stribild, n=62; Atripla, n=69) | |
| Atripla | 206 | 273 | 300 | 328 |
| Stribild | 239 | 295 | 321 | 360 |
(NCT00592124)
Timeframe: Measured through Week 21
| Intervention | Participants (Count of Participants) |
|---|---|
| Vaginal and Oral Tenofovir | 5 |
| Oral Tenofovir | 5 |
| Vaginal Tenofovir | 3 |
Median and inter-quartile range of the time between product usage and instance of vaginal intercourse (given gel was used before the encounter). (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | minutes (Median) |
|---|---|
| Vaginal and Oral Tenofovir | 60.0 |
| Vaginal Tenofovir | 60.0 |
Median and inter-quartile range of the time between product usage and instance of vaginal intercourse (given tablet was used before the encounter). (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | minutes (Median) |
|---|---|
| Vaginal and Oral Tenofovir | 60.0 |
| Oral Tenofovir | 90.0 |
Median and inter-quartile range of the time between product usage and instance of vaginal intercourse (given gel was used after the encounter). (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | minutes (Median) |
|---|---|
| Vaginal and Oral Tenofovir | 75.0 |
| Vaginal Tenofovir | 120.0 |
Median and inter-quartile range of the time between product usage and instance of vaginal intercourse (given tablet was used after the encounter). (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | minutes (Median) |
|---|---|
| Vaginal and Oral Tenofovir | 90.0 |
| Oral Tenofovir | 120.0 |
This represents the longest number of days in a row during the past 3 weeks that a participant missed using the study product. (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | days (Mean) |
|---|---|
| Vaginal and Oral Tenofovir | 0.9 |
| Oral Tenofovir | 0.9 |
| Vaginal Tenofovir | 0.9 |
Number and percentage of participants who had a product sharing event during the 6-week product use period, where a sharing event includes 1) being asked for the study product, or 2) selling, trading, or giving away study product, or 3) having someone take the study product from the participant. (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | Participants (Count of Participants) |
|---|---|
| Vaginal and Oral Tenofovir | 2 |
| Oral Tenofovir | 0 |
| Vaginal Tenofovir | 3 |
Participant self-reported product use. For each woman, adherence to each regimen was computed by dividing the number of daily doses she reported having taken by the number of doses expect if she were fully adherent. (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | percentage of expected doses (Mean) |
|---|---|
| Vaginal and Oral Tenofovir | 94 |
| Oral Tenofovir | 93.8 |
| Vaginal Tenofovir | 93.9 |
PK measures, including maximum concentrations (Cmax) in serum, tissue, and cervicovaginal lavage. (NCT00592124)
Timeframe: Measured through Week 21
| Intervention | ng/mL, ng/mg, ng/mL (Median) | ||
|---|---|---|---|
| Serum TFV Cmax | Tissue TFV | Cervicovaginal lavage | |
| Oral Tenofovir | 332 | 0.15 | 5380 |
| Vaginal and Oral Tenofovir | 337 | 104 | 1600000 |
| Vaginal Tenofovir | 3.9 | 113 | 3100000 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| TVD + PI/r | -0.026 |
| ABC/3TC + PI/r | 0.225 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mL/min (Mean) |
|---|---|
| TVD + PI/r | -8.4 |
| ABC/3TC + PI/r | -4.1 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| TVD + PI/r | -9.0 |
| ABC/3TC + PI/r | -3.7 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| TVD + PI/r | 1 |
| ABC/3TC + PI/r | 1 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| TVD + PI/r | -4 |
| ABC/3TC + PI/r | 14 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | cells/microliter (Mean) |
|---|---|
| TVD + PI/r | 8 |
| ABC/3TC + PI/r | 34 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | Ratio (Mean) |
|---|---|
| TVD + PI/r | -0.1 |
| ABC/3TC + PI/r | -0.1 |
The percentage of participants with HIV-1 RNA < 200 copies/mL based on TLOVR algorithm at Week 48 was summarized. Participants were considered nonresponders in the TLOVR analysis if they experienced virologic rebound prior to or at Week 48, discontinued study before Week 48, or added a new antiretroviral (ARV) agent prior to completion of the study. Virologic rebound was defined as 2 consecutive HIV-1 RNA values >= 200 copies/mL or the last HIV-1 RNA value >= 200 copies/mL followed by discontinuation from the study. (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| TVD + PI/r | 86.4 |
| ABC/3TC + PI/r | 83.3 |
The percentage of participants with PVR for HIV-1 RNA cutoff at 200 copies/mL at Week 48 was summarized. Pure virologic response was the percentage of subjects who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values >= 200 copies/mL or the last HIV-1 RNA value >= 200 copies/mL followed by discontinuation from the study. (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| TVD + PI/r | 99.2 |
| ABC/3TC + PI/r | 97.2 |
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. Pure virologic response was the proportion of participants who did not have a virologic rebound. Virologic rebound was defined as two consecutive HIV-1 RNA values >= 50 copies/mL or the last HIV-1 RNA value >= 50 copies/mL followed by discontinuation from the study. (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| TVD + PI/r | 93.0 |
| ABC/3TC + PI/r | 91.1 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Total Cholesterol | LDL (low-density lipoprotein) | HDL (high-density lipoprotein) | Triglycerides | |
| ABC/3TC + PI/r | -4 | 2 | 0 | -23 |
| TVD + PI/r | -21 | -6 | -2 | -51 |
Change = Week 48 value minus baseline value (NCT00724711)
Timeframe: Baseline to 48 weeks
| Intervention | pg/mL (Mean) | ||
|---|---|---|---|
| IL-10 | IL-6 | TNF-alpha | |
| ABC/3TC + PI/r | -0.2 | -0.6 | 4.7 |
| TVD + PI/r | 0.0 | -0.2 | 0.0 |
The percentage of participants with HIV-1 RNA < 200 copies/mL at Week 48 was summarized. (NCT00724711)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| On-Treatment Response Analysis (Missing = Failure) | Snapshot Responder Analysis (Virologic Success) | |
| ABC/3TC + PI/r | 82.1 | 82.1 |
| TVD + PI/r | 84.4 | 84.4 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 48 was summarized. (NCT00724711)
Timeframe: 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| TLOVR Responder Analysis | On-Treatment Response Analysis (Missing = Failure) | Snapshot Responder Analysis (Virologic Success) | |
| ABC/3TC + PI/r | 76.3 | 77.6 | 77.6 |
| TVD + PI/r | 77.9 | 79.9 | 79.9 |
"HBV DNA carries the genetic blueprint of the virus. How many HBV DNA particles or copies are found in the blood indicates how rapidly the virus is reproducing in the liver." (NCT00662545)
Timeframe: week 24
| Intervention | log 10 IU/ml (Median) |
|---|---|
| Entecavir Intensification | 2.4 |
| Standard of Care | 0.8 |
(NCT00662545)
Timeframe: entry, week 12, and week 24
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 5 |
| Standard of Care | 5 |
ALT flare: sudden increase in blood level of alanine transaminase (ALT) (NCT00662545)
Timeframe: every 4 weeks for 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
(NCT00662545)
Timeframe: every 4 weeks for 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
(NCT00662545)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Entecavir Intensification | 0 |
| Standard of Care | 0 |
(NCT00039741)
Timeframe: Randomization to 4 years
| Intervention | CD4 percent (% of total lymphocytes) (Mean) |
|---|---|
| Drug Class/PI | 13.7 |
| Drug Class/NNRTI | 15.2 |
| Switch Point (1K) | 15.1 |
| Switch Point (30K) | 13.9 |
(NCT00039741)
Timeframe: Baseline visit and 4 years after Study Entry
| Intervention | log10 HIV-1 RNA (Mean) |
|---|---|
| Drug Class/PI | -3.16 |
| Drug Class/NNRTI | -3.31 |
| Switch Point (1K) | -3.26 |
| Switch Point (30K) | -3.20 |
(NCT00039741)
Timeframe: Week 204
| Intervention | participants (Number) |
|---|---|
| Drug Class/PI | 92 |
| Drug Class/NNRTI | 93 |
| Switch Point (1K) | 95 |
| Switch Point (30K) | 90 |
(NCT00039741)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Drug Class/PI | 92 |
| Drug Class/NNRTI | 98 |
| Switch Point (1K) | 99 |
| Switch Point (30K) | 91 |
(NCT00039741)
Timeframe: Up to 6 yrs. (average 4.85 yrs.)
| Intervention | participants (Number) |
|---|---|
| Drug Class/PI | 6 |
| Drug Class/NNRTI | 4 |
| Switch Point (1K) | 5 |
| Switch Point (30K) | 5 |
"Adverse events were graded according to the following guidelines:~PACTG: The Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual) dated May 6, 2004.~PENTA: International Conference for Harmonization (ICH) requirements and the EU Clinical Trials Directive 2001/20/EC (20).~A rating of Grade 3 is severe and Grade 4 is life-threatening. The rate of serious (Grade 3 or above)events is reported as the number of events per 100 child/years." (NCT00039741)
Timeframe: Up to 6 yrs. (average 4.85 yrs.)
| Intervention | events/100 child-years (Mean) |
|---|---|
| Drug Class/PI | 0.16 |
| Drug Class/NNRTI | 0.17 |
| Switch Point (1K) | 0.16 |
| Switch Point (30K) | 0.17 |
25th Percentiles in weeks from randomization to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy (NCT00039741)
Timeframe: Up to 6 yrs. (average 4.85 yrs.)
| Intervention | Weeks (25th Percentile) (Number) |
|---|---|
| Drug Class/PI | 126 |
| Drug Class/NNRTI | 267 |
| Switch Point (1K) | 267 |
| Switch Point (30K) | 228 |
25th Percentiles in weeks from randomization HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy. (NCT00039741)
Timeframe: Up to 6 yrs. (average 4.85 yrs.)
| Intervention | Weeks (25th Percentile) (Number) |
|---|---|
| Drug Class/PI | 36 |
| Drug Class/NNRTI | 68 |
| Switch Point (1K) | 41 |
| Switch Point (30K) | 72 |
25th Percentiles in weeks from randomization to starting an alternative class ART regimen (based on initial randomized regimen) (NCT00039741)
Timeframe: Up to 6 yrs. (average 4.85 yrs.)
| Intervention | Weeks (25th Percentile) (Median) |
|---|---|
| Drug Class/PI | NA |
| Drug Class/NNRTI | NA |
| Switch Point (1K) | NA |
| Switch Point (30K) | NA |
"Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004, Clarification August 2009, which is available on the RCC website at (http://rcc.tech-res.com/). Adverse Events of Grade 3 or 4 laboratory abnormalities or signs and symptoms that were judged by the study team to be possibly or probably related to the study treatment.~Comparisons between age groups were not required as per protocol." (NCT00016718)
Timeframe: At study entry, weeks 2 and 4, every 4 weeks up to week 96 and every 6 weeks thereafter for Group 1 participants and at study entry, weeks 2 and 4, every 4 weeks up to week 144 and every 12 weeks thereafter for Groups 2 and 3
| Intervention | proportion of participants (Number) |
|---|---|
| Age Group 1 | 0.17 |
| Age Group 2 | 0.1 |
| Age Group 3 | 0.19 |
Proportion was calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00016718)
Timeframe: At week 16
| Intervention | proportion of participants (Number) |
|---|---|
| Age Group 1 | 0.83 |
| Age Group 2 | 0.86 |
| Age Group 3 | 0.81 |
Proportion was calculated as number of participants with HIV-1 RNA <= 50 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00016718)
Timeframe: At week 16
| Intervention | proportion of participants (Number) |
|---|---|
| Age Group 1 | 0.50 |
| Age Group 2 | 0.76 |
| Age Group 3 | 0.75 |
The per-protocol analysis of change in CD4+ cell count from baseline to Week 24 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% confidence interval (CI). (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 156 |
The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 48 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 163 |
The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 96 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 224 |
Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | ratio of trunk fat % : lower limb fat % (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.02 |
Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | ratio of trunk fat % : lower limb fat % (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.06 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | -0.08 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.71 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.23 |
This secondary outcome measure assessed the ratio of semen:plasma concentration of etravirine in paired semen and plasma samples collected from 14 male participants at Week 4 of treatment with etravirine and fixed dose tenofovir/emtricitabine. (NCT00959894)
Timeframe: 4 weeks
| Intervention | ratio of semen:plasma drug concentration (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.192 |
Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks
| Intervention | ng*hr/mL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 8024.40 |
The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring). (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.69 |
The primary study endpoint was the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 24 of study participation. The per-protocol primary analysis was conducted intention-to-treat, with missing evaluations counted as failures. Achievement of HIV-1 viral load below 50 copies/ml was defined as having HIV-1 RNA <50 copies/ml during the Week 24 analysis window (>18 and <30 weeks post-entry). (NCT00959894)
Timeframe: 24 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.87 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 24 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 24 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.89 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.82 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA 200 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.77 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.77 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.71 |
Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | percentage of body fat (Median) | ||
|---|---|---|---|
| Total body fat | Limb fat | Trunk fat | |
| Etravirine 400 mg Once Daily | 0.43 | 0.48 | 0.32 |
Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | percentage of body fat (Median) | ||
|---|---|---|---|
| Total body fat | Limb fat | Trunk fat | |
| Etravirine 400 mg Once Daily | 1.44 | 0.82 | 1.93 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | -7 | 1 | -9 | -16 | 1 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | 6 | 5 | -1 | -10 | 2 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | 6 | 4 | -5 | 3 | 2 |
Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks
| Intervention | ng/mL (Median) | |
|---|---|---|
| Etravirine trough plasma concentration | Etravirine peak plasma concentration | |
| Etravirine 400 mg Once Daily | 217.47 | 480.99 |
Per-protocol, genotype testing was conducted at confirmation of virologic failure if the confirmatory HIV-1 RNA was above the laboratory-specified threshold of 500 copies/mL. HIV-1 genotype was determined using the TRUGENE® HIV-1 assay (Siemens Healthcare Diagnostics, Tarrytown, NY) (NCT00959894)
Timeframe: 96 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Y181C | E138K | E138K, Y181C, M230L, M184I, K219E, V75I | No resistance-associated mutations detected | |
| Etravirine 400 mg Once Daily | 1 | 1 | 1 | 3 |
"The safety/tolerability endpoint was defined as the first grade 3 or higher sign, symptom or laboratory abnormality that was at least one grade higher than baseline among participants ever exposed to etravirine (regardless of treatment status), or permanent discontinuation of etravirine due to any toxicity (regardless of grade). Modification of tenofovir/emtricitabine was not a safety/tolerability event.~The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring)." (NCT00959894)
Timeframe: 96 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| At least one safety/tolerability event | Signs or Symptoms | Laboratory Abnormalities | |
| Etravirine 400 mg Once Daily | 23 | 13 | 10 |
Change from baseline to Week 240 (Atripla Week 96) in CD4 cell count = Week 240 (Atripla Week 96) CD4 cell count value minus baseline CD4 cell count value (NCT00112047)
Timeframe: Study/Atripla baseline to Week 240 (Atripla Week 96)
| Intervention | CD4 Cell count (Cells/mm^3) (Mean) |
|---|---|
| EFV+FTC+TDF/Atripla (From Study Baseline) | 346 |
| All Atripla (From Atripla Baseline) | 42 |
Change from study baseline to Week 144 in CD4 cell count = Week 144 CD4 cell count value minus study baseline CD4 cell count value (NCT00112047)
Timeframe: Baseline to Week 144
| Intervention | CD4 Cell Count (cells/mm^3) (Mean) |
|---|---|
| EFV+FTC+TDF | 312 |
| CBV+EFV | 271 |
Change from study baseline to Week 48 in CD4 cell count = Week 48 CD4 cell count value minus study baseline CD4 cell count value (NCT00112047)
Timeframe: Study baseline to Week 48
| Intervention | CD4 Cell Count (cells/mm^3) (Mean) |
|---|---|
| EFV+FTC+TDF | 190 |
| CBV+EFV | 158 |
Change from study baseline to Week 96 in CD4 cell count = Week 96 CD4 cell count value minus study baseline CD4 cell count value (NCT00112047)
Timeframe: Baseline to Week 96
| Intervention | CD4 Cell Count (cells/mm^3) (Mean) |
|---|---|
| EFV+FTC+TDF | 270 |
| CBV+EFV | 237 |
Change from study baseline to Week 144 in HIV-1 RNA in log10 scale (Week 144 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale). (NCT00112047)
Timeframe: Study baseline to Week 144
| Intervention | Log10 c/mL (Mean) |
|---|---|
| EFV+FTC+TDF | -3.32 |
| CBV+EFV | -3.30 |
Change from study baseline to Week 48 in HIV-1 RNA in log10 scale (Week 48 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale). (NCT00112047)
Timeframe: Study baseline to Week 48
| Intervention | Log10 c/mL (Mean) |
|---|---|
| EFV+FTC+TDF | -3.31 |
| CBV+EFV | -3.26 |
Change from study baseline to Week 96 in HIV-1 RNA in log10 scale (Week 96 HIV-1 RNA value in log10 scale minus study baseline HIV-1 RNA value in log10 scale). (NCT00112047)
Timeframe: Study baseline to Week 96
| Intervention | Log10 c/mL (Mean) |
|---|---|
| EFV+FTC+TDF | -3.30 |
| CBV+EFV | -3.25 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in limb fat = Week 240 (Atripla Week 96) limb fat value minus Week 144 (Atripla Baseline) limb fat value (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | limb fat (kg) (Mean) |
|---|---|
| All Atripla | 0.12 |
Change from Week 48 to Week 144 in limb fat = Week 144 limb fat value minus Week 48 limb fat value (NCT00112047)
Timeframe: Week 48 to Week 144
| Intervention | limb fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 1.13 |
| CBV+EFV | -1.09 |
Change from Week 48 to Week 96 in limb fat = Week 96 limb fat value minus Week 48 limb fat value. (NCT00112047)
Timeframe: Week 48 to Week 96
| Intervention | limb fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 0.74 |
| CBV+EFV | -0.77 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in total body fat = Week 240 (Atripla Week 96) total body fat value minus Week 144 (Atripla Baseline) total body fat value (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | total body fat (kg) (Mean) |
|---|---|
| All Atripla | 0.37 |
Change from Week 48 to Week 144 in total body fat = Week 144 total body fat value minus Week 48 total body fat value (NCT00112047)
Timeframe: Week 48 to Week 144
| Intervention | total body fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 2.47 |
| CBV+EFV | -1.18 |
Change from Week 48 to Week 96 in total body fat = Week 96 total body fat value minus Week 48 total body fat value (NCT00112047)
Timeframe: 48 weeks to 96 weeks
| Intervention | total body fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 1.69 |
| CBV+EFV | -0.82 |
Change from Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96) in trunk fat = Week 240 (Atripla Week 96) trunk fat value minus Week 144 (Atripla Baseline) trunk fat value (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | trunk fat (kg) (Mean) |
|---|---|
| All Atripla | 0.27 |
Change from Week 48 to Week 144 in trunk fat = Week 144 trunk fat value minus Week 48 trunk fat value (NCT00112047)
Timeframe: Week 48 to Week 144
| Intervention | trunk fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 1.30 |
| CBV+EFV | -0.10 |
Change from Week 48 to Week 96 in trunk fat = Week 96 trunk fat value minus Week 48 trunk fat value (NCT00112047)
Timeframe: Week 48 to Week 96
| Intervention | trunk fat (kg) (Mean) |
|---|---|
| EFV+FTC+TDF | 0.94 |
| CBV+EFV | -0.04 |
Participants who achieved/maintained confirmed HIV-1 RNA < 400 c/mL had to satisfy the following: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA < 400 c/mL on 2 consecutive visits prior to Week 144 visit (i.e., the first of the 2 consecutive HIV-1 RNA < 400 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA > 400 c/mL after achievement of confirmed HIV-1 RNA levels < 400 c/mL prior to Week 144 visit. (NCT00112047)
Timeframe: 144 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 70.9 |
| CBV+EFV | 58.1 |
Participants who achieved/maintained confirmed HIV-1 RNA < 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA < 400 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA < 400 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA > 400 c/mL after achievement of confirmed HIV RNA levels < 400 c/mL prior to Week 240 visit. (NCT00112047)
Timeframe: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| All Atripla | 87 |
Participants who achieved/maintained confirmed HIV-1 RNA < 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA < 400 c/mL on 2 consecutive visits prior to Week 48 visit (ie, the first of the 2 consecutive HIV-1 RNA < 400 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA > 400 c/mL after achievement of confirmed HIV RNA levels < 400 c/mL prior to Week 48 visit. (NCT00112047)
Timeframe: 48 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| EFV+FTC+TDF | 84.4 |
| CBV+EFV | 72.8 |
Participants who achieved/maintained confirmed HIV-1 RNA < 400 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA < 400 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA < 400 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA > 400 c/mL after achievement of confirmed HIV RNA levels < 400 c/mL prior to Week 96 visit. (NCT00112047)
Timeframe: 96 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 74.6 |
| CBV+EFV | 61.9 |
Participants who achieved/maintained confirmed HIV-1 RNA < 50 c/mL (c/mL) had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug, except nevirapine in place of EFV, prior to Week 144 visit; 2) achieved confirmed HIV-1 RNA < 50 c/mL on 2 consecutive visits prior to Week 144 visit (that is, the first of the 2 consecutive HIV-1 RNA < 50 c/mL occurred prior to the Week 144 visit; 3) not had confirmed HIV-1 RNA > 50 c/mL after achievement of confirmed HIV-1 RNA levels < 50 c/mL prior to Week 144 visit. (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of participants (Number) |
|---|---|
| EFV+FTC+TDF | 64.3 |
| CBV+EFV | 56.3 |
Participants who achieved/maintained confirmed HIV-1 RNA < 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 240 visit; 2) achieved confirmed HIV-1 RNA < 50 c/mL on 2 consecutive visits prior to Week 240 visit (that is, the first of the 2 consecutive HIV-1 RNA < 50 c/mL occurred prior to the Week 240 visit; 3) not had confirmed HIV-1 RNA > 50 c/mL after achievement of confirmed HIV RNA levels < 50 c/mL prior to Week 240 visit. (NCT00112047)
Timeframe: Week 144 (Atripla baseline) to Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| All Atripla | 85 |
Participants who achieved/maintained confirmed HIV-1 RNA < 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 48 visit; 2) achieved confirmed HIV-1 RNA < 50 c/mL on 2 consecutive visits prior to Week 48 visit (that is, the first of the 2 consecutive HIV-1 RNA < 50 c/mL occurred prior to the Week 48 visit; 3) not had confirmed HIV-1 RNA > 50 c/mL after achievement of confirmed HIV RNA levels < 50 c/mL prior to Week 48 visit. (NCT00112047)
Timeframe: Week 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 79.5 |
| CBV+EFV | 70.4 |
Participants who achieved/maintained confirmed HIV-1 RNA < 50 c/mL had to satisfy the following criteria: 1) not experienced death, permanent study drug discontinuation, or addition of new antiretroviral drug except nevirapine in place of EFV prior to Week 96 visit; 2) achieved confirmed HIV-1 RNA < 50 c/mL on 2 consecutive visits prior to Week 96 visit (that is, the first of the 2 consecutive HIV-1 RNA < 50 c/mL occurred prior to the Week 96 visit; 3) not had confirmed HIV-1 RNA > 50 c/mL after achievement of confirmed HIV RNA levels < 50 c/mL prior to Week 96 visit. (NCT00112047)
Timeframe: Week 96
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 67.2 |
| CBV+EFV | 60.9 |
The percentage of participants with plasma HIV-1 RNA < 50 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: 48 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 74.5 |
| CBV+EFV | 66.9 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 28 |
| CBV+EFV | 41 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Baseline to 48 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 19 |
| CBV+EFV | 30 |
TLOVR for participants with confirmed virologic response (2 consecutive HIV-1 RNA < 400 c/mL) prior to study drug discontinuation, was the time to the earliest of premature study regimen discontinuation, or confirmed HIV-1 RNA > 400 c/mL (2 consecutive HIV-1 RNA ≥ 400 c/mL, or the last HIV-1 RNA ≥ 400 c/mL followed by premature study regimen discontinuation due to loss to follow-up). Participants who did not achieve confirmed virologic response before premature study regimen discontinuation or last HIV-1 RNA, were assumed to have lost virologic response on Study Day 1. (NCT00112047)
Timeframe: Week 96
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 25 |
| CBV+EFV | 37 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 400 c/mL or last HIV-1 RNA ≥ 400 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 400 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| All Atripla | 13 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 34 |
| CBV+EFV | 43 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Baseline to 48 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 23 |
| CBV+EFV | 32 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Week 96
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 32 |
| CBV+EFV | 38 |
"TLOVR for participants who achieved a confirmed virologic response was the time to the earliest of: premature study regimen discontinuation or the first of 2 consecutive HIV-1 RNA ≥ 50 c/mL or last HIV-1 RNA ≥ 50 c/mL followed by loss to follow-up. If the time to HIV-1 RNA ≥ 50 c/mL was immediately preceded by missing scheduled visits then the time of virologic failure was replaced by the first such missing visit. Participants who had not achieved a confirmed virologic response before regimen discontinuation were considered non-responders on Study Day 1." (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| All Atripla | 15 |
The percentage of participants with plasma HIV-1 RNA < 400 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 63.1 |
| CBV+EFV | 51.6 |
The percentage of participants with plasma HIV-1 RNA < 400 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF/Atripla (From Study Baseline) | 87 |
| All Atripla (From Atripla Baseline) | 85 |
The percentage of participants with plasma HIV-1 RNA < 400 c/mL at Week 48. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 400 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: 48 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 80.4 |
| CBV+EFV | 69.3 |
The percentage of participants with plasma HIV-1 RNA < 50 c/mL at Week 144. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 60.8 |
| CBV+EFV | 50.4 |
The percentage of participants with plasma HIV-1 RNA < 50 c/mL at Week 240. Participants with missing observations/changes in ART were considered to have HIV-1 RNA ≥ 50 c/mL (i.e., ITT missing or switch=failure analysis). (NCT00112047)
Timeframe: Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF/Atripla (From Study Baseline) | 84 |
| All Atripla (From Atripla Baseline) | 82 |
Participants who achieved confirmed HIV-1 RNA < 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Baseline to 48 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 9 |
| CBV+EFV | 16 |
Participants who achieved confirmed HIV-1 RNA < 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 96
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 9 |
| CBV+EFV | 17 |
Participants who achieved confirmed HIV-1 RNA < 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Baseline to 48 Weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| EFV+FTC+TDF | 16 |
| CBV+EFV | 24 |
Participants who achieved confirmed HIV-1 RNA < 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 96
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 20 |
| CBV+EFV | 23 |
Participants who achieved confirmed HIV-1 RNA < 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of participants (Number) |
|---|---|
| EFV+FTC+TDF | 11 |
| CBV+EFV | 17 |
Participants who achieved confirmed HIV-1 RNA < 400 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF/Atripla (From Study Baseline) | 11 |
| All Atripla (From Atripla Baseline) | 2 |
Participants who achieved confirmed HIV-1 RNA < 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 144
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF | 21 |
| CBV+EFV | 25 |
Participants who achieved confirmed HIV-1 RNA < 50 c/mL but had not experienced a confirmed relapse were considered censored at the last HIV-1 RNA collection date. (NCT00112047)
Timeframe: Week 240 (Atripla Week 96)
| Intervention | Percentage of Participants (Number) |
|---|---|
| EFV+FTC+TDF/Atripla (From Study Baseline) | 22 |
| All Atripla (From Atripla Baseline) | 4 |
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey MCS. The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the MCS. PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and a SD of 10 (in the general population). (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | Composite Score (Mean) |
|---|---|
| All Atripla | 0.9 |
The change from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) in the SF-12v2 Health Survey: Physical Component Summary (PCS). The SF-12v2 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health. Results are expressed in terms of 2 composite scores: the PCS and the Mental Component Summary (MCS). PCS and MCS values can range from 0 to 100 and are designed to have a mean value of 50 and SD of 10 (in the general population). (NCT00112047)
Timeframe: Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)
| Intervention | Composite Score (Mean) |
|---|---|
| All Atripla | 0.0 |
"Participants were asked: How bothered are you with the side effects of your current treatment regimen? Possible responses were on a 4-category scale: does not bother me; bothers me a little bit; bothers me a lot; and bothers me terribly. For the evaluation of the change in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into does not bother me and bothers me (bothers me included bothers me a little bit; bothers me a lot; bothers me terribly)." (NCT00112047)
Timeframe: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Bothers me (W 144 and W 240) | Does not bother me (W 144 and W 240) | Bothers me (W 144); does not bother me (W 240) | Does not bother me (W 144); bothers me (W 240) | |
| All Atripla | 41 | 126 | 31 | 28 |
"Participants were asked: In general, how satisfied are you with your current treatment regimen? Possible responses were on a 4-category scale: very satisfied; somewhat satisfied; somewhat dissatisfied; and very dissatisfied. For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into very satisfied and not very satisfied (not very satisfied included very dissatisfied; somewhat dissatisfied; and somewhat satisfied)." (NCT00112047)
Timeframe: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Very satisfied (W 144 and W 240) | Not very satisfied (W 144 and W 240) | Very satisfied (W 144); not very satisfied (W 240) | Not very satisfied (W 144); very satisfied (W 240) | |
| All Atripla | 180 | 10 | 9 | 23 |
"Participants were asked: In general, how satisfied are you with the convenience and simplicity of your current treatment regimen? Possible responses were on a 4-category scale: very satisfied; somewhat satisfied; somewhat dissatisfied; and very dissatisfied. For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into very satisfied and not very satisfied (not very satisfied included very dissatisfied; somewhat dissatisfied; and somewhat satisfied)." (NCT00112047)
Timeframe: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Very satisfied (W 144 and W 240) | Not very satisfied (W 144 and W 240) | Very satisfied (W 144); not very satisfied (W 240) | Not very satisfied (W 144); very satisfied (W 240) | |
| All Atripla | 182 | 6 | 8 | 29 |
"Participants were asked: In general, how satisfied are you with the ability of your current treatment regimen to control your HIV infection? Possible responses were on a 4-category scale: very satisfied; somewhat satisfied; somewhat dissatisfied; and very dissatisfied. For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into very satisfied and not very satisfied (not very satisfied included very dissatisfied; somewhat dissatisfied; and somewhat satisfied)." (NCT00112047)
Timeframe: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Very satisfied (W 144 and W 240) | Not very satisfied (W 144 and W 240) | Very satisfied (W 144); not very satisfied (W 240) | Not very satisfied (W 144); very satisfied (W 240) | |
| All Atripla | 192 | 8 | 9 | 17 |
"Participants were asked: In general, how satisfied are you with your ability to tolerate your current treatment regimen? Possible responses were on a 4-category scale: very satisfied; somewhat satisfied; somewhat dissatisfied; and very dissatisfied. For the evaluation of changes in treatment satisfaction from Week 144 (Atripla baseline) to Week 240 (Atripla Week 96) responses were dichotomized into very satisfied and not very satisfied (not very satisfied included very dissatisfied; somewhat dissatisfied; and somewhat satisfied)." (NCT00112047)
Timeframe: Week 144 ([W 144]; Atripla baseline) to Week 240 ([W 240]; Atripla Week 96)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Very satisfied (W 144 and W 240) | Not very satisfied (W 144 and W 240) | Very satisfied (W 144); not very satisfied (W 240) | Not very satisfied (W 144); very satisfied (W 240) | |
| All Atripla | 166 | 21 | 13 | 26 |
Steady state(2 weeks after therapy change) (NCT00148759)
Timeframe: 24 hours
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| Group 1 | 142,160 |
| Group 2 | 152140 |
LPV Cmax at Steady State (NCT00148759)
Timeframe: 24 hours
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Group 1 | 12417 |
| Group 2 | 12271 |
Change in number of CD4 cells/mm^3 from baseline to Week 240. (NCT00100048)
Timeframe: Baseline and Week 240
| Intervention | cells/mm^3 (Mean) |
|---|---|
| MK-0518 b.i.d. | 301.7 |
| EVF Combo Therapy | 275.6 |
(NCT00100048)
Timeframe: Baseline and Week 96
| Intervention | cells/mm3 (Mean) |
|---|---|
| MK0518 b.i.d. | 221.2 |
| EFV Combo Therapy | 232.4 |
Mean change from baseline at Week 24 in CD4 Cell Count (cells/mm3) (NCT00100048)
Timeframe: Baseline and Week 24
| Intervention | cells/mm3 (Mean) |
|---|---|
| MK0518 100 mg b.i.d. | 184 |
| MK0518 200 mg b.i.d | 122 |
| MK0518 400 mg b.i.d. | 147 |
| MK0518 600 mg b.i.d. | 134 |
| EFV Combo Therapy | 101 |
Mean change from baseline at Week 24 in plasma HIV RNA (copies/mL) (NCT00100048)
Timeframe: Baseline and Week 24
| Intervention | copies/mL (Mean) |
|---|---|
| MK0518 100 mg b.i.d. | -2.39 |
| MK0518 200 mg b.i.d | -2.20 |
| MK0518 400 mg b.i.d. | -2.33 |
| MK0518 600 mg b.i.d. | -2.49 |
| EFV Combo Therapy | -2.44 |
HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay. (NCT00100048)
Timeframe: Baseline and Week 240
| Intervention | Log10Copies/mL (Mean) |
|---|---|
| MK-0518 b.i.d. | -2.29 |
| EVF Combo Therapy | -2.07 |
(NCT00100048)
Timeframe: Baseline and Week 96
| Intervention | copies/mL (Mean) |
|---|---|
| MK0518 b.i.d. | -2.30 |
| EFV Combo Therapy | -2.28 |
Mean change from baseline on Day 10 in plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) (copies/mL) (NCT00100048)
Timeframe: Baseline and Day 10
| Intervention | copies/mL (Mean) |
|---|---|
| MK0518 100 mg b.i.d. | -1.93 |
| MK0518 200 mg b.i.d | -1.98 |
| MK0518 400 mg b.i.d. | -1.66 |
| MK0518 600 mg b.i.d. | -2.16 |
| Placebo | -0.17 |
HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ UltraSensitive Assay. (NCT00100048)
Timeframe: Week 240
| Intervention | Participants (Number) |
|---|---|
| MK-0518 b.i.d. | 110 |
| EFV Combo Therapy | 24 |
(NCT00100048)
Timeframe: Week 24
| Intervention | participants (Number) |
|---|---|
| MK0518 100 mg b.i.d. | 31 |
| MK0518 200 mg b.i.d | 27 |
| MK0518 400 mg b.i.d. | 35 |
| MK0518 600 mg b.i.d. | 32 |
| EFV Combo Therapy | 32 |
HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay. (NCT00100048)
Timeframe: Week 240
| Intervention | Participants (Number) |
|---|---|
| MK-0518 b.i.d. | 115 |
| EVF Combo Therapy | 25 |
(NCT00100048)
Timeframe: 48 weeks
| Intervention | participants (Number) |
|---|---|
| MK0518 100 mg b.i.d. | 38 |
| MK0518 200 mg b.i.d | 34 |
| MK0518 400 mg b.i.d. | 40 |
| MK0518 600 mg b.i.d. | 36 |
| EFV Combo Therapy | 33 |
(NCT00100048)
Timeframe: Week 24
| Intervention | participants (Number) |
|---|---|
| MK0518 100 mg b.i.d. | 28 |
| MK0518 200 mg b.i.d | 27 |
| MK0518 400 mg b.i.d. | 33 |
| MK0518 600 mg b.i.d. | 32 |
| EFV Combo Therapy | 31 |
"An AE was defined as any unfavorable & unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to its use. Any worsening of a preexisting condition which was temporally associated with the use of the study drug, was also an AE.~A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was cancer, or was an overdose." (NCT00100048)
Timeframe: Week 240
| Intervention | Participants (Number) | |
|---|---|---|
| Adverse experiences | Serious adverse experiences | |
| EVF Combo Therapy | 35 | 4 |
| MK-0518 b.i.d. | 154 | 25 |
(NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| Discontinued with CAEs | Did Not Discontinue with CAEs | |
| EFV Combo Therapy | 0 | 38 |
| MK0518 100 mg b.i.d. | 0 | 39 |
| MK0518 200 mg b.i.d | 0 | 40 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 0 | 40 |
(NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| Discontinued With LAEs | Did Not Discontinue With LAEs | |
| EFV Combo Therapy | 0 | 38 |
| MK0518 100 mg b.i.d. | 0 | 39 |
| MK0518 200 mg b.i.d | 0 | 40 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 1 | 39 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. (NCT00100048)
Timeframe: 48 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With CAEs | Without CAEs | |
| EFV Combo Therapy | 34 | 4 |
| MK0518 100 mg b.i.d. | 31 | 8 |
| MK0518 200 mg b.i.d. | 35 | 5 |
| MK0518 400 mg b.i.d. | 36 | 5 |
| MK0518 600 mg b.i.d. | 35 | 5 |
"An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.~Serious CAEs are any AEs occurring at any dose that; Results~in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or~prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an~overdose." (NCT00100048)
Timeframe: 10 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| With CAEs | Without CAEs | With Serious CAEs | Without Serious CAEs | |
| MK0518 100 mg b.i.d. | 4 | 3 | 0 | 7 |
| MK0518 200 mg b.i.d. | 2 | 5 | 0 | 7 |
| MK0518 400 mg b.i.d. | 3 | 3 | 0 | 6 |
| MK0518 600 mg b.i.d. | 5 | 3 | 0 | 8 |
| Placebo | 5 | 2 | 0 | 7 |
Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs (NCT00100048)
Timeframe: 48 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With drug-related CAEs | Without drug-related CAEs | |
| EFV Combo Therapy | 27 | 11 |
| MK0518 100 mg b.i.d. | 18 | 21 |
| MK0518 200 mg b.i.d | 20 | 20 |
| MK0518 400 mg b.i.d. | 19 | 22 |
| MK0518 600 mg b.i.d. | 19 | 21 |
Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs (NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| With drug-related LAEs | Without drug-related LAEs | |
| EFV Combo Therapy | 3 | 35 |
| MK0518 100 mg b.i.d. | 3 | 36 |
| MK0518 200 mg b.i.d. | 6 | 34 |
| MK0518 400 mg b.i.d. | 4 | 37 |
| MK0518 600 mg b.i.d. | 2 | 38 |
(NCT00100048)
Timeframe: 96 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| HIV RNA <50 copies/mL | HIV RNA <400 copies/mL | |
| EFV Combo Therapy | 32 | 32 |
| MK0518 b.i.d. | 133 | 135 |
A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product (NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| With LAEs | Without LAEs | |
| EFV Combo Therapy | 8 | 30 |
| MK0518 100 mg b.i.d. | 8 | 31 |
| MK0518 200 mg b.i.d. | 7 | 33 |
| MK0518 400 mg b.i.d. | 11 | 30 |
| MK0518 600 mg b.i.d. | 5 | 35 |
Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose (NCT00100048)
Timeframe: 48 weeks
| Intervention | participants (Number) | |
|---|---|---|
| With Serious CAEs | Without Serious CAEs | |
| EFV Combo Therapy | 2 | 36 |
| MK0518 100 mg b.i.d. | 2 | 37 |
| MK0518 200 mg b.i.d. | 5 | 35 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 2 | 38 |
"An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product~An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product" (NCT00100048)
Timeframe: 144 Weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| With CAEs | Without CAEs | With serious CAEs | Without serious CAEs | |
| EFV Combo Therapy | 35 | 3 | 4 | 34 |
| MK0518 b.i.d. | 153 | 7 | 18 | 142 |
Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. Drug-related are as assessed by an investigator who is a qualified physician according to his/her best clinical judgment. (NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| With Serious drug-related CAEs | Without Serious drug-related CAEs | |
| EFV Combo Therapy | 0 | 38 |
| MK0518 100 mg b.i.d. | 0 | 39 |
| MK0518 200 mg b.i.d | 0 | 40 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 0 | 40 |
Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose (NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| With serious LAEs | Without serious LAEs | |
| EFV Combo Therapy | 0 | 38 |
| MK0518 100 mg b.i.d. | 0 | 39 |
| MK0518 200 mg b.i.d | 0 | 40 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 0 | 40 |
Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose (NCT00100048)
Timeframe: 48 Weeks
| Intervention | participants (Number) | |
|---|---|---|
| With serious LAEs | Without serious LAEs | |
| EFV Combo Therapy | 0 | 38 |
| MK0518 100 mg b.i.d. | 0 | 39 |
| MK0518 200 mg b.i.d. | 0 | 40 |
| MK0518 400 mg b.i.d. | 0 | 41 |
| MK0518 600 mg b.i.d. | 0 | 40 |
This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV. (NCT01214759)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Truvada and Raltegravir | 0 |
(NCT01214759)
Timeframe: 28 days
| Intervention | participants (Number) |
|---|---|
| Truvada and Raltegravir | 85 |
215 reviews available for adenine and HIV Coinfection
| Article | Year |
|---|---|
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Com | 2022 |
Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Heterocy | 2023 |
Antiretroviral therapy and weight gain in naive HIV-1 infected patient: a narrative review.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; HIV Infections; HIV Seropositi | 2022 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Emtricitabine; HIV Infections; HIV-1; Humans; Infant; T | 2023 |
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infecti | 2023 |
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Topics: Adenine; Adolescent; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Human | 2023 |
Biktarvy for the treatment of HIV infection: Progress and prospects.
Topics: Adenine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofov | 2023 |
Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review.
Topics: Adenine; Adolescent; Bone Density; Child; HIV; HIV Infections; Humans; Tenofovir | 2023 |
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Alanine; Contraceptive Devices, Female; De | 2019 |
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2019 |
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Hetero | 2019 |
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; | 2020 |
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Drug Combinations; Emtricitabi | 2020 |
Tenofovir alafenamide use in pregnant and lactating women living with HIV.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Lactation; Pregnancy; Pregnancy C | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Update on HIV prevention and preexposure prophylaxis.
Topics: Adenine; Antiviral Agents; Emtricitabine; Female; HIV Infections; Humans; Male; Physician Assistants | 2020 |
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; Hair; HIV Infections; Humans; Leukocytes, Mo | 2020 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as | 2020 |
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Emtricitabine; Equivalence Trials as Topic; HIV Infections; | 2020 |
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; H | 2021 |
Topical microbicides for preventing sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Intravaginal; Agaricales; Anti-HIV Agents; Anti-Infective A | 2021 |
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
Topics: Adenine; Adolescent; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Humans; Pre-Exposure | 2021 |
Tenofovir alafenamide nephrotoxicity: a case report and literature review.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Tenof | 2021 |
A cost-savings analysis of a candidate universal antiretroviral regimen.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Generic; Drugs, Investigational; Emtricitabine; | 2017 |
Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Prodrugs; Randomized Control | 2017 |
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropane | 2017 |
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as | 2017 |
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.
Topics: Adenine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidin | 2017 |
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; | 2018 |
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hep | 2018 |
Bictegravir.
Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic C | 2018 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; H | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Hum | 2019 |
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitab | 2019 |
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Tria | 2019 |
Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; H | 2013 |
Use of antiretrovirals for HIV prevention: what do we know and what don't we know?
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Chemoprevention; Female; HI | 2013 |
Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV | 2013 |
Bone health in children and adolescents with perinatal HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Bone Density; Bone Diseases; Child; HIV Infections; Humans; Or | 2013 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combina | 2013 |
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Monitoring; Emtricitabine; | 2013 |
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Monitoring; Emtricitabine; | 2013 |
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Monitoring; Emtricitabine; | 2013 |
Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Monitoring; Emtricitabine; | 2013 |
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Net | 2013 |
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organ | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccine | 2013 |
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2013 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug | 2014 |
Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.
Topics: Adenine; Animals; Female; Fetal Development; HIV Infections; Humans; Infant, Newborn; Organophosphon | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons.
Topics: Adenine; Anti-Retroviral Agents; HIV Infections; Humans; Immunosuppression Therapy; Kidney Diseases; | 2014 |
[Mechanism of action and pharmacokinetics of rilpivirine].
Topics: Adenine; Adult; Aged; Animals; Anti-HIV Agents; Biological Availability; Child; Cytochrome P-450 CYP | 2013 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Em | 2014 |
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Resistance, Viral; Drug Therapy | 2014 |
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.
Topics: Adenine; Anti-HIV Agents; Contraception; Contraceptives, Oral, Hormonal; Cytochrome P-450 CYP3A; Cyt | 2014 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Em | 2014 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; | 2014 |
Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
Topics: Adenine; Animals; Anti-HIV Agents; HIV Infections; Humans; Incidence; Kidney Diseases; Organophospho | 2014 |
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Combinations; Emtricitabine; H | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine | 2014 |
Review of tenofovir use in HIV-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bone and Bones; Child; Child, Preschool; Drug Utilizati | 2015 |
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Female; Gels; HIV Infections; Humans; Male; Organop | 2014 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Hu | 2014 |
The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvite | 2015 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance | 2014 |
Stribild: a review of component characteristics and combination drug efficacy.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Drug Synergism; Elvitegravir | 2015 |
[The newest developments of the study on anti-HIV drugs].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphates; Organophosphonates; Piperazines; | 2015 |
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Dru | 2016 |
The role of tenofovir alafenamide in future HIV management.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects | 2016 |
Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Glomerular Filtration Rate; HIV Inf | 2016 |
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
Topics: Adenine; Alanine; Antiviral Agents; HIV Infections; Humans; Tenofovir | 2016 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicista | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; | 2017 |
Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Bone Density; Female; HIV Infections; HIV-1; Humans; Prodr | 2016 |
The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; RNA, Viral; Tenofovir; Treatment O | 2016 |
Where next with preexposure prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; | 2017 |
Tenofovir alafenamide fumarate for the treatment of HIV infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Vir | 2016 |
Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Bone Density; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Leukoc | 2017 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtr | 2008 |
Tenofovir: what have over 1 million years of patient experience taught us?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Viral; HIV Infections; Humans; | 2008 |
Kidney disease in patients with HIV infection and AIDS.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Risk Factors; Tenofovir | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug T | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deox | 2008 |
Pharmacologic aspects of new antiretroviral drugs.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Comb | 2009 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Randomized Controlled | 2009 |
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or A | 2009 |
[Tenofovir: pharmacology and interactions].
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Biological Availability; Biotransformation; Child | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort St | 2008 |
[Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic | 2008 |
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou | 2008 |
[Tenofovir DF in rescue regimens].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Clinical Trials, Phase III as Topic; Drug Resistance, Mul | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug | 2008 |
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Dr | 2009 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosi | 2009 |
Pharmacogenetics of tenofovir treatment.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; HIV-1; Humans; Kidney Diseases; Ki | 2009 |
Renal toxicity associated with tenofovir use.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Hu | 2010 |
Economic evaluation of ART in resource-limited countries.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit | 2010 |
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Tenofovir | 2010 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Vir | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Th | 2010 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenof | 2010 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
Topics: Adenine; Chemoprevention; Deoxycytidine; Drug Interactions; Emtricitabine; Female; Food-Drug Interac | 2011 |
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab | 2011 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Disea | 2011 |
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycyti | 2011 |
Update on microbicide research and development - seeking new HIV prevention tools for women.
Topics: Adenine; Administration, Intravaginal; Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Infe | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
Topics: Adenine; Animals; Fanconi Syndrome; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Disea | 2011 |
The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cidofovir; Cytosine; Guanosine; Hepatitis B; HIV I | 2011 |
Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Endocrine System Dis | 2011 |
HIV prevention in southern Africa: why we must reassess our strategies?
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adolescent; Adult; Anti-HIV Agents; Circumcision, Male; | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications.
Topics: Adenine; Anti-HIV Agents; Female; Gels; HIV Infections; Humans; Male; Organophosphonates; Reverse Tr | 2011 |
Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Topics: Adenine; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical | 2012 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet | 2011 |
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-HIV Agents; Female; HIV Infections; HIV | 2012 |
How to manage HIV-infected patients with chronic kidney disease in the HAART era.
Topics: Adenine; Albuminuria; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; Cystatin | 2012 |
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV; HIV Infections; Humans | 2012 |
Microbicides for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Developing Cou | 2011 |
WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Topics: Adenine; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D | 2012 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; | 2012 |
Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Topics: Adenine; Administration, Intravaginal; Anti-Infective Agents; Antiviral Agents; Biopharmaceutics; Co | 2012 |
Overview of microbicides for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV; HIV Infectio | 2012 |
HIV prevention by oral preexposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-Retroviral Agents; Disease Models, Animal; Dose-Respons | 2012 |
A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Gels; HIV Infections; Humans; Organophosphonates; Reverse Transcr | 2012 |
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine | 2012 |
Role of raltegravir in HIV-1 management.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infe | 2012 |
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efav | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease | 2012 |
Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fuma | 2012 |
WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Topics: Adenine; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D | 2012 |
Topical microbicides for prevention of sexually transmitted infections.
Topics: Acrylic Resins; Adenine; Administration, Topical; Agaricales; Anti-HIV Agents; Anti-Infective Agents | 2012 |
[HIV preexposure prophylaxis].
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; | 2012 |
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitab | 2012 |
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directive Counseling; Emtricitabine; Evidence-Based Medicin | 2012 |
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2012 |
Update on tenofovir toxicity in the kidney.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Hepatitis B; HIV Infections; Humans; Kidney; Ki | 2013 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; | 2012 |
Current status of topical antiretroviral chemoprophylaxis.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprev | 2012 |
Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV I | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Hum | 2012 |
Oral antiretroviral chemoprophylaxis: current status.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; | 2012 |
The clinical pharmacology of antiretrovirals for HIV prevention.
Topics: Adenine; Administration, Oral; Administration, Topical; Anti-Retroviral Agents; Chemoprevention; Cli | 2012 |
Rectal microbicide development.
Topics: Adenine; Administration, Rectal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention | 2012 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combi | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; | 2012 |
Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Topics: Adenine; Animals; Anti-HIV Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug | 2002 |
Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
Topics: Adenine; Adenosine Monophosphate; Anti-HIV Agents; Biological Availability; HIV Infections; HIV-1; H | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Organ | 2003 |
Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Dideoxynucleosides; Drug R | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Th | 2003 |
Effect of tenofovir on didanosine absorption in patients with HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Clinical Trials a | 2003 |
Viral hepatitis B.
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis | 2003 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Com | 2004 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Com | 2004 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Com | 2004 |
Newer treatments for HIV in children.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Child; Deoxycytidine; Didanosine; Drug Therapy, Com | 2004 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox | 2003 |
Adefovir dipivoxil in the treatment of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hep | 2004 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combi | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanin | 2004 |
Fanconi's syndrome in HIV+ adults: report of three cases and literature review.
Topics: Adenine; Adult; Anti-Retroviral Agents; Bone Density; Calcitriol; Calcium; Fanconi Syndrome; Female; | 2004 |
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
Topics: Adenine; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Monophosphate; Deoxyribonucleotides; Di | 2004 |
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
Topics: Adenine; Administration, Oral; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2004 |
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
Topics: Adenine; Clinical Trials as Topic; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; HI | 2004 |
Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; HIV Infections; Humans; Kidney Function Tests; Male; | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudin | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Ch | 2004 |
Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Tenofovir | 2003 |
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatiti | 2004 |
Adefovir dipivoxil: review of a novel acyclic nucleoside analogue.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Viral; Hepatitis | 2004 |
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
Topics: Adenine; Area Under Curve; Biological Availability; Double-Blind Method; Drug Interactions; Half-Lif | 2005 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtrici | 2005 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi | 2005 |
Editorial comment: tenofovir nephrotoxicity--vigilance required.
Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organo | 2005 |
Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.
Topics: Adenine; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Reverse Tr | 2005 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Dr | 2004 |
Tenofovir and didanosine: a dangerous liaison.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; | 2005 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cycloprop | 2005 |
Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
Topics: Acidosis, Lactic; Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Fe | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials | 2005 |
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2006 |
Perspectives on the development of acyclic nucleotide analogs as antiviral drugs.
Topics: Adenine; Animals; Antiviral Agents; Dogs; Drug Design; Hepatitis B virus; Hepatitis B, Chronic; HIV | 2006 |
Tenofovir disoproxil fumarate for the treatment of HIV infection.
Topics: Adenine; Animals; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Ther | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; | 2006 |
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Topics: Adenine; Animals; Chemistry, Pharmaceutical; Deoxycytidine; Drug Administration Schedule; Drug Combi | 2006 |
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lami | 2006 |
Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Antagonism; Drug Resistance, Viral; HIV Infections; HIV R | 2006 |
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; HIV Infections; | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Em | 2007 |
Renal safety of tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Kidney; Kidney Diseases; | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; | 2007 |
Pre-exposure prophylaxis for HIV infection: what if it works?
Topics: Adenine; Anti-HIV Agents; Attitude of Health Personnel; Drug Administration Schedule; Female; HIV In | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance | 2007 |
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Em | 2007 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enz | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; | 2007 |
Tenofovir gel--the new HIV prevention 'banker'?
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Approval; Female; HIV Infections; | 2007 |
[Attention-getting sexually transmitted diseases: Hepatitis B].
Topics: Adenine; Adenosine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Guanine; Gua | 2007 |
Kidney biopsy in HIV: beyond HIV-associated nephropathy.
Topics: Acute Disease; Adenine; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2008 |
Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Drug Interactions; Drug Resistance, | 2008 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV | 1999 |
Strategies for second-line antiretroviral therapy in adults with HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Ther | 1999 |
Coming therapies: adefovir.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; HIV Infections; HIV-1; Humans; Organophosphona | 1999 |
The potential place of tenofovir in antiretroviral treatment regimens.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Organophosphonates; O | 2001 |
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
Topics: Adenine; Animals; Clinical Trials as Topic; Drug Industry; Hepatitis B, Chronic; HIV Infections; Hum | 2002 |
Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; | 1990 |
461 trials available for adenine and HIV Coinfection
| Article | Year |
|---|---|
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtric | 2021 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Huma | 2023 |
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emt | 2023 |
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Adherence; O | 2022 |
EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infection | 2023 |
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Biological Availability; Cross-Over Studies; Emtricitabine | 2022 |
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection i
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; Heterocyclic Compounds, | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylax | 2022 |
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Topics: Adenine; Aging; Anti-HIV Agents; Bone Density; COVID-19; Female; HIV Infections; Humans; Middle Aged | 2023 |
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Topics: Adenine; Aging; Anti-HIV Agents; Bone Density; COVID-19; Female; HIV Infections; Humans; Middle Aged | 2023 |
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Topics: Adenine; Aging; Anti-HIV Agents; Bone Density; COVID-19; Female; HIV Infections; Humans; Middle Aged | 2023 |
BEING: Bone Health in Aging Women with HIV: Impact of Switching Antiretroviral Therapy on Bone Mineral Density During the Perimenopausal Period.
Topics: Adenine; Aging; Anti-HIV Agents; Bone Density; COVID-19; Female; HIV Infections; Humans; Middle Aged | 2023 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 4 or | 2023 |
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
Topics: Adenine; Anti-HIV Agents; Birth Weight; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant | 2023 |
Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Leukocytes, Mononuclear; Tenofovir | 2023 |
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2023 |
Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.
Topics: Adenine; Adult; Anti-HIV Agents; Bone and Bones; Female; HIV Infections; Humans; Male; Middle Aged; | 2023 |
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Topics: Adenine; Adult; African People; Alanine; Anti-HIV Agents; HIV Infections; HIV Seropositivity; Humans | 2023 |
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Child; Emtricitabine; Female; HIV Infections; Humans; Male; | 2023 |
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions | 2023 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; He | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtric | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug | 2019 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; D | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; | 2019 |
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heter | 2019 |
Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Topics: Adenine; Alanine; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV | 2020 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV | 2020 |
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Central Nervous System Diseases; Creatinine; Drug Administ | 2019 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinati | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Hum | 2020 |
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Chromatography, Liquid; Drug Combinations; Emtricita | 2020 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira | 2020 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharm | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule | 2020 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Cross-Over Studies; Drug Combinations; Emtrici | 2020 |
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults
Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; H | 2020 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring | 2020 |
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Emtricitabine, Tenofovir Disopr | 2020 |
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Male; Organophos | 2021 |
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Male; Organophos | 2021 |
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Male; Organophos | 2021 |
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Estradiol; Female; HIV Infections; Humans; Male; Organophos | 2021 |
Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Topics: Adenine; Adolescent; Adolescent Health Services; Anti-HIV Agents; Condoms; Female; HIV Infections; H | 2020 |
Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Topics: Adenine; Adolescent; Adolescent Health Services; Anti-HIV Agents; Condoms; Female; HIV Infections; H | 2020 |
Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Topics: Adenine; Adolescent; Adolescent Health Services; Anti-HIV Agents; Condoms; Female; HIV Infections; H | 2020 |
Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Topics: Adenine; Adolescent; Adolescent Health Services; Anti-HIV Agents; Condoms; Female; HIV Infections; H | 2020 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2020 |
Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Black People; Female; HIV Infections; Humans; Incidence | 2020 |
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Male; Middl | 2021 |
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
Topics: Adenine; Adolescent; Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Me | 2021 |
Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; DNA; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Treat | 2021 |
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; Healthy Volunteers; HIV Infections; HIV-1; Humans; | 2021 |
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; Gestatio | 2021 |
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Counseling; Dried Blood Spot Testing; Drug Monitoring; | 2021 |
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Emtr | 2021 |
Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Homosexuality, Male; Humans; | 2021 |
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug | 2021 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Dr | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emt | 2017 |
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Directly Observed Therapy; Dried Blood Spot Tes | 2018 |
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Male; Medication Adherence; Organophosphate | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; | 2018 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Administ | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double- | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatit | 2018 |
Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Body Fluids; Dose-Response Relationship, Dr | 2018 |
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 2018 |
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph
Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Fem | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir,
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; E | 2018 |
MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.
Topics: Adenine; Colon; Enema; HIV Infections; Humans; Molecular Imaging; Organophosphates; Rectum; Spectrom | 2018 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; H | 2019 |
Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexua | 2019 |
Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men.
Topics: Adenine; Adult; Follow-Up Studies; HIV Infections; Homosexuality, Male; Humans; Logistic Models; Mal | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2019 |
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug | 2019 |
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Cross-Over Studies; Emtricitabine; Female; | 2019 |
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Contraceptive Agents, Hormonal; Contraceptive Dev | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Subst | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; | 2013 |
Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Bone and Bones; Bone Density; Cohort Studies; Down-Regu | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD | 2013 |
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Topics: Adenine; Adolescent; Anti-HIV Agents; Boston; CD4 Lymphocyte Count; Double-Blind Method; Follow-Up S | 2013 |
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.
Topics: Adenine; Adult; Anti-HIV Agents; Attitude to Health; Double-Blind Method; Female; HIV Infections; Hu | 2013 |
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004.
Topics: Adenine; Anti-HIV Agents; Bacterial Translocation; Cytokines; Fatty Acid-Binding Proteins; Female; H | 2013 |
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
Topics: Adenine; Adolescent; Adult; Amphetamine-Related Disorders; Anti-HIV Agents; Boston; Double-Blind Met | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interact | 2013 |
A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
Topics: Adenine; Administration, Rectal; Adult; Anti-HIV Agents; Double-Blind Method; Female; Gels; HIV Infe | 2013 |
Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
Topics: Adenine; Adolescent; Adult; AIDS Vaccines; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Heterosexu | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Gl | 2013 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, C | 2013 |
A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Drug | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Hum | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1 | 2013 |
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug; | 2013 |
Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HIV Infections; Hum | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV I | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bon | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HI | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; | 2013 |
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; CD4 Lymphocyte Cou | 2014 |
Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV | 2014 |
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anthropometry; Anti-HIV Agents; Benzoxazines; Biomark | 2014 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Calcitriol; Calcium; Double-Blind Method; Female; Fibro | 2013 |
Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Creatine Kinase; Deoxycytidine; Drug Therapy, Combinati | 2014 |
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.
Topics: Adenine; Adult; Africa, Eastern; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Fami | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration S | 2013 |
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HI | 2013 |
Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Double-Blind Method; Emtrici | 2013 |
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Deoxycytidine; Drug Combinations; Emtricitabine | 2014 |
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protei | 2013 |
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Bone Resorption; Female; HIV Infections; Humans; Middl | 2013 |
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxy | 2013 |
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.
Topics: Adenine; Adult; Anti-Infective Agents; Chemoprevention; env Gene Products, Human Immunodeficiency Vi | 2014 |
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Heter | 2013 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
Topics: Adenine; Administration, Oral; Adult; Demography; Dose-Response Relationship, Drug; Female; Hair; HI | 2014 |
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Gels; HIV Infections; H | 2014 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; G | 2014 |
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Creatinine; Deoxycytidine; Emtricitabi | 2014 |
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Female; HIV Infections | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblas | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblas | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblas | 2014 |
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cholecalciferol; Dietary Supplements; Female; Fibroblas | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxy | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2014 |
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Condoms; Deoxycytidine; Emtricitabine; Female; HIV Inf | 2014 |
Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents; Coitus; Double-Blind Method; Dr | 2014 |
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV | 2014 |
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Double-Blind Method; Female; Gels; He | 2014 |
Adherence in the CAPRISA 004 tenofovir gel microbicide trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Counsel | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopro | 2014 |
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Male; Middle A | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxy | 2014 |
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Botswana; Deoxycytidine; Emtricitabine; Female; Hematol | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug S | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agen | 2014 |
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype | 2014 |
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combinatio | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combinatio | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combinatio | 2014 |
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cohort Studies; Deoxycytidine; Drug Therapy, Combinatio | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combina | 2014 |
Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience.
Topics: Adenine; Administration, Oral; Africa, Eastern; Anti-HIV Agents; Clinical Protocols; Deoxycytidine; | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Topics: Absorptiometry, Photon; Adenine; Administration, Oral; Adult; Alanine; Bone Density; CD4 Lymphocyte | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinf | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; E | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality | 2014 |
Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Homosexuality | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycyti | 2014 |
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Antiviral Agents; Deoxycytidine; Drug | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combinati | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2014 |
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Intervie | 2015 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; | 2014 |
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Double-Blind Method; Female; Fertilizat | 2014 |
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Female; HIV Infections; Humans; M | 2014 |
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Fem | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans | 2014 |
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Topics: Adenine; Disease Progression; Female; Gels; HIV Infections; Humans; Organophosphonates; Placebos; Pr | 2015 |
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Ferti | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combi | 2014 |
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Disclosure; Female; Gels; HIV Infecti | 2014 |
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtr | 2014 |
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Contraceptive Agents, Female; Deoxycytidine; Drug Comb | 2015 |
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtric | 2015 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; G | 2014 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; G | 2014 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; G | 2014 |
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Clinical Protocols; Family Planning Services; Female; G | 2014 |
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; H | 2015 |
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Blac | 2014 |
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Deoxycytidine; Double-Blind Method; Drug Resistanc | 2015 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Do | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Africa South of the | 2015 |
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug-Related Side Effects and Adverse | 2015 |
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Organophospho | 2015 |
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycy | 2015 |
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012.
Topics: Accidents, Traffic; Adenine; Adult; Anti-HIV Agents; Cause of Death; Double-Blind Method; Drug Overd | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count | 2015 |
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; H | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, | 2015 |
Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Cervix Uteri; Female; Gels; HIV Infections; H | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2015 |
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Mi | 2015 |
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Topics: Adenine; Administration, Intravaginal; Adult; Double-Blind Method; Female; Follow-Up Studies; Gels; | 2015 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infec | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Doub | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Doub | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Doub | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Doub | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; | 2016 |
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Double-Blind Method; Emtricitabine; Fema | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em | 2016 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbi | 2016 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbi | 2016 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbi | 2016 |
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Comorbi | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobici | 2016 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtrici | 2017 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combin | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infe | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infe | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infe | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infe | 2017 |
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; HIV-1; | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Meth | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Meth | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Meth | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Meth | 2017 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine | 2008 |
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Respon | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideox | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclo | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclo | 2008 |
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepati | 2008 |
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricita | 2008 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidi | 2008 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophos | 2009 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophos | 2009 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophos | 2009 |
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
Topics: Adenine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Maternal-Fetal Exchange; Organophos | 2009 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Vir | 2009 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabin | 2008 |
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatit | 2008 |
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Counseling; Double-Blind Method; Female; Ghana; HIV Inf | 2008 |
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug The | 2009 |
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Belgium; Cross-Over Studies; Drug Interactions; Female; | 2009 |
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Drug Resistance, Viral; Drug Therapy, Combination; Fema | 2009 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug | 2009 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul | 2009 |
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinati | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtri | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2009 |
Safety evaluation of 1% tenofovir gel in healthy men.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Cellulose; Circumcision, Male; Gels; Glycerol; HI | 2009 |
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Body Composition; Cheek; Dideoxynucleosides; Female; H | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Ad | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Sc | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Respons | 2009 |
Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Black o | 2010 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; B | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycy | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug The | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycy | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleo | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Dr | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administrati | 2010 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidi | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosi | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentia | 2009 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2010 |
Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Female; HIV Infecti | 2010 |
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Interactions; Dr | 2010 |
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fema | 2009 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Admi | 2010 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Admi | 2010 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Admi | 2010 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Admi | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphoc | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; D | 2010 |
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Intera | 2010 |
Tenofovir/emtricitabine combination results in lower bone-mineral density.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infecti | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cycl | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulf | 2010 |
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dyslipide | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Lo | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administra | 2010 |
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; | 2010 |
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance | 2010 |
Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance.
Topics: Adenine; Adult; Antiviral Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Dens | 2010 |
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Deoxy | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan | 2011 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, V | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Dr | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtrici | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitab | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitab | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitab | 2011 |
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitab | 2011 |
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Fem | 2011 |
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Deoxyadenine Nucleotides; Deoxyguanin | 2011 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Th | 2011 |
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Double-Blind Method; Drug-Related Side Effects and Adve | 2011 |
Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; C-Reactive Protein; Coagulants; Dideoxynucleosides; Fem | 2011 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resist | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Com | 2011 |
Initial results reported on raltegravir once-daily dosing.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Em | 2011 |
Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV | 2011 |
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Topics: Adenine; Administration, Intravaginal; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; H | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Act | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropane | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deox | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Dru | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Dru | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtr | 2011 |
Predicting product adherence in a topical microbicide safety trial in Pune, India.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Condoms; Female; HI | 2012 |
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxyc | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymp | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymp | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymp | 2011 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymp | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; | 2012 |
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand.
Topics: Adenine; Administration, Oral; Adult; AIDS Vaccines; Communicable Disease Control; Double-Blind Meth | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular D | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropane | 2012 |
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; H | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides | 2011 |
Changes in condom use during a microbicide clinical trial in Pune, India.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Condoms; Counseling; Female; Follow-Up Studies; Gel | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycyt | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; D | 2012 |
Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
Topics: Adenine; Adult; Anti-HIV Agents; Boston; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1 | 2012 |
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Attitude to Health; Deoxycytidine; Emtricitab | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double | 2012 |
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholecalciferol; Double | 2012 |
Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Apoptosis; Bone Density; DNA, Mitochond | 2012 |
Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anaerobiosis; Anti-HIV Agents; Benzoxazines; Cyclopropanes; | 2012 |
A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Double-Blind Method; Drug Resistance, Viral; Drug Thera | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycy | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular F | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomar | 2012 |
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; H | 2012 |
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents, Local; Cervix Uteri; Cohort Studies; Female; Gels; | 2012 |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Bu | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleos | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-B | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxy | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; Contraception Behavior; Deoxycytid | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Preexposure prophylaxis for HIV infection among African women.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-Retroviral Agents; Case-Control Studies; Deox | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraception Behavior; Deoxycytidine; Double-Bl | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte | 2012 |
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents, Local; Bone and Bones | 2013 |
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Topics: Adenine; Administration, Oral; Administration, Rectal; Adult; Aged; Anti-HIV Agents; Double-Blind Me | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV P | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Inter | 2012 |
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Topics: Adenine; Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; DNA | 2013 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxyc | 2013 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; G | 2012 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Ov | 2013 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Ov | 2013 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Ov | 2013 |
Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Topics: Adenine; Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-HIV Agents; Cross-Ov | 2013 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2013 |
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Europe; Female; Fetal Blood; HIV Infe | 2013 |
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Topics: Adenine; Adult; Black or African American; Body Mass Index; CD4 Lymphocyte Count; Deoxycytidine; Dru | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopro | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administrati | 2012 |
Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir.
Topics: Adenine; Adult; Antiviral Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Double-Blind Method; He | 2013 |
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Topics: Absorptiometry, Photon; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Hig | 2013 |
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycy | 2013 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfa | 2013 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deo | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Female; HIV I | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Co | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Co | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Co | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Co | 2013 |
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; D | 2013 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy | 2002 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hep | 2002 |
A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Body Weight; CD4 Lymphocyte Count; Do | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; H | 2002 |
An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Follow-Up | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Femal | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studi | 2003 |
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Viral; Female; Genotype; HIV | 2003 |
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Chronic Disease; Female; HIV Infections; HIV-1; Humans; Male; Middl | 2003 |
Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Double-Blind Method; Fe | 2003 |
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral | 2003 |
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Topics: Adenine; Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Combinations; | 2004 |
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Met | 2004 |
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Hepatitis B Surface Antigens; He | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Renal safety of tenofovir in HIV treatment-experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; Humans; Kidney Disease | 2004 |
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatogra | 2004 |
Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclo | 2004 |
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Topics: Adenine; Codon; Cohort Studies; France; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; | 2004 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Live | 2004 |
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Topics: Adenine; Cohort Studies; Drug Therapy, Combination; France; Genotype; HIV Infections; HIV Reverse Tr | 2004 |
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Hum | 2004 |
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Amino Acid Substitution; Double-Blind Method; Drug Admi | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immuno | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration S | 2004 |
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
Topics: Adenine; Adult; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Gels; HIV Infecti | 2004 |
Tenofovir regimen compared with Combivir.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Europe; | 2005 |
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Topics: Adenine; Adult; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; O | 2005 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Female; HIV Infec | 2005 |
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Topics: Adenine; Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymp | 2005 |
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Topics: Adenine; Anti-HIV Agents; Cell Count; Chromatography, Liquid; Cross-Sectional Studies; Didanosine; H | 2005 |
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hu | 2005 |
Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Epidemiologic Me | 2005 |
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Combinations | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections | 2005 |
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enfuvirtide; | 2005 |
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypophosph | 2006 |
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; H | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Re | 2005 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; C | 2005 |
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Ac | 2006 |
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Female; Genotype; HIV Infections; Humans; Middle Aged; | 2006 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosi | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropane | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Ther | 2006 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Ma | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; | 2006 |
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte C | 2006 |
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Topics: Adenine; Adolescent; Age Factors; Anti-Retroviral Agents; Bone Density; Bone Development; Child; Fem | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infe | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e | 2006 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Fat Distribution; Dideoxynucleosides; Female | 2006 |
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combinati | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Vira | 2006 |
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Double-Blind Me | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavi | 2006 |
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infection | 2007 |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; | 2007 |
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; | 2006 |
Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Cholesterol; Cholesterol, | 2007 |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Body Weight; Creatinine; Fe | 2007 |
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleos | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cre | 2007 |
The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Cholesterol; Drug Administration Schedule; Female | 2007 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; D | 2008 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; D | 2008 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; D | 2008 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; D | 2008 |
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Topics: Adenine; Adult; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Drug Administratio | 2007 |
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Multiple, Viral; Drug T | 2007 |
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Glomerular Filtration Rate; H | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromat | 2007 |
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
Topics: Adenine; Alleles; Didanosine; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; HIV I | 2007 |
Pregnancy prevention practices among women with multiple partners in an HIV prevention trial.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Condoms; Contraception; Contraception Behavior; Contrac | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2008 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedu | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; | 2007 |
Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Topics: Adenine; Administration, Intravaginal; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Th | 2008 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV | 2007 |
Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didano | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug T | 2007 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytid | 2008 |
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; CD4 Lymp | 2008 |
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Topics: Adenine; Adult; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV P | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lympho | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Thera | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; | 2008 |
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Topics: Adenine; Administration, Intravaginal; Adult; Anti-Infective Agents, Local; Cohort Studies; Female; | 2008 |
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; Cyclo | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mit | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mit | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mit | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mit | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Tra | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Tra | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Tra | 2008 |
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Topics: Adenine; Adult; Female; Gene Frequency; Genotype; HIV Infections; Humans; Kidney; Male; Membrane Tra | 2008 |
An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; | 2008 |
Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Biological Availability; Female; Half-Life; | 1995 |
Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS-Related Complex; Alanine Transaminase; Aspartate A | 1996 |
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Carnitine; Digestive System; Double-Blind Method; Female; HIV Core | 1997 |
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Carnitine; CD4 Lymphocyte Count; Cytomegalovi | 1997 |
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Double-Blind Method; Female; HIV Infections; Humans; M | 1998 |
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
Topics: Adenine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcri | 1999 |
Oxidative DNA base damage in lymphocytes of HIV-infected drug users.
Topics: Adenine; Adolescent; Adult; Chromatin; Cytosine; DNA Damage; Guanine; HIV Infections; Humans; Lympho | 1999 |
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Double-Blind Method; Female; Hep | 1999 |
Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.
Topics: Adenine; Adolescent; Antiviral Agents; Area Under Curve; Child; Child, Preschool; Female; Half-Life; | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therap | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, | 2000 |
New drug, new hope.
Topics: Adenine; Anti-HIV Agents; Carnitine; CD4 Lymphocyte Count; Clinical Trials as Topic; Dose-Response R | 1998 |
PMPA trials recruiting.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; H | 1998 |
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Genes, Viral; Genotype; HIV Infections; HIV Reverse T | 2001 |
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus Infections; Double-Blind Method; Dru | 2001 |
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Double-Blind Method; Drug Tolerance; Female; Genotype; HIV Infectio | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV-1; H | 2001 |
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Topics: Adenine; Double-Blind Method; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcri | 2002 |
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infec | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2002 |
1275 other studies available for adenine and HIV Coinfection
| Article | Year |
|---|---|
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Creatinine; Cystatin C; Female; HIV Infections; Humans; Ki | 2021 |
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Female; Hete | 2021 |
Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Drug Stability; Female; HIV Infections; HIV-1; Humans; M | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; | 2021 |
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Fumarates; HIV Infections; Humans; Tablet | 2022 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; | 2022 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infect | 2021 |
Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Topics: Adenine; Adult; Anti-HIV Agents; COVID-19 Drug Treatment; Drug Interactions; Emtricitabine; Female; | 2022 |
The Effect of Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Pregnancy on Gestational Weight Gain.
Topics: Adenine; Anti-Retroviral Agents; Body Mass Index; Female; Gestational Weight Gain; HIV Infections; H | 2022 |
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; T | 2022 |
Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kenya; Medication Adherence; Organophospha | 2022 |
Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Organophospha | 2021 |
Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Female; HIV; HIV Infections; Humans; Organophosphate | 2022 |
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3 | 2022 |
The use of tenofovir in patients with COVID-19.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; COVID-19 Drug Treatment; HIV Infections; Humans; Tenofov | 2022 |
Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Female; HIV Infections; Humans; Male; Medication Adhere | 2022 |
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Female; HIV Infections; Humans; Postpart | 2022 |
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtri | 2022 |
The making of the one pill-Developing single tablet regimens for HIV and for HCV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Diso | 2022 |
The transformation of HIV therapy: One pill once a day.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; HIV Infections; Humans; Organophosphonat | 2022 |
Tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Female; HIV Infections; Mice; Tenofovir | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2022 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; F | 2022 |
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphates; Tablets; Tenofovir | 2022 |
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Topics: Adenine; Adult; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Phosphates; Prospective Studi | 2022 |
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocycl | 2022 |
HBV in pregnancy: time to consider tenofovir alafenamide (TAF).
Topics: Adenine; Alanine; Female; Hepatitis B virus; HIV Infections; Humans; Pregnancy; Tenofovir | 2022 |
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B, Chronic; HIV Infections; Humans; Milk, Huma | 2022 |
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or Mor | 2022 |
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV-1; Humans; Hypertension; L | 2023 |
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtr | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Li | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; | 2022 |
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Contraceptive Agents; Diphosphates; Emtricitabin | 2022 |
Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Kidney; Lamivud | 2023 |
Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Tenofovir | 2023 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds | 2021 |
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Topics: Adenine; Alanine; Alanine Transaminase; Anti-Retroviral Agents; Canada; Cholesterol; Coinfection; He | 2022 |
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Topics: Adenine; Adolescent; Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; Female; HIV Infections; | 2022 |
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocy | 2023 |
Persistently elevated alkaline phosphatase could be related to Paget's disease of bone in a patient receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; HIV Infections; HIV Seropositivity; Humans; M | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Human | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; HIV Infections; Mice; Mice, Inbred C57BL; Pre-Expo | 2023 |
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Fa | 2023 |
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Fa | 2023 |
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Fa | 2023 |
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Fa | 2023 |
Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.
Topics: Adenine; Chitosan; Drug Carriers; Drug Liberation; HIV Infections; Humans; Nanoparticles; Particle S | 2022 |
Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.
Topics: Adenine; Chitosan; Drug Carriers; Drug Liberation; HIV Infections; Humans; Nanoparticles; Particle S | 2022 |
Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.
Topics: Adenine; Chitosan; Drug Carriers; Drug Liberation; HIV Infections; Humans; Nanoparticles; Particle S | 2022 |
Fabrication of PEGylated Chitosan Nanoparticles Containing Tenofovir Alafenamide: Synthesis and Characterization.
Topics: Adenine; Chitosan; Drug Carriers; Drug Liberation; HIV Infections; Humans; Nanoparticles; Particle S | 2022 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; H | 2023 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; H | 2023 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; H | 2023 |
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; H | 2023 |
Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
Topics: Adenine; Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Europe; Female; Heterocyclic Compoun | 2023 |
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Tenofovir; Treatment Outcom | 2023 |
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or Mo | 2023 |
Preliminary Evaluation of Stability Data for Dolutegravir-Containing Triple Active Formulations Intended for PEPFAR. Degradation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide as the Limiting Factor.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Hygroscopic Agents; Tablets; Tenofovir | 2023 |
Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Hu | 2023 |
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Health Care Costs; Health Expenditures; HIV Infections; Hu | 2023 |
Weight gain in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Hum | 2023 |
Changes in Leptin to Adiponectin Ratio After Antiretroviral Therapy: A Pilot Observational Study.
Topics: Adenine; Adipokines; Adiponectin; HIV Infections; Humans; Leptin; Prospective Studies | 2023 |
Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Emtricitabine; HIV Infections; | 2023 |
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Topics: Adenine; Adult; Anti-HIV Agents; Belgium; Cohort Studies; Drug Combinations; Emtricitabine; Female; | 2023 |
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Renal Insufficiency, Chronic; Tenofovir | 2023 |
Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-R | 2023 |
Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; HIV Infections; Macaca mulatta; Rats; Rats, Sprague-Dawl | 2023 |
Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation.
Topics: Adenine; Anti-HIV Agents; Chemometrics; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections | 2023 |
Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocy | 2023 |
[Sleep disorders related to HIV treatment.]
Topics: Adenine; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Pyridones; Sleep Wake Disor | 2023 |
High rates of kidney impairment among older people (≥ 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; F | 2023 |
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Organophosph | 2023 |
Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Diabetes Insipidus; Diabetes Mellitus; Fanconi Syndro | 2023 |
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.
Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; | 2023 |
Transcriptomics age acceleration in prolonged treated HIV infection.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Transcriptome | 2023 |
Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2023 |
Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.
Topics: Adenine; Adolescent; Adult; Female; Fumarates; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Red | 2023 |
Malignant syphilis in HIV negative patient treated with ibrutinib.
Topics: Adenine; HIV Infections; Humans; Piperidines; Syphilis | 2023 |
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocycli | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 o | 2023 |
The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report.
Topics: Adenine; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Drug Interactions; Female; HIV Infecti | 2023 |
Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Cobicistat; Drug Combinations; Female; HIV Infections; H | 2023 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofov | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Midd | 2019 |
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Interactions; F | 2019 |
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Emtricitabine; Female; HIV Infections; HIV-1; Humans; | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infecti | 2019 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Act | 2019 |
Where Were the Women? Gender Parity in Clinical Trials.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Emtri | 2019 |
New PrEP formulation approved…but only for some.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; Female; HIV Infections; Humans; Male; Pre-Ex | 2019 |
Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Fem | 2019 |
Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; beta 2-Microglobulin; Biomarkers; CD4 Ly | 2019 |
Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Drug Substitution; Female; Germany; HIV Infec | 2019 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, D | 2020 |
Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV | 2019 |
Response to Noe, Oldenbuettel and Jaeger.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Drug Implants; Female; Fuma | 2020 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Com | 2020 |
Not all is perfect with Tenofovir alafenamide.
Topics: Adenine; Alanine; HIV Infections; Humans; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?
Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Pre-Exposure Prophylaxis; T | 2020 |
Descovy Approved for HIV Prexposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Emtricitabine; HIV Infections; Humans; Tenofovir; United St | 2020 |
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2020 |
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphoc | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drugs, Generic; Emtricitabine; F | 2020 |
How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States?
Topics: Adenine; Alanine; Anti-HIV Agents; Cost-Benefit Analysis; Decision Making, Shared; Emtricitabine, Te | 2020 |
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Substitution; Female; Glomerular Filtration Rate; HIV | 2020 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Esophageal Neoplasms; Gastrosto | 2020 |
Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.
Topics: Adenine; Adolescent; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphates; Tenofo | 2020 |
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Amides; Anti-HIV Agents; Depression; Emtricitabine; Female; | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; H | 2020 |
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; HIV | 2020 |
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Topics: Adenine; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Monitoring; Drug Substitution; Drug Th | 2020 |
Immunoassay for HIV Drug Metabolites Tenofovir and Tenofovir Diphosphate.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Immunoassay; Medication Adherence; Organophosphate | 2020 |
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Fema | 2020 |
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtric | 2020 |
Weighing considerations with newer antiretrovirals.
Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Hetero | 2020 |
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Fumarates; HIV Infections; Rabbits; Sheep; Tenofov | 2020 |
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus Infections | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; | 2020 |
Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cholangiopancreatography, Magnetic Resonance; Diabetes Mellitus; | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
Topics: Acute Disease; Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug | 2020 |
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Topics: Adenine; Administration, Oral; Animals; Cross-Sectional Studies; Drug Combinations; Emtricitabine; H | 2020 |
DISCOVER: much accomplished, but not yet for all.
Topics: Adenine; Alanine; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Pre-Exposure Prophylax | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; | 2020 |
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhib | 2020 |
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fr | 2021 |
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure | 2020 |
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis.
Topics: Adenine; Alanine; Cost-Benefit Analysis; Emtricitabine; Family; HIV Infections; Humans; Pre-Exposure | 2020 |
Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; | 2020 |
Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Cholesterol; DNA, Mitochondrial; HIV Infections; HIV-1 | 2020 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate: integrating systematic review findings into practice and policy.
Topics: Adenine; Alanine; HIV Infections; Humans; Policy; Tenofovir | 2020 |
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; H | 2021 |
PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
Topics: Adenine; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Pre-Exposure Prophyl | 2021 |
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Topics: Adenine; Alanine; HIV Infections; Humans; Liver Transplantation; Retrospective Studies; Tenofovir | 2021 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections | 2020 |
Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots.
Topics: Adenine; Dried Blood Spot Testing; HIV Infections; Humans; Organophosphates; Prospective Studies | 2021 |
Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Black People; Female; HIV Infections; Humans; I | 2021 |
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Topics: Adenine; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cobicistat; Dose-Response Relationsh | 2021 |
A rare case of acute tubular necrosis tenofovir alafenamide-related.
Topics: Adenine; Alanine; HIV Infections; Humans; Necrosis; Tenofovir | 2021 |
Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide.
Topics: Adenine; Alanine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chromatography, Liquid; F | 2021 |
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Medication Adherence; Organop | 2021 |
Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Brazil; Drug Resistance, Viral; Female; HIV Infections; HIV R | 2021 |
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV.
Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocy | 2021 |
Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney Function Tests; Tenof | 2021 |
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, | 2022 |
A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Edema; HIV Infections; HIV-1; Infusions, Subcutane | 2021 |
Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
Topics: Adenine; Alanine; Anti-HIV Agents; Cohort Studies; Emtricitabine; Emtricitabine, Tenofovir Disoproxi | 2021 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organoph | 2017 |
Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Vir | 2017 |
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio | 2017 |
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug I | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV | 2017 |
Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV I | 2017 |
[Update in HIV therapy: tenofovir alafenamide].
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Tenofovir | 2016 |
Improvement in renal function and resolution of proteinuria in an HIV-infected patient switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Alanine; Antiviral Agents; Drug Substitution; Female; HIV Infections; Humans; Kidney Diseas | 2017 |
Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
Topics: Adenine; Antiviral Agents; HIV; HIV Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2018 |
Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Topics: Adenine; Alanine; Anti-HIV Agents; Cell Line, Tumor; Chromatography, Liquid; DNA Replication; Half-L | 2017 |
Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
Topics: Adenine; Alanine; Anti-HIV Agents; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Mitoc | 2017 |
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, M | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Fe | 2018 |
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B, | 2017 |
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Fe | 2017 |
Role of tenofovir alafenamide in the jungle of antiretroviral prescription.
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; H | 2018 |
Regimen Change: Gilead's TAF Drugs Toppling TDFs in HIV Treatment.
Topics: Adenine; Alanine; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combi | 2017 |
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cells, | 2017 |
Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Biopsy; Culture Media; HIV Infections; Humans; Male; | 2018 |
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Chromatography, Liquid; Cross-Ove | 2018 |
Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Topics: Adenine; Alanine; Anti-HIV Agents; Cytoplasm; Databases, Factual; Dose-Response Relationship, Drug; | 2018 |
Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Epithelium; Estradi | 2018 |
Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R.
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, | 2018 |
Translation of clinical trial data to changes in clinical practice: rapid transition from tenofovir disoproxil fumarate to tenofovir alafenamide-based therapies in a Sydney HIV clinic.
Topics: Adenine; Alanine; Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Australia; HIV Infe | 2018 |
To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
Topics: Adenine; Alanine; Anti-HIV Agents; Guanine; HIV Infections; Humans; Tenofovir | 2018 |
CROI 2018: Advances in Antiretroviral Therapy.
Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; | 2018 |
Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Tablets; Tenofov | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, | 2018 |
Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Topics: Adenine; Administration, Rectal; Alanine; Animals; Anti-HIV Agents; Anti-Infective Agents; Enema; HI | 2019 |
Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chemoprevention; Fem | 2018 |
What did we learn from the bictegravir switch studies?
Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compoun | 2018 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T | 2018 |
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cross-Sectional Studies; Elvitegravir, Cobicistat, Emtrici | 2018 |
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Topics: Actinobacteria; Adenine; Alanine; Anti-Retroviral Agents; Bacteria; Endocytosis; Female; Gardnerella | 2018 |
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.
Topics: Adenine; Alanine; Anti-Retroviral Agents; Deoxyadenosines; Drug Resistance, Viral; HIV Infections; H | 2018 |
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
Topics: Adenine; Administration, Cutaneous; Animals; Antiviral Agents; Drug Delivery Systems; Emtricitabine; | 2018 |
Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
Topics: Adenine; Adult; Antiviral Agents; Dried Blood Spot Testing; Female; HIV Infections; Humans; Male; Mi | 2019 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV | 2019 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle | 2018 |
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Topics: Adenine; Anti-Retroviral Agents; Blood Cells; Emtricitabine; Genitalia, Male; HIV Infections; Humans | 2019 |
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Elvitegravir, Cobicistat, E | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; | 2019 |
Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Cell Line; Delayed-Action Preparations; Drug Liberation; Emtricit | 2019 |
Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.
Topics: Adenine; Adolescent; Anti-HIV Agents; Health Surveys; HIV Infections; Homosexuality, Male; Humans; M | 2019 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administr | 2019 |
Fanconi Syndrome and Tenofovir Alafenamide: A Case Report.
Topics: Adenine; Alanine; Antiviral Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Ten | 2019 |
Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Ma | 2019 |
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cervix Uteri; Drug Resistance, | 2019 |
Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Chromatography, Liquid; Comorbidity; Female; HIV Infect | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; | 2019 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; | 2019 |
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Stud | 2019 |
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
Topics: Adenine; Adult; Anti-Retroviral Agents; Central Nervous System Stimulants; Condoms; HIV Infections; | 2019 |
Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Female; HIV; HIV Infections; Humans; Male; Medication A | 2019 |
Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Monitoring; Female; HIV; HIV Infections; Hum | 2019 |
Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California.
Topics: Adenine; Adolescent; Adult; Black or African American; California; Emtricitabine; HIV Infections; Ho | 2019 |
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cell Count; Emtricitabine; HIV Infections; HIV-1; H | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compo | 2019 |
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Benzimidazoles; Blood Chemical Analysis; Chromatograph | 2019 |
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Topics: Adenine; Adult; Anti-HIV Agents; Dried Blood Spot Testing; Emtricitabine; Female; HIV Infections; Ho | 2019 |
Widening the Net for Pre-Exposure Prophylaxis for HIV
Topics: Adenine; Attitude to Health; Emtricitabine; Female; HIV Infections; Humans; Male; Phosphorous Acids; | 2019 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infe | 2020 |
Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Cross-Over Studies; Female; HIV; HIV Infections; Humans; Ke | 2019 |
Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.
Topics: Adenine; Alanine; Hepatitis B, Chronic; HIV Infections; Humans; Liver Transplantation; Tenofovir | 2020 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nut | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; | 2019 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmi | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi | 2013 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug | 2013 |
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
Topics: Adenine; Adult; Alpha-Globulins; Anti-Retroviral Agents; beta 2-Microglobulin; Biomarkers; Chi-Squar | 2013 |
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistanc | 2013 |
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross- | 2014 |
Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy.
Topics: Adenine; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; HIV Infections; Humans; Organophosphon | 2013 |
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1 | 2013 |
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antigens, CD34; Drug Evaluation, Preclini | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtrici | 2013 |
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Topics: Adenine; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cervix Uteri; Chemistry, Pharma | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxyc | 2013 |
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B viru | 2013 |
Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men.
Topics: Adenine; Adult; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Emtricitabine; Focus Groups; | 2014 |
Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Counseling; Deoxycytidine; Drug Resistance, Viral; D | 2013 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resi | 2013 |
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Health Re | 2013 |
Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com | 2013 |
In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Platelets; Case-Control Studies; CD40 Ligand; Cyclic GMP; Deo | 2013 |
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug | 2013 |
Vulnerability in research ethics: a way forward.
Topics: Adenine; Alzheimer Disease; Anti-HIV Agents; Cambodia; Community-Based Participatory Research; Ethic | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studi | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Ther | 2013 |
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community-Based Participatory Research; Deoxycyt | 2013 |
Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Chemoprevention; Deoxycytidine; Emtricitabine; Female; Heal | 2013 |
Peripheral T-cell apoptosis is not differentially affected by antiretroviral regimens in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-S | 2013 |
The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; | 2013 |
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug R | 2013 |
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Deoxycytidine; Emtricita | 2013 |
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Deoxycyt | 2013 |
Ethics and pre-exposure prophylaxis for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2013 |
Topical microbicides--what's new?
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Delivery Systems; Female; Gels; | 2013 |
HIV pre-exposure prophylaxis in injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
Topics: Adenine; Age Factors; Anti-Retroviral Agents; Cohort Studies; Contraindications; Female; France; Glo | 2013 |
Tenofovir helps prevent HIV in drug users.
Topics: Adenine; Anti-HIV Agents; Drug Users; HIV Infections; Humans; Organophosphonates; Substance-Related | 2013 |
Complera for the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV | 2013 |
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtri | 2013 |
[Pre-exposure prophylaxis for HIV transmission? No, unless].
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Org | 2013 |
Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphon | 2013 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; | 2013 |
Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
Topics: Adenine; Anti-HIV Agents; Asymptomatic Diseases; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Deoxycyt | 2013 |
Tenofovir-related nephrotoxicity: an ongoing clinical challenge.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Organo | 2013 |
Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; HIV Infe | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; | 2013 |
An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.
Topics: Adenine; Administration, Intravaginal; Antiviral Agents; Drug Delivery Systems; HeLa Cells; Heterose | 2013 |
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro | 2013 |
Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; | 2013 |
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
Topics: Adenine; Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Deoxycytidine; Drug R | 2013 |
Antiretroviral preexposure prophylaxis for preventing HIV infection in high-risk individuals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphonates; P | 2013 |
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudi | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Co | 2014 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cycl | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidi | 2013 |
Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Drug Therap | 2013 |
Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; | 2013 |
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
Topics: Adenine; Adult; Female; Hepatitis B virus; Hepatitis Delta Virus; HIV; HIV Infections; Humans; Inter | 2013 |
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Comorbidity; Denmark; Female; H | 2014 |
Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Inter | 2013 |
Preexposure prophylaxis reduces HIV risk in injection-drug users.
Topics: Adenine; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Comorbidity; Deox | 2013 |
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Dideoxynucl | 2014 |
In vivo antiviral activity of telbivudine against HIV-1: a case report.
Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
HIV antiretroviral prophylaxis for injecting drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
HIV antiretroviral prophylaxis for injecting drug users - Authors' reply.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; gag Gene Products, Human Immunodeficienc | 2013 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; | 2013 |
Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Bone | 2013 |
Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Epithelium; Female; HIV Infections; Humans; Models, Stat | 2013 |
Prophylactic tenofovir reduced HIV infection in injectable drug users.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Organophosphonates; Substance Abuse, | 2013 |
Acute kidney injury as a presentation of primary renal diffuse large B-cell lymphoma in HIV.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antinematodal Agents; Biopsy; HIV Infections; | 2014 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohor | 2014 |
An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databas | 2014 |
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes.
Topics: Adenine; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Ma | 2013 |
Low prevalence of renal dysfunction in HIV-infected pregnant women: implications for guidelines for the prevention of mother-to-child transmission of HIV.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Creatinine; F | 2013 |
Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Homosexua | 2013 |
A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Clinical Medicine; Creatinine; Cross-Sectional Studies; D | 2014 |
[Efficacy and tolerability of antiretroviral therapy containing tenofovir disoproxil fumarate-emtricitabine-efavirenz in treatment-naive patients infected with HIV-1 in Bobo Dioulasso (Burkina Faso, 2009-2011)].
Topics: Adenine; Adult; Anti-Retroviral Agents; Burkina Faso; Deoxycytidine; Drug Combinations; Drug-Related | 2013 |
Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.
Topics: Adenine; Adult; Anti-HIV Agents; Fractures, Stress; HIV Infections; Humans; Kidney Diseases; Male; O | 2014 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Mult | 2014 |
Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fat | 2014 |
Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2013 |
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Body Mass Index; Cohort Studies; Female; Glomerular Fi | 2014 |
Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female | 2014 |
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV- | 2014 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resis | 2014 |
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infecti | 2013 |
Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Topics: Adenine; Female; Gels; HIV Infections; Humans; Models, Theoretical; Organophosphonates; Reverse Tran | 2014 |
Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention.
Topics: Adenine; Animals; Anti-HIV Agents; Caveolins; Cell Line; Chitosan; Drug Delivery Systems; Fluorometr | 2014 |
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Cost-Benefit Analysis; Female; Forecasting; Herpes Gen | 2014 |
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligop | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclop | 2014 |
Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV I | 2014 |
HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cell Proliferation; Cells, Cu | 2014 |
Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Cross-Sectional | 2014 |
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Female; Glomerul | 2014 |
Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; | 2014 |
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Glomerular Fi | 2014 |
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; | 2014 |
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Disease Management; Emtricitabine; Female; HIV Infections; | 2014 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; | 2014 |
Focal bone lesions in HIV-positive patient treated with tenofovir.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonat | 2014 |
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2015 |
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Condoms; Disclosure; Female; Gels; HIV Infections | 2014 |
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2014 |
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Genitalia, | 2014 |
Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Mal | 2014 |
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Case-Control Studies; Condoms; Double-Blind | 2014 |
Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Creatinine; Fanconi Syndrome; Female; Glomeru | 2014 |
Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcripta | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P | 2014 |
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; India; Kidney Disea | 2014 |
Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study.
Topics: Adenine; Adult; Ambulatory Care Facilities; Anti-HIV Agents; CD4 Lymphocyte Count; Delivery of Healt | 2014 |
PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Topics: Adenine; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Dose-Response Relationship, Dr | 2014 |
Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Anti-Infective Agents; Drug Delivery Systems | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymp | 2014 |
Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Fanconi Syndrome; Fibroblast Growth Factor-23; Fibrob | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo | 2014 |
The preventive misconception: experiences from CAPRISA 004.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; Gels; HIV Infecti | 2014 |
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Substitution; Emtricita | 2014 |
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HI | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtric | 2014 |
ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; Gynecology; HIV Infections; H | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Com | 2014 |
An interesting case of 'diabetic foot ulcer' in an HIV-positive patient.
Topics: Adenine; Aged; Antiretroviral Therapy, Highly Active; Biopsy; Deoxycytidine; Diabetes Mellitus, Type | 2015 |
Perceptions of emtricitabine-tenofovir in HIV PrEP.
Topics: Adenine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Organophos | 2014 |
Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Disease Transmission, Infectious; HIV Inf | 2014 |
Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Disease Transmission, Infectious; HIV Inf | 2014 |
Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Disease Transmission, Infectious; HIV Inf | 2014 |
Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Disease Transmission, Infectious; HIV Inf | 2014 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cycl | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Huma | 2014 |
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Fem | 2014 |
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Data Collection; Deoxycytidine; Drug Combinations; | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Com | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Inf | 2014 |
A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; HIV Infections; Humans; Male; Middle Aged; Organoph | 2014 |
Tenofovir in HIV-infected children. Antiretroviral efficacy, but beware of adverse effects on bone and the kidneys.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; Child; Dose-Response Relationship, Drug; HIV Infections; Hu | 2014 |
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis | 2014 |
Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Delayed-Action Preparations; Deoxyc | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infection | 2014 |
Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; California; Deoxycytidine; Emtricitabine; Health | 2014 |
Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Topics: Adenine; Adult; Anilides; Anti-Infective Agents, Local; Colon; Drug Evaluation, Preclinical; Drug St | 2014 |
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtrici | 2014 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycy | 2015 |
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Topical; Anti-HIV Agents; Chemistry, Pharmace | 2015 |
Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosid | 2015 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV | 2014 |
Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis D, Chronic; HIV Infections; Humans; Liver Cirrhosis; Mal | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV | 2014 |
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Combinations; Drug Substi | 2015 |
A clinical prediction tool for targeted pre-antiretroviral therapy creatinine testing applied to the TREAT Asia HIV observational database cohort.
Topics: Adenine; Anti-HIV Agents; Clinical Medicine; Creatinine; Decision Support Techniques; Female; HIV In | 2014 |
Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Contraceptive Agents, Female; Delayed-Action Preparations; Deoxyc | 2014 |
Assessing adherence to the 2010 antiretroviral guidelines at the antiretroviral rollout clinic in 1 military hospital, South Africa: a retrospective, cross sectional study.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Monitoring; Drug Substitution; | 2014 |
High prevalence of signs of renal damage despite normal renal function in a cohort of HIV-infected patients: evaluation of associated factors.
Topics: Adenine; Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; D | 2014 |
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HI | 2014 |
Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.
Topics: Adenine; Adult; Amino Acid Substitution; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count | 2015 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2014 |
When is good good enough for HIV-1 prophylaxis?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organo | 2014 |
[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].
Topics: Adenine; Algorithms; Anti-HIV Agents; Biopsy; Cardiovascular Diseases; Disease Management; Evidence- | 2014 |
Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fema | 2015 |
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.
Topics: Adenine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Female; HIV Infections; Macaca nemes | 2015 |
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Desiccation; | 2015 |
[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Topics: Absorptiometry, Photon; Adenine; Anti-HIV Agents; Antiviral Agents; Body Composition; HIV Infections | 2014 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinic | 2015 |
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Blood Chemical Analysis; Chemoprevention; Deoxyc | 2014 |
HIV testing in pregnancy.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss | 2014 |
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Carriers; Drug Combin | 2015 |
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtr | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabin | 2015 |
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Alleles; Anti-HIV Agents; Biomarkers, Pharmacological; Case-Control Studies; Fanconi Syndro | 2015 |
Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
Topics: Adenine; Administration, Topical; Adult; Anti-HIV Agents; Biomarkers; Cellulose; DNA; Environmental | 2014 |
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cohort Studies; Deoxycytidine; Disease | 2015 |
Models for predicting effective HIV chemoprevention in women.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cell Culture Techniques; Cell Survival; Ch | 2015 |
Quiz Page January 2015: acute kidney injury in a patient with well-controlled HIV infection.
Topics: Acute Kidney Injury; Adenine; Aged, 80 and over; Anti-HIV Agents; Biopsy; CD4 Lymphocyte Count; Diag | 2015 |
Preexposure prophylaxis: a path forward.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Male; Organophos | 2015 |
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Genotype; Glomerular Filtration Rate; HIV I | 2015 |
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Contraceptive Agents; Deoxycytidine; Emtricitabi | 2015 |
Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Utilization; Drug-Related Side | 2015 |
Clinical trials. Renal safety of TDF as pre-exposure prophylaxis for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Glomerulus; Male; Organophos | 2015 |
Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV In | 2015 |
Synthesis of novel 2',3'-difluorinated 5'-deoxythreosyl phosphonic acid nucleosides as antiviral agents.
Topics: Acetates; Adenine; Anti-HIV Agents; Benzophenones; Chromatography, Thin Layer; Drug Design; Glyceral | 2015 |
Preventing HIV in women--still trying to find their VOICE.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans | 2015 |
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte C | 2015 |
Pre-exposure prophylaxis in women fails to prevent HIV infection in African study.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophospho | 2015 |
Renal tubular dysfunction associated with tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Developing Countries; Diagnosis, Differential; Female; | 2014 |
Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Apoptosis; Cell Line; Cell Survival; | 2015 |
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M | 2015 |
Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M | 2015 |
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antibody Affinity; Cohort Studies; Female; HIV; HIV Antibodi | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte C | 2015 |
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
Topics: Adenine; Adult; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Female; HIV Infections; Huma | 2015 |
Antiretroviral chemoprophylaxis: new successes and questions.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Deoxycytidine; Drug Combinations; | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops | 2015 |
Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Cell Survival; Cyclohexa | 2015 |
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Cytosol; Drug Interactions; Female; HIV In | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV | 2015 |
Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Drug Implants; Equipment Design; HIV Infections; H | 2015 |
Preexposure prophylaxis for HIV infection.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophospho | 2015 |
Pre-exposure prophylaxis works--it's time to deliver.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Health Services Accessibility; HIV Infection | 2015 |
Infectious disease: New HIV-1 prodrug shows promise in phase III trials.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Female; HIV Infections; Humans; Male; Organopho | 2015 |
HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Deoxycytidine; Emtricitabine; Female; Fertile Perio | 2015 |
Many in VOICE trial didn't use provided prevention products.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Female; Gels; HIV Infections; Humans; M | 2015 |
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD34; Bone Marrow; CD8-Positive T-Lymphocytes; Disease | 2015 |
VOICE reveals the need to improve adherence in PrEP trials.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophospho | 2015 |
Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Male; M | 2016 |
The FACTS about women and pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antibiotic Prophylaxis; Female; HIV Infections; HIV-1; Humans; Post-Exposu | 2015 |
Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Tenofovir | 2015 |
Tenofovir alafenamide for HIV: time to switch?
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2016 |
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bisexuality; Chlamydia Infections; Community Health Ser | 2016 |
Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Topics: Adenine; Biological Assay; Dried Blood Spot Testing; Emtricitabine; Erythrocytes; Hematocrit; HIV In | 2016 |
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Heterocyc | 2016 |
Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.
Topics: Acute Kidney Injury; Adenine; Alanine; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infect | 2016 |
[New NRTI with optimized long-term tolerance].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Drug Tolerance; HIV Infections; Humans; Tenofo | 2015 |
CDC trial: HIV PrEP works for heterosexuals. A 63% reduction in HIV risk.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Heterosexuality; HIV Inf | 2011 |
Tenofovir tablet not effective in preventing HIV in women.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tablets; Tenofovir | 2011 |
Tenofovir alafenamide: safer, but questions remain.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; HIV Infections; HIV-1; Humans; Organophosphonates; Tenof | 2016 |
Editorial.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effect | 2016 |
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn | 2016 |
[Brief notes. Approval recommendation for fixed combination Descovy(R) in treatment of HIV].
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug | 2016 |
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Area Under Curve; Case-Control Studies; Female; Glomerular | 2016 |
Determinants of bone diseases in tenofovir-treated HIV patients.
Topics: Adenine; Anti-HIV Agents; Bone Diseases; HIV Infections; Humans; Tenofovir | 2016 |
[Optimized therapy].
Topics: Adenine; Alanine; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy | 2016 |
Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Emtricitabine; HIV Infections; HIV-1; Humans | 2016 |
Real-World Experiences with Tenofovir Disoproxil Fumarate: Is this the "B-Ticket"?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Tenofovir | 2016 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabin | 2016 |
Immune reconstitution inflammatory syndrome associated with dermatophytoses in two HIV-1 positive patients in rural Tanzania: a case report.
Topics: Adenine; Adult; Africa; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2016 |
Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Black People; Chicago; Cities; Condoms; | 2016 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combination | 2017 |
Tenofovir disoproxil fumarate-associated bone loss: does vitamin D-binding protein play a role?
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Tenofovir; Vitamin D-Binding Protein | 2017 |
[Tenofovir alafenamide fumarate - a new generation of tenofovir].
Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Tenofovir | 2016 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat | 2017 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat | 2017 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat | 2017 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat | 2017 |
Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organic Cation Transporter 1; Tenofovir | 2017 |
Response to "Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1".
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organic Cation Transporter 1; Tenofovir | 2017 |
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HI | 2017 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organoph | 2017 |
Tenofovir prodrugs: similar but not the same.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Prodrugs; Reverse Transcriptase Inhibitors; Tenofo | 2017 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid | 2008 |
Genetic basis of variation in tenofovir drug susceptibility in HIV-1.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genetic Variation; Genotype; | 2008 |
Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; Cyclopr | 2008 |
FDA notifications. FDA's tentative approval for generic Tenofovir.
Topics: Adenine; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; Reverse Transcri | 2008 |
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV- | 2008 |
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Mul | 2008 |
Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Topics: Adenine; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Glomerular Filtration Rat | 2008 |
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Deoxycytidine; Emtricitabine; HIV Inf | 2008 |
Can a topical microbicide prevent rectal HIV transmission?
Topics: Adenine; Animals; Anti-Infective Agents, Local; HIV Infections; Macaca; Organophosphonates; Tenofovi | 2008 |
Tenofovir-associated decline in renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease In | 2008 |
Antiretroviral rounds. Is that "one pill" treatment enough?
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir | 2008 |
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
Topics: Adenine; Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Chemoprevention; Deoxycy | 2008 |
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2008 |
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Dideo | 2008 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Centra | 2009 |
Disinhibition and risk compensation: scope, definitions, and perspective.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Counseling; Female; HIV Infecti | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2008 |
Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2008 |
Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.
Topics: Adenine; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; D | 2008 |
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropane | 2008 |
[First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Ther | 2008 |
[Complete HAART in a single pill. New milestone for improving compliance].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; D | 2008 |
[HIV therapy and adherence].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Comb | 2008 |
[One pill--all HAART. Complete divergent HAART in a single tablet per day].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycytidine; Drug Admini | 2008 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisp | 2009 |
The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.
Topics: Adenine; Anti-HIV Agents; Bayes Theorem; Data Interpretation, Statistical; Databases, Nucleic Acid; | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabin | 2008 |
[A case of acute renal failure involving high amounts of tenofovir after HAART start].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Fail | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc | 2009 |
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
Topics: Adenine; Adult; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged | 2009 |
Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Fanconi Syndrome; HIV Infections; Huma | 2009 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface An | 2009 |
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; | 2009 |
HIV-1 infection of human penile explant tissue and protection by candidate microbicides.
Topics: Adenine; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytokines; Foreskin; HIV Infections; HIV-1; H | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; | 2009 |
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studi | 2009 |
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Computer Simulation; Cost-Benefit Analysis; Deoxyc | 2009 |
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Human | 2008 |
[Introduction. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosp | 2008 |
[Conclusions. Tenofovir].
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Hu | 2008 |
A preemptive strike against HIV.
Topics: Adenine; Animals; Clinical Trials as Topic; HIV Infections; Humans; Organophosphonates; Reverse Tran | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, C | 2009 |
Study shows people can safely switch to Atripla.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2009 |
Reverse transcriptase inhibitors as potential colorectal microbicides.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Infective Agents, Local; Colon; Drug Resistance, Viral; Fur | 2009 |
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Epi | 2009 |
Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
Topics: Adenine; Bone Density Conservation Agents; Fanconi Syndrome; Female; Fractures, Bone; HIV Infections | 2009 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanos | 2009 |
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
Topics: Adenine; Antiviral Agents; Base Sequence; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genetic V | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; | 2009 |
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Topics: Adenine; Adult; Anti-HIV Agents; Diabetes Insipidus; Didanosine; Drug Therapy, Combination; Fanconi | 2009 |
Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Diabetes Insipidus; Didanosine; Drug Therapy, Co | 2009 |
Gilead is going strong.
Topics: Adenine; Anti-HIV Agents; California; Commerce; Drug Combinations; Drug Industry; HIV Infections; Hu | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinav | 2009 |
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Glomerular Filtration Rate; HIV In | 2009 |
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Topics: Adenine; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2009 |
Rationing antiretroviral therapy in Africa--treating too few, too late.
Topics: Adenine; Africa; Anti-Retroviral Agents; CD4 Lymphocyte Count; Developing Countries; Drug Administra | 2009 |
Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination; HIV Infections; Humans; O | 2009 |
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; | 2009 |
Generic Truvada approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricita | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, V | 2009 |
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; HI | 2009 |
Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Drug Therapy, | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Inf | 2009 |
Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; D | 2009 |
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Female | 2009 |
Tenofovir-associated renal and bone toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Fanconi Syndrome; Female; Glycosuria; HIV Infections; H | 2009 |
Tapping into combination pills for HIV.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Drug Industry; Efavirenz, Emtrici | 2009 |
FDA notifications. Tenofovir in India receives tentative approval.
Topics: Adenine; Drug Approval; HIV Infections; India; Organophosphonates; Reverse Transcriptase Inhibitors; | 2009 |
Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
Topics: Adenine; Adult; Aged; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Ac | 2009 |
HIV clinics are halting enrolment of new patients as funding stalls, MSF warns.
Topics: Adenine; Anti-HIV Agents; Developing Countries; Drug Costs; HIV Infections; Hospitals, Special; Huma | 2009 |
The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; HIV Infectio | 2009 |
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Inf | 2009 |
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxaz | 2009 |
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female; | 2010 |
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucle | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymp | 2010 |
HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
Topics: Adenine; Anti-HIV Agents; Diagnostic Tests, Routine; Glomerular Filtration Rate; Health Resources; H | 2009 |
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guan | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flo | 2009 |
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; | 2009 |
[One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lympho | 2009 |
Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Topics: Acetylglucosaminidase; Adenine; Adult; Aged; Albuminuria; Anti-Retroviral Agents; Creatinine; Cross- | 2009 |
Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
Topics: Adenine; Adult; Blood Flow Velocity; Deoxycytidine; Edema; Emtricitabine; HIV Infections; Humans; Le | 2009 |
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Creatinine; Fanconi Syndrome; | 2010 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; | 2009 |
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; | 2009 |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity | 2009 |
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2009 |
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Epidemiologic Me | 2010 |
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynuc | 2010 |
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Huma | 2010 |
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Topics: Adenine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface | 2010 |
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Infective Agents; Antiviral Agents; Biomarkers; | 2009 |
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug C | 2009 |
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.
Topics: Adenine; Adult; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Fem | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Respons | 2010 |
Microbicide research already benefiting thousands--experts.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Biomedical Research; HIV In | 2009 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricita | 2010 |
Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Incidence; Organophosphonates; R | 2010 |
Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectio | 2010 |
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combin | 2010 |
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; California; Cohort Studies; Drug Resistance, Vira | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxyc | 2010 |
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Case-Control Studies; Child; Child, Preschool; England; Female | 2010 |
Recent FDA approvals and changes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Approval | 2010 |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HI | 2010 |
Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
Topics: Adenine; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Kidney Disease | 2010 |
Tenofovir and changes in renal function.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Re | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Vir | 2010 |
Single-tablet Quad regimen achieves high rate of virologic suppression.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials, Phase II as Top | 2010 |
Disseminated bartonellosis presenting as neuroretinitis in a young adult with human immunodeficiency virus infection.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Bartonella; Bartonella Infections; Biopsy; Deoxycyt | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; | 2010 |
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Organophosp | 2010 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developin | 2010 |
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphon | 2010 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytid | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HI | 2010 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV In | 2010 |
Recent FDA approvals and changes.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Child; Delayed-Action Preparations; Didanosine; Drug Ap | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; D | 2010 |
[HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].
Topics: Adenine; Alkynes; Anti-HIV Agents; Autoantibodies; Benzoxazines; Cyclopropanes; Deoxycytidine; Diagn | 2010 |
Prevalence and factors associated with renal dysfunction among HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Fem | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Vir | 2010 |
Advantages of low-cost generic tenofovir instead of D4T for first-line antiretroviral therapy in Burma: a 2-year experience.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; HIV Infectio | 2010 |
The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial.
Topics: Adenine; Anti-HIV Agents; Cameroon; Ethics, Research; Female; HIV Infections; Human Rights; Humans; | 2010 |
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Cost-Be | 2010 |
FDA notifications. Updated Atripla label approved.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Labeling; Efavirenz, Emtricitabine, | 2010 |
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Org | 2010 |
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Femal | 2010 |
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; L | 2010 |
HIV/AIDS. At last, vaginal gel scores victory against HIV.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents, Local; Female; HIV Infections; H | 2010 |
No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Ef | 2010 |
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.
Topics: Adenine; Cardiovascular Diseases; Dideoxynucleosides; HIV Infections; Humans; Male; Middle Aged; Org | 2010 |
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-S | 2010 |
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atherosclerosis; Female; HIV Infections; HIV-1; Huma | 2010 |
Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency.
Topics: Adenine; Adult; Female; HIV Infections; HIV-1; Humans; Hyperparathyroidism; Male; Middle Aged; Organ | 2010 |
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Dose-Response Relationship, | 2010 |
Antiretroviral vaginal gel shows promise against HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Clinical Trials as Topic; Female; Gels; HIV | 2010 |
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Chromatography, Li | 2010 |
After CAPRISA 004: time to re-evaluate the HIV lexicon.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Female; Gels; HIV Infe | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Fe | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Dru | 2010 |
Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
Topics: Adenine; Adult; Antiviral Agents; Female; France; Hepatitis B Antibodies; Hepatitis B Antigens; Hepa | 2010 |
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Biopsy; Drug Administration Schedule; Female; | 2010 |
Trial results finally show potential for microbicidal HIV gel.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Female; Gels; HIV; HIV Infections; Hum | 2010 |
Still a long wait for approved HIV-protective gel.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine, Tenofovir | 2010 |
Low bone mineral density with tenofovir: does statistically significant mean clinically significant?
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Bone Diseases; Female; Fractures, Bone; HIV Infection | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d | 2011 |
Preventing HIV infection: turning the tide for young women.
Topics: Adenine; Adolescent; Africa South of the Sahara; Antiviral Agents; Female; HIV Infections; HIV-1; Hu | 2010 |
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2010 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; | 2010 |
A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Calcifi | 2010 |
In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.
Topics: Adenine; Anilides; Anti-Infective Agents; Benzofurans; Cell Line; Cell Survival; Cervix Uteri; Epith | 2010 |
Implications of HIV PrEP trials results.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; | 2011 |
Prevention. Study reveals that vaginal gel reduces HIV, herpes.
Topics: Adenine; Female; Gels; Herpes Genitalis; HIV Infections; Humans; Organophosphonates; Reverse Transcr | 2010 |
Virologic and clinical outcomes in HIV/HBV coinfected patients on tenofovir-containing HAART.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infection | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas D | 2011 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2010 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cr | 2010 |
Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Child; Child, | 2010 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Topics: Absorptiometry, Photon; Adenine; Aged; Antiretroviral Therapy, Highly Active; Bone Density; Cohort S | 2010 |
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropane | 2010 |
[Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocy | 2011 |
The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Didano | 2011 |
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Cohort Studies; Drug Interactions; Fe | 2010 |
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
Topics: Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; K | 2011 |
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Topics: Acute Kidney Injury; Adenine; Animals; Anti-HIV Agents; Drug Administration Schedule; Glycosuria; HI | 2010 |
Oral preexposure prophylaxis for HIV--another arrow in the quiver?
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Vi | 2010 |
Lipid-lowering effect of tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Anticholesteremic Agents; Female; HIV Infections; Humans; Lipids; M | 2011 |
First real success for anti-HIV gel: a new start for HIV microbicides?
Topics: Adenine; Adolescent; Adult; Anti-Infective Agents; Controlled Clinical Trials as Topic; Disease Tran | 2010 |
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Canada; Female; Herpes Simplex; Herpesvirus 1 | 2011 |
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV | 2011 |
Avascular necrosis of the talus in a HIV-infected patient.
Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; | 2010 |
The ART of preventing HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Circumcision, Male; Deoxycytidine; Emtricit | 2011 |
Microbicides & their implications in HIV prevention.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infections; H | 2010 |
HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV-2; Humans; India; Organophosphonates; Prevalence; Teno | 2010 |
AIDS: Drugs that prevent HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Administration, Intravaginal; Administration, Oral; Ani | 2011 |
HIV prevention in women: next steps.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Coitus; | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; De | 2011 |
Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adenine; Aged; Anti-HIV Agents; Diabetes Mellitus, Type 2; Dr | 2011 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administra | 2011 |
Is tenofovir-related renal toxicity incompletely reversible?
Topics: Adenine; Adult; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases | 2011 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combina | 2011 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Fa | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; D | 2011 |
Analysis of resistance testing in South Trinidad.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infectio | 2010 |
Low incidence of renal impairment observed in tenofovir-treated patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; | 2011 |
Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.
Topics: Adenine; Adult; Anti-HIV Agents; HIV Infections; Humans; Isotope Labeling; Linear Models; Organophos | 2011 |
[HIV and AIDS: what's new in 2010?].
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Chemoprevention; Gels; HIV Infections; Humans; Org | 2011 |
[Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir].
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Middle Aged; Organophospho | 2011 |
Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Culture Techniques; Cell Line; Cell Sur | 2011 |
Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Follow-Up Studies; Hepatitis B Surface Antigens; Hepatitis B | 2011 |
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricit | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Age Factors; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Co | 2011 |
Preexposure chemoprophylaxis for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Costs; Drug Therapy, Combination; Emtricitabine; HIV I | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropan | 2011 |
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
Topics: Adenine; Anti-HIV Agents; Cell Line; Drug Synergism; HIV Envelope Protein gp120; HIV Infections; HIV | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabi | 2011 |
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Topics: Adenine; Anti-Retroviral Agents; Biomarkers, Pharmacological; Cardiovascular Diseases; CD4 Lymphocyt | 2011 |
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease | 2011 |
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Deoxyadenine Nucleotides; HIV Infections; HIV Re | 2011 |
Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
Topics: Adenine; Adolescent; Adult; Child; Cohort Studies; Creatinine; Female; Follow-Up Studies; Glomerular | 2011 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; C | 2011 |
Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.
Topics: Adenine; Adult; Anti-HIV Agents; Diphosphates; Fanconi Syndrome; HIV Infections; Humans; Male; Middl | 2011 |
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Topics: Adenine; Adult; Africa; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Fem | 2011 |
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Topics: Adenine; Administration, Topical; Animals; Base Sequence; CD4-Positive T-Lymphocytes; Chimera; Disea | 2011 |
[Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytid | 2011 |
Early end for FEM-PrEP HIV prevention trial.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emt | 2011 |
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Kidney; Kidney Diseases; Kidney Tubules; M | 2011 |
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organopho | 2011 |
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney; | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Rel | 2011 |
Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV Inf | 2011 |
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Topics: Adenine; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Incidence; Models, | 2011 |
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Case-Control Studies; Female; G | 2011 |
Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion.
Topics: Adenine; Adhesiveness; Analysis of Variance; Animals; Anti-HIV Agents; Cell Survival; Chitosan; Drug | 2011 |
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans | 2011 |
Determination of kidney function before tenofovir initiation: four-fold difference in need of tenofovir dose reduction depending on method used.
Topics: Adenine; Adult; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rat | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Com | 2011 |
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.
Topics: Adenine; Adult; Blood-Brain Barrier; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; M | 2011 |
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine | 2011 |
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.
Topics: Adenine; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Organophosphonat | 2011 |
pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Cell Line; Cell Survival; Drug Carriers; Dru | 2011 |
Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophos | 2011 |
Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
Topics: Adenine; Animals; Cardiomyopathies; Cell Separation; DNA, Mitochondrial; Female; HIV Infections; HIV | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; | 2011 |
Antiretrovirals for HIV prevention: translating promise into praxis.
Topics: Adenine; Administration, Cutaneous; Administration, Oral; Algorithms; Anti-HIV Agents; Anti-Retrovir | 2011 |
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Africa South of the Sahara; Anti-HIV Ag | 2011 |
Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Randomized Controlled Trials a | 2011 |
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Devel | 2011 |
Antiretroviral prophylaxis: a defining moment in HIV control.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Clinical Trials as | 2011 |
Association of osteonecrosis and osteoporosis in HIV-1-infected patients.
Topics: Absorptiometry, Photon; Adenine; Alcohol Drinking; Anti-HIV Agents; California; Female; HIV Infectio | 2011 |
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infect | 2011 |
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidi | 2011 |
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Body Weight; Cohort Studies; Female; Glomerular Filtr | 2011 |
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; | 2012 |
A case of lactic acidosis (LA) after administration of tenofovir and metformin in a diabetic patient with recently diagnosed HIV infection.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Diabetes Mellitus, Type 2; HIV Infections; Humans; Hypog | 2011 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtrici | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD | 2011 |
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glo | 2011 |
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepati | 2011 |
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.
Topics: Adenine; Anti-Retroviral Agents; Cell Line; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HI | 2011 |
Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL2; Dideoxynucleosides; Endotheli | 2011 |
Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Or | 2011 |
Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Kidney | 2011 |
Modeling interventions to assess HIV epidemic impact in Africa.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; Humans; Organophosphonates; Tenofovir | 2011 |
Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Topics: Adenine; Adult; Alpha-Globulins; Anti-HIV Agents; Creatinine; Female; Glomerular Filtration Rate; HI | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; | 2011 |
Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Therapy, Combin | 2012 |
Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil | 2011 |
Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Drug Administration Schedule; Female; Glomerular | 2012 |
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Antiviral Agents; Area Under | 2012 |
Microbicide might protect pregnant women from HIV. Susceptibility is high for them.
Topics: Adenine; Disease Susceptibility; Female; HIV Infections; Humans; Organophosphonates; Pregnancy; Preg | 2011 |
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.
Topics: Adenine; Adult; Albuminuria; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; Chi-Square Dis | 2011 |
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
Topics: Adenine; Adult; Analgesics, Opioid; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; | 2011 |
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Remodeling; CD4 Lymphocy | 2011 |
Resistance data in the ARTEN trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopept | 2011 |
Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinatio | 2012 |
Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Administration, Topical; Anti-HIV Agent | 2012 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combi | 2011 |
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug T | 2011 |
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Drug Stability; Female; Half-Life; HIV Infection | 2012 |
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Combinations; Educational Stat | 2012 |
Re.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Topics: Adenine; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy | 2011 |
Re.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; HIV Infections; Homosexuality, Male; Humans; Male; Organoph | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dr | 2012 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cli | 2012 |
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Huma | 2011 |
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; | 2012 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delaye | 2012 |
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosid | 2012 |
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combi | 2012 |
In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Child; Child | 2011 |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Topics: Adenine; Anti-HIV Agents; Apoptosis; Cardiovascular Diseases; Cell Adhesion Molecules; Coronary Vess | 2011 |
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Deoxycytidine; Emtricitabine; Female; | 2011 |
FDA notifications. Complera approved.
Topics: Adenine; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Emtricitabine; HIV Infectio | 2011 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; H | 2012 |
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; H | 2012 |
Tenofovir-induced nephrotoxicity: myths and facts.
Topics: Adenine; Animals; Anti-HIV Agents; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Kidney Di | 2012 |
Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Body Weight; Demography; Dideoxynucleosides; | 2012 |
Combination of antiretroviral drugs as microbicides.
Topics: Adenine; Anti-Infective Agents, Local; Anti-Retroviral Agents; Drug Therapy, Combination; HIV Infect | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Vira | 2012 |
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans | 2012 |
HIV preexposure prophylaxis: new data and potential use.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Evidence-Based Me | 2011 |
Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Dideoxyn | 2012 |
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hi | 2012 |
An unrecognised case of tenofovir-associated Fanconi syndrome.
Topics: Adenine; Adolescent; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; Humans; Male; Organophosphon | 2012 |
Association of tenofovir exposure with kidney disease risk in HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infectio | 2012 |
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Topics: Adenine; Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genomics | 2012 |
Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up | 2012 |
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Deoxycyt | 2012 |
Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antibodies, Monoclonal; Antiretroviral Therap | 2012 |
Least among equals.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2012 |
Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Body Mass Index; Bone Density; Case-Control | 2012 |
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; CD4-Positive T-Lymphocytes; Female; HIV Infe | 2012 |
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fuma | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; Franc | 2012 |
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Topics: Adenine; Anti-HIV Agents; Body Size; Child Development; Drug Therapy, Combination; Female; HIV Infec | 2012 |
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide.
Topics: Adenine; Animals; Anti-Infective Agents; Benzalkonium Compounds; Biomarkers; Carboxymethylcellulose | 2012 |
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Anti-HIV Agents; Body Fluids | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; | 2012 |
HIV-1 and HIV-2 infections induce autophagy in Jurkat and CD4+ T cells.
Topics: Adenine; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 12; Autophagy-Related P | 2012 |
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Topics: Adenine; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Cervix Uteri; Chromatography, High Press | 2012 |
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings.
Topics: Adenine; Anti-Infective Agents; Antiviral Agents; Biocompatible Materials; Body Fluids; Contraceptiv | 2012 |
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Topics: Adenine; Antiviral Agents; Cell Culture Techniques; Chemoprevention; Contraceptive Devices, Female; | 2012 |
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Female; HIV Infections; Hum | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, | 2012 |
Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Follow-Up Studies; | 2012 |
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topi | 2012 |
Reformulated tenofovir gel for use as a dual compartment microbicide.
Topics: Adenine; Anti-HIV Agents; Anti-Infective Agents; Disease Transmission, Infectious; Female; HIV Infec | 2012 |
Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?
Topics: Adenine; Anti-HIV Agents; Body Size; Female; HIV Infections; Humans; Infant, Newborn; Male; Organoph | 2012 |
Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lym | 2012 |
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; O | 2012 |
Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
Topics: Adenine; Administration, Oral; Amniotic Fluid; Animals; Anti-HIV Agents; Chromatography, High Pressu | 2012 |
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropa | 2012 |
An intravaginal ring for the simultaneous delivery of multiple drugs.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Delayed-Action Preparat | 2012 |
The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.
Topics: Adenine; Atherosclerosis; Chemokine CCL2; HIV Infections; Interleukin-6; Organophosphonates; Prospec | 2012 |
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2012 |
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.
Topics: Adenine; Administration, Intravaginal; Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Co | 2012 |
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort S | 2012 |
Efavirenz and psychosis: is there a link?
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Efavirenz, E | 2012 |
Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Contraceptive Devices, Female; Delayed-Action Pr | 2012 |
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Antiretroviral Therapy, Highly A | 2012 |
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HI | 2012 |
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.
Topics: Adenine; Adult; Antiviral Agents; Congenital Abnormalities; Female; Hepatitis B; Hepatitis B virus; | 2012 |
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Administra | 2012 |
Preexposure prophylaxis for HIV--where do we go from here?
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention.
Topics: Adenine; Adolescent; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female | 2012 |
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec | 2012 |
The introduction of new antiretroviral-based HIV prevention methods into health systems: an update.
Topics: Adenine; Africa South of the Sahara; Anti-Retroviral Agents; Deoxycytidine; Drug Combinations; Emtri | 2012 |
Prevention. Using PrEP cost-effective in high-risk MSM groups.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Costs; Emtricitabine; HIV Infection | 2012 |
Research. Fetuses unaffected by tenofovir, 1-year-olds appear slightly smaller.
Topics: Adenine; Female; Fetus; Growth; HIV Infections; Humans; Infant; Organophosphonates; Pregnancy; Pregn | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycyti | 2012 |
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Topics: Adenine; Administration, Oral; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Intr | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus | 2012 |
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disea | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, C | 2012 |
FDA paves the way for pre-exposure HIV prophylaxis.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Emtrici | 2012 |
Tenofovir-associated proteinuria.
Topics: Adenine; Anti-HIV Agents; Creatine; Female; HIV Infections; Humans; Male; Middle Aged; Organophospho | 2013 |
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Centers for Disease Control and Preven | 2012 |
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV | 2012 |
High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Kidney; Kidne | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox | 2012 |
Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
Topics: Adenine; Anti-HIV Agents; Catalysis; Creatine Kinase, Mitochondrial Form; Enzyme Stability; Follow-U | 2013 |
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.
Topics: Adenine; Adult; Africa South of the Sahara; Anti-Retroviral Agents; Cost-Benefit Analysis; Drug Resi | 2012 |
Preexposure prophylaxis for the prevention of HIV transmission to women.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Cost-Benefit Analysis; Deoxycytidine; Directive Counselin | 2013 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopro | 2013 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Hu | 2012 |
FDA treads carefully with PrEP.
Topics: Adenine; Anti-HIV Agents; Chemoprevention; Deoxycytidine; Drug Approval; Drug Combinations; Drug Res | 2012 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Chemical Analysis; Chromatography, Liquid; Deoxycytidine; Des | 2013 |
Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Topics: Adenine; Administration, Mucosal; Anti-Infective Agents; Cell Line; Cell Survival; Chemoprevention; | 2012 |
Antiretroviral medications as prevention: will the new paradigm reverse the HIV epidemic?
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Epidemics; Female | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communi | 2012 |
Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.
Topics: Adenine; Adult; Cohort Studies; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; | 2012 |
Quantification of tenofovir in human plasma by solid-phase extraction and high-performance liquid chromatography coupled with UV detection.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Infections; | 2012 |
A perspective on progress and gaps in HIV prevention science.
Topics: Adenine; Administration, Oral; Administration, Topical; Anal Canal; Anti-HIV Agents; Chemoprevention | 2012 |
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Didan | 2012 |
Drug-induced acute interstitial nephritis mimicking acute tubular necrosis after initiation of tenofovir-containing antiretroviral therapy in patient with HIV-1 infection.
Topics: Acute Disease; Adenine; Aged; Anti-Retroviral Agents; Biopsy; Diagnosis, Differential; HIV Infection | 2012 |
The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Calcium; Cohort Studies; Ethnicity; Female; HIV Infec | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabi | 2013 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 | 2013 |
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Chromatography, High Pressure Liqui | 2012 |
Clinical decisions. Preexposure prophylaxis for HIV prevention--polling results.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphon | 2012 |
Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infecti | 2013 |
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
Topics: Adenine; Anti-HIV Agents; Central Nervous System; Drug Administration Schedule; Drug Interactions; F | 2012 |
Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Topics: Adenine; Adolescent; Adult; Age Factors; Anti-HIV Agents; Biological Availability; Child; Chromatogr | 2013 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyt | 2012 |
Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
Topics: Adenine; Anti-HIV Agents; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Failure | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytid | 2012 |
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; Humans; Live | 2013 |
Microbicides are promoted as offering a 'female-controlled' HIV prevention method: so can they revolutionize the HIV crisis of young women in Kenya?
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; Awards and Prizes; Chemopreventi | 2012 |
[Preexposure prophylaxis for HIV infection--current data and recommendations].
Topics: Adenine; Africa; Anti-HIV Agents; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Resistanc | 2012 |
An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Creatine Kinase; Creatine Kinase, MB Form; Electrophoresis; | 2013 |
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Topics: Adenine; Adult; Anti-HIV Agents; Blood Cells; Deoxycytidine; Diphosphates; Emtricitabine; Female; HI | 2013 |
Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Genotype; | 2013 |
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
Topics: Adenine; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Efav | 2012 |
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtr | 2013 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Co | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Bl | 2012 |
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic | 2013 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hep | 2013 |
Elvitegravir/cobicistat, mirabegron, and linaclotide.
Topics: Acetanilides; Adenine; Anti-Retroviral Agents; Carbamates; Constipation; Deoxycytidine; Drug Combina | 2012 |
Novel HIV-1 treatment Stribild™ gains regulatory approval.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, | 2012 |
Improved adherence expected with new HIV combo treatment.
Topics: Adenine; Aged; Aged, 80 and over; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Dru | 2012 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Fe | 2013 |
Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.
Topics: Adenine; Adolescent; Anti-HIV Agents; Black or African American; Child; Cohort Studies; Female; Hisp | 2013 |
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Topics: Acetylglucosaminidase; Acute-Phase Proteins; Adenine; Adult; beta 2-Microglobulin; Biomarkers; Femal | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
Coverage, context and targeted prevention: optimising our impact.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Deoxycytidine; Emtricitabine; Female; Health Prioritie | 2013 |
Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.
Topics: Adenine; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; HIV Infections; Humans; Hydrogen-I | 2013 |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinati | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organop | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organop | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organop | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organop | 2013 |
Antiretroviral preexposure prophylaxis for HIV prevention.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Organophospho | 2013 |
Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.
Topics: Adenine; Adult; Anti-HIV Agents; Attention; Female; HIV Infections; Humans; Middle Aged; Organophosp | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; | 2013 |
Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Gene Expression Regulation, Enzymologic; Gene Expr | 2012 |
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfectio | 2013 |
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Deoxycytidine | 2013 |
Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Male; Organop | 2013 |
HIV transmission may be prevented by intravaginal tenofovir ring.
Topics: Adenine; Administration, Intravaginal; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infection | 2012 |
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine | 2013 |
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Female; Genotype; Hepatitis B e A | 2013 |
ASN clinical pathological conference. Tenofovir-related ATN (severe).
Topics: Adenine; Anti-HIV Agents; Biopsy; Diagnosis, Differential; Glomerulonephritis, IGA; HIV Infections; | 2013 |
Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure.
Topics: Adenine; Adult; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fum | 2012 |
A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.
Topics: Adenine; Anti-HIV Agents; Computer Simulation; Drug Resistance, Viral; HIV Infections; Humans; Medic | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies | 2013 |
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV In | 2002 |
Tenofovir DF expanded access. Criteria for U.S. program.
Topics: Adenine; Drug Approval; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compoun | 2001 |
Antiretroviral news from ICAAC 2000.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance; HIV I | 2000 |
Tenofovir gel studied.
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase I as Topic; Female; Gels; HIV Infections; Humans; O | 2002 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Dr | 2002 |
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Topics: Adenine; Anti-HIV Agents; Databases, Factual; Dideoxynucleosides; Drug Resistance, Viral; Drug Thera | 2002 |
[First nucleotide analog against HIV. Lowers viral load also in drug resistance].
Topics: Adenine; Anti-HIV Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Viral; HIV Infections | 2002 |
[Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV-1 | 2002 |
Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatine Kinase; HIV Infections; Hu | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans | 2002 |
Editorial comment: a tale of two viruses.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV I | 2002 |
Would switching the protease inhibitors (PI) to tenoforvir be an option in controlling hypertriglyceridaemia secondary to PIs? A case report.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Male; Middle Aged; O | 2002 |
Tenofovir DF trial announced by Gilead.
Topics: Adenine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Infections; Hu | 2000 |
Prevention: new approach will test tenofovir for persons at high risk.
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcripta | 2002 |
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidne | 2002 |
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; He | 2003 |
Tenofovir (Viread(R)) access for poor countries.
Topics: Adenine; Developing Countries; HIV Infections; Humans; Organophosphonates; Organophosphorus Compound | 2002 |
Tenofovir helps beat hepatitis B.
Topics: Adenine; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis B; Hepatitis B virus; HIV; HIV Infections | 2003 |
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, | 2003 |
New uses for tenofovir: more questions about d4T.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Organophosphorus Com | 2003 |
Renal lesions in HIV-1-positive patient treated with tenofovir.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Fanconi Syndrome; HIV Infections; HIV-1; Humans; Male | 2003 |
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Topics: Acidosis; Adenine; Adult; Anti-HIV Agents; Creatinine; Diabetes Insipidus, Nephrogenic; Drug Monitor | 2003 |
Manufacturer end adefovir development.
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Reverse Transcriptase Inhibitors | 2000 |
[96-week treatment outcome confirms long term efficacy of tenofovir DF].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as | 2003 |
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
Topics: Acetaldehyde; Adenine; Chromatography, Liquid; HIV Infections; Humans; Organophosphonates; Organopho | 2003 |
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Interactions; Female; HIV In | 2003 |
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Enfuvirtide; Ganciclovir; Hepa | 2003 |
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; H | 2003 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV- | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; Gastrointestinal Diseases; HIV Inf | 2003 |
Preemptive use of antiretroviral drugs to prevent sexual transmission of HIV to high-risk uninfected MSM.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic | 2003 |
Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography.
Topics: Adenine; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Infections; Humans; Organophosph | 2003 |
Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Topics: Adenine; Adult; Didanosine; Drug Interactions; Fatal Outcome; Female; HIV Infections; Humans; Male; | 2003 |
[HIV therapy: tenofir DF is available in 68 developing countries at production costs price].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Developing Countries; Drug Costs; Drug Industry; Hea | 2003 |
Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Male; Or | 2003 |
Summaries for patients. Treatment for resistant HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; | 2003 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; Hepatitis B virus; HIV Infectio | 2003 |
Cambodia: can a drug provide some protection?
Topics: Adenine; Animals; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; Haplorhini | 2003 |
[Further indications for tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Te | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B viru | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; | 2003 |
Acute tubular necrosis in a patient receiving tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Co | 2003 |
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Mode | 2004 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organoph | 2003 |
BMS issues PK notice regarding ATV + TDF.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Clinical Trials as Topic; Drug Indus | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphoru | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lam | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; | 2003 |
Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection.
Topics: Adenine; Aged; Child; Clinical Trials as Topic; Counseling; Education, Continuing; HIV Infections; H | 2004 |
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Adminis | 2004 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates | 2003 |
Can AIDS drug also prevent HIV infection?
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Homosexuality, Ma | 2004 |
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Topics: Adenine; Adenosine Triphosphate; Cells, Cultured; DNA Primers; DNA Transposable Elements; Drug Resis | 2004 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HI | 2004 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compou | 2003 |
Hepatitis B infection in an HIV-positive man treated with tenofovir: a case of re-infection or reactivation?
Topics: Adenine; Adult; Hepatitis B Antibodies; Hepatitis B virus; HIV Infections; Humans; Male; Organophosp | 2004 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavi | 2003 |
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Mul | 2004 |
Tenofovir-related nephrotoxicity in HIV-infected patients.
Topics: Acute Kidney Injury; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzo | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Dru | 2004 |
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocyt | 2004 |
Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Didanosine; Drug Interactions; Drug Therapy, Combinatio | 2004 |
Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hyp | 2004 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, | 2004 |
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infecti | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV | 2004 |
The K65R mutation in HIV-1 reverse transcriptase.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse | 2004 |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resis | 2004 |
Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Mitochondrial; HIV Infections; HIV-1; Humans; Kidney Diseases; | 2004 |
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans | 2004 |
Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient.
Topics: Adenine; Anti-HIV Agents; Drug Eruptions; Hepatitis B, Chronic; HIV Infections; Humans; Lichenoid Er | 2004 |
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Hydr | 2004 |
AIDS research. Cambodian leader throws novel prevention trial into limbo.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; HIV Infections; Hum | 2004 |
Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Area Under Curve; Comorbidity; Didanosine; Drug Interact | 2004 |
Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Topics: Acute Disease; Adenine; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Huma | 2004 |
Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, | 2004 |
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Testis Barrier; Cyclopropanes; Enfuvir | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug T | 2004 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyc | 2004 |
Prevention trials starting.
Topics: Adenine; Adult; Africa; Clinical Trials as Topic; Female; HIV Infections; Humans; Male; Middle Aged; | 2004 |
Cambodia stops important tenofovir prevention trial.
Topics: Adenine; Cambodia; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse T | 2004 |
Trial of antiretroviral for HIV prevention on hold.
Topics: Adenine; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Double-Blind Method; Ethics | 2004 |
Intracellular pharmacology of emtricitabine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Half-Life; HIV Infections; Humans; Organopho | 2004 |
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infe | 2004 |
Tenofovir, equivalence, and noninferiority.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Organophosp | 2004 |
Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV I | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directe | 2004 |
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
Topics: Adenine; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Organo | 2004 |
Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Genetic; Didanosine; DNA | 2004 |
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
Topics: Adenine; Albuminuria; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; C | 2004 |
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Drug Combinations; Drug Interactions; Gels; Half- | 2005 |
Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Gene Frequency; Genes, Vi | 2005 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combinatio | 2004 |
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Topics: Adenine; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Interactions; Drug Therapy, C | 2004 |
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Topics: Adenine; Anti-HIV Agents; Creatinine; Cross-Sectional Studies; Cystatin C; Cystatins; Glomerular Fil | 2005 |
Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; R | 2005 |
The experts speak. Studying the potential of tenofovir to prevent sexual transmission of HIV: first steps. Interview by Vicki Glaser.
Topics: Adenine; Communicable Disease Control; Female; HIV Infections; Humans; Male; Organophosphonates; Pri | 2005 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; D | 2005 |
Tenofovir-induced acute renal failure in an HIV patient with normal renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Inf | 2005 |
Tenofovir: a pill to prevent HIV?
Topics: Adenine; Anti-HIV Agents; Drugs, Investigational; HIV Infections; Humans; Organophosphonates; Tenofo | 2005 |
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Organo | 2005 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Org | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gab | 2005 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2005 |
Women testing tenofovir for HIV prevention.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Nigeria; Organop | 2005 |
AIDS clinical trials. More woes for novel HIV prevention approach.
Topics: Adenine; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resis | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Fem | 2005 |
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; D | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV | 2005 |
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; France; HIV Infections; H | 2005 |
Fatal lactic acidosis associated with tenofovir and abacavir.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Dideoxynucleosides; Fatal Outcome; HIV Infections; Human | 2005 |
[Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir].
Topics: Acute Kidney Injury; Adenine; Adult; Diabetes Insipidus; Fanconi Syndrome; HIV Infections; Humans; M | 2005 |
Tenofovir helpful for patients with HBV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B; HIV Infections; Humans | 2005 |
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Po | 2005 |
The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
Topics: Adenine; Antiviral Agents; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hyp | 2006 |
We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
Topics: Adenine; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophosphonates; Public O | 2005 |
The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?
Topics: Adenine; Global Health; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Organophospho | 2005 |
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides | 2005 |
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidne | 2005 |
Tenofovir and changes in renal function.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Kidney Dise | 2005 |
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under | 2005 |
Progression of renal impairment under therapy with tenofovir.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV | 2005 |
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Case-Control Studies; Creatinine; Dose-Response Rela | 2005 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bup | 2005 |
Protests may slow down trials.
Topics: Adenine; Bisexuality; Clinical Trials as Topic; Europe; HIV Infections; Homosexuality, Male; Humans; | 2005 |
Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia.
Topics: Adenine; Anti-HIV Agents; Bone Density Conservation Agents; Fanconi Syndrome; HIV Infections; Humans | 2006 |
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fanconi Syndrome; Female; HIV Infec | 2005 |
High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multip | 2005 |
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combinatio | 2005 |
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral-experienced HIV-1-infected subjects treated with tenofovir combination therapy.
Topics: Adenine; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; H | 2005 |
AIDS. Promote HIV chemoprophylaxis research, don't prevent it.
Topics: Adenine; Africa; Anti-HIV Agents; Asia; Community Participation; Controlled Clinical Trials as Topic | 2005 |
The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Community Networks; HIV Infections; Human Rights | 2005 |
Response to Joep M. A. Lange.
Topics: Adenine; Cambodia; Clinical Trials as Topic; Health Services Accessibility; HIV Infections; Humans; | 2005 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; | 2005 |
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Immunologic; Drug Admi | 2005 |
Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels.
Topics: Absorption; Adenine; Adult; Alkaline Phosphatase; Antiretroviral Therapy, Highly Active; beta 2-Micr | 2005 |
Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
Topics: Adenine; Antiviral Agents; DNA, Viral; Genes, Viral; Genotype; Hepatitis B e Antigens; Hepatitis B, | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV | 2005 |
Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.
Topics: Adenine; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Mass Spectrometr | 2006 |
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; DNA, V | 2005 |
Stakeholder consultation to address issues related to tenofovir prophylactic research.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Referral and Consultation; Res | 2005 |
A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2005 |
Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged | 2006 |
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; D | 2006 |
Tenofovir trials raise ethical issues.
Topics: Adenine; Clinical Trials as Topic; Ethics, Medical; HIV Infections; Humans; Organophosphonates; Reve | 2005 |
Substitutions in the reverse transcriptase and protease genes of HIV-1 subtype B in untreated individuals and patients treated with antiretroviral drugs.
Topics: Adenine; Anti-Retroviral Agents; Base Sequence; Guanine; HIV Infections; HIV Protease; HIV Reverse T | 2005 |
[Simply convincing. New fixed combination for HIV therapy].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxycyti | 2005 |
Should tenofovir ever be used in association with didanosine?
Topics: Adenine; Anti-HIV Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; | 2005 |
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B; | 2006 |
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Topics: Acid-Base Equilibrium; Acute Kidney Injury; Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents | 2006 |
Case study: an active, 24-year-old woman positive for HIV.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; Disease Progression; Emtricitabine; Female; H | 2006 |
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Mitochondrial; Dru | 2006 |
Retrovirus meeting. Novel attacks on HIV move closer to reality.
Topics: Adenine; Animals; Anti-HIV Agents; Evolution, Molecular; HIV Infections; HIV-1; Humans; Organic Chem | 2006 |
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, | 2006 |
Serum creatinine changes in HIV-seropositive patients receiving tenofovir.
Topics: Acute Kidney Injury; Adenine; Creatinine; Cross-Sectional Studies; HIV Infections; Humans; Organopho | 2006 |
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bio | 2006 |
Registration problems for antiretrovirals in Africa.
Topics: Adenine; Africa; Anti-Retroviral Agents; Developing Countries; Drug and Narcotic Control; HIV Infect | 2006 |
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive | 2006 |
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infe | 2006 |
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dyslipidemias; HIV Infections; Huma | 2006 |
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Hepatitis B e Antigens; Hepatitis B, Chro | 2006 |
Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2006 |
Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Glucose; Didanosine; Drug Therapy, Combination; Fasting; Fema | 2006 |
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Evolution; | 2006 |
Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Hum | 2006 |
The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Organophos | 2006 |
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lam | 2006 |
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Organophosphonat | 2006 |
Report from the 13th retrovirus conference. Renal tenofovir debate continues.
Topics: Adenine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Organophosphonates; Reverse Tra | 2006 |
Truvada trials hold promise for new HIV prevention strategy. Once-a-day might keep HIV away.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Female; HIV Inf | 2006 |
FDA makes final approvals.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infect | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabin | 2006 |
Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study.
Topics: Adenine; Adult; HIV Infections; HIV-1; Humans; Kidney; Middle Aged; Organophosphonates; Prospective | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivu | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Hu | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combinat | 2006 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Disease | 2006 |
FDA notifications. Two tenofovir containing products are approved.
Topics: Adenine; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Rever | 2006 |
Moving toward assured access to treatment in microbicide trials. Global Campaign for Microbicides.
Topics: Adenine; Anti-HIV Agents; Cambodia; Cameroon; Clinical Trials as Topic; Consensus Development Confer | 2006 |
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Bias; Cross-Over Studies; Drug Interactions; France; H | 2007 |
AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing.
Topics: Adenine; Anti-HIV Agents; Cambodia; Clinical Trials as Topic; Developing Countries; Female; HIV Infe | 2006 |
Hypokalemia in HIV patients on tenofovir.
Topics: Adenine; Adolescent; Adult; Body Weight; Child; Didanosine; Drug Therapy, Combination; Female; HIV I | 2006 |
Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Cell Count; Cell Line; Cell Survival; DNA, Viral; Drug R | 2006 |
Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hepatitis; HIV Infec | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Topics: Adenine; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combina | 2006 |
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Creatinine; Female; HIV Infection | 2006 |
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hypophosphate | 2006 |
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestions for safer use.
Topics: Adenine; Creatinine; Dose-Response Relationship, Drug; Fanconi Syndrome; Glomerular Filtration Rate; | 2006 |
Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases.
Topics: Acute Kidney Injury; Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; H | 2006 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule | 2006 |
Hepatitis delta virus super-infection in a co-infected patient with the human immunodeficiency virus type 1 and a surface antigen-negative hepatitis B virus variant.
Topics: Adenine; Alanine Transaminase; Amino Acid Sequence; Anti-HIV Agents; Follow-Up Studies; Hepatitis B; | 2006 |
Chemoprophylaxis of HIV infection: moving forward with caution.
Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1; | 2006 |
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral; | 2006 |
Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Electron Transport | 2006 |
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; | 2006 |
The role of tenofovir in the prevention of HIV infections.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Tenofovir | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distributi | 2006 |
One pill, once daily: now an option for HIV patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug C | 2006 |
A once-daily combination tablet (Atripla) for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Dr | 2006 |
Once-daily dosing and the treatment of HIV disease.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration S | 2006 |
Pre-exposure prophylaxis effective.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Administration Schedule; Female; Ghana; HIV | 2006 |
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; Haplotypes; HIV Infections; Humans; Membrane Transport P | 2006 |
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Fanconi Syndrome; Female; Gene Frequenc | 2006 |
A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Topics: Adenine; Adult; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; | 2006 |
HIV prophylaxis still has no clear cut answer.
Topics: Adenine; Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; National | 2006 |
Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward.
Topics: Adenine; Adolescent; Adult; Condoms; Double-Blind Method; Female; HIV Infections; Humans; Organophos | 2006 |
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infectio | 2006 |
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infecti | 2007 |
Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Topics: Adenine; Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; H | 2006 |
Anti-HIV agents. Trying times for tenofovir and abacavir.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Comb | 2003 |
Five-year data out on Viread.
Topics: Adenine; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; HIV Infections; Humans; | 2006 |
Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
Topics: Adenine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; L | 2004 |
Workshop explores racial PK differences, TDF-PI interaction.
Topics: Adenine; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Racial Groups; Reverse | 2006 |
Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is significantly associated with TDF and consists of ubiquitous mitochondrial CK.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Creatine Kinase, Mitochondrial Form; Female; | 2006 |
Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans | 2007 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HI | 2007 |
Prevention. Anti-HIV drug could prevent transmission in women.
Topics: Adenine; Administration, Topical; Female; HIV Infections; Humans; Organophosphonates; Reverse Transc | 2007 |
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
Topics: Adenine; Anti-HIV Agents; Confounding Factors, Epidemiologic; HIV Infections; Humans; Membrane Trans | 2007 |
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; | 2007 |
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphona | 2007 |
Response to Blaas et al., 'Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases'.
Topics: Acute Kidney Injury; Adenine; HIV Infections; Humans; Liver Cirrhosis; Organophosphonates; Reverse T | 2007 |
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; | 2007 |
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Erythrocytes; HIV Infections | 2007 |
Medicines Control Council and registration backlog of antiretrovirals.
Topics: Adenine; Anti-Retroviral Agents; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtrici | 2007 |
Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Hypersensit | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black | 2007 |
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Fluorescent Antibo | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosi | 2007 |
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring.
Topics: Adenine; Calibration; Drug Monitoring; HIV Infections; Humans; Mass Spectrometry; Organophosphonates | 2007 |
Chronic renal failure among HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Female; Glomerular F | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combinati | 2007 |
Reversibility of cirrhosis in HIV/HBV coinfection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, V | 2007 |
Does tenofovir influence efavirenz pharmacokinetics?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazi | 2007 |
Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Topics: Adenine; CD4 Lymphocyte Count; DNA, Viral; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; H | 2007 |
Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Drug Combinations; Female; HIV Infections; Humans; | 2007 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
Topics: Adenine; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Retroviral Agents; Antivi | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infecti | 2007 |
Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
Topics: Adenine; Adult; Drug Eruptions; Drug Therapy, Combination; Exanthema; Female; HIV Infections; HIV Pr | 2007 |
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedul | 2007 |
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Cohort Studies; Comorbidity; Female; Follow-Up Studies | 2008 |
Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; HIV Infections; Humans; | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reve | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly A | 2007 |
Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Cause of Death; Drug Monitoring; Drug Synergism; Fanconi Syndrome; Female; Guideline | 2007 |
Effect of tenofovir on renal glomerular and tubular function.
Topics: Adenine; Anti-Retroviral Agents; Case-Control Studies; Cross-Sectional Studies; Glomerular Filtratio | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycy | 2007 |
A second chance for microbicides.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Infective Agents; Clinical Trials as Topic; Female; HIV Infect | 2007 |
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Fanconi Syndrome; Fe | 2007 |
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Female; Hepatitis B; Hepatitis B vir | 2007 |
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; H | 2007 |
Adverse events experienced by three children taking tenofovir and didanosine in combination.
Topics: Adenine; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infect | 2007 |
[Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir].
Topics: Adenine; Adult; Fractures, Bone; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideli | 2007 |
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomar | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Hi | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazi | 2007 |
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
Topics: Adenine; Amino Acid Sequence; Deoxycytidine; Drug Resistance, Multiple, Viral; Genetic Variation; HI | 2007 |
Diverse approaches useful for microbicide trials.
Topics: Adenine; Animals; Anti-HIV Agents; Anti-Infective Agents; Bias; Clinical Trials as Topic; Female; HI | 2007 |
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Topics: Adenine; Biomarkers; Creatinine; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases | 2007 |
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; HIV | 2007 |
Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.
Topics: Adenine; Adolescent; Adult; beta 2-Microglobulin; Child; Child, Preschool; Cross-Sectional Studies; | 2007 |
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2007 |
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Dideoxynucleosides; Dideo | 2008 |
Female-initiated prevention strategies key to tackling HIV.
Topics: Adenine; Africa South of the Sahara; Anti-HIV Agents; Condoms, Female; Diaphragm; Female; HIV Infect | 2007 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; | 2007 |
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.
Topics: Adenine; Blotting, Western; Cell Line; Clone Cells; Cytidine Deaminase; DNA Mutational Analysis; DNA | 2007 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions | 2008 |
Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Fema | 2007 |
Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2007 |
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases.
Topics: Adenine; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Italy; Kidney; Mal | 2007 |
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; | 2008 |
Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.
Topics: Adenine; Anti-HIV Agents; Diphosphates; Guanosine; HIV Infections; HIV-1; Humans; Leukocytes, Mononu | 2008 |
Acute renal failure after initiation of tenofovir disoproxil fumarate.
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; HIV Infections; Humans; Male; Middle Aged; Organophos | 2007 |
Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context.
Topics: Adenine; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Organophosphonates; Reverse Transc | 2008 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Commu | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepa | 2008 |
Can the new humanized mouse model give HIV research a boost.
Topics: Adenine; Administration, Intravaginal; Animals; Deoxycytidine; Disease Models, Animal; Disease Susce | 2008 |
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Anim | 2008 |
Design, synthesis and anti-HIV activity of homologous PMEA derivatives.
Topics: Adenine; Anti-HIV Agents; Drug Design; HIV Infections; HIV-1; Humans | 2008 |
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Glomerular | 2007 |
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
Topics: Adenine; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-HIV Agents; Child; F | 2008 |
European CHMP issues positive opinion for Atripla.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, | 2007 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; | 2008 |
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2008 |
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine | 2008 |
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse | 2008 |
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Geno | 2008 |
FDA grants tentative approval to first generic version of antiretroviral Viread.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Organophosphonates; | 2008 |
European Commission approves Atripla.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; | 2008 |
Does tenofovir increase efavirenz hepatotoxicity?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemi | 2008 |
[Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV In | 2008 |
[Severe hypokalemia and tenofovir].
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Hypokalemia; Male; Middle Aged; Organophosphonates | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideox | 2008 |
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; | 2008 |
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Topics: Adenine; Antiviral Agents; Cell-Free System; Cloning, Molecular; Culture Techniques; Drug Resistance | 1995 |
AIDS research. New drug shows promise in monkeys.
Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Ve | 1995 |
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Base Sequence; Cells, Cultured; HIV Infection | 1995 |
Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Brain; Cytopathogenic Effect, Viral; Disease | 1995 |
Changes in purine nucleotide content in the lymphocyte subpopulations of patients infected with HIV.
Topics: Adenine; Adenosine Diphosphate; Adenosine Triphosphate; Adult; CD4-Positive T-Lymphocytes; Female; G | 1994 |
MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; DNA, Viral; Guanine; HIV | 1996 |
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; D | 1998 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Did | 1998 |
Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
Topics: Adenine; Animals; Anti-HIV Agents; Biological Availability; Cytomegalovirus; Cytomegalovirus Infecti | 1999 |
Compassionate use for tenofovir.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; Humans; Organopho | 2000 |
NDA submitted for adefovir.
Topics: Adenine; Carnitine; Drug Approval; Drug Packaging; Drug Therapy, Combination; HIV Infections; Humans | 1999 |
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Codon; Cohort Studies; Cyc | 2000 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Hu | 2000 |
Promising results for tenofovir.
Topics: Adenine; Clinical Trials, Phase II as Topic; HIV Infections; Humans; Organophosphonates; Organophosp | 2000 |
The treatment pipeline: new therapies are on the way.
Topics: Adenine; AIDS Vaccines; Anti-HIV Agents; Enfuvirtide; Granulocyte-Macrophage Colony-Stimulating Fact | 1999 |
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Tra | 2000 |
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progress | 2001 |
Mechanistic study on the cytostatic and tumor cell differentiation-inducing properties of 9-(2-phosphonylmethoxyethyl)adenine (PMEA, adefovir)-collected publications.
Topics: Adenine; Animals; Antineoplastic Agents; Antiviral Agents; Cell Differentiation; Cell Division; Cell | 2000 |
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV In | 2001 |
CDC to revisit AZT, post-exposure guidelines. Centers for Disease Control and Prevention.
Topics: Adenine; Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Org | 1996 |
PMPA--first human results.
Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Haplorhini; HIV; HIV Infections; Human | 1997 |
Update on antivirals.
Topics: Adenine; Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Clinical Trials as Topic; Dosage Forms; Drug | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne | 1997 |
Three drugs now in expanded access.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections | 1997 |
Adefovir dipivoxil (Preveon) expanded access begins.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials | 1997 |
Expanded access programs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Health Services Accessibility; HIV I | 1997 |
Expanded access for adefovir.
Topics: Adenine; Anti-HIV Agents; Carnitine; Drugs, Investigational; HIV Infections; Humans | 1998 |
Adefovir dipivoxil (Preveon) expanded access restrictions being eased.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, | 1998 |
Expanded access.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infec | 1997 |
Adefovir dipivoxil (Preveon) improved expanded-access program.
Topics: Adenine; Anti-HIV Agents; Drugs, Investigational; HIV Infections; Humans; United States | 1998 |
Adefovir dipivoxil (Preveon) new results with hepatitis B, HIV.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Dru | 1998 |
Looking down the drug pipeline.
Topics: Adenine; Animals; Anti-HIV Agents; Biological Availability; Chlorobenzenes; Clinical Trials as Topic | 1998 |
T-20 and adefovir for salvage therapy -- expect no miracles.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Costs; Drug Resistance, Microbial; Drug The | 1998 |
Options when HIV treatments fail.
Topics: Adenine; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideo | 1998 |
I want a new drug. An overview of three new anti-HIV drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopr | 1998 |
What's new, what's next?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Carbamates; Decision Making; Dideoxynucleosides; Drug Re | 1998 |
Preveon expanded access program broadened.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections; | 1998 |
Kidney dysfunction: a safety update on adefovir (preveon).
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Creatinine; Fanconi Syndrome; HIV Infections; Humans; Hy | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes | 1998 |
A rocky road for nucleotide analogs.
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topi | 1998 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials a | 1998 |
What's new, what's next?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes | 1999 |
Antiretroviral therapy: rehashes, leftovers, and a pinch of new data.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Congresses as Topic; Cycl | 1998 |
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combin | 1998 |
The new drugs and how to use them.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug | 1999 |
Lower doses of adefovir dipivoxil (Preveon).
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Comb | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infect | 1998 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors | 1999 |
Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhi | 1999 |
Adefovir rejected.
Topics: Adenine; Drug Approval; HIV Infections; Humans; United States Food and Drug Administration | 1999 |
More trouble for adefovir.
Topics: Adenine; Anti-HIV Agents; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV Pro | 1999 |
Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes | 1998 |
New expanded access drugs for use in combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Dideoxynucleosides; Drug I | 1998 |
Update on tenofovir (PMPA) compassionate access study.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Middle Aged; Orga | 1999 |
Tenofovir (PMPA) compassionate access study opens.
Topics: Adenine; Clinical Trials as Topic; HIV Infections; Humans; Organophosphorus Compounds; Patient Selec | 1999 |
FDA panel fails to recommend adefovir approval. Food and Drug Administration.
Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Kidney Diseases; Salvage Therapy; U | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Investigational; Health Services Accessibility; HIV | 1999 |
Novel approaches for the treatment of HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug | 1998 |
CRIA clinical trials.
Topics: Adenine; Alkynes; Anabolic Agents; Anti-HIV Agents; Benzoxazines; Blood Glucose; Clinical Trials as | 1998 |
[Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV I | 2001 |
Tenofovir ready for approval.
Topics: Adenine; Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphoru | 2001 |
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.
Topics: Acute Kidney Injury; Adenine; Adult; Antiviral Agents; Cytochrome-c Oxidase Deficiency; Dissection; | 2001 |
Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Microbial Sensi | 2001 |
Encouraging results for tenofovir.
Topics: Adenine; Clinical Trials, Phase III as Topic; HIV Infections; HIV-1; Humans; Organophosphonates; Org | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administra | 2001 |
Tenofovir: Gilead applies for approval; expanded access liberalized.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Approval; Drug Industry; Health Services Access | 2001 |
Tenofovir: FDA hearing October 3, public comment deadlines September 26.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; Humans; Organop | 2001 |
Tenofovir: FDA hearing on important new antiretroviral.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reve | 2001 |
Tenacious tenofovir struts its stuff in a virtual ICAAC.
Topics: Adenine; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Comb | 2001 |
From the Food and Drug Administration.
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Cathartics; Defibrillators, Implantable; HIV Infecti | 2001 |
Expanded access to tenofovir.
Topics: Adenine; Canada; Europe; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Rev | 2001 |
Tenofovir approved: broad indication.
Topics: Adenine; Drug Approval; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reve | 2001 |
Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Topics: Adenine; Anti-HIV Agents; Biological Availability; Drug Approval; Drug Therapy, Combination; HIV Inf | 2002 |
More uses for tenofovir?
Topics: Adenine; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Reverse Transcripta | 2001 |
Nutrient deficiency associated with new HIV medication.
Topics: Adenine; HIV Infections; Humans; Nutrition Disorders; Organophosphonates; Organophosphorus Compounds | 2002 |
Gilead sciences releases Viread.
Topics: Adenine; Drug Approval; Drug Industry; HIV Infections; Humans; Organophosphonates; Organophosphorus | 2002 |
New antiretroviral for HIV infection.
Topics: Adenine; Anti-HIV Agents; HIV Infections; Humans; Organophosphonates; Organophosphorus Compounds; Te | 2002 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hep | 2002 |
[Tenofovir--a new option for combination therapy].
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Organophosphonates; Org | 2002 |
[No comparison with NRTI. Tenofovir is robust against resistance trouble].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections | 2002 |
[Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte C | 2002 |
[First nucleotide analog on the market. New drug for the pretreated patient].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Drug Approval; Drug Therapy, Combinati | 2002 |
Drugs in development.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Cyclic N-Oxides; HIV Infections; Humans; Nitrile | 2002 |
8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, 28-31 October 2001.
Topics: Adenine; Anti-HIV Agents; Greece; HIV Infections; Humans; Organophosphonates; Organophosphorus Compo | 2002 |
Adefovir nephrotoxicity and mitochondrial DNA depletion.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mito | 2002 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; | 1992 |